id,url,seo_score,path,code,content_type,indexability,depth,title_len,meta_len,word_count,inlinks,unique_inlinks,match_score,path_to_file,path_to_image,path_to_text,named_entities,disease_category,country,category,search_terms,diseases,x,y,cluster,text_snippets,cluster_keywords,domain,demand,findability,optimization_level,search_volume,topic
1,https://fachportal.roche.de/user.html,7,fachportal_roche_de_user_html.txt,200,html,Indexable,3,7,0,734,0,0,0.935483870967742,fachportal_roche_de__html.txt,image/fachportal_roche_de__html.txt.png,text/fachportal_roche_de__html.txt.txt,[],Other,Germany,Offer outline,,,-38.101135,-3.0381336,0,"The content presents an overview of Roche's specialized portal designed for healthcare professionals, highlighting various therapeutic areas such as neuroscience, oncology, and more. It emphasizes Roche's products, including clinical data and downloadable resources for practitioners. The portal also offers services like newsletters and event information, aimed at keeping professionals updated on the latest research and developments in their respective fields. Overall, the purpose is to provide comprehensive, accessible information and tools for healthcare professionals to enhance their daily practice.","oncology, professionals, data",fachportal.roche.de,Rising,0.706851677472224,high,395,General Offer Outline
2,https://fachportal.roche.de/,8,fachportal_roche_de_.txt,200,html,Indexable,0,15,0,1625,4586,1514,1,fachportal_roche_de_.txt,image/fachportal_roche_de_.txt.png,text/fachportal_roche_de_.txt.txt,[],Other,Germany,Offer outline,,,-36.41366,-5.2351255,0,"The content provides an overview of Roche's specialized portal for healthcare professionals, detailing various therapeutic areas such as neuroscience, oncology, and hematology. It highlights available resources, including product information, clinical data, downloadable materials, and updates on upcoming conferences and educational events. The purpose of the portal is to facilitate access to current research and therapeutic tools for professionals in clinical settings, ensuring they have comprehensive knowledge and support for their practice. Additionally, it encourages registration for enhanced access to exclusive content and services.","oncology, professionals, data",fachportal.roche.de,Flat,0.045345041899772,high,138,General Offer Outline
3,https://fachportal.roche.de/beyond-services/basistexte/.html,1,fachportal_roche_de_beyond_services_basistexte__html.txt,200,html,Non-Indexable,,0,0,2343,44,44,1,fachportal_roche_de_beyond_services_basistexte__html.txt,image/fachportal_roche_de_beyond_services_basistexte__html.txt.png,text/fachportal_roche_de_beyond_services_basistexte__html.txt.txt,"['Avastin', 'Alecensa']",Oncology-Hematology,Germany,Medication information,"Alecensa, Avastin, active ingredients, indications, contraindications, side effects, cancer treatments",,13.16796,-29.166094,1,"The content contains detailed information about two pharmaceutical products, Alecensa and Avastin, developed by Roche. For each product, it outlines the active ingredients, composition, indications for use, and possible contraindications and side effects. The content serves as a professional reference for healthcare providers, emphasizing the therapeutic applications of these medications in specific cancer treatments, along with necessary precautions and regulatory information. There's also a note about the availability of further details upon request.","drug, reporting, adverse",fachportal.roche.de,Flat,0.774166903675593,low,363,Drug Safety
4,https://fachportal.roche.de/beyond-services/basistexte/ALE_ROZ_GAV_PA.html,6,fachportal_roche_de_beyond_services_basistexte_ALE_ROZ_GAV_PA_html.txt,200,html,Indexable,,14,0,1339,0,0,1,fachportal_roche_de_beyond_services_basistexte_ALE_ROZ_GAV_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_ALE_ROZ_GAV_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_ALE_ROZ_GAV_PA_html.txt.txt,['Alecensa'],Oncology-Hematology,Germany,Medication information,"Alecensa, alectinib, non-small cell lung cancer, contraindications, side effects",non-small cell lung cancer,13.172633,-28.20449,1,"The content outlines important information about the pharmaceutical product Alecensa® (alectinib) provided by Roche. It includes details such as its composition, indications for use (specifically for the treatment of non-small cell lung cancer), contraindications, and potential side effects. The content is primarily aimed at healthcare professionals, facilitating access to essential information about the drug's application and safety profile. Additionally, it provides contact information for further inquiries.","drug, reporting, adverse",fachportal.roche.de,Rising,0.725872092312568,medium,154,Drug Safety
5,https://fachportal.roche.de/beyond-services/basistexte/ALE_ROZ_PA.html,6,fachportal_roche_de_beyond_services_basistexte_ALE_ROZ_PA_html.txt,200,html,Indexable,,10,0,1339,0,0,1,fachportal_roche_de_beyond_services_basistexte_ALE_ROZ_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_ALE_ROZ_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_ALE_ROZ_PA_html.txt.txt,"['Rozlytrek', 'Alecensa']",Oncology-Hematology,Germany,Medication information,"Alecensa, Rozlytrek, active ingredients, administration methods, indications for use, contraindications, side effects",,3.4087539,-33.41976,1,"The content features information about two pharmaceutical products from Roche, Alecensa® and Rozlytrek®. It includes details such as active ingredients, administration methods, indications for use, contraindications, side effects, and additional notes pertinent to healthcare professionals. This content serves as a resource for medical professionals to understand the therapeutic applications and safety information of these medications, supporting informed decision-making in clinical settings.","drug, reporting, adverse",fachportal.roche.de,Falling,0.394568432822284,medium,109,Drug Safety
6,https://fachportal.roche.de/beyond-services/basistexte/ALE_TEC_ROZ_PA.html,6,fachportal_roche_de_beyond_services_basistexte_ALE_TEC_ROZ_PA_html.txt,200,html,Indexable,,14,0,2002,0,0,1,fachportal_roche_de_beyond_services_basistexte_ALE_TEC_ROZ_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_ALE_TEC_ROZ_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_ALE_TEC_ROZ_PA_html.txt.txt,"['Rozlytrek', 'Alecensa']",Oncology-Hematology,Germany,Medication information,"Alecensa, Rozlytrek, active ingredients, side effects, contraindications",,12.204845,-28.88612,1,"The content provides detailed information about Roche's pharmaceutical products, specifically ""Alecensa"" and ""Rozlytrek."" It includes their active ingredients, usage indications, potential side effects, and contraindications. The content is aimed at healthcare professionals, offering insights into the therapeutic applications of these medications for certain cancer types, while also advising on monitoring for adverse effects. Overall, it serves as a resource for professionals to understand the safety and efficacy of these treatments.","drug, reporting, adverse",fachportal.roche.de,Flat,0.0769514846950399,medium,126,Drug Safety
7,https://fachportal.roche.de/beyond-services/basistexte/Alecensa_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Alecensa_PA_html.txt,200,html,Indexable,,11,0,931,0,0,1,fachportal_roche_de_beyond_services_basistexte_Alecensa_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Alecensa_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Alecensa_PA_html.txt.txt,"['Alecenna', 'NSCLC']",Oncology-Hematology,Germany,Medication information,"Alecenna, active ingredient, non-small cell lung cancer (NSCLC), side effects, contraindications",non-small cell lung cancer,19.70618,-27.59868,1,"The content of the content features information about a pharmaceutical product, Alecenna, including its active ingredient, uses, dosage, and side effects. It provides technical details aimed at healthcare professionals, emphasizing its application in the treatment of specific types of cancer, particularly non-small cell lung cancer (NSCLC). The content also outlines potential side effects and contraindications associated with the medication, making this a specialized resource for medical professionals.","drug, reporting, adverse",fachportal.roche.de,Rising,0.646867559313824,medium,15,Drug Safety
8,https://fachportal.roche.de/beyond-services/basistexte/Avastin_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Avastin_PA_html.txt,200,html,Indexable,,10,0,1213,0,0,1,fachportal_roche_de_beyond_services_basistexte_Avastin_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Avastin_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Avastin_PA_html.txt.txt,['Avastin'],Oncology-Hematology,Germany,Medication information,"Avastin, bevacizumab, chemotherapy, metastatic breast cancer, colorectal cancer, potential side effects, adverse reactions","metastatic breast cancer, metastatic colorectal cancer",20.421219,-27.699934,1,"The content presents information about the pharmaceutical product Avastin (bevacizumab), detailing its composition, indications, application methods, and potential side effects. It discusses the use of Avastin in combination with chemotherapy for various cancer treatments, including metastatic breast and colorectal cancers. It also lists possible adverse reactions, emphasizing the importance of this information for healthcare professionals utilizing the drug in clinical settings. The overall purpose of the content is to provide comprehensive product details for medical professionals.","drug, reporting, adverse",fachportal.roche.de,Falling,0.863208107485687,medium,442,Drug Safety
9,https://fachportal.roche.de/beyond-services/basistexte/COL_POL_PA.html,6,fachportal_roche_de_beyond_services_basistexte_COL_POL_PA_html.txt,200,html,Indexable,,10,0,1235,0,0,1,fachportal_roche_de_beyond_services_basistexte_COL_POL_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_COL_POL_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_COL_POL_PA_html.txt.txt,"['Polivy', 'Columvi']",Oncology-Hematology,Germany,Medication information,"Columvi, Polivy, active ingredients, side effects, warnings",,16.408585,-38.83005,1,"The content provides detailed information about two pharmaceutical products, Columvi and Polivy, including their active ingredients, formulations, indications for use, side effects, and warnings. It is targeted toward healthcare professionals and emphasizes the importance of reporting any adverse effects. The content also includes contact information for reporting and additional inquiries, indicating a focus on safety and compliance in the medical context.","drug, reporting, adverse",fachportal.roche.de,Falling,0.144853039409753,medium,381,Drug Safety
10,https://fachportal.roche.de/beyond-services/basistexte/Columvi_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Columvi_PA_html.txt,200,html,Indexable,,10,0,975,0,0,1,fachportal_roche_de_beyond_services_basistexte_Columvi_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Columvi_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Columvi_PA_html.txt.txt,"['Columi', 'Glofitamab']",Oncology-Hematology,Germany,Medication information,"Glofitamab, Columi, dosage forms, indications for use, side effects",,11.8596525,-37.216976,1,"The content features information about Columi, a pharmaceutical product developed by Roche. It includes details on its composition, active ingredient (Glofitamab), dosage forms, indications for use, and potential side effects. The content emphasizes the need for monitoring and reporting any adverse effects, providing contact information for healthcare professionals to report issues. The content serves as a resource for medical professionals regarding the safe and effective use of this treatment.","drug, reporting, adverse",fachportal.roche.de,Falling,0.824516027772779,medium,219,Drug Safety
11,https://fachportal.roche.de/beyond-services/basistexte/Erivedge_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Erivedge_PA_html.txt,200,html,Indexable,,11,0,956,0,0,0.971014492753623,fachportal_roche_de_beyond_services_basistexte_Erivedge_PA_html.txt.txt,image/fachportal_roche_de_beyond_services_basistexte_Erivedge_PA_html.txt.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Erivedge_PA_html.txt.txt.txt,"['Erivedge', 'Vismodegib']",Oncology-Hematology,Germany,Medication information,"Erivedge, Vismodegib, metastatic basal cell carcinoma, contraindications, side effects, pregnancy",metastatic basal cell carcinoma,21.227558,-34.774662,1,"The content provides information about a pharmaceutical product, Erivedge, which contains the active ingredient Vismodegib. It includes details on its composition, indications for use in patients with metastatic basal cell carcinoma, contraindications, and potential side effects. There are also cautionary notes about usage in specific populations, particularly regarding pregnancy. The content aims to inform healthcare professionals about the drug's safety and application in clinical settings.","drug, reporting, adverse",fachportal.roche.de,All,0.201546838057712,medium,400,Drug Safety
12,https://fachportal.roche.de/beyond-services/basistexte/Evrysdi_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Evrysdi_PA_html.txt,200,html,Indexable,,10,0,974,0,0,1,fachportal_roche_de_beyond_services_basistexte_Evrysdi_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Evrysdi_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Evrysdi_PA_html.txt.txt,"['Evrysdi', 'SMA']",Neurology,Germany,Medication information,"Evrysdi, risdiplam, spinal muscular atrophy (SMA), potential side effects",spinal muscular atrophy,21.525303,-38.481808,1,"The content provides detailed information about the medication Evrysdi (risdiplam), including its composition, usage, and potential side effects. It outlines its application in treating spinal muscular atrophy (SMA) and highlights the importance of reporting any adverse effects. Additionally, it includes contact information for professionals to report safety concerns, underscoring its focus on maintaining patient safety and regulatory compliance.","drug, reporting, adverse",fachportal.roche.de,Rising,0.184915229156139,medium,11,Drug Safety
13,https://fachportal.roche.de/beyond-services/basistexte/Gavreto_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Gavreto_PA_html.txt,200,html,Indexable,,10,0,734,0,0,1,fachportal_roche_de_beyond_services_basistexte_Gavreto_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Gavreto_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Gavreto_PA_html.txt.txt,[],Other,Germany,Offer outline,,,-8.03799,-18.379042,3,"The content displays a section from Roche's professional portal, intended for healthcare professionals. It highlights various categories such as products, clinical data, downloads, services, events, and medical inquiries, emphasizing the resources available for professionals interacting with Roche's offerings. The portal aims to provide exclusive benefits and support to users engaged in the healthcare field.","users, page, website",fachportal.roche.de,Falling,0.0179670531867819,medium,30,Website Metadata
14,https://fachportal.roche.de/beyond-services/basistexte/Gazyvaro_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Gazyvaro_PA_html.txt,200,html,Indexable,,11,0,1018,0,0,1,fachportal_roche_de_beyond_services_basistexte_Gazyvaro_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Gazyvaro_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Gazyvaro_PA_html.txt.txt,"['FL', 'Gazyvaro', 'CLL']",Oncology-Hematology,Germany,Medication information,"Gazyvaro, chronic lymphocytic leukemia, CLL, follicular lymphoma, FL, obinutuzumab, side effects, contraindications","chronic lymphocytic leukemia, follicular lymphoma",17.746235,-32.164745,1,"The content presents information about a pharmaceutical product called Gazyvaro®, highlighting its use, composition, and indications for chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). It details the active ingredient, obinutuzumab, and provides guidance on potential side effects and contraindications associated with its use. The purpose of the content is to inform healthcare professionals about the therapeutic application and important safety information related to the product.","drug, reporting, adverse",fachportal.roche.de,All,0.655986648208164,medium,268,Drug Safety
15,https://fachportal.roche.de/beyond-services/basistexte/gyn_PA.html,6,fachportal_roche_de_beyond_services_basistexte_gyn_PA_html.txt,200,html,Indexable,,6,0,4065,0,0,1,fachportal_roche_de_beyond_services_basistexte_gyn_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_gyn_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_gyn_PA_html.txt.txt,"['Herceptin', 'Perjeta']",Oncology-Hematology,Germany,Medication information,"Herceptin, Perjeta, indications for treatment, drug administration, side effects, metastatic breast cancer",metastatic breast cancer,15.569275,-28.756454,1,"The content features information from Roche's professional portal about the medications Herceptin® and Perjeta®, including their uses, formulations, and important safety information for healthcare providers. It discusses indications for treatment, specifics regarding drug administration, and potential side effects associated with these therapies, particularly in the context of metastatic breast cancer. The content aims to inform healthcare professionals about the proper use and considerations surrounding these treatments.","drug, reporting, adverse",fachportal.roche.de,Falling,0.552623794849339,medium,329,Drug Safety
16,https://fachportal.roche.de/beyond-services/basistexte/haema_heamo_PA.html,6,fachportal_roche_de_beyond_services_basistexte_haema_heamo_PA_html.txt,200,html,Indexable,,14,0,2148,0,0,1,fachportal_roche_de_beyond_services_basistexte_haema_heamo_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_haema_heamo_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_haema_heamo_PA_html.txt.txt,"['Columvi', 'Polivy']",Oncology-Hematology,Germany,Medication information,"Polivy, Columvi, active ingredients, side effects",,12.29139,-31.80759,1,"The content contains detailed information regarding two pharmaceutical products by Roche: Polivy® and Columvi®. It outlines key details such as active ingredients, indications, contraindications, and potential side effects. The page emphasizes the importance of monitoring safety and encourages healthcare professionals to report any adverse effects. Additionally, it includes contact information for further inquiries and compliance requirements.","drug, reporting, adverse",fachportal.roche.de,Falling,0.288842074792921,medium,303,Drug Safety
17,https://fachportal.roche.de/beyond-services/basistexte/haema_PA.html,6,fachportal_roche_de_beyond_services_basistexte_haema_PA_html.txt,200,html,Indexable,,8,0,1995,0,0,1,fachportal_roche_de_beyond_services_basistexte_haema_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_haema_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_haema_PA_html.txt.txt,"['Each', 'Columvi', 'Polivy']",Oncology-Hematology,Germany,Medication information,"Polivy, Columvi, active ingredients, indications, contraindications, side effects, safety information",,3.4565063,-35.14666,1,"The content features content from Roche's professional portal, focusing on two pharmaceutical products: Polivy and Columvi, which are used for manufacturing infusion solutions. Each product entry includes details such as active ingredients, indications for use, contraindications, potential side effects, and important safety information. The content emphasizes the importance of reporting any adverse effects to Roche and provides contact information for health professionals. The content is aimed at healthcare providers, offering critical information for safe medication management.","drug, reporting, adverse",fachportal.roche.de,All,0.473840266088406,medium,78,Drug Safety
18,https://fachportal.roche.de/beyond-services/basistexte/Hemlibra_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Hemlibra_PA_html.txt,200,html,Indexable,,11,0,887,0,0,1,fachportal_roche_de_beyond_services_basistexte_Hemlibra_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Hemlibra_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Hemlibra_PA_html.txt.txt,"['Hemlibra', 'Emicizumab', 'Additional']",Oncology-Hematology,Germany,Medication information,"Hemlibra, Emicizumab, hemophilia A, contraindications, side effects",hemophilia A,18.598185,-1.7715688,4,"The content features information from Roche's professional portal, focusing on the drug Hemlibra. It details its active ingredient (Emicizumab), its composition, applications for the treatment of hemophilia A, as well as contraindications and side effects. The portal serves healthcare professionals by providing essential information on the product, including updates and guidelines for use. Additional links and resources for patients and medical inquiries are also mentioned, indicating a comprehensive approach to pharmaceutical information.","technologies, artificial, ai",fachportal.roche.de,Flat,0.687468201124225,medium,253,Technology
19,https://fachportal.roche.de/beyond-services/basistexte/HER2pos_PA.html,6,fachportal_roche_de_beyond_services_basistexte_HER2pos_PA_html.txt,200,html,Indexable,,10,0,3402,0,0,0.970588235294118,fachportal_roche_de_beyond_services_basistexte_HER2pos_PA_html.txt.txt,image/fachportal_roche_de_beyond_services_basistexte_HER2pos_PA_html.txt.txt.png,text/fachportal_roche_de_beyond_services_basistexte_HER2pos_PA_html.txt.txt.txt,"['Herceptin', 'Perjeta', 'Kadcyla']",Oncology-Hematology,Germany,Medication information,"Herceptin, Perjeta, Kadcyla, metastatic breast cancer, dosage forms, potential side effects",metastatic breast cancer,16.309778,-28.793587,1,"The content features content from Roche's professional portal, specifically addressing important information related to the use of Herceptin® and Perjeta® (pertuzumab/trastuzumab) and Kadcyla® in treating metastatic breast cancer. It highlights dosage forms, application contexts, and potential side effects of these medications. Additionally, it details necessary guidelines for healthcare professionals to ensure patient safety and appropriate therapeutic use, including reporting procedures for adverse effects and considerations during pregnancy.","drug, reporting, adverse",fachportal.roche.de,Rising,0.071397064708013,medium,340,Drug Safety
20,https://fachportal.roche.de/beyond-services/basistexte/Herceptin_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Herceptin_PA_html.txt,200,html,Indexable,,12,0,2387,0,0,1,fachportal_roche_de_beyond_services_basistexte_Herceptin_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Herceptin_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Herceptin_PA_html.txt.txt,"['Herceptin', 'Perjeta']",Oncology-Hematology,Germany,Medication information,"Herceptin, Perjeta, HER2-positive metastatic breast cancer, safety information, side effects",HER2-positive metastatic breast cancer,14.915864,-29.051382,1,"The content is from Roche's professional portal, providing detailed information about their pharmaceutical products, specifically Herceptin® and Perjeta®. It includes important usage guidelines, safety information, and potential side effects associated with these medications, targeting healthcare professionals. The content informs about treatment for HER2-positive metastatic breast cancer and emphasizes the need for reporting adverse effects to ensure patient safety.","drug, reporting, adverse",fachportal.roche.de,Falling,0.498371927881888,medium,495,Drug Safety
21,https://fachportal.roche.de/beyond-services/basistexte.html,6,fachportal_roche_de_beyond_services_basistexte_html.txt,200,html,Non-Indexable,,23,0,7260,0,0,1,fachportal_roche_de_beyond_services_basistexte_html.txt,image/fachportal_roche_de_beyond_services_basistexte_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_html.txt.txt,"['Avastin', 'Adverse', 'Alecensa']",Oncology-Hematology,Germany,Medication information,"Alecensa, Avastin, active ingredients, lung cancer, colon cancer, adverse effects, contraindications","lung cancer, colon cancer",14.003079,-27.603369,1,"The content displays information from Roche's professional portal regarding two pharmaceutical products: Alecensa and Avastin. It includes details about their active ingredients, applications, and indications for use in treating specific types of cancer, emphasizing their roles in therapy for patients with advanced forms of lung and colon cancers. Adverse effects and contraindications are also highlighted, alongside regulatory information pertinent to healthcare professionals. Additionally, the content mentions the significance of adhering to guidelines specific to healthcare specialists.","drug, reporting, adverse",fachportal.roche.de,Flat,0.291802507389044,medium,317,Drug Safety
22,https://fachportal.roche.de/beyond-services/basistexte/KAD_HER_PA.html,6,fachportal_roche_de_beyond_services_basistexte_KAD_HER_PA_html.txt,200,html,Indexable,,10,0,2807,0,0,1,fachportal_roche_de_beyond_services_basistexte_KAD_HER_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_KAD_HER_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_KAD_HER_PA_html.txt.txt,"['Herceptin', 'Perjeta']",Oncology-Hematology,Germany,Medication information,"Herceptin, trastuzumab, Perjeta, pertuzumab, metastatic breast cancer, side effects, contraindications",metastatic breast cancer,15.546236,-29.205132,1,"The content from Roche's website provides detailed information about two pharmaceutical products: Herceptin® (trastuzumab) and Perjeta® (pertuzumab), including their formulation, usage, and indications for the treatment of metastatic breast cancer. It emphasizes the importance of consulting with Roche's medical safety team regarding any administration-related concerns, especially during pregnancy. The content also outlines potential side effects and contraindications associated with these treatments, serving as a resource for healthcare professionals to ensure safe patient care.","drug, reporting, adverse",fachportal.roche.de,Falling,0.326533295701595,medium,262,Drug Safety
23,https://fachportal.roche.de/beyond-services/basistexte/KAD_PER_HER_PA.html,6,fachportal_roche_de_beyond_services_basistexte_KAD_PER_HER_PA_html.txt,200,html,Indexable,,14,0,2807,0,0,0.972222222222222,fachportal_roche_de_beyond_services_basistexte_KAD_PER_HER_PA_html.txt.txt,image/fachportal_roche_de_beyond_services_basistexte_KAD_PER_HER_PA_html.txt.txt.png,text/fachportal_roche_de_beyond_services_basistexte_KAD_PER_HER_PA_html.txt.txt.txt,"['Herceptin', 'Perjeta']",Oncology-Hematology,Germany,Medication information,"Herceptin, Perjeta, metastatic breast cancer, side effects",metastatic breast cancer,16.063282,-28.756683,1,"The content appears to be from Roche's professional portal, focusing on important information regarding the use of Herceptin® and Perjeta® for treating metastatic breast cancer. It details the composition, indications, and potential side effects of these medications, as well as specific recommendations for monitoring and reporting any adverse effects. The content is aimed at healthcare professionals to ensure safe usage and compliance with medical guidelines.","drug, reporting, adverse",fachportal.roche.de,Falling,0.921582741954772,medium,415,Drug Safety
24,https://fachportal.roche.de/beyond-services/basistexte/Kadcyla_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Kadcyla_PA_html.txt,200,html,Indexable,,10,0,1154,0,0,1,fachportal_roche_de_beyond_services_basistexte_Kadcyla_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Kadcyla_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Kadcyla_PA_html.txt.txt,['Kadcyla'],Oncology-Hematology,Germany,Medication information,"Kadcyla, usage guidelines, safety information, composition, indications, side effects",,16.805021,-40.446926,1,"The content displays information related to the pharmaceutical product Kadcyla, including important usage guidelines and safety information. It outlines its composition, indications for use, and potential side effects, emphasizing the need for healthcare professionals to consult specific guidelines when administering the drug. The content serves as a resource for medical professionals to ensure proper administration and monitoring of patients using the medication.","drug, reporting, adverse",fachportal.roche.de,Flat,0.176443984255096,medium,44,Drug Safety
25,https://fachportal.roche.de/beyond-services/basistexte/LC_GYN_GI_PA.html,6,fachportal_roche_de_beyond_services_basistexte_LC_GYN_GI_PA_html.txt,200,html,Indexable,,12,0,5149,0,0,1,fachportal_roche_de_beyond_services_basistexte_LC_GYN_GI_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_LC_GYN_GI_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_LC_GYN_GI_PA_html.txt.txt,"['Each', 'Alecsensa', 'Rozlytrek']",Oncology-Hematology,Germany,Medication information,"Alecsensa, Rozlytrek, active ingredients, side effects",,3.1941922,-33.293903,1,"The content contains detailed information about pharmaceutical products from Roche, specifically the medications Alecsensa and Rozlytrek. Each section outlines the active ingredients, indications for use, dosage forms, and potential side effects. It serves as a resource for healthcare professionals, providing essential data for informed decision-making regarding treatment options. Additionally, it includes instructions for reporting adverse effects and general regulatory information.","drug, reporting, adverse",fachportal.roche.de,Flat,0.61900406177966,medium,296,Drug Safety
26,https://fachportal.roche.de/beyond-services/basistexte/LC_PA.html,6,fachportal_roche_de_beyond_services_basistexte_LC_PA_html.txt,200,html,Indexable,,5,0,2002,0,0,1,fachportal_roche_de_beyond_services_basistexte_LC_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_LC_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_LC_PA_html.txt.txt,"['ALK', 'Alecensa', 'NSCLC']",Oncology-Hematology,Germany,Medication information,"Alecensa, alectinib, ALK-positive non-small cell lung cancer, NSCLC, side effects",ALK-positive non-small cell lung cancer,16.163225,-27.105587,1,"The content contains detailed information about the pharmaceutical product Alecensa® (alectinib), a medication used for the treatment of ALK-positive non-small cell lung cancer (NSCLC). It includes the composition of the capsules, indications for use, contraindications, and potential side effects. The information serves as a resource for healthcare professionals and is likely part of a broader platform aimed at providing clinical data and support regarding Roche's products.","drug, reporting, adverse",fachportal.roche.de,Falling,0.584064631671342,medium,259,Drug Safety
27,https://fachportal.roche.de/beyond-services/basistexte/Lunsumio_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Lunsumio_PA_html.txt,200,html,Indexable,,11,0,953,0,0,1,fachportal_roche_de_beyond_services_basistexte_Lunsumio_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Lunsumio_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Lunsumio_PA_html.txt.txt,"['Mosunetuzumab', 'Lunisum']",Oncology-Hematology,Germany,Medication information,"Lunisum, Mosunetuzumab, potential side effects, contraindications",,11.614829,-32.700665,1,"The content provides detailed information about the drug Lunisum® (Mosunetuzumab), including its composition, application, potential side effects, and contraindications. It emphasizes the importance of reporting any adverse reactions to Roche and provides contact information for such notifications. The content is intended for healthcare professionals, facilitating safe and informed use of the medication. Additionally, it mentions the necessity of following specific guidelines for handling the drug.","drug, reporting, adverse",fachportal.roche.de,All,0.377144563076503,medium,28,Drug Safety
28,https://fachportal.roche.de/beyond-services/basistexte/Mabthera_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Mabthera_PA_html.txt,200,html,Indexable,,11,0,734,0,0,1,fachportal_roche_de_beyond_services_basistexte_Mabthera_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Mabthera_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Mabthera_PA_html.txt.txt,[],Other,Germany,Offer outline,,,-21.06137,-19.230719,0,"The content showcases Roche's professional portal, designed for healthcare professionals. It features navigation options such as product information, clinical data, downloads, services, events, and medical inquiries. The platform aims to provide exclusive benefits and resources tailored to the needs of professionals in the pharmaceutical field.","oncology, professionals, data",fachportal.roche.de,All,0.785207282551311,medium,84,General Offer Outline
29,https://fachportal.roche.de/beyond-services/basistexte/neuro_PA.html,6,fachportal_roche_de_beyond_services_basistexte_neuro_PA_html.txt,200,html,Indexable,,8,0,1423,0,0,1,fachportal_roche_de_beyond_services_basistexte_neuro_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_neuro_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_neuro_PA_html.txt.txt,"['Evrysdi', 'Enspryng', 'June']",Other,Germany,Medication information,"Enspryng, Evrysdi, active ingredients, side effects, warnings",,12.470624,-32.12157,1,"The content of the content provides detailed information about two pharmaceutical products by Roche: Enspryng® and Evrysdi®. It includes their active ingredients, indications for use, potential side effects, and warnings. The content emphasizes the importance of reporting any side effects to the company and relevant health authorities, highlighting the products' specific applications in treating certain medical conditions. The update is sourced as of June 2021 and is intended for healthcare professionals.","drug, reporting, adverse",fachportal.roche.de,Falling,0.107320696418741,medium,430,Drug Safety
30,https://fachportal.roche.de/beyond-services/basistexte/OCR_ENS_PA.html,6,fachportal_roche_de_beyond_services_basistexte_OCR_ENS_PA_html.txt,200,html,Indexable,,10,0,1183,0,0,1,fachportal_roche_de_beyond_services_basistexte_OCR_ENS_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_OCR_ENS_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_OCR_ENS_PA_html.txt.txt,"['Ocrevus', 'Enspryng', 'Additional']",Immunology,Germany,Medication information,"Enspryng, Ocrevus, active ingredients, side effects, usage guidelines",,11.679359,-31.87807,1,"The content presents detailed information on two pharmaceutical products by Roche: Enspryng® and Ocrevus®. It outlines their active ingredients, composition, application areas, side effects, and usage guidelines. This content is intended for healthcare professionals, emphasizing the importance of monitoring side effects and providing instructions for safe use. Additional contact information is provided for reporting adverse reactions and inquiries related to the products.","drug, reporting, adverse",fachportal.roche.de,Falling,0.367702079534937,medium,493,Drug Safety
31,https://fachportal.roche.de/beyond-services/basistexte/Ocrevus_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Ocrevus_PA_html.txt,200,html,Indexable,,10,0,1000,0,0,1,fachportal_roche_de_beyond_services_basistexte_Ocrevus_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Ocrevus_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Ocrevus_PA_html.txt.txt,['Ocrevus'],Neurology,Germany,Medication information,"Ocrevus, ocrelizumab, multiple sclerosis, potential side effects, contraindications",multiple sclerosis,8.707159,-33.680546,1,"The content displays content from Roche's professional portal, specifically providing detailed information about the drug Ocrevus (ocrelizumab). It outlines its composition, indications for use (treating multiple sclerosis), potential side effects, and contraindications. The content serves as a resource for healthcare professionals, ensuring they have access to critical information regarding the medication's application and safety. Additionally, it contains links for further resources and reporting side effects.","drug, reporting, adverse",fachportal.roche.de,Rising,0.182808553009881,medium,159,Drug Safety
32,https://fachportal.roche.de/beyond-services/basistexte/PER_HER_PA.html,6,fachportal_roche_de_beyond_services_basistexte_PER_HER_PA_html.txt,200,html,Indexable,,10,0,2387,0,0,1,fachportal_roche_de_beyond_services_basistexte_PER_HER_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_PER_HER_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_PER_HER_PA_html.txt.txt,"['Fachportal', 'Herceptin', 'Pertuzumab']",Oncology-Hematology,Germany,Medication information,"Herceptin, Pertuzumab, side effects",,12.820932,-33.209785,1,"The content contains information from Roche's Fachportal, focusing on specific pharmaceutical products, particularly Herceptin® and Pertuzumab. It outlines critical details regarding their application, usage, and potential side effects, emphasizing the importance of following medical guidelines during treatment. The content serves as a resource for healthcare professionals, providing essential information to ensure safe and informed usage of these medications.","drug, reporting, adverse",fachportal.roche.de,All,0.904936829760223,medium,487,Drug Safety
33,https://fachportal.roche.de/beyond-services/basistexte/PHE_PER_HER_PA.html,6,fachportal_roche_de_beyond_services_basistexte_PHE_PER_HER_PA_html.txt,200,html,Indexable,,14,0,2982,0,0,1,fachportal_roche_de_beyond_services_basistexte_PHE_PER_HER_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_PHE_PER_HER_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_PHE_PER_HER_PA_html.txt.txt,"['Herceptin', 'Perjeta', 'Kadcyla']",Oncology-Hematology,Germany,Medication information,"Herceptin, trastuzumab, Perjeta, Kadcyla, HER2-positive metastatic breast cancer, side effects",HER2-positive metastatic breast cancer,20.317366,-29.102705,1,"The content displays important information regarding the use of Herceptin® (trastuzumab) and associated medications (Perjeta® and Kadcyla®) for the treatment of HER2-positive metastatic breast cancer. It outlines critical safety measures, particularly for women of childbearing age, and emphasizes the importance of reporting any adverse events. The content also provides details on the composition, administration, and potential side effects of these medications, serving as a resource for healthcare professionals involved in patient care and treatment decisions.","drug, reporting, adverse",fachportal.roche.de,Falling,0.283645524945122,medium,63,Drug Safety
34,https://fachportal.roche.de/beyond-services/basistexte/Phesgo_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Phesgo_PA_html.txt,200,html,Indexable,,9,0,1329,0,0,1,fachportal_roche_de_beyond_services_basistexte_Phesgo_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Phesgo_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Phesgo_PA_html.txt.txt,"['PHESGO', 'Pertuzumab', 'Trastuzumab']",Oncology-Hematology,Germany,Medication information,"PHESGO, Pertuzumab, Trastuzumab, breast cancer, adverse effects, side effects, indications",breast cancer,20.180347,-33.406,1,"The content displays information about a pharmaceutical product, PHESGO®, which is an injectable solution containing Pertuzumab and Trastuzumab. It emphasizes the importance of reporting adverse effects and provides instructions for healthcare professionals on the safe use of the medication, particularly in special populations such as pregnant women. Additionally, it outlines potential side effects and the drug's indications, reinforcing its role in treating certain types of breast cancer. The content is aimed at medical professionals, facilitating the safe and informed use of the product.","drug, reporting, adverse",fachportal.roche.de,All,0.914460897067622,medium,189,Drug Safety
35,https://fachportal.roche.de/beyond-services/basistexte/piasky_PA.html,6,fachportal_roche_de_beyond_services_basistexte_piasky_PA_html.txt,200,html,Indexable,,9,0,991,0,0,0.970149253731343,fachportal_roche_de_beyond_services_basistexte_piasky_PA_html.txt.txt,image/fachportal_roche_de_beyond_services_basistexte_piasky_PA_html.txt.txt.png,text/fachportal_roche_de_beyond_services_basistexte_piasky_PA_html.txt.txt.txt,"['Pliasky', 'Crovalimab']",Immunology,Germany,Medication information,"Pliasky, Crovalimab, paroxysmal nocturnal hemoglobinuria, side effects",paroxysmal nocturnal hemoglobinuria,20.011696,-37.307205,1,"The content displays information about the pharmaceutical product ""Pliasky®,"" an injection/infusion solution containing the active ingredient Crovalimab. It details its composition, usage indications—specifically for patients with paroxysmal nocturnal hemoglobinuria—and associated warnings, including potential side effects and specific patient considerations. Additionally, it emphasizes the importance of reporting adverse effects to Roche and provides contact information for medical inquiries. The content is aimed at healthcare professionals, facilitating safe administration and monitoring of the medication.","drug, reporting, adverse",fachportal.roche.de,Rising,0.949901135342842,medium,193,Drug Safety
36,https://fachportal.roche.de/beyond-services/basistexte/POL_MAB_PA.html,6,fachportal_roche_de_beyond_services_basistexte_POL_MAB_PA_html.txt,200,html,Indexable,,10,0,994,0,0,1,fachportal_roche_de_beyond_services_basistexte_POL_MAB_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_POL_MAB_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_POL_MAB_PA_html.txt.txt,['Polivy'],Oncology-Hematology,Germany,Medication information,"Polivy, formulation, safety monitoring, adverse effects, proper use, safety",,4.058068,-35.334488,1,"The content appears to be from a professional portal dedicated to Roche's products and clinical data. It features information about the medication Polivy®, including details on its formulation and safety monitoring. There is a focus on reporting adverse effects and ensuring proper use of the drug, highlighting the importance of safety within healthcare practices. The portal likely serves as a resource for healthcare professionals seeking specific information related to Roche's pharmaceutical offerings.","drug, reporting, adverse",fachportal.roche.de,Falling,0.637455888080827,medium,262,Drug Safety
37,https://fachportal.roche.de/beyond-services/basistexte/Polivy_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Polivy_PA_html.txt,200,html,Indexable,,9,0,994,0,0,1,fachportal_roche_de_beyond_services_basistexte_Polivy_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Polivy_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Polivy_PA_html.txt.txt,"['Polatuzumab', 'Vedotin']",Oncology-Hematology,Germany,Medication information,"Polatuzumab Vedotin, active substance, indications, potential side effects, adverse effects",,5.693079,-34.021206,1,"The content appears to be from a professional portal related to Roche's pharmaceutical products, specifically detailing the drug Polatuzumab Vedotin. It outlines the drug's active substance, indications, and potential side effects. Additionally, it mentions the importance of reporting any adverse effects and provides contact information for further inquiries. The content is geared towards healthcare professionals, emphasizing safety and regulatory compliance.","drug, reporting, adverse",fachportal.roche.de,All,0.771054833267288,medium,153,Drug Safety
38,https://fachportal.roche.de/beyond-services/basistexte/Rozlytrek_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Rozlytrek_PA_html.txt,200,html,Indexable,,12,0,1142,0,0,0.971428571428571,fachportal_roche_de_beyond_services_basistexte_Rozlytrek_PA_html.txt.txt,image/fachportal_roche_de_beyond_services_basistexte_Rozlytrek_PA_html.txt.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Rozlytrek_PA_html.txt.txt.txt,"['Rozlytrek', 'NTRK']",Oncology-Hematology,Germany,Medication information,"Rozlytrek, entrectinib, NTRK fusion-related cancers, dosage forms, potential side effects",NTRK fusion-related cancers,19.444683,-32.575336,1,"The content presents detailed information about a specific medication, Rozlytrek, including its active ingredient, entrectinib, and its dosage forms (capsules and granules). It outlines the composition, indications for use, particularly in the context of NTRK fusion-related cancers, and potential side effects. The content emphasizes the need for reporting any adverse effects and provides contact information for healthcare professionals. Overall, it serves as a professional resource for understanding the drug's applications and safety monitoring.","drug, reporting, adverse",fachportal.roche.de,Flat,0.344802942743614,medium,385,Drug Safety
39,https://fachportal.roche.de/beyond-services/basistexte/TEC_ALE_AVA_KAD_PA.html,6,fachportal_roche_de_beyond_services_basistexte_TEC_ALE_AVA_KAD_PA_html.txt,200,html,Indexable,,18,0,2493,0,0,0.973684210526316,fachportal_roche_de_beyond_services_basistexte_TEC_ALE_AVA_KAD_PA_html.txt.txt,image/fachportal_roche_de_beyond_services_basistexte_TEC_ALE_AVA_KAD_PA_html.txt.txt.png,text/fachportal_roche_de_beyond_services_basistexte_TEC_ALE_AVA_KAD_PA_html.txt.txt.txt,['Tecentriq'],Oncology-Hematology,Germany,Medication information,"Tecentriq, atezolizumab, dosage, usage instructions, indications, patient conditions, side effects",,19.372591,-39.650116,1,"The content contains detailed information about the pharmaceutical product Tecentriq (atezolizumab), including its composition, dosage, and usage instructions. It outlines specific medical indications, relevant patient conditions, and potential side effects associated with the treatment. The content appears to be tailored for healthcare professionals, providing crucial data for the administration and understanding of the drug in clinical settings.","drug, reporting, adverse",fachportal.roche.de,All,0.349769013511795,medium,456,Drug Safety
40,https://fachportal.roche.de/beyond-services/basistexte/TEC_ALE_PA.html,6,fachportal_roche_de_beyond_services_basistexte_TEC_ALE_PA_html.txt,200,html,Indexable,,10,0,1594,0,0,1,fachportal_roche_de_beyond_services_basistexte_TEC_ALE_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_TEC_ALE_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_TEC_ALE_PA_html.txt.txt,"['Tecentriq', 'Alecensa']",Oncology-Hematology,Germany,Medication information,"Alecensa, Tecentriq, active ingredients, indications for use, contraindications, potential side effects, lung cancer",lung cancer,14.501904,-26.666765,1,"The content presents detailed information on two pharmaceutical products from Roche: Alecensa and Tecentriq. It outlines their active ingredients, indications for use, contraindications, and potential side effects. The focus is on the specific applications of these drugs in treating different types of lung cancer, highlighting their therapeutic roles and relevant clinical considerations. The content is tailored for healthcare professionals, emphasizing the scientific and medical aspects of the products.","drug, reporting, adverse",fachportal.roche.de,Rising,0.617132631509869,medium,77,Drug Safety
41,https://fachportal.roche.de/beyond-services/basistexte/TEC_AVA_ALE_ROZ.html,6,fachportal_roche_de_beyond_services_basistexte_TEC_AVA_ALE_ROZ_html.txt,200,html,Indexable,,15,0,2481,0,0,0.972602739726027,fachportal_roche_de_beyond_services_basistexte_TEC_AVA_ALE_ROZ_html.txt.txt,image/fachportal_roche_de_beyond_services_basistexte_TEC_AVA_ALE_ROZ_html.txt.txt.png,text/fachportal_roche_de_beyond_services_basistexte_TEC_AVA_ALE_ROZ_html.txt.txt.txt,"['Avastin', 'Alecensa']",Oncology-Hematology,Germany,Medication information,"Alecensa, Avastin, active ingredients, side effects, cancer",,13.620276,-28.480196,1,"The content presents information from Roche's professional portal, detailing two pharmaceutical products: Alecensa and Avastin. It includes their active ingredients, indications for use, contraindications, potential side effects, and specific treatment applications, particularly for various types of cancer. The content is aimed at healthcare professionals, providing essential data for informed medical decision-making related to these therapies.","drug, reporting, adverse",fachportal.roche.de,Flat,0.410481565005442,medium,320,Drug Safety
42,https://fachportal.roche.de/beyond-services/basistexte/TEC_AVA_PA.html,6,fachportal_roche_de_beyond_services_basistexte_TEC_AVA_PA_html.txt,200,html,Indexable,,10,0,1876,0,0,1,fachportal_roche_de_beyond_services_basistexte_TEC_AVA_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_TEC_AVA_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_TEC_AVA_PA_html.txt.txt,"['Avastin', 'Bevacizumab']",Oncology-Hematology,Germany,Medication information,"Avastin, Bevacizumab, chemotherapy, metastatic breast cancer, colorectal cancer, side effects, contraindications","metastatic breast cancer, metastatic colorectal cancer",20.147108,-27.63653,1,"The content appears to provide detailed information about a pharmaceutical product named Avastin, which contains the active substance Bevacizumab. It outlines the product's uses in combination with chemotherapy for various types of cancer, including metastatic breast and colorectal cancers. Additionally, the content lists potential side effects and contraindications associated with the treatment. Overall, the content is targeted at healthcare professionals, offering clinical data and guidelines relevant to the use of this medication.","drug, reporting, adverse",fachportal.roche.de,Falling,0.586884710581495,medium,360,Drug Safety
43,https://fachportal.roche.de/beyond-services/basistexte/TEC_KAD_PA.html,6,fachportal_roche_de_beyond_services_basistexte_TEC_KAD_PA_html.txt,200,html,Indexable,,10,0,1817,0,0,1,fachportal_roche_de_beyond_services_basistexte_TEC_KAD_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_TEC_KAD_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_TEC_KAD_PA_html.txt.txt,['Tecentriq'],Oncology-Hematology,Germany,Medication information,"Tecentriq, atezolizumab, cancer, dosage, adverse reactions, contraindications, cancer treatment protocols",,21.323523,-27.9825,1,"The content appears to focus on a specific pharmaceutical product, Tecentriq (atezolizumab), detailing its formulation, usage, and indications for various types of cancer. It outlines specific dosage information and patient conditions for which the drug is indicated, as well as potential adverse reactions and contraindications. The content serves as a professional reference for healthcare providers regarding the administration and clinical data associated with Tecentriq, emphasizing its role in cancer treatment protocols.","drug, reporting, adverse",fachportal.roche.de,All,0.130817025611275,medium,228,Drug Safety
44,https://fachportal.roche.de/beyond-services/basistexte/TEC_KAD_PHE_PA.html,6,fachportal_roche_de_beyond_services_basistexte_TEC_KAD_PHE_PA_html.txt,200,html,Indexable,,14,0,2412,0,0,1,fachportal_roche_de_beyond_services_basistexte_TEC_KAD_PHE_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_TEC_KAD_PHE_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_TEC_KAD_PHE_PA_html.txt.txt,"['Tecentriq', 'Atezolizumab']",Oncology-Hematology,Germany,Medication information,"Tecentriq, Atezolizumab, dosing information, indications, administration, side effects, contraindications",,19.246565,-39.634605,1,"The content provides detailed information about a pharmaceutical product, Tecentriq, which contains Atezolizumab. It includes dosing information, indications for use, and guidance on administration alongside other treatments. It also outlines possible side effects and contraindications, catering to medical professionals. The content is designed to aid healthcare providers in understanding the product's application and safety profile in various clinical scenarios.","drug, reporting, adverse",fachportal.roche.de,Falling,0.0019842468950541,medium,479,Drug Safety
45,https://fachportal.roche.de/beyond-services/basistexte/TEC_PHE_PER_HER_PA.html,6,fachportal_roche_de_beyond_services_basistexte_TEC_PHE_PER_HER_PA_html.txt,200,html,Indexable,,18,0,2984,0,0,1,fachportal_roche_de_beyond_services_basistexte_TEC_PHE_PER_HER_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_TEC_PHE_PER_HER_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_TEC_PHE_PER_HER_PA_html.txt.txt,"['Tecentriq', 'NSCLC', 'TNBC']",Oncology-Hematology,Germany,Medication information,"Tecentriq, active ingredients, dosage forms, therapeutic indications, non-small cell lung cancer, NSCLC, triple-negative breast cancer, TNBC, side effects, precautions","non-small cell lung cancer, triple-negative breast cancer",21.315441,-27.205147,1,"The content provides detailed information about the pharmaceutical product Tecentriq, including its active ingredients, dosage forms, and therapeutic indications. It outlines specific conditions and combinations for its use, such as in combination with other treatments for various cancers like non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Additionally, it mentions possible side effects and necessary precautions, emphasizing its use in a clinical context for healthcare professionals.","drug, reporting, adverse",fachportal.roche.de,Flat,0.337349845672715,medium,420,Drug Safety
46,https://fachportal.roche.de/beyond-services/basistexte/Tecentriq_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Tecentriq_PA_html.txt,200,html,Indexable,,12,0,1397,0,0,1,fachportal_roche_de_beyond_services_basistexte_Tecentriq_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Tecentriq_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Tecentriq_PA_html.txt.txt,['Tecentriq'],Oncology-Hematology,Germany,Medication information,"Tecentriq, dosing instructions, side effects, patient conditions",,17.14019,-41.01624,1,"The content in the content pertains to a specific pharmaceutical product, Tecentriq, providing detailed information about its formulation, indications, and usage guidelines. It includes dosing instructions, side effects, and relevant patient conditions for which the drug is indicated. The content is intended for healthcare professionals, ensuring they have the necessary details for prescribing and managing treatment with Tecentriq.","drug, reporting, adverse",fachportal.roche.de,All,0.63181912046202,medium,147,Drug Safety
47,https://fachportal.roche.de/beyond-services/basistexte/Vabysmo_PA.html,6,fachportal_roche_de_beyond_services_basistexte_Vabysmo_PA_html.txt,200,html,Indexable,,10,0,999,0,0,1,fachportal_roche_de_beyond_services_basistexte_Vabysmo_PA_html.txt,image/fachportal_roche_de_beyond_services_basistexte_Vabysmo_PA_html.txt.png,text/fachportal_roche_de_beyond_services_basistexte_Vabysmo_PA_html.txt.txt,['Vabysmo'],Ophthalmology,Germany,Medication information,"Vabysmo, active ingredient, indications, dosage information, side effects",,15.7244625,-36.389534,1,"The content presents detailed information about a pharmaceutical product, Vabysmo® (120 mg/ml injection solution), including its active ingredient, indications, dosage information, and potential side effects. It emphasizes the importance of monitoring for adverse reactions and encourages healthcare professionals to report any side effects to Roche. The content serves as a resource for medical professionals, facilitating understanding of the product's clinical applications and safety protocols.","drug, reporting, adverse",fachportal.roche.de,Flat,0.0771324158897828,medium,480,Drug Safety
48,https://fachportal.roche.de/beyond-services/dbc/.html,1,fachportal_roche_de_beyond_services_dbc__html.txt,200,html,Non-Indexable,,0,0,1613,2,2,1,fachportal_roche_de_beyond_services_dbc__html.txt,image/fachportal_roche_de_beyond_services_dbc__html.txt.png,text/fachportal_roche_de_beyond_services_dbc__html.txt.txt,[],Other,Germany,Technology,,,-6.277356,-18.47915,3,"The content appears to consist of technical and coding elements likely related to the infrastructure of Roche's online platform for healthcare professionals. It includes metadata, scripts, and various user interface components geared toward facilitating access and providing information about Roche's products and services. The focus seems to be on providing a tailored experience for users, emphasizing features like user login, resource access, and event management. Overall, the purpose is to create an efficient and secure online environment for healthcare professionals to explore Roche's offerings.","users, page, website",fachportal.roche.de,Rising,0.576462309191712,low,330,Website Metadata
49,https://fachportal.roche.de/beyond-services/dbc.html,1,fachportal_roche_de_beyond_services_dbc_html.txt,200,html,Non-Indexable,,3,0,734,0,0,1,fachportal_roche_de_beyond_services_dbc_html.txt,image/fachportal_roche_de_beyond_services_dbc_html.txt.png,text/fachportal_roche_de_beyond_services_dbc_html.txt.txt,"['Notably', 'Pharmaceuticals']",Other,Germany,Offer outline,,,-22.8023,-18.626354,0,"The content displays a professional portal from Roche Pharmaceuticals, designed for healthcare providers. It includes sections for various topics such as product information, clinical data, downloads, and medical inquiries. Notably, there are links for patient resources and instructions on reporting side effects related to Roche products, emphasizing safety and communication for healthcare professionals. The portal aims to facilitate access to important information and services related to Roche's offerings.","oncology, professionals, data",fachportal.roche.de,Falling,0.796160937771895,low,19,General Offer Outline
50,https://fachportal.roche.de/beyond-services/dbc/virtuelle-visitenkarte.html,6,fachportal_roche_de_beyond_services_dbc_virtuelle_visitenkarte_html.txt,200,html,Indexable,,22,0,734,0,0,1,fachportal_roche_de_beyond_services_dbc_virtuelle_visitenkarte_html.txt,image/fachportal_roche_de_beyond_services_dbc_virtuelle_visitenkarte_html.txt.png,text/fachportal_roche_de_beyond_services_dbc_virtuelle_visitenkarte_html.txt.txt,"['Fachportal', 'Medical', 'Science']",Other,Germany,Offer outline,,,-24.089401,-21.158266,0,"The content displays an interface for Roche's Fachportal, a specialized resource for healthcare professionals. It includes links to different sections like product overviews, clinical data, services, and events. Additionally, there are useful links to Roche's Medical Science, pipeline information, and specific patient resources. There is also a section addressing the reporting of side effects related to Roche products, providing contact information for these reports. The overall purpose is to facilitate access to essential information and services for healthcare providers.","oncology, professionals, data",fachportal.roche.de,Flat,0.0510269429027695,medium,328,General Offer Outline
51,https://fachportal.roche.de/beyond-services/dbc/virtuelle-visitenkarte-open.html,6,fachportal_roche_de_beyond_services_dbc_virtuelle_visitenkarte_open_html.txt,200,html,Indexable,,22,0,734,0,0,1,fachportal_roche_de_beyond_services_dbc_virtuelle_visitenkarte_open_html.txt,image/fachportal_roche_de_beyond_services_dbc_virtuelle_visitenkarte_open_html.txt.png,text/fachportal_roche_de_beyond_services_dbc_virtuelle_visitenkarte_open_html.txt.txt,[],Other,Germany,Offer outline,,,-23.431173,-18.872183,0,"The content displays an interface from Roche's portal for healthcare professionals. It offers various sections, including product overviews, clinical data, and additional relevant resources. There are links for professionals and references for patient guidance on specific conditions. The portal also includes contact information for reporting side effects related to Roche products, emphasizing the company's commitment to safety and communication with medical professionals.","oncology, professionals, data",fachportal.roche.de,Rising,0.984821008367486,medium,148,General Offer Outline
52,https://fachportal.roche.de/beyond-services/landingpages/neuroscience/sma.html,1,fachportal_roche_de_beyond_services_landingpages_neuroscience_sma_html.txt,200,html,Indexable,,3,0,734,0,0,1,fachportal_roche_de_beyond_services_landingpages_neuroscience_sma_html.txt,image/fachportal_roche_de_beyond_services_landingpages_neuroscience_sma_html.txt.png,text/fachportal_roche_de_beyond_services_landingpages_neuroscience_sma_html.txt.txt,[],Other,Germany,Offer outline,,,-23.710106,-18.489788,0,"The content displays the homepage of Roche's specialized portal for healthcare professionals. It includes sections for products, clinical data, downloads, and services, along with links for patient information and reporting adverse effects related to Roche products. The portal is designed to provide exclusive benefits and resources relevant to medical professionals and patients. Additionally, contact information for reporting side effects is clearly presented.","oncology, professionals, data",fachportal.roche.de,All,0.705271673934403,low,100,General Offer Outline
53,https://fachportal.roche.de/beyond-services/landingpages/ophthalmologie/vabysmo-ziemssen-holz.html?namespace=s7classic,6,fachportal_roche_de_beyond_services_landingpages_ophthalmologie_vabysmo_ziemssen_holz_html_namespace_s7classic.txt,200,html,Non-Indexable,,21,0,815,0,0,0.982758620689655,fachportal_roche_de_beyond_services_landingpages_ophthalmologie_vabysmo_ziemssen_holz_html_namespace_s7classic.txt.txt,image/fachportal_roche_de_beyond_services_landingpages_ophthalmologie_vabysmo_ziemssen_holz_html_namespace_s7classic.txt.txt.png,text/fachportal_roche_de_beyond_services_landingpages_ophthalmologie_vabysmo_ziemssen_holz_html_namespace_s7classic.txt.txt.txt,['Vabysmo'],Ophthalmology,Germany,Medication information,"Vabysmo, expert opinion, analysis",,17.590267,-37.385395,1,"The content features information about the pharmaceutical product Vabysmo® and highlights a discussion where experts review its impact after one year of practical use. It includes the names of two professionals, suggesting that their insights or findings will be shared. The focus is on gathering expert opinion and analysis, likely aimed at healthcare professionals interested in the product’s application and effectiveness.","drug, reporting, adverse",fachportal.roche.de,Flat,0.102329864030732,medium,418,Drug Safety
54,https://fachportal.roche.de/beyond-services/landingpages/ophthalmologie/vabysmo-ziemssen-holz.html,6,fachportal_roche_de_beyond_services_landingpages_ophthalmologie_vabysmo_ziemssen_holz_html.txt,200,html,Non-Indexable,,21,0,815,0,0,1,fachportal_roche_de_beyond_services_landingpages_ophthalmologie_vabysmo_ziemssen_holz_html.txt,image/fachportal_roche_de_beyond_services_landingpages_ophthalmologie_vabysmo_ziemssen_holz_html.txt.png,text/fachportal_roche_de_beyond_services_landingpages_ophthalmologie_vabysmo_ziemssen_holz_html.txt.txt,['Vabysmo'],Ophthalmology,Germany,Medication information,"Vabysmo, clinical outcomes, professional insights",,8.572736,-37.387897,1,"The content features a section from Roche's professional website discussing the practical use of the pharmaceutical product Vabysmo. It highlights an assessment by experts after one year of usage, indicating a focus on clinical outcomes and professional insights. Additionally, it mentions two doctors involved in this evaluation, suggesting a collaborative approach to understanding the product's impact in a clinical setting.","drug, reporting, adverse",fachportal.roche.de,Flat,0.300525625527423,medium,249,Drug Safety
55,https://fachportal.roche.de/beyond-services/pairs/.html,1,fachportal_roche_de_beyond_services_pairs__html.txt,200,html,Non-Indexable,,0,0,2375,3,3,0.962264150943396,fachportal_roche_de_beyond_services_pairs__html.txt.txt,image/fachportal_roche_de_beyond_services_pairs__html.txt.txt.png,text/fachportal_roche_de_beyond_services_pairs__html.txt.txt.txt,[],Other,Germany,Technology,,,-3.3507671,-19.441502,3,"The content appears to be a collection of technical and metadata elements for a web page related to Roche's professional portal, focusing on their products and services. It includes coding scripts, style definitions, and user interface elements intended to enhance user experience for healthcare professionals, facilitating navigation and access to Roche's resources and tools. The purpose seems to be to provide a structured layout for content, manage user interactions, and comply with privacy regulations while engaging users on the platform.","users, page, website",fachportal.roche.de,All,0.676309111420964,low,133,Website Metadata
56,https://fachportal.roche.de/beyond-services/pairs.html,6,fachportal_roche_de_beyond_services_pairs_html.txt,200,html,Non-Indexable,,11,0,900,5,4,1,fachportal_roche_de_beyond_services_pairs_html.txt,image/fachportal_roche_de_beyond_services_pairs_html.txt.png,text/fachportal_roche_de_beyond_services_pairs_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-34.5087,-11.071751,0,"The content outlines the various sections of Roche's professional portal, detailing areas of focus such as neuroscience, oncology, and hemophilia, along with comprehensive product information and clinical data. It serves as a resource for healthcare professionals by providing access to educational materials, services, and programs related to patient access and compassionate use. Additionally, it includes contacts for medical inquiries and information on reporting side effects related to Roche products, reinforcing the company's commitment to transparency and support within the healthcare community.","oncology, professionals, data",fachportal.roche.de,All,0.109498053824719,medium,103,General Offer Outline
57,https://fachportal.roche.de/beyond-services/pairs/pairs-rechtliche-hinweise.html,6,fachportal_roche_de_beyond_services_pairs_pairs_rechtliche_hinweise_html.txt,200,html,Indexable,,27,0,1162,7,5,1,fachportal_roche_de_beyond_services_pairs_pairs_rechtliche_hinweise_html.txt,image/fachportal_roche_de_beyond_services_pairs_pairs_rechtliche_hinweise_html.txt.png,text/fachportal_roche_de_beyond_services_pairs_pairs_rechtliche_hinweise_html.txt.txt,[],Other,Germany,Offer outline,,,-32.76191,-14.350123,0,"The content is an overview of Roche's specialized fields, products, and services aimed at healthcare professionals. It includes sections on various therapeutic areas such as neuroscience, oncology, and rheumatology, as well as access to clinical data, downloadable resources, and additional information services. The content also outlines legal disclaimers regarding the accuracy and use of the provided information, and details about liability limitations, while emphasizing that the content is informative and not an offer for securities. Overall, the purpose of this content is to provide healthcare professionals with information about Roche's offerings and a framework for navigating their resources.","oncology, professionals, data",fachportal.roche.de,Falling,0.248969650827425,medium,170,General Offer Outline
58,https://fachportal.roche.de/beyond-services/rechtliche-informationen/internal-exclusion.html,6,fachportal_roche_de_beyond_services_rechtliche_informationen_internal_exclusion_html.txt,200,html,Indexable,,18,0,767,0,0,0.977777777777778,fachportal_roche_de_beyond_services_rechtliche_informationen_internal_exclusion_html.txt.txt,image/fachportal_roche_de_beyond_services_rechtliche_informationen_internal_exclusion_html.txt.txt.png,text/fachportal_roche_de_beyond_services_rechtliche_informationen_internal_exclusion_html.txt.txt.txt,[],Other,Germany,Metainformation,,,-0.05519773,-21.305424,3,"The content displays a thank-you message from Roche's specialized portal, indicating that the user has successfully made themselves ""invisible"" or ""internal"" within the portal. It advises users that this status is marked in their local browser storage and notes the temporary nature of this marking, suggesting they repeat the process regularly to maintain it. The content emphasizes user privacy and functionality within the portal.","users, page, website",fachportal.roche.de,Flat,0.415138242760171,medium,410,Website Metadata
59,https://fachportal.roche.de/beyond-services/schulungsmaterial/.html,9,fachportal_roche_de_beyond_services_schulungsmaterial__html.txt,200,html,Non-Indexable,3,34,34,818,13,13,0.969230769230769,fachportal_roche_de_beyond_services_schulungsmaterial__html.txt.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial__html.txt.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial__html.txt.txt.txt,"['CSS', 'Its']",Other,Germany,Technology,,,-2.6999357,-18.710129,3,"The content appears to be a technical backend content for a website serving healthcare professionals, specifically focusing on Roche's pharmacovigilance training materials. The content includes metadata, JavaScript, and CSS code elements indicative of a web page setup rather than user-facing content. Its purpose seems to provide a structured environment for accessing and managing training resources related to drug safety and monitoring, highlighting registration options and user interaction components on the site. The style guides and technical scripts facilitate enhanced user experience and content accessibility for registered professionals.","users, page, website",fachportal.roche.de,All,0.362375737540864,high,482,Website Metadata
60,https://fachportal.roche.de/beyond-services/schulungsmaterial.html,10,fachportal_roche_de_beyond_services_schulungsmaterial_html.txt,200,html,Non-Indexable,2,34,34,842,18,18,0.96875,fachportal_roche_de_beyond_services_schulungsmaterial_html.txt.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial_html.txt.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial_html.txt.txt.txt,['Its'],Other,Germany,Patient support,,,5.3738737,-37.158215,1,"The content presents a section from Roche's professional portal, focusing on pharmacovigilance training materials. It allows users to download and order training materials, with filtering options for products, indications, and user categories. The page also includes links to related resources, as well as contact information for reporting adverse drug reactions. Its primary purpose is to provide healthcare professionals with resources and support related to drug safety and monitoring.","drug, reporting, adverse",fachportal.roche.de,All,0.800100899651257,high,263,Drug Safety
61,https://fachportal.roche.de/beyond-services/schulungsmaterial/pv-material-columvi.html,10,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_columvi_html.txt,200,html,Non-Indexable,2,34,34,845,1,1,0.976190476190476,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_columvi_html.txt.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_columvi_html.txt.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_columvi_html.txt.txt.txt,"['Information', 'Columvi', 'Medical']",Other,Germany,Medication information,"Columvi, pharmacovigilance, adverse effects, training resources",,5.243425,-37.652042,1,"The content displays a section of Roche's professional portal focused on pharmacovigilance training materials. It allows users to download and order training resources specifically related to the product ""Columvi."" Additionally, it contains information for reporting adverse effects and provides contact details for Roche's Medical Information team. Overall, the content serves to support healthcare professionals in understanding the safety and monitoring of medications.","drug, reporting, adverse",fachportal.roche.de,Falling,0.0364509700017464,high,67,Drug Safety
62,https://fachportal.roche.de/beyond-services/schulungsmaterial/pv-material-enspryng.html,10,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_enspryng_html.txt,200,html,Non-Indexable,2,34,34,845,1,1,1,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_enspryng_html.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_enspryng_html.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_enspryng_html.txt.txt,['Enspray'],Other,Germany,Patient support,"Enspray, adverse drug reactions, drug safety",,4.7487025,-37.54062,1,"The content features a section of Roche's professional portal dedicated to pharmacovigilance training materials. It allows users to download and order training resources related to the product ""Enspray"" across various indications. Additionally, it provides contact information for reporting adverse drug reactions and accessing the medical information team, along with links to legal information and privacy policies. The overall purpose is to support healthcare professionals in understanding and managing drug safety.","drug, reporting, adverse",fachportal.roche.de,Flat,0.904645127036642,high,433,Drug Safety
63,https://fachportal.roche.de/beyond-services/schulungsmaterial/pv-material-erivedge.html,10,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_erivedge_html.txt,200,html,Non-Indexable,2,34,34,845,1,1,0.976470588235294,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_erivedge_html.txt.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_erivedge_html.txt.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_erivedge_html.txt.txt.txt,['Erivedge'],Other,Germany,Medication information,"Erivedge, drug safety, pharmacovigilance",,6.9940786,-38.611755,1,"The content presents a section from Roche's professional portal focused on pharmacovigilance training materials. It allows users to download and order educational resources related to the monitoring of drug safety, specifically highlighting a product named Erivedge. The page also includes options to filter related materials and contact information for reporting adverse effects. Overall, it serves as a centralized resource for healthcare professionals seeking training on drug safety practices.","drug, reporting, adverse",fachportal.roche.de,Rising,0.0184963770152209,high,69,Drug Safety
64,https://fachportal.roche.de/beyond-services/schulungsmaterial/pv-material-esbriet.html,10,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_esbriet_html.txt,200,html,Non-Indexable,2,34,34,845,1,1,1,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_esbriet_html.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_esbriet_html.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_esbriet_html.txt.txt,"['Information', 'Esbriet', 'Medical', 'Team']",Other,Germany,Medication information,"Esbriet, pharmacovigilance, adverse effects, medication safety",,6.2477193,-37.703968,1,"The content displays a section of Roche's professional portal focused on pharmacovigilance training materials. It includes options to download or order these materials, specifically related to the product Esbriet across all indications. Additionally, there are links to related resources, contact information for reporting adverse effects, and service hours for the Medical Information Team. This content aims to support healthcare professionals in accessing essential training resources and guidance related to medication safety.","drug, reporting, adverse",fachportal.roche.de,Falling,0.10012552585423,high,50,Drug Safety
65,https://fachportal.roche.de/beyond-services/schulungsmaterial/pv-material-hemlibra.html,10,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_hemlibra_html.txt,200,html,Non-Indexable,2,34,34,845,1,1,1,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_hemlibra_html.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_hemlibra_html.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_hemlibra_html.txt.txt,"['Hemlibra', 'Emicizumab', 'Users']",Other,Germany,Medication information,"Hemlibra, Emicizumab, pharmacovigilance, adverse reactions",,8.129866,-35.813866,1,"The content appears to showcase a section of Roche's professional portal dedicated to pharmacovigilance training materials. Users can download and order educational resources related to the drug Hemlibra (Emicizumab). It includes options for filtering the materials by product, indication, and user group. Additionally, there are links for further information, including contact details for reporting adverse reactions and accessing medical information support.","drug, reporting, adverse",fachportal.roche.de,Falling,0.127657107523083,high,103,Drug Safety
66,https://fachportal.roche.de/beyond-services/schulungsmaterial/pv-material-kadcyla.html,10,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_kadcyla_html.txt,200,html,Non-Indexable,2,34,34,845,1,1,1,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_kadcyla_html.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_kadcyla_html.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_kadcyla_html.txt.txt,['Kadcyla'],Other,Germany,Medication information,"Kadcyla, risks, adverse effects, educational resources",,5.9938374,-36.204357,1,"The content of the content focuses on pharmacovigilance training materials offered by Roche. It allows professionals to download and order educational resources related to their product, Kadcyla, specifically concerning risks associated with it. Additionally, the page provides links for more information, including contact details for reporting adverse effects and accessing medical information support.","drug, reporting, adverse",fachportal.roche.de,All,0.308357968034825,high,493,Drug Safety
67,https://fachportal.roche.de/beyond-services/schulungsmaterial/pv-material-lunsumio.html,10,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_lunsumio_html.txt,200,html,Non-Indexable,2,34,34,845,1,1,1,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_lunsumio_html.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_lunsumio_html.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_lunsumio_html.txt.txt,['Lunsumio'],Other,Germany,Medication information,"Lunsumio, pharmacovigilance, adverse events, drug safety, monitoring",,6.6178937,-37.81866,1,"The content highlights a section of Roche's professional portal focused on pharmacovigilance training materials. It allows users to download and order relevant resources, specifically mentioning the product ""Lunsumio."" The page also provides links to various resources, including contact information for reporting adverse events. The overall purpose is to support healthcare professionals with educational materials on drug safety and monitoring.","drug, reporting, adverse",fachportal.roche.de,Falling,0.905691086016633,high,294,Drug Safety
68,https://fachportal.roche.de/beyond-services/schulungsmaterial/pv-material-mabthera.html,10,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_mabthera_html.txt,200,html,Non-Indexable,2,34,34,845,1,1,1,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_mabthera_html.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_mabthera_html.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_mabthera_html.txt.txt,"['Mabthera', 'Users']",Other,Germany,Offer outline,"Mabthera, pharmacovigilance, adverse effects",,5.6211925,-38.44018,1,"The content shows a section of Roche's professional portal, specifically related to pharmacovigilance training materials. Users can download and order training resources pertaining to the product ""Mabthera,"" applicable across various indications. The page also includes options for filtering selections and offers links to pertinent information, such as FAQs and contact details for reporting adverse effects. Overall, it serves to facilitate access to important educational materials for healthcare professionals.","drug, reporting, adverse",fachportal.roche.de,Flat,0.185733028207824,high,350,Drug Safety
69,https://fachportal.roche.de/beyond-services/schulungsmaterial/pv-material-piasky.html,10,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_piasky_html.txt,200,html,Non-Indexable,2,34,34,845,1,1,1,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_piasky_html.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_piasky_html.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_piasky_html.txt.txt,"['Plasky', 'Training', 'Materials', 'Pharmacovigilance']",Other,Germany,Offer outline,"Plasky, pharmacovigilance, adverse effects",,8.012831,-37.26277,1,"The content presents the ""Pharmacovigilance Training Materials"" section on Roche's professional portal. It allows users to download and order training materials related to pharmacovigilance, specifically for the product ""Plasky."" The page also offers a user interface for filtering search results and includes links to additional resources, as well as contact information for reporting adverse effects and reaching the medical information team.","drug, reporting, adverse",fachportal.roche.de,Rising,0.389336890326617,high,498,Drug Safety
70,https://fachportal.roche.de/beyond-services/schulungsmaterial/pv-material-roactemra.html,10,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_roactemra_html.txt,200,html,Non-Indexable,2,34,34,845,1,1,1,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_roactemra_html.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_roactemra_html.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_roactemra_html.txt.txt,['Additional'],Other,Germany,Offer outline,"RoActemra, pharmacovigilance, side effects, educational resources, indications, data privacy policies",,6.6327615,-37.0412,1,"The content presents a section of Roche's professional portal dedicated to pharmacovigilance training materials. It allows users to download and order educational resources related to the drug RoActemra, covering various indications. The page features filters for selecting relevant materials and includes contact information for reporting side effects and accessing medical support. Additional links provide access to legal information and data privacy policies.","drug, reporting, adverse",fachportal.roche.de,Flat,0.281298708666836,high,202,Drug Safety
71,https://fachportal.roche.de/beyond-services/schulungsmaterial/pv-material-tecentriq.html,10,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_tecentriq_html.txt,200,html,Non-Indexable,2,34,34,845,1,1,1,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_tecentriq_html.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_tecentriq_html.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_tecentriq_html.txt.txt,['Tecentriq'],Oncology-Hematology,Germany,Medication information,"Tecentriq, pharmacovigilance, adverse drug reactions",,4.9714627,-38.728886,1,"The content of the content focuses on training materials related to pharmacovigilance for Roche's product, Tecentriq. It offers users the option to download and order relevant educational resources. Additionally, there is a section for reporting adverse drug reactions, including contact details for Roche's medical information team, which highlights the site's emphasis on safety and compliance.","drug, reporting, adverse",fachportal.roche.de,All,0.729246129180954,high,20,Drug Safety
72,https://fachportal.roche.de/beyond-services/schulungsmaterial/pv-material-vabysmo.html,10,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_vabysmo_html.txt,200,html,Non-Indexable,2,34,34,845,1,1,1,fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_vabysmo_html.txt,image/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_vabysmo_html.txt.png,text/fachportal_roche_de_beyond_services_schulungsmaterial_pv_material_vabysmo_html.txt.txt,['Vabysmo'],Other,Germany,Medication information,"Vabysmo, pharmacovigilance, side effects",,5.6421814,-37.94295,1,"The content features a section of Roche's professional portal dedicated to pharmacovigilance training materials. It allows users to download and order educational resources related to the medication Vabysmo. The page includes filtering options for product and indication categories, and it also provides contact information for reporting side effects and inquiries. The purpose of the portal is to support healthcare professionals with relevant information and resources.","drug, reporting, adverse",fachportal.roche.de,Rising,0.643573366581497,high,126,Drug Safety
73,https://fachportal.roche.de/beyond-services/whatsapp_service.html?cid=ned-SI-20240129-none-HAE-so-10011036,9,fachportal_roche_de_beyond_services_whatsapp_service_html_cid_ned_SI_20240129_none_HAE_so_10011036.txt,200,html,Non-Indexable,3,16,197,1253,9,2,0.980769230769231,fachportal_roche_de_beyond_services_whatsapp_service_html_cid_ned_SI_20240129_none_HAE_so_10011036.txt.txt,image/fachportal_roche_de_beyond_services_whatsapp_service_html_cid_ned_SI_20240129_none_HAE_so_10011036.txt.txt.png,text/fachportal_roche_de_beyond_services_whatsapp_service_html_cid_ned_SI_20240129_none_HAE_so_10011036.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-37.324417,-9.582094,0,"The content focuses on the various therapeutic areas and products offered by Roche, emphasizing their commitment to neuroscience, oncology, and precision medicine, among others. It serves as a professional portal, providing access to clinical data, downloadable resources, and updates on products and services relevant to healthcare professionals. Additionally, it offers features like a WhatsApp service for real-time news and newsletters, ensuring that users stay informed about the latest developments in their fields of interest. The overall purpose is to facilitate information sharing and enhance professional engagement with Roche's innovative solutions.","oncology, professionals, data",fachportal.roche.de,Flat,0.0598723945930494,high,267,General Offer Outline
74,https://fachportal.roche.de/beyond-services/whatsapp_service.html,10,fachportal_roche_de_beyond_services_whatsapp_service_html.txt,200,html,Indexable,1,16,197,1253,16,5,0.968253968253968,fachportal_roche_de_beyond_services_whatsapp_service_html.txt.txt,image/fachportal_roche_de_beyond_services_whatsapp_service_html.txt.txt.png,text/fachportal_roche_de_beyond_services_whatsapp_service_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-29.584108,9.212007,0,"The content provides a structured overview of Roche's areas of expertise and product offerings, encompassing various therapeutic fields such as oncology, hematology, neuroscience, and ophthalmology. It serves as a resource for healthcare professionals by detailing available products, clinical data, and downloadable materials. Additionally, it features services like a WhatsApp news subscription and newsletters to keep professionals informed about updates in their specific areas of interest. Overall, the content aims to facilitate access to Roche’s information and enhance communication within the medical community.","oncology, professionals, data",fachportal.roche.de,Falling,0.207173816207039,high,80,General Offer Outline
75,https://fachportal.roche.de/external-redirects.html,6,fachportal_roche_de_external_redirects_html.txt,200,html,Indexable,,18,0,734,0,0,0.959183673469388,fachportal_roche_de_external_redirects_html.txt.txt,image/fachportal_roche_de_external_redirects_html.txt.txt.png,text/fachportal_roche_de_external_redirects_html.txt.txt.txt,"['Fachportal', 'Medical', 'Science']",Other,Germany,Other,,,-26.442802,-20.048264,0,"The content displays the Roche Fachportal, a professional resource designed for healthcare providers. It includes navigation options for various topics, such as products and clinical data. Additionally, there are useful links related to Roche Medical Science and their pipeline, along with sections dedicated to patient support and reporting adverse drug reactions. The purpose of the platform is to provide essential information and services tailored for professionals in the pharmaceutical field.","oncology, professionals, data",fachportal.roche.de,All,0.185020750023043,medium,493,General Offer Outline
76,https://fachportal.roche.de/fachgebiete/dermatoonkologie_dermatologie/dermatoonkologie.html,10,fachportal_roche_de_fachgebiete_dermatoonkologie_dermatologie_dermatoonkologie_html.txt,200,html,Indexable,1,16,71,3162,6,6,1,fachportal_roche_de_fachgebiete_dermatoonkologie_dermatologie_dermatoonkologie_html.txt,image/fachportal_roche_de_fachgebiete_dermatoonkologie_dermatologie_dermatoonkologie_html.txt.png,text/fachportal_roche_de_fachgebiete_dermatoonkologie_dermatologie_dermatoonkologie_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,"melanoma, pemphigus vulgaris","melanoma, pemphigus vulgaris",-32.103577,7.502862,0,"The content consists of sections related to Roche's specialized areas, product offerings, clinical data, and various services aimed at healthcare professionals. It outlines different therapeutic fields, such as oncology, neurology, and dermatology, while highlighting specific diseases and associated Roche products, including detailed information on conditions like melanoma and pemphigus vulgaris. The purpose is to provide healthcare professionals with resources, product information, clinical data, and avenues for reporting adverse effects, enhancing their ability to treat patients effectively using Roche's pharmaceutical solutions.","oncology, professionals, data",fachportal.roche.de,Falling,0.345615346231339,high,355,General Offer Outline
77,https://fachportal.roche.de/fachgebiete/gastrointestinale_onkologie.html,7,fachportal_roche_de_fachgebiete_gastrointestinale_onkologie_html.txt,200,html,Indexable,1,27,0,2684,13,10,0.971428571428571,fachportal_roche_de_fachgebiete_gastrointestinale_onkologie_html.txt.txt,image/fachportal_roche_de_fachgebiete_gastrointestinale_onkologie_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_gastrointestinale_onkologie_html.txt.txt.txt,['HCC'],Oncology-Hematology,Germany,Offer outline,"hepatocellular carcinoma, oncology, neurology, hematology, early diagnosis, treatment options",hepatocellular carcinoma,-14.974102,1.7761365,0,"The content serves as an overview of Roche's specialized areas in pharmaceuticals, focusing on various medical fields such as oncology, neurology, and hematology. It highlights Roche's products, clinical data, and services, promoting their innovative solutions for early diagnosis and treatment, particularly in hepatocellular carcinoma (HCC). Additionally, it emphasizes the importance of interdisciplinary collaboration in improving cancer care and includes resources such as podcasts and articles aimed at healthcare professionals. The overall purpose is to provide detailed information about Roche's offerings and advancements in patient care and treatment options.","oncology, professionals, data",fachportal.roche.de,Falling,0.393523131494097,high,85,General Offer Outline
78,https://fachportal.roche.de/fachgebiete/gastrointestinale_onkologie/indikationen/hcc_indikation/ueber_hcc/krankheitsbild-hcc.html,10,fachportal_roche_de_fachgebiete_gastrointestinale_onkologie_indikationen_hcc_indikation_ueber_hcc_krankheitsbild_hcc_html.txt,200,html,Indexable,2,38,98,2881,3,2,1,fachportal_roche_de_fachgebiete_gastrointestinale_onkologie_indikationen_hcc_indikation_ueber_hcc_krankheitsbild_hcc_html.txt,image/fachportal_roche_de_fachgebiete_gastrointestinale_onkologie_indikationen_hcc_indikation_ueber_hcc_krankheitsbild_hcc_html.txt.png,text/fachportal_roche_de_fachgebiete_gastrointestinale_onkologie_indikationen_hcc_indikation_ueber_hcc_krankheitsbild_hcc_html.txt.txt,[],Oncology-Hematology,Germany,Disease information,"liver cancer, immunotherapy, angiogenesis inhibition",liver cancer,-12.812514,2.9225929,0,"The content provides a comprehensive overview of Roche's focus areas, products, clinical data, and available services, emphasizing various medical specialties such as oncology, neurology, and ophthalmology. It outlines detailed information on liver cancer, including its prevalence, risk factors, and treatment standards, particularly the use of immunotherapy and angiogenesis inhibition. The purpose is to inform healthcare professionals about Roche’s offerings and to facilitate access to clinical information and resources related to specific diseases. Additionally, it encourages medical inquiries and highlights the importance of patient support and early diagnosis through innovative algorithms.","oncology, professionals, data",fachportal.roche.de,Falling,0.987477932712699,high,487,General Offer Outline
79,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/artikel/focus_me.html,10,fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_focus_me_html.txt,200,html,Indexable,2,8,143,1525,66,21,1,fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_focus_me_html.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_focus_me_html.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_focus_me_html.txt.txt,"['Focus', 'Me']",Oncology-Hematology,Germany,Offer outline,"neuroscience, oncology, precision medicine, app, Focus Me, breast cancer, gynecological tumors, digital support, patient compliance, survival rates","breast cancer, gynecological tumors",-17.255028,-5.099331,0,"The content focuses on Roche's specialized areas and services, highlighting its offerings in various fields such as neuroscience, oncology, and precision medicine. It details the resources available for healthcare professionals, including clinical data, downloadable materials, and a dedicated app called Focus Me for patients with breast cancer and gynecological tumors. This app aims to connect patients, provide information about treatments, and facilitate communication with healthcare providers. Additionally, the content emphasizes the importance of digital support in enhancing patient compliance and improving survival rates. Overall, the content serves to inform and equip medical professionals and patients with helpful tools and resources in the oncology space.","oncology, professionals, data",fachportal.roche.de,Falling,0.239440173924619,high,100,General Offer Outline
80,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/artikel/subkutan_beim_mammakarzinom.html,10,fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_subkutan_beim_mammakarzinom_html.txt,200,html,Indexable,2,40,92,5521,7,3,0.978947368421053,fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_subkutan_beim_mammakarzinom_html.txt.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_subkutan_beim_mammakarzinom_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_subkutan_beim_mammakarzinom_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,breast cancer,-12.474123,-1.5815247,0,"The content primarily focuses on Roche's offerings in various medical fields, including neuroscience, oncology, and hematology, among others. It discusses the advantages of subcutaneous therapies, particularly in breast cancer treatment, highlighting how they can reduce the workload of healthcare professionals and improve patient experiences. The goal is to inform medical professionals about Roche's innovative treatment options, clinical data, downloadable resources, and relevant services. Additionally, the content addresses the importance of easing the burden on healthcare practitioners amid a workforce shortage in the healthcare sector. Overall, the purpose is to promote Roche's products and enhance understanding of their benefits in clinical settings.","oncology, professionals, data",fachportal.roche.de,Flat,0.322427592078792,high,84,General Offer Outline
81,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/artikel/yoga_und_brustkrebs.html?namespace=s7classic,6,fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_yoga_und_brustkrebs_html_namespace_s7classic.txt,200,html,Non-Indexable,3,19,0,1576,0,0,0.981308411214953,fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_yoga_und_brustkrebs_html_namespace_s7classic.txt.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_yoga_und_brustkrebs_html_namespace_s7classic.txt.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_yoga_und_brustkrebs_html_namespace_s7classic.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,"breast cancer, yoga, meditation, complementary methods, patient care",breast cancer,-19.67716,-4.620688,0,"The content is a comprehensive overview of Roche's offerings and services, particularly focusing on various medical specialties such as oncology, neurology, and immunology. It highlights Roche's products, clinical data, and resources for healthcare professionals, including downloadable materials and educational content. Additionally, it discusses the integration of complementary methods like yoga and meditation in breast cancer treatment to improve patients' quality of life, with resources and courses provided for both patients and healthcare providers. The purpose is to inform and support professionals about Roche's medical innovations and promote holistic approaches to patient care.","oncology, professionals, data",fachportal.roche.de,Falling,0.500034433639438,medium,155,General Offer Outline
82,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/artikel/yoga_und_brustkrebs.html,7,fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_yoga_und_brustkrebs_html.txt,200,html,Indexable,2,19,0,1576,60,20,1,fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_yoga_und_brustkrebs_html.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_yoga_und_brustkrebs_html.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_artikel_yoga_und_brustkrebs_html.txt.txt,[],Oncology-Hematology,Germany,Patient support,"breast cancer, yoga, meditation, cancer treatment",breast cancer,-19.36406,-5.0183034,0,"The content focuses on various medical specialties and services provided by Roche, particularly in relation to cancer treatment and support for breast cancer patients. It emphasizes the importance of improving quality of life and mental well-being through complementary practices like yoga and meditation, which are tailored for women during and after breast cancer therapy. The content aims to inform healthcare professionals about Roche's offerings, promote patient education, and provide resources for integrating holistic approaches into traditional cancer treatment. Additionally, it highlights the availability of clinical data and downloadable materials, strengthening Roche's commitment to professional collaboration and patient care.","oncology, professionals, data",fachportal.roche.de,Rising,0.592285603271244,high,449,General Offer Outline
83,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/gynaekoonkologie/.html,6,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie__html.txt,200,html,Non-Indexable,3,15,0,1387,9,9,1,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie__html.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie__html.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie__html.txt.txt,['HTML'],Oncology-Hematology,Germany,Offer outline,,,0.6718148,-8.105613,7,"The content primarily consists of HTML and script elements for a webpage designed for healthcare professionals, specifically focused on oncology, particularly gynecological oncology. It appears to be part of an online portal providing access to Roche's product information and services. The content includes features for searching, bookmarking, and downloading resources, indicating that the website aims to enhance user experience for healthcare professionals seeking information related to Roche's offerings in cancer treatment. The overall purpose is to facilitate access to relevant medical information and resources tailored for professional use.","event, exclusive, website",fachportal.roche.de,Rising,0.0450061029947169,medium,435,Events & Patient Care
84,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/gynaekoonkologie.html,7,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_html.txt,200,html,Indexable,1,15,0,1422,35,29,0.973684210526316,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_html.txt.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-24.156721,-4.475563,0,"The content provides an overview of Roche's specialized areas in healthcare, emphasizing various fields such as neuroscience, oncology, gynecology, and more. It outlines the company’s products, services, and clinical data available for healthcare professionals, along with resources for patient care. Additionally, it highlights ongoing events, podcasts, and educational materials related to women's health and cancer treatment, aiming to support healthcare providers in improving patient outcomes. The purpose of the content is to inform professionals about Roche's offerings and innovations in the medical field.","oncology, professionals, data",fachportal.roche.de,Rising,0.924845727646048,high,347,General Offer Outline
85,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/gynaekoonkologie/infektionskrankheiten.html,10,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_infektionskrankheiten_html.txt,200,html,Indexable,2,21,70,958,4,2,1,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_infektionskrankheiten_html.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_infektionskrankheiten_html.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_infektionskrankheiten_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,"urinary tract infections, sexually transmitted infections",-30.532177,1.9884249,0,"The content provides an overview of Roche's specialized areas in healthcare, highlighting various fields such as neuroscience, oncology, and hematology. It also lists Roche's products, clinical data, and downloadable resources for healthcare professionals. Additionally, it includes information about services offered, such as newsletters and patient resources, and emphasizes the importance of early treatment for conditions like urinary tract infections and sexually transmitted infections. The purpose is to facilitate access to Roche's medical products and information for professionals in the healthcare sector.","oncology, professionals, data",fachportal.roche.de,All,0.156165942222203,high,496,General Offer Outline
86,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/gynaekoonkologie/kinderwunsch.html,10,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_kinderwunsch_html.txt,200,html,Indexable,2,12,81,1011,4,2,0.97752808988764,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_kinderwunsch_html.txt.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_kinderwunsch_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_kinderwunsch_html.txt.txt.txt,[],Oncology-Hematology,Germany,Patient support,,,-17.183645,-2.431983,0,"The content provides a detailed overview of Roche's areas of expertise, products, and services, emphasizing their focus on various medical fields such as oncology, neurology, and women's health. It highlights resources available for healthcare professionals, including clinical data, downloadable materials, and educational content related to patient care and treatment options. Additionally, it addresses specific patient concerns, such as fertility preservation during cancer treatment, and outlines digital tools and support available for both professionals and patients. Overall, the purpose is to inform and equip healthcare providers with comprehensive resources for managing patient care.","oncology, professionals, data",fachportal.roche.de,Falling,0.145487075237014,high,249,General Offer Outline
87,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/gynaekoonkologie/knochengesundheit.html,10,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_knochengesundheit_html.txt,200,html,Indexable,2,17,33,973,4,2,0.978723404255319,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_knochengesundheit_html.txt.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_knochengesundheit_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_knochengesundheit_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-30.975801,5.47196,0,"The content appears to be a structured overview of Roche's specialized medical fields and services, emphasizing various areas such as neuroscience, oncology, and hematology. It provides access to product information, clinical data, downloadable resources, and additional services like newsletters and podcasts. The purpose is to inform healthcare professionals about Roche's offerings, support tools, and the importance of monitoring health conditions, particularly in relation to bone health and women's health. The content also includes references to patient-focused resources and emphasizes the need to report any side effects from therapies.","oncology, professionals, data",fachportal.roche.de,Flat,0.227534882188633,high,360,General Offer Outline
88,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/gynaekoonkologie/mammakarzinom.html,10,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_mammakarzinom_html.txt,200,html,Indexable,2,13,74,1298,4,2,0.977777777777778,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_mammakarzinom_html.txt.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_mammakarzinom_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_mammakarzinom_html.txt.txt.txt,['Focus'],Oncology-Hematology,Germany,Other,,breast cancer,-9.174119,1.4880626,0,"The content provides an overview of Roche's specialized areas in pharmaceuticals, focusing on various fields such as neuroscience, oncology, and personalized medicine. It lists Roche's products, clinical data, and downloadable materials, emphasizing advancements in cancer diagnostics and treatments like the use of biomarkers and molecular profiling for personalized therapy options. Additionally, it introduces patient support initiatives, such as the Focus MeApp, and highlights information on fertility preservation for breast cancer patients, aiming to cater to both healthcare professionals and patients seeking reliable resources and information. The purpose of the content is to inform and assist medical professionals and patients about Roche’s offerings and innovations in health care.","oncology, professionals, data",fachportal.roche.de,Falling,0.783763649838308,high,357,General Offer Outline
89,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/gynaekoonkologie/ovarialkarzinom.html,10,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_ovarialkarzinom_html.txt,200,html,Indexable,2,15,67,1061,4,2,1,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_ovarialkarzinom_html.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_ovarialkarzinom_html.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_ovarialkarzinom_html.txt.txt,['Focus'],Oncology-Hematology,Germany,Offer outline,,ovarian cancer,-17.168905,-2.1207,0,"The content is an overview of Roche's specialized portal, highlighting various fields of medicine that the company focuses on, such as oncology, neuroscience, and hematology. It provides a comprehensive look at Roche's product offerings, clinical data, downloadable materials, and additional services aimed at healthcare professionals. The content emphasizes personalized medicine, particularly in the context of ovarian cancer treatment and tumor profiling, while also introducing supportive resources like the Focus MeApp for patients. The overall purpose is to inform medical professionals about Roche's products, clinical advancements, and community engagement tools.","oncology, professionals, data",fachportal.roche.de,Flat,0.825596779437723,high,402,General Offer Outline
90,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/gynaekoonkologie/praenataltestung.html,10,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_praenataltestung_html.txt,200,html,Indexable,2,15,67,972,4,2,0.978494623655914,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_praenataltestung_html.txt.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_praenataltestung_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_praenataltestung_html.txt.txt.txt,['NIPT'],Other,Germany,Offer outline,,,-9.623763,-4.528086,0,"The content outlines the various therapeutic areas and services offered by Roche, particularly focusing on its products and clinical data related to conditions such as neuroscience, oncology, and women's health. It emphasizes non-invasive prenatal testing (NIPT) as an innovative service, detailing its benefits and the process involved. Additionally, the content targets healthcare professionals by providing resources like downloads, newsletters, and information about ongoing medical education and events. The overall purpose is to present Roche’s offerings and facilitate access to relevant information for professionals in the healthcare industry.","oncology, professionals, data",fachportal.roche.de,Falling,0.749911369686636,high,479,General Offer Outline
91,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/gynaekoonkologie/schwangerschaftsrisiken.html,10,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_schwangerschaftsrisiken_html.txt,200,html,Indexable,2,23,65,1042,4,2,1,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_schwangerschaftsrisiken_html.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_schwangerschaftsrisiken_html.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_schwangerschaftsrisiken_html.txt.txt,[],Other,Germany,Offer outline,"diabetes, preeclampsia","diabetes, preeclampsia",-36.070534,5.4444723,0,"The content provides an overview of Roche's various therapeutic areas and products, highlighting their focus on fields like neuroscience, oncology, and women's health. It emphasizes the company's commitment to reliable diagnostics and therapy monitoring, particularly in conditions like diabetes and preeclampsia. The content also mentions resources available for healthcare professionals, including clinical data, downloadable materials, and digital tools to support patient management and facilitate communication regarding health issues. Overall, the content serves to inform medical professionals about Roche's offerings and advancements in the pharmaceutical sector.","oncology, professionals, data",fachportal.roche.de,Falling,0.687502516286752,high,252,General Offer Outline
92,https://fachportal.roche.de/fachgebiete/gynaekoonkologie/gynaekoonkologie/zervixkarzinom.html,10,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_zervixkarzinom_html.txt,200,html,Indexable,2,14,77,986,4,2,1,fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_zervixkarzinom_html.txt,image/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_zervixkarzinom_html.txt.png,text/fachportal_roche_de_fachgebiete_gynaekoonkologie_gynaekoonkologie_zervixkarzinom_html.txt.txt,['Focus'],Oncology-Hematology,Germany,Offer outline,"cervical cancer, Focus MeApp",cervical cancer,-11.056022,-2.3056915,0,"The content primarily serves as an informational resource for healthcare professionals, outlining Roche's areas of expertise, product offerings, clinical data, and various services related to different medical fields, including oncology and women's health. It highlights the importance of early detection and reliable screening for diseases such as cervical cancer, and promotes tools like the Focus MeApp, which connects patients and healthcare professionals. Additionally, the content encourages professionals to report any adverse effects related to Roche products. Overall, its purpose is to provide comprehensive support and resources for medical practitioners and patients in the context of Roche's pharmaceutical solutions.","oncology, professionals, data",fachportal.roche.de,Falling,0.943234130204944,high,471,General Offer Outline
93,https://fachportal.roche.de/fachgebiete/haematologie/chips/dlbcl.html,7,fachportal_roche_de_fachgebiete_haematologie_chips_dlbcl_html.txt,200,html,Indexable,2,5,0,3281,30,15,1,fachportal_roche_de_fachgebiete_haematologie_chips_dlbcl_html.txt,image/fachportal_roche_de_fachgebiete_haematologie_chips_dlbcl_html.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_chips_dlbcl_html.txt.txt,"['DLBCL', 'B', 'Large', 'Cell', 'Diffuse', 'Lymphoma']",Oncology-Hematology,Germany,Disease information,Diffuse Large B-Cell Lymphoma (DLBCL),Diffuse Large B-Cell Lymphoma,-16.847107,8.319807,0,"The content is organized around various therapeutic areas and Roche's products, focusing on specific medical fields such as neuroscience, oncology, and hematology. It provides detailed information on clinical data, product overviews, treatment options, and ongoing research, particularly related to Diffuse Large B-Cell Lymphoma (DLBCL). Additionally, it includes resources like downloadable materials, expert interviews, and updates from medical conferences. The purpose of the content is to inform healthcare professionals about Roche's offerings and advancements in various medical therapies, emphasizing the importance of innovative treatments and patient care strategies.","oncology, professionals, data",fachportal.roche.de,Falling,0.814639262087605,high,369,General Offer Outline
94,https://fachportal.roche.de/fachgebiete/haematologie/chips/fl.html,2,fachportal_roche_de_fachgebiete_haematologie_chips_fl_html.txt,200,html,Indexable,2,2,0,3420,11,9,1,fachportal_roche_de_fachgebiete_haematologie_chips_fl_html.txt,image/fachportal_roche_de_fachgebiete_haematologie_chips_fl_html.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_chips_fl_html.txt.txt,['B'],Oncology-Hematology,Germany,Offer outline,"follicular lymphoma, diffuse large B-cell lymphoma","follicular lymphoma, diffuse large B-cell lymphoma",-25.390406,6.667432,0,"The content outlines the various therapeutic areas and products offered by Roche, including neuroscience, oncology, and hematology. It promotes Roche's specialized portal for healthcare professionals where they can access clinical data, downloadable materials, and resources related to treatment options and guidance for specific conditions such as follicular lymphoma and diffuse large B-cell lymphoma. Additionally, it invites professionals to subscribe to updates on new approvals, clinical congress data, and educational materials. The purpose is to provide healthcare professionals with comprehensive information and resources regarding Roche's pharmaceutical offerings and their applications in medical practice.","oncology, professionals, data",fachportal.roche.de,Rising,0.222791952535209,low,198,General Offer Outline
95,https://fachportal.roche.de/fachgebiete/haematologie/chips/kongressupdates.html,10,fachportal_roche_de_fachgebiete_haematologie_chips_kongressupdates_html.txt,200,html,Non-Indexable,2,15,99,1918,10,5,1,fachportal_roche_de_fachgebiete_haematologie_chips_kongressupdates_html.txt,image/fachportal_roche_de_fachgebiete_haematologie_chips_kongressupdates_html.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_chips_kongressupdates_html.txt.txt,[],Other,Germany,Offer outline,,,-33.879536,1.9456612,0,"The content primarily focuses on Roche's range of therapeutic areas and products, presenting an organized overview for healthcare professionals. It includes sections for different medical specialties such as oncology and neurology, along with resources like clinical data, downloadable materials, and services offered by the company. The purpose of the content is to provide comprehensive information about Roche's products, facilitate access to medical resources, and support healthcare professionals in their practices, particularly in managing various diseases and treatments.","oncology, professionals, data",fachportal.roche.de,Flat,0.792833573018581,high,119,General Offer Outline
96,https://fachportal.roche.de/fachgebiete/haematologie.html,7,fachportal_roche_de_fachgebiete_haematologie_html.txt,200,html,Indexable,1,11,0,3421,16,14,1,fachportal_roche_de_fachgebiete_haematologie_html.txt,image/fachportal_roche_de_fachgebiete_haematologie_html.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_html.txt.txt,[],Other,Germany,Offer outline,,,-27.920628,6.7267747,0,"The content of the content focuses on Roche's areas of expertise, product overview, clinical data, and services related to various therapeutic fields such as oncology, hematology, neurology, and dermatology. It provides information about Roche's products, including updates on new treatment options and clinical trials. Additionally, it mentions resources available for healthcare professionals, including downloadable materials and newsletters. The overall purpose is to support healthcare professionals by providing comprehensive information on Roche's offerings and to keep them informed about the latest advancements in medical science and treatment options.","oncology, professionals, data",fachportal.roche.de,Falling,0.597698496088286,high,439,General Offer Outline
97,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/cll/ueber-cll/krankheitsbild-cll.html,7,fachportal_roche_de_fachgebiete_haematologie_indikationen_cll_ueber_cll_krankheitsbild_cll_html.txt,200,html,Indexable,2,18,0,1541,7,6,0.98019801980198,fachportal_roche_de_fachgebiete_haematologie_indikationen_cll_ueber_cll_krankheitsbild_cll_html.txt.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_cll_ueber_cll_krankheitsbild_cll_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_cll_ueber_cll_krankheitsbild_cll_html.txt.txt.txt,['CLL'],Oncology-Hematology,Germany,Disease information,"chronic lymphocytic leukemia (CLL), treatment options, genetic factors",chronic lymphocytic leukemia,-16.21297,8.210842,0,"The content serves as a comprehensive resource for healthcare professionals regarding Roche's products and services, particularly focusing on various medical specialties such as oncology, neuroscience, and hematology. It provides insights into specific conditions like chronic lymphocytic leukemia (CLL), its diagnosis, symptoms, and treatment options, highlighting the importance of genetic factors in prognosis and therapy selection. The content also invites medical inquiries, offers downloadable resources, and emphasizes patient-centered information, reflecting Roche's role in advancing healthcare and supporting clinicians in their practice.","oncology, professionals, data",fachportal.roche.de,Rising,0.407571462201531,high,378,General Offer Outline
98,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/cll/ueber-cll/mrd-diagnostik.html?namespace=s7classic,6,fachportal_roche_de_fachgebiete_haematologie_indikationen_cll_ueber_cll_mrd_diagnostik_html_namespace_s7classic.txt,200,html,Non-Indexable,4,14,0,2078,0,0,1,fachportal_roche_de_fachgebiete_haematologie_indikationen_cll_ueber_cll_mrd_diagnostik_html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_cll_ueber_cll_mrd_diagnostik_html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_cll_ueber_cll_mrd_diagnostik_html_namespace_s7classic.txt.txt,"['MRD', 'CLL']",Oncology-Hematology,Germany,Offer outline,"chronic lymphocytic leukemia, minimal residual disease","chronic lymphocytic leukemia, minimal residual disease",-26.53634,7.1282673,0,"The content of the content is organized around Roche's pharmaceutical expertise and services, covering various medical fields such as neuroscience, oncology, hematology, and more. It outlines Roche's product offerings, clinical data, and educational resources related to specific diseases like chronic lymphocytic leukemia (CLL) and minimal residual disease (MRD). The content also highlights medical inquiries and offers multimedia resources, including videos and downloadable materials for professionals seeking information about Roche's therapies and research. Overall, the purpose is to provide healthcare professionals with comprehensive access to Roche’s products, services, and clinical insights.","oncology, professionals, data",fachportal.roche.de,Falling,0.0958637734962539,medium,474,General Offer Outline
99,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/cll/ueber-cll/mrd-diagnostik.html,6,fachportal_roche_de_fachgebiete_haematologie_indikationen_cll_ueber_cll_mrd_diagnostik_html.txt,200,html,Indexable,3,14,0,2078,3,3,0.979381443298969,fachportal_roche_de_fachgebiete_haematologie_indikationen_cll_ueber_cll_mrd_diagnostik_html.txt.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_cll_ueber_cll_mrd_diagnostik_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_cll_ueber_cll_mrd_diagnostik_html.txt.txt.txt,"['MRD', 'CLL']",Oncology-Hematology,Germany,Offer outline,,chronic lymphocytic leukemia,-17.061247,9.019816,0,"The content primarily serves as a professional resource for healthcare providers, detailing Roche's therapeutic areas and products, including specific information on various medical fields such as oncology, hematology, and neurology. It provides access to clinical data, downloadable materials, and educational resources, emphasizing the importance of minimal residual disease (MRD) diagnostics and treatment options for chronic lymphocytic leukemia (CLL). The purpose of the content is to facilitate knowledge sharing and to support medical professionals in their clinical practices by offering detailed product information and insights into current therapies and research developments.","oncology, professionals, data",fachportal.roche.de,Flat,0.438373371760915,medium,440,General Offer Outline
100,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/dlbcl/artikel/bedeutung-1l-therapie.html,6,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_bedeutung_1l_therapie_html.txt,200,html,Non-Indexable,3,21,0,1647,20,11,0.980769230769231,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_bedeutung_1l_therapie_html.txt.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_bedeutung_1l_therapie_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_bedeutung_1l_therapie_html.txt.txt.txt,"['DLBCL', 'B']",Oncology-Hematology,Germany,Offer outline,"DLBCL, progression-free survival",diffuse large B-cell lymphoma,-16.938648,7.6022706,0,"The content is a structured outline of Roche's offerings, focusing on various medical fields, including neuroscience, oncology, and hematology. It highlights Roche's products and services, providing clinical data, downloadable resources, and information on ongoing medical inquiries. The content emphasizes the importance of innovative treatments, particularly for conditions like diffuse large B-cell lymphoma (DLBCL), and discusses the significance of progression-free survival as an indicator for long-term patient outcomes. Overall, the purpose of the content is to inform healthcare professionals about Roche's medical advancements and available resources in the treatment of serious health conditions.","oncology, professionals, data",fachportal.roche.de,All,0.461593619126791,medium,489,General Offer Outline
101,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/dlbcl/artikel/bispezifische-antikoerper.html,7,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_bispezifische_antikoerper_html.txt,200,html,Non-Indexable,2,24,0,1798,22,12,1,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_bispezifische_antikoerper_html.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_bispezifische_antikoerper_html.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_bispezifische_antikoerper_html.txt.txt,['Hodgkin'],Oncology-Hematology,Germany,Research,"bispecific antibodies, non-Hodgkin lymphoma, immunotherapy, potential side effects, clinical applications, treatment options",non-Hodgkin lymphoma,-10.988857,3.0920136,0,"The content discusses various therapeutic areas and products offered by Roche, focusing particularly on innovations in cancer treatment, particularly through bispecific antibodies. It delves into the mechanisms, applications, and potential side effects associated with bispecific antibodies, especially in the context of non-Hodgkin lymphoma and other malignancies. The content aims to inform healthcare professionals about Roche's advancements in immunotherapy, providing insights into clinical applications, treatment options, and ongoing research efforts, highlighting the potential of these therapies to improve patient outcomes.","oncology, professionals, data",fachportal.roche.de,Flat,0.282975364759893,high,219,General Offer Outline
102,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/dlbcl/artikel/folgetherapien-vermeiden.html,7,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_folgetherapien_vermeiden_html.txt,200,html,Non-Indexable,2,24,0,1542,23,11,0.981308411214953,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_folgetherapien_vermeiden_html.txt.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_folgetherapien_vermeiden_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_folgetherapien_vermeiden_html.txt.txt.txt,"['DLBCL', 'B']",Oncology-Hematology,Germany,Offer outline,"oncology, hemophilia, neuroscience, first-line therapies, diffuse large B-cell lymphoma, DLBCL",diffuse large B-cell lymphoma,-16.287323,9.148736,0,"The content primarily provides an overview of Roche's medical expertise and product offerings across various therapeutic areas, such as oncology, hemophilia, and neuroscience. It outlines the purpose of the Roche expert portal, which serves as a resource for healthcare professionals to access clinical data, product information, and downloadable materials. Furthermore, it discusses the significance of effective first-line therapies for patients with diffuse large B-cell lymphoma (DLBCL), highlighting the high burden and costs associated with subsequent treatments. The aim is to inform professionals about advancements in treatment, support for patient care, and the implications of therapy on overall healthcare systems.","oncology, professionals, data",fachportal.roche.de,Flat,0.530217898691576,high,361,General Offer Outline
103,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/dlbcl/artikel/versorgung-auf-dem-land.html,6,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_versorgung_auf_dem_land_html.txt,200,html,Non-Indexable,3,23,0,1799,11,9,1,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_versorgung_auf_dem_land_html.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_versorgung_auf_dem_land_html.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_artikel_versorgung_auf_dem_land_html.txt.txt,"['CAR', 'Germany', 'T']",Oncology-Hematology,Germany,Offer outline,"oncology, hematology, bi-specific antibodies, CAR-T cell treatments",,-14.78771,8.195221,0,"The content provides an overview of Roche's areas of expertise and services, particularly in oncology, hematology, and other medical fields. It discusses the current challenges in hematological care in Germany, including demographic changes, an increasing patient load, and a shortage of healthcare professionals. Additionally, it highlights the importance of innovative therapies, such as bi-specific antibodies and CAR-T cell treatments, while emphasizing the need for comprehensive patient access to care and collaboration between healthcare sectors. The purpose of the content is to inform healthcare professionals about Roche's offerings and address critical issues in health provision related to cancer treatment.","oncology, professionals, data",fachportal.roche.de,All,0.749504279903923,medium,204,General Offer Outline
104,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/dlbcl/ueber_dlbcl/krankheitsbild-dlbcl.html,6,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_ueber_dlbcl_krankheitsbild_dlbcl_html.txt,200,html,Indexable,3,20,0,1505,11,9,0.981308411214953,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_ueber_dlbcl_krankheitsbild_dlbcl_html.txt.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_ueber_dlbcl_krankheitsbild_dlbcl_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_ueber_dlbcl_krankheitsbild_dlbcl_html.txt.txt.txt,"['DLBCL', 'B', 'Large', 'Cell', 'Diffuse', 'Lymphoma']",Oncology-Hematology,Germany,Disease information,"Diffuse Large B-Cell Lymphoma (DLBCL), treatment options, patient support",Diffuse Large B-Cell Lymphoma,-23.764519,7.4748654,0,"The content provides an overview of Roche's expertise in various medical fields, including oncology, neurology, and precision medicine, as well as details about their pharmaceutical products and clinical data. It serves as a resource for healthcare professionals, offering comprehensive information on diseases such as Diffuse Large B-Cell Lymphoma (DLBCL), its symptoms, treatment options, and patient support. Additionally, it emphasizes Roche's medical services, event participation, and channels for medical inquiries, indicating a purpose of fostering professional education and patient care within the pharmaceutical context.","oncology, professionals, data",fachportal.roche.de,Rising,0.883034090309612,medium,448,General Offer Outline
105,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/dlbcl/ueber_dlbcl/unmet-medical-need-dlbcl.html?namespace=s7classic,6,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_ueber_dlbcl_unmet_medical_need_dlbcl_html_namespace_s7classic.txt,200,html,Non-Indexable,4,29,0,1436,0,0,1,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_ueber_dlbcl_unmet_medical_need_dlbcl_html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_ueber_dlbcl_unmet_medical_need_dlbcl_html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_ueber_dlbcl_unmet_medical_need_dlbcl_html_namespace_s7classic.txt.txt,"['DLBCL', 'B']",Oncology-Hematology,Germany,Offer outline,,diffuse large B-cell lymphoma,-17.378906,8.166399,0,"The content focuses on Roche's offerings in various therapeutic areas, including oncology, neurology, and hematology, specifically addressing products and services related to diffuse large B-cell lymphoma (DLBCL). It highlights the significance of early therapy, presents expert interviews discussing treatment challenges, and emphasizes ongoing efforts to improve patient outcomes through research and clinical studies. Additionally, it provides resources for medical professionals, including downloadable materials and contact information for inquiries about Roche's pharmaceutical products. The purpose is to inform healthcare professionals about Roche's innovations and support available for managing specific health conditions effectively.","oncology, professionals, data",fachportal.roche.de,All,0.0611210410045786,medium,111,General Offer Outline
106,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/dlbcl/ueber_dlbcl/unmet-medical-need-dlbcl.html,6,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_ueber_dlbcl_unmet_medical_need_dlbcl_html.txt,200,html,Indexable,3,29,0,1436,12,9,1,fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_ueber_dlbcl_unmet_medical_need_dlbcl_html.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_ueber_dlbcl_unmet_medical_need_dlbcl_html.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_dlbcl_ueber_dlbcl_unmet_medical_need_dlbcl_html.txt.txt,"['DLBCL', 'B']",Oncology-Hematology,Germany,Offer outline,,diffuse large B-cell lymphoma,-17.67817,8.325813,0,"The content focuses on Roche's offerings in various medical specialties, including neuroscience, oncology, and hematology, along with detailed product information, clinical data, and resources for healthcare professionals. It emphasizes therapeutic options for conditions like diffuse large B-cell lymphoma (DLBCL), highlighting medical needs, treatment challenges, and collaborations aimed at improving patient outcomes. The site also provides avenues for professional inquiries, downloadable materials, and access to expert interviews, serving as a comprehensive resource for medical professionals seeking updated information about Roche's products and services.","oncology, professionals, data",fachportal.roche.de,All,0.562704913672903,medium,394,General Offer Outline
107,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/fl/ueber_fl/krankheitsbild-fl.html,6,fachportal_roche_de_fachgebiete_haematologie_indikationen_fl_ueber_fl_krankheitsbild_fl_html.txt,200,html,Indexable,3,17,0,1455,8,6,1,fachportal_roche_de_fachgebiete_haematologie_indikationen_fl_ueber_fl_krankheitsbild_fl_html.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_fl_ueber_fl_krankheitsbild_fl_html.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_fl_ueber_fl_krankheitsbild_fl_html.txt.txt,['FL'],Oncology-Hematology,Germany,Offer outline,"follicular lymphoma, oncology, neuroscience, hematology, treatment options",follicular lymphoma,-27.387835,-7.215157,0,"The content serves as a comprehensive informational resource for healthcare professionals about Roche's pharmaceutical offerings and services, specifically focusing on various areas of medicine such as oncology, neuroscience, and hematology. It outlines Roche's product portfolio, clinical data, treatment options, and guidelines for specific conditions like follicular lymphoma (FL). Additionally, it offers access to resources such as newsletters, podcasts, and downloadable materials, emphasizing the company's commitment to supporting medical inquiries and advancements in patient care.","oncology, professionals, data",fachportal.roche.de,Rising,0.817117788109152,medium,433,General Offer Outline
108,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/fl/ueber_fl/mrd-diagnostik-fl.html?namespace=s7classic,6,fachportal_roche_de_fachgebiete_haematologie_indikationen_fl_ueber_fl_mrd_diagnostik_fl_html_namespace_s7classic.txt,200,html,Non-Indexable,5,19,0,3294,0,0,0.983050847457627,fachportal_roche_de_fachgebiete_haematologie_indikationen_fl_ueber_fl_mrd_diagnostik_fl_html_namespace_s7classic.txt.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_fl_ueber_fl_mrd_diagnostik_fl_html_namespace_s7classic.txt.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_fl_ueber_fl_mrd_diagnostik_fl_html_namespace_s7classic.txt.txt.txt,['MRD'],Oncology-Hematology,Germany,Offer outline,,,-37.251343,7.336914,0,"The content provides a comprehensive overview of Roche's specialized areas in pharmaceuticals, focusing on various medical fields such as oncology, neurology, and rheumatology. It discusses Roche's products, clinical data, and resources available for healthcare professionals, including videos and materials on treatment approaches like minimal residual disease (MRD) diagnostics. The purpose of the content is to inform healthcare professionals about Roche’s offerings, including specific medications, their applications, and pertinent clinical information, while facilitating access to further resources like newsletters and medical inquiries.","oncology, professionals, data",fachportal.roche.de,Flat,0.376456986162949,medium,27,General Offer Outline
109,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/fl/ueber_fl/mrd-diagnostik-fl.html,6,fachportal_roche_de_fachgebiete_haematologie_indikationen_fl_ueber_fl_mrd_diagnostik_fl_html.txt,200,html,Indexable,4,19,0,3294,5,5,1,fachportal_roche_de_fachgebiete_haematologie_indikationen_fl_ueber_fl_mrd_diagnostik_fl_html.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_fl_ueber_fl_mrd_diagnostik_fl_html.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_fl_ueber_fl_mrd_diagnostik_fl_html.txt.txt,['Gazyvaro'],Oncology-Hematology,Germany,Offer outline,"oncology, neuroscience, rheumatology, MabThera, Gazyvaro, potential side effects",,-34.64375,7.8045287,0,"The content provides an overview of Roche's specialized areas, products, clinical data, and services, aimed at healthcare professionals. It emphasizes fields such as oncology, neuroscience, and rheumatology, and details specific medications like MabThera and Gazyvaro, including their indications, compositions, potential side effects, and associated medical inquiries. The purpose is to inform medical professionals about Roche's offerings and to facilitate access to clinical support and educational resources related to their pharmaceutical products.","oncology, professionals, data",fachportal.roche.de,All,0.779422273151443,medium,27,General Offer Outline
110,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/pnh/ueber-pnh/krankheitsbild-pnh.html?namespace=s7classic,10,fachportal_roche_de_fachgebiete_haematologie_indikationen_pnh_ueber_pnh_krankheitsbild_pnh_html_namespace_s7classic.txt,200,html,Non-Indexable,2,18,60,1489,0,0,1,fachportal_roche_de_fachgebiete_haematologie_indikationen_pnh_ueber_pnh_krankheitsbild_pnh_html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_pnh_ueber_pnh_krankheitsbild_pnh_html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_pnh_ueber_pnh_krankheitsbild_pnh_html_namespace_s7classic.txt.txt,['PNH'],Oncology-Hematology,Germany,Offer outline,"paroxysmal nocturnal hemoglobinuria, C5 complement inhibitors",paroxysmal nocturnal hemoglobinuria,-21.973307,12.604123,0,"The content is structured as an informative resource for healthcare professionals, focusing on Roche's expertise in various medical fields such as neurology, oncology, and hematology. It discusses conditions like paroxysmal nocturnal hemoglobinuria (PNH) and highlights Roche's therapeutic options, including C5 complement inhibitors. The purpose of the content is to provide detailed information on Roche's products, services, and clinical data, along with guidance for medical inquiries and patient care, enhancing professional knowledge and informing treatment decisions.","oncology, professionals, data",fachportal.roche.de,Flat,0.473240542660671,high,167,General Offer Outline
111,https://fachportal.roche.de/fachgebiete/haematologie/indikationen/pnh/ueber-pnh/krankheitsbild-pnh.html,10,fachportal_roche_de_fachgebiete_haematologie_indikationen_pnh_ueber_pnh_krankheitsbild_pnh_html.txt,200,html,Indexable,1,18,60,1489,13,5,1,fachportal_roche_de_fachgebiete_haematologie_indikationen_pnh_ueber_pnh_krankheitsbild_pnh_html.txt,image/fachportal_roche_de_fachgebiete_haematologie_indikationen_pnh_ueber_pnh_krankheitsbild_pnh_html.txt.png,text/fachportal_roche_de_fachgebiete_haematologie_indikationen_pnh_ueber_pnh_krankheitsbild_pnh_html.txt.txt,['PNH'],Oncology-Hematology,Germany,Disease information,"paroxysmal nocturnal hemoglobinuria, C5 complement inhibitors, treatment options",paroxysmal nocturnal hemoglobinuria,22.698452,-1.7793701,4,"The content provides an overview of Roche's expertise and product offerings across various medical fields such as neuroscience, oncology, and hematology. It specifically addresses paroxysmal nocturnal hemoglobinuria (PNH), detailing its clinical presentation, diagnosis challenges, and treatment options, emphasizing the significance of C5 complement inhibitors in managing the condition. The purpose is to inform healthcare professionals about available resources, treatment modalities, and support for PNH patients, while also facilitating access to scientific data and clinical guidelines.","technologies, artificial, ai",fachportal.roche.de,All,0.0546702879363074,high,263,Technology
112,https://fachportal.roche.de/fachgebiete/haemophilie_A/.html?namespace=s7classic,6,fachportal_roche_de_fachgebiete_haemophilie_A__html_namespace_s7classic.txt,200,html,Non-Indexable,4,12,0,1928,0,0,1,fachportal_roche_de_fachgebiete_haemophilie_A__html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_haemophilie_A__html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_haemophilie_A__html_namespace_s7classic.txt.txt,"['HAVEN', 'HEMLIBRA']",Oncology-Hematology,Germany,Medication information,"HEMLIBRA, hemophilia A, HAVEN 3, HAVEN 4, prophylaxis, joint health, treatment effectiveness, personalized treatment options, patient resources, economic considerations",hemophilia A,19.864967,0.54997814,4,"The content provides detailed information regarding the use of HEMLIBRA for the prophylaxis of bleeding in patients with severe or moderate hemophilia A. It highlights clinical studies, such as HAVEN 3 and HAVEN 4, demonstrating the treatment's effectiveness in maintaining or improving joint health and supporting active lifestyles without bleeding events. The content also emphasizes personalized treatment options, patient resources, and economic considerations related to HEMLIBRA. Additionally, it mentions the importance of proper planning for patients traveling with hemophilia, underlining the company's commitment to patient education and support.","technologies, artificial, ai",fachportal.roche.de,All,0.206589994127097,medium,56,Technology
113,https://fachportal.roche.de/fachgebiete/haemophilie_A/.html,6,fachportal_roche_de_fachgebiete_haemophilie_A__html.txt,200,html,Non-Indexable,3,12,0,1928,3,3,1,fachportal_roche_de_fachgebiete_haemophilie_A__html.txt,image/fachportal_roche_de_fachgebiete_haemophilie_A__html.txt.png,text/fachportal_roche_de_fachgebiete_haemophilie_A__html.txt.txt,"['HAVEN', 'Hemophilia', 'HEMLIBRA']",Oncology-Hematology,Germany,Medication information,"HEMLIBRA, Hemophilia A, bleeding prophylaxis, HAVEN 3, HAVEN 4",Hemophilia A,19.9074,0.69870883,4,"The content discusses HEMLIBRA, a treatment for severe and moderate Hemophilia A, highlighting its benefits in improving joint health and reducing bleeding events during physical activities, as shown in clinical studies like HAVEN 3 and HAVEN 4. It emphasizes the drug's approval in over 110 countries and its role in providing effective bleeding prophylaxis for patients. The content also includes resources for healthcare professionals regarding the management of Hemophilia A, patient support platforms, and practical advice for travel preparedness. Overall, the purpose is to inform professionals about HEMLIBRA's efficacy, safety, and the support available for patients with Hemophilia A.","technologies, artificial, ai",fachportal.roche.de,Flat,0.083172880551514,medium,129,Technology
114,https://fachportal.roche.de/fachgebiete/nephrologie/artikel/newsletter_nephrologie.html,6,fachportal_roche_de_fachgebiete_nephrologie_artikel_newsletter_nephrologie_html.txt,200,html,Indexable,3,22,0,1214,4,2,1,fachportal_roche_de_fachgebiete_nephrologie_artikel_newsletter_nephrologie_html.txt,image/fachportal_roche_de_fachgebiete_nephrologie_artikel_newsletter_nephrologie_html.txt.png,text/fachportal_roche_de_fachgebiete_nephrologie_artikel_newsletter_nephrologie_html.txt.txt,['MIRCERA'],CVRM,Germany,Medication information,"chronic kidney disease, renal anemia, MIRCERA, formulations, indications, safety information","chronic kidney disease, renal anemia",6.1553273,-32.167553,1,"The content describes the various therapeutic areas and services offered by Roche, with a specific focus on products related to conditions such as chronic kidney disease and renal anemia. It includes details about Roche's product MIRCERA, its formulations, indications, and safety information. The content serves as a comprehensive resource for healthcare professionals, providing access to clinical data, downloadable materials, and the opportunity to subscribe to newsletters for updates on specific medical topics. Overall, the purpose is to inform and support professionals in using Roche’s products effectively in clinical settings.","drug, reporting, adverse",fachportal.roche.de,Rising,0.303641116447686,medium,423,Drug Safety
115,https://fachportal.roche.de/fachgebiete/nephrologie/artikel/newsletter_nephrologie1.html,6,fachportal_roche_de_fachgebiete_nephrologie_artikel_newsletter_nephrologie1_html.txt,200,html,Indexable,,22,0,1136,0,0,0.976744186046512,fachportal_roche_de_fachgebiete_nephrologie_artikel_newsletter_nephrologie1_html.txt.txt,image/fachportal_roche_de_fachgebiete_nephrologie_artikel_newsletter_nephrologie1_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_nephrologie_artikel_newsletter_nephrologie1_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,"chronic kidney disease, anemia",-35.464764,-6.75658,0,"The content focuses on Roche's areas of expertise, highlighting various therapeutic fields such as neuroscience, oncology, and nephrology. It serves as a comprehensive resource for healthcare professionals, providing information on pharmaceutical products, clinical data, and downloadable materials related to treatments, particularly for chronic kidney disease and anemia. Additionally, it promotes features like newsletters and expert interviews, emphasizing Roche's commitment to keeping healthcare professionals informed about current research and treatment options.","oncology, professionals, data",fachportal.roche.de,Falling,0.944389724511064,medium,30,General Offer Outline
116,https://fachportal.roche.de/fachgebiete/nephrologie/artikel/therapieoptionen-bei-renaler-anaemie.html,9,fachportal_roche_de_fachgebiete_nephrologie_artikel_therapieoptionen_bei_renaler_anaemie_html.txt,200,html,Indexable,3,35,122,1402,6,1,0.97979797979798,fachportal_roche_de_fachgebiete_nephrologie_artikel_therapieoptionen_bei_renaler_anaemie_html.txt.txt,image/fachportal_roche_de_fachgebiete_nephrologie_artikel_therapieoptionen_bei_renaler_anaemie_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_nephrologie_artikel_therapieoptionen_bei_renaler_anaemie_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-32.171127,-6.99311,0,"The content primarily focuses on Roche's therapeutic areas and products, providing an overview of different medical specialties such as oncology, neurology, and nephrology. It includes sections on clinical data, downloadable materials, expert interviews, and resources for healthcare professionals, aimed at supporting them in patient care, particularly in areas like renal anemia treatment. The purpose of the content is to provide a comprehensive resource for medical professionals to access information about Roche's offerings and advancements in various fields.","oncology, professionals, data",fachportal.roche.de,Falling,0.252914149967648,high,475,General Offer Outline
117,https://fachportal.roche.de/fachgebiete/nephrologie/artikel/zulassungserweiterung.html,9,fachportal_roche_de_fachgebiete_nephrologie_artikel_zulassungserweiterung_html.txt,200,html,Indexable,3,21,79,1477,9,4,1,fachportal_roche_de_fachgebiete_nephrologie_artikel_zulassungserweiterung_html.txt,image/fachportal_roche_de_fachgebiete_nephrologie_artikel_zulassungserweiterung_html.txt.png,text/fachportal_roche_de_fachgebiete_nephrologie_artikel_zulassungserweiterung_html.txt.txt,[],Other,Germany,Offer outline,,renal anemia,-31.567757,6.824592,0,"The content focuses on Roche's specialized areas in pharmaceuticals, providing healthcare professionals with categorized information about various therapeutic fields such as neuroscience, oncology, and nephrology. It highlights products and services, clinical data, and downloadable resources, emphasizing their offerings for chronic conditions, including renal anemia in children. The purpose of the content is to facilitate access to evidence-based information and support for healthcare professionals, helping them stay informed about Roche's product range and relevant medical updates. Additionally, it promotes user registration for unlimited access to content and encourages the reporting of adverse events related to Roche products.","oncology, professionals, data",fachportal.roche.de,Flat,0.471626759020643,high,275,General Offer Outline
118,https://fachportal.roche.de/fachgebiete/nephrologie/indikationen/renale_anaemie/ueber_renale_anaemie/ckd_und_enale_anaemie.html,7,fachportal_roche_de_fachgebiete_nephrologie_indikationen_renale_anaemie_ueber_renale_anaemie_ckd_und_enale_anaemie_html.txt,200,html,Non-Indexable,2,21,0,1399,11,5,1,fachportal_roche_de_fachgebiete_nephrologie_indikationen_renale_anaemie_ueber_renale_anaemie_ckd_und_enale_anaemie_html.txt,image/fachportal_roche_de_fachgebiete_nephrologie_indikationen_renale_anaemie_ueber_renale_anaemie_ckd_und_enale_anaemie_html.txt.png,text/fachportal_roche_de_fachgebiete_nephrologie_indikationen_renale_anaemie_ueber_renale_anaemie_ckd_und_enale_anaemie_html.txt.txt,[],CVRM,Germany,Offer outline,"chronic kidney disease, renal anemia","chronic kidney disease, renal anemia",-4.15957,-16.12035,3,"The content features content from Roche's professional portal, focusing on chronic kidney disease and renal anemia. It invites healthcare professionals to register for unlimited access to current, evidence-based clinical information. The design emphasizes user engagement with options for registration and login, indicating a tailored approach for professionals in the medical field.","users, page, website",fachportal.roche.de,Flat,0.9041537487519,high,231,Website Metadata
119,https://fachportal.roche.de/fachgebiete/neuroscience/.html,6,fachportal_roche_de_fachgebiete_neuroscience__html.txt,200,html,Non-Indexable,3,12,0,1775,4,4,1,fachportal_roche_de_fachgebiete_neuroscience__html.txt,image/fachportal_roche_de_fachgebiete_neuroscience__html.txt.png,text/fachportal_roche_de_fachgebiete_neuroscience__html.txt.txt,"['Subcutaneous', 'MS', 'Therapy']",Neurology,Germany,Medication information,"Subcutaneous MS Therapy, multiple sclerosis",multiple sclerosis,22.440327,25.239408,4,"The content presents a webpage focused on neuroscience, highlighting collaborative efforts for advancements in the field. It features a section on ""Subcutaneous MS Therapy,"" which provides information about a new formulation of a highly effective therapy for multiple sclerosis. The design is professional, aimed at healthcare professionals, and encourages users to learn more about the therapy.","technologies, artificial, ai",fachportal.roche.de,Falling,0.354888953406171,medium,200,Technology
120,https://fachportal.roche.de/fachgebiete/neuroscience/chips/multiple-sclerose/artikel/dgn-leitlinien.html,6,fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_artikel_dgn_leitlinien_html.txt,200,html,Non-Indexable,3,10,0,2834,32,6,1,fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_artikel_dgn_leitlinien_html.txt,image/fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_artikel_dgn_leitlinien_html.txt.png,text/fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_artikel_dgn_leitlinien_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-25.223433,11.508855,0,"The content outlines various therapeutic areas and services provided by Roche, focusing on the company's products and clinical data across multiple medical disciplines, such as neuroscience, oncology, and hemophilia. It serves to inform medical professionals about Roche's product offerings, download resources, clinical guidelines, and the latest news and updates relevant to their practice. The content emphasizes the importance of professional access to detailed medical information and resources, reinforcing Roche's commitment to support healthcare providers in patient care.","oncology, professionals, data",fachportal.roche.de,Falling,0.792949304335282,medium,365,General Offer Outline
121,https://fachportal.roche.de/fachgebiete/neuroscience/chips/multiple-sclerose/artikel/ivp.html?namespace=s7classic,9,fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_artikel_ivp_html_namespace_s7classic.txt,200,html,Non-Indexable,,31,154,1062,0,0,1,fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_artikel_ivp_html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_artikel_ivp_html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_artikel_ivp_html_namespace_s7classic.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-24.72822,10.147927,0,"The content outlines the various therapeutic areas and products offered by Roche, emphasizing key fields such as neuroscience, oncology, and hematology. It serves as a resource hub for healthcare professionals, providing clinical data, downloadable materials, and information about services related to infusion therapies. The purpose of this content is to support medical practitioners with relevant information and tools for effective patient management, particularly in specialized treatment areas. Additionally, it includes contact information for inquiries and safety reporting related to Roche products.","oncology, professionals, data",fachportal.roche.de,Falling,0.471305113473659,high,497,General Offer Outline
122,https://fachportal.roche.de/fachgebiete/neuroscience/chips/multiple-sclerose/artikel/progression-messen-multiple-sklerose.html,9,fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_artikel_progression_messen_multiple_sklerose_html.txt,200,html,Non-Indexable,3,18,191,1724,17,4,1,fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_artikel_progression_messen_multiple_sklerose_html.txt,image/fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_artikel_progression_messen_multiple_sklerose_html.txt.png,text/fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_artikel_progression_messen_multiple_sklerose_html.txt.txt,[],Other,Germany,Offer outline,,,-35.367485,0.5029696,0,"The content appears to be a comprehensive overview of Roche's specialized fields and products, particularly in healthcare areas such as neuroscience, oncology, and rheumatology. It outlines various clinical data, downloadable resources, and educational materials related to these specializations. The purpose of this content is to provide healthcare professionals with detailed information about Roche's offerings, clinical assessments, and digital health solutions, facilitating better patient management and treatment options. Additionally, it emphasizes ongoing education and resources to support professionals in their practice.","oncology, professionals, data",fachportal.roche.de,Falling,0.279140460825251,high,405,General Offer Outline
123,https://fachportal.roche.de/fachgebiete/neuroscience/chips/multiple-sclerose/ms-bp-teaserrohlinge.html?namespace=s7classic,6,fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_ms_bp_teaserrohlinge_html_namespace_s7classic.txt,200,html,Non-Indexable,,20,0,1186,1,1,1,fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_ms_bp_teaserrohlinge_html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_ms_bp_teaserrohlinge_html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_neuroscience_chips_multiple_sclerose_ms_bp_teaserrohlinge_html_namespace_s7classic.txt.txt,['Ocrevus'],Oncology-Hematology,Germany,Medication information,"Ocrevus, oncology, rheumatology, neuroscience, indications, contraindications, side effects",,-35.610474,7.9724727,0,"The content primarily serves as an overview of Roche's specialized areas, products, clinical data, and services related to various medical fields, including neuroscience, oncology, and rheumatology. It provides detailed information on specific products like Ocrevus, including indications, contraindications, side effects, and relevant contact information for healthcare professionals. The purpose of this content is to offer healthcare professionals access to key resources and data about Roche's pharmaceutical offerings while ensuring they can report any adverse effects observed with Roche products.","oncology, professionals, data",fachportal.roche.de,Falling,0.871232483487463,medium,311,General Offer Outline
124,https://fachportal.roche.de/fachgebiete/neuroscience/indikationen/digitale-gesundheitsloesungen_indikation/ueber-digitale-gesundheitsloesungen/doppelpack-aus-rct-und-rwd.html,6,fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_doppelpack_aus_rct_und_rwd_html.txt,200,html,Indexable,3,26,0,1968,8,7,1,fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_doppelpack_aus_rct_und_rwd_html.txt,image/fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_doppelpack_aus_rct_und_rwd_html.txt.png,text/fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_doppelpack_aus_rct_und_rwd_html.txt.txt,"['RWE', 'RCT']",Other,Germany,Offer outline,,,-9.769012,-7.8065104,0,"The content outlines the expertise areas and services offered by Roche, primarily focusing on various fields such as neuroscience, oncology, and precision medicine. It provides a comprehensive overview of Roche's products, clinical data, and digital health solutions, emphasizing the importance of integrating real-world evidence (RWE) alongside traditional clinical trial data (RCT) to enhance patient care. Additionally, the content discusses the digital transformation in healthcare, patient-centered care, and the need for better data interoperability for improved healthcare outcomes. The purpose of the content is to inform healthcare professionals about Roche's offerings and to promote the modernization of healthcare practices through effective data utilization and technology integration.","oncology, professionals, data",fachportal.roche.de,Falling,0.867306142644979,medium,87,General Offer Outline
125,https://fachportal.roche.de/fachgebiete/neuroscience/indikationen/digitale-gesundheitsloesungen_indikation/ueber-digitale-gesundheitsloesungen/ehealth-in-der-neurologie.html,9,fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_ehealth_in_der_neurologie_html.txt,200,html,Indexable,3,25,165,1869,24,11,1,fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_ehealth_in_der_neurologie_html.txt,image/fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_ehealth_in_der_neurologie_html.txt.png,text/fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_ehealth_in_der_neurologie_html.txt.txt,"['Digital', 'Applications', 'Health']",Other,Germany,Technology,,,-9.756008,-8.630189,0,"The content focuses on the various areas of expertise and product offerings of Roche, highlighting their advancements in healthcare, particularly in fields such as neurology, oncology, and digital health solutions. It provides a comprehensive overview of Roche's medical products, clinical data, and emerging digital applications designed to enhance patient care, facilitate disease management, and improve healthcare delivery through technology. Additionally, it explains regulatory aspects related to digital health applications like Digital Health Applications (DiGA) and differentiates between types of digital healthcare solutions. The purpose of this content is to inform healthcare professionals about Roche's resources, services, and innovations in the pharmaceutical sector.","oncology, professionals, data",fachportal.roche.de,All,0.31641414235202,high,401,General Offer Outline
126,https://fachportal.roche.de/fachgebiete/neuroscience/indikationen/digitale-gesundheitsloesungen_indikation/ueber-digitale-gesundheitsloesungen/how-to-diga.html,6,fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_how_to_diga_html.txt,200,html,Indexable,3,11,0,2599,10,7,1,fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_how_to_diga_html.txt,image/fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_how_to_diga_html.txt.png,text/fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_how_to_diga_html.txt.txt,"['Sclerosis', 'Multiple', 'MS']",Neurology,Germany,Technology,"Multiple Sclerosis, digital health applications, patient management, disease understanding, regulatory aspects",Multiple Sclerosis,20.8326,22.45561,4,"The content provides an overview of Roche's digital health solutions, particularly focusing on their applications designed to support patients with complex neurological conditions such as Multiple Sclerosis (MS). It discusses the role of digital health applications (DiGA) in facilitating patient management, enhancing communication with healthcare providers, and improving disease understanding. The content emphasizes the importance of these tools in alleviating the burden on traditional healthcare and highlights the evidence supporting their efficacy. The content also mentions the regulatory aspects of digital health products, aiming to inform healthcare professionals about the benefits and integration of these solutions in clinical practice.","technologies, artificial, ai",fachportal.roche.de,All,0.747480566368545,medium,232,Technology
127,https://fachportal.roche.de/fachgebiete/neuroscience/indikationen/digitale-gesundheitsloesungen_indikation/ueber-digitale-gesundheitsloesungen/nachgefragt-mehrwert-von-apps-auf-rezept.html,6,fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_nachgefragt_mehrwert_von_apps_auf_rezept_html.txt,200,html,Indexable,3,41,0,1522,7,6,0.989247311827957,fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_nachgefragt_mehrwert_von_apps_auf_rezept_html.txt.txt,image/fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_nachgefragt_mehrwert_von_apps_auf_rezept_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_nachgefragt_mehrwert_von_apps_auf_rezept_html.txt.txt.txt,['German'],Other,Germany,Technology,,,6.9254,7.5745144,7,"The content primarily revolves around Roche's focus on various therapeutic areas, including neuroscience, oncology, and digital health solutions. It highlights Roche’s commitment to innovation in healthcare, particularly through the integration of digital health applications (DiGA) that aim to enhance patient care and facilitate earlier disease monitoring. The content discusses the challenges and opportunities within the digital health space, emphasizing the importance of patient trust, data security, and the effective integration of technologies into healthcare practices. Additionally, it mentions Roche's efforts to support startups in navigating the German healthcare market and stresses the need for collaborative approaches to improve health outcomes.","event, exclusive, website",fachportal.roche.de,Falling,0.161161085086661,medium,99,Events & Patient Care
128,https://fachportal.roche.de/fachgebiete/neuroscience/indikationen/digitale-gesundheitsloesungen_indikation/ueber-digitale-gesundheitsloesungen/von-rwe-bis-apps.html,6,fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_von_rwe_bis_apps_html.txt,200,html,Indexable,3,39,0,2732,6,6,1,fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_von_rwe_bis_apps_html.txt,image/fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_von_rwe_bis_apps_html.txt.png,text/fachportal_roche_de_fachgebiete_neuroscience_indikationen_digitale_gesundheitsloesungen_indikation_ueber_digitale_gesundheitsloesungen_von_rwe_bis_apps_html.txt.txt,"['Brisa', 'App']",Other,Germany,Technology,,,6.3612137,5.6451674,7,"The content focuses on Roche's diverse areas of expertise in healthcare, detailing their products, services, clinical data, and the impact of digital health solutions. It emphasizes the development and benefits of digital applications, such as the Brisa App, aimed at enhancing patient care through personal data management, facilitating communication between healthcare providers and patients, and integrating real-world evidence into medical decisions. The content also discusses the challenges and advancements in digital health, emphasizing patient-centered approaches and the importance of regulatory compliance for medical applications. Overall, it aims to inform healthcare professionals about Roche's innovations and the evolving landscape of digital health solutions.","event, exclusive, website",fachportal.roche.de,Rising,0.526174868853566,medium,473,Events & Patient Care
129,https://fachportal.roche.de/fachgebiete/neuroscience/women-s-health/womenshealth-weltfrauentag-2023.html?namespace=s7classic,9,fachportal_roche_de_fachgebiete_neuroscience_women_s_health_womenshealth_weltfrauentag_2023_html_namespace_s7classic.txt,200,html,Non-Indexable,3,36,181,1147,0,0,1,fachportal_roche_de_fachgebiete_neuroscience_women_s_health_womenshealth_weltfrauentag_2023_html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_neuroscience_women_s_health_womenshealth_weltfrauentag_2023_html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_neuroscience_women_s_health_womenshealth_weltfrauentag_2023_html_namespace_s7classic.txt.txt,[],Other,Germany,Offer outline,,,-36.824753,6.0139523,0,"The content outlines key areas of focus for Roche, including various medical specialties such as neuroscience, oncology, and rheumatology. It serves as a comprehensive resource for healthcare professionals, providing insights into Roche's products, clinical data, and services. Additionally, it highlights specific initiatives related to women's health and neuroimmunology, featuring events like panel discussions and educational resources. Overall, the purpose is to support professionals with relevant information and tools related to Roche's pharmaceutical offerings and ongoing research.","oncology, professionals, data",fachportal.roche.de,Rising,0.0497102529407458,high,155,General Offer Outline
130,https://fachportal.roche.de/fachgebiete/onkologie/artikel/bispezifische-antikoerper-in-der-immunonkologie.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_bispezifische_antikoerper_in_der_immunonkologie_html.txt,200,html,Indexable,3,90,0,1197,3,1,1,fachportal_roche_de_fachgebiete_onkologie_artikel_bispezifische_antikoerper_in_der_immunonkologie_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_bispezifische_antikoerper_in_der_immunonkologie_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_bispezifische_antikoerper_in_der_immunonkologie_html.txt.txt,[],Oncology-Hematology,Germany,Disease information,"oncology, hematology, neurology, immuno-oncology therapies, bispecific antibodies, immune responses, cancer treatment, tumor-specific antigens",,-15.784424,5.365973,0,"The content primarily focuses on the various therapeutic areas and products offered by Roche, a pharmaceutical company. It provides an overview of specific medical fields such as oncology, hematology, and neurology, detailing innovative treatment approaches, including immuno-oncology therapies and bispecific antibodies. The content emphasizes clinical data, service offerings, and downloadable resources for professionals, highlighting Roche's commitment to advancing medical research and patient care. Additionally, it addresses the importance of understanding immune responses in cancer treatment and the development of new therapies targeting tumor-specific antigens.","oncology, professionals, data",fachportal.roche.de,Flat,0.591969474783241,medium,47,General Offer Outline
131,https://fachportal.roche.de/fachgebiete/onkologie/artikel/das-beste-aus-zwei-welten.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_das_beste_aus_zwei_welten_html.txt,200,html,Indexable,3,25,0,1501,1,1,1,fachportal_roche_de_fachgebiete_onkologie_artikel_das_beste_aus_zwei_welten_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_das_beste_aus_zwei_welten_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_das_beste_aus_zwei_welten_html.txt.txt,['RWD'],Other,Germany,Research,,,-10.893896,-4.056929,0,"The content outlines Roche's professional portal, detailing various therapeutic areas and products. It emphasizes the integration of randomized controlled trials (RCTs) with real-world data (RWD) to improve the understanding of treatment efficacy and effectiveness in diverse patient populations. This approach aims to enhance evidence generation in medical care and ultimately benefit patients. Additionally, the content provides links to Roche's product overview, medical inquiries, event notifications, and ongoing studies, reflecting the company's commitment to transparency and continuous improvement in healthcare.","oncology, professionals, data",fachportal.roche.de,Flat,0.89180075237599,medium,445,General Offer Outline
132,https://fachportal.roche.de/fachgebiete/onkologie/artikel/eine-vertane-chance.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_eine_vertane_chance_html.txt,200,html,Indexable,3,19,0,1132,3,1,1,fachportal_roche_de_fachgebiete_onkologie_artikel_eine_vertane_chance_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_eine_vertane_chance_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_eine_vertane_chance_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-15.082453,4.0723963,0,"The content outlines the various therapeutic areas and services offered by Roche, detailing specific fields such as oncology, neuroscience, and hematology. It provides an overview of Roche's products, clinical data, downloadable materials, and medical inquiries, emphasizing a focus on personalized therapy and the importance of molecular diagnostics in cancer treatment. Additionally, it includes insights from healthcare professionals, highlighting ongoing challenges in patient treatment and advancements in targeted therapies. The purpose is to inform healthcare professionals about Roche's offerings and current issues in treatment practices, particularly in oncology.","oncology, professionals, data",fachportal.roche.de,Falling,0.962585767053074,medium,345,General Offer Outline
133,https://fachportal.roche.de/fachgebiete/onkologie/artikel/fortschritt-durch-bispezifische-antikoerper.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_fortschritt_durch_bispezifische_antikoerper_html.txt,200,html,Indexable,3,42,0,1184,5,3,1,fachportal_roche_de_fachgebiete_onkologie_artikel_fortschritt_durch_bispezifische_antikoerper_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_fortschritt_durch_bispezifische_antikoerper_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_fortschritt_durch_bispezifische_antikoerper_html.txt.txt,['T'],Oncology-Hematology,Germany,Offer outline,"oncology, neuroscience, hematology, bispecific antibodies, cancer treatments, tumors, T cells",,-11.208087,2.7203047,0,"The content outlines the various therapeutic areas and products offered by Roche, emphasizing their focus on multiple fields such as oncology, neuroscience, hematology, and more. It highlights the role of bispecific antibodies in innovative cancer treatments, detailing their mechanisms and benefits in targeting tumors while recruiting T cells for enhanced therapeutic effects. The content serves as an information hub for healthcare professionals, providing clinical data, resources, and insights into Roche's drug pipeline and services, ultimately reflecting the company's commitment to advancing medical treatments and supporting patient care.","oncology, professionals, data",fachportal.roche.de,Falling,0.430411740454104,medium,93,General Offer Outline
134,https://fachportal.roche.de/fachgebiete/onkologie/artikel/gesundheitsdaten-aus-der-routineversorgung.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_gesundheitsdaten_aus_der_routineversorgung_html.txt,200,html,Indexable,3,42,0,1519,1,1,1,fachportal_roche_de_fachgebiete_onkologie_artikel_gesundheitsdaten_aus_der_routineversorgung_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_gesundheitsdaten_aus_der_routineversorgung_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_gesundheitsdaten_aus_der_routineversorgung_html.txt.txt,['RWD'],Oncology-Hematology,Germany,Research,,,-10.500193,-4.7809157,0,"The content serves as a resource hub for healthcare professionals involved with Roche's diverse range of pharmaceutical products and services, focusing heavily on areas such as oncology, neurology, and personalized medicine. It emphasizes the importance of integrating real-world data (RWD) into clinical practice and research, highlighting its potential to improve treatment outcomes and address gaps in patient care. The content also discusses advancements in research methodologies, such as registry-based randomized controlled trials (RRCTs), which are designed to provide insights closer to everyday clinical scenarios compared to traditional clinical trials. Overall, the purpose is to inform users about Roche's innovations while encouraging the use of comprehensive data to enhance medical practices.","oncology, professionals, data",fachportal.roche.de,All,0.553376864356782,medium,19,General Offer Outline
135,https://fachportal.roche.de/fachgebiete/onkologie/artikel/informatik-und-medizin.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_informatik_und_medizin_html.txt,200,html,Indexable,3,22,0,1667,1,1,1,fachportal_roche_de_fachgebiete_onkologie_artikel_informatik_und_medizin_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_informatik_und_medizin_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_informatik_und_medizin_html.txt.txt,"['Data', 'World', 'RWD', 'Real']",Other,Germany,Technology,,,-10.191096,-5.016935,0,"The content provides an overview of Roche's professional portal, highlighting various therapeutic areas such as oncology, neurology, and hematology, as well as the products and services Roche offers. It focuses on the integration of Real World Data (RWD) into clinical practices, advocating for its role in improving medical outcomes and managing risks associated with polypharmacy. The content emphasizes the importance of data analysis in healthcare, discussing challenges and methodologies involved in interpreting RWD to enhance patient care and inform treatment decisions. Overall, the content aims to showcase Roche's commitment to utilizing advanced data analysis to advance personalized medicine and improve healthcare delivery.","oncology, professionals, data",fachportal.roche.de,Rising,0.0498635107333398,medium,495,General Offer Outline
136,https://fachportal.roche.de/fachgebiete/onkologie/artikel/macht-individualisierte-medizin-erst-moeglich.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_macht_individualisierte_medizin_erst_moeglich_html.txt,200,html,Indexable,3,44,0,1845,2,1,0.981132075471698,fachportal_roche_de_fachgebiete_onkologie_artikel_macht_individualisierte_medizin_erst_moeglich_html.txt.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_macht_individualisierte_medizin_erst_moeglich_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_macht_individualisierte_medizin_erst_moeglich_html.txt.txt.txt,"['RWE', 'RCT']",Oncology-Hematology,Germany,Technology,,,-9.635142,-6.9835877,0,"The content outlines Roche's expertise across various medical fields, including oncology, hematology, and neurology, among others. It emphasizes the importance of integrating real-world evidence (RWE) with randomized clinical trial data (RCT) to enhance personalized medicine. The discussion highlights the challenges and opportunities related to patient data management and the transformative potential of digital health innovations. The overall purpose is to inform healthcare professionals about Roche's commitment to improving patient outcomes through advanced data utilization and innovative treatment strategies.","oncology, professionals, data",fachportal.roche.de,Flat,0.568077250862998,medium,148,General Offer Outline
137,https://fachportal.roche.de/fachgebiete/onkologie/artikel/muessen-wir-der-onkologie-einen-korb-geben.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_muessen_wir_der_onkologie_einen_korb_geben_html.txt,200,html,Indexable,3,42,0,2011,30,10,1,fachportal_roche_de_fachgebiete_onkologie_artikel_muessen_wir_der_onkologie_einen_korb_geben_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_muessen_wir_der_onkologie_einen_korb_geben_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_muessen_wir_der_onkologie_einen_korb_geben_html.txt.txt,[],Oncology-Hematology,Germany,Research,,,-11.548243,1.9211876,0,"The content primarily discusses Roche's focus on innovative clinical trial designs in oncology, particularly in the context of rare mutations and treatment options. It emphasizes the importance of new study methodologies, such as basket, umbrella, and platform studies, to effectively evaluate targeted therapies for small patient populations with limited treatment options. The piece underlines the challenges of recruiting participants for clinical trials and the potential of real-world data to complement clinical findings. Overall, the content aims to inform healthcare professionals about Roche's ongoing research efforts and the evolution of clinical study designs to enhance patient outcomes in oncology.","oncology, professionals, data",fachportal.roche.de,Falling,0.316006128344228,medium,39,General Offer Outline
138,https://fachportal.roche.de/fachgebiete/onkologie/artikel/neue-nenerationen-therapeutischer-antikoerper.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_neue_nenerationen_therapeutischer_antikoerper_html.txt,200,html,Indexable,3,44,0,1340,4,2,1,fachportal_roche_de_fachgebiete_onkologie_artikel_neue_nenerationen_therapeutischer_antikoerper_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_neue_nenerationen_therapeutischer_antikoerper_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_neue_nenerationen_therapeutischer_antikoerper_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-20.532602,7.751813,0,"The content is an overview of Roche's specialized medical fields and its products related to various areas such as oncology, neuroscience, and rheumatology. It highlights Roche's advancements in therapeutic antibodies, particularly bispecific antibodies, emphasizing their potential in improving treatment options for complex diseases like cancer. The content serves as an informative resource for healthcare professionals, providing access to clinical data, downloadable materials, and updates on Roche's ongoing product development and services. The main purpose is to present Roche's contributions to medical science and facilitate knowledge sharing among professionals in the pharmaceutical field.","oncology, professionals, data",fachportal.roche.de,All,0.980819514180299,medium,426,General Offer Outline
139,https://fachportal.roche.de/fachgebiete/onkologie/artikel/nutzung-von-versorgungsdaten-in-der-medizin.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_nutzung_von_versorgungsdaten_in_der_medizin_html.txt,200,html,Indexable,3,43,0,1533,1,1,1,fachportal_roche_de_fachgebiete_onkologie_artikel_nutzung_von_versorgungsdaten_in_der_medizin_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_nutzung_von_versorgungsdaten_in_der_medizin_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_nutzung_von_versorgungsdaten_in_der_medizin_html.txt.txt,['Germany'],Oncology-Hematology,Germany,Other,,,-9.77101,-6.9994545,0,"The content provides an overview of Roche's specialized areas in healthcare, emphasizing therapeutic fields like neuroscience, oncology, and precision medicine. It details the company's products, clinical data, and downloadable resources for healthcare professionals. Additionally, the content discusses the challenges and potential of utilizing real-world data in medical research in Germany, highlighting issues related to data privacy and the need for better infrastructure for data access and analysis. The overall purpose is to inform professionals about Roche's offerings and ongoing initiatives aimed at enhancing data-driven healthcare practices.","oncology, professionals, data",fachportal.roche.de,Falling,0.844998419112352,medium,31,General Offer Outline
140,https://fachportal.roche.de/fachgebiete/onkologie/artikel/onkodigital-brauchen-wir-noch-schnittstellen.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_onkodigital_brauchen_wir_noch_schnittstellen_html.txt,200,html,Indexable,3,46,0,907,3,1,0.980952380952381,fachportal_roche_de_fachgebiete_onkologie_artikel_onkodigital_brauchen_wir_noch_schnittstellen_html.txt.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_onkodigital_brauchen_wir_noch_schnittstellen_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_onkodigital_brauchen_wir_noch_schnittstellen_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-34.60187,5.567475,0,"The content appears to be an overview of Roche's specialized areas and services in pharmaceuticals, specifically targeting healthcare professionals. It includes sections on different medical fields such as neuroscience, oncology, and rheumatology, along with product listings, clinical data, downloadable resources, and additional services like medical inquiries and newsletters. The purpose of the content is to provide comprehensive information about Roche's products and initiatives, facilitating access to relevant data and resources for healthcare professionals engaged in various therapeutic domains.","oncology, professionals, data",fachportal.roche.de,Rising,0.38208602768485,medium,201,General Offer Outline
141,https://fachportal.roche.de/fachgebiete/onkologie/artikel/real-world-data-chancen-auf-eine-bessere-versorgung.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_real_world_data_chancen_auf_eine_bessere_versorgung_html.txt,200,html,Indexable,3,53,0,932,3,1,1,fachportal_roche_de_fachgebiete_onkologie_artikel_real_world_data_chancen_auf_eine_bessere_versorgung_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_real_world_data_chancen_auf_eine_bessere_versorgung_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_real_world_data_chancen_auf_eine_bessere_versorgung_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-25.315971,-2.720896,0,"The content outlines various sections of Roche's professional portal, detailing their focus areas such as neuroscience, oncology, and various therapeutic fields. It serves as a resource for medical professionals, providing an overview of Roche's products, clinical data, and downloadable materials. Additionally, it highlights services like newsletters, podcasts, and community platforms aimed at supporting patients and healthcare providers. The content emphasizes Roche's commitment to generating real-world data to enhance oncology care and the importance of integrating this information into treatment decisions.","oncology, professionals, data",fachportal.roche.de,All,0.953911911718062,medium,222,General Offer Outline
142,https://fachportal.roche.de/fachgebiete/onkologie/artikel/saemtliche-onkogene-entschluesselt.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_saemtliche_onkogene_entschluesselt_html.txt,200,html,Indexable,3,33,0,1100,3,1,1,fachportal_roche_de_fachgebiete_onkologie_artikel_saemtliche_onkogene_entschluesselt_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_saemtliche_onkogene_entschluesselt_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_saemtliche_onkogene_entschluesselt_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-20.408134,4.4580164,0,"The content is an overview of Roche's professional portal, highlighting various fields of expertise within the company, including neuroscience, oncology, and rheumatology. It outlines the availability of products, clinical data, downloadable materials, and additional services related to their offerings. Additionally, it showcases Roche's commitment to advancing cancer treatment through molecular genetic analysis and the identification of tumor-specific mutations. The purpose is to provide healthcare professionals with comprehensive resources and information about Roche's pharmaceutical solutions and ongoing research.","oncology, professionals, data",fachportal.roche.de,All,0.720356521189973,medium,416,General Offer Outline
143,https://fachportal.roche.de/fachgebiete/onkologie/artikel/wer-ist-das-bessere-molekulare-tumorboard.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_wer_ist_das_bessere_molekulare_tumorboard_html.txt,200,html,Indexable,3,42,0,1541,3,1,1,fachportal_roche_de_fachgebiete_onkologie_artikel_wer_ist_das_bessere_molekulare_tumorboard_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_wer_ist_das_bessere_molekulare_tumorboard_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_wer_ist_das_bessere_molekulare_tumorboard_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-10.630655,-6.481482,0,"The content outlines the various areas of expertise and product categories offered by Roche, focusing on specific fields such as neuroscience, oncology, and personalized medicine. It discusses the integration of clinical data, downloadable resources, and services aimed at healthcare professionals. Additionally, the content highlights the use of artificial intelligence in molecular tumor boards, emphasizing its potential to enhance efficiency in decision-making processes while also acknowledging the necessity of human oversight. Overall, the purpose is to provide healthcare professionals with comprehensive information on Roche's products and services, as well as insights into innovations within oncology.","oncology, professionals, data",fachportal.roche.de,All,0.912218793221713,medium,171,General Offer Outline
144,https://fachportal.roche.de/fachgebiete/onkologie/artikel/wir-werden-an-den-punkt-einer-selbstlernenden-medizin-kommen.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_wir_werden_an_den_punkt_einer_selbstlernenden_medizin_kommen_html.txt,200,html,Indexable,3,60,0,2132,3,1,1,fachportal_roche_de_fachgebiete_onkologie_artikel_wir_werden_an_den_punkt_einer_selbstlernenden_medizin_kommen_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_wir_werden_an_den_punkt_einer_selbstlernenden_medizin_kommen_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_wir_werden_an_den_punkt_einer_selbstlernenden_medizin_kommen_html.txt.txt,"['Munich', 'COVID', 'Ludwig', 'Maximilian', 'University']",Other,Germany,Research,,,-9.303841,-6.754875,0,"The content serves as an overview of Roche’s specialized areas and product offerings, focusing on various fields such as neuroscience, oncology, and personalized medicine. It also emphasizes the importance of data sharing and collaboration during the COVID-19 pandemic and outlines ongoing projects, particularly a partnership with Ludwig Maximilian University in Munich aimed at improving the accessibility and utility of clinical data for advancements in research and patient care. The content highlights challenges and progress in integrating medical data while advocating for patient privacy, ultimately aspiring to enhance treatment efficacy through better data utilization in healthcare.","oncology, professionals, data",fachportal.roche.de,All,0.282067185837861,medium,374,General Offer Outline
145,https://fachportal.roche.de/fachgebiete/onkologie/artikel/zielgerichteter-ansatz-an-krebszellen.html,6,fachportal_roche_de_fachgebiete_onkologie_artikel_zielgerichteter_ansatz_an_krebszellen_html.txt,200,html,Indexable,3,37,0,1272,4,2,1,fachportal_roche_de_fachgebiete_onkologie_artikel_zielgerichteter_ansatz_an_krebszellen_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_artikel_zielgerichteter_ansatz_an_krebszellen_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_artikel_zielgerichteter_ansatz_an_krebszellen_html.txt.txt,"['Conjugates', 'Antibody', 'Drug', 'ADC']",Oncology-Hematology,Germany,Medication information,"oncology, Antibody-Drug Conjugates (ADCs)",,-9.996444,1.7758046,0,"The content provides a comprehensive overview of Roche's various therapeutic areas and product offerings, emphasizing oncology and related treatments. It details advanced medication approaches such as Antibody-Drug Conjugates (ADCs), which are designed to target cancer cells more effectively while minimizing effects on healthy cells. The content aims to inform healthcare professionals about Roche's innovative technologies, current products, clinical data, and the potential future applications of ADC technology in oncology and beyond. Additionally, it includes resources for medical inquiries and patient support.","oncology, professionals, data",fachportal.roche.de,Flat,0.878801667689768,medium,358,General Offer Outline
146,https://fachportal.roche.de/fachgebiete/onkologie/chips/zukunft-der-onkologie.html,7,fachportal_roche_de_fachgebiete_onkologie_chips_zukunft_der_onkologie_html.txt,200,html,Indexable,2,21,0,1338,18,18,1,fachportal_roche_de_fachgebiete_onkologie_chips_zukunft_der_onkologie_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_chips_zukunft_der_onkologie_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_chips_zukunft_der_onkologie_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-22.708672,0.64697415,0,"The content outlines the various therapeutic areas and corresponding products offered by Roche, emphasizing their focus on multiple fields including neuroscience, oncology, and personalized medicine. It also highlights the availability of clinical data, downloadable resources, and services for healthcare professionals, such as medical inquiries and podcasts. The content aims to provide comprehensive information and support for professionals working in medicine and healthcare, particularly in oncology and related fields, ensuring they have access to essential resources and data for informed decision-making.","oncology, professionals, data",fachportal.roche.de,All,0.951496206432656,high,220,General Offer Outline
147,https://fachportal.roche.de/fachgebiete/onkologie/onkologie.html,7,fachportal_roche_de_fachgebiete_onkologie_onkologie_html.txt,200,html,Indexable,1,9,0,1051,107,54,1,fachportal_roche_de_fachgebiete_onkologie_onkologie_html.txt,image/fachportal_roche_de_fachgebiete_onkologie_onkologie_html.txt.png,text/fachportal_roche_de_fachgebiete_onkologie_onkologie_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-26.032925,0.3203593,0,"The content appears to be an overview of Roche's specialized medical portal, focusing on various therapeutic areas including neuroscience, oncology, and hematology. It highlights available products, clinical data, resources for medical professionals, and support services such as newsletters, podcasts, and medical inquiries. The purpose is to provide healthcare professionals with accessible information about Roche's offerings and innovations in treatment, particularly for cancer and other serious conditions, thereby facilitating better patient care.","oncology, professionals, data",fachportal.roche.de,Rising,0.26304272779362,high,145,General Offer Outline
148,https://fachportal.roche.de/fachgebiete/ophthalmologie/artikel/ophthaversum-for-nurses.html,6,fachportal_roche_de_fachgebiete_ophthalmologie_artikel_ophthaversum_for_nurses_html.txt,200,html,Indexable,,23,0,1314,2,2,1,fachportal_roche_de_fachgebiete_ophthalmologie_artikel_ophthaversum_for_nurses_html.txt,image/fachportal_roche_de_fachgebiete_ophthalmologie_artikel_ophthaversum_for_nurses_html.txt.png,text/fachportal_roche_de_fachgebiete_ophthalmologie_artikel_ophthaversum_for_nurses_html.txt.txt,['Vabysmo'],Oncology-Hematology,Germany,Offer outline,"Vabysmo, safety monitoring, regulatory compliance",,-30.346024,-22.731989,0,"The content primarily serves as an informational resource for healthcare professionals regarding Roche’s pharmaceutical products and services, particularly focusing on areas such as neuroscience and oncology. It includes sections on product overviews, clinical data, downloadable materials, and resources for healthcare practitioners. Additionally, it provides guidance on the handling and administration of specific medications like Vabysmo, highlighting safety monitoring and regulatory compliance. The purpose of the content is to facilitate informed use of Roche’s products and enhance communication between healthcare providers and the company.","oncology, professionals, data",fachportal.roche.de,Falling,0.863046763517304,medium,21,General Offer Outline
149,https://fachportal.roche.de/fachgebiete/ophthalmologie/artikel/telemedizin-teil-1.html,10,fachportal_roche_de_fachgebiete_ophthalmologie_artikel_telemedizin_teil_1_html.txt,200,html,Indexable,2,44,60,1319,4,2,0.976190476190476,fachportal_roche_de_fachgebiete_ophthalmologie_artikel_telemedizin_teil_1_html.txt.txt,image/fachportal_roche_de_fachgebiete_ophthalmologie_artikel_telemedizin_teil_1_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_ophthalmologie_artikel_telemedizin_teil_1_html.txt.txt.txt,[],Other,Germany,Offer outline,,,4.310513,6.680503,7,"The content provides an overview of Roche's specialized areas in medicine, focusing on various fields such as neuroscience, oncology, and ophthalmology. It outlines the company's medical products and services while emphasizing the importance of digital healthcare solutions, specifically telemedicine, in addressing challenges like accessibility and physician shortages. The content aims to inform healthcare professionals about Roche's offerings, the role of digital tools in modern medical practice, and guidance on integrating telemedicine into clinical workflows.","event, exclusive, website",fachportal.roche.de,Rising,0.0169480331990109,high,268,Events & Patient Care
150,https://fachportal.roche.de/fachgebiete/ophthalmologie/ophthaversum.html,7,fachportal_roche_de_fachgebiete_ophthalmologie_ophthaversum_html.txt,200,html,Indexable,1,14,0,1111,33,18,0.971428571428571,fachportal_roche_de_fachgebiete_ophthalmologie_ophthaversum_html.txt.txt,image/fachportal_roche_de_fachgebiete_ophthalmologie_ophthaversum_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_ophthalmologie_ophthaversum_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-29.853964,11.294838,0,"The content outlines the various therapeutic areas and products offered by Roche, focusing on specific fields such as neuroscience, oncology, and ophthalmology. It provides an overview of Roche's medical resources, including clinical data, downloadable materials, and services for healthcare professionals. Additionally, it emphasizes Roche's initiatives in telemedicine and patient engagement, aiming to enhance medical care and inform healthcare providers about recent advancements. The purpose is to serve as a comprehensive resource for medical professionals seeking information about Roche’s products, clinical studies, and ongoing educational events.","oncology, professionals, data",fachportal.roche.de,Rising,0.508675472054522,high,62,General Offer Outline
151,https://fachportal.roche.de/fachgebiete/pneumologie/pneumologie.html,9,fachportal_roche_de_fachgebiete_pneumologie_pneumologie_html.txt,200,html,Indexable,3,11,66,1304,2,2,0.96969696969697,fachportal_roche_de_fachgebiete_pneumologie_pneumologie_html.txt.txt,image/fachportal_roche_de_fachgebiete_pneumologie_pneumologie_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_pneumologie_pneumologie_html.txt.txt.txt,[],Other,Germany,Disease information,"oncology, neurology, respiratory diseases, idiopathic pulmonary fibrosis, cystic fibrosis","idiopathic pulmonary fibrosis, cystic fibrosis",-30.240103,5.7011056,0,"The content primarily serves as an informative portal for healthcare professionals regarding Roche's various therapeutic areas and products. It outlines key medical specialties such as oncology, neurology, and respiratory diseases, highlighting specific conditions like idiopathic pulmonary fibrosis and cystic fibrosis. Additionally, it provides access to clinical data, downloadable materials, and resources for medical inquiries, underscoring Roche's commitment to educating professionals about its pharmaceutical offerings and ongoing research developments. The overall purpose is to facilitate access to crucial medical information and promote Roche’s products within the healthcare community.","oncology, professionals, data",fachportal.roche.de,Falling,0.815608283897782,high,392,General Offer Outline
152,https://fachportal.roche.de/fachgebiete/praezisionsmedizin/chips/die-erste-frage.html?namespace=s7classic,6,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_die_erste_frage_html_namespace_s7classic.txt,200,html,Non-Indexable,4,15,0,841,0,0,0.980582524271845,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_die_erste_frage_html_namespace_s7classic.txt.txt,image/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_die_erste_frage_html_namespace_s7classic.txt.txt.png,text/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_die_erste_frage_html_namespace_s7classic.txt.txt.txt,"['Medicine', 'Precision']",Other,Germany,Technology,,,-8.389559,-5.8381166,0,"The content features a section from Roche's professional website, focusing on ""Precision Medicine."" It highlights the importance of recognizing individual differences in patients to tailor treatments effectively. The content suggests that understanding these distinctions is fundamental to the principles of precision medicine, hinting at further exploration of the topic through additional links and resources.","oncology, professionals, data",fachportal.roche.de,Rising,0.594304677960351,medium,112,General Offer Outline
153,https://fachportal.roche.de/fachgebiete/praezisionsmedizin/chips/die-erste-frage.html,6,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_die_erste_frage_html.txt,200,html,Non-Indexable,3,15,0,841,18,6,1,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_die_erste_frage_html.txt,image/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_die_erste_frage_html.txt.png,text/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_die_erste_frage_html.txt.txt,"['Medicine', 'Precision']",Other,Germany,Disease information,,,-0.25157002,-1.6702925,7,"The content presents a webpage from Roche's professional portal, focusing on the topic of ""Precision Medicine."" It highlights the need to understand individual differences in patients to tailor medical treatments effectively. The accompanying graphics and layout suggest a user-friendly approach to conveying complex medical information, with options for exploring related themes such as therapeutic applications and key focus areas within the field.","event, exclusive, website",fachportal.roche.de,Falling,0.403440100978145,medium,105,Events & Patient Care
154,https://fachportal.roche.de/fachgebiete/praezisionsmedizin/chips/entitaetsunabhaengiger_therapieansatz.html,9,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_entitaetsunabhaengiger_therapieansatz_html.txt,200,html,Indexable,3,35,210,1119,15,12,1,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_entitaetsunabhaengiger_therapieansatz_html.txt,image/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_entitaetsunabhaengiger_therapieansatz_html.txt.png,text/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_entitaetsunabhaengiger_therapieansatz_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-27.476038,-3.2430146,0,"The content primarily focuses on Roche's various therapeutic areas and products, detailing their offerings in fields such as neuroscience, oncology, and hematology, among others. It emphasizes clinical data, downloadable resources, and educational materials for healthcare professionals. The content also highlights Roche's commitment to precision medicine and personalized treatment approaches, particularly in oncology, and encourages engagement through channels like newsletters and podcasts. Overall, the purpose is to provide comprehensive support and information for medical professionals regarding Roche's innovations and services.","oncology, professionals, data",fachportal.roche.de,Falling,0.890699539712929,high,337,General Offer Outline
155,https://fachportal.roche.de/fachgebiete/praezisionsmedizin/chips/experteninterview-benedikt-westphalen.html,9,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_experteninterview_benedikt_westphalen_html.txt,200,html,Non-Indexable,3,45,139,3096,2,2,1,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_experteninterview_benedikt_westphalen_html.txt,image/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_experteninterview_benedikt_westphalen_html.txt.png,text/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_experteninterview_benedikt_westphalen_html.txt.txt,"['CUPISCO', 'CUP']",Oncology-Hematology,Germany,Offer outline,,cancer of unknown primary,-10.142596,2.4649003,0,"The content provides an overview of Roche's specialized fields and medical services, focusing on various oncology sub-disciplines and precision medicine. It highlights information on products, clinical data, and resources available for professionals, as well as detailing the significant findings of the CUPISCO study related to molecularly guided therapy for patients with cancer of unknown primary (CUP). The purpose of this content is to inform healthcare professionals about Roche's offerings, advancements in precision oncology, and the implications of recent clinical studies for treatment strategies.","oncology, professionals, data",fachportal.roche.de,Rising,0.641067004467389,high,25,General Offer Outline
156,https://fachportal.roche.de/fachgebiete/praezisionsmedizin/chips/experteninterview.html?namespace=s7classic,6,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_experteninterview_html_namespace_s7classic.txt,200,html,Non-Indexable,5,50,0,847,0,0,0.980952380952381,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_experteninterview_html_namespace_s7classic.txt.txt,image/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_experteninterview_html_namespace_s7classic.txt.txt.png,text/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_experteninterview_html_namespace_s7classic.txt.txt.txt,"['Arndt', 'PLATON', 'Vogel', 'Prof', 'Q', 'Dr']",Oncology-Hematology,Germany,Research,"pancreatic cancer, testing, treatment protocols, PLATON network",pancreatic cancer,9.950357,-5.126333,7,"The content features content from a professional portal focused on precision medicine, specifically discussing study results related to pancreatic cancer. It highlights a Q&A session with a medical expert, Prof. Dr. Arndt Vogel, addressing testing and treatment protocols while introducing insights into the PLATON network. The portal aims to provide healthcare professionals with access to clinical data, products, and valuable resources.","event, exclusive, website",fachportal.roche.de,All,0.798486339503166,medium,254,Events & Patient Care
157,https://fachportal.roche.de/fachgebiete/praezisionsmedizin/chips/experteninterview.html,6,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_experteninterview_html.txt,200,html,Indexable,4,50,0,847,6,2,0.976470588235294,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_experteninterview_html.txt.txt,image/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_experteninterview_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_experteninterview_html.txt.txt.txt,"['Arndt', 'Vogel', 'Prof', 'Dr']",Oncology-Hematology,Germany,Research,,pancreatic cancer,-1.3561597,-8.545305,7,"The content features content focused on precision medicine within Roche's professional portal. It discusses study results related to pancreatic cancer and includes insights from Prof. Dr. Arndt Vogel regarding testing and therapy practices. The portal also emphasizes access to exclusive benefits and services for healthcare professionals, highlighting Roche's commitment to providing valuable clinical data and resources.","event, exclusive, website",fachportal.roche.de,All,0.14760651735073,medium,58,Events & Patient Care
158,https://fachportal.roche.de/fachgebiete/praezisionsmedizin/chips/schwerpunktthemen.html?namespace=s7classic,6,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_schwerpunktthemen_html_namespace_s7classic.txt,200,html,Non-Indexable,4,17,0,1077,0,0,1,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_schwerpunktthemen_html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_schwerpunktthemen_html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_schwerpunktthemen_html_namespace_s7classic.txt.txt,[],Oncology-Hematology,Germany,Offer outline,"oncology, hematology, precision medicine, personalized medicine, cancer therapies, molecular alterations, cancer treatment",,-15.925608,0.54912686,0,"The content presented is an overview of Roche's professional website, which highlights their various therapeutic areas, products, clinical data, and services. It provides insights into fields such as oncology, hematology, and precision medicine, and offers access to podcasts, research materials, and downloadable resources. The purpose is to inform healthcare professionals about Roche's offerings, clinical insights, and advancements in treatments, particularly in personalized medicine and cancer therapies. Additionally, it emphasizes the importance of understanding molecular alterations in cancer treatment and facilitates engagement through expert dialogues and resources.","oncology, professionals, data",fachportal.roche.de,All,0.178526512356128,medium,99,General Offer Outline
159,https://fachportal.roche.de/fachgebiete/praezisionsmedizin/chips/schwerpunktthemen.html,6,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_schwerpunktthemen_html.txt,200,html,Indexable,3,17,0,1077,11,11,0.976470588235294,fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_schwerpunktthemen_html.txt.txt,image/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_schwerpunktthemen_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_praezisionsmedizin_chips_schwerpunktthemen_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-20.552187,0.23769383,0,"The content primarily revolves around the various therapeutic areas and products offered by Roche, including fields such as neuroscience, oncology, and precision medicine. It provides resources like clinical data, downloadable materials, and information about services for healthcare professionals. Additionally, the content emphasizes the importance of precision medicine and features insights from expert discussions and podcasts on current treatment landscapes and advancements in cancer therapies. Overall, the purpose is to serve as a comprehensive informational portal for professionals in the pharmaceutical and healthcare industries.","oncology, professionals, data",fachportal.roche.de,Falling,0.913938852334821,medium,488,General Offer Outline
160,https://fachportal.roche.de/fachgebiete/praezisionsmedizin.html,10,fachportal_roche_de_fachgebiete_praezisionsmedizin_html.txt,200,html,Indexable,2,17,196,2355,84,38,1,fachportal_roche_de_fachgebiete_praezisionsmedizin_html.txt,image/fachportal_roche_de_fachgebiete_praezisionsmedizin_html.txt.png,text/fachportal_roche_de_fachgebiete_praezisionsmedizin_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-21.878063,2.278042,0,"The content serves as an overview of Roche's professional portal, highlighting the company's focus areas in various fields such as neuroscience, oncology, and precision medicine. It outlines the resources available, including product details, clinical data, downloadable materials, and services for healthcare professionals. Additionally, it emphasizes the importance of personalized medicine and targeted therapies, particularly in cancer treatment, and provides information about ongoing studies and outcomes. The purpose is to offer comprehensive support and information for healthcare providers regarding Roche's products and advancements in treatment options.","oncology, professionals, data",fachportal.roche.de,Rising,0.277409991536323,high,457,General Offer Outline
161,https://fachportal.roche.de/fachgebiete/praezisionsmedizin/indikationen/umfassendes_tumorprofiling/ueber_umfassendes_tumorprofiling/umfassendes_tumorprofiling.html,6,fachportal_roche_de_fachgebiete_praezisionsmedizin_indikationen_umfassendes_tumorprofiling_ueber_umfassendes_tumorprofiling_umfassendes_tumorprofiling_html.txt,200,html,Indexable,3,26,0,1599,3,2,1,fachportal_roche_de_fachgebiete_praezisionsmedizin_indikationen_umfassendes_tumorprofiling_ueber_umfassendes_tumorprofiling_umfassendes_tumorprofiling_html.txt,image/fachportal_roche_de_fachgebiete_praezisionsmedizin_indikationen_umfassendes_tumorprofiling_ueber_umfassendes_tumorprofiling_umfassendes_tumorprofiling_html.txt.png,text/fachportal_roche_de_fachgebiete_praezisionsmedizin_indikationen_umfassendes_tumorprofiling_ueber_umfassendes_tumorprofiling_umfassendes_tumorprofiling_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-9.091348,1.7812697,0,"The content provides an overview of Roche's specialized areas in pharmaceuticals, emphasizing various medical fields such as oncology, neuroscience, and precision medicine. It highlights Roche's product offerings, clinical data, and various services aimed at healthcare professionals, including comprehensive genomic profiling for cancer treatment. Additionally, it outlines specific diagnostic tests available for solid tumors, such as FoundationOneCDx, and discusses the importance of understanding genomic alterations in personalizing cancer therapies. Overall, the content serves as a resource for healthcare professionals to access vital information on Roche's products, services, and research initiatives.","oncology, professionals, data",fachportal.roche.de,All,0.403764488665301,medium,452,General Offer Outline
162,https://fachportal.roche.de/fachgebiete/praezisionsmedizin/indikationen/zielgerichtete_therapie/ueber_zielgerichtete_therapie/zielgerichtete-therapie.html,9,fachportal_roche_de_fachgebiete_praezisionsmedizin_indikationen_zielgerichtete_therapie_ueber_zielgerichtete_therapie_zielgerichtete_therapie_html.txt,200,html,Indexable,3,23,126,1118,3,2,0.986842105263158,fachportal_roche_de_fachgebiete_praezisionsmedizin_indikationen_zielgerichtete_therapie_ueber_zielgerichtete_therapie_zielgerichtete_therapie_html.txt.txt,image/fachportal_roche_de_fachgebiete_praezisionsmedizin_indikationen_zielgerichtete_therapie_ueber_zielgerichtete_therapie_zielgerichtete_therapie_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_praezisionsmedizin_indikationen_zielgerichtete_therapie_ueber_zielgerichtete_therapie_zielgerichtete_therapie_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-19.782358,5.7069583,0,"The content outlines Roche's expertise across various medical fields such as neuroscience, oncology, and precision medicine, emphasizing their products and services. It discusses targeted therapies aimed at specific genetic abnormalities, contrasting them with traditional chemotherapy. The content also provides contact information for medical inquiries and highlights the company's commitment to personalized medicine through the understanding of genetic variations in patients. Overall, the content serves as a resource for healthcare professionals, offering insights into Roche's products, clinical data, and patient support initiatives.","oncology, professionals, data",fachportal.roche.de,Flat,0.672455187752677,high,128,General Offer Outline
163,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/artikel/lets_fokus.html?namespace=s7classic,9,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_lets_fokus_html_namespace_s7classic.txt,200,html,Non-Indexable,3,11,698,2165,0,0,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_lets_fokus_html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_lets_fokus_html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_lets_fokus_html_namespace_s7classic.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-19.665558,3.4263344,0,"The content focuses on Roche's specialized areas in pharmaceuticals, highlighting various medical fields such as oncology, neuroscience, and rheumatology. It serves as a comprehensive resource for professionals, providing access to product overviews, clinical data, downloadable materials, and additional services related to Roche's offerings. The purpose is to facilitate informed decision-making among healthcare professionals by presenting current evidence-based clinical information, along with insights into emerging treatment strategies like cancer immunotherapy. Overall, this platform aims to enhance the collaboration between different medical disciplines and improve patient care outcomes.","oncology, professionals, data",fachportal.roche.de,Falling,0.684885532268974,high,209,General Offer Outline
164,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/artikel/lets_fokus.html,10,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_lets_fokus_html.txt,200,html,Indexable,2,11,698,2165,12,6,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_lets_fokus_html.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_lets_fokus_html.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_lets_fokus_html.txt.txt,['NSCLC'],Oncology-Hematology,Germany,Offer outline,,non-small cell lung cancer,-15.748701,3.2339213,0,"The content focuses on Roche's specialized areas within the pharmaceutical field, such as oncology, neuroscience, and precision medicine. It provides an overview of Roche’s products, clinical data, and resources available for professionals including downloads, newsletters, and podcasts. The purpose is to inform healthcare professionals about Roche's offerings, facilitate access to clinical information, and support ongoing education and collaboration in areas like cancer immunotherapy and treatment strategies for non-small cell lung cancer (NSCLC). The content emphasizes the complexities of modern therapies and the importance of interdisciplinary approaches in oncology.","oncology, professionals, data",fachportal.roche.de,Flat,0.230763276005153,high,398,General Offer Outline
165,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/artikel/mehralslungenkrebs_annettesgeschichte.html,9,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_annettesgeschichte_html.txt,200,html,Indexable,3,42,42,2931,3,1,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_annettesgeschichte_html.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_annettesgeschichte_html.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_annettesgeschichte_html.txt.txt,['Annette'],Oncology-Hematology,Germany,Patient support,"oncology, neurology, precision medicine, lung cancer",lung cancer,-16.88959,-6.452888,0,"The content primarily serves as an informational portal for healthcare professionals regarding Roche's products and therapeutic areas. It covers various specialties, including oncology, neurology, and precision medicine, and provides details about Roche's medical services, clinical data, and downloadable resources. Additionally, it features patient stories, like that of Annette, a lung cancer survivor, highlighting her journey and the importance of awareness, early diagnosis, and support systems for patients with cancer. The purpose is to educate healthcare providers while also fostering community support and engagement in oncology.","oncology, professionals, data",fachportal.roche.de,All,0.0878756873848064,high,239,General Offer Outline
166,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/artikel/mehralslungenkrebs_christiansgeschichte.html,9,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_christiansgeschichte_html.txt,200,html,Indexable,3,44,56,2565,5,2,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_christiansgeschichte_html.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_christiansgeschichte_html.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_christiansgeschichte_html.txt.txt,[],Oncology-Hematology,Germany,Patient support,lung cancer,lung cancer,-15.714961,-3.4160676,0,"The content focuses on Roche's pharmaceutical offerings across multiple therapeutic areas, such as oncology, neuroscience, and ophthalmology. It provides an overview of their products and clinical data, alongside resources for healthcare professionals, including downloadable materials and access to events. Additionally, a personal narrative is included that highlights the experience of a lung cancer patient, emphasizing the emotional and psychological challenges faced during the diagnosis and treatment journey. This narrative aims to raise awareness and encourage dialogue about lung cancer, while also reflecting on the importance of patient engagement and shared decision-making in therapy options. Overall, the content intends to serve as a professional resource while fostering a deeper understanding of the patient experience in cancer treatment.","oncology, professionals, data",fachportal.roche.de,Falling,0.610044882661174,high,384,General Offer Outline
167,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/artikel/mehralslungenkrebs_evaundjuliasgeschichte.html,9,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_evaundjuliasgeschichte_html.txt,200,html,Indexable,3,95,71,3754,3,1,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_evaundjuliasgeschichte_html.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_evaundjuliasgeschichte_html.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_evaundjuliasgeschichte_html.txt.txt,[],Oncology-Hematology,Germany,Patient support,,lung cancer,-16.021885,-6.4501905,0,"The content of the content primarily focuses on Roche's expertise and product offerings in various therapeutic areas, such as oncology, neurology, and hematology. It describes the company's resources, including clinical data, downloadable materials, and support services for healthcare professionals. Additionally, the content highlights personal stories from patients dealing with lung cancer, illustrating their experiences and the importance of community and support networks. The purpose of the content is to inform healthcare professionals about Roche's services while providing a platform for patient engagement and education, emphasizing the need for open dialogue regarding cancer diagnoses and treatment options.","oncology, professionals, data",fachportal.roche.de,Rising,0.490604793950986,high,206,General Offer Outline
168,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/artikel/mehralslungenkrebs_karensgeschichte.html,9,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_karensgeschichte_html.txt,200,html,Indexable,3,40,61,2778,3,1,0.981132075471698,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_karensgeschichte_html.txt.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_karensgeschichte_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_karensgeschichte_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,lung cancer,-16.909182,-5.0022616,0,"The content serves as an overview of Roche's offerings, focusing on various medical specialties like neuroscience, oncology, and precision medicine. It highlights the company's products, clinical data, and services, designed for healthcare professionals. Additionally, it features personal stories, such as that of a lung cancer activist, which aims to raise awareness about lung cancer and the importance of individualized treatment strategies. The narrative emphasizes the need for sensitivity regarding patient experiences and challenges prevailing stigmas associated with lung cancer. Overall, the content aims to inform and educate medical professionals about Roche's contributions to patient care, while also advocating for greater understanding and support for those living with cancer.","oncology, professionals, data",fachportal.roche.de,Flat,0.731491119841366,high,167,General Offer Outline
169,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/artikel/mehralslungenkrebs_nilsgeschichte.html,9,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_nilsgeschichte_html.txt,200,html,Indexable,3,38,81,2613,3,1,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_nilsgeschichte_html.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_nilsgeschichte_html.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_nilsgeschichte_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-25.635674,-3.1163435,0,"The content is structured as a resource portal for healthcare professionals focusing on Roche's various therapeutic areas, including neuroscience, oncology, and precision medicine. It provides an overview of Roche's products, clinical data, downloadable materials, and services available for healthcare professionals. Additionally, it showcases patient stories, emphasizing personal experiences with cancer treatment and the importance of seeking second opinions in medical care. The purpose of the content is to inform healthcare professionals about Roche's offerings while highlighting the human aspect of patient care through real-life narratives.","oncology, professionals, data",fachportal.roche.de,Flat,0.512395693596167,high,206,General Offer Outline
170,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/artikel/mehralslungenkrebs_uwesgeschichte.html,9,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_uwesgeschichte_html.txt,200,html,Indexable,3,38,57,2465,3,1,0.980769230769231,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_uwesgeschichte_html.txt.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_uwesgeschichte_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_mehralslungenkrebs_uwesgeschichte_html.txt.txt.txt,[],Oncology-Hematology,Germany,Disease information,"oncology, nephrology, rheumatology, lung cancer, early detection, patient engagement, support networks",lung cancer,-15.645775,-5.867124,0,"The content primarily serves as an informational guide for healthcare professionals regarding Roche's therapeutic areas, products, clinical data, and available services. It outlines specific fields of focus, such as oncology, nephrology, and rheumatology, while providing access to clinical data and downloadable resources. Additionally, the narrative includes a personal story about a lung cancer survivor, emphasizing the psychological impacts of cancer and the importance of early detection, patient engagement, and support networks. The content aims to raise awareness about lung cancer, showcasing individual experiences alongside the professional information provided by Roche, fostering a comprehensive understanding of both the medical and human aspects of cancer treatment.","oncology, professionals, data",fachportal.roche.de,Flat,0.28213613306963,high,137,General Offer Outline
171,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/artikel/operables-nsclc-lets-fokus-neue-chancen-beim-operablen-nsclc.html?namespace=s7classic,9,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_operables_nsclc_lets_fokus_neue_chancen_beim_operablen_nsclc_html_namespace_s7classic.txt,200,html,Non-Indexable,,47,531,2074,0,0,0.986754966887417,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_operables_nsclc_lets_fokus_neue_chancen_beim_operablen_nsclc_html_namespace_s7classic.txt.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_operables_nsclc_lets_fokus_neue_chancen_beim_operablen_nsclc_html_namespace_s7classic.txt.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_operables_nsclc_lets_fokus_neue_chancen_beim_operablen_nsclc_html_namespace_s7classic.txt.txt.txt,['NSCLC'],Oncology-Hematology,Germany,Disease information,"oncology, neuroscience, rare diseases, non-small cell lung cancer (NSCLC), cancer treatments, side effects",non-small cell lung cancer,-16.146862,2.1743486,0,"The content outlines Roche's specialized areas in pharmaceuticals, emphasizing various therapeutic fields such as oncology, neuroscience, and rare diseases. It serves as a resource for healthcare professionals, providing an overview of Roche's products, clinical data, and downloadable materials. Additionally, it features video series and discussions focused on advancements in cancer treatments, specifically non-small cell lung cancer (NSCLC), aiming to educate and inform practitioners about the latest therapeutic strategies and research findings. The portal also includes resources for reporting side effects and other regulatory information.","oncology, professionals, data",fachportal.roche.de,Falling,0.446486859704318,high,55,General Offer Outline
172,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/artikel/operables-nsclc-lets-fokus-neue-chancen-beim-operablen-nsclc.html,9,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_operables_nsclc_lets_fokus_neue_chancen_beim_operablen_nsclc_html.txt,200,html,Indexable,,47,531,2074,0,0,0.984732824427481,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_operables_nsclc_lets_fokus_neue_chancen_beim_operablen_nsclc_html.txt.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_operables_nsclc_lets_fokus_neue_chancen_beim_operablen_nsclc_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_operables_nsclc_lets_fokus_neue_chancen_beim_operablen_nsclc_html.txt.txt.txt,"['Fachportal', 'NSCLC']",Oncology-Hematology,Germany,Offer outline,"non-small cell lung cancer (NSCLC), adjuvant therapies, immunotherapy",non-small cell lung cancer,-15.270705,5.8615847,0,"The content is an overview of Roche's Fachportal, highlighting various therapeutic areas such as neuroscience, oncology, and precision medicine. It emphasizes Roche's pharmaceutical products, clinical data, and educational resources for medical professionals. Additionally, it features discussions on the treatment of conditions like non-small cell lung cancer (NSCLC), focusing on the importance of adjuvant therapies and immunotherapy. The purpose of the content is to provide healthcare professionals with insights, research, and tools to enhance patient care and treatment decision-making.","oncology, professionals, data",fachportal.roche.de,Falling,0.450666509832242,high,230,General Offer Outline
173,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/artikel/Perspektivwechsel-opNSCLC.html,9,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_Perspektivwechsel_opNSCLC_html.txt,200,html,Indexable,3,67,195,3248,19,4,0.979166666666667,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_Perspektivwechsel_opNSCLC_html.txt.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_Perspektivwechsel_opNSCLC_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_Perspektivwechsel_opNSCLC_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-21.46896,1.1723487,0,"The content serves as an overview of Roche's specialized fields and resources dedicated to healthcare professionals. It highlights various therapeutic areas, including oncology, neuroscience, and precision medicine, and provides access to Roche's products, clinical data, and downloadable educational materials. Additionally, it emphasizes the importance of personalized treatment approaches in oncology and features case studies and medical insights related to specific treatments. The content aims to support professionals in understanding and utilizing Roche's offerings for enhanced patient care.","oncology, professionals, data",fachportal.roche.de,Rising,0.114202632881966,high,282,General Offer Outline
174,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/artikel/symposien-mitschnitte-deutsche-gesellschaft-fuer-pneumologie-und-beatmungsmedizin-e-v-2024.html?namespace=s7classic,6,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_symposien_mitschnitte_deutsche_gesellschaft_fuer_pneumologie_und_beatmungsmedizin_e_v_2024_html_namespace_s7classic.txt,200,html,Non-Indexable,3,93,0,1109,0,0,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_symposien_mitschnitte_deutsche_gesellschaft_fuer_pneumologie_und_beatmungsmedizin_e_v_2024_html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_symposien_mitschnitte_deutsche_gesellschaft_fuer_pneumologie_und_beatmungsmedizin_e_v_2024_html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_symposien_mitschnitte_deutsche_gesellschaft_fuer_pneumologie_und_beatmungsmedizin_e_v_2024_html_namespace_s7classic.txt.txt,[],Oncology-Hematology,Germany,Offer outline,"immunotherapy, lung cancer",lung cancer,-18.563377,-0.13349111,0,"The content highlights the various therapeutic areas and products offered by Roche, including oncology, neuroscience, and hematology, among others. It serves as a professional resource for healthcare providers, providing access to clinical data, downloadable materials, and information on events and services. Additionally, the content discusses specific topics such as immunotherapy for lung cancer and invitations for registration to access more detailed evidence-based clinical information. Overall, its purpose is to inform and engage professionals in the healthcare field about Roche's offerings and advancements in medical science.","oncology, professionals, data",fachportal.roche.de,Falling,0.712522711380438,medium,62,General Offer Outline
175,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/artikel/symposien-mitschnitte-deutsche-gesellschaft-fuer-pneumologie-und-beatmungsmedizin-e-v-2024.html,7,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_symposien_mitschnitte_deutsche_gesellschaft_fuer_pneumologie_und_beatmungsmedizin_e_v_2024_html.txt,200,html,Indexable,2,93,0,1109,6,2,0.987577639751553,fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_symposien_mitschnitte_deutsche_gesellschaft_fuer_pneumologie_und_beatmungsmedizin_e_v_2024_html.txt.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_symposien_mitschnitte_deutsche_gesellschaft_fuer_pneumologie_und_beatmungsmedizin_e_v_2024_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_artikel_symposien_mitschnitte_deutsche_gesellschaft_fuer_pneumologie_und_beatmungsmedizin_e_v_2024_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,"immunotherapy, lung cancer","lung cancer, immunotherapy",-20.809881,2.652657,0,"The content of the content outlines the various therapeutic areas and products associated with Roche, focusing on specialized fields such as neuroscience, oncology, and precision medicine. It describes available resources, including clinical data and downloadable materials, intended for medical professionals. Additionally, it highlights events and educational content, such as symposiums and podcasts, aimed at advancing knowledge in specific medical topics, particularly in relation to lung cancer and immunotherapy. The overall purpose is to provide healthcare professionals with comprehensive access to Roche's pharmaceutical offerings and relevant medical information.","oncology, professionals, data",fachportal.roche.de,Flat,0.913139128816316,high,13,General Offer Outline
176,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/chips/NSCLC.html?namespace=s7classic,10,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_NSCLC_html_namespace_s7classic.txt,200,html,Non-Indexable,2,5,78,2700,0,0,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_NSCLC_html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_NSCLC_html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_NSCLC_html_namespace_s7classic.txt.txt,"['Its', 'NSCLC']",Oncology-Hematology,Germany,Offer outline,"oncology, neurology, rheumatology, non-small cell lung cancer (NSCLC)",non-small cell lung cancer,-16.655766,4.031709,0,"The content appears to be a comprehensive overview of Roche's various areas of expertise and product offerings, targeting healthcare professionals. It includes detailed sections on therapeutic fields such as oncology, neurology, and rheumatology, along with a summary of available products, clinical data, and downloadable resources. The content promotes educational events, expert interviews, and recent findings, particularly related to non-small cell lung cancer (NSCLC) and other specific conditions. Its primary purpose is to provide medical professionals with valuable insights and resources to enhance their practice and stay updated on Roche’s innovations and therapies.","oncology, professionals, data",fachportal.roche.de,All,0.587782437298674,high,327,General Offer Outline
177,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/chips/NSCLC.html,10,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_NSCLC_html.txt,200,html,Indexable,1,5,78,2700,43,37,0.972972972972973,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_NSCLC_html.txt.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_NSCLC_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_NSCLC_html.txt.txt.txt,['NSCLC'],Oncology-Hematology,Germany,Offer outline,"immunotherapy, non-small cell lung cancer (NSCLC), oncology, neuroscience, precision medicine",non-small cell lung cancer,-14.59892,0.5188469,0,"The content primarily serves as a professional resource hub focused on various therapeutic areas and products offered by Roche. It outlines specific medical fields such as oncology, neuroscience, and precision medicine, and provides access to clinical data, product information, downloadable resources, and educational services for healthcare professionals. The content emphasizes recent advancements in cancer treatment, notably immunotherapy for non-small cell lung cancer (NSCLC), and highlights events, expert discussions, and interviews to support practitioners in staying informed about the latest research and therapeutic options.","oncology, professionals, data",fachportal.roche.de,Rising,0.673074650618325,high,300,General Offer Outline
178,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/chips/Operables_NSCLC.html?namespace=s7classic,6,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_Operables_NSCLC_html_namespace_s7classic.txt,200,html,Non-Indexable,3,15,0,2807,0,0,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_Operables_NSCLC_html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_Operables_NSCLC_html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_Operables_NSCLC_html_namespace_s7classic.txt.txt,['NSCLC'],Oncology-Hematology,Germany,Offer outline,"non-small cell lung cancer, molecular genetic testing, targeted therapies",non-small cell lung cancer,-12.9555855,1.7045494,0,"The content provided outlines Roche's specialized portal, focusing on various medical fields such as neuroscience, oncology, and precision medicine. It serves as a comprehensive resource for healthcare professionals, offering insights into Roche's products, clinical data, downloadable materials, and services related to specific diseases, particularly non-small cell lung cancer (NSCLC). The portal emphasizes the importance of molecular genetic testing, targeted therapies, and interprofessional collaboration in treatment pathways. Additionally, it features expert interviews and information on events, reflecting Roche's commitment to enhancing medical knowledge and patient care in oncology.","oncology, professionals, data",fachportal.roche.de,Rising,0.833344909890812,medium,368,General Offer Outline
179,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/chips/Operables_NSCLC.html,7,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_Operables_NSCLC_html.txt,200,html,Indexable,2,15,0,2807,34,30,0.976190476190476,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_Operables_NSCLC_html.txt.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_Operables_NSCLC_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_Operables_NSCLC_html.txt.txt.txt,['NSCLC'],Oncology-Hematology,Germany,Offer outline,,non-small cell lung cancer,-16.067259,1.276319,0,"The content of this content is focused on Roche's pharmaceutical offerings and expertise in various therapeutic areas, particularly oncology, including non-small cell lung cancer (NSCLC). It highlights Roche’s products, clinical data, services, and provides educational resources such as videos and expert interviews related to cancer treatments. The purpose of the content is to serve as a professional portal for healthcare providers, offering comprehensive information on Roche's innovations and therapies, latest clinical research, and tools aimed at improving patient outcomes in oncology and other medical fields.","oncology, professionals, data",fachportal.roche.de,Falling,0.42819832634401,high,147,General Offer Outline
180,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/chips/science_stories.html,7,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_science_stories_html.txt,200,html,Indexable,2,15,0,2758,28,28,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_science_stories_html.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_science_stories_html.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_science_stories_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-22.056997,0.8776454,0,"The content provides an overview of Roche's specialized areas, products, clinical data, and services targeted at healthcare professionals. It highlights specific therapeutic fields such as oncology, neurology, and precision medicine, alongside resources like newsletters, podcasts, and patient testimonials. The purpose is to inform medical professionals about Roche's offerings and recent advancements in cancer treatment and patient care, emphasizing the importance of personalized medicine and ongoing collaboration within the healthcare community.","oncology, professionals, data",fachportal.roche.de,Falling,0.13127824807089,high,207,General Offer Outline
181,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/chips/SCLC.html?namespace=s7classic,6,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_SCLC_html_namespace_s7classic.txt,200,html,Non-Indexable,3,7,0,2262,0,0,0.978494623655914,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_SCLC_html_namespace_s7classic.txt.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_SCLC_html_namespace_s7classic.txt.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_SCLC_html_namespace_s7classic.txt.txt.txt,['SCLC'],Oncology-Hematology,Germany,Research,"chemoimmunotherapy, small cell lung cancer (SCLC)",small cell lung cancer,-17.089323,0.3650711,0,"The content primarily focuses on Roche's specialization in various therapeutic areas, including oncology, neuroscience, and hematology. It serves as a professional portal providing healthcare professionals with an overview of Roche's products, clinical data, latest research findings, and information on therapies like chemoimmunotherapy for cancers such as small cell lung cancer (SCLC). Additionally, it offers resources like expert interviews and podcasts, emphasizing advancements in treatment strategies and patient care over the years. The purpose of this content is to inform and support healthcare professionals in their understanding and application of Roche's medical innovations and research in clinical practice.","oncology, professionals, data",fachportal.roche.de,Rising,0.0649408249756792,medium,163,General Offer Outline
182,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/chips/SCLC.html,7,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_SCLC_html.txt,200,html,Indexable,2,7,0,2262,30,30,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_SCLC_html.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_SCLC_html.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_chips_SCLC_html.txt.txt,['SCLC'],Oncology-Hematology,Germany,Research,"oncology, neuroscience, precision medicine, cancer immunotherapy, small cell lung cancer (SCLC)",small cell lung cancer,-15.740636,3.3261209,0,"The content provides an overview of Roche's specialized areas of expertise and the various therapeutic fields it addresses, such as oncology, neuroscience, and precision medicine. It highlights Roche's product offerings, clinical data, and educational resources for healthcare professionals, including downloadable materials, expert interviews, and information on recent clinical studies. Additionally, it discusses advancements in cancer immunotherapy, particularly in small cell lung cancer (SCLC), while emphasizing Roche's contributions to treatment options and patient care in this area. Overall, the purpose of the content is to inform medical professionals about Roche’s products, services, and ongoing research efforts in the pharmaceutical field.","oncology, professionals, data",fachportal.roche.de,Flat,0.294327063182318,high,172,General Offer Outline
183,https://fachportal.roche.de/fachgebiete/thorakale_onkologie.html?namespace=s7classic,7,fachportal_roche_de_fachgebiete_thorakale_onkologie_html_namespace_s7classic.txt,200,html,Non-Indexable,2,19,0,2616,0,0,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_html_namespace_s7classic.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,lung cancer,-23.48927,-4.579707,0,"The content provides an overview of Roche's professional portal, specifically detailing the company's focus areas, which include various medical fields like oncology, neuroscience, and rheumatology. It outlines sections dedicated to Roche's products, clinical data, downloadable materials, and additional services such as newsletters and podcasts. The content emphasizes the company's commitment to advancing healthcare through innovative therapies and personalized medicine, highlighting recent findings and expert discussions, particularly in lung cancer treatment. Overall, the purpose is to inform healthcare professionals about Roche's offerings and the latest developments in their therapeutic areas.","oncology, professionals, data",fachportal.roche.de,All,0.585632986115482,high,389,General Offer Outline
184,https://fachportal.roche.de/fachgebiete/thorakale_onkologie.html,7,fachportal_roche_de_fachgebiete_thorakale_onkologie_html.txt,200,html,Indexable,1,19,0,2616,40,36,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_html.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_html.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_html.txt.txt,['NSCLC'],Oncology-Hematology,Germany,Offer outline,,non-small cell lung cancer,-15.794973,4.3245206,0,"The content focuses on Roche's various therapeutic areas, including neuroscience, oncology, and precision medicine, emphasizing the company's medical products and services tailored for healthcare professionals. It provides an overview of clinical data, downloadable resources, and expert insights into cancer treatments, particularly for non-small cell lung cancer (NSCLC). The content also highlights ongoing events, podcasts, and expert interviews that discuss recent advancements and practical implications in the treatment of various diseases. Overall, the purpose is to inform healthcare professionals about Roche's offerings and facilitate access to important medical information and resources.","oncology, professionals, data",fachportal.roche.de,All,0.555671157396408,high,90,General Offer Outline
185,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/indikationen/nsclc_indikation/kit_beim_mnsclc/ansprechen_auf_kit.html,10,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_ansprechen_auf_kit_html.txt,200,html,Indexable,2,18,97,2723,8,8,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_ansprechen_auf_kit_html.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_ansprechen_auf_kit_html.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_ansprechen_auf_kit_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,"oncology, neuroscience, precision medicine, cancer immunotherapy",,-20.811623,3.4813116,0,"The content provides an overview of Roche's specialized fields in pharmaceuticals and their related products and services. It categorizes areas such as oncology, neuroscience, and precision medicine, highlighting the resources available for healthcare professionals, including clinical data, downloads, and medical inquiries. The purpose is to inform professionals about Roche's offerings, support their clinical practice, and facilitate access to current, evidence-based information. It also emphasizes the significance of personalized approaches in treatment and ongoing research in areas like cancer immunotherapy.","oncology, professionals, data",fachportal.roche.de,Flat,0.372423138920072,high,333,General Offer Outline
186,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/indikationen/nsclc_indikation/kit_beim_mnsclc/aus-dem-praxisalltag-bericht-einer-aerztin-zur-therapie-des-metastasierten-nsclc.html,10,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_aus_dem_praxisalltag_bericht_einer_aerztin_zur_therapie_des_metastasierten_nsclc_html.txt,200,html,Indexable,2,80,204,2867,8,8,0.989417989417989,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_aus_dem_praxisalltag_bericht_einer_aerztin_zur_therapie_des_metastasierten_nsclc_html.txt.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_aus_dem_praxisalltag_bericht_einer_aerztin_zur_therapie_des_metastasierten_nsclc_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_aus_dem_praxisalltag_bericht_einer_aerztin_zur_therapie_des_metastasierten_nsclc_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,"oncology, neuroscience, haemophilia, cancer immunotherapy, personalized medicine",,-23.783514,7.3962393,0,"The content of the content focuses on the various therapeutic areas and product offerings of Roche, a pharmaceutical company. It highlights specific fields such as oncology, neuroscience, and haemophilia, and provides access to clinical data, downloadable materials, and medical information services. Additionally, it discusses innovative therapies like cancer immunotherapy and personalized medicine, aiming to inform healthcare professionals about treatment options and resources available for patient care. The purpose is to serve as a comprehensive resource for medical professionals to access Roche's products and clinical insights effectively.","oncology, professionals, data",fachportal.roche.de,Falling,0.0825099279647853,high,466,General Offer Outline
187,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/indikationen/nsclc_indikation/kit_beim_mnsclc/krebsimmuntherapie_beim_nsclc.html?namespace=s7classic,9,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_krebsimmuntherapie_beim_nsclc_html_namespace_s7classic.txt,200,html,Non-Indexable,3,54,171,2596,0,0,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_krebsimmuntherapie_beim_nsclc_html_namespace_s7classic.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_krebsimmuntherapie_beim_nsclc_html_namespace_s7classic.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_krebsimmuntherapie_beim_nsclc_html_namespace_s7classic.txt.txt,['NSCLC'],Oncology-Hematology,Germany,Offer outline,"immunotherapy, oncology, precision medicine, tailored therapies, non-small cell lung cancer (NSCLC)",non-small cell lung cancer,-16.009916,4.5035977,0,"The content outlines Roche's specialized offerings in various medical fields, including neuroscience, oncology, and immunotherapy. It serves as a professional portal where healthcare professionals can access information on Roche's products, clinical data, and additional resources. The purpose of the content is to provide detailed insights into Roche's treatment options, clinical trial data, and support services, promoting the company's commitment to precision medicine and tailored therapies for patients, particularly those with challenging conditions like non-small cell lung cancer (NSCLC). Additionally, it emphasizes the importance of individualized treatment approaches and the collaborative efforts across medical disciplines.","oncology, professionals, data",fachportal.roche.de,Rising,0.530043908436235,high,181,General Offer Outline
188,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/indikationen/nsclc_indikation/kit_beim_mnsclc/krebsimmuntherapie_beim_nsclc.html,10,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_krebsimmuntherapie_beim_nsclc_html.txt,200,html,Indexable,2,54,171,2596,15,9,0.985507246376812,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_krebsimmuntherapie_beim_nsclc_html.txt.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_krebsimmuntherapie_beim_nsclc_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_krebsimmuntherapie_beim_nsclc_html.txt.txt.txt,['NSCLC'],Oncology-Hematology,Germany,Offer outline,"none-small cell lung cancer (NSCLC), platinum-based chemotherapy",non-small cell lung cancer,-15.374234,4.798347,0,"The content provides an overview of Roche's expertise in various medical fields, including neuroscience, oncology, and precision medicine. It highlights the company’s range of products and services available to healthcare professionals, emphasizing clinical data and treatment options for conditions like non-small cell lung cancer (NSCLC). Additionally, it addresses practical challenges physicians face when treating patients with specific medical profiles, such as those ineligible for platinum-based chemotherapy, and encourages engagement through medical inquiries and access to evidence-based information on their portal. The purpose of the content is to inform healthcare professionals about Roche's products, share clinical insights, and facilitate communication regarding medical inquiries.","oncology, professionals, data",fachportal.roche.de,Rising,0.454752928743802,high,29,General Offer Outline
189,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/indikationen/nsclc_indikation/kit_beim_mnsclc/redir_ttf-1-negative-patient_innen.html,9,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_redir_ttf_1_negative_patient_innen_html.txt,200,html,Indexable,3,28,77,2599,6,6,0.986013986013986,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_redir_ttf_1_negative_patient_innen_html.txt.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_redir_ttf_1_negative_patient_innen_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_redir_ttf_1_negative_patient_innen_html.txt.txt.txt,['NSCLC'],Oncology-Hematology,Germany,Offer outline,"non-small cell lung cancer (NSCLC), targeted therapies",non-small cell lung cancer,-18.027857,1.8475056,0,"The content is an overview of the Roche professional portal, focusing on various medical specialties such as neuroscience, oncology, and precision medicine. It provides information about Roche’s products, clinical data, and resources available for healthcare professionals, including downloadable materials and details on targeted therapies, such as treatments for non-small cell lung cancer (NSCLC). The purpose of the content is to support medical professionals by offering access to evidence-based clinical information, therapeutic options, and efficient communication channels for medical inquiries related to Roche products.","oncology, professionals, data",fachportal.roche.de,Falling,0.33125070791587,high,164,General Offer Outline
190,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/indikationen/nsclc_indikation/kit_beim_mnsclc/redir_umfrage-ergebnisse_ttf-1_und_IC3.html,6,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_redir_umfrage_ergebnisse_ttf_1_und_IC3_html.txt,200,html,Indexable,3,32,0,2608,6,6,1,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_redir_umfrage_ergebnisse_ttf_1_und_IC3_html.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_redir_umfrage_ergebnisse_ttf_1_und_IC3_html.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_nsclc_indikation_kit_beim_mnsclc_redir_umfrage_ergebnisse_ttf_1_und_IC3_html.txt.txt,"['Tecentriq', 'Germany', 'NSCLC']",Oncology-Hematology,Germany,Offer outline,"Tecentriq, non-small cell lung cancer, precision medicine, immunotherapy, predictive biomarkers, diagnostics",non-small cell lung cancer,-10.391363,1.6867104,0,"The content is a detailed overview of Roche's medical and pharmaceutical services, emphasizing their products and clinical data across various therapeutic areas including oncology, hematology, and neuroscience. It highlights Roche's commitment to precision medicine and immunotherapy, particularly focusing on the efficacy of their drug Tecentriq for treating non-small cell lung cancer (NSCLC). The content also includes survey results regarding the awareness and application of predictive biomarkers by healthcare professionals in Germany, stressing the significance of diagnostics in optimizing treatment options. Overall, the purpose of the content is to inform healthcare professionals about Roche's products, clinical data, and the importance of individualized treatment approaches through biomarkers.","oncology, professionals, data",fachportal.roche.de,Flat,0.213615329971933,medium,287,General Offer Outline
191,https://fachportal.roche.de/fachgebiete/thorakale_onkologie/indikationen/sclc_indikation/ueber_das_sclc/extensive-stage_sclc.html,10,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_sclc_indikation_ueber_das_sclc_extensive_stage_sclc_html.txt,200,html,Indexable,2,22,607,2431,15,5,0.984251968503937,fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_sclc_indikation_ueber_das_sclc_extensive_stage_sclc_html.txt.txt,image/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_sclc_indikation_ueber_das_sclc_extensive_stage_sclc_html.txt.txt.png,text/fachportal_roche_de_fachgebiete_thorakale_onkologie_indikationen_sclc_indikation_ueber_das_sclc_extensive_stage_sclc_html.txt.txt.txt,['SCLC'],Oncology-Hematology,Germany,Disease information,"immunotherapy, chemotherapy, small cell lung cancer (SCLC)",small cell lung cancer,-14.376288,1.6979539,0,"The content primarily focuses on Roche's expertise and offerings in various medical fields, with a strong emphasis on oncology, specifically small cell lung cancer (SCLC) and its treatment advancements. It discusses the historical challenges in treating advanced SCLC, detailing how the introduction of immunotherapy combined with chemotherapy has significantly improved patient outcomes over the last five years. The content serves to inform healthcare professionals about Roche's products, services, and the latest treatment protocols, thereby supporting informed medical practice and patient care. Additionally, it provides access to clinical data, downloadable resources, and contact information for medical inquiries.","oncology, professionals, data",fachportal.roche.de,Falling,0.298885597490006,high,341,General Offer Outline
192,https://fachportal.roche.de/fachgebiete/uro_onkologie/uro_onkologie.html,7,fachportal_roche_de_fachgebiete_uro_onkologie_uro_onkologie_html.txt,200,html,Indexable,1,13,0,845,5,5,1,fachportal_roche_de_fachgebiete_uro_onkologie_uro_onkologie_html.txt,image/fachportal_roche_de_fachgebiete_uro_onkologie_uro_onkologie_html.txt.png,text/fachportal_roche_de_fachgebiete_uro_onkologie_uro_onkologie_html.txt.txt,"['Uro', 'Oncology']",Oncology-Hematology,Germany,Offer outline,"urothelial carcinoma, personalized medicine",urothelial carcinoma,4.479571,-11.251206,7,"The content highlights the Uro-Oncology section of Roche's professional portal, focusing on personalized medicine for urothelial carcinoma. It emphasizes the aim to enhance patient perspectives and outcomes in this area. The content is designed for medical professionals, offering resources related to Roche's products and clinical data relevant to uro-oncology.","event, exclusive, website",fachportal.roche.de,Rising,0.053228776215502,high,224,Events & Patient Care
193,https://fachportal.roche.de/legalpages/bildnachweise.html,10,fachportal_roche_de_legalpages_bildnachweise_html.txt,200,html,Non-Indexable,1,13,13,2006,1514,1514,1,fachportal_roche_de_legalpages_bildnachweise_html.txt,image/fachportal_roche_de_legalpages_bildnachweise_html.txt.png,text/fachportal_roche_de_legalpages_bildnachweise_html.txt.txt,[],Other,Germany,Offer outline,,,-29.654354,10.363844,0,"The content appears to provide a comprehensive overview of Roche's specialties and product offerings related to various medical fields, including neuroscience, oncology, ophthalmology, and hematology. It serves as a professional resource, offering access to clinical data, downloadable materials, and additional services relevant to healthcare professionals. The content also includes information on ongoing events, newsletters, and educational resources, catering to the needs of medical practitioners and researchers in the pharmaceutical sector.","oncology, professionals, data",fachportal.roche.de,Rising,0.139459646644326,high,300,General Offer Outline
194,https://fachportal.roche.de/legalpages/datenschutz.html?namespace=s7classic,10,fachportal_roche_de_legalpages_datenschutz_html_namespace_s7classic.txt,200,html,Non-Indexable,2,11,11,6782,0,0,0.972602739726027,fachportal_roche_de_legalpages_datenschutz_html_namespace_s7classic.txt.txt,image/fachportal_roche_de_legalpages_datenschutz_html_namespace_s7classic.txt.txt.png,text/fachportal_roche_de_legalpages_datenschutz_html_namespace_s7classic.txt.txt.txt,"['GDPR', 'EU']",Other,Germany,Metainformation,,,-6.4644375,-26.429369,3,"The content outlines Roche's product areas, services, and data privacy policies on their specialized website for medical professionals. It details various therapeutic fields, including neuroscience, oncology, and hematology, emphasizing the company's commitment to data protection for patients, customers, and partners. The purpose is to inform users about the available products and services while ensuring compliance with data protection regulations, including the EU's GDPR. It also covers user rights regarding data access, correction, and deletion, alongside technical details related to website use and cookies.","users, page, website",fachportal.roche.de,Flat,0.279789739439536,high,320,Website Metadata
195,https://fachportal.roche.de/legalpages/datenschutz.html,10,fachportal_roche_de_legalpages_datenschutz_html.txt,200,html,Non-Indexable,1,11,11,6782,1535,1515,1,fachportal_roche_de_legalpages_datenschutz_html.txt,image/fachportal_roche_de_legalpages_datenschutz_html.txt.png,text/fachportal_roche_de_legalpages_datenschutz_html.txt.txt,['GDPR'],Oncology-Hematology,Germany,Offer outline,,,-5.9977407,-26.291624,3,"The content outlines Roche's product offerings and services across various medical fields, including oncology, hematology, and ophthalmology. It emphasizes the importance of data privacy and explains how Roche processes personal data in accordance with global and local regulations, specifically referencing GDPR compliance. The content is designed for professionals seeking detailed information about Roche's products, clinical data, and services while ensuring that users understand their rights regarding personal data and privacy. The content also covers topics like website functionality, data protection measures, and the use of cookies, reflecting Roche's commitment to transparency and compliance.","users, page, website",fachportal.roche.de,Falling,0.902909858431244,high,265,Website Metadata
196,https://fachportal.roche.de/legalpages/impressum.html,7,fachportal_roche_de_legalpages_impressum_html.txt,200,html,Non-Indexable,1,9,9,904,1534,1515,0.96078431372549,fachportal_roche_de_legalpages_impressum_html.txt.txt,image/fachportal_roche_de_legalpages_impressum_html.txt.txt.png,text/fachportal_roche_de_legalpages_impressum_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-27.05607,10.701423,0,"The content is focused on providing an overview of Roche's various therapeutic areas, products, clinical data, and services available to professionals in the medical field. It highlights specific fields such as neuroscience, oncology, and hemophilia, and offers downloadable materials and resources. Additionally, there are sections for legal information, safety reporting, and contact details for Roche, indicating a comprehensive approach to support healthcare professionals and ensure accurate communication regarding pharmaceutical offerings.","oncology, professionals, data",fachportal.roche.de,Falling,0.878651523302372,high,59,General Offer Outline
197,https://fachportal.roche.de/legalpages/rechtliche-hinweise.html,10,fachportal_roche_de_legalpages_rechtliche_hinweise_html.txt,200,html,Non-Indexable,1,19,19,1168,1534,1515,1,fachportal_roche_de_legalpages_rechtliche_hinweise_html.txt,image/fachportal_roche_de_legalpages_rechtliche_hinweise_html.txt.png,text/fachportal_roche_de_legalpages_rechtliche_hinweise_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-34.15658,7.125894,0,"The content focuses on Roche's areas of specialization within the pharmaceutical industry, detailing various therapeutic domains such as neuroscience, oncology, and hematology. It outlines Roche's products and services, providing clinical data and downloadable materials for healthcare professionals. Additionally, the site includes legal disclaimers regarding the information provided and encourages reporting adverse effects related to Roche products. The overall purpose is to serve as a comprehensive resource for professionals seeking detailed information about Roche's offerings and relevant clinical insights.","oncology, professionals, data",fachportal.roche.de,Falling,0.802304498221525,high,242,General Offer Outline
198,https://fachportal.roche.de/medizinische_anfragen/medinfo_umfrageergebnisse.html,6,fachportal_roche_de_medizinische_anfragen_medinfo_umfrageergebnisse_html.txt,200,html,Indexable,3,25,0,1290,3,1,0.974358974358974,fachportal_roche_de_medizinische_anfragen_medinfo_umfrageergebnisse_html.txt.txt,image/fachportal_roche_de_medizinische_anfragen_medinfo_umfrageergebnisse_html.txt.txt.png,text/fachportal_roche_de_medizinische_anfragen_medinfo_umfrageergebnisse_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-35.74628,5.261553,0,"The content provides an overview of Roche's specialized areas and products, emphasizing their focus on various fields such as neuroscience, oncology, and precision medicine. It details available products, clinical data, and downloadable materials for healthcare professionals. Furthermore, it highlights Roche's commitment to customer feedback, showing how they evaluate and improve their medical information services based on user responses. The purpose of the content is to inform healthcare professionals about Roche's offerings and to facilitate effective communication and support regarding their pharmaceutical inquiries.","oncology, professionals, data",fachportal.roche.de,Rising,0.0869471831489023,medium,188,General Offer Outline
199,https://fachportal.roche.de/medizinische_anfragen/medizinische-anfragen.html,7,fachportal_roche_de_medizinische_anfragen_medizinische_anfragen_html.txt,200,html,Indexable,2,21,0,945,114,44,1,fachportal_roche_de_medizinische_anfragen_medizinische_anfragen_html.txt,image/fachportal_roche_de_medizinische_anfragen_medizinische_anfragen_html.txt.png,text/fachportal_roche_de_medizinische_anfragen_medizinische_anfragen_html.txt.txt,[],Other,Germany,Offer outline,,,-7.4425507,-18.754398,3,"The content depicts a section of Roche's professional portal, which emphasizes the provision of medical information. It highlights the company's commitment to addressing medical and pharmaceutical inquiries from healthcare professionals. The design features a visual element showcasing individuals engaged in conversation, reinforcing the collaborative approach to sharing knowledge and information. The portal aims to serve as a valuable resource for professionals seeking detailed insights into Roche's products and services.","users, page, website",fachportal.roche.de,Flat,0.56010549729449,high,284,Website Metadata
200,https://fachportal.roche.de/medizinische_anfragen/temperaturabweichungen.html,9,fachportal_roche_de_medizinische_anfragen_temperaturabweichungen_html.txt,200,html,Indexable,3,57,136,886,6,2,1,fachportal_roche_de_medizinische_anfragen_temperaturabweichungen_html.txt,image/fachportal_roche_de_medizinische_anfragen_temperaturabweichungen_html.txt.png,text/fachportal_roche_de_medizinische_anfragen_temperaturabweichungen_html.txt.txt,[],Other,Germany,Medication information,,,4.1067734,-34.652843,1,"The content features a section from Roche's professional portal, addressing inquiries regarding the storage of their products, particularly in cases where there has been a deviation from recommended storage temperatures. It invites users to seek an assessment on the usability of the medication under such conditions. The content emphasizes that only questions related to original Roche products will be addressed, and provides a web form to submit specific details about the product and temperature discrepancies.","drug, reporting, adverse",fachportal.roche.de,All,0.827973166722634,high,363,Drug Safety
201,https://fachportal.roche.de/medizinische_anfragen/wie-wir-arbeiten.html,9,fachportal_roche_de_medizinische_anfragen_wie_wir_arbeiten_html.txt,200,html,Indexable,3,19,162,873,6,2,1,fachportal_roche_de_medizinische_anfragen_wie_wir_arbeiten_html.txt,image/fachportal_roche_de_medizinische_anfragen_wie_wir_arbeiten_html.txt.png,text/fachportal_roche_de_medizinische_anfragen_wie_wir_arbeiten_html.txt.txt,[],Other,Germany,Offer outline,,,-31.263315,2.5436962,0,"The content is an overview of Roche's specialized areas, products, and services aimed at healthcare professionals. It provides information on various therapeutic fields such as neuroscience, oncology, and hematology, while also offering access to clinical data, downloadable materials, and support services for medical inquiries. The purpose is to facilitate the dissemination of detailed product information, foster communication with healthcare providers, and ensure the effective use of Roche's pharmaceutical products.","oncology, professionals, data",fachportal.roche.de,Rising,0.912854067175143,high,419,General Offer Outline
202,https://fachportal.roche.de/podcasts/expertendialoge/praezisionsoknkologie_onkologie_und_chirurgie_hand_in_hand.html,9,fachportal_roche_de_podcasts_expertendialoge_praezisionsoknkologie_onkologie_und_chirurgie_hand_in_hand_html.txt,200,html,Indexable,3,57,444,1044,63,21,1,fachportal_roche_de_podcasts_expertendialoge_praezisionsoknkologie_onkologie_und_chirurgie_hand_in_hand_html.txt,image/fachportal_roche_de_podcasts_expertendialoge_praezisionsoknkologie_onkologie_und_chirurgie_hand_in_hand_html.txt.png,text/fachportal_roche_de_podcasts_expertendialoge_praezisionsoknkologie_onkologie_und_chirurgie_hand_in_hand_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-22.333908,-0.35436058,0,"The content of the content primarily focuses on Roche's offerings in various specialized medical fields, including neuroscience, oncology, and precision medicine. It serves as a professional resource, providing an overview of Roche's products, clinical data, and available services. Additionally, the content highlights educational materials and resources such as podcasts and newsletters aimed at healthcare professionals, emphasizing the importance of personalized medicine and biomarker testing in oncology. Overall, the purpose is to inform and support healthcare providers with comprehensive information regarding Roche's medical products and innovations.","oncology, professionals, data",fachportal.roche.de,Rising,0.287665518156715,high,189,General Offer Outline
203,https://fachportal.roche.de/podcasts/expertendialoge/sprechen_sie_pathologisch.html,9,fachportal_roche_de_podcasts_expertendialoge_sprechen_sie_pathologisch_html.txt,200,html,Indexable,4,26,70,1044,4,2,1,fachportal_roche_de_podcasts_expertendialoge_sprechen_sie_pathologisch_html.txt,image/fachportal_roche_de_podcasts_expertendialoge_sprechen_sie_pathologisch_html.txt.png,text/fachportal_roche_de_podcasts_expertendialoge_sprechen_sie_pathologisch_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-19.6259,1.1787105,0,"The content of the content primarily focuses on Roche's specialized fields within pharmaceutical development, including various areas of oncology, neuroscience, and precision medicine, among others. It highlights product overviews, clinical data, downloadable resources, and services aimed at medical professionals. Additionally, it emphasizes the importance of communication and collaboration in oncology, particularly in the context of companion diagnostics and molecular testing. The purpose of the content is to provide healthcare professionals with resources, insights, and updates relevant to Roche's products and therapeutic areas.","oncology, professionals, data",fachportal.roche.de,All,0.0762510987448081,high,219,General Offer Outline
204,https://fachportal.roche.de/podcasts/expertendialoge/tiefe_einblicke_in_die_molekulare_testung.html,9,fachportal_roche_de_podcasts_expertendialoge_tiefe_einblicke_in_die_molekulare_testung_html.txt,200,html,Indexable,4,41,68,1148,15,7,0.979381443298969,fachportal_roche_de_podcasts_expertendialoge_tiefe_einblicke_in_die_molekulare_testung_html.txt.txt,image/fachportal_roche_de_podcasts_expertendialoge_tiefe_einblicke_in_die_molekulare_testung_html.txt.txt.png,text/fachportal_roche_de_podcasts_expertendialoge_tiefe_einblicke_in_die_molekulare_testung_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-25.878914,-5.0192285,0,"The content primarily serves as an informational portal for healthcare professionals regarding Roche's therapeutic areas and products. It encompasses various medical fields such as oncology, neurology, and precision medicine, providing an overview of Roche's offerings, clinical data, downloadable resources, and insights into molecular testing and diagnostics. The purpose is to facilitate access to Roche's products and clinical information while promoting knowledge sharing through resources like podcasts and expert dialogues. Overall, it aims to support professionals in their medical practice and enhance patient care.","oncology, professionals, data",fachportal.roche.de,Flat,0.34988305747975,high,336,General Offer Outline
205,https://fachportal.roche.de/podcasts/expertendialoge/vision_zero.html,9,fachportal_roche_de_podcasts_expertendialoge_vision_zero_html.txt,200,html,Indexable,3,11,57,1072,12,5,1,fachportal_roche_de_podcasts_expertendialoge_vision_zero_html.txt,image/fachportal_roche_de_podcasts_expertendialoge_vision_zero_html.txt.png,text/fachportal_roche_de_podcasts_expertendialoge_vision_zero_html.txt.txt,"['Vision', 'Zero']",Oncology-Hematology,Germany,Offer outline,,,-22.478521,5.753563,0,"The content appears to provide an overview of Roche's specialized fields, products, clinical data, services, and resources for healthcare professionals. It highlights various therapeutic areas including oncology, hematology, and neuroscience, indicating Roche’s commitment to personalized medicine and innovative treatments. Additionally, there are mentions of initiatives like Vision Zero aimed at reducing cancer-related mortality, emphasizing the importance of preventive strategies and patient involvement in treatment decisions. The site serves as a resource hub for professionals looking to access essential information about Roche's offerings and contribute to informed patient care.","oncology, professionals, data",fachportal.roche.de,All,0.377505727263774,high,187,General Offer Outline
206,https://fachportal.roche.de/podcasts/expertendialoge/was_tun_bei_schlechtem_allgemeinzustand.html,9,fachportal_roche_de_podcasts_expertendialoge_was_tun_bei_schlechtem_allgemeinzustand_html.txt,200,html,Indexable,4,70,70,1052,6,3,0.978947368421053,fachportal_roche_de_podcasts_expertendialoge_was_tun_bei_schlechtem_allgemeinzustand_html.txt.txt,image/fachportal_roche_de_podcasts_expertendialoge_was_tun_bei_schlechtem_allgemeinzustand_html.txt.txt.png,text/fachportal_roche_de_podcasts_expertendialoge_was_tun_bei_schlechtem_allgemeinzustand_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-25.75858,-3.1872935,0,"The content from the Roche website is focused on various therapeutic areas and products offered by the company, including neuroscience, oncology, and precision medicine. It provides an overview of clinical data related to their products, downloadable resources, and services available for healthcare professionals. Additionally, there are sections dedicated to podcasts and expert dialogues on specific medical topics, particularly in oncology, discussing treatment approaches and patient management. Overall, the purpose of the site is to serve as a professional resource for healthcare providers, offering detailed information on Roche's contributions to various medical fields.","oncology, professionals, data",fachportal.roche.de,Falling,0.410680553953067,high,441,General Offer Outline
207,https://fachportal.roche.de/podcasts/expertendialoge/was_tun_nach_op_beim_nsclc.html,9,fachportal_roche_de_podcasts_expertendialoge_was_tun_nach_op_beim_nsclc_html.txt,200,html,Indexable,4,27,452,1085,10,5,0.975609756097561,fachportal_roche_de_podcasts_expertendialoge_was_tun_nach_op_beim_nsclc_html.txt.txt,image/fachportal_roche_de_podcasts_expertendialoge_was_tun_nach_op_beim_nsclc_html.txt.txt.png,text/fachportal_roche_de_podcasts_expertendialoge_was_tun_nach_op_beim_nsclc_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-23.568573,1.4905533,0,"The content outlines the structure and offerings of Roche's professional portal, highlighting various therapeutic areas such as neuroscience, oncology, and rheumatology. It emphasizes the availability of Roche's products, clinical data, and downloadable resources, as well as services like newsletters and podcasts focused on current medical discussions. The content aims to inform healthcare professionals about Roche's contributions to therapeutic advancements and patient care, particularly in specialized medical fields. Additionally, it underscores the importance of molecular testing and personalized medicine in optimizing treatment options for patients, specifically in oncology.","oncology, professionals, data",fachportal.roche.de,Rising,0.858374371805947,high,247,General Offer Outline
208,https://fachportal.roche.de/produkte/dermatoonkologie_dermatologie/cotellic/produktuebersicht/produktinformation.html,7,fachportal_roche_de_produkte_dermatoonkologie_dermatologie_cotellic_produktuebersicht_produktinformation_html.txt,200,html,Indexable,2,31,0,1247,2,2,1,fachportal_roche_de_produkte_dermatoonkologie_dermatologie_cotellic_produktuebersicht_produktinformation_html.txt,image/fachportal_roche_de_produkte_dermatoonkologie_dermatologie_cotellic_produktuebersicht_produktinformation_html.txt.png,text/fachportal_roche_de_produkte_dermatoonkologie_dermatologie_cotellic_produktuebersicht_produktinformation_html.txt.txt,[],Other,Germany,Offer outline,,,-33.67964,5.1536956,0,"The content focuses on Roche's pharmaceutical offerings and services, categorizing them by medical specialties such as neuroscience, oncology, and rheumatology. It provides comprehensive product information, including clinical data, downloadable materials, and various services available for medical inquiries. The purpose is to serve healthcare professionals by providing essential resources related to Roche's products and their applications, alongside relevant medical and safety information. Additionally, it encourages engagement through account creation for accessing further clinical insights and resources.","oncology, professionals, data",fachportal.roche.de,All,0.826280344884603,high,20,General Offer Outline
209,https://fachportal.roche.de/produkte/dermatoonkologie_dermatologie/erivedge/produktuebersicht/produktinformation.html,7,fachportal_roche_de_produkte_dermatoonkologie_dermatologie_erivedge_produktuebersicht_produktinformation_html.txt,200,html,Indexable,2,31,0,1309,3,3,0.982608695652174,fachportal_roche_de_produkte_dermatoonkologie_dermatologie_erivedge_produktuebersicht_produktinformation_html.txt.txt,image/fachportal_roche_de_produkte_dermatoonkologie_dermatologie_erivedge_produktuebersicht_produktinformation_html.txt.txt.png,text/fachportal_roche_de_produkte_dermatoonkologie_dermatologie_erivedge_produktuebersicht_produktinformation_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-32.807503,4.519841,0,"The content serves as a comprehensive resource for professionals in the pharmaceutical field, specifically focusing on Roche's product offerings, clinical data, and therapeutic areas. It outlines various specialties, such as neuroscience, oncology, and rheumatology, and provides access to product information, educational materials, and clinical studies. Additionally, it offers options for medical inquiries and promotes user registration for unrestricted access to clinical information. Overall, the purpose is to support healthcare professionals with detailed and accessible information regarding Roche's pharmaceuticals and related services.","oncology, professionals, data",fachportal.roche.de,Falling,0.34354150865014,high,199,General Offer Outline
210,https://fachportal.roche.de/produkte/dermatoonkologie_dermatologie/zelboraf/produktuebersicht/produktinformation.html,7,fachportal_roche_de_produkte_dermatoonkologie_dermatologie_zelboraf_produktuebersicht_produktinformation_html.txt,200,html,Indexable,2,31,0,1289,3,3,1,fachportal_roche_de_produkte_dermatoonkologie_dermatologie_zelboraf_produktuebersicht_produktinformation_html.txt,image/fachportal_roche_de_produkte_dermatoonkologie_dermatologie_zelboraf_produktuebersicht_produktinformation_html.txt.png,text/fachportal_roche_de_produkte_dermatoonkologie_dermatologie_zelboraf_produktuebersicht_produktinformation_html.txt.txt,['Zelboraf'],Oncology-Hematology,Germany,Offer outline,"Zelboraf, melanoma, oncology, neuroscience, hematology, clinical data",melanoma,-20.275143,7.8082943,0,"The content serves as an overview of Roche's various therapeutic areas and offerings, including details about specific products like Zelboraf, which targets certain mutations in melanoma. It provides insights into Roche's focus on diverse medical fields such as oncology, neuroscience, and hematology, while also offering resources like clinical data, downloadable materials, and contact information for medical inquiries. The purpose is to inform healthcare professionals about Roche's products and services and to facilitate access to vital clinical information.","oncology, professionals, data",fachportal.roche.de,Falling,0.0394100201306769,high,128,General Offer Outline
211,https://fachportal.roche.de/produkte/gastrointestinale_onkologie/tecentriq_avastin_hcc/produktuebersicht/anwendungsbereich.html,7,fachportal_roche_de_produkte_gastrointestinale_onkologie_tecentriq_avastin_hcc_produktuebersicht_anwendungsbereich_html.txt,200,html,Indexable,2,47,0,2949,4,4,1,fachportal_roche_de_produkte_gastrointestinale_onkologie_tecentriq_avastin_hcc_produktuebersicht_anwendungsbereich_html.txt,image/fachportal_roche_de_produkte_gastrointestinale_onkologie_tecentriq_avastin_hcc_produktuebersicht_anwendungsbereich_html.txt.png,text/fachportal_roche_de_produkte_gastrointestinale_onkologie_tecentriq_avastin_hcc_produktuebersicht_anwendungsbereich_html.txt.txt,"['Avastin', 'Tecentriq']",Oncology-Hematology,Germany,Offer outline,"oncology, neuroscience, ophthalmology, Tecentriq, Avastin, liver cancer treatment, innovative therapies, clinical information",liver cancer,-20.39861,7.422293,0,"The content is structured as an overview of Roche's specialized areas, products, clinical data, and additional services tailored for healthcare professionals. It highlights various therapeutic fields, including oncology, neuroscience, and ophthalmology, while also providing details on specific products such as Tecentriq and Avastin for liver cancer treatment. Additionally, it emphasizes the importance of innovative therapies and access to current clinical information, encouraging professionals to register for unlimited access. The purpose is to serve as a comprehensive resource for medical professionals to understand Roche's offerings and advancements in treatment options.","oncology, professionals, data",fachportal.roche.de,Flat,0.152586675076665,high,130,General Offer Outline
212,https://fachportal.roche.de/produkte/gynaekoonkologie/herceptin/produktuebersicht/anwendungsbereich.html,7,fachportal_roche_de_produkte_gynaekoonkologie_herceptin_produktuebersicht_anwendungsbereich_html.txt,200,html,Indexable,2,31,0,3828,3,3,1,fachportal_roche_de_produkte_gynaekoonkologie_herceptin_produktuebersicht_anwendungsbereich_html.txt,image/fachportal_roche_de_produkte_gynaekoonkologie_herceptin_produktuebersicht_anwendungsbereich_html.txt.png,text/fachportal_roche_de_produkte_gynaekoonkologie_herceptin_produktuebersicht_anwendungsbereich_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-22.251362,3.0039704,0,"The content focuses on Roche's various therapeutic areas, products, and services aimed at healthcare professionals. It provides an overview of specific fields such as oncology, neurology, and rheumatology, along with detailed product information, clinical data, and access to downloadable resources. The purpose is to offer comprehensive medical information, resources for ongoing education, and facilitate communication for medical inquiries related to Roche's pharmaceutical offerings. Additionally, it highlights current studies and advancements in cancer treatment, emphasizing Roche's commitment to healthcare innovation.","oncology, professionals, data",fachportal.roche.de,All,0.759667887912336,high,357,General Offer Outline
213,https://fachportal.roche.de/produkte/gynaekoonkologie/kadcyla/produktuebersicht/anwendungsbereich.html,7,fachportal_roche_de_produkte_gynaekoonkologie_kadcyla_produktuebersicht_anwendungsbereich_html.txt,200,html,Indexable,2,30,0,2109,3,3,0.98,fachportal_roche_de_produkte_gynaekoonkologie_kadcyla_produktuebersicht_anwendungsbereich_html.txt.txt,image/fachportal_roche_de_produkte_gynaekoonkologie_kadcyla_produktuebersicht_anwendungsbereich_html.txt.txt.png,text/fachportal_roche_de_produkte_gynaekoonkologie_kadcyla_produktuebersicht_anwendungsbereich_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-30.256582,10.137315,0,"The content is an overview of Roche's specialized portal, targeting healthcare professionals. It outlines various therapeutic areas covered by Roche, such as oncology, neurology, and ophthalmology, and provides access to products, clinical data, and downloadable resources. The purpose is to facilitate information dissemination regarding Roche's pharmaceutical offerings, clinical studies, and tools for medical inquiries, ultimately enhancing patient care and professional engagement within the healthcare community.","oncology, professionals, data",fachportal.roche.de,Rising,0.211950624541,high,98,General Offer Outline
214,https://fachportal.roche.de/produkte/gynaekoonkologie/perjeta/produktuebersicht/anwendungsbereich.html,7,fachportal_roche_de_produkte_gynaekoonkologie_perjeta_produktuebersicht_anwendungsbereich_html.txt,200,html,Indexable,2,30,0,3210,4,4,1,fachportal_roche_de_produkte_gynaekoonkologie_perjeta_produktuebersicht_anwendungsbereich_html.txt,image/fachportal_roche_de_produkte_gynaekoonkologie_perjeta_produktuebersicht_anwendungsbereich_html.txt.png,text/fachportal_roche_de_produkte_gynaekoonkologie_perjeta_produktuebersicht_anwendungsbereich_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-34.623154,3.1559114,0,"The content serves as an overview and navigational guide for healthcare professionals seeking information about Roche's various therapeutic areas, products, clinical data, and services. It highlights key focus areas such as oncology and neurology while providing details about specific drugs, their applications, and clinical studies related to them. Additionally, it offers resources for downloads, medical inquiries, events, and newsletters, emphasizing Roche's commitment to evidence-based information and professional education in the pharmaceutical field.","oncology, professionals, data",fachportal.roche.de,Rising,0.134285186169122,high,349,General Offer Outline
215,https://fachportal.roche.de/produkte/gynaekoonkologie/phesgo/produktuebersicht/anwendungsbereich.html,7,fachportal_roche_de_produkte_gynaekoonkologie_phesgo_produktuebersicht_anwendungsbereich_html.txt,200,html,Indexable,2,29,0,3760,2,2,1,fachportal_roche_de_produkte_gynaekoonkologie_phesgo_produktuebersicht_anwendungsbereich_html.txt,image/fachportal_roche_de_produkte_gynaekoonkologie_phesgo_produktuebersicht_anwendungsbereich_html.txt.png,text/fachportal_roche_de_produkte_gynaekoonkologie_phesgo_produktuebersicht_anwendungsbereich_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-28.0121,5.304189,0,"The content serves as a comprehensive resource for healthcare professionals regarding Roche's extensive range of products and clinical research across various therapeutic areas, such as oncology, hematology, and neurology. It provides insights into current treatments, clinical data, and access to educational materials. Additionally, it emphasizes patient management tools, ongoing studies, and medical inquiries related to Roche products, ultimately aiming to enhance the understanding and application of their pharmaceutical offerings in clinical practice.","oncology, professionals, data",fachportal.roche.de,Rising,0.944551118120945,high,154,General Offer Outline
216,https://fachportal.roche.de/produkte/gynaekoonkologie/tecentriq_mtnbc/produktuebersicht/anwendungsbereich.html,7,fachportal_roche_de_produkte_gynaekoonkologie_tecentriq_mtnbc_produktuebersicht_anwendungsbereich_html.txt,200,html,Indexable,2,38,0,2013,4,4,1,fachportal_roche_de_produkte_gynaekoonkologie_tecentriq_mtnbc_produktuebersicht_anwendungsbereich_html.txt,image/fachportal_roche_de_produkte_gynaekoonkologie_tecentriq_mtnbc_produktuebersicht_anwendungsbereich_html.txt.png,text/fachportal_roche_de_produkte_gynaekoonkologie_tecentriq_mtnbc_produktuebersicht_anwendungsbereich_html.txt.txt,['Fachportal'],Other,Germany,Offer outline,,,-23.53485,11.349096,0,"The content describes the Roche Fachportal, a specialized platform aimed at healthcare professionals, providing comprehensive information on Roche's product offerings across various medical fields such as oncology, neurology, and hemophilia. It outlines the portal's features, including product overviews, clinical data, and downloadable resources, as well as avenues for medical inquiries. The purpose is to facilitate access to up-to-date and evidence-based information regarding Roche's pharmaceuticals and associated clinical studies, thereby supporting healthcare professionals in their practice.","oncology, professionals, data",fachportal.roche.de,Flat,0.711770794354999,high,451,General Offer Outline
217,https://fachportal.roche.de/produkte/haematologie/columvi/produktuebersicht/anwendungsbereich.html,10,fachportal_roche_de_produkte_haematologie_columvi_produktuebersicht_anwendungsbereich_html.txt,200,html,Indexable,2,17,141,1543,69,23,1,fachportal_roche_de_produkte_haematologie_columvi_produktuebersicht_anwendungsbereich_html.txt,image/fachportal_roche_de_produkte_haematologie_columvi_produktuebersicht_anwendungsbereich_html.txt.png,text/fachportal_roche_de_produkte_haematologie_columvi_produktuebersicht_anwendungsbereich_html.txt.txt,"['Columvi', 'DLBCL', 'B']",Oncology-Hematology,Germany,Offer outline,"DBLCL, Columvi, specific therapies, clinical data",diffuse large B-cell lymphoma,-25.328304,7.677914,0,"The content outlines various sections of the Roche professional portal, highlighting areas such as neuroscience, oncology, and services related to their pharmaceutical products. It provides access to product overviews, clinical data, downloadable materials, and information on specific therapies, particularly focusing on the treatment of diffuse large B-cell lymphoma (DLBCL) with the drug Columvi. Additionally, it offers resources like medical inquiries, newsletters, and podcasts to support healthcare professionals. Overall, the purpose of the content is to serve as a comprehensive resource for professionals seeking detailed, evidence-based information about Roche's offerings and advancements in medical treatments.","oncology, professionals, data",fachportal.roche.de,Falling,0.453062800652738,high,14,General Offer Outline
218,https://fachportal.roche.de/produkte/haematologie/gazyvaro_cll/produktuebersicht/anwendungsbereich.html,7,fachportal_roche_de_produkte_haematologie_gazyvaro_cll_produktuebersicht_anwendungsbereich_html.txt,200,html,Indexable,2,35,0,1637,14,6,0.98019801980198,fachportal_roche_de_produkte_haematologie_gazyvaro_cll_produktuebersicht_anwendungsbereich_html.txt.txt,image/fachportal_roche_de_produkte_haematologie_gazyvaro_cll_produktuebersicht_anwendungsbereich_html.txt.txt.png,text/fachportal_roche_de_produkte_haematologie_gazyvaro_cll_produktuebersicht_anwendungsbereich_html.txt.txt.txt,"['FL', 'GAZYVARO', 'CLL', 'Lunsumio']",Oncology-Hematology,Germany,Medication information,"GAZYVARO, Lunsumio, chronic lymphocytic leukemia, CLL, follicular lymphoma","chronic lymphocytic leukemia, follicular lymphoma",-22.524899,9.748544,0,"The content provides a detailed overview of Roche's operations in various therapeutic areas, including oncology, neuroscience, and hematology. It emphasizes the range of products and services available, focusing on specific medications like GAZYVARO and Lunsumio for treating chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). The content is aimed at healthcare professionals, featuring clinical data, treatment guidelines, and specific characteristics of Roche’s pharmaceutical offerings. It also includes instructions for medical inquiries and reporting adverse effects, illustrating Roche's commitment to patient safety and informed healthcare practices.","oncology, professionals, data",fachportal.roche.de,Flat,0.67691827300562,high,331,General Offer Outline
219,https://fachportal.roche.de/produkte/haematologie/gazyvaro_fl/produktuebersicht/anwendungsbereich.html,7,fachportal_roche_de_produkte_haematologie_gazyvaro_fl_produktuebersicht_anwendungsbereich_html.txt,200,html,Indexable,2,34,0,1776,10,5,0.98,fachportal_roche_de_produkte_haematologie_gazyvaro_fl_produktuebersicht_anwendungsbereich_html.txt.txt,image/fachportal_roche_de_produkte_haematologie_gazyvaro_fl_produktuebersicht_anwendungsbereich_html.txt.txt.png,text/fachportal_roche_de_produkte_haematologie_gazyvaro_fl_produktuebersicht_anwendungsbereich_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-33.567093,7.8998504,0,"The content focuses on the various therapeutic areas and products offered by Roche, including information about their specific applications, clinical data, and treatment guidelines. It provides a comprehensive overview of Roche's pharmaceutical offerings in disciplines such as oncology, hematology, neurology, and more. The purpose is to equip healthcare professionals with essential information regarding Roche's products, clinical studies, and resources available for patient care, while also facilitating easy access to downloadable materials and medical inquiries.","oncology, professionals, data",fachportal.roche.de,Flat,0.120421787714221,high,291,General Offer Outline
220,https://fachportal.roche.de/produkte/haematologie/lunsumio/produktuebersicht/anwendungsbereich.html,7,fachportal_roche_de_produkte_haematologie_lunsumio_produktuebersicht_anwendungsbereich_html.txt,200,html,Indexable,2,31,0,1574,21,10,0.979381443298969,fachportal_roche_de_produkte_haematologie_lunsumio_produktuebersicht_anwendungsbereich_html.txt.txt,image/fachportal_roche_de_produkte_haematologie_lunsumio_produktuebersicht_anwendungsbereich_html.txt.txt.png,text/fachportal_roche_de_produkte_haematologie_lunsumio_produktuebersicht_anwendungsbereich_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,"follicular lymphoma, oncology, neuroscience, rheumatology",follicular lymphoma,-25.990343,7.532253,0,"The content outlines the resources available on Roche's professional portal, presenting various therapeutic areas such as neuroscience, oncology, and rheumatology, alongside their product offerings, clinical data, and services. It emphasizes the availability of specific medical information and guidelines for healthcare professionals regarding treatment options and clinical studies, particularly for conditions like follicular lymphoma. The purpose of the content is to provide professionals with comprehensive access to Roche's pharmaceutical products, research, and support services to enhance patient care and medical knowledge.","oncology, professionals, data",fachportal.roche.de,Flat,0.130178951755703,high,208,General Offer Outline
221,https://fachportal.roche.de/produkte/rheumatologie/mabthera/downloads.html,6,fachportal_roche_de_produkte_rheumatologie_mabthera_downloads_html.txt,200,html,Indexable,,23,0,734,0,0,0.97841726618705,fachportal_roche_de_produkte_haematologie_mabthera_downloads_html.txt,image/fachportal_roche_de_produkte_haematologie_mabthera_downloads_html.txt.png,text/fachportal_roche_de_produkte_haematologie_mabthera_downloads_html.txt.txt,[],Other,Germany,Offer outline,,,-6.4795504,-21.027323,3,"The content displays a login interface for Roche's professional portal, focusing on services offered to healthcare professionals. It includes options for registration and signing in, as well as a link to DocCheck, indicating a secure and specialized access process. The portal likely provides exclusive benefits, clinical data, and additional resources aimed at medical professionals.","users, page, website",fachportal.roche.de,Falling,0.132021962955578,medium,361,Website Metadata
222,https://fachportal.roche.de/produkte/haematologie/mabthera/produktuebersicht/produktinformation.html,10,fachportal_roche_de_produkte_haematologie_mabthera_produktuebersicht_produktinformation_html.txt,200,html,Indexable,2,31,115,2751,14,7,1,fachportal_roche_de_produkte_haematologie_mabthera_produktuebersicht_produktinformation_html.txt,image/fachportal_roche_de_produkte_haematologie_mabthera_produktuebersicht_produktinformation_html.txt.png,text/fachportal_roche_de_produkte_haematologie_mabthera_produktuebersicht_produktinformation_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,"neuroscience, oncology, hematology, MabThera, hematological malignancies, autoimmune diseases, side effects","hematological malignancies, autoimmune diseases",-24.47573,9.886867,0,"The content provides an overview of Roche's specialized fields and products aimed at healthcare professionals. It outlines various therapeutic areas such as neuroscience, oncology, and hematology, and includes sections for clinical data, downloadable materials, and services. Additionally, it features specific products like MabThera, detailing its application in treating hematological malignancies and autoimmune diseases. The content emphasizes Roche's commitment to providing evidence-based clinical information and encourages medical inquiries and reporting of side effects related to their products.","oncology, professionals, data",fachportal.roche.de,Flat,0.661869065147035,high,452,General Offer Outline
223,https://fachportal.roche.de/produkte/haematologie/polivy/produktuebersicht/anwendungsbereich.html?namespace=s7classic,6,fachportal_roche_de_produkte_haematologie_polivy_produktuebersicht_anwendungsbereich_html_namespace_s7classic.txt,200,html,Non-Indexable,3,29,0,1511,0,0,0.982608695652174,fachportal_roche_de_produkte_haematologie_polivy_produktuebersicht_anwendungsbereich_html_namespace_s7classic.txt.txt,image/fachportal_roche_de_produkte_haematologie_polivy_produktuebersicht_anwendungsbereich_html_namespace_s7classic.txt.txt.png,text/fachportal_roche_de_produkte_haematologie_polivy_produktuebersicht_anwendungsbereich_html_namespace_s7classic.txt.txt.txt,"['Polivy', 'DLBCL', 'B']",Oncology-Hematology,Germany,Offer outline,"Polivy, diffuse large B-cell lymphoma (DLBCL), therapeutic areas, clinical data, evidence-based data",diffuse large B-cell lymphoma,-21.180399,11.103485,0,"The content is a structured overview of Roche's professional portal, detailing various therapeutic areas such as neuroscience, ophthalmology, oncology, and more. It serves the purpose of providing medical professionals with access to Roche's products, clinical data, downloadable materials, and additional resources for patient care. The content emphasizes the importance of registration for accessing specific clinical information and highlights Roche’s commitment to supporting healthcare providers with evidence-based data and resources related to their therapies, including specific products like Polivy for treating diffuse large B-cell lymphoma (DLBCL).","oncology, professionals, data",fachportal.roche.de,Falling,0.0464484253872628,medium,346,General Offer Outline
224,https://fachportal.roche.de/produkte/haematologie/polivy/produktuebersicht/anwendungsbereich.html,7,fachportal_roche_de_produkte_haematologie_polivy_produktuebersicht_anwendungsbereich_html.txt,200,html,Indexable,2,29,0,1511,53,22,1,fachportal_roche_de_produkte_haematologie_polivy_produktuebersicht_anwendungsbereich_html.txt,image/fachportal_roche_de_produkte_haematologie_polivy_produktuebersicht_anwendungsbereich_html.txt.png,text/fachportal_roche_de_produkte_haematologie_polivy_produktuebersicht_anwendungsbereich_html.txt.txt,['Polivy'],Oncology-Hematology,Germany,Offer outline,"Polivy, oncology, neurology, therapeutic applications, efficacy, safety profiles",,-36.14779,7.9995213,0,"The content is structured as an overview of Roche's therapeutic areas, products, clinical data, and services, primarily aimed at healthcare professionals. It outlines various medical fields, such as oncology and neurology, and provides information on specific products like Polivy, including their therapeutic applications, study designs, efficacy, and safety profiles. Additionally, it emphasizes the need for registered access to exclusive content and encourages healthcare professionals to register for more detailed and evidence-based clinical information regarding Roche's offerings. The content is designed to support medical professionals by providing relevant resources and insights into Roche's pharmaceutical innovations and therapies.","oncology, professionals, data",fachportal.roche.de,Rising,0.733842076803654,high,235,General Offer Outline
225,https://fachportal.roche.de/produkte/nephrologie/mircera/produktuebersicht/produktinformation.html,7,fachportal_roche_de_produkte_nephrologie_mircera_produktuebersicht_produktinformation_html.txt,200,html,Indexable,2,30,0,2060,41,16,1,fachportal_roche_de_produkte_nephrologie_mircera_produktuebersicht_produktinformation_html.txt,image/fachportal_roche_de_produkte_nephrologie_mircera_produktuebersicht_produktinformation_html.txt.png,text/fachportal_roche_de_produkte_nephrologie_mircera_produktuebersicht_produktinformation_html.txt.txt,['MIRCERA'],Other,Germany,Offer outline,"MIRCERA, anemia, chronic kidney disease, neuroscience, oncology, nephrology",anemia in chronic kidney disease,-34.511868,-7.014046,0,"The content outlines the content structure of Roche's professional portal, emphasizing various therapeutic areas such as neuroscience, oncology, and nephrology. It provides an overview of available products, clinical data, downloadable materials, and services related to these specialties. Additionally, it highlights specific products like MIRCERA for treating anemia in chronic kidney disease, and offers medical inquiries and support contact details. The purpose of the content is to facilitate access to Roche's resources and information for healthcare professionals.","oncology, professionals, data",fachportal.roche.de,Falling,0.570174150346122,high,276,General Offer Outline
226,https://fachportal.roche.de/produkte/nephrologie/neorecormon/produktuebersicht/produktinformation.html,7,fachportal_roche_de_produkte_nephrologie_neorecormon_produktuebersicht_produktinformation_html.txt,200,html,Indexable,2,34,0,1379,4,4,0.98,fachportal_roche_de_produkte_nephrologie_neorecormon_produktuebersicht_produktinformation_html.txt.txt,image/fachportal_roche_de_produkte_nephrologie_neorecormon_produktuebersicht_produktinformation_html.txt.txt.png,text/fachportal_roche_de_produkte_nephrologie_neorecormon_produktuebersicht_produktinformation_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-35.045883,6.0012255,0,"The content outlines various therapeutic areas and products offered by Roche, showcasing their focus on specific medical fields such as neuroscience, oncology, and nephrology. It highlights the availability of clinical data, product information, downloadable resources, and services designed for healthcare professionals. Additionally, it provides contact information for medical inquiries and encourages users to create an account for access to comprehensive clinical information. Overall, the purpose is to serve as a resource hub for professionals seeking information regarding Roche's pharmaceutical products and related medical services.","oncology, professionals, data",fachportal.roche.de,All,0.302790124217026,high,391,General Offer Outline
227,https://fachportal.roche.de/produkte/neuroscience/enspryng/produktuebersicht/anwendungshinweise.html,7,fachportal_roche_de_produkte_neuroscience_enspryng_produktuebersicht_anwendungshinweise_html.txt,200,html,Indexable,2,31,0,1568,25,12,1,fachportal_roche_de_produkte_neuroscience_enspryng_produktuebersicht_anwendungshinweise_html.txt,image/fachportal_roche_de_produkte_neuroscience_enspryng_produktuebersicht_anwendungshinweise_html.txt.png,text/fachportal_roche_de_produkte_neuroscience_enspryng_produktuebersicht_anwendungshinweise_html.txt.txt,"['NMOSD', 'Enspryng']",Other,Germany,Offer outline,"Enspryng, NMOSD",NMOSD,-36.327408,7.08233,0,"The content outlines various areas of expertise and products offered by Roche, particularly in fields such as neuroscience, oncology, and hematology. It serves as a resource for healthcare professionals, providing access to clinical data, product information, and educational materials related to Roche’s pharmaceutical offerings. The purpose is to facilitate informed use and discussions around Roche’s drugs, including detailed insights into specific therapies like Enspryng for NMOSD, as well as to streamline communication regarding medical inquiries and adverse events reporting.","oncology, professionals, data",fachportal.roche.de,Falling,0.288975750330295,high,11,General Offer Outline
228,https://fachportal.roche.de/produkte/pneumologie/esbriet/produktuebersicht/produktinformation.html,10,fachportal_roche_de_produkte_pneumologie_esbriet_produktuebersicht_produktinformation_html.txt,200,html,Indexable,2,30,52,1297,3,3,0.979166666666667,fachportal_roche_de_produkte_pneumologie_esbriet_produktuebersicht_produktinformation_html.txt.txt,image/fachportal_roche_de_produkte_pneumologie_esbriet_produktuebersicht_produktinformation_html.txt.txt.png,text/fachportal_roche_de_produkte_pneumologie_esbriet_produktuebersicht_produktinformation_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-34.28154,4.674135,0,"The content primarily focuses on Roche’s areas of expertise and its pharmaceutical products. It outlines various therapeutic categories such as neuroscience, oncology, and rheumatology, while providing links to clinical data, product overviews, and educational materials. Additionally, it features contact information for medical inquiries and encourages professionals to register for access to comprehensive clinical information. The overall purpose is to serve as a resource for healthcare professionals seeking detailed information about Roche’s offerings and innovations in medicine.","oncology, professionals, data",fachportal.roche.de,Rising,0.734841661805858,high,447,General Offer Outline
229,https://fachportal.roche.de/produkte/pneumologie/pulmozyme/produktuebersicht/produktinformation.html,10,fachportal_roche_de_produkte_pneumologie_pulmozyme_produktuebersicht_produktinformation_html.txt,200,html,Indexable,2,32,26,1271,3,3,0.979591836734694,fachportal_roche_de_produkte_pneumologie_pulmozyme_produktuebersicht_produktinformation_html.txt.txt,image/fachportal_roche_de_produkte_pneumologie_pulmozyme_produktuebersicht_produktinformation_html.txt.txt.png,text/fachportal_roche_de_produkte_pneumologie_pulmozyme_produktuebersicht_produktinformation_html.txt.txt.txt,['Pulmozyme'],Other,Germany,Offer outline,"cystic fibrosis, Pulmozyme",cystic fibrosis,-31.421913,6.7101808,0,"The content primarily serves as an informative portal for healthcare professionals, detailing Roche's various therapeutic areas and product offerings, including neurology, oncology, and respiratory diseases. It outlines the clinical data related to Roche’s products, downloadable materials, and medical inquiries, while providing insights into specific treatments like Pulmozyme for cystic fibrosis. The purpose is to facilitate access to comprehensive and evidence-based information about Roche's pharmaceuticals and services, fostering engagement with healthcare professionals through resources such as newsletters, podcasts, and clinical queries.","oncology, professionals, data",fachportal.roche.de,All,0.438707114975633,high,23,General Offer Outline
230,https://fachportal.roche.de/produkte/produkte_uebersicht.html,7,fachportal_roche_de_produkte_produkte_uebersicht_html.txt,200,html,Indexable,1,21,0,1622,1643,1516,0.966101694915254,fachportal_roche_de_produkte_produkte_uebersicht_html.txt.txt,image/fachportal_roche_de_produkte_produkte_uebersicht_html.txt.txt.png,text/fachportal_roche_de_produkte_produkte_uebersicht_html.txt.txt.txt,[],Other,Germany,Medication information,,,-36.159817,9.215783,0,"The content appears to be a comprehensive overview of Roche's product offerings, showcasing a variety of pharmaceuticals organized by therapeutic areas such as oncology, neuroscience, and other medical fields. It lists specific products, their formulations, and administration methods, serving as a resource for healthcare professionals seeking detailed information about Roche's medications. The purpose of the content is to provide easy access to product information, clinical data, and related services, aiding professionals in their medical decision-making and patient management.","oncology, professionals, data",fachportal.roche.de,Rising,0.729996451379874,high,48,General Offer Outline
231,https://fachportal.roche.de/produkte/rheumatologie/mabthera/produktuebersicht.html,6,fachportal_roche_de_produkte_rheumatologie_mabthera_produktuebersicht_html.txt,200,html,Indexable,,30,0,734,0,0,1,fachportal_roche_de_produkte_rheumatologie_mabthera_produktuebersicht_html.txt,image/fachportal_roche_de_produkte_rheumatologie_mabthera_produktuebersicht_html.txt.png,text/fachportal_roche_de_produkte_rheumatologie_mabthera_produktuebersicht_html.txt.txt,[],Other,Germany,Offer outline,,,-22.032112,-19.026297,0,"The content depicts a professional portal from Roche, designed for healthcare professionals. It includes navigation options for product information, clinical data, downloads, services, and event details. Additionally, it features sections for patient resources and instructions for reporting side effects related to Roche products, emphasizing safety and communication with healthcare authorities. The overall purpose is to provide comprehensive support and information relevant to medical professionals and patients.","oncology, professionals, data",fachportal.roche.de,Flat,0.236772311746957,medium,44,General Offer Outline
232,https://fachportal.roche.de/produkte/rheumatologie/roactemra/produktuebersicht/produktinformation.html,7,fachportal_roche_de_produkte_rheumatologie_roactemra_produktuebersicht_produktinformation_html.txt,200,html,Indexable,2,32,0,1797,6,3,1,fachportal_roche_de_produkte_rheumatologie_roactemra_produktuebersicht_produktinformation_html.txt,image/fachportal_roche_de_produkte_rheumatologie_roactemra_produktuebersicht_produktinformation_html.txt.png,text/fachportal_roche_de_produkte_rheumatologie_roactemra_produktuebersicht_produktinformation_html.txt.txt,[],Other,Germany,Offer outline,"RoActemra, neuroscience, oncology, rheumatology, clinical data",,-33.13242,5.2293544,0,"The content appears to be from a professional portal dedicated to Roche's pharmaceutical products and services, highlighting various therapeutic areas such as neuroscience, oncology, and rheumatology. It provides an overview of available products, clinical data, download materials, and additional services for healthcare professionals. The portal also facilitates medical inquiries and includes specific product information, like RoActemra, along with resources for further education and engagement with Roche's medical science initiatives. Overall, its purpose is to serve as a comprehensive resource for healthcare professionals seeking information on Roche's offerings and clinical data.","oncology, professionals, data",fachportal.roche.de,Flat,0.541986545691527,high,383,General Offer Outline
233,https://fachportal.roche.de/produkte/thorakale_-onkologie/alecensa--nsclc/produktuebersicht/anwendungsbereich.html,10,fachportal_roche_de_produkte_thorakale__onkologie_alecensa__nsclc_produktuebersicht_anwendungsbereich_html.txt,200,html,Indexable,2,17,651,2553,15,9,1,fachportal_roche_de_produkte_thorakale__onkologie_alecensa__nsclc_produktuebersicht_anwendungsbereich_html.txt,image/fachportal_roche_de_produkte_thorakale__onkologie_alecensa__nsclc_produktuebersicht_anwendungsbereich_html.txt.png,text/fachportal_roche_de_produkte_thorakale__onkologie_alecensa__nsclc_produktuebersicht_anwendungsbereich_html.txt.txt,"['ALK', 'NSCLC']",Oncology-Hematology,Germany,Offer outline,,ALK-positive non-small cell lung cancer,-20.641233,6.7419157,0,"The content primarily focuses on Roche's specialized areas in the pharmaceutical sector, highlighting various therapeutic domains such as oncology, neuroscience, and ophthalmology. It aims to offer healthcare professionals access to detailed product information, clinical data, and resources related to Roche's offerings. The content also emphasizes the importance of precision medicine and molecular testing in treating conditions like ALK-positive non-small cell lung cancer (NSCLC) and includes various support services and communications options for professionals seeking medical inquiries. Overall, the purpose is to provide an organized platform for professionals to access Roche's medical resources and stay informed about innovative therapies and clinical advancements.","oncology, professionals, data",fachportal.roche.de,Rising,0.0746241876095313,high,63,General Offer Outline
234,https://fachportal.roche.de/produkte/thorakale_-onkologie/tecentriq--nsclc/produktuebersicht/Anwendungsbereich.html,7,fachportal_roche_de_produkte_thorakale__onkologie_tecentriq__nsclc_produktuebersicht_Anwendungsbereich_html.txt,200,html,Indexable,2,38,0,3501,37,14,0.982300884955752,fachportal_roche_de_produkte_thorakale__onkologie_tecentriq__nsclc_produktuebersicht_Anwendungsbereich_html.txt.txt,image/fachportal_roche_de_produkte_thorakale__onkologie_tecentriq__nsclc_produktuebersicht_Anwendungsbereich_html.txt.txt.png,text/fachportal_roche_de_produkte_thorakale__onkologie_tecentriq__nsclc_produktuebersicht_Anwendungsbereich_html.txt.txt.txt,['NSCLC'],Oncology-Hematology,Germany,Offer outline,"immunotherapy, non-small cell lung cancer (NSCLC)",non-small cell lung cancer,-14.580094,1.1679021,0,"The content serves as an informational portal for medical professionals regarding Roche's various therapeutic areas and products, specifically focusing on oncology and other clinical specialties. It outlines available services, clinical data, and resources on specific treatments—particularly emphasizing immunotherapy for non-small cell lung cancer (NSCLC). The purpose is to provide healthcare professionals with comprehensive, evidence-based information, facilitating informed decisions in patient care and treatment strategies. Additionally, it encourages users to create accounts for unrestricted access to resources and highlights ongoing support for medical inquiries.","oncology, professionals, data",fachportal.roche.de,Flat,0.989628236592311,high,336,General Offer Outline
235,https://fachportal.roche.de/produkte/thorakale_-onkologie/tecentriq--operables-nsclc/produktuebersicht/Anwendungsbereich.html,7,fachportal_roche_de_produkte_thorakale__onkologie_tecentriq__operables_nsclc_produktuebersicht_Anwendungsbereich_html.txt,200,html,Indexable,2,48,0,2845,74,29,1,fachportal_roche_de_produkte_thorakale__onkologie_tecentriq__operables_nsclc_produktuebersicht_Anwendungsbereich_html.txt,image/fachportal_roche_de_produkte_thorakale__onkologie_tecentriq__operables_nsclc_produktuebersicht_Anwendungsbereich_html.txt.png,text/fachportal_roche_de_produkte_thorakale__onkologie_tecentriq__operables_nsclc_produktuebersicht_Anwendungsbereich_html.txt.txt,['NSCLC'],Oncology-Hematology,Germany,Offer outline,"immunotherapy, non-small cell lung cancer (NSCLC), oncology, neuroscience, hematology, therapeutic options, individualized treatment strategies",non-small cell lung cancer,-14.893224,3.7800672,0,"The content is a comprehensive overview of Roche's specialized areas in pharmaceuticals and their related products and services, focusing on various therapeutic fields such as oncology, neuroscience, and hematology. It highlights Roche's offerings in clinical data, downloadable resources, medical inquiries, and ongoing clinical studies, particularly referencing immunotherapy treatments for non-small cell lung cancer (NSCLC). Additionally, it emphasizes Roche's commitment to delivering innovative therapeutic options, enhancing patient outcomes, and the importance of individualized treatment strategies within modern medicine.","oncology, professionals, data",fachportal.roche.de,Rising,0.208498014610049,high,126,General Offer Outline
236,https://fachportal.roche.de/produkte/thorakale_-onkologie/tecentriq--sclc/produktuebersicht/Anwendungsbereich.html,7,fachportal_roche_de_produkte_thorakale__onkologie_tecentriq__sclc_produktuebersicht_Anwendungsbereich_html.txt,200,html,Indexable,2,37,0,2450,13,9,0.982142857142857,fachportal_roche_de_produkte_thorakale__onkologie_tecentriq__sclc_produktuebersicht_Anwendungsbereich_html.txt.txt,image/fachportal_roche_de_produkte_thorakale__onkologie_tecentriq__sclc_produktuebersicht_Anwendungsbereich_html.txt.txt.png,text/fachportal_roche_de_produkte_thorakale__onkologie_tecentriq__sclc_produktuebersicht_Anwendungsbereich_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-34.556534,3.9875681,0,"The content primarily serves as an informative resource for healthcare professionals regarding Roche's product offerings and therapeutic areas, including neuroscience, oncology, and rheumatology. It highlights Roche's expertise in various medical fields, detailing products, clinical data, and services related to their pharmaceutical solutions. The purpose of the content is to facilitate access to medical information, support clinical inquiries, and promote Roche's advancements in treatments, particularly in oncology and precision medicine. Additionally, it invites professionals to engage further by creating accounts for unlimited access to evidence-based clinical information.","oncology, professionals, data",fachportal.roche.de,All,0.910667391611969,high,13,General Offer Outline
237,https://fachportal.roche.de/produkte/transplantationen/cellcept/produktuebersicht/produktinformation.html,10,fachportal_roche_de_produkte_transplantationen_cellcept_produktuebersicht_produktinformation_html.txt,200,html,Indexable,2,48,17,1776,2,2,1,fachportal_roche_de_produkte_transplantationen_cellcept_produktuebersicht_produktinformation_html.txt,image/fachportal_roche_de_produkte_transplantationen_cellcept_produktuebersicht_produktinformation_html.txt.png,text/fachportal_roche_de_produkte_transplantationen_cellcept_produktuebersicht_produktinformation_html.txt.txt,['DNA'],Immunology,Germany,Offer outline,,,-21.645037,9.145042,0,"The content provides an overview of Roche's specialized areas in medicine, including fields such as neuroscience, oncology, and transplantation. It details the products offered by Roche, focusing on specific medications like CellCept and their applications in transplant medicine. The content serves to inform healthcare professionals about Roche's offerings, including clinical data, product information, and educational materials, while encouraging them to engage with the company's resources through a professional portal. It also highlights the importance of long-term immunosuppression in transplant recipients and the role of DNA synthesis inhibitors in preventing organ rejection.","oncology, professionals, data",fachportal.roche.de,Rising,0.247257861820978,high,305,General Offer Outline
238,https://fachportal.roche.de/produkte/uro-onkologie/tecentriq_metastasiertes_uc/produktuebersicht/anwendungsbereich.html,10,fachportal_roche_de_produkte_uro_onkologie_tecentriq_metastasiertes_uc_produktuebersicht_anwendungsbereich_html.txt,200,html,Indexable,2,50,106,1721,2,2,1,fachportal_roche_de_produkte_uro_onkologie_tecentriq_metastasiertes_uc_produktuebersicht_anwendungsbereich_html.txt,image/fachportal_roche_de_produkte_uro_onkologie_tecentriq_metastasiertes_uc_produktuebersicht_anwendungsbereich_html.txt.png,text/fachportal_roche_de_produkte_uro_onkologie_tecentriq_metastasiertes_uc_produktuebersicht_anwendungsbereich_html.txt.txt,[],Other,Germany,Offer outline,,,-35.64272,-7.278219,0,"The content provides an overview of Roche's expert portal, detailing various therapeutic areas such as neuroscience, oncology, and rheumatology. It outlines resources available for healthcare professionals, including product information, clinical data, and downloadable materials. The portal also offers services like medical inquiries and patient support resources. Overall, the purpose of the content is to inform and assist healthcare professionals in accessing Roche's products and clinical information effectively.","oncology, professionals, data",fachportal.roche.de,All,0.124676638866023,high,297,General Offer Outline
239,https://fachportal.roche.de/search.html,7,fachportal_roche_de_search_html.txt,200,html,Indexable,,14,0,808,0,0,0.945945945945946,fachportal_roche_de_search_html.txt.txt,image/fachportal_roche_de_search_html.txt.txt.png,text/fachportal_roche_de_search_html.txt.txt.txt,[],Other,Germany,Other,,,-5.4170694,-20.23752,3,"The content displays a search results page from Roche's professional portal, indicating no results were found for the search query. It suggests verifying the spelling or trying a different term. The layout includes navigation options such as areas of expertise, products, clinical data, downloads, services, events, and medical inquiries, emphasizing its focus on providing resources for healthcare professionals.","users, page, website",fachportal.roche.de,Flat,0.370252026871281,high,446,Website Metadata
240,https://fachportal.roche.de/user/.html,8,fachportal_roche_de_user__html.txt,200,html,Non-Indexable,2,7,0,710,980,980,0.868421052631579,fachportal_roche_de_services__html.txt.txt,image/fachportal_roche_de_services__html.txt.txt.png,text/fachportal_roche_de_services__html.txt.txt.txt,[],Other,Germany,Offer outline,,,-35.792923,-7.988563,0,"The content appears to outline the features and offerings of Roche's professional portal, which serves healthcare professionals by providing access to a wide range of therapeutic areas, products, clinical data, and training resources. It includes sections on various specializations such as neuroscience, oncology, and hematology, along with downloadable materials and information about ongoing events and integration with platforms like DocCheck for easier access. The main purpose is to support professionals in their clinical practice by delivering essential tools, updates, and insights into Roche's therapies and research developments.","oncology, professionals, data",fachportal.roche.de,All,0.654188100160305,high,105,General Offer Outline
241,https://fachportal.roche.de/services/apotheke_kompakt.html,10,fachportal_roche_de_services_apotheke_kompakt_html.txt,200,html,Indexable,1,16,49,1291,3,1,1,fachportal_roche_de_services_apotheke_kompakt_html.txt,image/fachportal_roche_de_services_apotheke_kompakt_html.txt.png,text/fachportal_roche_de_services_apotheke_kompakt_html.txt.txt,[],Other,Germany,Offer outline,,rare diseases,-27.00568,6.1162286,0,"The content is an overview of Roche's specialized areas and products, emphasizing their focus on various therapeutic domains such as neuroscience, oncology, and hematology. It highlights the services they offer, including clinical data access, downloadable materials, and educational events for pharmacy professionals. A recent event discussed rare diseases, showcasing expert insights and the importance of pharmacy support. Overall, the content serves to inform healthcare professionals about Roche’s offerings, recent developments, and opportunities for further education and collaboration.","oncology, professionals, data",fachportal.roche.de,Flat,0.845440274886804,high,23,General Offer Outline
242,https://fachportal.roche.de/services/newsletter/newsletter_nephrologie.html,6,fachportal_roche_de_services_newsletter_newsletter_nephrologie_html.txt,200,html,Non-Indexable,3,11,0,1199,2,1,0.972602739726027,fachportal_roche_de_services_newsletter_newsletter_nephrologie_html.txt.txt,image/fachportal_roche_de_services_newsletter_newsletter_nephrologie_html.txt.txt.png,text/fachportal_roche_de_services_newsletter_newsletter_nephrologie_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-36.63317,-2.632793,0,"The content serves as an overview of Roche's specialized portal for healthcare professionals, highlighting various therapeutic areas such as neuroscience, oncology, and nephrology, among others. It provides structured information about Roche's products, clinical data, and downloadable resources. Additionally, it offers updates on medical news, services, and patient support initiatives, ensuring that healthcare professionals have access to relevant materials and expert insights. Overall, the purpose of the content is to facilitate informed decision-making and enhance support for patients and healthcare providers engaged with Roche's products and services.","oncology, professionals, data",fachportal.roche.de,Rising,0.380399254390765,medium,122,General Offer Outline
243,https://fachportal.roche.de/services/newsletter/newsletter_onkologie.html,7,fachportal_roche_de_services_newsletter_newsletter_onkologie_html.txt,200,html,Non-Indexable,2,21,0,1628,99,43,0.971830985915493,fachportal_roche_de_services_newsletter_newsletter_onkologie_html.txt.txt,image/fachportal_roche_de_services_newsletter_newsletter_onkologie_html.txt.txt.png,text/fachportal_roche_de_services_newsletter_newsletter_onkologie_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-26.402712,5.4976754,0,"The content outlines the various therapeutic areas and products that Roche offers, specifically targeting professionals in the medical field. It features sections on neuroscience, oncology, and other specialized medical fields, along with resources like clinical data, downloadable materials, and newsletters aimed at healthcare practitioners. The purpose of the content is to provide comprehensive information about Roche's medical products and services, facilitate access to necessary tools for professionals, and keep them informed about the latest developments in their respective fields, particularly oncology and hematology.","oncology, professionals, data",fachportal.roche.de,Falling,0.538976831238198,high,349,General Offer Outline
244,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/.html,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen__html.txt,200,html,Non-Indexable,3,0,0,3794,16,16,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen__html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen__html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen__html.txt.txt,"['Congress', 'American', 'ESMO', 'Cancer']",Oncology-Hematology,Germany,Research,,,5.4242682,-9.578763,7,"The content is focused on Roche's podcast series, which features discussions among experts about various topics in oncology and hematology. It highlights the format of engaging conversations that can be listened to conveniently, covering recent advancements presented at major oncology congresses, such as ESMO and the American Cancer Congress. The episodes aim to keep medical professionals informed about breakthroughs in cancer treatment and research while providing practical insights relevant to clinical practice. The overall purpose is to facilitate continuous learning and sharing of knowledge among healthcare professionals in the oncology field.","event, exclusive, website",fachportal.roche.de,Rising,0.671625396882122,low,233,Events & Patient Care
245,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/brustkrebs-auch-im-haeuslichen-umfeld-behandeln-1278753.html,9,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_brustkrebs_auch_im_haeuslichen_umfeld_behandeln_1278753_html.txt,200,html,Non-Indexable,3,125,809,1336,5,5,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_brustkrebs_auch_im_haeuslichen_umfeld_behandeln_1278753_html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_brustkrebs_auch_im_haeuslichen_umfeld_behandeln_1278753_html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_brustkrebs_auch_im_haeuslichen_umfeld_behandeln_1278753_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,"subcutaneous antibody administration, HER2-positive breast cancer",HER2-positive breast cancer,-12.303745,-0.7192627,0,"The content serves as an overview of Roche's specialized fields and product offerings within various medical disciplines, including cancer treatment, neuroscience, and hematology. It highlights Roche's commitment to advancing patient care through innovative therapies, such as subcutaneous antibody administration for HER2-positive breast cancer, which is discussed in a podcast format featuring expert insights. The purpose of this content is to provide healthcare professionals with an accessible resource for Roche's clinical data, product information, services, and ongoing medical education, thus supporting informed decision-making in patient treatment.","oncology, professionals, data",fachportal.roche.de,Flat,0.574543763970972,high,304,General Offer Outline
246,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/die-rolle-der-interdisziplinaeren-zusammenarbeit-1278726.html,9,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_die_rolle_der_interdisziplinaeren_zusammenarbeit_1278726_html.txt,200,html,Non-Indexable,3,61,729,1372,5,5,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_die_rolle_der_interdisziplinaeren_zusammenarbeit_1278726_html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_die_rolle_der_interdisziplinaeren_zusammenarbeit_1278726_html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_die_rolle_der_interdisziplinaeren_zusammenarbeit_1278726_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-21.333591,1.099792,0,"The content provides an overview of Roche's specialized fields, products, clinical data, and services aimed at healthcare professionals. It highlights key areas such as oncology, neuroscience, and rare diseases, and emphasizes the importance of interdisciplinary collaboration in treatment decisions, particularly in relation to personalized therapy based on tumor profiles. The content serves as a resource for medical professionals seeking detailed information about Roche's offerings, recent developments in treatment strategies, and access to educational materials like podcasts and newsletters.","oncology, professionals, data",fachportal.roche.de,Falling,0.0468468436792975,high,111,General Offer Outline
247,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/ernaehrung-bei-krebs-1278755.html,10,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_ernaehrung_bei_krebs_1278755_html.txt,200,html,Non-Indexable,2,70,317,1415,10,7,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_ernaehrung_bei_krebs_1278755_html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_ernaehrung_bei_krebs_1278755_html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_ernaehrung_bei_krebs_1278755_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-21.949066,-1.0880182,0,"The content outlines the various therapeutic areas and services provided by Roche, including product overviews, clinical data, and downloadable resources. It features sections on diverse medical fields such as oncology, hematology, and neurology, highlighting a focus on nutrition's role in cancer treatment. The content appears to serve as a professional resource for healthcare providers, offering podcasts, expert dialogues, and support for medical inquiries related to Roche's pharmaceutical products and research initiatives.","oncology, professionals, data",fachportal.roche.de,Rising,0.862123293103027,high,347,General Offer Outline
248,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/fortschritte-bei-der-therapie-des-cup-syndroms-dank-der-molekular-begruendeten-therapie-1498211.html,9,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_fortschritte_bei_der_therapie_des_cup_syndroms_dank_der_molekular_begruendeten_therapie_1498211_html.txt,200,html,Non-Indexable,3,86,387,1310,7,7,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_fortschritte_bei_der_therapie_des_cup_syndroms_dank_der_molekular_begruendeten_therapie_1498211_html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_fortschritte_bei_der_therapie_des_cup_syndroms_dank_der_molekular_begruendeten_therapie_1498211_html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_fortschritte_bei_der_therapie_des_cup_syndroms_dank_der_molekular_begruendeten_therapie_1498211_html.txt.txt,"['Unknown', 'Primary', 'CUPISCO', 'CUP', 'Cancer']",Oncology-Hematology,Germany,Offer outline,"oncology, precision medicine, Cancer of Unknown Primary (CUP), CUPISCO study, treatment methodologies",Cancer of Unknown Primary,-12.546663,1.8768687,0,"The content provides an overview of Roche's specialized areas and available products, particularly in fields such as oncology, neuroscience, and precision medicine. It emphasizes clinical data, downloadable resources, and additional services offered, such as newsletters and podcasts. The focus is on communicating advancements in oncology, particularly relating to the Cancer of Unknown Primary (CUP), through expert discussions and studies like the CUPISCO study. The purpose is to inform healthcare professionals about Roche's offerings and the latest developments in treatment methodologies, thereby facilitating better patient care.","oncology, professionals, data",fachportal.roche.de,All,0.430458494855241,high,389,General Offer Outline
249,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen.html,10,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_html.txt,200,html,Non-Indexable,2,39,271,3476,134,44,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-25.788858,2.7725556,0,"The content provides an overview of Roche's specialization areas and services aimed at healthcare professionals, covering various medical fields such as oncology, hematology, and neurology. It highlights Roche's product offerings, clinical data, and downloadable resources, as well as features like podcasts that discuss recent advancements in medical research. The aim is to inform and support professionals in their practice by offering accessible content on therapeutic developments, clinical studies, and expert discussions.","oncology, professionals, data",fachportal.roche.de,Rising,0.62162710838396,high,385,General Offer Outline
250,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/interdisziplinaere-zusammenarbeit-bei-tumorerkrankungen-1367502.html,10,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_interdisziplinaere_zusammenarbeit_bei_tumorerkrankungen_1367502_html.txt,200,html,Non-Indexable,2,54,379,1333,13,8,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_interdisziplinaere_zusammenarbeit_bei_tumorerkrankungen_1367502_html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_interdisziplinaere_zusammenarbeit_bei_tumorerkrankungen_1367502_html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_interdisziplinaere_zusammenarbeit_bei_tumorerkrankungen_1367502_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-24.730644,1.3561755,0,"The content is a detailed overview of Roche's areas of expertise and product offerings, aimed at healthcare professionals. It highlights various fields such as neuroscience, oncology, and rheumatology, and emphasizes the importance of interdisciplinary collaboration in treating complex diseases, particularly cancer. The content also features resources like clinical data, podcasts, and medical inquiries, showcasing Roche's commitment to providing valuable insights and support for healthcare providers. The purpose is to facilitate access to Roche's products and services while promoting ongoing education and collaboration in the medical community.","oncology, professionals, data",fachportal.roche.de,Rising,0.914118314567692,high,321,General Offer Outline
251,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/jung-und-brustkrebs-1278655.html,9,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_jung_und_brustkrebs_1278655_html.txt,200,html,Non-Indexable,3,56,387,1328,1,1,0.981308411214953,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_jung_und_brustkrebs_1278655_html.txt.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_jung_und_brustkrebs_1278655_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_jung_und_brustkrebs_1278655_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-18.52482,-0.6022612,0,"The content appears to be an overview of Roche's specialized areas within oncology and other fields, such as neuroscience and hematology. It serves as a resource portal for healthcare professionals, providing access to product information, clinical data, downloadable materials, and educational resources like podcasts and expert discussions. The focus is on enhancing medical understanding and communication regarding Roche's therapies and innovations, particularly in cancer treatment, while also addressing practical aspects of patient care and support.","oncology, professionals, data",fachportal.roche.de,All,0.758121488873422,high,255,General Offer Outline
252,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/liquid-biopsy-1278617.html,9,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_liquid_biopsy_1278617_html.txt,200,html,Non-Indexable,3,58,183,1337,6,6,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_liquid_biopsy_1278617_html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_liquid_biopsy_1278617_html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_liquid_biopsy_1278617_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-20.490162,3.0844395,0,"The content provides an overview of Roche's specialized areas in pharmaceuticals, such as neuroscience, oncology, and precision medicine, among others. It highlights Roche's products and services, including access to clinical data and downloadable resources for healthcare professionals. Additionally, it features discussions from experts on topics like liquid biopsies in oncology, fostering a dialogue around recent advancements and clinical practices within the field. The purpose is to serve as a comprehensive resource for professionals seeking detailed information and support related to Roche's medical offerings.","oncology, professionals, data",fachportal.roche.de,All,0.668799450171613,high,167,General Offer Outline
253,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/molekulare-tumoranalysen-bei-gastroenterologischen-tumoren-1278757.html,9,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_molekulare_tumoranalysen_bei_gastroenterologischen_tumoren_1278757_html.txt,200,html,Non-Indexable,3,58,332,1296,6,6,0.986301369863014,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_molekulare_tumoranalysen_bei_gastroenterologischen_tumoren_1278757_html.txt.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_molekulare_tumoranalysen_bei_gastroenterologischen_tumoren_1278757_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_molekulare_tumoranalysen_bei_gastroenterologischen_tumoren_1278757_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-33.726524,6.837196,0,"The content is focused on Roche's specialized areas in healthcare, including fields such as neuroscience, oncology, hematology, and precision medicine, among others. It provides a comprehensive overview of Roche's products, clinical data, and services intended for healthcare professionals. The purpose is to facilitate access to information about Roche's therapeutic options, clinical trials, and expert discussions, while also promoting resources such as podcasts and newsletters for ongoing education and updates in the pharmaceutical field.","oncology, professionals, data",fachportal.roche.de,Falling,0.637805058652966,high,209,General Offer Outline
254,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/molekulare-tumorboards-1278643.html,9,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_molekulare_tumorboards_1278643_html.txt,200,html,Non-Indexable,3,70,492,1320,2,2,0.981818181818182,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_molekulare_tumorboards_1278643_html.txt.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_molekulare_tumorboards_1278643_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_molekulare_tumorboards_1278643_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-37.140465,-7.0938544,0,"The content provides an overview of Roche's professional portal, outlining various medical specialties including oncology, neurology, and precision medicine. It lists resources such as product information, clinical data, downloadable materials, and services available for healthcare professionals. Additionally, it highlights educational content like podcasts and expert dialogues focused on current topics in medicine, particularly related to oncology and precision medicine, aiming to support medical professionals in their practice and enhance patient care.","oncology, professionals, data",fachportal.roche.de,Rising,0.593196830631794,high,258,General Offer Outline
255,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/personalisierte-gesundheitsversorgung-1278607.html,9,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_personalisierte_gesundheitsversorgung_1278607_html.txt,200,html,Non-Indexable,3,66,193,1312,6,6,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_personalisierte_gesundheitsversorgung_1278607_html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_personalisierte_gesundheitsversorgung_1278607_html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_personalisierte_gesundheitsversorgung_1278607_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-29.881168,0.25355297,0,"The content provides an overview of Roche's specialized areas in pharmaceuticals, including various fields such as neuroscience, oncology, hematology, and precision medicine. It outlines the company's product offerings, clinical data, downloadable resources, and services for medical professionals. Additionally, it includes information about educational podcasts and expert dialogues aimed at discussing advancements in personalized medicine and oncology. The purpose of the content is to serve as a resource hub for healthcare professionals seeking detailed information about Roche's products, services, and latest scientific discussions.","oncology, professionals, data",fachportal.roche.de,All,0.904217933802828,high,321,General Offer Outline
256,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/stigmatisierung-bei-hcc-patientinnen-1278737.html,10,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_stigmatisierung_bei_hcc_patientinnen_1278737_html.txt,200,html,Non-Indexable,2,37,724,1308,5,2,0.983870967741936,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_stigmatisierung_bei_hcc_patientinnen_1278737_html.txt.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_stigmatisierung_bei_hcc_patientinnen_1278737_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_stigmatisierung_bei_hcc_patientinnen_1278737_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-25.188778,3.7768576,0,"The content focuses on Roche's specialized areas in healthcare, covering various fields such as neuroscience, oncology (including multiple specific types), hemophilia, and more. It highlights Roche's products and services, clinical data, and resources available for healthcare professionals. Additionally, the content mentions podcasts and expert dialogues that address significant issues, including patient stigma related to certain cancers, and explores therapy options and advancements in early detection. The overarching purpose is to provide professionals with valuable information, resources, and ongoing education related to Roche's therapeutic areas.","oncology, professionals, data",fachportal.roche.de,Falling,0.910403387276248,high,452,General Offer Outline
257,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/therapie-des-hcc-verbesserte-chancen-durch-interdisziplinaere-zusammenarbeit-1278676.html,10,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_therapie_des_hcc_verbesserte_chancen_durch_interdisziplinaere_zusammenarbeit_1278676_html.txt,200,html,Non-Indexable,2,76,716,1319,5,2,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_therapie_des_hcc_verbesserte_chancen_durch_interdisziplinaere_zusammenarbeit_1278676_html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_therapie_des_hcc_verbesserte_chancen_durch_interdisziplinaere_zusammenarbeit_1278676_html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_therapie_des_hcc_verbesserte_chancen_durch_interdisziplinaere_zusammenarbeit_1278676_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-35.033573,-2.1476867,0,"The content is an overview of Roche's professional portal, highlighting various therapeutic areas including neuroscience, oncology, and hematology. It serves as a resource for healthcare professionals, providing information on Roche's products, clinical data, downloadable materials, and services like newsletters and podcasts. Additionally, it features expert dialogues on specific therapies, emphasizing interdisciplinary approaches in treatment. The purpose of the content is to support medical professionals with relevant updates and resources related to Roche's pharmaceutical offerings and advancements in treatment options.","oncology, professionals, data",fachportal.roche.de,All,0.567563377278371,high,381,General Offer Outline
258,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/tumoragnostische-therapieansaetze-am-beispiel-des-markers-ntrk-1278638.html,9,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_tumoragnostische_therapieansaetze_am_beispiel_des_markers_ntrk_1278638_html.txt,200,html,Non-Indexable,3,61,520,1316,1,1,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_tumoragnostische_therapieansaetze_am_beispiel_des_markers_ntrk_1278638_html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_tumoragnostische_therapieansaetze_am_beispiel_des_markers_ntrk_1278638_html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_tumoragnostische_therapieansaetze_am_beispiel_des_markers_ntrk_1278638_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-18.811922,2.3735006,0,"The content provides an overview of Roche's specialized areas and product offerings, focusing on various fields such as oncology, neuroscience, and hematology. It outlines services available for medical professionals, including clinical data, downloadable resources, and podcasts discussing current medical topics like tumor-agnostic therapies and precision medicine. The purpose of the content is to serve as a comprehensive portal for healthcare professionals to access Roche’s medical resources, support, and educational materials efficiently.","oncology, professionals, data",fachportal.roche.de,Flat,0.436199614523307,high,108,General Offer Outline
259,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/ueberlebensvorteil-beim-fruehen-her2-pos-mammakarzinom-1415694.html,10,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_ueberlebensvorteil_beim_fruehen_her2_pos_mammakarzinom_1415694_html.txt,200,html,Non-Indexable,2,49,378,1319,8,6,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_ueberlebensvorteil_beim_fruehen_her2_pos_mammakarzinom_1415694_html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_ueberlebensvorteil_beim_fruehen_her2_pos_mammakarzinom_1415694_html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_ueberlebensvorteil_beim_fruehen_her2_pos_mammakarzinom_1415694_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-33.644764,-8.173058,0,"The content outlines various aspects of Roche's professional portal, focusing on their therapeutic areas, products, clinical data, and available services for healthcare professionals. It includes information on specific medical fields like oncology and neurology, presents access to product information and clinical studies, and features educational resources such as podcasts and expert dialogues. The overall purpose is to provide healthcare professionals with comprehensive, organized access to Roche's pharmaceutical offerings and relevant medical information.","oncology, professionals, data",fachportal.roche.de,Flat,0.0302855529847561,high,19,General Offer Outline
260,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/vom-kampfgas-zur-immuntherapie-1278647.html,10,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_vom_kampfgas_zur_immuntherapie_1278647_html.txt,200,html,Non-Indexable,2,71,598,1258,19,9,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_vom_kampfgas_zur_immuntherapie_1278647_html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_vom_kampfgas_zur_immuntherapie_1278647_html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_vom_kampfgas_zur_immuntherapie_1278647_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-27.530815,5.051949,0,"The content appears to be an overview of Roche's offerings in various medical fields, including oncology, neurology, and hematology. It discusses available products, clinical data, and resources for healthcare professionals, such as podcasts, newsletters, and expert interviews. The purpose of the content is to provide professionals with comprehensive information on Roche's products, clinical research, and advancements in treatment methods, particularly focusing on personalized medicine and therapeutic innovations. It emphasizes engagement through educational resources and supports inquiries related to medical and pharmaceutical questions.","oncology, professionals, data",fachportal.roche.de,Flat,0.690510572871273,high,173,General Offer Outline
261,https://fachportal.roche.de/services/podcasts/expertendialoge-fuer-onkologen/zns-metastasen-beim-nsclc-1278654.html,10,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_zns_metastasen_beim_nsclc_1278654_html.txt,200,html,Non-Indexable,2,25,409,1223,39,11,1,fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_zns_metastasen_beim_nsclc_1278654_html.txt,image/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_zns_metastasen_beim_nsclc_1278654_html.txt.png,text/fachportal_roche_de_services_podcasts_expertendialoge_fuer_onkologen_zns_metastasen_beim_nsclc_1278654_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-17.366327,1.5754958,0,"The content serves as a resource for healthcare professionals regarding Roche's pharmaceutical offerings across various medical fields, including oncology, neuroscience, and hematology. It provides an overview of Roche's products, clinical data, downloadable materials, and services, aiming to facilitate access to important medical information and foster communication among experts. Additionally, it features podcasts and discussions on current topics in oncology, emphasizing the importance of regular surveillance and mutation testing in treating specific cancer types. Overall, the purpose is to support professionals in their clinical practice and enhance patient care through shared knowledge and resources.","oncology, professionals, data",fachportal.roche.de,All,0.668304166241282,high,447,General Offer Outline
262,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/.html,6,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen__html.txt,200,html,Non-Indexable,4,30,0,1914,67,67,0.974683544303797,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen__html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen__html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen__html.txt.txt.txt,['Nervenahrung'],Neurology,Germany,Other,,,22.02589,23.55358,4,"The content features a promotional overview of the Roche podcast titled ""Nervenahrung,"" aimed at active neurologists. It emphasizes the challenges of staying updated in the field of neuroscience and promotes regular discussions on various neuroscience topics involving guest experts. The podcast is designed to be engaging and informative, catering specifically to neurologists' professional development.","technologies, artificial, ai",fachportal.roche.de,Falling,0.210880497174239,medium,289,Technology
263,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen.html,7,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_html.txt,200,html,Indexable,2,30,0,1938,173,87,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_html.txt.txt,[],Other,Germany,Offer outline,,,-34.77278,2.2829604,0,"The content is an overview of Roche's specialized areas and offerings within their professional portal, highlighting various therapeutic fields including neuroscience, oncology, and rheumatology. It outlines Roche's products, clinical data, downloadable resources, and services aimed at healthcare professionals. Additionally, the content promotes educational materials such as podcasts and newsletters to keep medical staff updated on scientific developments. Overall, it serves as a comprehensive resource for professionals seeking information about Roche’s pharmaceutical innovations and support services.","oncology, professionals, data",fachportal.roche.de,Flat,0.38547087572062,high,77,General Offer Outline
264,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-002-das-oct-bei-neurodegeneration-und-ms-meuth-albrecht-1287143.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_002_das_oct_bei_neurodegeneration_und_ms_meuth_albrecht_1287143_html.txt,200,html,Indexable,4,47,152,2026,14,14,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_002_das_oct_bei_neurodegeneration_und_ms_meuth_albrecht_1287143_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_002_das_oct_bei_neurodegeneration_und_ms_meuth_albrecht_1287143_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_002_das_oct_bei_neurodegeneration_und_ms_meuth_albrecht_1287143_html.txt.txt,['Its'],Other,Germany,Offer outline,,,-25.09156,-17.757889,0,"The content of the content revolves around Roche’s specialized areas in the pharmaceutical field, including various medical disciplines such as neuroscience, oncology, and dermatology. Its primary purpose is to serve as a professional portal, providing an overview of Roche's products, clinical data, and educational resources. The content also highlights offerings like podcasts for medical professionals and information about conferences, emphasizing Roche's commitment to ongoing education and support for healthcare providers. Additionally, it includes compliance information regarding reporting adverse effects related to Roche products.","oncology, professionals, data",fachportal.roche.de,Flat,0.310545003282045,high,100,General Offer Outline
265,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-003-neue-s2k-leitlinie-ms-maeurer-heesen-1287147.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_003_neue_s2k_leitlinie_ms_maeurer_heesen_1287147_html.txt,200,html,Indexable,4,36,126,1977,14,14,0.985185185185185,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_003_neue_s2k_leitlinie_ms_maeurer_heesen_1287147_html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_003_neue_s2k_leitlinie_ms_maeurer_heesen_1287147_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_003_neue_s2k_leitlinie_ms_maeurer_heesen_1287147_html.txt.txt.txt,"['Neuroscience', 'Hematology', 'Oncology']",Oncology-Hematology,Germany,Offer outline,,,-31.525776,-10.967097,0,"The content provides an overview of Roche's specialized areas in pharmaceuticals, including categories such as Neuroscience, Oncology, and Hematology, among others. It highlights the company's products and services, offering resources such as clinical data, downloadable materials, and educational podcasts aimed at healthcare professionals. Additionally, the content discusses continuing education initiatives, event participation, and provides links to regulatory resources for reporting adverse effects, all aimed at enhancing medical knowledge and patient care.","oncology, professionals, data",fachportal.roche.de,Flat,0.205633858242271,high,107,General Offer Outline
266,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-006-persistierende-foramen-ovale-pfo-verschluss-schlaganfall-1287156.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_006_persistierende_foramen_ovale_pfo_verschluss_schlaganfall_1287156_html.txt,200,html,Indexable,4,61,185,1945,14,14,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_006_persistierende_foramen_ovale_pfo_verschluss_schlaganfall_1287156_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_006_persistierende_foramen_ovale_pfo_verschluss_schlaganfall_1287156_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_006_persistierende_foramen_ovale_pfo_verschluss_schlaganfall_1287156_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-32.036255,-3.14418,0,"The content outlines various aspects of Roche's offerings and services, focusing on their specialization in fields such as neuroscience, oncology, and hematology. It provides an overview of Roche's products, clinical data, and downloadable resources aimed at healthcare professionals. Additionally, the content highlights specialized educational materials, such as podcasts for continuing medical education, and emphasizes the importance of consulting with healthcare providers regarding treatment. Overall, the purpose is to inform and support medical professionals about Roche's innovations and educational resources in the pharmaceutical sector.","oncology, professionals, data",fachportal.roche.de,Rising,0.444652782094195,high,489,General Offer Outline
267,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-008-jahresrueckblick-s2k-leitlinie-alzheimer-biomarker-1287161.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_008_jahresrueckblick_s2k_leitlinie_alzheimer_biomarker_1287161_html.txt,200,html,Indexable,4,53,216,1945,14,14,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_008_jahresrueckblick_s2k_leitlinie_alzheimer_biomarker_1287161_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_008_jahresrueckblick_s2k_leitlinie_alzheimer_biomarker_1287161_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_008_jahresrueckblick_s2k_leitlinie_alzheimer_biomarker_1287161_html.txt.txt,[],Other,Germany,Offer outline,,,-33.668125,-0.34349132,0,"The content appears to be an overview of the resources and information available on Roche's professional portal, specifically targeting various therapeutic areas such as neuroscience, oncology, and hematology. It outlines sections related to Roche's products, clinical data, downloadable materials, and educational services like podcasts and newsletters aimed at healthcare professionals. The purpose of the content is to provide comprehensive access to Roche's pharmaceutical offerings, enhance medical education, and facilitate communication around its products and research initiatives.","oncology, professionals, data",fachportal.roche.de,Falling,0.695557841696481,high,445,General Offer Outline
268,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-010-kopfschmerzen-1287184.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_010_kopfschmerzen_1287184_html.txt,200,html,Indexable,4,25,138,1943,14,14,0.982142857142857,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_010_kopfschmerzen_1287184_html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_010_kopfschmerzen_1287184_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_010_kopfschmerzen_1287184_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-34.393032,-0.1589123,0,"The content appears to be a comprehensive guide on Roche's various medical specialties and services targeted at healthcare professionals. It covers numerous therapeutic areas such as neuroscience, oncology, and rheumatology, along with a detailed product overview and access to clinical data. Additionally, it includes educational resources like podcasts and newsletters aimed at enhancing medical knowledge among practitioners. The purpose of this content is to provide professionals with essential information on Roche's offerings, foster continuous education, and maintain compliance with regulatory reporting for any adverse events related to their products.","oncology, professionals, data",fachportal.roche.de,All,0.506112406944356,high,113,General Offer Outline
269,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-011-milch-und-ms-1287189.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_011_milch_und_ms_1287189_html.txt,200,html,Indexable,,24,160,1972,0,0,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_011_milch_und_ms_1287189_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_011_milch_und_ms_1287189_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_011_milch_und_ms_1287189_html.txt.txt,[],Other,Germany,Offer outline,,autoimmune diseases,-37.25647,1.2242149,0,"The content outlines various areas of focus within Roche's expertise, including neuroscience, oncology, and precision medicine, alongside a comprehensive overview of its products and services aimed at healthcare professionals. It features clinical data, downloadable materials for medical practitioners, and educational resources like podcasts focused on specific medical topics, such as the role of milk in autoimmune diseases. The content emphasizes continuing medical education and provides insights into Roche's innovative solutions, while also highlighting the importance of professional consultation for individual patient treatment.","oncology, professionals, data",fachportal.roche.de,Rising,0.101214014609517,high,337,General Offer Outline
270,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-015-impfungen-2022-grippe-und-covid-19-1287217.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_015_impfungen_2022_grippe_und_covid_19_1287217_html.txt,200,html,Indexable,4,48,173,2019,14,14,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_015_impfungen_2022_grippe_und_covid_19_1287217_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_015_impfungen_2022_grippe_und_covid_19_1287217_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_015_impfungen_2022_grippe_und_covid_19_1287217_html.txt.txt,['COVID'],Other,Germany,Offer outline,"COVID-19, flu, vaccinations",,-40.200447,-1.6763166,0,"The content from the Roche professional website covers various therapeutic areas and product offerings related to neuroscience, oncology, and immunology, among others. It highlights clinical data, downloadable resources, and educational services, including podcasts and newsletters, designed for healthcare professionals. The content also addresses recent developments in vaccinations, specifically COVID-19 and flu, featuring insights from expert discussions. The primary purpose is to provide current medical information and resources to support professionals in their practice and to enhance patient care.","oncology, professionals, data",fachportal.roche.de,All,0.451970105446987,high,145,General Offer Outline
271,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-016-jahresrueckblick-2022-1287226.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_016_jahresrueckblick_2022_1287226_html.txt,200,html,Indexable,4,32,132,1890,14,14,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_016_jahresrueckblick_2022_1287226_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_016_jahresrueckblick_2022_1287226_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_016_jahresrueckblick_2022_1287226_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-34.1229,-5.35706,0,"The content focuses on Roche's specialized areas and medical products across various fields like neuroscience, oncology, and hemophilia. It provides access to clinical data, downloadable resources, and additional services aimed at healthcare professionals. Furthermore, it highlights educational initiatives such as podcasts and newsletters to keep medical personnel updated on relevant topics and advances in the field. The overall purpose is to support healthcare professionals with comprehensive information and resources pertaining to Roche's offerings and the latest developments in medical science.","oncology, professionals, data",fachportal.roche.de,Falling,0.930808257626274,high,499,General Offer Outline
272,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-019-mikroangiopathie-1287266.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_019_mikroangiopathie_1287266_html.txt,200,html,Indexable,,28,181,2047,0,0,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_019_mikroangiopathie_1287266_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_019_mikroangiopathie_1287266_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_019_mikroangiopathie_1287266_html.txt.txt,['Its'],Oncology-Hematology,Germany,Offer outline,,,-32.704662,-2.383759,0,"The content provides a detailed overview of Roche's specialized areas within the pharmaceutical sector, covering various fields such as neuroscience, oncology, and hematology. Its purpose is to serve as a comprehensive resource for healthcare professionals, offering information on Roche's products, clinical data, downloadable materials, and educational services. Additionally, it highlights podcasts and discussions featuring experts, aimed at continuing medical education for practitioners. The content emphasizes Roche’s commitment to research and innovation while ensuring users navigate relevant topics effectively.","oncology, professionals, data",fachportal.roche.de,Falling,0.9583666798118,high,199,General Offer Outline
273,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-020-susac-syndrom-1287272.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_020_susac_syndrom_1287272_html.txt,200,html,Indexable,,25,190,2047,0,0,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_020_susac_syndrom_1287272_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_020_susac_syndrom_1287272_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_020_susac_syndrom_1287272_html.txt.txt,[],Other,Germany,Offer outline,,,-37.351536,-5.858315,0,"The content outlines various sections of a professional portal dedicated to Roche's therapeutic areas and products, including neuroscience, oncology, and hematology. It highlights clinical data resources, downloadable materials, and educational services such as podcasts that focus on specific medical topics and treatments. The purpose is to provide healthcare professionals with comprehensive information and updates related to Roche's offerings, while encouraging engagement through events and newsletters. Additionally, it emphasizes the importance of consulting healthcare providers for any medical concerns, reinforcing the portal's educational intent rather than serving as a direct treatment guide.","oncology, professionals, data",fachportal.roche.de,Falling,0.410412141826473,high,480,General Offer Outline
274,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-021-kompetenznetzwerk-ms-kknms-1287276.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_021_kompetenznetzwerk_ms_kknms_1287276_html.txt,200,html,Indexable,,40,203,2038,0,0,0.984,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_021_kompetenznetzwerk_ms_kknms_1287276_html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_021_kompetenznetzwerk_ms_kknms_1287276_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_021_kompetenznetzwerk_ms_kknms_1287276_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-31.469334,-2.3610425,0,"The content outlines the key areas of focus for Roche, including various therapeutic fields such as neuroscience, oncology, and hematology. It serves as a professional portal that aggregates resources such as product overviews, clinical data, and educational materials for healthcare professionals. The content also promotes podcasts and newsletters aimed at delivering advanced knowledge and updates about Roche's products and ongoing research. Additionally, it emphasizes the importance of consulting medical professionals for individual treatment advice and encourages reporting any adverse effects related to Roche's therapies.","oncology, professionals, data",fachportal.roche.de,All,0.398172647991685,high,30,General Offer Outline
275,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-023-MOGAD-1289726.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_023_MOGAD_1289726_html.txt,200,html,Indexable,3,17,158,2050,15,4,0.980769230769231,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_023_MOGAD_1289726_html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_023_MOGAD_1289726_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_023_MOGAD_1289726_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-31.369999,-2.312294,0,"The content primarily serves as a resource hub for medical professionals working with Roche's various therapeutic areas, including neuroscience, oncology, and hematology. The website offers an overview of Roche's products and clinical data, downloadable materials, and educational services like podcasts intended for healthcare professionals. Additionally, it emphasizes the importance of consulting healthcare providers regarding individual patient treatments and includes information on reporting adverse effects related to Roche's products. Overall, the purpose is to provide comprehensive support and up-to-date medical information for professionals in the field.","oncology, professionals, data",fachportal.roche.de,Falling,0.145337777028065,high,80,General Offer Outline
276,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-024-chronische-immunneuropathie-1316301.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_024_chronische_immunneuropathie_1316301_html.txt,200,html,Indexable,,39,190,2042,0,0,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_024_chronische_immunneuropathie_1316301_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_024_chronische_immunneuropathie_1316301_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_024_chronische_immunneuropathie_1316301_html.txt.txt,[],Other,Germany,Offer outline,,,-37.836163,-2.4691663,0,"The content provides an overview of Roche's specialized areas, products, clinical data, and educational services tailored for healthcare professionals. It emphasizes various fields including neuroscience, oncology, and rare diseases, presenting resources such as podcasts and educational materials aimed at enhancing medical knowledge. The content is designed to support healthcare providers with up-to-date information and clinical insights, fostering better patient care while ensuring that sensitive medical advice is appropriately framed and that healthcare professionals remain the primary source of treatment guidance.","oncology, professionals, data",fachportal.roche.de,Rising,0.480869351257212,high,374,General Offer Outline
277,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-025-rza-riesenzellarteriitis-1341306.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_025_rza_riesenzellarteriitis_1341306_html.txt,200,html,Indexable,,38,180,2055,0,0,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_025_rza_riesenzellarteriitis_1341306_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_025_rza_riesenzellarteriitis_1341306_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_025_rza_riesenzellarteriitis_1341306_html.txt.txt,[],Other,Germany,Offer outline,,,-38.574814,-6.181154,0,"The content serves as an overview of Roche's professional portal, outlining various medical specialties, products, clinical data, downloadable resources, and services offered by the company. It highlights specific focus areas such as neuroscience, oncology, hemophilia, and rheumatology, providing direct access to relevant information for healthcare professionals. The inclusion of podcasts and educational content reinforces Roche's commitment to ongoing medical education, while also emphasizing the importance of consulting healthcare providers for individual patient treatment. Overall, the content aims to serve as a comprehensive resource for medical professionals, facilitating their access to Roche's innovations and expertise.","oncology, professionals, data",fachportal.roche.de,All,0.313305718335189,high,256,General Offer Outline
278,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-026-amyotrophe-lateralsklerose-als-1341358.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_026_amyotrophe_lateralsklerose_als_1341358_html.txt,200,html,Indexable,,44,190,2031,0,0,0.984496124031008,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_026_amyotrophe_lateralsklerose_als_1341358_html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_026_amyotrophe_lateralsklerose_als_1341358_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_026_amyotrophe_lateralsklerose_als_1341358_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-33.438286,-1.6347986,0,"The content serves as an informational overview for healthcare professionals regarding Roche's various therapeutic areas and products. It highlights Roche's commitment to advancing medical knowledge and treatment options in fields such as neuroscience, oncology, and more. The content includes links to clinical data, downloadable materials, and educational resources like podcasts for continued medical education, emphasizing the importance of consulting healthcare providers for individual treatment decisions. Overall, it aims to provide comprehensive support and resources for medical professionals involved in patient care.","oncology, professionals, data",fachportal.roche.de,Falling,0.168746023525399,high,193,General Offer Outline
279,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-027-digitale-medizin-1376194.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_027_digitale_medizin_1376194_html.txt,200,html,Indexable,,28,149,2047,0,0,0.982608695652174,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_027_digitale_medizin_1376194_html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_027_digitale_medizin_1376194_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_027_digitale_medizin_1376194_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-35.2339,-8.657799,0,"The content primarily serves as an informational portal for healthcare professionals, detailing Roche's various fields of expertise and products. It covers therapeutic areas including neuroscience, oncology, and rheumatology, while also offering clinical data, downloadable materials, and services for medical professionals. Additionally, the site features podcasts for continuous education, emphasizing the importance of collaboration and information sharing among healthcare providers. The purpose of the content is to provide professionals with comprehensive resources and updates related to Roche's pharmaceutical innovations and clinical practices.","oncology, professionals, data",fachportal.roche.de,Rising,0.626169647349623,high,237,General Offer Outline
280,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-030-als-1471054.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_030_als_1471054_html.txt,200,html,Indexable,4,15,146,2031,23,23,0.980392156862745,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_030_als_1471054_html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_030_als_1471054_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_030_als_1471054_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-36.741425,-4.0378137,0,"The content provided outlines the structure and offerings of Roche's professional portal, focusing on various therapeutic areas such as neuroscience, oncology, and rheumatology. It serves as a resource for professionals, offering access to product overviews, clinical data, downloadable materials, and educational services including podcasts for medical professionals. The purpose of the content is to inform healthcare providers about Roche’s products, services, and ongoing developments in medical science, while emphasizing the importance of consulting healthcare professionals for individual treatment decisions.","oncology, professionals, data",fachportal.roche.de,Flat,0.877330088921808,high,130,General Offer Outline
281,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-031-myasthenia-gravis-1505934.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_031_myasthenia_gravis_1505934_html.txt,200,html,Indexable,4,29,159,2043,23,23,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_031_myasthenia_gravis_1505934_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_031_myasthenia_gravis_1505934_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_031_myasthenia_gravis_1505934_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-31.881224,3.4560897,0,"The content primarily focuses on providing information about Roche's specialized fields in pharmaceuticals, including areas such as neuroscience, oncology, and hematology. It aims to serve healthcare professionals by offering easy access to product overviews, clinical data, downloadable resources, and educational materials, such as podcasts and newsletters, related to various medical topics. Additionally, it emphasizes the importance of professional medical consultation and encourages reporting of any side effects from Roche products. Overall, the purpose is to facilitate ongoing education and awareness for medical professionals regarding Roche's offerings and developments in treatment protocols.","oncology, professionals, data",fachportal.roche.de,Falling,0.518797086801912,high,85,General Offer Outline
282,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-032-tumor-und-autoimmunitaet-bei-ms-1572396.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_032_tumor_und_autoimmunitaet_bei_ms_1572396_html.txt,200,html,Indexable,4,40,169,2037,23,23,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_032_tumor_und_autoimmunitaet_bei_ms_1572396_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_032_tumor_und_autoimmunitaet_bei_ms_1572396_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_032_tumor_und_autoimmunitaet_bei_ms_1572396_html.txt.txt,[],Other,Germany,Offer outline,,,-34.442932,-3.7616267,0,"The content outlines the various therapeutic areas and services offered by Roche, emphasizing information tailored for healthcare professionals. It provides an overview of Roche's products across numerous specialties such as neuroscience, oncology, and hematology, along with clinical data and downloadable resources. Additionally, it features educational podcasts targeting medical professionals, addressing specific clinical topics and treatment considerations. The overarching purpose is to inform and support healthcare providers with resources, training, and ongoing education related to Roche's offerings.","oncology, professionals, data",fachportal.roche.de,All,0.757689370414828,high,463,General Offer Outline
283,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-033-car-t-zellen.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_033_car_t_zellen_html.txt,200,html,Indexable,3,24,189,2115,25,25,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_033_car_t_zellen_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_033_car_t_zellen_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_033_car_t_zellen_html.txt.txt,"['CAR', 'T']",Oncology-Hematology,Germany,Offer outline,,,-33.307415,-3.3730881,0,"The content is focused on Roche's specialized areas of expertise in pharmaceuticals, covering various fields such as neuroscience, oncology, and hematology. It provides an overview of Roche's products, clinical data, downloadable resources, and services for healthcare professionals. Additionally, it promotes educational podcasts tailored for medical staff, discussing advanced topics like CAR-T cell therapy. The purpose is to inform and support professionals with relevant medical knowledge and resources, while also emphasizing the importance of consulting healthcare providers for treatment decisions.","oncology, professionals, data",fachportal.roche.de,Flat,0.213300804774993,high,211,General Offer Outline
284,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-034-mrt-entwicklungen.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_034_mrt_entwicklungen_html.txt,200,html,Indexable,3,29,153,2103,25,25,0.981481481481482,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_034_mrt_entwicklungen_html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_034_mrt_entwicklungen_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_034_mrt_entwicklungen_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-36.548527,-1.9060467,0,"The content serves as an overview of Roche's specialized portal for healthcare professionals, highlighting various therapeutic areas such as neuroscience, oncology, and more. It provides a structured navigation guide to Roche's products, clinical data, downloadable resources, and services, including podcasts aimed at medical training and healthcare information. The content emphasizes Roche's commitment to sharing educational material and clinical insights without substituting professional medical advice, while also offering channels for reporting adverse effects related to their products. Overall, the purpose is to inform and educate medical professionals about Roche's offerings and advancements in healthcare.","oncology, professionals, data",fachportal.roche.de,Flat,0.0034277992938602,high,423,General Offer Outline
285,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-036-neuropsychologie-und-neurologie-1671190.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_036_neuropsychologie_und_neurologie_1671190_html.txt,200,html,Indexable,3,41,151,2106,25,25,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_036_neuropsychologie_und_neurologie_1671190_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_036_neuropsychologie_und_neurologie_1671190_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_036_neuropsychologie_und_neurologie_1671190_html.txt.txt,[],Other,Germany,Offer outline,,,-34.870018,0.4487644,0,"The content outlines various areas of expertise and services offered by Roche, particularly in the field of healthcare and pharmaceuticals. It highlights specific medical specialties such as neuroscience, oncology, and rheumatology, and provides an overview of available products, clinical data, and downloadable materials related to these areas. Additionally, the content promotes educational resources like podcasts for medical professionals, emphasizing the importance of consulting healthcare providers for individual treatment decisions. Overall, the purpose of the content is to inform healthcare professionals about Roche's offerings while providing a platform for further education and collaboration in the medical field.","oncology, professionals, data",fachportal.roche.de,Flat,0.851547449075861,high,359,General Offer Outline
286,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-aan-2022-neuro-news-aus-seattle-tag1-1287167.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag1_1287167_html.txt,200,html,Indexable,,74,191,1666,6,6,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag1_1287167_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag1_1287167_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag1_1287167_html.txt.txt,"['Congress', 'AAN']",Oncology-Hematology,Germany,Offer outline,,,-33.193867,-5.1624417,0,"The content primarily explores Roche's various specialties, including areas such as neuroscience, oncology, and hematology, while providing a detailed overview of their products and clinical data. It emphasizes educational resources for medical professionals, such as podcasts and newsletters that discuss recent advancements and relevant findings from conferences like the AAN Congress. Additionally, the content highlights Roche's commitment to sharing knowledge and facilitating communication among healthcare providers. Overall, the purpose is to inform and engage medical professionals with the latest developments and offerings within the pharmaceutical field.","oncology, professionals, data",fachportal.roche.de,All,0.456347017963743,high,65,General Offer Outline
287,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-aan-2022-neuro-news-aus-seattle-tag2-1287170.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag2_1287170_html.txt,200,html,Indexable,,74,191,1666,6,6,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag2_1287170_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag2_1287170_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag2_1287170_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-32.158577,-10.626979,0,"The content serves as a comprehensive resource portal for healthcare professionals, detailing various therapeutic fields and Roche's products and services. It includes sections on neuroscience, oncology, hematology, and more, providing clinical data, downloadable materials, and educational podcasts aimed at supporting medical practitioners. Additionally, it emphasizes the importance of consulting healthcare professionals for specific medical advice and encourages reporting any adverse effects related to Roche products. The overall purpose is to disseminate knowledge and resources about Roche's innovations in medicine and support ongoing education for medical staff.","oncology, professionals, data",fachportal.roche.de,Falling,0.0263483932660146,high,431,General Offer Outline
288,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-aan-2022-neuro-news-aus-seattle-tag3-1287171.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag3_1287171_html.txt,200,html,Indexable,,74,191,1666,6,6,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag3_1287171_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag3_1287171_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag3_1287171_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-32.07109,3.6649535,0,"The content serves as an overview of Roche's specialized areas in pharmaceuticals, highlighting various medical fields such as neuroscience, oncology, and hematology. It details the products offered by Roche, clinical data related to those products, and resources for medical professionals, including downloads and podcasts aimed at continuing medical education. Additionally, the content emphasizes the importance of consulting healthcare professionals regarding treatment, while providing information on reporting adverse drug reactions. Overall, it functions as a comprehensive portal for professionals seeking up-to-date information and resources related to Roche's medical offerings.","oncology, professionals, data",fachportal.roche.de,All,0.892328364687694,high,40,General Offer Outline
289,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-aan-2022-neuro-news-aus-seattle-tag5-1287175.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag5_1287175_html.txt,200,html,Indexable,,74,191,1666,6,6,0.984732824427481,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag5_1287175_html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag5_1287175_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2022_neuro_news_aus_seattle_tag5_1287175_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-36.64213,-4.0614457,0,"The content of the content focuses on the various therapeutic areas covered by Roche, including neuroscience, oncology, and rheumatology, along with an overview of their products and services. It serves as a professional resource for medical personnel, offering access to clinical data, downloadable materials, and educational podcasts. The content also emphasizes the importance of consulting medical professionals regarding treatment and highlights Roche's commitment to sharing knowledge through events and newsletters, fostering a collaborative atmosphere within the medical community.","oncology, professionals, data",fachportal.roche.de,Flat,0.462871620294309,high,181,General Offer Outline
290,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-aan-2023-neuro-news-aus-boston-tag-1-1287242.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_1_1287242_html.txt,200,html,Indexable,,56,173,1507,5,5,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_1_1287242_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_1_1287242_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_1_1287242_html.txt.txt,"['Congress', 'AAN']",Oncology-Hematology,Germany,Offer outline,,,-38.62994,-6.2147,0,"The content outlines various resources and information available on Roche's professional portal, specifically focusing on therapeutic areas such as neuroscience, oncology, and hemophilia. It includes sections on products, clinical data, and downloadable materials relevant to healthcare professionals. Additionally, it highlights services like newsletters and podcasts, particularly detailing a podcast series aimed at providing educational content for medical practitioners at the AAN Congress 2023. The overall purpose is to inform and support medical professionals with up-to-date scientific information and Roche's offerings.","oncology, professionals, data",fachportal.roche.de,Falling,0.441282112557999,high,186,General Offer Outline
291,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-aan-2023-neuro-news-aus-boston-tag-2-1287247.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_2_1287247_html.txt,200,html,Indexable,,56,173,1507,5,5,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_2_1287247_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_2_1287247_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_2_1287247_html.txt.txt,"['Fachportal', 'Congress', 'AAN', 'Its']",Other,Germany,Offer outline,,,-36.010086,2.8690302,0,"The content is a comprehensive overview of the Roche Fachportal, detailing various medical specialties and products offered by Roche, including neuroscience, oncology, and pharmacology. It highlights resources such as clinical data, downloadable materials, and services tailored for healthcare professionals. The portal also features podcasts that share insights from medical experts, particularly surrounding recent conferences like the AAN Congress 2023. Its main purpose is to provide medical professionals with easy access to essential information, updates, and educational resources related to Roche's offerings.","oncology, professionals, data",fachportal.roche.de,Falling,0.0992890855952683,high,330,General Offer Outline
292,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-aan-2023-neuro-news-aus-boston-tag-3-1287251.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_3_1287251_html.txt,200,html,Indexable,,56,173,1507,5,5,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_3_1287251_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_3_1287251_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_3_1287251_html.txt.txt,"['Congress', 'AAN']",Oncology-Hematology,Germany,Metainformation,,,-35.73645,-5.5186605,0,"The content provides an overview of Roche's professional portal, highlighting various therapeutic areas such as neuroscience, oncology, and hematology, as well as their products and clinical data. It features educational resources like podcasts and newsletters aimed at healthcare professionals, particularly focused on updates from the AAN Congress 2023. The portal serves to facilitate access to medical information and resources related to Roche’s innovations and services while emphasizing the importance of consulting healthcare providers for treatment decisions.","oncology, professionals, data",fachportal.roche.de,Rising,0.613539504720797,high,400,General Offer Outline
293,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-aan-2023-neuro-news-aus-boston-tag-4-1287253.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_4_1287253_html.txt,200,html,Indexable,,56,173,1508,5,5,0.984732824427481,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_4_1287253_html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_4_1287253_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2023_neuro_news_aus_boston_tag_4_1287253_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-31.756678,-8.515905,0,"The content focuses on Roche's various therapeutic areas, including neuroscience, oncology, and hematology, among others. It serves as a comprehensive portal for healthcare professionals seeking information on Roche's products, clinical data, and educational resources such as podcasts and newsletters. Additionally, it emphasizes the importance of consulting medical professionals for individual health concerns while providing a platform for reporting adverse effects related to Roche's therapies. Overall, the purpose is to facilitate access to medical information and updates in the pharmaceutical field, enhancing knowledge and collaboration among healthcare providers.","oncology, professionals, data",fachportal.roche.de,All,0.0562625635121481,high,187,General Offer Outline
294,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-aan-2024-neuro-news-aus-denver-tag-2-1437558.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2024_neuro_news_aus_denver_tag_2_1437558_html.txt,200,html,Indexable,4,58,255,1432,9,9,0.984732824427481,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2024_neuro_news_aus_denver_tag_2_1437558_html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2024_neuro_news_aus_denver_tag_2_1437558_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2024_neuro_news_aus_denver_tag_2_1437558_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-36.612637,-3.5885906,0,"The content outlines the features of Roche's professional portal, showcasing various therapeutic areas such as neuroscience, oncology, and rheumatology. It provides an overview of Roche's products, clinical data, and resources available for healthcare professionals, including downloadable materials and podcasts focusing on recent medical developments. The purpose of the content is to serve as a comprehensive resource for medical professionals seeking information about Roche’s offerings and advancements, while also emphasizing the importance of consulting healthcare providers for individual patient care.","oncology, professionals, data",fachportal.roche.de,Falling,0.0911061212268807,high,88,General Offer Outline
295,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-aan-2024-neuro-news-aus-denver-tag-3-1438880.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2024_neuro_news_aus_denver_tag_3_1438880_html.txt,200,html,Indexable,4,58,255,1432,27,27,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2024_neuro_news_aus_denver_tag_3_1438880_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2024_neuro_news_aus_denver_tag_3_1438880_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_aan_2024_neuro_news_aus_denver_tag_3_1438880_html.txt.txt,[],Other,Germany,Offer outline,,,-29.986725,10.895219,0,"The content provides an overview of Roche's specialization areas, products, clinical data, and services, emphasizing various therapeutic fields such as neuroscience, oncology, and ophthalmology. It also highlights resources available for medical professionals, including podcasts for continuous education, event updates, and downloadable materials. The purpose is to support healthcare professionals with informative content related to Roche's offerings and updates in medical science, while also ensuring compliance and safety through reporting mechanisms for adverse events.","oncology, professionals, data",fachportal.roche.de,Flat,0.947034418101618,high,97,General Offer Outline
296,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-ctad-2022-neuro-news-aus-san-francisco-highlights-1287225.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ctad_2022_neuro_news_aus_san_francisco_highlights_1287225_html.txt,200,html,Indexable,,69,198,1324,3,3,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ctad_2022_neuro_news_aus_san_francisco_highlights_1287225_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ctad_2022_neuro_news_aus_san_francisco_highlights_1287225_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ctad_2022_neuro_news_aus_san_francisco_highlights_1287225_html.txt.txt,[],Other,Germany,Offer outline,,,-34.951427,2.76676,0,"The content provides an overview of Roche's specialized areas in various medical fields, including neuroscience, oncology, and rheumatology, as well as information about their products, clinical data, and educational services. It emphasizes resources for healthcare professionals, such as podcasts for ongoing medical education, updates on clinical trials, and access to download materials. The purpose of the content is to serve as a comprehensive resource for medical professionals seeking detailed information about Roche’s therapeutic areas and offerings, while also ensuring compliance with regulatory requirements regarding adverse event reporting.","oncology, professionals, data",fachportal.roche.de,Rising,0.0717652994876344,high,369,General Offer Outline
297,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-ctad-2022-neuro-news-aus-san-francisco-tag1-1287219.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ctad_2022_neuro_news_aus_san_francisco_tag1_1287219_html.txt,200,html,Indexable,,65,162,1310,3,3,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ctad_2022_neuro_news_aus_san_francisco_tag1_1287219_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ctad_2022_neuro_news_aus_san_francisco_tag1_1287219_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ctad_2022_neuro_news_aus_san_francisco_tag1_1287219_html.txt.txt,[],Other,Germany,Offer outline,,,-31.694408,-11.284713,0,"The content of the content outlines Roche's specialized areas within the pharmaceutical sector, specifically focusing on various fields such as neuroscience, oncology, and hematology. It serves as a professional portal for healthcare professionals to access information about Roche's products, clinical data, and educational materials. The content also highlights available services for medical professionals, including podcasts and newsletters, while emphasizing the importance of consulting healthcare providers for medical issues rather than solely relying on the provided educational content. Overall, the purpose is to inform and equip professionals with necessary insights and resources related to Roche's offerings in the healthcare landscape.","oncology, professionals, data",fachportal.roche.de,All,0.180179586481364,high,113,General Offer Outline
298,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-ctad-2022-neuro-news-aus-san-francisco-tag2-1287221.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ctad_2022_neuro_news_aus_san_francisco_tag2_1287221_html.txt,200,html,Indexable,,65,128,1304,3,3,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ctad_2022_neuro_news_aus_san_francisco_tag2_1287221_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ctad_2022_neuro_news_aus_san_francisco_tag2_1287221_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ctad_2022_neuro_news_aus_san_francisco_tag2_1287221_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-34.138374,-4.5355945,0,"The content focuses on Roche's specialized products and services across various medical fields such as neuroscience, oncology, and hematology. It offers a comprehensive overview of Roche's offerings, including product details, clinical data, downloadable resources, and educational podcasts aimed at healthcare professionals. Additionally, it emphasizes continuous education through events and media, such as newsletters and podcasts, and underscores the importance of consulting healthcare providers for personalized medical advice. Overall, the purpose is to provide healthcare professionals with accessible information and resources to support their clinical practice.","oncology, professionals, data",fachportal.roche.de,All,0.311097185357002,high,26,General Offer Outline
299,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-dgn-23-neuro-news-aus-berlin-02-1287289.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_dgn_23_neuro_news_aus_berlin_02_1287289_html.txt,200,html,Indexable,,58,214,1344,3,3,0.984126984126984,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_dgn_23_neuro_news_aus_berlin_02_1287289_html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_dgn_23_neuro_news_aus_berlin_02_1287289_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_dgn_23_neuro_news_aus_berlin_02_1287289_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-34.358532,6.0155907,0,"The content of this content is a detailed overview of Roche's pharmaceutical offerings and resources for healthcare professionals. It highlights various therapeutic areas such as neuroscience, oncology, and immunology, and provides access to product information, clinical data, and downloadable materials. Additionally, the content mentions educational resources like podcasts and newsletters aimed at medical personnel, emphasizing ongoing medical education and communication of new clinical insights. The purpose is to support and inform healthcare professionals about Roche's products, services, and recent developments in medicine.","oncology, professionals, data",fachportal.roche.de,Flat,0.725573689780648,high,197,General Offer Outline
300,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-dgn-23-neuro-news-aus-berlin-03-1287290.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_dgn_23_neuro_news_aus_berlin_03_1287290_html.txt,200,html,Indexable,,58,214,1345,3,3,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_dgn_23_neuro_news_aus_berlin_03_1287290_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_dgn_23_neuro_news_aus_berlin_03_1287290_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_dgn_23_neuro_news_aus_berlin_03_1287290_html.txt.txt,[],Other,Germany,Offer outline,,,-32.66778,-0.96153295,0,"The content serves as a comprehensive overview of Roche's pharmaceutical offerings and resources, aimed at healthcare professionals. It encompasses various therapeutic areas such as neuroscience, oncology, and rheumatology, along with information on Roche's products, clinical data, and downloadable materials. Additionally, it highlights educational content, including podcasts for medical professionals, and provides updates from medical congresses. The purpose is to inform and support healthcare providers with relevant medical and therapeutic information, while adhering to best practices in patient care.","oncology, professionals, data",fachportal.roche.de,Flat,0.988370962182758,high,166,General Offer Outline
301,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-ECTRIMS-2022-neuro-news-aus-Amsterdam-tag1-1287198.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ECTRIMS_2022_neuro_news_aus_Amsterdam_tag1_1287198_html.txt,200,html,Indexable,,74,168,1244,2,2,0.985401459854015,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ECTRIMS_2022_neuro_news_aus_Amsterdam_tag1_1287198_html.txt.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ECTRIMS_2022_neuro_news_aus_Amsterdam_tag1_1287198_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ECTRIMS_2022_neuro_news_aus_Amsterdam_tag1_1287198_html.txt.txt.txt,"['Congress', 'ECTRIMS']",Other,Germany,Offer outline,,,-36.02431,-4.1758237,0,"The content focuses on Roche's various therapeutic areas, products, and services aimed at healthcare professionals. It provides an overview of specific medical fields such as neuroscience, oncology, and rheumatology, offering clinical data and downloadable resources. Additionally, it highlights events like the ECTRIMS Congress and includes educational podcasts targeted at medical personnel, emphasizing the importance of professional consultation for treatment. The purpose of this content is to inform and support healthcare professionals with relevant product information, clinical insights, and continuous education pertaining to Roche's offerings.","oncology, professionals, data",fachportal.roche.de,Rising,0.794649879881156,high,468,General Offer Outline
302,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-ectrims-23-neuro-news-aus-mailand-01-1287281.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ectrims_23_neuro_news_aus_mailand_01_1287281_html.txt,200,html,Indexable,,63,194,1271,2,2,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ectrims_23_neuro_news_aus_mailand_01_1287281_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ectrims_23_neuro_news_aus_mailand_01_1287281_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_ectrims_23_neuro_news_aus_mailand_01_1287281_html.txt.txt,"['Congress', 'ECTRIMS']",Other,Germany,Offer outline,,,-36.030807,-9.277358,0,"The content provides an overview of Roche's specialized areas, products, clinical data, and services aimed at healthcare professionals. It highlights various fields such as neuroscience, oncology, and dermatology, and mentions resources for downloading information and attending events like the ECTRIMS Congress. There is also a focus on educational content for medical personnel through podcasts and newsletters. Overall, the purpose is to inform industry professionals about Roche's offerings and updates in medical science, promoting research and engagement within the healthcare community.","oncology, professionals, data",fachportal.roche.de,Falling,0.415159367561939,high,89,General Offer Outline
303,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-neurowoche-2022-neuro-news-aus-berlin-tag1-1287200.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_neurowoche_2022_neuro_news_aus_berlin_tag1_1287200_html.txt,200,html,Indexable,,65,331,1507,4,4,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_neurowoche_2022_neuro_news_aus_berlin_tag1_1287200_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_neurowoche_2022_neuro_news_aus_berlin_tag1_1287200_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_neurowoche_2022_neuro_news_aus_berlin_tag1_1287200_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-32.341396,-5.4505258,0,"The content provides an overview of Roche's specialized areas and products, emphasizing various fields such as neuroscience, oncology, and hematology. It highlights resources available to healthcare professionals, including clinical data, downloadable materials, podcasts for medical education, and information on ongoing events like congresses. The content serves to inform professionals about Roche's offerings and to promote continued education and engagement within the medical community, while ensuring compliance with health protocols.","oncology, professionals, data",fachportal.roche.de,Falling,0.472334234815619,high,372,General Offer Outline
304,https://fachportal.roche.de/services/podcasts/nervennahrung-fuer-neurologen/podcast-neurowoche-2022-neuro-news-aus-berlin-tag4-1287214.html,9,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_neurowoche_2022_neuro_news_aus_berlin_tag4_1287214_html.txt,200,html,Indexable,,65,231,1473,4,4,1,fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_neurowoche_2022_neuro_news_aus_berlin_tag4_1287214_html.txt,image/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_neurowoche_2022_neuro_news_aus_berlin_tag4_1287214_html.txt.png,text/fachportal_roche_de_services_podcasts_nervennahrung_fuer_neurologen_podcast_neurowoche_2022_neuro_news_aus_berlin_tag4_1287214_html.txt.txt,[],Other,Germany,Offer outline,,,-35.153008,-2.5445385,0,"The content showcases various therapeutic areas and products offered by Roche, including specialized fields such as neuroscience, oncology, and rheumatology. It outlines resources and services available for healthcare professionals, including clinical data, educational podcasts, and newsletters. The purpose is to provide comprehensive information and support for medical professionals regarding Roche's offerings, advancements in treatment, and ongoing medical education initiatives, while also emphasizing the importance of consulting with healthcare providers regarding patient care.","oncology, professionals, data",fachportal.roche.de,Falling,0.550771323912938,high,319,General Offer Outline
305,https://fachportal.roche.de/services/podcasts/neuro-news-aus-berlin-2024/.html,9,fachportal_roche_de_services_podcasts_neuro_news_aus_berlin_2024__html.txt,200,html,Non-Indexable,4,40,300,1097,4,4,1,fachportal_roche_de_services_podcasts_neuro_news_aus_berlin_2024__html.txt,image/fachportal_roche_de_services_podcasts_neuro_news_aus_berlin_2024__html.txt.png,text/fachportal_roche_de_services_podcasts_neuro_news_aus_berlin_2024__html.txt.txt,"['Berlin', 'DGN', 'Congress', 'November']",Neurology,Germany,Events,,,23.351349,23.027313,4,"The content features content related to the DGN Congress 2024, highlighting a special podcast series. It invites participants to engage with clinically relevant topics in neurology, with the event scheduled to take place in Berlin from November 6 to 9, 2024. The platform aims to provide professionals with insights and updates from the congress.","technologies, artificial, ai",fachportal.roche.de,Rising,0.0732033638595065,high,133,Technology
306,https://fachportal.roche.de/services/podcasts/neuro-news-aus-berlin-2024/folge-1.html,9,fachportal_roche_de_services_podcasts_neuro_news_aus_berlin_2024_folge_1_html.txt,200,html,Non-Indexable,3,79,279,1111,10,6,0.975903614457831,fachportal_roche_de_services_podcasts_neuro_news_aus_berlin_2024_folge_1_html.txt.txt,image/fachportal_roche_de_services_podcasts_neuro_news_aus_berlin_2024_folge_1_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_neuro_news_aus_berlin_2024_folge_1_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-39.057957,-2.2805266,0,"The content primarily serves as a professional resource for healthcare providers, focusing on various therapeutic areas covered by Roche, including neuroscience, oncology, and rare diseases. It outlines available products, clinical data, and downloadable materials, fostering knowledge dissemination among medical professionals. Additionally, it features podcasts and details about upcoming events and research findings, enhancing engagement and collaboration within the medical community. Overall, the purpose is to provide comprehensive support and information to professionals working in the pharmaceutical and healthcare sectors.","oncology, professionals, data",fachportal.roche.de,Rising,0.511161429330907,high,411,General Offer Outline
307,https://fachportal.roche.de/services/podcasts/neuro-news-aus-berlin-2024/folge-3.html,9,fachportal_roche_de_services_podcasts_neuro_news_aus_berlin_2024_folge_3_html.txt,200,html,Non-Indexable,3,79,264,1111,10,6,1,fachportal_roche_de_services_podcasts_neuro_news_aus_berlin_2024_folge_3_html.txt,image/fachportal_roche_de_services_podcasts_neuro_news_aus_berlin_2024_folge_3_html.txt.png,text/fachportal_roche_de_services_podcasts_neuro_news_aus_berlin_2024_folge_3_html.txt.txt,[],Other,Germany,Offer outline,,,-34.915165,0.7825853,0,"The content outlines Roche's specialized areas of focus within their pharmaceutical offerings, such as neuroscience, oncology, and rheumatology. It serves as a comprehensive portal for professionals, providing access to product overviews, clinical data, downloadable resources, and updates on services. Additionally, it highlights various events and informative podcasts aimed at healthcare professionals, emphasizing Roche's commitment to sharing knowledge and advancements in treatment. The purpose is to support medical professionals by facilitating easy access to relevant information regarding Roche's products and innovations in the medical field.","oncology, professionals, data",fachportal.roche.de,Flat,0.523000974024574,high,265,General Offer Outline
308,https://fachportal.roche.de/services/podcasts/neuro-news-aus-kopenhagen/.html,6,fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen__html.txt,200,html,Non-Indexable,4,48,0,1046,3,3,1,fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen__html.txt,image/fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen__html.txt.png,text/fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen__html.txt.txt,"['September', 'Copenhagen', 'ECTRIMS']",Neurology,Germany,Events,,,23.310755,23.132345,4,"The content is promoting a special podcast series related to the ECTRIMS 2024 event, scheduled for September 18-20, 2024, in Copenhagen. It highlights that the podcast will feature clinically relevant contributions across various areas of neurology, aimed at professionals in the field. The content appears to be designed to keep listeners informed about the latest developments and insights from the conference.","technologies, artificial, ai",fachportal.roche.de,All,0.851940834338807,medium,189,Technology
309,https://fachportal.roche.de/services/podcasts/neuro-news-aus-kopenhagen/folge-1.html,9,fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen_folge_1_html.txt,200,html,Non-Indexable,3,87,280,1022,9,5,0.975609756097561,fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen_folge_1_html.txt.txt,image/fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen_folge_1_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen_folge_1_html.txt.txt.txt,['ECTRIMS'],Other,Germany,Offer outline,,,-35.315826,1.5440367,0,"The content outlines the different therapeutic areas and services provided by Roche, highlighting their focus on various medical fields such as neuroscience, oncology, and rheumatology, among others. It mentions the availability of clinical data, product information, and downloadable resources for professionals in the healthcare industry. Additionally, it emphasizes Roche’s engagement in events like the ECTRIMS congress, featuring podcasts that cover relevant clinical insights. The overall purpose of the content is to serve as a resource hub for healthcare professionals looking for comprehensive information on Roche's products, research, and medical advancements.","oncology, professionals, data",fachportal.roche.de,Flat,0.742576641985057,high,49,General Offer Outline
310,https://fachportal.roche.de/services/podcasts/neuro-news-aus-kopenhagen/folge-2.html,9,fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen_folge_2_html.txt,200,html,Non-Indexable,3,87,222,1006,9,5,1,fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen_folge_2_html.txt,image/fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen_folge_2_html.txt.png,text/fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen_folge_2_html.txt.txt,['Its'],Other,Germany,Offer outline,,,-27.776258,3.8870292,0,"The content outlines various professional resources available through Roche's specialized portal, focusing on different therapeutic areas such as neuroscience, oncology, and hematology. It offers an overview of Roche's products, clinical data, and downloadable materials pertinent to healthcare professionals. The content also highlights podcasts and events, providing updates on relevant medical congresses and discussions. Its primary purpose is to serve as a comprehensive resource hub for medical professionals to access information about Roche's products, research, and ongoing medical advancements.","oncology, professionals, data",fachportal.roche.de,All,0.392235353932157,high,288,General Offer Outline
311,https://fachportal.roche.de/services/podcasts/neuro-news-aus-kopenhagen.html,6,fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen_html.txt,200,html,Non-Indexable,3,48,0,1079,5,5,1,fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen_html.txt,image/fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen_html.txt.png,text/fachportal_roche_de_services_podcasts_neuro_news_aus_kopenhagen_html.txt.txt,['ECTRIMS'],Oncology-Hematology,Germany,Offer outline,,,-38.519924,-3.396762,0,"The content primarily focuses on Roche's various therapeutic areas, products, and services, particularly in neuroscience and oncology. It provides access to clinical data, downloadable materials, and information about ongoing events, such as the upcoming ECTRIMS congress in 2024. Additionally, it features resources for medical professionals, including podcasts that discuss new clinical insights from conferences and details on new therapies. The overall purpose is to support healthcare professionals with relevant data and updates related to Roche's medical offerings.","oncology, professionals, data",fachportal.roche.de,Rising,0.224600963469962,medium,162,General Offer Outline
312,https://fachportal.roche.de/services/podcasts/onkologe-overseas-onko-news-aus-chicago/.html,6,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago__html.txt,200,html,Non-Indexable,4,24,0,1115,7,7,1,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago__html.txt,image/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago__html.txt.png,text/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago__html.txt.txt,[],Oncology-Hematology,Germany,Metainformation,,,-7.603085,-13.77209,3,"The content focuses on the features and functionalities of Roche's professional portal, specifically highlighting its services related to oncology podcasts. It appears to be designed for healthcare professionals, providing them with access to specialized information and resources. The content includes various metadata tags that assist with website management and navigation, as well as elements for user interaction such as login and registration prompts. Overall, the primary purpose is to facilitate engagement and access to Roche's offerings in the field of oncology.","users, page, website",fachportal.roche.de,All,0.92226579666006,medium,345,Website Metadata
313,https://fachportal.roche.de/services/podcasts/onkologe-overseas-onko-news-aus-chicago/folge-1.html,9,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_1_html.txt,200,html,Non-Indexable,3,51,186,1346,22,8,1,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_1_html.txt,image/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_1_html.txt.png,text/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_1_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-23.470226,0.22498831,0,"The content outlines the offerings of Roche's professional portal, highlighting various therapeutic areas such as neuroscience, oncology, and precision medicine. It provides a comprehensive overview of Roche's products, clinical data, and downloadable resources, along with information about services like podcasts and expert dialogues focused on oncology. The purpose is to facilitate access to Roche's products and innovations, share insights from medical events, and keep healthcare professionals updated on the latest trends and research in the pharmaceutical industry.","oncology, professionals, data",fachportal.roche.de,All,0.193711675093616,high,47,General Offer Outline
314,https://fachportal.roche.de/services/podcasts/onkologe-overseas-onko-news-aus-chicago/folge-2.html,9,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_2_html.txt,200,html,Non-Indexable,3,34,238,1311,22,8,1,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_2_html.txt,image/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_2_html.txt.png,text/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_2_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-22.848091,5.6791673,0,"The content provides an overview of Roche's specialized areas and products, specifically in the fields of oncology, neuroscience, ophthalmology, and other medical disciplines. It details various services, clinical data, and downloadable materials accessible through their professional platform. The content emphasizes educational offerings such as podcasts and expert discussions from major medical congresses, focusing on recent advancements and findings in cancer treatment and therapies. Overall, the purpose is to inform healthcare professionals about Roche's resources, innovations, and updates in medicine.","oncology, professionals, data",fachportal.roche.de,Falling,0.690094445870937,high,330,General Offer Outline
315,https://fachportal.roche.de/services/podcasts/onkologe-overseas-onko-news-aus-chicago/folge-3.html,9,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_3_html.txt,200,html,Non-Indexable,3,107,168,1297,22,8,0.979166666666667,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_3_html.txt.txt,image/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_3_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_3_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-18.718876,3.5624213,0,"The content presents an overview of Roche's specialized areas and products, focusing on various therapeutic fields including oncology, neuroscience, and hematology. It highlights the availability of clinical data, downloadable materials, and additional services such as podcasts and expert dialogues that inform healthcare professionals about the latest developments in oncology and other medical fields. The purpose of this content is to provide professionals with comprehensive resources and updates that aid in their clinical practice and understanding of Roche's offerings.","oncology, professionals, data",fachportal.roche.de,Falling,0.0957967852617543,high,348,General Offer Outline
316,https://fachportal.roche.de/services/podcasts/onkologe-overseas-onko-news-aus-chicago/folge-4.html,9,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_4_html.txt,200,html,Non-Indexable,3,79,212,1265,22,8,0.979166666666667,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_4_html.txt.txt,image/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_4_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_4_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-23.039047,2.831696,0,"The content consists of a comprehensive overview of Roche's specialized fields, products, clinical data, and services designed for healthcare professionals. It provides information on areas such as oncology, neurology, and rare diseases, and features updates on recent scientific breakthroughs and podcasts related to ongoing medical congresses. The purpose of this content is to serve as a resource for healthcare professionals to access Roche's products, download relevant materials, stay updated on clinical developments, and engage with expert dialogues in the medical community.","oncology, professionals, data",fachportal.roche.de,Flat,0.3837918985779,high,325,General Offer Outline
317,https://fachportal.roche.de/services/podcasts/onkologe-overseas-onko-news-aus-chicago/folge-5.html,9,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_5_html.txt,200,html,Non-Indexable,3,70,162,1275,22,8,0.979166666666667,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_5_html.txt.txt,image/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_5_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_5_html.txt.txt.txt,"['Congress', 'American', 'Cancer']",Oncology-Hematology,Germany,Offer outline,,,-21.946777,0.50858796,0,"The content focuses on Roche's specialized areas of expertise within the pharmaceutical industry, particularly in oncology, neuroscience, and various medical fields. It provides an overview of Roche's product offerings, including detailed clinical data and downloadable resources for healthcare professionals. Additionally, it highlights ongoing educational initiatives such as podcasts and expert dialogues, particularly related to the American Cancer Congress, aimed at sharing the latest research, developments, and insights in oncology. The purpose is to support medical professionals with relevant information and resources related to Roche's products and services.","oncology, professionals, data",fachportal.roche.de,Rising,0.786565206047623,high,466,General Offer Outline
318,https://fachportal.roche.de/services/podcasts/onkologe-overseas-onko-news-aus-chicago/folge-6.html,9,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_6_html.txt,200,html,Non-Indexable,3,94,202,1330,22,8,0.979166666666667,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_6_html.txt.txt,image/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_6_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_folge_6_html.txt.txt.txt,"['Congress', 'American', 'Cancer']",Oncology-Hematology,Germany,Offer outline,,,-29.651575,9.040912,0,"The content outlines the offerings of Roche in various medical fields, such as oncology, neurology, and ophthalmology. It provides resources for healthcare professionals, including product overviews, clinical data, downloadable materials, and access to multimedia content such as podcasts and newsletters. The content emphasizes Roche's commitment to advancing medical knowledge and sharing the latest research findings, particularly from significant events like the American Cancer Congress, thereby serving as an educational tool for professionals in the pharmaceutical and medical sectors.","oncology, professionals, data",fachportal.roche.de,Falling,0.720481218280417,high,204,General Offer Outline
319,https://fachportal.roche.de/services/podcasts/onkologe-overseas-onko-news-aus-chicago.html,7,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_html.txt,200,html,Non-Indexable,2,24,0,1149,15,15,0.977272727272727,fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_html.txt.txt,image/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_onkologe_overseas_onko_news_aus_chicago_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-22.425783,1.4210111,0,"The content is a comprehensive overview of Roche's specialized fields, products, and services targeted at healthcare professionals. It highlights various therapeutic areas, such as oncology, neurology, and immunology, providing access to clinical data, downloadable resources, and informative podcasts. The content aims to keep healthcare professionals updated on the latest advancements in cancer research and other medical disciplines, showcasing Roche's commitment to education and innovation in the pharmaceutical sector.","oncology, professionals, data",fachportal.roche.de,Rising,0.425415919898948,high,320,General Offer Outline
320,https://fachportal.roche.de/services/podcasts/onkonews-aus-barcelona-2024/.html,6,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024__html.txt,200,html,Non-Indexable,3,26,0,1179,18,7,0.974025974025974,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024__html.txt.txt,image/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024__html.txt.txt.png,text/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024__html.txt.txt.txt,"['Each', 'Harald', 'Barcelona', 'European', 'Congress', 'ESMO', 'Hosted', 'Cancer', 'Huesmann']",Oncology-Hematology,Germany,Events,"immunotherapy, lung cancer, prostate cancer","lung cancer, prostate cancer",25.717577,-14.052939,12,"The content provides an overview of a podcast series titled ""OnkoNews"" that covers the European Cancer Congress (ESMO 2024) taking place in Barcelona. Hosted by Harald Müller-Huesmann, the podcast features discussions on groundbreaking findings in cancer research, innovative therapies, and emerging treatment strategies, all aimed at professionals in oncology. Each episode focuses on specific topics such as advances in immunotherapy, gender-sensitive oncology, and particular types of cancer like lung and prostate cancer. The purpose of the content is to inform and engage healthcare professionals with the latest developments in cancer treatment and research during the congress.","cancer, breast, lung",fachportal.roche.de,Flat,0.696680028711357,medium,275,Disease Information
321,https://fachportal.roche.de/services/podcasts/onkonews-aus-barcelona-2024/folge-1.html,10,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_1_html.txt,200,html,Non-Indexable,2,72,295,1306,13,8,1,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_1_html.txt,image/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_1_html.txt.png,text/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_1_html.txt.txt,"['Congress', 'ESMO']",Oncology-Hematology,Germany,Offer outline,,,-16.301085,-5.229144,0,"The content of the content serves as an overview of Roche's specialized fields, products, clinical data, and services, particularly in the context of oncology and other medical areas. It highlights Roche's commitment to providing resources for healthcare professionals, including downloadable materials, podcasts, and newsletters that focus on advancements in cancer therapy and related medical fields. Additionally, it outlines upcoming events such as the ESMO Congress, where new research and developments will be discussed, emphasizing Roche's active role in supporting continuous education and collaboration in oncology.","oncology, professionals, data",fachportal.roche.de,Flat,0.761035189113757,high,10,General Offer Outline
322,https://fachportal.roche.de/services/podcasts/onkonews-aus-barcelona-2024/folge-2.html,10,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_2_html.txt,200,html,Non-Indexable,2,84,297,1299,17,10,1,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_2_html.txt,image/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_2_html.txt.png,text/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_2_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-30.178898,1.0327432,0,"The content of the content revolves around Roche's specialized fields and the array of products and services it offers in areas such as oncology, neuroscience, and hematology. It highlights various resources available to healthcare professionals, including clinical data, downloadable materials, and podcasts discussing recent advancements in medical research. The purpose of this content is to provide comprehensive information to professionals about Roche's pharmaceutical offerings and to facilitate engagement through resources like expert dialogues and event updates.","oncology, professionals, data",fachportal.roche.de,Flat,0.296475958905539,high,478,General Offer Outline
323,https://fachportal.roche.de/services/podcasts/onkonews-aus-barcelona-2024/folge-3.html,10,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_3_html.txt,200,html,Non-Indexable,2,64,294,1301,14,9,1,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_3_html.txt,image/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_3_html.txt.png,text/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_3_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-22.74192,-5.0575256,0,"The content primarily serves as an informational gateway for healthcare professionals interested in Roche's offerings in various medical fields, particularly oncology and precision medicine. It highlights different therapeutic areas, provides access to clinical data, product overviews, and downloadable materials. Additionally, it features podcasts discussing recent advancements and ongoing research presented at oncology conferences, emphasizing issues like gender-sensitive oncology and innovative treatment options. The content aims to facilitate knowledge sharing and promote Roche's products and services while keeping healthcare professionals updated on industry developments.","oncology, professionals, data",fachportal.roche.de,Rising,0.170986556076631,high,373,General Offer Outline
324,https://fachportal.roche.de/services/podcasts/onkonews-aus-barcelona-2024/folge-4.html,10,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_4_html.txt,200,html,Non-Indexable,2,75,295,1270,14,9,1,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_4_html.txt,image/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_4_html.txt.png,text/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_4_html.txt.txt,"['European', 'Congress', 'Cancer']",Oncology-Hematology,Germany,Offer outline,,,-19.874582,2.4800856,0,"The content focuses on Roche's specialized fields within pharmaceuticals, highlighting areas such as oncology, neuroscience, and hematology. It provides an overview of Roche's products and clinical data, as well as resources for healthcare professionals, including downloadable materials, newsletters, and podcasts. It emphasizes Roche's commitment to facilitating knowledge exchange through events like the European Cancer Congress and offers insights into recent advancements in cancer treatments. The overall purpose is to support medical professionals with information about Roche’s offerings and research developments.","oncology, professionals, data",fachportal.roche.de,Rising,0.0381694625835234,high,385,General Offer Outline
325,https://fachportal.roche.de/services/podcasts/onkonews-aus-barcelona-2024/folge-5.html,10,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_5_html.txt,200,html,Non-Indexable,2,69,245,1262,14,9,0.976190476190476,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_5_html.txt.txt,image/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_5_html.txt.txt.png,text/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_5_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-26.669384,5.561737,0,"The content focuses on Roche's various areas of expertise in the pharmaceutical field, including oncology, neurology, and hematology, providing an overview of its products and clinical data related to these specialties. It emphasizes resources available for healthcare professionals, such as downloadable materials, podcasts, and expert dialogues that discuss recent medical findings and therapy advancements. The purpose of the site is to inform and support medical professionals in their practice by providing access to Roche's offerings and current developments in research and treatment.","oncology, professionals, data",fachportal.roche.de,All,0.0855336253410771,high,235,General Offer Outline
326,https://fachportal.roche.de/services/podcasts/onkonews-aus-barcelona-2024/folge-6.html,10,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_6_html.txt,200,html,Non-Indexable,2,67,297,1273,14,9,1,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_6_html.txt,image/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_6_html.txt.png,text/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_folge_6_html.txt.txt,"['European', 'Congress', 'Cancer']",Oncology-Hematology,Germany,Offer outline,,,-20.419838,2.0966363,0,"The content focuses on Roche's specialized areas and products related to various medical disciplines, particularly oncology, neuroscience, and precision medicine. It provides an overview of Roche's offerings, clinical data, downloadable resources, and services aimed at healthcare professionals. Additionally, it highlights events, podcasts, and expert dialogues, particularly covering recent advancements in cancer treatment and research discussed at the European Cancer Congress. The purpose is to inform and engage healthcare professionals with relevant information about Roche's innovations and ongoing clinical developments.","oncology, professionals, data",fachportal.roche.de,Rising,0.92687001756737,high,291,General Offer Outline
327,https://fachportal.roche.de/services/podcasts/onkonews-aus-barcelona-2024.html,7,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_html.txt,200,html,Non-Indexable,1,26,0,1213,29,16,1,fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_html.txt,image/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_html.txt.png,text/fachportal_roche_de_services_podcasts_onkonews_aus_barcelona_2024_html.txt.txt,"['European', 'Congress', 'Cancer']",Oncology-Hematology,Germany,Offer outline,,,-19.713654,-2.7795243,0,"The content provides an overview of Roche's professional portal, detailing various areas of expertise and available products in fields such as oncology, neurology, and immunology. It highlights services, clinical data, and downloadable resources for healthcare professionals. Additionally, it promotes podcasts discussing recent advancements in cancer treatment and ongoing medical events like the European Cancer Congress. The overall purpose is to inform and engage healthcare professionals about Roche's offerings, clinical research, and insights into contemporary medical practices.","oncology, professionals, data",fachportal.roche.de,Flat,0.80351464404326,high,93,General Offer Outline
328,https://fachportal.roche.de/suche.html,7,fachportal_roche_de_suche_html.txt,200,html,Indexable,,5,0,840,0,0,1,fachportal_roche_de_suche_html.txt,image/fachportal_roche_de_suche_html.txt.png,text/fachportal_roche_de_suche_html.txt.txt,[],Other,Germany,Metainformation,,,-3.4752533,-21.762913,3,"The content depicts a search results page from Roche's professional portal, indicating that no search results were found. It includes a prompt suggesting users check their spelling or try searching with different keywords. The design is clean and user-friendly, aimed at facilitating navigation for healthcare professionals seeking information related to Roche's products and services.","users, page, website",fachportal.roche.de,Falling,0.669315677081101,high,70,Website Metadata
329,https://fachportal.roche.de/test_raysono.html,7,fachportal_roche_de_test_raysono_html.txt,200,html,Indexable,,12,0,734,0,0,0.953488372093023,fachportal_roche_de_test_raysono_html.txt.txt,image/fachportal_roche_de_test_raysono_html.txt.txt.png,text/fachportal_roche_de_test_raysono_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-22.504396,-19.213678,0,"The content displays content from Roche's professional portal aimed at healthcare providers. It includes sections for product listings, clinical data, useful links, and resources for patients. There is also a section detailing the reporting of side effects for Roche products, along with contact information for reporting. The emphasis is on providing comprehensive resources to support healthcare professionals in their use of Roche's products and managing patient care.","oncology, professionals, data",fachportal.roche.de,Falling,0.813726841681726,high,365,General Offer Outline
330,https://fachportal.roche.de/veranstaltungen/2023/10/dgho_2023.html?namespace=s7classic,9,fachportal_roche_de_veranstaltungen_2023_10_dgho_2023_html_namespace_s7classic.txt,200,html,Non-Indexable,4,9,49,1187,0,0,0.976190476190476,fachportal_roche_de_veranstaltungen_2023_10_dgho_2023_html_namespace_s7classic.txt.txt,image/fachportal_roche_de_veranstaltungen_2023_10_dgho_2023_html_namespace_s7classic.txt.txt.png,text/fachportal_roche_de_veranstaltungen_2023_10_dgho_2023_html_namespace_s7classic.txt.txt.txt,['DGHO'],Oncology-Hematology,Germany,Offer outline,,,-21.900784,6.688465,0,"The content focuses on Roche's areas of expertise in the pharmaceutical field, particularly in various medical specialties such as oncology, hematology, and neuroscience. It provides an overview of Roche's products and services, highlighting clinical data, downloadable materials, and resources for healthcare professionals. Additionally, it promotes upcoming events, such as the DGHO annual congress, which addresses new approaches in diagnostics and therapies for blood and cancer diseases. The purpose is to inform professionals about Roche’s innovations, encourage engagement in discussions about treatment options, and facilitate communication regarding patient care.","oncology, professionals, data",fachportal.roche.de,Rising,0.129592957402849,high,333,General Offer Outline
331,https://fachportal.roche.de/veranstaltungen/2023/10/dgho_2023.html,9,fachportal_roche_de_veranstaltungen_2023_10_dgho_2023_html.txt,200,html,Indexable,3,9,49,1187,6,1,0.96875,fachportal_roche_de_veranstaltungen_2023_10_dgho_2023_html.txt.txt,image/fachportal_roche_de_veranstaltungen_2023_10_dgho_2023_html.txt.txt.png,text/fachportal_roche_de_veranstaltungen_2023_10_dgho_2023_html.txt.txt.txt,['DGHO'],Oncology-Hematology,Germany,Offer outline,,,-37.783573,-0.75782764,0,"The content serves as an overview of Roche's website for professionals, highlighting the various therapeutic areas the company focuses on, including neuroscience, oncology, and hematology. It outlines the available products, clinical data, downloadable materials, and services. Additionally, it mentions a forthcoming event, the DGHO annual conference, detailing its agenda, speakers, and Roche's involvement in discussions about new diagnostic and treatment approaches. The purpose of the content is to inform healthcare professionals about Roche’s offerings and relevant medical events, enabling better engagement with the company’s resources.","oncology, professionals, data",fachportal.roche.de,All,0.499302985183423,high,399,General Offer Outline
332,https://fachportal.roche.de/veranstaltungen/2024/01/MEDEAcompact-Lungenkarzinom-praktisch-und-alltagsrelevant.html,9,fachportal_roche_de_veranstaltungen_2024_01_MEDEAcompact_Lungenkarzinom_praktisch_und_alltagsrelevant_html.txt,200,html,Indexable,,57,98,945,0,0,1,fachportal_roche_de_veranstaltungen_2024_01_MEDEAcompact_Lungenkarzinom_praktisch_und_alltagsrelevant_html.txt,image/fachportal_roche_de_veranstaltungen_2024_01_MEDEAcompact_Lungenkarzinom_praktisch_und_alltagsrelevant_html.txt.png,text/fachportal_roche_de_veranstaltungen_2024_01_MEDEAcompact_Lungenkarzinom_praktisch_und_alltagsrelevant_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,"oncology, neurology, hematology, small cell lung cancer",small cell lung cancer,-16.782099,3.100872,0,"The content provides an overview of Roche's specialized areas in pharmaceuticals, including various therapeutic domains such as oncology, neurology, and hematology. It highlights Roche's products, clinical data, downloadable resources, and details about upcoming events focused on current treatment options for specific conditions, notably small cell lung cancer. The purpose of the content is to inform healthcare professionals about Roche's offerings, facilitate access to relevant medical information, and encourage participation in discussions and events related to their products and therapeutic advancements.","oncology, professionals, data",fachportal.roche.de,Rising,0.482366465943779,high,361,General Offer Outline
333,https://fachportal.roche.de/veranstaltungen/2024/02/kontroversen-in-der-senologie-von-der-testung-bis-zur-therapie.html,9,fachportal_roche_de_veranstaltungen_2024_02_kontroversen_in_der_senologie_von_der_testung_bis_zur_therapie_html.txt,200,html,Indexable,,64,16,1100,0,0,1,fachportal_roche_de_veranstaltungen_2024_02_kontroversen_in_der_senologie_von_der_testung_bis_zur_therapie_html.txt,image/fachportal_roche_de_veranstaltungen_2024_02_kontroversen_in_der_senologie_von_der_testung_bis_zur_therapie_html.txt.png,text/fachportal_roche_de_veranstaltungen_2024_02_kontroversen_in_der_senologie_von_der_testung_bis_zur_therapie_html.txt.txt,[],Oncology-Hematology,Germany,Events,,breast cancer,-20.727726,-0.50153935,0,"The content discusses Roche's range of therapeutic areas and services, highlighting specializations in neuroscience, oncology, and other medical fields. It includes information about various products, clinical data, downloadable resources, and events for healthcare professionals, emphasizing the company’s commitment to sharing expert knowledge on contemporary treatment strategies. Additionally, it announces a virtual event focused on controversies in breast cancer therapy and provides contact information for inquiries related to the event. The overall aim is to facilitate collaboration and the exchange of medical insights among professionals in the field.","oncology, professionals, data",fachportal.roche.de,Falling,0.479918751773972,high,259,General Offer Outline
334,https://fachportal.roche.de/veranstaltungen/2024/06/entscheidungsbaum-ms-therapie.html,9,fachportal_roche_de_veranstaltungen_2024_06_entscheidungsbaum_ms_therapie_html.txt,200,html,Indexable,,29,237,987,0,0,0.976190476190476,fachportal_roche_de_veranstaltungen_2024_06_entscheidungsbaum_ms_therapie_html.txt.txt,image/fachportal_roche_de_veranstaltungen_2024_06_entscheidungsbaum_ms_therapie_html.txt.txt.png,text/fachportal_roche_de_veranstaltungen_2024_06_entscheidungsbaum_ms_therapie_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-27.122929,11.011933,0,"The content provides an overview of Roche's specialized areas and offerings in the pharmaceutical sector, focusing on various medical fields such as neuroscience, oncology, and hemophilia. It outlines the company's products, clinical data, downloadable materials, services, and upcoming events related to medicine. It also highlights the opportunity for professionals to engage with Roche through events, inquiries, and patient safety reporting, illustrating the company’s commitment to advancing medical knowledge and practice. Overall, the content is aimed at healthcare professionals seeking information on Roche's products and services.","oncology, professionals, data",fachportal.roche.de,Falling,0.995578730205104,high,216,General Offer Outline
335,https://fachportal.roche.de/veranstaltungen/2024/06/MEDEAcompact-Lungenkarzinom-juni.html,9,fachportal_roche_de_veranstaltungen_2024_06_MEDEAcompact_Lungenkarzinom_juni_html.txt,200,html,Indexable,,34,64,1029,0,0,0.977011494252874,fachportal_roche_de_veranstaltungen_2024_06_MEDEAcompact_Lungenkarzinom_juni_html.txt.txt,image/fachportal_roche_de_veranstaltungen_2024_06_MEDEAcompact_Lungenkarzinom_juni_html.txt.txt.png,text/fachportal_roche_de_veranstaltungen_2024_06_MEDEAcompact_Lungenkarzinom_juni_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-22.608238,4.359142,0,"The content serves as an overview of various fields and services provided by Roche, focusing on its products and ongoing therapeutic research. It outlines several specialized areas such as neuroscience, oncology (including specific types like thoracic and gynecological), hemophilia, and precision medicine, among others. Additionally, it details available clinical data, downloadable materials, and upcoming medical events, including seminars on specific cancer treatments. The content is aimed at healthcare professionals looking for comprehensive information on Roche's offerings and resources.","oncology, professionals, data",fachportal.roche.de,All,0.0011835744197439,high,348,General Offer Outline
336,https://fachportal.roche.de/veranstaltungen/2024/10/horizonte-post-esmo-2024.html,9,fachportal_roche_de_veranstaltungen_2024_10_horizonte_post_esmo_2024_html.txt,200,html,Non-Indexable,,24,62,979,0,0,0.974683544303797,fachportal_roche_de_veranstaltungen_2024_10_horizonte_post_esmo_2024_html.txt.txt,image/fachportal_roche_de_veranstaltungen_2024_10_horizonte_post_esmo_2024_html.txt.txt.png,text/fachportal_roche_de_veranstaltungen_2024_10_horizonte_post_esmo_2024_html.txt.txt.txt,['ESMO'],Other,Germany,Offer outline,,,-3.4211013,-5.4717607,7,"The content serves as an overview of Roche's specialized portal for healthcare professionals, highlighting areas of expertise such as neuroscience, oncology, and rare diseases. It emphasizes the availability of Roche’s products, clinical data, and downloadable resources. Additionally, it promotes a virtual event focused on gynecology and relevant medical updates from the ESMO conference, inviting specialists to discuss questions and clinical practices. The content aims to provide professionals with access to valuable information and foster collaboration in patient care.","event, exclusive, website",fachportal.roche.de,Flat,0.820939001022072,high,42,Events & Patient Care
337,https://fachportal.roche.de/veranstaltungen/2024/10/medeacompact-lungenkarzinom-oktober.html,9,fachportal_roche_de_veranstaltungen_2024_10_medeacompact_lungenkarzinom_oktober_html.txt,200,html,Indexable,,37,64,1070,0,0,1,fachportal_roche_de_veranstaltungen_2024_10_medeacompact_lungenkarzinom_oktober_html.txt,image/fachportal_roche_de_veranstaltungen_2024_10_medeacompact_lungenkarzinom_oktober_html.txt.png,text/fachportal_roche_de_veranstaltungen_2024_10_medeacompact_lungenkarzinom_oktober_html.txt.txt,['CME'],Oncology-Hematology,Germany,Offer outline,,lung cancer,-31.502228,-5.4929876,0,"The content primarily focuses on Roche's diverse pharmaceutical offerings and medical expertise, detailing various specialties such as neuroscience, oncology, and rheumatology. It also emphasizes Roche's clinical services, including access to clinical data, downloadable resources, and information on events related to medical practice, specifically in lung cancer treatment. The purpose of the content is to provide healthcare professionals with a comprehensive overview of Roche's products, services, and opportunities for continuing medical education (CME) through virtual events and expert discussions. Overall, it serves as a resource hub for professionals seeking information and updates on Roche's contributions to healthcare.","oncology, professionals, data",fachportal.roche.de,Rising,0.898416313234793,high,44,General Offer Outline
338,https://fachportal.roche.de/veranstaltungen/2024/11/21-aio-herbstkongress-2024.html,10,fachportal_roche_de_veranstaltungen_2024_11_21_aio_herbstkongress_2024_html.txt,200,html,Non-Indexable,2,27,205,1013,3,2,1,fachportal_roche_de_veranstaltungen_2024_11_21_aio_herbstkongress_2024_html.txt,image/fachportal_roche_de_veranstaltungen_2024_11_21_aio_herbstkongress_2024_html.txt.png,text/fachportal_roche_de_veranstaltungen_2024_11_21_aio_herbstkongress_2024_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-27.47857,11.36381,0,"The content of the content primarily focuses on Roche's specialization in various medical fields, including neuroscience, oncology, and hemophilia, among others. It outlines the products and services offered by Roche, including clinical data, downloadable materials, and upcoming events such as the AIOHerbstkongress 2024. The purpose of the content is to provide healthcare professionals with comprehensive information regarding Roche's offerings, research initiatives, and opportunities for continuing education within the pharmaceutical landscape.","oncology, professionals, data",fachportal.roche.de,Flat,0.194974190500151,high,168,General Offer Outline
339,https://fachportal.roche.de/veranstaltungen/2024/11/blitzlichter-der-europaeischen-herbstkongresse-2024.html,10,fachportal_roche_de_veranstaltungen_2024_11_blitzlichter_der_europaeischen_herbstkongresse_2024_html.txt,200,html,Indexable,1,50,92,531,5,3,0.981132075471698,fachportal_roche_de_veranstaltungen_2024_11_blitzlichter_der_europaeischen_herbstkongresse_2024_html.txt.txt,image/fachportal_roche_de_veranstaltungen_2024_11_blitzlichter_der_europaeischen_herbstkongresse_2024_html.txt.txt.png,text/fachportal_roche_de_veranstaltungen_2024_11_blitzlichter_der_europaeischen_herbstkongresse_2024_html.txt.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-32.30535,-5.594949,0,"The content outlines the various therapeutic areas and services provided by Roche, focusing on its commitment to advancing healthcare through specialized products and clinical data across numerous fields such as oncology, neuroscience, and hematology. It emphasizes upcoming virtual events, including a conference on the latest therapies, and offers resources for medical professionals, such as downloadable materials and contact information for inquiries. The purpose of the content is to inform healthcare professionals about Roche's offerings, events, and opportunities for engagement within the medical community.","oncology, professionals, data",fachportal.roche.de,Falling,0.169898324915891,high,140,General Offer Outline
340,https://fachportal.roche.de/veranstaltungen/2024/11/medeaconnect_2024.html,10,fachportal_roche_de_veranstaltungen_2024_11_medeaconnect_2024_html.txt,200,html,Non-Indexable,2,17,67,1407,20,10,1,fachportal_roche_de_veranstaltungen_2024_11_medeaconnect_2024_html.txt,image/fachportal_roche_de_veranstaltungen_2024_11_medeaconnect_2024_html.txt.png,text/fachportal_roche_de_veranstaltungen_2024_11_medeaconnect_2024_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,lung cancer,-17.39157,-6.0200667,0,"The content outlines the features of Roche's specialized website designed for healthcare professionals, highlighting various therapeutic areas such as neuroscience, oncology, and rare diseases among others. It provides an overview of Roche's products, clinical data, and downloadable materials related to these areas. Additionally, it announces an upcoming virtual event focused on lung cancer, featuring expert discussions and educational resources. The purpose of the content is to facilitate access to Roche's medical products, services, and latest developments, while promoting engagement within the medical community.","oncology, professionals, data",fachportal.roche.de,Flat,0.936702342616378,high,411,General Offer Outline
341,https://fachportal.roche.de/veranstaltungen/2024/12/highlights-vom-ash-haematologie-2024.html,10,fachportal_roche_de_veranstaltungen_2024_12_highlights_vom_ash_haematologie_2024_html.txt,200,html,Indexable,2,37,147,361,2,1,0.978021978021978,fachportal_roche_de_veranstaltungen_2024_12_highlights_vom_ash_haematologie_2024_html.txt.txt,image/fachportal_roche_de_veranstaltungen_2024_12_highlights_vom_ash_haematologie_2024_html.txt.txt.png,text/fachportal_roche_de_veranstaltungen_2024_12_highlights_vom_ash_haematologie_2024_html.txt.txt.txt,['ASH'],Oncology-Hematology,Germany,Offer outline,,,-24.93026,4.549282,0,"The content outlines the various therapeutic areas and products offered by Roche, such as neuroscience, oncology, hematology, and precision medicine. It highlights resources available for professionals, including clinical data, downloadable materials, and services. The content also mentions an upcoming virtual event focused on hematology (ASH 2024), detailing the agenda and speakers. The purpose of the content is to provide healthcare professionals with comprehensive information on Roche's medical offerings, events, and relevant resources to support patient care.","oncology, professionals, data",fachportal.roche.de,Falling,0.229160009995878,high,47,General Offer Outline
342,https://fachportal.roche.de/veranstaltungen/2024/12/wrap-up-gynaekoonkologie.html,9,fachportal_roche_de_veranstaltungen_2024_12_wrap_up_gynaekoonkologie_html.txt,200,html,Indexable,,25,167,893,0,0,0.974683544303797,fachportal_roche_de_veranstaltungen_2024_12_wrap_up_gynaekoonkologie_html.txt.txt,image/fachportal_roche_de_veranstaltungen_2024_12_wrap_up_gynaekoonkologie_html.txt.txt.png,text/fachportal_roche_de_veranstaltungen_2024_12_wrap_up_gynaekoonkologie_html.txt.txt.txt,"['Breast', 'Antonio', 'Symposium', 'Registration', 'San', 'Cancer']",Oncology-Hematology,Germany,Events,,breast cancer,24.806196,-11.395703,12,"The content promotes a virtual event focused on gynecologic oncology and highlights the latest data from the San Antonio Breast Cancer Symposium 2024. It invites healthcare professionals to discuss key findings with experts during an online session. Registration is encouraged, and additional resources such as downloadable flyers are available for attendees.","cancer, breast, lung",fachportal.roche.de,Rising,0.173714003810857,high,59,Disease Information
343,https://fachportal.roche.de/veranstaltungen/2024/haematologische-sommerkongresse-2024.html,10,fachportal_roche_de_veranstaltungen_2024_haematologische_sommerkongresse_2024_html.txt,200,html,Indexable,2,35,194,2633,7,3,1,fachportal_roche_de_veranstaltungen_2024_haematologische_sommerkongresse_2024_html.txt,image/fachportal_roche_de_veranstaltungen_2024_haematologische_sommerkongresse_2024_html.txt.png,text/fachportal_roche_de_veranstaltungen_2024_haematologische_sommerkongresse_2024_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-22.988752,9.499024,0,"The content of this content provides a comprehensive overview of Roche's pharmaceutical offerings, focusing on various therapeutic areas such as neuroscience, oncology, hematology, and more. It highlights upcoming events, such as international hematology congresses, where Roche will present new clinical data and developments. Additionally, the content emphasizes resources available for medical professionals, including product information, clinical data, downloadable materials, and services. Overall, the purpose is to serve as a professional resource, keeping healthcare professionals informed about Roche’s innovations and contributions to medicine.","oncology, professionals, data",fachportal.roche.de,Flat,0.162439189349782,high,167,General Offer Outline
344,https://fachportal.roche.de/veranstaltungen/2024/neuroscience-kongressherbst-ectrims-2024/.html,1,fachportal_roche_de_veranstaltungen_2024_neuroscience_kongressherbst_ectrims_2024__html.txt,200,html,Indexable,4,0,0,4364,7,3,1,fachportal_roche_de_veranstaltungen_2024_neuroscience_kongressherbst_ectrims_2024__html.txt,image/fachportal_roche_de_veranstaltungen_2024_neuroscience_kongressherbst_ectrims_2024__html.txt.png,text/fachportal_roche_de_veranstaltungen_2024_neuroscience_kongressherbst_ectrims_2024__html.txt.txt,['HTTP'],Other,Germany,Metainformation,,,-0.45270857,-21.845142,3,"The content displays an error message indicating that a webpage related to Roche's portal is currently unavailable, specifically showing an HTTP 504 error. This suggests that the server took too long to respond, potentially due to server overload or issues with the website itself. It prompts the user to refresh the page.","users, page, website",fachportal.roche.de,All,0.396094311503319,low,98,Website Metadata
345,https://fachportal.roche.de/veranstaltungen/2024/neuroscience-kongressherbst-ectrims-dgn-2024.html,10,fachportal_roche_de_veranstaltungen_2024_neuroscience_kongressherbst_ectrims_dgn_2024_html.txt,200,html,Indexable,1,104,176,1564,12,5,1,fachportal_roche_de_veranstaltungen_2024_neuroscience_kongressherbst_ectrims_dgn_2024_html.txt,image/fachportal_roche_de_veranstaltungen_2024_neuroscience_kongressherbst_ectrims_dgn_2024_html.txt.png,text/fachportal_roche_de_veranstaltungen_2024_neuroscience_kongressherbst_ectrims_dgn_2024_html.txt.txt,[],Oncology-Hematology,Germany,Research,,,-32.43302,2.3321261,0,"The content primarily serves as an informational portal for healthcare professionals regarding Roche's focus areas, product offerings, clinical data, and resources related to various medical specialties, particularly in neuroscience, oncology, and hematology. It aims to provide updates on recent scientific findings, ongoing studies, and educational opportunities such as podcasts and symposiums. Additionally, it includes prompts for reporting adverse drug reactions, emphasizing Roche's commitment to patient safety and engagement within the healthcare community.","oncology, professionals, data",fachportal.roche.de,Falling,0.342747467299105,high,29,General Offer Outline
346,https://fachportal.roche.de/veranstaltungen/2025/.html,1,fachportal_roche_de_veranstaltungen_2025__html.txt,200,html,Indexable,4,0,0,1619,2,2,1,fachportal_roche_de_veranstaltungen_2025__html.txt,image/fachportal_roche_de_veranstaltungen_2025__html.txt.png,text/fachportal_roche_de_veranstaltungen_2025__html.txt.txt,[],Other,Germany,Metainformation,,,-3.9851792,-19.733932,3,"The content appears to be a fragment of code and metadata related to Roche's professional website, specifically focusing on their healthcare portal. It includes technical elements for user interface components, cookie consent notices, and navigation. The purpose is to enhance user experience for healthcare professionals accessing Roche's resources, such as events and product information. Overall, it emphasizes user engagement and navigation efficiency within Roche's digital services.","users, page, website",fachportal.roche.de,Falling,0.946922454940621,low,57,Website Metadata
347,https://fachportal.roche.de/veranstaltungen/2025/01/wrap-up-nrw-post-san-antonio-fuer-speaker.html,9,fachportal_roche_de_veranstaltungen_2025_01_wrap_up_nrw_post_san_antonio_fuer_speaker_html.txt,200,html,Indexable,,44,100,997,0,0,0.979166666666667,fachportal_roche_de_veranstaltungen_2025_01_wrap_up_nrw_post_san_antonio_fuer_speaker_html.txt.txt,image/fachportal_roche_de_veranstaltungen_2025_01_wrap_up_nrw_post_san_antonio_fuer_speaker_html.txt.txt.png,text/fachportal_roche_de_veranstaltungen_2025_01_wrap_up_nrw_post_san_antonio_fuer_speaker_html.txt.txt.txt,"['Breast', 'Antonio', 'Symposium', 'San', 'Cancer']",Oncology-Hematology,Germany,Offer outline,,breast cancer,-18.1958,-2.147519,0,"The content appears to be an overview of Roche's professional portal, highlighting various therapeutic areas such as neuroscience, oncology, and hematology, along with Roche's product offerings and services. It includes information about clinical data, downloadable resources, and events like a virtual discussion on breast cancer from the San Antonio Breast Cancer Symposium. The purpose of this content is to facilitate access to Roche’s medical resources for healthcare professionals and provide them with updated information and tools to enhance patient care and participation in clinical studies.","oncology, professionals, data",fachportal.roche.de,All,0.182051681159587,high,40,General Offer Outline
348,https://fachportal.roche.de/veranstaltungen/2025/02/.html,2,fachportal_roche_de_veranstaltungen_2025_02__html.txt,200,html,Non-Indexable,2,2,0,710,4,4,1,fachportal_roche_de_veranstaltungen_2025_02__html.txt,image/fachportal_roche_de_veranstaltungen_2025_02__html.txt.png,text/fachportal_roche_de_veranstaltungen_2025_02__html.txt.txt,[],Other,Germany,Offer outline,,,-6.4480257,-19.241163,3,"The content appears to be from a professional portal related to Roche, highlighting the opportunity to discover exclusive advantages for users. It includes options for logging in or registering, indicating a focus on providing tailored content or services to registered professionals. The general theme suggests an emphasis on enhanced access to information or resources within the healthcare or pharmaceutical sector.","users, page, website",fachportal.roche.de,All,0.315144516127616,low,380,Website Metadata
349,https://fachportal.roche.de/veranstaltungen/2025/02.html,1,fachportal_roche_de_veranstaltungen_2025_02_html.txt,200,html,Indexable,3,2,0,734,0,0,1,fachportal_roche_de_veranstaltungen_2025_02_html.txt,image/fachportal_roche_de_veranstaltungen_2025_02_html.txt.png,text/fachportal_roche_de_veranstaltungen_2025_02_html.txt.txt,[],Other,Germany,Offer outline,,,-24.380142,-18.139305,0,"The content shows a professional portal for Roche, focusing on resources for healthcare professionals. It includes sections for product overviews, clinical data, and useful links related to Roche's medical science and pipeline. There are dedicated areas for patient information and a segment for reporting side effects associated with Roche products. Overall, it serves as a centralized platform for accessing important information and services related to Roche's pharmaceutical offerings.","oncology, professionals, data",fachportal.roche.de,Falling,0.861961985032247,low,138,General Offer Outline
350,https://fachportal.roche.de/veranstaltungen/2025/04/.html,1,fachportal_roche_de_veranstaltungen_2025_04__html.txt,200,html,Non-Indexable,3,2,0,710,2,2,0.963636363636364,fachportal_roche_de_veranstaltungen_2025_04__html.txt.txt,image/fachportal_roche_de_veranstaltungen_2025_04__html.txt.txt.png,text/fachportal_roche_de_veranstaltungen_2025_04__html.txt.txt.txt,"['Anmelden', 'Registrieren']",Other,Germany,Offer outline,,,-7.0381875,-22.616846,3,"The content appears to be from a professional portal associated with Roche, offering exclusive benefits to registered users. The content invites users to discover additional advantages available through this specialized platform. There are also options for logging in (""Anmelden"") or registering (""Registrieren""). This suggests a focus on providing value-added services or resources tailored for professionals in the pharmaceutical field.","users, page, website",fachportal.roche.de,Flat,0.609488342716586,low,207,Website Metadata
351,https://fachportal.roche.de/veranstaltungen/2025/04.html,1,fachportal_roche_de_veranstaltungen_2025_04_html.txt,200,html,Indexable,4,2,0,734,0,0,1,fachportal_roche_de_veranstaltungen_2025_04_html.txt,image/fachportal_roche_de_veranstaltungen_2025_04_html.txt.png,text/fachportal_roche_de_veranstaltungen_2025_04_html.txt.txt,[],Other,Germany,Offer outline,,,-23.229824,-18.116526,0,"The content features a professional portal for Roche, aimed at healthcare professionals. It includes sections for various topics such as product information, clinical data, and useful links related to Roche's medical services. Additionally, there are resources for patient support and guidance on reporting side effects, along with contact information for further assistance. The overall layout is designed to facilitate access to important information and services pertinent to Roche’s offerings.","oncology, professionals, data",fachportal.roche.de,Flat,0.987798364154094,low,97,General Offer Outline
352,https://fachportal.roche.de/veranstaltungen/2025.html,6,fachportal_roche_de_veranstaltungen_2025_html.txt,200,html,Indexable,5,4,0,734,0,0,1,fachportal_roche_de_veranstaltungen_2025_html.txt,image/fachportal_roche_de_veranstaltungen_2025_html.txt.png,text/fachportal_roche_de_veranstaltungen_2025_html.txt.txt,[],Other,Germany,Offer outline,,,-22.633415,-18.723055,0,"The content displays a section of Roche's professional portal, which provides resources for healthcare professionals. It includes navigation options for specialized areas, product information, clinical data, and various services. There are also links for patient support and guidelines for reporting adverse effects related to Roche products, emphasizing its focus on safety and communication. The layout appears user-friendly, aimed at facilitating access to important pharmaceutical information and services.","oncology, professionals, data",fachportal.roche.de,Rising,0.15192295281259,medium,155,General Offer Outline
353,https://fachportal.roche.de/veranstaltungen/b_zell_foren/bzf-maerz-2025.html,10,fachportal_roche_de_veranstaltungen_b_zell_foren_bzf_maerz_2025_html.txt,200,html,Indexable,2,22,79,1043,5,4,1,fachportal_roche_de_veranstaltungen_b_zell_foren_bzf_maerz_2025_html.txt,image/fachportal_roche_de_veranstaltungen_b_zell_foren_bzf_maerz_2025_html.txt.png,text/fachportal_roche_de_veranstaltungen_b_zell_foren_bzf_maerz_2025_html.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-29.597462,-9.57685,0,"The content primarily focuses on providing detailed information about Roche's offerings and services in various medical fields, including neuroscience, oncology, and hemophilia, among others. It serves as a resource for healthcare professionals by presenting product overviews, clinical data, and educational events like the BZellForum. The purpose is to engage medical practitioners with relevant updates and facilitate access to Roche's products, research, and digital services. Additionally, it includes options for communication and support related to patient treatment and event participation.","oncology, professionals, data",fachportal.roche.de,All,0.386389007191888,high,353,General Offer Outline
354,https://fachportal.roche.de/veranstaltungen/b_zell_foren/bzf_startseite.html?namespace=s7classic,7,fachportal_roche_de_veranstaltungen_b_zell_foren_bzf_startseite_html_namespace_s7classic.txt,200,html,Non-Indexable,2,12,0,1285,0,0,1,fachportal_roche_de_veranstaltungen_b_zell_foren_bzf_startseite_html_namespace_s7classic.txt,image/fachportal_roche_de_veranstaltungen_b_zell_foren_bzf_startseite_html_namespace_s7classic.txt.png,text/fachportal_roche_de_veranstaltungen_b_zell_foren_bzf_startseite_html_namespace_s7classic.txt.txt,[],Oncology-Hematology,Germany,Offer outline,,,-24.336811,11.112971,0,"The content focuses on Roche's offerings in various medical fields, including neuroscience, oncology, and hemophilia, among others. It highlights the company's commitment to education and collaboration in advancing knowledge and treatment in these areas, particularly through events like the BZellForum, which provides a platform for expert-led discussions and training. Additionally, the content mentions resources available for healthcare professionals, such as clinical data, product overviews, and the ability to subscribe to updates and newsletters for ongoing information on Roche's developments. Overall, the purpose is to inform and support professionals in the medical community regarding Roche's products and educational initiatives.","oncology, professionals, data",fachportal.roche.de,All,0.654446419637891,high,361,General Offer Outline
355,https://fachportal.roche.de/veranstaltungen.html,8,fachportal_roche_de_veranstaltungen_html.txt,200,html,Indexable,1,15,0,1555,1533,1515,0.956521739130435,fachportal_roche_de_veranstaltungen_html.txt.txt,image/fachportal_roche_de_veranstaltungen_html.txt.txt.png,text/fachportal_roche_de_veranstaltungen_html.txt.txt.txt,[],Other,Germany,Offer outline,,,-29.87907,10.9571495,0,"The content of the content primarily focuses on Roche's various therapeutic areas and the related products, services, and clinical data available to healthcare professionals. It outlines Roche's involvement in fields such as neuroscience, oncology, hematology, and ophthalmology, providing links to product overviews, clinical information, and downloadable materials. Additionally, it highlights upcoming events, conferences, and educational opportunities for professionals in these medical specialties, emphasizing Roche's commitment to disseminating innovative research and fostering communication within the medical community.","oncology, professionals, data",fachportal.roche.de,Rising,0.909627208341866,high,102,General Offer Outline
356,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/Beyond-Services/roche-pairs/PAIRS_Manuel_Master.pdf,0,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_Beyond_Services_roche_pairs_PAIRS_Manuel_Master_pdf.txt,200,pdf,Non-Indexable,,0,0,0,1,1,0.915966386554622,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_Beyond-Services_roche-pairs_PAIRS_Manuel_Master.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_Beyond-Services_roche-pairs_PAIRS_Manuel_Master.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_Beyond-Services_roche-pairs_PAIRS_Manuel_Master.pdf.txt,"['Innovative', 'Research', 'Access', 'Services', 'PAIRS', 'Patient']",Other,Germany,Technology,,,-19.06746,-28.461437,0,"The content provides a detailed overview of the PAIRS (Patient Access to Innovative Research and Services) application used by healthcare professionals to manage patient requests and drug supply logistics associated with Roche, a pharmaceutical company. It outlines functionalities like managing patient information, submitting new patient requests, ordering medication, reporting adverse events, and maintaining contact and site details. The content serves as a user guide for physicians, ensuring they understand how to navigate the system, submit requests, and comply with regulatory obligations while managing patient treatment with Roche's medications.","oncology, professionals, data",fachportal.roche.de,All,0.740642466309234,low,216,General Offer Outline
357,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/Beyond-Services/roche-pairs/Roche-DE-PAIRS-Datenschutzhinweis-02.pdf,5,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_Beyond_Services_roche_pairs_Roche_DE_PAIRS_Datenschutzhinweis_02_pdf.txt,200,pdf,Non-Indexable,,33,0,0,5,5,0.897058823529412,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_Beyond-Services_roche-pairs_Roche-DE-PAIRS-Datenschutzhinweis-02.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_Beyond-Services_roche-pairs_Roche-DE-PAIRS-Datenschutzhinweis-02.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_Beyond-Services_roche-pairs_Roche-DE-PAIRS-Datenschutzhinweis-02.pdf.txt,"['Registry', 'Supply', 'Access', 'PAIRS', 'Integrated', 'Patient']",Other,Germany,Metainformation,,,-7.7363763,-27.443848,3,"The content provides detailed information regarding data protection rights related to Roche's compassionate use programs and individual treatment trials. It outlines the types of personal and medical data processed through the PAIRS (Patient Access Integrated Registry and Supply) platform, the responsibilities of Roche concerning data handling, and the legal basis for such processing. Additionally, it explains how and to whom data may be shared, the retention period for the data, and the rights patients hold under data protection laws, including the right to access, rectify, or delete their data. The purpose of this content is to ensure transparency and compliance with data protection regulations while informing patients about their rights and the handling of their sensitive information in the context of clinical interventions.","users, page, website",fachportal.roche.de,All,0.502749284065156,medium,180,Website Metadata
358,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/Beyond-Services/roche-pairs/Roche-DE-PAIRS-Datenschutzhinweis-fuer-behandelnde-Fachkraft-02.pdf,5,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_Beyond_Services_roche_pairs_Roche_DE_PAIRS_Datenschutzhinweis_fuer_behandelnde_Fachkraft_02_pdf.txt,200,pdf,Non-Indexable,,60,0,0,5,5,0.895705521472393,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_Beyond-Services_roche-pairs_Roche-DE-PAIRS-Datenschutzhinweis-fuer-behandelnde-Fachkraft-02.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_Beyond-Services_roche-pairs_Roche-DE-PAIRS-Datenschutzhinweis-fuer-behandelnde-Fachkraft-02.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_Beyond-Services_roche-pairs_Roche-DE-PAIRS-Datenschutzhinweis-fuer-behandelnde-Fachkraft-02.pdf.txt,"['GDPR', 'AG', 'Pharma']",Other,Germany,Metainformation,,,-6.905869,-27.058529,3,"The content is a privacy notice from Roche Pharma AG regarding the processing of personal data in connection with their compassionate use programs and individual treatment trials. It outlines the purpose of data collection, the legal basis for processing, the data categories involved, the entities responsible for data handling, and the rights of individuals concerning their data. The content emphasizes Roche's commitment to data protection and compliance with relevant privacy laws, including GDPR, and provides information on how individuals can exercise their rights or raise concerns.","users, page, website",fachportal.roche.de,All,0.690613821732739,medium,334,Website Metadata
359,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/documents/fachgebiete/haematologie/chips/kongressupdates/asco-2024/EHA_2024_P1239_Stella_ctDNA_Glofitamab_M-DE-00022087_08_12_2025.pdf,5,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_haematologie_chips_kongressupdates_asco_2024_EHA_2024_P1239_Stella_ctDNA_Glofitamab_M_DE_00022087_08_12_2025_pdf.txt,200,pdf,Non-Indexable,3,23,0,0,3,1,0.945544554455446,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_haematologie_chips_kongressupdates_asco-2024_EHA_2024_P1239_Stella_ctDNA_Glofitamab_M-DE-00022087_08_12_2025.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_haematologie_chips_kongressupdates_asco-2024_EHA_2024_P1239_Stella_ctDNA_Glofitamab_M-DE-00022087_08_12_2025.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_haematologie_chips_kongressupdates_asco-2024_EHA_2024_P1239_Stella_ctDNA_Glofitamab_M-DE-00022087_08_12_2025.pdf.txt,"['Association', 'DNA', 'Glofitamab', 'European', 'EHA', 'LBCL', 'II', 'B', 'Phase', 'RR', 'Hematology']",Oncology-Hematology,Germany,Research,"Glofitamab, relapsed/refractory large B-cell lymphoma, RR LBCL, Phase II trial, efficacy, safety, response rates, durability, molecular subtypes, circulating tumor DNA, ctDNA, treatment outcomes, high-risk patient groups",large B-cell lymphoma,29.485727,-20.433586,12,"The content is an abstract from a scientific poster presented at the European Hematology Association (EHA) 2024 conference, detailing research on Glofitamab, a bispecific antibody designed for treating relapsed/refractory large B-cell lymphoma (RR LBCL). The purpose of the report is to present findings from a Phase II trial on the efficacy and safety of Glofitamab, emphasizing its high response rates and durability across various molecular subtypes of the disease. Additionally, the study investigates the prognostic value of circulating tumor DNA (ctDNA) levels and their kinetics in relation to treatment outcomes, suggesting that Glofitamab could be effective even in high-risk patient groups.","cancer, breast, lung",fachportal.roche.de,All,0.902544695062044,medium,384,Disease Information
360,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/documents/fachgebiete/nephrologie/artikel/therapieoptionen-bei-renaler-anaemie/mircera_K26_Interview.pdf,0,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_nephrologie_artikel_therapieoptionen_bei_renaler_anaemie_mircera_K26_Interview_pdf.txt,200,pdf,Non-Indexable,4,0,0,0,1,1,0.936046511627907,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_nephrologie_artikel_therapieoptionen-bei-renaler-anaemie_mircera_K26_Interview.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_nephrologie_artikel_therapieoptionen-bei-renaler-anaemie_mircera_K26_Interview.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_nephrologie_artikel_therapieoptionen-bei-renaler-anaemie_mircera_K26_Interview.pdf.txt,"['MIRCERA', 'Factor', 'Inducible', 'Hypoxia', 'ESA']",CVRM,Germany,Medication information,"MIRCERA, renal anemia, erythropoiesis-stimulating agent, Hypoxia-Inducible Factor stabilizers",renal anemia,23.015032,-1.3109753,4,"The content discusses the treatment of renal anemia in patients, focusing on the use of MIRCERA, a long-acting erythropoiesis-stimulating agent (ESA) produced by Roche. It outlines the complexities of managing anemia, the importance of avoiding transfusions, and the therapeutic goals. The content highlights MIRCERA's features compared to other ESAs, emphasizing its longer half-life, benefits for patient compliance, and reduced frequency of injections, particularly in outpatient settings. It also examines the implications of MIRCERA's approval for pediatric patients and discusses the potential future of anemia treatment, including the integration of new therapies like Hypoxia-Inducible Factor stabilizers. Overall, the purpose is to inform healthcare professionals about renal anemia management and the advantages of MIRCERA in therapy.","technologies, artificial, ai",fachportal.roche.de,All,0.374328998424144,low,20,Technology
361,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/documents/fachgebiete/nephrologie/artikel/therapieoptionen-bei-renaler-anaemie/mircera_K26_Keyfactkarte_20240624_RZ.pdf,0,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_nephrologie_artikel_therapieoptionen_bei_renaler_anaemie_mircera_K26_Keyfactkarte_20240624_RZ_pdf.txt,200,pdf,Non-Indexable,4,0,0,0,1,1,0.941176470588235,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_nephrologie_artikel_therapieoptionen-bei-renaler-anaemie_mircera_K26_Keyfactkarte_20240624_RZ.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_nephrologie_artikel_therapieoptionen-bei-renaler-anaemie_mircera_K26_Keyfactkarte_20240624_RZ.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_nephrologie_artikel_therapieoptionen-bei-renaler-anaemie_mircera_K26_Keyfactkarte_20240624_RZ.pdf.txt,"['MIRCERA', 'Frank', 'Dellanna', 'Dr', 'Professor']",CVRM,Germany,Medication information,"MIRCERA, renal anemia, erythropoiesis-stimulating agents (ESAs), chronic kidney disease","renal anemia, chronic kidney disease",24.337,-0.9004201,4,"The content primarily discusses the treatment of renal anemia in pediatric patients starting from three months old, focusing on the pharmaceutical product MIRCERA and its use alongside other erythropoiesis-stimulating agents (ESAs). It includes an interview with Professor Dr. Frank Dellanna, where he elaborates on the goals of successfully treating renal anemia, the advantages of using long-acting MIRCERA over traditional ESAs, and considerations regarding treatment challenges in clinical practice. The content serves as a resource for healthcare professionals by providing insights into the efficacy and safety of MIRCERA, as well as its differences from other ESAs, ultimately aiming to improve patient care in those with chronic kidney disease.","technologies, artificial, ai",fachportal.roche.de,Flat,0.622011218861116,low,417,Technology
362,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/documents/fachgebiete/neuromuskulaere-erkrankungen/home/Infografik_DMD.pdf,0,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_neuromuskulaere_erkrankungen_home_Infografik_DMD_pdf.txt,200,pdf,Non-Indexable,3,0,0,0,9,8,0.936619718309859,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_neuromuskulaere-erkrankungen_home_Infografik_DMD.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_neuromuskulaere-erkrankungen_home_Infografik_DMD.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_neuromuskulaere-erkrankungen_home_Infografik_DMD.pdf.txt,"['Muscular', 'DMD', 'Dystrophy', 'Duchenne']",Other,Germany,Disease information,"Duchenne Muscular Dystrophy, DMD, corticosteroids, gene therapies, functional dystrophin protein production",Duchenne Muscular Dystrophy,22.541677,28.706978,4,"The content discusses Duchenne Muscular Dystrophy (DMD), a rare genetic disorder caused by mutations in the dystrophin gene that leads to muscle weakness and eventual loss of muscle function. It highlights the impacts of DMD on patients, primarily boys, as they typically experience progressive muscle deterioration, often becoming wheelchair-bound in their teenage years and facing respiratory support needs later. The content emphasizes the importance of early diagnosis and intervention to maintain quality of life. Additionally, it outlines current treatment approaches, including corticosteroids and emerging gene therapies aimed at restoring functional dystrophin protein production. The purpose of the content is to provide information on DMD, its genetic basis, clinical implications, and potential therapeutic advancements.","technologies, artificial, ai",fachportal.roche.de,Flat,0.0930774461759468,low,263,Technology
363,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/documents/fachgebiete/neuroscience/chips/alzheimer/behandlung/volkskrankheit-alzheimer-therapieren/Flyer-neotivCare.pdf,5,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_neuroscience_chips_alzheimer_behandlung_volkskrankheit_alzheimer_therapieren_Flyer_neotivCare_pdf.txt,200,pdf,Non-Indexable,4,8,0,0,1,1,0.941176470588235,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_neuroscience_chips_alzheimer_behandlung_volkskrankheit-alzheimer-therapieren_Flyer-neotivCare.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_neuroscience_chips_alzheimer_behandlung_volkskrankheit-alzheimer-therapieren_Flyer-neotivCare.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_neuroscience_chips_alzheimer_behandlung_volkskrankheit-alzheimer-therapieren_Flyer-neotivCare.pdf.txt,['CE'],Neurology,Germany,Technology,"neotivCare app, cognitive impairments, memory issues, mild cognitive impairment, early dementia, sensitivity, specificity","mild cognitive impairment, early dementia",23.284103,26.486311,4,"The content promotes the neotivCare app, designed as a CE-certified medical product for diagnosing cognitive impairments related to memory issues. It highlights the app's validation against detailed neuropsychological testing, emphasizing its sensitivity and specificity. The app aims to facilitate patient assessment at home and reduce the complexity of the diagnostic process for healthcare providers, particularly in identifying mild cognitive impairment or early dementia in individuals aged 60 to 80. The overall purpose is to enhance the detection and monitoring of cognitive difficulties.","technologies, artificial, ai",fachportal.roche.de,Rising,0.594662770169743,medium,332,Technology
364,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/documents/fachgebiete/neuroscience/chips/alzheimer/diagnose/perspektive-intervention/Flyer-neotivCare.pdf,5,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_neuroscience_chips_alzheimer_diagnose_perspektive_intervention_Flyer_neotivCare_pdf.txt,200,pdf,Non-Indexable,4,8,0,0,1,1,0.942196531791908,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_neuroscience_chips_alzheimer_diagnose_perspektive-intervention_Flyer-neotivCare.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_neuroscience_chips_alzheimer_diagnose_perspektive-intervention_Flyer-neotivCare.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_fachgebiete_neuroscience_chips_alzheimer_diagnose_perspektive-intervention_Flyer-neotivCare.pdf.txt,"['CE', 'Alzheimer']",Neurology,Germany,Technology,"neotivCare app, diagnosing memory impairments, neuropsychological tests, cognitive decline, early-stage Alzheimer's disease",Alzheimer's disease,23.460316,26.50223,4,"The content promotes the neotivCare app, a CE-certified medical product designed to assist in diagnosing memory impairments, particularly in older adults. It highlights the app's validation against neuropsychological tests, emphasizing its robustness and ease of use for patients at home. Additionally, it mentions the app's potential to simplify the diagnostic process for healthcare professionals dealing with cognitive issues. The overall focus is on enhancing the detection and monitoring of cognitive decline, such as early-stage Alzheimer's disease.","technologies, artificial, ai",fachportal.roche.de,Flat,0.823617314962747,medium,10,Technology
365,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/documents/services/Roche_Customer-Web-Portal.pdf,6,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_documents_services_Roche_Customer_Web_Portal_pdf.txt,200,pdf,Non-Indexable,2,25,0,0,1,1,0.913793103448276,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_services_Roche_Customer-Web-Portal.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_services_Roche_Customer-Web-Portal.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_documents_services_Roche_Customer-Web-Portal.pdf.txt,"['Portal', 'Web', 'Customer']",Other,Germany,Technology,,,-5.776276,-21.807653,3,"The content promotes the new Roche Customer Web Portal. It highlights features such as online ordering, order status tracking, and access to saved templates. The portal allows users to download invoices, view balance reports, and simulate prices, providing convenience without waiting times. The design emphasizes accessibility across devices and encourages users to contact Roche for further information.","users, page, website",fachportal.roche.de,Falling,0.994700187206251,medium,458,Website Metadata
366,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/home/vearnstaltungen/document/anfahrt-und-gebaeudeplan.pdf,0,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_home_vearnstaltungen_document_anfahrt_und_gebaeudeplan_pdf.txt,200,pdf,Non-Indexable,,2,0,0,1,1,0.920634920634921,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_home_vearnstaltungen_document_anfahrt-und-gebaeudeplan.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_home_vearnstaltungen_document_anfahrt-und-gebaeudeplan.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_home_vearnstaltungen_document_anfahrt-und-gebaeudeplan.pdf.txt,"['G', 'Penzberg']",Other,Germany,Other,,,-0.8819547,-22.126373,3,"The content is a site map for Roche's Penzberg facility, showing the layout of various buildings and facilities within the complex. It highlights key locations such as building G.371 (likely a conference room) and G.362 (production area), as well as visitor parking areas. The map is designed to guide visitors and staff through the site, indicating the intended pathways and building numbers for easier navigation.","users, page, website",fachportal.roche.de,Flat,0.546219697816156,low,497,Website Metadata
367,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/nephrologie/boutique-page/downloads/cnk-pflegedossier.pdf,0,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_nephrologie_boutique_page_downloads_cnk_pflegedossier_pdf.txt,200,pdf,Non-Indexable,,0,0,0,1,1,0.92,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_nephrologie_boutique-page_downloads_cnk-pflegedossier.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_nephrologie_boutique-page_downloads_cnk-pflegedossier.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_nephrologie_boutique-page_downloads_cnk-pflegedossier.pdf.txt,['CKD'],CVRM,Germany,Disease information,"chronic kidney disease, CKD, cardiovascular risks, preventive measures, treatment strategies",chronic kidney disease,27.03702,-0.53969,4,"The content provides an in-depth overview of chronic kidney disease (CKD), including its definition, prevalence, progression, causes, risk factors, symptoms, diagnosis, treatment options, and associated complications. It highlights that CKD affects a significant portion of the population, outlining the potential cardiovascular risks and the importance of early detection and management to slow disease progression. The content is intended to inform healthcare professionals and caregivers about CKD's complexities and the importance of monitoring, preventive measures, and treatment strategies to improve patient outcomes.","technologies, artificial, ai",fachportal.roche.de,All,0.716431894751557,low,263,Technology
368,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/nephrologie/mircera/material_fuer_aerzte/Mircera-bei-Kindern-und-Jugendlichen.pdf,0,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_nephrologie_mircera_material_fuer_aerzte_Mircera_bei_Kindern_und_Jugendlichen_pdf.txt,200,pdf,Non-Indexable,4,0,0,0,2,1,0.919463087248322,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_nephrologie_mircera_material_fuer_aerzte_Mircera-bei-Kindern-und-Jugendlichen.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_nephrologie_mircera_material_fuer_aerzte_Mircera-bei-Kindern-und-Jugendlichen.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_nephrologie_mircera_material_fuer_aerzte_Mircera-bei-Kindern-und-Jugendlichen.pdf.txt,"['MIRCERA', 'Schaefer', 'Franz', 'Dr', 'CKD', 'Professor', 'ESA']",CVRM,Germany,Medication information,"MIRCERA, anemia, chronic kidney disease (CKD), erythropoiesis-stimulating agents (ESA)","anemia, chronic kidney disease",24.639788,-0.84879524,4,"The content focuses on the pediatric use of the medication MIRCERA, specifically for managing anemia in children with chronic kidney disease (CKD). It summarizes various studies and clinical trials that investigate the efficacy and safety of transitioning pediatric patients from traditional erythropoiesis-stimulating agents (ESA) to MIRCERA. Additionally, it highlights an accompanying podcast featuring Professor Dr. Franz Schaefer, who discusses the challenges and treatment considerations for children with CKD. The overarching purpose is to inform healthcare professionals about MIRCERA's clinical results and its implementation in the pediatric population, emphasizing its role in improving patient outcomes and quality of life.","technologies, artificial, ai",fachportal.roche.de,All,0.155519498705115,low,108,Technology
369,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/neuroscience/artikel/ms/HMA0_One_Pager_EBM_update_Ocre_s.c.pdf,0,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_neuroscience_artikel_ms_HMA0_One_Pager_EBM_update_Ocre_s_c_pdf.txt,200,pdf,Non-Indexable,,0,0,0,2,2,0.930769230769231,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_neuroscience_artikel_ms_HMA0_One_Pager_EBM_update_Ocre_s.c.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_neuroscience_artikel_ms_HMA0_One_Pager_EBM_update_Ocre_s.c.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_neuroscience_artikel_ms_HMA0_One_Pager_EBM_update_Ocre_s.c.pdf.txt,"['German', 'EBM', 'Ocrevus', 'Einheitlicher']",Neurology,Germany,Offer outline,"Ocrevus, intravenous (i.v.), subcutaneous (s.c.), EBM",,10.355643,-36.438583,1,"The content appears to be a content or brochure related to Ocrevus, a medication by Roche used for specific medical treatments. The title is in German, indicating it covers billing options (""Abrechnungsmöglichkeiten"") for Ocrevus in both intravenous (i.v.) and subcutaneous (s.c.) forms, according to the EBM (Einheitlicher Bewertungsmaßstab). The purpose of this content is likely to provide healthcare professionals with guidance on how to process insurance claims or reimbursements for this medication.","drug, reporting, adverse",fachportal.roche.de,Falling,0.959459877644712,low,327,Drug Safety
370,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/neuroscience/patientenangebote/dokumente/230803_MEINSERVICE_A5.pdf,0,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_neuroscience_patientenangebote_dokumente_230803_MEINSERVICE_A5_pdf.txt,200,pdf,Non-Indexable,,0,0,0,2,2,0.940298507462687,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_neuroscience_patientenangebote_dokumente_230803_MEINSERVICE_A5.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_neuroscience_patientenangebote_dokumente_230803_MEINSERVICE_A5.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_neuroscience_patientenangebote_dokumente_230803_MEINSERVICE_A5.pdf.txt,"['Service', 'Sclerosis', 'Multiple', 'Mein', 'MS']",Neurology,Germany,Patient support,"Multiple Sclerosis, MS",Multiple Sclerosis,20.710283,23.223175,4,"The content serves as a promotional flyer for Roche's ""Mein Service"" program, which is designed to assist individuals affected by Multiple Sclerosis (MS). It provides a step-by-step guide on how to register for the service, which includes visiting a specific website, filling out a form, and confirming registration via email. The flyer highlights the availability of personal support for users and encourages them to access additional information related to MS through their website and social media. The overall purpose is to facilitate access to resources and support for those impacted by MS.","technologies, artificial, ai",fachportal.roche.de,All,0.877639077887923,low,466,Technology
371,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/Precision-Medicine/boutique-page/downloads/sopub_42800_Roche_IMR_E-Lizenz.pdf,0,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_Precision_Medicine_boutique_page_downloads_sopub_42800_Roche_IMR_E_Lizenz_pdf.txt,200,pdf,Non-Indexable,4,0,0,0,2,2,0.924137931034483,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_Precision-Medicine_boutique-page_downloads_sopub_42800_Roche_IMR_E-Lizenz.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_Precision-Medicine_boutique-page_downloads_sopub_42800_Roche_IMR_E-Lizenz.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_Precision-Medicine_boutique-page_downloads_sopub_42800_Roche_IMR_E-Lizenz.pdf.txt,"['Unknown', 'Primary', 'CUP', 'Cancer']",Oncology-Hematology,Germany,Research,"Cancer of Unknown Primary, tumor diagnostics, targeted therapies, molecular tumor profiling, chemotherapy, genomic alterations, precision medicine",Cancer of Unknown Primary,34.802635,-16.527569,12,"The content discusses the outcomes of a global study involving 436 patients with Cancer of Unknown Primary (CUP) across 34 countries, highlighting the importance of modern tumor diagnostics and targeted therapies. It emphasizes the role of molecular tumor profiling in personalizing treatment for CUP patients, which can significantly improve their prognosis compared to conventional chemotherapy. The study's findings indicate that a substantial proportion of CUP patients could benefit from targeted therapies based on identified genomic alterations, marking a significant advancement in the treatment of this complex and aggressive condition. The overall purpose of the content is to inform healthcare professionals about new research findings and advancements in precision medicine related to CUP.","cancer, breast, lung",fachportal.roche.de,Rising,0.790914111720953,low,28,Disease Information
372,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/veranstaltungen/2024/12/wrap-up-gynaekoonkologie/documents/20240506_SABCS_2024_Einladungsflyer.pdf,5,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_2024_12_wrap_up_gynaekoonkologie_documents_20240506_SABCS_2024_Einladungsflyer_pdf.txt,200,pdf,Non-Indexable,,30,0,0,1,1,0.939759036144578,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_2024_12_wrap-up-gynaekoonkologie_documents_20240506_SABCS_2024_Einladungsflyer.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_2024_12_wrap-up-gynaekoonkologie_documents_20240506_SABCS_2024_Einladungsflyer.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_2024_12_wrap-up-gynaekoonkologie_documents_20240506_SABCS_2024_Einladungsflyer.pdf.txt,"['Zoom', 'Participants', 'Achim', 'CET', 'HR', 'Breast', 'December', 'Antonio', 'Prof', 'QR', 'Scheduled', 'Symposium', 'Dr', 'San', 'Cancer']",Oncology-Hematology,Germany,Events,"breast cancer, HR-positive, HER2-positive","breast cancer, HR-positive breast cancer, HER2-positive breast cancer",8.777588,-6.726326,7,"The content is a virtual event flyer for a discussion event organized by Roche, focusing on the latest updates from the San Antonio Breast Cancer Symposium. Scheduled for December 16, 2024, from 18:00 to 20:30 (CET) on Zoom, it features expert presentations on topics related to breast cancer, including data on HR-positive and HER2-positive breast cancer. The event will be led by Prof. Dr. Achim Wöckel, and includes a final discussion period. Participants can register via a provided QR code.","event, exclusive, website",fachportal.roche.de,Rising,0.0784467691641703,medium,324,Events & Patient Care
373,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/veranstaltungen/2025/02/neuronale/documents/Final_neuRonale_2025_STD_A5_Flyer_RZ_241025_HS.pdf,1,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_2025_02_neuronale_documents_Final_neuRonale_2025_STD_A5_Flyer_RZ_241025_HS_pdf.txt,200,pdf,Non-Indexable,2,0,0,0,2,2,0.950617283950617,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_2025_02_neuronale_documents_Final_neuRonale_2025_STD_A5_Flyer_RZ_241025_HS.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_2025_02_neuronale_documents_Final_neuRonale_2025_STD_A5_Flyer_RZ_241025_HS.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_2025_02_neuronale_documents_Final_neuRonale_2025_STD_A5_Flyer_RZ_241025_HS.pdf.txt,"['Kongresszentrum', 'Rosengarten', 'Mannheim', 'CME', 'February']",Neurology,Germany,Events,,,27.562435,26.885595,4,"The content is a promotional poster for the ""neuRonale 2025"" event, organized by Roche. It features a visually appealing design with neural patterns and announces the dates and location: February 7-8, 2025, at the Kongresszentrum Rosengarten in Mannheim. The poster encourages attendees to ""save the date"" and mentions that CME certification is being sought for the event, highlighting its educational significance in the field of neurology.","technologies, artificial, ai",fachportal.roche.de,Falling,0.946451973197858,low,442,Technology
374,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/veranstaltungen/b-zell-foren/bzf-03-2024/docs/2024-03-BZF-Teilnehmervertrag-einzel.pdf,0,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_b_zell_foren_bzf_03_2024_docs_2024_03_BZF_Teilnehmervertrag_einzel_pdf.txt,200,pdf,Non-Indexable,,0,0,0,1,1,0.896103896103896,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_b-zell-foren_bzf-03-2024_docs_2024-03-BZF-Teilnehmervertrag-einzel.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_b-zell-foren_bzf-03-2024_docs_2024-03-BZF-Teilnehmervertrag-einzel.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_b-zell-foren_bzf-03-2024_docs_2024-03-BZF-Teilnehmervertrag-einzel.pdf.txt,"['B', 'Forum', 'Zell', 'March']",Other,Germany,Events,,,6.0468655,3.4042614,7,"The content is a registration form for the ""B-Zell-Forum"" organized by Roche, scheduled to take place virtually from March 15 to March 16, 2024. The form includes fields for personal and contact information, as well as guidelines stating that complete and signed applications are required for participation. It emphasizes that Roche will cover certain educational costs but excludes travel and accommodation expenses. The content outlines compliance with legal and ethical standards related to industry collaboration in healthcare.","event, exclusive, website",fachportal.roche.de,Rising,0.699698400504851,low,235,Events & Patient Care
375,https://fachportal.roche.de/content/dam/nextgen/whitelabel/emea/de3/de/veranstaltungen/b-zell-foren/bzf-maerz-2025/documents/25_03_28_TNV_B-Zell-Forum_Maerz_006238F6.pdf,0,fachportal_roche_de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_b_zell_foren_bzf_maerz_2025_documents_25_03_28_TNV_B_Zell_Forum_Maerz_006238F6_pdf.txt,200,pdf,Non-Indexable,3,0,0,0,1,1,0.91566265060241,https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_b-zell-foren_bzf-maerz-2025_documents_25_03_28_TNV_B-Zell-Forum_Maerz_006238F6.pdf,image/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_b-zell-foren_bzf-maerz-2025_documents_25_03_28_TNV_B-Zell-Forum_Maerz_006238F6.pdf.png,text/https_fachportal.roche.de_content_dam_nextgen_whitelabel_emea_de3_de_veranstaltungen_b-zell-foren_bzf-maerz-2025_documents_25_03_28_TNV_B-Zell-Forum_Maerz_006238F6.pdf.txt,"['B', 'Forum', 'Cell', 'March']",Other,Germany,Events,,,10.211183,3.380991,7,"The content is a registration form for the ""B-Cell Forum"" taking place virtually from March 28 to March 29, 2025. It is organized by Roche and includes fields for personal information, contact details, and compliance with regulatory guidelines for participants. The form highlights that complete registrations submitted by March 21, 2025, will be accepted, and it clarifies the inclusion criteria and terms for participation, emphasizing the prohibition of covering certain expenses.","event, exclusive, website",fachportal.roche.de,All,0.635407917550533,low,244,Events & Patient Care
376,https://rochepro.fr/content/dam/nextgen/whitelabel/demo/gb/en/documents/perjeta_prescribing-4.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_demo_gb_en_documents_perjeta_prescribing_4_pdf.txt,200,pdf,Non-Indexable,,21,0,0,3,1,0.914893617021277,https_rochepro.fr_content_dam_nextgen_whitelabel_demo_gb_en_documents_perjeta_prescribing-4.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_demo_gb_en_documents_perjeta_prescribing-4.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_demo_gb_en_documents_perjeta_prescribing-4.pdf.txt,['PERJETA'],Oncology-Hematology,France,Medication information,"PERJETA, pertuzumab, trastuzumab, breast cancer, HER2-positive early breast cancer, adverse reactions, side effects, neoadjuvant treatments, adjuvant treatments","breast cancer, HER2-positive early breast cancer",20.398596,-29.245375,1,"The content provides a detailed summary of adverse reactions associated with the pharmaceutical agent PERJETA (pertuzumab) when used in combination with trastuzumab and chemotherapy for breast cancer treatment. It outlines the frequency and severity of various side effects reported in clinical trials, specifically focusing on different body systems affected during neoadjuvant and adjuvant treatments. The purpose of the content is to inform healthcare professionals about the safety profile and potential risks linked to PERJETA, assisting them in making informed treatment decisions for patients with HER2-positive early breast cancer.","drug, reporting, adverse",rochepro.fr,Falling,0.780097194738093,medium,325,Drug Safety
377,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/maladies-rares/amyotrophie-spinale/pour-vos-patients/sma-parcours-dispensation-00006088-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_maladies_rares_amyotrophie_spinale_pour_vos_patients_sma_parcours_dispensation_00006088_1_pdf.txt,200,pdf,Non-Indexable,3,105,0,0,2,2,0.907514450867052,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_amyotrophie-spinale_pour-vos-patients_sma-parcours-dispensation-00006088-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_amyotrophie-spinale_pour-vos-patients_sma-parcours-dispensation-00006088-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_amyotrophie-spinale_pour-vos-patients_sma-parcours-dispensation-00006088-1.pdf.txt,['Illustrations'],Other,France,Offer outline,,,-19.111504,-31.706596,0,"The content provides an overview of the treatment dispensing process by community pharmacists for a pharmaceutical company, Roche. It outlines the stages from the initial prescription and coordination between hospital and community pharmacy, to the pharmacist dispensing the treatment to the patient. The process also emphasizes patient autonomy in managing their treatment and confirming renewals with the pharmacist. Illustrations facilitate understanding, and contact information for medical inquiries is provided at the end. Overall, it aims to ensure a smooth and informed treatment journey for patients.","oncology, professionals, data",rochepro.fr,Falling,0.953329724620862,medium,295,General Offer Outline
378,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/maladies-rares/amyotrophie-spinale/pour-vous/en-savoir-plus-sma/amyotrophie-spinale-maladie-rare-multi-systemique-00007281-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_maladies_rares_amyotrophie_spinale_pour_vous_en_savoir_plus_sma_amyotrophie_spinale_maladie_rare_multi_systemique_00007281_1_pdf.txt,200,pdf,Non-Indexable,3,79,0,0,3,2,0.899038461538462,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_amyotrophie-spinale_pour-vous_en-savoir-plus-sma_amyotrophie-spinale-maladie-rare-multi-systemique-00007281-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_amyotrophie-spinale_pour-vous_en-savoir-plus-sma_amyotrophie-spinale-maladie-rare-multi-systemique-00007281-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_amyotrophie-spinale_pour-vous_en-savoir-plus-sma_amyotrophie-spinale-maladie-rare-multi-systemique-00007281-1.pdf.txt,"['Muscular', 'SMA', 'Atrophy', 'Spinal', 'SMN']",Neurology,France,Disease information,"Spinal Muscular Atrophy, SMA, SMN1 gene, SMN protein",spinal muscular atrophy,22.216581,28.288055,4,"The content discusses Spinal Muscular Atrophy (SMA), a genetic disease characterized by muscular atrophy and weakness due to the absence or malfunction of the SMN1 gene, leading to insufficient functional SMN protein. It outlines the symptoms, the progression of different types of SMA, and the systemic impact on multiple organs beyond just the motor neurons, including muscle, cardiovascular, respiratory, and gastrointestinal systems. The purpose of the content appears to be to provide an overview of SMA, its underlying biological mechanisms, and the ongoing research aimed at understanding the multifunctional role of SMN protein in various tissues, which could lead to new therapeutic approaches.","technologies, artificial, ai",rochepro.fr,Rising,0.968242947443297,medium,434,Technology
379,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/maladies-rares/hemophilie/pour-pharmacien-officine/hemophilie-fiche-check-list-pharmacien-00002816-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_maladies_rares_hemophilie_pour_pharmacien_officine_hemophilie_fiche_check_list_pharmacien_00002816_2_pdf.txt,200,pdf,Non-Indexable,3,137,0,0,2,2,0.907608695652174,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-pharmacien-officine_hemophilie-fiche-check-list-pharmacien-00002816-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-pharmacien-officine_hemophilie-fiche-check-list-pharmacien-00002816-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-pharmacien-officine_hemophilie-fiche-check-list-pharmacien-00002816-2.pdf.txt,['Produced'],Oncology-Hematology,France,Offer outline,"hemophilia, treatment, medication storage, patient safety, effective treatment delivery",hemophilia,18.10136,-0.41758966,4,"The content is a practical checklist specifically designed for pharmacists to facilitate the dispensing of treatment for hemophilia. Produced by Roche, it outlines essential steps and considerations for pharmacists, including communication protocols with healthcare teams, training requirements, and logistical checks for medication storage. The checklist emphasizes collaboration with specialized teams to ensure patient safety and effective treatment delivery. The information is structured clearly to aid pharmacists in their responsibilities regarding patient care.","technologies, artificial, ai",rochepro.fr,Falling,0.232390039847206,medium,440,Technology
380,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/maladies-rares/hemophilie/pour-pharmacien-officine/parcours-patient-A4-00003440-1.0.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_maladies_rares_hemophilie_pour_pharmacien_officine_parcours_patient_A4_00003440_1_0_pdf.txt,200,pdf,Non-Indexable,3,49,0,0,2,2,0.904191616766467,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-pharmacien-officine_parcours-patient-A4-00003440-1.0.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-pharmacien-officine_parcours-patient-A4-00003440-1.0.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-pharmacien-officine_parcours-patient-A4-00003440-1.0.pdf.txt,[],Other,France,Patient support,,,-18.953861,-30.548111,0,"The content is an infographic created by Roche, outlining the patient journey for receiving treatment in a pharmacy setting after hospital care. It describes the process in six steps, starting from hospital admission, through the transition to community pharmacy distribution, and detailing how the hospital supports this transition. The infographic emphasizes the preparedness for treatment in pharmacies, management of specific cases, and the ongoing role of the hospital in patient care. It aims to inform patients about how to access their medications post-hospitalization.","oncology, professionals, data",rochepro.fr,All,0.188086411676175,medium,443,General Offer Outline
381,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/maladies-rares/hemophilie/pour-vos-patients/fiche-pratique-hemophilie-douleurs-00008596-1.0.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_maladies_rares_hemophilie_pour_vos_patients_fiche_pratique_hemophilie_douleurs_00008596_1_0_pdf.txt,200,pdf,Non-Indexable,3,36,0,0,2,2,0.902857142857143,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-douleurs-00008596-1.0.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-douleurs-00008596-1.0.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-douleurs-00008596-1.0.pdf.txt,[],Oncology-Hematology,France,Patient support,"hemophilia, pain, hemarthrosis, hematomas, physical activity, alternative medicine","hemophilia, hemarthrosis, hematomas",20.722393,1.9524304,4,"The content discusses the management and understanding of pain, particularly in the context of patients with hemophilia. It defines pain as a subjective but real sensory and emotional experience linked to tissue injury, and emphasizes the importance of recognizing, assessing, and discussing pain to manage it effectively. It also highlights specific types of pain associated with hemophilia, such as hemarthrosis and hematomas, and outlines prevention and treatment strategies, including physical activity, alternative medicine, and communication with healthcare professionals. The overall purpose is to provide patients with guidance on effectively managing pain and improving their quality of life.","technologies, artificial, ai",rochepro.fr,Rising,0.624281258540107,medium,370,Technology
382,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/maladies-rares/hemophilie/pour-vos-patients/fiche-pratique-hemophilie-sante-mentale-00007993-1.0.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_maladies_rares_hemophilie_pour_vos_patients_fiche_pratique_hemophilie_sante_mentale_00007993_1_0_pdf.txt,200,pdf,Non-Indexable,3,42,0,0,2,2,0.9,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-sante-mentale-00007993-1.0.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-sante-mentale-00007993-1.0.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-sante-mentale-00007993-1.0.pdf.txt,['Its'],Oncology-Hematology,France,Patient support,"hemophilia, psychological support, therapeutic education, psychological services, exercise, relaxation techniques",hemophilia,20.71386,2.1316247,4,"The content focuses on the management and psychological support for individuals living with hemophilia. Its purpose is to highlight the importance of autonomy, psychological follow-up, and therapeutic education in managing the condition. The content emphasizes the need for understanding the disease, engaging in physical activities, and accessing psychological services, while also suggesting that support from family and patient associations is crucial. It also mentions the benefits of exercise for mental and physical well-being, and it endorses various activities that are compatible with hemophilia, as well as relaxation techniques to improve patients' quality of life.","technologies, artificial, ai",rochepro.fr,Rising,0.121089397438457,medium,174,Technology
383,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/maladies-rares/hemophilie/pour-vos-patients/fiche-pratique-hemophilie-sexualite-00008597-1.0.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_maladies_rares_hemophilie_pour_vos_patients_fiche_pratique_hemophilie_sexualite_00008597_1_0_pdf.txt,200,pdf,Non-Indexable,3,59,0,0,2,2,0.903409090909091,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-sexualite-00008597-1.0.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-sexualite-00008597-1.0.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-sexualite-00008597-1.0.pdf.txt,[],Oncology-Hematology,France,Patient support,"hemophilia, condoms, sexually transmitted infections, unintended pregnancies, lubricant, unusual bleeding",hemophilia,20.712074,0.7706619,4,"The content provides information on safe sexual practices for individuals with hemophilia, emphasizing the importance of prevention and communication. It highlights the necessity of using condoms to reduce the risk of sexually transmitted infections and unintended pregnancies, as well as the benefits of using lubricant to prevent injuries. The content stresses the need for consent and effective communication between partners to ensure a safe and pleasurable experience. Additionally, it addresses potential complications related to hemophilia during sexual activities, advising on monitoring for unusual bleeding and consulting a physician when necessary. Overall, the content aims to educate individuals with hemophilia on how to engage in sexual activities safely while managing their condition.","technologies, artificial, ai",rochepro.fr,Falling,0.393476982093634,medium,234,Technology
384,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/maladies-rares/hemophilie/pour-vos-patients/fiche-pratique-hemophilie-tatouages-piercings-00008598-1.0.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_maladies_rares_hemophilie_pour_vos_patients_fiche_pratique_hemophilie_tatouages_piercings_00008598_1_0_pdf.txt,200,pdf,Non-Indexable,3,62,0,0,2,2,0.903225806451613,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-tatouages-piercings-00008598-1.0.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-tatouages-piercings-00008598-1.0.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-tatouages-piercings-00008598-1.0.pdf.txt,[],Oncology-Hematology,France,Patient support,"hemophilia, tattoo, piercing, bleeding issues, body art, bleeding disorders",hemophilia,21.16071,0.63255113,4,"The content provides guidelines for individuals with hemophilia who are considering getting a tattoo or piercing. It emphasizes the importance of consulting with a doctor beforehand to ensure safety and proper treatment for any potential bleeding issues. The guidelines include discussing hemophilia with the tattoo artist or piercer, choosing certified professionals, and following specific precautions to minimize risks. The content aims to inform and empower individuals with bleeding disorders to make safe decisions regarding body art while addressing their unique health considerations.","technologies, artificial, ai",rochepro.fr,All,0.531393189051694,medium,230,Technology
385,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/maladies-rares/hemophilie/pour-vos-patients/fiche-pratique-hemophilie-voyage-00008595-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_maladies_rares_hemophilie_pour_vos_patients_fiche_pratique_hemophilie_voyage_00008595_1_pdf.txt,200,pdf,Non-Indexable,3,47,0,0,2,2,0.906432748538012,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-voyage-00008595-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-voyage-00008595-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_maladies-rares_hemophilie_pour-vos-patients_fiche-pratique-hemophilie-voyage-00008595-1.pdf.txt,[],Other,France,Patient support,,,-4.655829,-35.599,1,"The content is an informative poster likely produced by Roche, focusing on travel preparations for individuals requiring medical care. It outlines key considerations before going on vacation, such as notifying healthcare providers and insurance companies, checking local vaccination centers, and ensuring sufficient medication for the trip. Additionally, it includes a list of essential items to pack, including prophylactic treatments, an insulated bag for medications, necessary health documents, and a complete first aid kit. The overall purpose is to promote health awareness and preparedness for travelers.","drug, reporting, adverse",rochepro.fr,Falling,0.281409852929255,medium,92,Drug Safety
386,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/neurologie/sclerose-en-plaques/evenements/sep-programme-roche-en-neuroscience-2023-00009625-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_evenements_sep_programme_roche_en_neuroscience_2023_00009625_1_pdf.txt,200,pdf,Non-Indexable,3,56,0,0,1,1,0.903954802259887,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_evenements_sep-programme-roche-en-neuroscience-2023-00009625-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_evenements_sep-programme-roche-en-neuroscience-2023-00009625-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_evenements_sep-programme-roche-en-neuroscience-2023-00009625-1.pdf.txt,['Attendees'],Neurology,France,Events,,,19.448261,22.050755,4,"The extracted content outlines a schedule for an event organized by a pharmaceutical company, focusing on advancements in neurological treatments and patient care. It includes various sessions such as workshops, inspiring plenières, and discussions led by experts in the field. The purpose of the event appears to be to foster knowledge sharing, collaboration, and innovative thinking among healthcare professionals regarding neurological conditions and therapies. Attendees will engage in brainstorming sessions, explore new practices, and discuss the latest scientific developments related to patient care and treatment adherence.","technologies, artificial, ai",rochepro.fr,Flat,0.945121576940175,medium,118,Technology
387,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/neurologie/sclerose-en-plaques/evenements/sep-remis-exosquelettes-mythe-realite-00009769-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_evenements_sep_remis_exosquelettes_mythe_realite_00009769_1_pdf.txt,200,pdf,Non-Indexable,3,78,0,0,1,1,0.908045977011494,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_evenements_sep-remis-exosquelettes-mythe-realite-00009769-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_evenements_sep-remis-exosquelettes-mythe-realite-00009769-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_evenements_sep-remis-exosquelettes-mythe-realite-00009769-1.pdf.txt,"['Gallien', 'Exoskeletons', 'November', 'Dr', 'Exosquelettes', 'Philippe', 'Neurosciences']",Neurology,France,Events,,,20.944904,22.475,4,"The content is an event poster for a workshop titled ""Exosquelettes : mythe ou réalité ?"" (Exoskeletons: myth or reality?), scheduled for November 24th. It features two speakers, Dr. Cécile Donzé and Dr. Philippe Gallien, who specialize in physical medicine and rehabilitation. The agenda includes discussions on the definitions and roles of exoskeletons, user expectations, how to choose an exoskeleton, and other advancements in assistive devices. The event is organized by Roche under its Neurosciences division.","technologies, artificial, ai",rochepro.fr,Rising,0.328897552320981,medium,126,Technology
388,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/neurologie/sclerose-en-plaques/evenements/sep-remis-sclerose-en-plaques-permis-de-conduire-00009780-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_evenements_sep_remis_sclerose_en_plaques_permis_de_conduire_00009780_1_pdf.txt,200,pdf,Non-Indexable,3,81,0,0,1,1,0.897297297297297,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_evenements_sep-remis-sclerose-en-plaques-permis-de-conduire-00009780-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_evenements_sep-remis-sclerose-en-plaques-permis-de-conduire-00009780-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_evenements_sep-remis-sclerose-en-plaques-permis-de-conduire-00009780-1.pdf.txt,"['French', 'SEP', 'March']",Neurology,France,Disease information,"multiple sclerosis, legal aspects, medical fitness to drive, regulations, documentation, communication",multiple sclerosis,24.899073,25.708652,4,"The content discusses the legal and medical aspects surrounding the ability to drive for individuals with specific medical conditions, particularly focusing on multiple sclerosis (SEP) and its implications for driving. It outlines the regulations set by the French decree dated March 28, 2022, which categorizes medical conditions as either compatible or incompatible with driving, emphasizing the responsibilities of drivers, doctors, and medical examiners. The purpose is to provide guidance on medical fitness to drive and the legal ramifications for individuals who may not comply with medical assessments related to their ability to safely operate a vehicle. It also highlights the importance of documentation and communication between healthcare providers and patients regarding these issues.","technologies, artificial, ai",rochepro.fr,Falling,0.335265974931967,medium,316,Technology
389,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/neurologie/sclerose-en-plaques/evenements/sep-remis-traitement-haute-efficacite-00009774-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_evenements_sep_remis_traitement_haute_efficacite_00009774_1_pdf.txt,200,pdf,Non-Indexable,3,93,0,0,1,1,0.908045977011494,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_evenements_sep-remis-traitement-haute-efficacite-00009774-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_evenements_sep-remis-traitement-haute-efficacite-00009774-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_evenements_sep-remis-traitement-haute-efficacite-00009774-1.pdf.txt,"['Paris', 'Colamarino', 'Implementation', 'Renato', 'Marie', 'Antibes', 'Colpaert', 'Neurosciences', 'Highly', 'Dr', 'November', 'Effective', 'Treatment']",Neurology,France,Events,,,18.363787,22.079794,4,"This content is an event poster for a workshop titled ""Implementation of a Highly Effective Treatment,"" scheduled for November 24. It features speakers Marie-Hélène Colpaert from Paris and Dr. Renato Colamarino from Antibes. The workshop will address various support methods for patients, including therapeutic education and information sharing. It emphasizes the importance of responding to specific questions related to patient pathways during treatment implementation. The event is presented by Roche in Neurosciences.","technologies, artificial, ai",rochepro.fr,All,0.73428608783337,medium,132,Technology
390,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/neurologie/sclerose-en-plaques/pour-vous/infographie-ambition-autonomie-00009680-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_pour_vous_infographie_ambition_autonomie_00009680_1_pdf.txt,200,pdf,Non-Indexable,3,50,0,0,2,2,0.909638554216868,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_pour-vous_infographie-ambition-autonomie-00009680-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_pour-vous_infographie-ambition-autonomie-00009680-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_pour-vous_infographie-ambition-autonomie-00009680-1.pdf.txt,['MS'],Neurology,France,Research,"multiple sclerosis, patient autonomy, measurement tool, psychometric validation",multiple sclerosis,23.746542,22.446053,4,"The content is an infographic from Roche presenting findings related to patient autonomy, specifically for individuals with multiple sclerosis (MS). It outlines the current challenges patients face due to their symptoms and the inadequacy of existing tools for monitoring their condition. The main objective is to develop a measurement tool focusing on maintaining patient autonomy across various life spheres. It highlights a study involving 653 patients, which initially featured 131 questions but was refined to 36 in 10 social dimensions. The next step involves psychometric validation of this tool.","technologies, artificial, ai",rochepro.fr,Falling,0.801524997588504,medium,286,Technology
391,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/neurologie/sclerose-en-plaques/pour-vous/integration-prise-en-charge-autonomie-00008786-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_pour_vous_integration_prise_en_charge_autonomie_00008786_1_pdf.txt,200,pdf,Non-Indexable,3,97,0,0,2,2,0.901734104046243,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_pour-vous_integration-prise-en-charge-autonomie-00008786-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_pour-vous_integration-prise-en-charge-autonomie-00008786-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_pour-vous_integration-prise-en-charge-autonomie-00008786-1.pdf.txt,[],Other,France,Patient support,,,3.5354369,3.7984376,7,"The content is an infographic created for Roche, focusing on how to integrate patient autonomy into healthcare practices. It highlights various strategies, such as addressing specific patient needs, early engagement, and collaboration among healthcare professionals. The content emphasizes the importance of understanding what matters to patients and ensuring they are an active part of their care, rather than having decisions made for them. The overall message encourages holistic and personalized approaches to patient management.","event, exclusive, website",rochepro.fr,Rising,0.331546818652242,medium,477,Events & Patient Care
392,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/neurologie/sclerose-en-plaques/pour-vous/roles-sociaux-autonomie-00008788-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_pour_vous_roles_sociaux_autonomie_00008788_1_pdf.txt,200,pdf,Non-Indexable,3,83,0,0,2,2,0.905660377358491,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_pour-vous_roles-sociaux-autonomie-00008788-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_pour-vous_roles-sociaux-autonomie-00008788-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_pour-vous_roles-sociaux-autonomie-00008788-1.pdf.txt,[],Other,France,Patient support,,,22.180712,12.6250725,4,"This content is a visual infographic created for Roche, addressing social roles related to autonomy, particularly in the context of caregiving and accessibility. It features various illustrations that discuss challenges and considerations in maintaining autonomy, such as having support for household tasks, barriers to accessibility, and the bureaucratic processes involved in obtaining assistance. The central question invites viewers to reflect on the social roles connected to autonomy, aiming to engage the audience in a discussion on these important themes.","technologies, artificial, ai",rochepro.fr,Falling,0.380519484755396,medium,388,Technology
393,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/neurologie/sclerose-en-plaques/pour-vous/signification-autonomie-patient-sep-00008787-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_pour_vous_signification_autonomie_patient_sep_00008787_1_pdf.txt,200,pdf,Non-Indexable,3,73,0,0,2,2,0.906432748538012,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_pour-vous_signification-autonomie-patient-sep-00008787-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_pour-vous_signification-autonomie-patient-sep-00008787-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_neurologie_sclerose-en-plaques_pour-vous_signification-autonomie-patient-sep-00008787-1.pdf.txt,['SEP'],Neurology,France,Patient support,"multiple sclerosis, autonomy, treatment options, SEP patients",multiple sclerosis,19.1538,22.048986,4,"The content produced by Roche discusses the concept of autonomy for patients with multiple sclerosis (SEP). It emphasizes the importance of creating an adapted environment, pursuing personal passions despite the illness, and regaining control over one’s life. The infographic highlights key elements such as support from loved ones, decision-making regarding treatment options, and understanding the implications of their diagnosis. The overall goal is to illustrate what autonomy means for SEP patients and encourage a proactive approach to managing their condition.","technologies, artificial, ai",rochepro.fr,Flat,0.614532944670935,medium,20,Technology
394,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/cahiers-creatifs/cahier-creatif-etre-active-00009386-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_cahiers_creatifs_cahier_creatif_etre_active_00009386_1_pdf.txt,200,pdf,Non-Indexable,3,31,0,0,2,2,0.905405405405405,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-etre-active-00009386-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-etre-active-00009386-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-etre-active-00009386-1.pdf.txt,[],Other,France,Patient support,,,20.769674,15.274024,4,"The content discusses the importance of staying active both physically and mentally, especially during challenging times such as illness. It emphasizes engaging in sports, creative activities like writing and drawing, and enjoying simple pleasures like cooking and gardening. It also provides practical advice for promoting well-being, such as maintaining good sleep habits and having open communication with loved ones. Overall, the purpose of the content is to encourage individuals to embrace active participation in life, find joy in everyday activities, and seek support during difficult periods.","technologies, artificial, ai",rochepro.fr,Rising,0.584862154290327,medium,462,Technology
395,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/cahiers-creatifs/cahier-creatif-garder-appetit-00009385-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_cahiers_creatifs_cahier_creatif_garder_appetit_00009385_1_pdf.txt,200,pdf,Non-Indexable,3,36,0,0,2,2,0.907284768211921,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-garder-appetit-00009385-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-garder-appetit-00009385-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-garder-appetit-00009385-1.pdf.txt,[],Other,France,Patient support,,,-0.08131024,-2.7433481,7,"The content is a guide provided by Roche aimed at encouraging individuals, particularly those undergoing treatment that may affect appetite, to maintain a balanced and enjoyable diet. It emphasizes the importance of varied nutrition, cooking colorful and flavorful meals, and engaging in regular physical activity. The content offers practical tips and creative exercises, promoting self-care and the enjoyment of eating, while also addressing potential dietary challenges related to medical treatments. Overall, it serves as a resource for improving appetite and health through mindful eating practices.","event, exclusive, website",rochepro.fr,Falling,0.533394470232748,medium,436,Events & Patient Care
396,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/cahiers-creatifs/cahier-creatif-mieux-vivre-emotions-00009383-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_cahiers_creatifs_cahier_creatif_mieux_vivre_emotions_00009383_1_pdf.txt,200,pdf,Non-Indexable,3,49,0,0,2,2,0.904458598726115,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-mieux-vivre-emotions-00009383-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-mieux-vivre-emotions-00009383-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-mieux-vivre-emotions-00009383-1.pdf.txt,[],Oncology-Hematology,France,Patient support,,,24.559914,-17.017832,12,"The content is a guide intended for individuals undergoing cancer treatment, focusing on understanding and managing emotions associated with their medical experience. It emphasizes the legitimacy of varied emotional responses such as anxiety, anger, and sadness and encourages patients to express and share these feelings with their loved ones and healthcare providers. The guide includes creative exercises for tracking emotions, coping strategies, and resources for professional support, ultimately aiming to help individuals navigate their emotional challenges during treatment and improve their overall well-being.","cancer, breast, lung",rochepro.fr,Flat,0.970532604403728,medium,415,Disease Information
397,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/cahiers-creatifs/cahier-creatif-preserver-vie-couple-00009384-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_cahiers_creatifs_cahier_creatif_preserver_vie_couple_00009384_1_pdf.txt,200,pdf,Non-Indexable,3,46,0,0,2,2,0.904458598726115,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-preserver-vie-couple-00009384-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-preserver-vie-couple-00009384-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-preserver-vie-couple-00009384-1.pdf.txt,[],Oncology-Hematology,France,Patient support,,cancer,24.546402,-16.53756,12,"The content appears to be a creative workbook designed for women dealing with cancer, focusing particularly on preserving their relationship and intimacy with their partners during and after treatment. It offers practical advice, activities, and reflections to help maintain a couple's life and intimacy, acknowledging the challenges posed by the medical condition and its treatment. The workbook emphasizes communication, self-care, and adapting to changes in one's body and sexual experiences, encouraging users to express their emotions and questions regarding sexuality and health. Overall, the purpose of the content is to provide support and resources to help women navigate their intimate relationships while coping with cancer.","cancer, breast, lung",rochepro.fr,Falling,0.504521904183293,medium,90,Disease Information
398,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/cahiers-creatifs/cahier-creatif-rester-zen-00009591-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_cahiers_creatifs_cahier_creatif_rester_zen_00009591_1_pdf.txt,200,pdf,Non-Indexable,3,29,0,0,2,2,0.904761904761905,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-rester-zen-00009591-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-rester-zen-00009591-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-rester-zen-00009591-1.pdf.txt,[],Other,France,Patient support,,,20.852966,15.256415,4,"The content focuses on wellness and mindfulness practices, emphasizing the connection between the body and mind to attain harmony. It provides various creative exercises, meditative practices, and relaxation techniques designed to help individuals reconnect with themselves, manage stress, and improve their emotional well-being. Additionally, the content includes practical advice on nutrition and mental health support, making it a resource for individuals seeking to enhance their overall quality of life. The purpose is to encourage users to engage in self-care and develop a positive mindset while addressing emotional and physical health.","technologies, artificial, ai",rochepro.fr,Flat,0.170903440374459,medium,450,Technology
399,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/cahiers-creatifs/cahier-creatif-sentir-belle-00009590-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_cahiers_creatifs_cahier_creatif_sentir_belle_00009590_1_pdf.txt,200,pdf,Non-Indexable,3,35,0,0,2,2,0.906040268456376,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-sentir-belle-00009590-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-sentir-belle-00009590-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cahiers-creatifs_cahier-creatif-sentir-belle-00009590-1.pdf.txt,[],Oncology-Hematology,France,Patient support,,,24.035082,-16.300879,12,"The content discusses self-care and emotional well-being, particularly in the context of cancer treatment. It emphasizes the importance of self-content and offers creative exercises, such as writing, drawing, and coloring, to promote positive feelings and allow patients to express their emotions. The content also includes practical advice for personal care, like skincare, nutrition, and hair maintenance, specifically tailored for individuals undergoing medical treatments. The purpose is to provide support and encouragement to enhance the quality of life for patients through various self-care practices and creative expression.","cancer, breast, lung",rochepro.fr,All,0.402483021088875,medium,183,Disease Information
400,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/cancer-bronchique/pour-vos-patients/infographie-cancer-poumon-non-fumeur-00003017.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vos_patients_infographie_cancer_poumon_non_fumeur_00003017_pdf.txt,200,pdf,Non-Indexable,3,83,0,0,3,2,0.908571428571429,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-bronchique_pour-vos-patients_infographie-cancer-poumon-non-fumeur-00003017.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-bronchique_pour-vos-patients_infographie-cancer-poumon-non-fumeur-00003017.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-bronchique_pour-vos-patients_infographie-cancer-poumon-non-fumeur-00003017.pdf.txt,[],Oncology-Hematology,France,Disease information,"lung cancer, molecular alterations, environmental risk factors, occupational risk factors, targeted therapies, personalized medicine, late diagnosis, nonspecific symptoms",lung cancer,31.198355,-16.6793,12,"The extracted content provides an overview of lung cancer in non-smokers, emphasizing molecular alterations, environmental and occupational risk factors, and the differences in treatment response compared to smokers. It discusses the demographic characteristics of affected patients, particularly focusing on women, and highlights the importance of targeted therapies and personalized medicine. The content also points out the challenges related to the late diagnosis and varies symptoms that are often nonspecific, reinforcing the need for improved awareness and understanding of lung cancer in non-smokers. Overall, the purpose is to inform healthcare professionals about the unique aspects of lung cancer in non-smokers, encouraging further research and attention in this area.","cancer, breast, lung",rochepro.fr,Flat,0.731299721213784,medium,311,Disease Information
401,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/cancer-bronchique/pour-vos-patients/parcours-non-fumeur-symptomes-cancer-bronchique-therapie-ciblee-00001928.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vos_patients_parcours_non_fumeur_symptomes_cancer_bronchique_therapie_ciblee_00001928_pdf.txt,200,pdf,Non-Indexable,3,118,0,0,3,2,0.905940594059406,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-bronchique_pour-vos-patients_parcours-non-fumeur-symptomes-cancer-bronchique-therapie-ciblee-00001928.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-bronchique_pour-vos-patients_parcours-non-fumeur-symptomes-cancer-bronchique-therapie-ciblee-00001928.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-bronchique_pour-vos-patients_parcours-non-fumeur-symptomes-cancer-bronchique-therapie-ciblee-00001928.pdf.txt,"['NON', 'Path', 'FUMEUR', 'Le', 'SMOKER']",Oncology-Hematology,France,Disease information,"bronchial cancer, difficulty breathing, weight loss, unusual fatigue, biopsy procedures, genetic analysis, personalized treatment options",bronchial cancer,28.825861,-17.13532,12,"The infographic titled ""Le parcours du NON-FUMEUR"" (The Path of the NON-SMOKER) focuses on the journey from experiencing specific symptoms to receiving targeted therapy for bronchial cancer in non-smokers. It outlines symptoms such as difficulty breathing, weight loss, and unusual fatigue that serve as alert signals for seeking medical consultation. The process includes consultations with healthcare providers, diagnostic imaging, tumor suspicion, biopsy procedures, genetic analysis, and ultimately leading to personalized treatment options. The overall message emphasizes the importance of timely diagnosis and intervention.","cancer, breast, lung",rochepro.fr,Flat,0.796624765379203,medium,451,Disease Information
402,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/cancer-du-sein/pour-vous/brochure-regards-croises-definition-parcours-soins-00011029-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_cancer_du_sein_pour_vous_brochure_regards_croises_definition_parcours_soins_00011029_1_pdf.txt,200,pdf,Non-Indexable,3,90,0,0,2,2,0.9,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-du-sein_pour-vous_brochure-regards-croises-definition-parcours-soins-00011029-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-du-sein_pour-vous_brochure-regards-croises-definition-parcours-soins-00011029-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-du-sein_pour-vous_brochure-regards-croises-definition-parcours-soins-00011029-1.pdf.txt,['France'],Oncology-Hematology,France,Disease information,"breast cancer, diagnosis, therapy, personalized care, coordinated treatment plans, lifestyle factors, environmental factors, individualized approaches, oncological care",breast cancer,18.696257,-14.90398,12,"The content discusses the evolving healthcare pathways for breast cancer treatment in France, highlighting advancements in diagnosis, therapy, and support systems. It provides an overview of mortality trends, emphasizing the gradual decline in breast cancer fatalities, and outlines changes in patient care over the past decade. The content illustrates the importance of personalized care and coordinated treatment plans, as well as the impact of lifestyle and environmental factors on breast cancer risk. The overall purpose is to inform about the continuous improvements in breast cancer management and the need for individualized approaches in oncological care.","cancer, breast, lung",rochepro.fr,Rising,0.0863983464135339,medium,341,Disease Information
403,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/cancer-du-sein/pour-vous/brochure-regards-croises-personnalisation-parcours-therapeutique-00011030-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_cancer_du_sein_pour_vous_brochure_regards_croises_personnalisation_parcours_therapeutique_00011030_1_pdf.txt,200,pdf,Non-Indexable,3,71,0,0,2,2,0.907216494845361,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-du-sein_pour-vous_brochure-regards-croises-personnalisation-parcours-therapeutique-00011030-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-du-sein_pour-vous_brochure-regards-croises-personnalisation-parcours-therapeutique-00011030-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-du-sein_pour-vous_brochure-regards-croises-personnalisation-parcours-therapeutique-00011030-1.pdf.txt,['France'],Oncology-Hematology,France,Disease information,"breast cancer, therapeutic progress, personalized treatment approaches, multidisciplinary consultations, surgical practices, outpatient procedures, coordinated care, support programs",breast cancer,19.162199,-15.115315,12,"The extracted content discusses advancements in the management and treatment of breast cancer, particularly highlighting the evolving patient care pathway over the past decade. It explores the reduction in breast cancer mortality due to therapeutic progress, the integration of personalized treatment approaches, the role of multidisciplinary consultations, and developments in surgical practices like outpatient procedures. The content serves to inform stakeholders about key trends and testimonies from healthcare professionals, emphasizing the importance of coordinated care, support programs, and the patient's active role in their treatment journey. Overall, it aims to provide a comprehensive overview of the state of breast cancer care in France and the ongoing efforts to optimize treatment pathways.","cancer, breast, lung",rochepro.fr,Falling,0.214496120679486,medium,262,Disease Information
404,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/cancer-du-sein/pour-vous/cancer-sein-bloc-anatomie-sein-00009025-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_cancer_du_sein_pour_vous_cancer_sein_bloc_anatomie_sein_00009025_1_pdf.txt,200,pdf,Non-Indexable,3,36,0,0,1,1,0.89375,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-du-sein_pour-vous_cancer-sein-bloc-anatomie-sein-00009025-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-du-sein_pour-vous_cancer-sein-bloc-anatomie-sein-00009025-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-du-sein_pour-vous_cancer-sein-bloc-anatomie-sein-00009025-1.pdf.txt,['Anatomie'],Other,France,Disease information,,,-2.5562353,-25.058996,3,"The content appears to be an informational graphic produced by Roche, focused on the topic of breast anatomy, as indicated by the title ""Anatomie du sein."" The illustration features a detailed representation of breast structures, likely aimed at educating viewers about the anatomy for medical or health-related purposes. The overall design is clean and professional, typical for pharmaceutical educational materials.","users, page, website",rochepro.fr,Rising,0.853166258346462,medium,123,Website Metadata
405,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/cancer-du-sein/pour-vous/cancer-sein-module-fatigue-00001779-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_cancer_du_sein_pour_vous_cancer_sein_module_fatigue_00001779_1_pdf.txt,200,pdf,Non-Indexable,3,45,0,0,1,1,0.897435897435898,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-du-sein_pour-vous_cancer-sein-module-fatigue-00001779-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-du-sein_pour-vous_cancer-sein-module-fatigue-00001779-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_cancer-du-sein_pour-vous_cancer-sein-module-fatigue-00001779-1.pdf.txt,['Additional'],Oncology-Hematology,France,Disease information,"breast cancer, cancer-related fatigue, psychological support, physical activity, tailored interventions",breast cancer,25.286314,-16.957966,12,"The content discusses cancer-related fatigue, particularly in breast cancer patients, highlighting its prevalence, defining characteristics, and impact on quality of life. It details the challenges associated with recognizing and assessing fatigue, as well as recommending practical strategies for managing it, including psychological support and physical activity. Additional emphasis is placed on the multifactorial nature of fatigue and the importance of continuous assessment and tailored interventions to enhance patient care during and after cancer treatment. The overall purpose of the content is to inform healthcare providers about the complexities of cancer-related fatigue and to recommend ways to support patients effectively.","cancer, breast, lung",rochepro.fr,Rising,0.703984653972942,medium,449,Disease Information
406,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/formations-miri/module-accompagnement-patients-atteints-chc-00002142-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_formations_miri_module_accompagnement_patients_atteints_chc_00002142_1_pdf.txt,200,pdf,Non-Indexable,3,79,0,0,1,1,0.916230366492147,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_formations-miri_module-accompagnement-patients-atteints-chc-00002142-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_formations-miri_module-accompagnement-patients-atteints-chc-00002142-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_formations-miri_module-accompagnement-patients-atteints-chc-00002142-1.pdf.txt,"['CHC', 'Bobigny', 'Hospital', 'Avicenne', 'Nahon', 'Carcinoma', 'Hepatocellular', 'Professor', 'Its']",Oncology-Hematology,France,Patient support,"Hepatocellular Carcinoma, treatment planning, patient education",Hepatocellular Carcinoma,22.122639,-14.884438,12,"The content appears to be a detailed outline from a pharmaceutical or healthcare content that discusses the initial patient contact and management protocol for suspected Hepatocellular Carcinoma (CHC) at the Avicenne Hospital in Bobigny under the guidance of Professor Nahon. Its purpose is to establish a structured approach for healthcare providers to support patients from their first contact through diagnosis, treatment planning, and ongoing care, emphasizing the importance of communication, psychological support, and coordination among medical professionals. The content also addresses potential complexities in patient care, such as co-morbidities and socio-economic factors, while detailing steps for consultations, treatment announcements, and patient education.","cancer, breast, lung",rochepro.fr,Flat,0.858595491274925,medium,161,Disease Information
407,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/formations-miri/module-carcinome-hepatocellulaire-00002137-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_formations_miri_module_carcinome_hepatocellulaire_00002137_1_pdf.txt,200,pdf,Non-Indexable,3,62,0,0,2,1,0.922651933701657,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_formations-miri_module-carcinome-hepatocellulaire-00002137-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_formations-miri_module-carcinome-hepatocellulaire-00002137-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_formations-miri_module-carcinome-hepatocellulaire-00002137-1.pdf.txt,"['Key', 'France', 'HCC']",Oncology-Hematology,France,Disease information,"hepatocellular carcinoma, HCC, liver cancer, chronic liver diseases, cirrhosis, screening programs","hepatocellular carcinoma, liver cancer, chronic liver diseases, cirrhosis",27.752409,-15.045045,12,"The content provides an extensive overview of hepatocellular carcinoma (HCC), primarily focusing on its epidemiology, causes, and treatment strategies in France, as well as the importance of early diagnosis and screening. It cites various studies and statistics regarding the incidence of liver cancer, the underlying causes such as chronic liver diseases and cirrhosis, and the prognosis associated with different stages of HCC. The content emphasizes the necessity of organized screening programs, particularly for high-risk groups, to improve early detection and treatment outcomes. Key roles of healthcare professionals in coordinating patient care throughout the HCC management process are also highlighted. Overall, the purpose of the content is to draw attention to the increasing burden of HCC and the need for effective screening and treatment pathways within the healthcare system.","cancer, breast, lung",rochepro.fr,Flat,0.250344665746224,medium,453,Disease Information
408,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/formations-miri/module-immunologie-cancer-foie-00002139-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_formations_miri_module_immunologie_cancer_foie_00002139_1_pdf.txt,200,pdf,Non-Indexable,3,56,0,0,1,1,0.915730337078652,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_formations-miri_module-immunologie-cancer-foie-00002139-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_formations-miri_module-immunologie-cancer-foie-00002139-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_formations-miri_module-immunologie-cancer-foie-00002139-1.pdf.txt,['T'],Oncology-Hematology,France,Research,"tumor microenvironments, immune responses, T cells, macrophages, dendritic cells, immune suppression, cytokines, immunotherapy, T cell exhaustion, cancer treatment",,30.666893,-18.114555,12,"The extracted content appears to be a detailed scientific discussion surrounding tumor microenvironments and immune responses in cancer, particularly focusing on the various cell types involved, mechanisms of immune suppression, and the roles of specific cytokines. It references different immune cell populations (like T cells, macrophages, and dendritic cells) and emphasizes their interactions within the tumor microenvironment. The purpose is to provide insights into the complexities of immune response against tumors and the therapeutic implications of targeting these pathways in cancer treatment, especially in relation to immunotherapy and the challenges of T cell exhaustion. Overall, the content is likely aimed at researchers or professionals in oncology and immunology.","cancer, breast, lung",rochepro.fr,Rising,0.0804932879296567,medium,340,Disease Information
409,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/formations-miri/module-traitements-carcinome-hepatocellulaire-00002140-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_formations_miri_module_traitements_carcinome_hepatocellulaire_00002140_1_pdf.txt,200,pdf,Non-Indexable,3,74,0,0,1,1,0.922279792746114,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_formations-miri_module-traitements-carcinome-hepatocellulaire-00002140-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_formations-miri_module-traitements-carcinome-hepatocellulaire-00002140-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_formations-miri_module-traitements-carcinome-hepatocellulaire-00002140-1.pdf.txt,"['France', 'HCC']",Oncology-Hematology,France,Disease information,"hepatocellular carcinoma, liver cirrhosis, palliative options, curative options, surgical resections, liver transplantation, radiofrequency ablation","hepatocellular carcinoma, liver cirrhosis",27.418453,-15.279343,12,"The content discusses the challenges and treatment strategies for hepatocellular carcinoma (HCC) and liver cirrhosis, focusing on diagnostics, treatment options, and prognosis in France. It highlights the prevalence of late-stage diagnosis, the need for better screening, and compares various treatment modalities including palliative and curative options, such as surgical resections, liver transplantation, and innovative therapies like radiofrequency ablation. The content serves to inform medical professionals about the complexities of managing HCC, emphasizing the importance of individualized patient care based on specific clinical criteria and prognostic scores.","cancer, breast, lung",rochepro.fr,All,0.872607740282686,medium,413,Disease Information
410,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/pour-vos-patients/brochure-planches-anatomiques-foie-00007955-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vos_patients_brochure_planches_anatomiques_foie_00007955_1_pdf.txt,200,pdf,Non-Indexable,3,63,0,0,2,2,0.91304347826087,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_brochure-planches-anatomiques-foie-00007955-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_brochure-planches-anatomiques-foie-00007955-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_brochure-planches-anatomiques-foie-00007955-1.pdf.txt,[],Oncology-Hematology,France,Disease information,"fatty liver disease, hepatitis, fibrosis, cirrhosis, liver cancer, hepatocellular carcinoma","fatty liver disease, hepatitis, fibrosis, cirrhosis, liver cancer, hepatocellular carcinoma",27.631575,-8.968498,12,"The content primarily discusses the anatomy and functionality of the liver within the human digestive system. It details the liver’s structure, including its lobes and cells (hepatocytes), and explains its vital functions such as detoxification, protein synthesis, and metabolism of carbohydrates and fats. Additionally, the content addresses liver diseases, including fatty liver disease, hepatitis, fibrosis, cirrhosis, and the development of liver cancer (hepatocellular carcinoma). The purpose of the content seems to be to educate readers about liver health and related medical conditions, potentially in a biomedical or pharmaceutical context, given its reference to Roche.","cancer, breast, lung",rochepro.fr,Flat,0.52437030914371,medium,416,Disease Information
411,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/pour-vos-patients/chc-carnet-suivi-patient-00006742-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vos_patients_chc_carnet_suivi_patient_00006742_1_pdf.txt,200,pdf,Non-Indexable,3,48,0,0,2,2,0.908045977011494,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_chc-carnet-suivi-patient-00006742-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_chc-carnet-suivi-patient-00006742-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_chc-carnet-suivi-patient-00006742-1.pdf.txt,[],Oncology-Hematology,France,Disease information,"liver cancer, hepatocellular carcinoma, treatment options","liver cancer, hepatocellular carcinoma",24.051804,-15.546542,12,"The content appears to be an informational guide intended for patients dealing with liver cancer, specifically hepatocellular carcinoma. It provides detailed information about the disease, including its causes, symptoms, diagnosis, and treatment options, as well as practical advice for patients on managing their health and navigating their treatment journey. The purpose of the content is to educate and empower patients by offering a comprehensive resource that includes contact information for medical teams, recommendations for nutritional and physical well-being, and guidance on communicating effectively with healthcare professionals. There is also a focus on monitoring and support throughout the treatment process to improve patient outcomes.","cancer, breast, lung",rochepro.fr,Rising,0.11570144527328,medium,210,Disease Information
412,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/pour-vos-patients/chc-livret-parcours-soins-professionnels-00009092-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vos_patients_chc_livret_parcours_soins_professionnels_00009092_1_pdf.txt,200,pdf,Non-Indexable,3,100,0,0,2,2,0.910526315789474,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_chc-livret-parcours-soins-professionnels-00009092-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_chc-livret-parcours-soins-professionnels-00009092-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_chc-livret-parcours-soins-professionnels-00009092-1.pdf.txt,[],Other,France,Disease information,"hepatitis, cirrhosis, fatty liver disease, prevention, lifestyle modifications, treatment options, screenings","hepatitis, cirrhosis, fatty liver disease",27.679325,-8.727262,12,"The content appears to be an informational brochure aimed at educating patients, caregivers, and the general public about liver health, diseases, and their management. It discusses various liver functions, potential diseases—such as hepatitis, cirrhosis, and fatty liver disease—and their causes, symptoms, and treatment options. The purpose of the brochure is to emphasize the importance of prevention, lifestyle modifications, and regular medical follow-ups for maintaining liver health. It also outlines the various healthcare professionals involved in the patient's care journey and provides guidance on navigating potential healthcare complexities related to liver diseases. Additionally, it encourages awareness and detection of liver-related health issues through screenings and lifestyle adjustments.","cancer, breast, lung",rochepro.fr,Flat,0.62447472278153,medium,28,Disease Information
413,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/pour-vos-patients/hcc-flyer-temoignages-patients-00009406-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vos_patients_hcc_flyer_temoignages_patients_00009406_1_pdf.txt,200,pdf,Non-Indexable,3,81,0,0,2,2,0.911111111111111,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_hcc-flyer-temoignages-patients-00009406-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_hcc-flyer-temoignages-patients-00009406-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_hcc-flyer-temoignages-patients-00009406-1.pdf.txt,['QR'],Other,France,Patient support,"liver diseases, video testimonials, QR codes, resources",liver diseases,3.4038696,-4.188876,7,"The content is an informative poster created for Roche, focusing on liver diseases and daily life. It invites viewers to access video testimonials from patients sharing their experiences and challenges related to liver illnesses. The content emphasizes collaborative efforts with healthcare experts to provide valuable insights and support for individuals managing these conditions. Additionally, it encourages engagement through QR codes for further resources and videos.","event, exclusive, website",rochepro.fr,Rising,0.335303539778459,medium,161,Events & Patient Care
414,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/pour-vos-patients/memo-patient-chimioembolisation-hepatique-00006619-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vos_patients_memo_patient_chimioembolisation_hepatique_00006619_1_pdf.txt,200,pdf,Non-Indexable,3,66,0,0,2,2,0.916230366492147,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_memo-patient-chimioembolisation-hepatique-00006619-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_memo-patient-chimioembolisation-hepatique-00006619-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_memo-patient-chimioembolisation-hepatique-00006619-1.pdf.txt,['Its'],Oncology-Hematology,France,Disease information,"chemoembolization, liver cancer, chemotherapy drugs",liver cancer,27.41798,-19.768099,12,"The content discusses the process and purpose of chemoembolization as a treatment for liver cancer. It explains how this procedure involves injecting chemotherapy drugs directly into the tumor while simultaneously blocking blood flow to it, thereby depriving cancer cells of oxygen and nutrients. The content also provides anatomical information about the liver, the circumstances under which chemoembolization is recommended, and the steps involved in the procedure, including preparation and post-treatment care. Its primary aim is to inform patients about this treatment option, its benefits, and what to expect during and after the procedure.","cancer, breast, lung",rochepro.fr,Rising,0.865936792926643,medium,213,Disease Information
415,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/pour-vos-patients/memo-patient-ponction-biopsie-hepatique-00006606-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vos_patients_memo_patient_ponction_biopsie_hepatique_00006606_1_pdf.txt,200,pdf,Non-Indexable,3,64,0,0,2,2,0.91005291005291,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_memo-patient-ponction-biopsie-hepatique-00006606-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_memo-patient-ponction-biopsie-hepatique-00006606-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_memo-patient-ponction-biopsie-hepatique-00006606-1.pdf.txt,[],Other,France,Disease information,"liver biopsy, hepatitis, cirrhosis, percutaneous, transjugular","hepatitis, cirrhosis",29.670427,-13.129792,12,"The content discusses the procedure and purpose of performing a liver biopsy, specifically highlighting its role in diagnosing various liver diseases, such as hepatitis and cirrhosis. It outlines the circumstances under which a liver biopsy is recommended, the methods of performing the biopsy (percutaneous and transjugular), and the importance of the biopsy results in guiding patient treatment. Additionally, the content addresses patient concerns regarding the procedure and potential complications, aiming to inform and reassure individuals undergoing this diagnostic exam. Overall, the purpose is to provide comprehensive information on liver biopsy for both healthcare professionals and patients.","cancer, breast, lung",rochepro.fr,All,0.301329686757898,medium,453,Disease Information
416,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/pour-vos-patients/memo-patient-transplantation-hepatique-00006620-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vos_patients_memo_patient_transplantation_hepatique_00006620_1_pdf.txt,200,pdf,Non-Indexable,3,63,0,0,2,2,0.914893617021277,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_memo-patient-transplantation-hepatique-00006620-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_memo-patient-transplantation-hepatique-00006620-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vos-patients_memo-patient-transplantation-hepatique-00006620-1.pdf.txt,"['France', 'Key']",Other,France,Disease information,"liver transplantation, liver diseases, transplantation",liver disease,30.527327,0.74285007,4,"The content provides an overview of liver transplantation in France, detailing the number of patients waiting for and receiving grafts, the criteria for donor allocation, and indications for the procedure. It highlights that approximately 15,000 people have functioning liver grafts, and around 1,300 transplants are performed annually. Key information includes the types of liver diseases that may require transplantation, the process of receiving a graft, and post-operative care. The content aims to educate patients and families about liver transplantation, explaining both the medical and logistical aspects of the procedure.","technologies, artificial, ai",rochepro.fr,Rising,0.573155238306323,medium,197,Technology
417,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/pour-vous/deuxieme-edition-grand-angle-00006643-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_deuxieme_edition_grand_angle_00006643_1_pdf.txt,200,pdf,Non-Indexable,3,87,0,0,3,2,0.911764705882353,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vous_deuxieme-edition-grand-angle-00006643-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vous_deuxieme-edition-grand-angle-00006643-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vous_deuxieme-edition-grand-angle-00006643-1.pdf.txt,"['Liver', 'Barcelona', 'Clinic', 'HCC', 'BCLC', 'Cancer']",Oncology-Hematology,France,Disease information,"hepatocellular carcinoma, HCC, cirrhosis, Barcelona Clinic Liver Cancer (BCLC) system","hepatocellular carcinoma, cirrhosis",27.704851,-15.391424,12,"The content discusses advancements and complexities in the treatment and management of hepatocellular carcinoma (HCC), particularly in patients with cirrhosis. It emphasizes the importance of early detection and personalized care, highlighting the necessity for a multidisciplinary approach involving various specialists for optimized treatment strategies. The content outlines the classification system used for HCC staging, particularly the Barcelona Clinic Liver Cancer (BCLC) system, and stresses the role of general practitioners and gastroenterologists in early screening and coordination of care. Overall, the purpose of the content is to inform healthcare professionals about current therapeutic options and the importance of a collaborative clinical approach in improving patient outcomes for HCC.","cancer, breast, lung",rochepro.fr,Rising,0.944178563219359,medium,52,Disease Information
418,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/pour-vous/premiere-edition-grand-angle-00001366-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_premiere_edition_grand_angle_00001366_1_pdf.txt,200,pdf,Non-Indexable,3,89,0,0,3,2,0.911764705882353,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vous_premiere-edition-grand-angle-00001366-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vous_premiere-edition-grand-angle-00001366-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_carcinome-hepatocellulaire_pour-vous_premiere-edition-grand-angle-00001366-1.pdf.txt,"['States', 'United', 'France', 'HCC']",Oncology-Hematology,France,Disease information,"hepatocellular carcinoma, HCC, chronic liver disease, clinical guidelines, early detection, treatment strategies",hepatocellular carcinoma,28.033722,-15.0627365,12,"The content is a comprehensive overview of hepatocellular carcinoma (HCC), addressing various aspects such as early detection, treatment strategies, and cost-effectiveness analyses in France and the United States. It highlights the complexity of HCC management due to its association with chronic liver disease, the importance of a multidisciplinary approach in patient care, and the need for better screening methods to improve patient outcomes. It also discusses the rising incidence and mortality rates associated with HCC, emphasizing the role of healthcare professionals in optimizing care pathways for patients with this serious condition, and the significance of adherence to clinical guidelines for early detection and treatment initiation. The content serves as a resource for medical professionals to enhance their understanding and coordination in managing HCC effectively.","cancer, breast, lung",rochepro.fr,Falling,0.724377145228957,medium,280,Disease Information
419,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-alcool-cancer-00000108-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_alcool_cancer_00000108_2_pdf.txt,200,pdf,Indexable,3,72,0,0,2,1,0.9,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-alcool-cancer-00000108-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-alcool-cancer-00000108-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-alcool-cancer-00000108-2.pdf.txt,[],Oncology-Hematology,France,Disease information,"breast cancer, colorectal cancer, oral cancer, alcohol dependency","breast cancer, colorectal cancer, oral cancer, alcohol dependency",30.815521,-14.490056,12,"The content discusses the risks associated with alcohol consumption, particularly in relation to cancer and cancer treatments. It emphasizes that drinking more than two glasses of alcohol per day increases the risk of developing various cancers, such as breast, colorectal, and oral cancers. The content advises abstaining from alcohol during cancer treatment due to its harmful effects on treatment efficacy and overall nutritional balance. It also addresses alcohol dependency and encourages individuals to consult health professionals for support and management. Overall, the purpose of this content is to raise awareness about the negative impact of alcohol on health, especially concerning cancer prevention and treatment.","cancer, breast, lung",rochepro.fr,Flat,0.912968796783643,medium,476,Disease Information
420,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-anemie-00003083-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_anemie_00003083_2_pdf.txt,200,pdf,Indexable,3,72,0,0,2,1,0.902097902097902,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-anemie-00003083-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-anemie-00003083-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-anemie-00003083-2.pdf.txt,['B'],Oncology-Hematology,France,Disease information,"anemia, cancer, balanced diet, iron, B vitamins, cancer treatments",anemia,27.706417,-18.473183,12,"The content discusses anemia, particularly in the context of cancer patients, and highlights its causes, symptoms, and treatments. It emphasizes the importance of maintaining a balanced diet rich in iron and B vitamins to prevent and manage anemia. Additionally, the content advises patients not to arbitrarily stop their treatments without medical consultation, suggesting that addressing anemia can help improve their energy and overall well-being. It also touches on the impact of cancer treatments on appetite, weight, and nutrition, encouraging patients to stay active and monitor their dietary habits for better health outcomes.","cancer, breast, lung",rochepro.fr,All,0.297734959639344,medium,412,Disease Information
421,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-biopsie-mammaire-00000311-3.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_biopsie_mammaire_00000311_3_pdf.txt,200,pdf,Indexable,3,73,0,0,2,1,0.901960784313726,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-biopsie-mammaire-00000311-3.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-biopsie-mammaire-00000311-3.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-biopsie-mammaire-00000311-3.pdf.txt,[],Oncology-Hematology,France,Disease information,"breast biopsy, ultrasound, mammography, cancer, diagnostic tool, tissue samples",breast cancer,34.59536,-11.511133,12,"The content is a detailed explanation of the procedures and techniques involved in breast biopsies, particularly those guided by ultrasound or mammography, as well as the purpose behind these interventions. It discusses different types of biopsies, the preparation required for patients, the process during the procedure, and the subsequent analysis of tissue samples to determine the presence of cancer. The aim is to inform patients about what to expect during a breast biopsy, ensuring they understand the importance of this diagnostic tool in confirming or ruling out cancerous lesions.","cancer, breast, lung",rochepro.fr,Flat,0.72540395635065,medium,252,Disease Information
422,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-bronchique-petites-cellules-00000022-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_bronchique_petites_cellules_00000022_2_pdf.txt,200,pdf,Indexable,3,88,0,0,2,1,0.900584795321638,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-bronchique-petites-cellules-00000022-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-bronchique-petites-cellules-00000022-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-bronchique-petites-cellules-00000022-2.pdf.txt,['SCLC'],Oncology-Hematology,France,Disease information,"lung cancer, small cell lung cancer (SCLC), imaging tests, smoking cessation, supportive care, clinical trials, treatment strategies, follow-up process","lung cancer, small cell lung cancer",31.020817,-17.338493,12,"The content is a comprehensive overview of lung cancer, specifically focusing on small cell lung cancer (SCLC) and its diagnosis, treatment, and management. It discusses the importance of imaging tests for diagnosis, the role of specialists, the urgency of initiating treatment, and the different treatment strategies based on the cancer type. Additionally, it highlights the significance of smoking cessation in improving treatment outcomes and prognosis. It also touches on supportive care, clinical trials, and the follow-up process to monitor for recurrence and manage quality of life during and after treatment. Overall, the purpose of the content is to inform patients and healthcare providers about the key aspects of diagnosing and treating lung cancer effectively.","cancer, breast, lung",rochepro.fr,Flat,0.435701267777922,medium,174,Disease Information
423,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-carcinome-basocellulaire-00000526-4.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_carcinome_basocellulaire_00000526_4_pdf.txt,200,pdf,Indexable,3,76,0,0,2,1,0.904761904761905,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-carcinome-basocellulaire-00000526-4.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-carcinome-basocellulaire-00000526-4.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-carcinome-basocellulaire-00000526-4.pdf.txt,['BCC'],Oncology-Hematology,France,Disease information,"basal cell carcinoma, surgery, radiotherapy, early intervention",basal cell carcinoma,32.805885,-13.227001,12,"The extracted content discusses basal cell carcinoma (BCC), the most common type of skin cancer. It outlines risk factors for developing BCC, such as sun exposure, skin type, hereditary factors, and previous health conditions. The content describes the appearance and symptoms of BCC, its prevalence, and the importance of early diagnosis. Additionally, it details treatment options like surgery, radiotherapy, and other methods, emphasizing the effectiveness of early intervention. The purpose of the content is to inform readers about BCC, its risks, symptoms, treatments, and preventive measures to promote skin health and awareness.","cancer, breast, lung",rochepro.fr,Flat,0.0345789641319363,medium,178,Disease Information
424,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-col-uterus-00000524-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_col_uterus_00000524_2_pdf.txt,200,pdf,Indexable,3,77,0,0,2,1,0.896103896103896,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-col-uterus-00000524-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-col-uterus-00000524-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-col-uterus-00000524-2.pdf.txt,"['Papanicolaou', 'HPV', 'Pap', 'Human', 'Papillomavirus']",Oncology-Hematology,France,Disease information,"cervical cancer, Papanicolaou test, Pap smear, HPV, vaccination, treatment protocols, follow-up care",cervical cancer,31.15894,-13.8609,12,"The content discusses cervical cancer, its causes, diagnostic methods, prevention, and treatment options. It highlights the importance of regular screenings, such as the Papanicolaou test (Pap smear), which can detect precancerous lesions and early-stage tumors, significantly improving treatment outcomes. The content also mentions the role of HPV (Human Papillomavirus) in causing cervical cancer and emphasizes vaccination as a preventive measure. Furthermore, it outlines the treatment protocols for different stages of the disease and the importance of follow-up care to ensure quality of life post-treatment. Overall, the content aims to inform about cervical cancer awareness, prevention, and treatment strategies.","cancer, breast, lung",rochepro.fr,Flat,0.703658163955732,medium,473,Disease Information
425,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-colon-alimentation-00002777-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_colon_alimentation_00002777_2_pdf.txt,200,pdf,Indexable,3,64,0,0,2,1,0.901234567901235,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-colon-alimentation-00002777-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-colon-alimentation-00002777-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-colon-alimentation-00002777-2.pdf.txt,[],Oncology-Hematology,France,Patient support,"colorectal cancer, gastrointestinal issues, diarrhea, nausea, vomiting, constipation, colostomy, ileostomy, dietary strategies, balanced diet",colorectal cancer,27.537638,-22.05572,12,"The extracted content discusses dietary considerations for patients undergoing treatment for colorectal cancer, particularly focusing on managing nutritional challenges that may arise due to the disease or its treatments. It highlights various gastrointestinal issues such as diarrhea, nausea, vomiting, and constipation, and presents dietary strategies to alleviate these symptoms. The content emphasizes the importance of a balanced diet to maintain nutritional health and stability during treatment and recovery while underlining specific foods to include or avoid. Additionally, it addresses concerns for patients who have undergone surgeries like colostomy or ileostomy, providing tailored advice for their dietary adjustments. Overall, the purpose is to guide individuals with colorectal cancer in managing their diet to support their health during treatment.","cancer, breast, lung",rochepro.fr,Falling,0.915445215067767,medium,169,Disease Information
426,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-colorectal-00000176-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_colorectal_00000176_2_pdf.txt,200,pdf,Indexable,3,69,0,0,2,1,0.902597402597403,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-colorectal-00000176-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-colorectal-00000176-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-colorectal-00000176-2.pdf.txt,[],Oncology-Hematology,France,Disease information,"colorectal cancer, screening methods, colonoscopy, surgery, chemotherapy",colorectal cancer,29.777634,-13.60407,12,"The content discusses colorectal cancer, focusing on its prevalence, risk factors, symptoms, and screening methods. It highlights the importance of regular screening, particularly for individuals over 50, and explains the various scenarios that warrant closer monitoring, such as a family history of colorectal cancer. Additionally, it outlines diagnostic procedures like colonoscopy, treatment options including surgery and chemotherapy, and public health recommendations for reducing risk factors such as diet and lifestyle choices. The purpose of the content is to inform the public about colorectal cancer, its detection, prevention, and treatment.","cancer, breast, lung",rochepro.fr,Flat,0.438003479623795,medium,237,Disease Information
427,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-ovaire-00003413-3.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_ovaire_00003413_3_pdf.txt,200,pdf,Indexable,3,70,0,0,2,1,0.9,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-ovaire-00003413-3.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-ovaire-00003413-3.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-ovaire-00003413-3.pdf.txt,[],Oncology-Hematology,France,Disease information,"ovarian cancer, surgery, chemotherapy, genetic predisposition",ovarian cancer,31.868874,-14.930822,12,"The content discusses ovarian cancer, its symptoms, diagnosis, treatment options, and associated risks. It highlights the challenges of early detection due to the subtle beginnings of the disease, leading to often late diagnoses. It outlines various treatment methodologies, including surgery and chemotherapy, while noting factors that may contribute to the risk of developing ovarian cancer, such as genetic predisposition. The content also addresses the psychological impact of a cancer diagnosis and the importance of comprehensive care, including emotional support. Overall, the purpose is to inform readers about ovarian cancer's complexities and the importance of medical intervention and support.","cancer, breast, lung",rochepro.fr,Falling,0.454350927121993,medium,47,Disease Information
428,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-poumon-00000178-3.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_poumon_00000178_3_pdf.txt,200,pdf,Indexable,3,68,0,0,2,1,0.9,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-poumon-00000178-3.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-poumon-00000178-3.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-poumon-00000178-3.pdf.txt,['CT'],Oncology-Hematology,France,Disease information,"lung cancer, radiography, CT scans, bronchoscopy, non-small cell lung cancer, small cell lung cancer, personalized treatment plans, follow-up care","lung cancer, non-small cell lung cancer, small cell lung cancer",30.18337,-17.177464,12,"The content discusses the diagnosis, risk factors, types, and treatments of lung cancer, specifically detailing symptoms that should prompt immediate medical consultation. It highlights key diagnostic procedures like radiography, CT scans, and bronchoscopy, along with the significance of tobacco as a primary risk factor. The content also differentiates between two types of lung cancer—non-small cell and small cell—explaining their characteristics and treatment options. Furthermore, it emphasizes the importance of personalized treatment plans and follow-up care post-treatment. Overall, the content serves as an informative guide about lung cancer for patients and healthcare professionals.","cancer, breast, lung",rochepro.fr,Flat,0.256566243623559,medium,68,Disease Information
429,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-prostate-00003414-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_prostate_00003414_2_pdf.txt,200,pdf,Indexable,3,73,0,0,4,3,0.901315789473684,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-prostate-00003414-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-prostate-00003414-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-prostate-00003414-2.pdf.txt,['PSA'],Oncology-Hematology,France,Disease information,"prostate cancer, PSA levels, benign prostatic hyperplasia, rectal examinations, biopsies, surgery, radiotherapy, hormone therapy, focal ultrasound therapy, follow-ups","prostate cancer, benign prostatic hyperplasia",32.305393,-11.8031,12,"The content provides detailed information about prostate cancer, including its diagnosis, treatment options, and management. It discusses the significance of PSA levels in diagnosing prostate conditions, such as benign prostatic hyperplasia and prostate cancer, and describes the diagnostic procedures like rectal examinations and biopsies. The treatment approaches outlined include surgery, radiotherapy, hormone therapy, and emerging techniques like focal ultrasound therapy. It emphasizes that regular follow-ups are crucial for monitoring potential recurrences after treatment. The purpose of the content is to inform readers about prostate cancer, its risks, detection methods, and available treatment options, thereby raising awareness of this common male cancer.","cancer, breast, lung",rochepro.fr,Falling,0.991858289718618,medium,273,Disease Information
430,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-prostate-dosage-psa-00003425-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_prostate_dosage_psa_00003425_2_pdf.txt,200,pdf,Indexable,3,73,0,0,1,1,0.895705521472393,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-prostate-dosage-psa-00003425-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-prostate-dosage-psa-00003425-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-prostate-dosage-psa-00003425-2.pdf.txt,"['PSA', 'Prostate', 'Specific', 'Antigen']",Oncology-Hematology,France,Disease information,"Prostate-Specific Antigen, PSA, prostate cancer, blood test, biopsy",prostate cancer,32.491154,-11.555599,12,"The content discusses the measurement of Prostate-Specific Antigen (PSA) and its significance in the screening and monitoring of prostate cancer. It explains how the PSA level is determined through a simple blood test, highlighting that results are reported in nanograms per milliliter and what these results mean in various contexts—whether for initial screening or ongoing cancer surveillance. The content also mentions that elevated PSA levels do not definitively indicate cancer, as they can result from various factors, and emphasizes the necessity of additional tests, such as a biopsy, for accurate diagnosis. Overall, the content serves to inform readers about the importance and interpretation of PSA testing in relation to prostate health.","cancer, breast, lung",rochepro.fr,All,0.371757261730136,medium,332,Disease Information
431,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-rein-00000177-3.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_rein_00000177_3_pdf.txt,200,pdf,Indexable,3,66,0,0,2,1,0.898648648648649,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-rein-00000177-3.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-rein-00000177-3.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-rein-00000177-3.pdf.txt,[],Oncology-Hematology,France,Disease information,"kidney cancer, imaging, biopsies, partial nephrectomy, immunotherapy, targeted therapies",kidney cancer,29.907768,-16.164146,12,"The content provides an overview of kidney cancer, focusing on diagnosis, treatment, risk factors, and follow-up care. It explains the process of diagnosing kidney tumors through imaging and biopsies, the surgical options available such as partial nephrectomy, and the use of immunotherapy and targeted therapies as treatment methods. Additionally, it outlines the risk factors associated with kidney cancer, emphasizing the importance of early detection and regular monitoring for potential recurrence. The content appears to be educational, aimed at informing patients and healthcare professionals about kidney cancer management.","cancer, breast, lung",rochepro.fr,Flat,0.855540992919333,medium,62,Disease Information
432,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-sein-statut-her2-00000050-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_sein_statut_her2_00000050_2_pdf.txt,200,pdf,Indexable,3,64,0,0,2,1,0.89375,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-sein-statut-her2-00000050-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-sein-statut-her2-00000050-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-sein-statut-her2-00000050-2.pdf.txt,"['IHC', 'HIS', 'Hybridization', 'Situ']",Oncology-Hematology,France,Disease information,"HER2, breast cancer, ImmunoHistoChemistry, Hybridization In Situ, targeted anti-HER2 therapies, HER2-positive tumors",breast cancer,34.96715,-14.256978,12,"The content discusses the importance of assessing HER2 status in breast cancer patients. It explains how the HER2 test is conducted, including two primary techniques—ImmunoHistoChemistry (IHC) and Hybridization In Situ (HIS). The results categorize tumors as HER2 negative, low, uncertain, or positive, guiding treatment options, specifically targeted anti-HER2 therapies for those with positive results. The content provides information on who can order the test, the typical timeframe for results, and highlights that 12-20% of breast cancer patients may have HER2-positive tumors, emphasizing the significance of HER2 status in determining treatment strategies.","cancer, breast, lung",rochepro.fr,Rising,0.387246815043134,medium,40,Disease Information
433,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-sein-triple-negatif-00000227-3.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_sein_triple_negatif_00000227_3_pdf.txt,200,pdf,Indexable,3,84,0,0,2,1,0.895705521472393,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-sein-triple-negatif-00000227-3.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-sein-triple-negatif-00000227-3.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-sein-triple-negatif-00000227-3.pdf.txt,"['Treatment', 'TNBC']",Oncology-Hematology,France,Disease information,"triple-negative breast cancer, BRCA1, BRCA2, chemotherapy, surgery, radiotherapy, immunotherapy, genetic mutations, clinical trials",triple-negative breast cancer,33.26311,-16.060446,12,"The content discusses triple-negative breast cancer (TNBC), highlighting its characteristics, risk factors, treatment options, and the significance of genetic mutations like BRCA1 and BRCA2. It explains that about 15% of breast cancer cases are classified as triple-negative, which lack estrogen, progesterone, and HER2 receptors. Treatment approaches include chemotherapy, surgery, radiotherapy, and immunotherapy, especially for patients with specific genetic mutations. The purpose of the content is to inform patients and healthcare providers about TNBC, its management, and the role of genetic factors in treatment decisions, while also emphasizing the importance of clinical trials for advancing treatment options.","cancer, breast, lung",rochepro.fr,All,0.123032670970625,medium,95,Disease Information
434,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-tete-cou-00005518-3.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_tete_cou_00005518_3_pdf.txt,200,pdf,Indexable,3,81,0,0,2,1,0.894736842105263,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-tete-cou-00005518-3.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-tete-cou-00005518-3.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-tete-cou-00005518-3.pdf.txt,"['UADT', 'HPV']",Oncology-Hematology,France,Disease information,"UADT cancers, pharynx cancer, larynx cancer, oral cavity cancer, smoking, alcohol consumption, human papillomavirus (HPV) infection, surgery, radiotherapy, chemotherapy","cancers of the upper aerodigestive tract, cancers related to the pharynx, cancers related to the larynx, cancers related to the oral cavity",31.8859,-15.2599325,12,"The extracted content discusses the risk factors, diagnosis, and treatment of cancers of the upper aerodigestive tract (UADT), particularly focusing on cancers related to the pharynx, larynx, and oral cavity. It highlights the link between smoking and alcohol consumption with increased cancer risk, the significance of human papillomavirus (HPV) infection, and occupational exposures as potential contributors. The content also outlines symptoms to watch for, the diagnostic process involving various medical specialists, statistical data on UADT cancers, and a detailed description of treatment options, including surgery, radiotherapy, and chemotherapy. Overall, the purpose of the content is to inform and educate readers about UADT cancers, their risk factors, symptoms, and the importance of early diagnosis and comprehensive treatment planning.","cancer, breast, lung",rochepro.fr,Falling,0.145678697086143,medium,38,Disease Information
435,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-cancer-vessie-00000492-4.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_cancer_vessie_00000492_4_pdf.txt,200,pdf,Indexable,3,71,0,0,2,1,0.9,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-vessie-00000492-4.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-vessie-00000492-4.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-cancer-vessie-00000492-4.pdf.txt,[],Oncology-Hematology,France,Disease information,"bladder cancer, cytology, cystoscopy, surgery, chemotherapy, immunotherapy, risk factors, recurrence",bladder cancer,31.383398,-15.250933,12,"The content provides a detailed overview of bladder cancer, covering its diagnosis, treatment options, and follow-up care. It explains the diagnostic procedures such as cytology and cystoscopy, the types of treatments available depending on the tumor's stage (including surgery, chemotherapy, and immunotherapy), and the importance of a multidisciplinary approach in treatment planning. Additionally, the content discusses risk factors for bladder cancer and emphasizes the need for regular monitoring after treatment to manage recurrence. Overall, the purpose of the content is to educate readers about bladder cancer management and the crucial steps involved in diagnosis and treatment.","cancer, breast, lung",rochepro.fr,Rising,0.543701804280855,medium,96,Disease Information
436,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-carcinome-hepatocellulaire-00000182-3.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_carcinome_hepatocellulaire_00000182_3_pdf.txt,200,pdf,Indexable,3,78,0,0,2,1,0.907975460122699,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-carcinome-hepatocellulaire-00000182-3.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-carcinome-hepatocellulaire-00000182-3.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-carcinome-hepatocellulaire-00000182-3.pdf.txt,"['HCC', 'CT']",Oncology-Hematology,France,Disease information,"hepatocellular carcinoma, HCC, CT scans, MRIs, cirrhosis, surgical procedures, radiofrequency ablation, targeted therapies","hepatocellular carcinoma, liver cancer, cirrhosis",29.416039,-14.518313,12,"The extracted content discusses the diagnosis, symptoms, and treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. It emphasizes the importance of imaging techniques such as CT scans and MRIs in diagnosing liver tumors and monitoring liver health. The content also addresses risk factors, particularly cirrhosis, and outlines various treatment options, including surgical procedures, radiofrequency ablation, and targeted therapies. Additionally, it highlights the significance of regular medical follow-ups for patients with liver conditions. Overall, the purpose of the content is to provide information about HCC for better awareness, diagnosis, and treatment planning.","cancer, breast, lung",rochepro.fr,All,0.582978807649436,medium,458,Disease Information
437,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-coloscopie-00001515-4.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_coloscopie_00001515_4_pdf.txt,200,pdf,Indexable,3,46,0,0,2,1,0.904761904761905,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-coloscopie-00001515-4.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-coloscopie-00001515-4.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-coloscopie-00001515-4.pdf.txt,[],Other,France,Disease information,"colonoscopy, dietary restrictions, laxatives, polyps, colorectal issues",,32.31156,-3.1477015,4,"The extracted content discusses the preparation, procedure, and implications of a colonoscopy, a medical examination used to visualize the inner lining of the colon. It emphasizes the importance of proper preparation for the exam, including dietary restrictions and the use of laxatives to ensure a clean colon. The content details what the procedure entails, potential findings such as polyps or other abnormalities, and explains the subsequent steps for analysis and treatment. It serves to inform patients about the importance of colonoscopy as a reliable screening method for colorectal issues and outlines what they can expect during and after the procedure.","technologies, artificial, ai",rochepro.fr,Falling,0.3930316251287,medium,346,Technology
438,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-comprendre-analyses-sang-00003079-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_comprendre_analyses_sang_00003079_2_pdf.txt,200,pdf,Indexable,3,76,0,0,1,1,0.900621118012422,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-comprendre-analyses-sang-00003079-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-comprendre-analyses-sang-00003079-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-comprendre-analyses-sang-00003079-2.pdf.txt,"['LDH', 'GGT']",CVRM,France,Disease information,"diabetes, cancer, liver health, LDH, GGT, complete blood counts, hemoglobin, platelet levels","diabetes, liver disease, cancer",30.280851,-3.592861,4,"The content discusses various biological markers and blood tests relevant for monitoring health, especially in the context of diabetes, liver health, and cancer. It explains how intense physical activity can affect blood sugar levels, the significance of different enzymes such as LDH and GGT, and the implications of results from complete blood counts (like hemoglobin and platelet levels). The purpose of this content is to educate readers about interpreting blood test results, understanding normal ranges for various markers, and recognizing the importance of regular monitoring during medical treatment. Additionally, it emphasizes the need to consult healthcare professionals for proper interpretation of test results.","technologies, artificial, ai",rochepro.fr,Falling,0.475061036599535,medium,81,Technology
439,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-diarrhee-chimiotherapie-00000210-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_diarrhee_chimiotherapie_00000210_2_pdf.txt,200,pdf,Indexable,3,69,0,0,2,1,0.90625,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-diarrhee-chimiotherapie-00000210-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-diarrhee-chimiotherapie-00000210-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-diarrhee-chimiotherapie-00000210-2.pdf.txt,[],Oncology-Hematology,France,Patient support,,,27.479809,-21.942009,12,"The extracted content provides detailed guidance on managing diarrhea, particularly as a side effect of cancer treatment. It emphasizes the importance of hydration, recommending specific amounts and types of fluids to drink. The content outlines dietary recommendations to minimize diarrhea, suggesting easily digestible foods and cautioning against fibrous or fatty items. Additionally, it stresses the necessity of informing healthcare providers about any symptoms, as early intervention is crucial to avoid complications like dehydration. Overall, the content aims to educate patients on how to manage this side effect effectively, ensuring their overall well-being during treatment.","cancer, breast, lung",rochepro.fr,Flat,0.933930970783381,medium,163,Disease Information
440,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-effets-indesirables-peau-ongles-00000359-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_effets_indesirables_peau_ongles_00000359_2_pdf.txt,200,pdf,Indexable,3,61,0,0,2,1,0.898809523809524,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-effets-indesirables-peau-ongles-00000359-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-effets-indesirables-peau-ongles-00000359-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-effets-indesirables-peau-ongles-00000359-2.pdf.txt,[],Oncology-Hematology,France,Patient support,"chemotherapy, targeted therapies, skin reactions, acne, hypoallergenic makeup, psychological impact, dermatological effects, side effects",,27.83227,-22.485138,12,"The extracted content discusses the side effects of cancer treatments, specifically chemotherapy and targeted therapies, focusing on skin and nail issues. It describes various skin reactions that can resemble acne and occur in visible areas like the face and torso. Additionally, the content provides tips for using hypoallergenic makeup to conceal these skin issues and emphasizes the psychological impact of visible side effects on patients' quality of life. It also addresses other potential effects on nails and provides guidance for managing these side effects through protective measures and medical consultation. Overall, the purpose of the content is to inform patients about the possible dermatological effects of cancer treatments and offer practical advice for coping with them.","cancer, breast, lung",rochepro.fr,Rising,0.0077507941973199,medium,235,Disease Information
441,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-effets-secondaires-chimiotherapie-00003782-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_effets_secondaires_chimiotherapie_00003782_2_pdf.txt,200,pdf,Indexable,3,76,0,0,2,1,0.905882352941177,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-effets-secondaires-chimiotherapie-00003782-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-effets-secondaires-chimiotherapie-00003782-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-effets-secondaires-chimiotherapie-00003782-2.pdf.txt,[],Oncology-Hematology,France,Disease information,"chemotherapy, cancer treatment, side effects, fatigue, hair loss, changes in blood cell counts, supportive care",,27.81416,-20.427374,12,"The content focuses on the side effects of chemotherapy as part of cancer treatment, describing how these effects can manifest at different stages of the treatment process and vary from person to person. It covers the causes of side effects, such as the impact on rapidly dividing cells, both cancerous and healthy. The content also emphasizes the importance of supportive care in managing these side effects to improve patients' quality of life. It provides detailed information on various side effects, including fatigue, hair loss, and changes in blood cell counts, while encouraging communication with healthcare teams for appropriate management and support. Overall, the purpose of the content is to inform patients about the nature of chemotherapy, potential side effects, and available supportive measures.","cancer, breast, lung",rochepro.fr,All,0.603438458351674,medium,446,Disease Information
442,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-essentiel-fatigue-cancer-00000329-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_essentiel_fatigue_cancer_00000329_2_pdf.txt,200,pdf,Indexable,3,74,0,0,2,1,0.900621118012422,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-essentiel-fatigue-cancer-00000329-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-essentiel-fatigue-cancer-00000329-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-essentiel-fatigue-cancer-00000329-2.pdf.txt,[],Oncology-Hematology,France,Patient support,"cancer-related fatigue, chemotherapy, radiation, management strategies, coping with fatigue, healthy routine, physical activity",cancer-related fatigue,24.994608,-16.872604,12,"The content discusses the impact of cancer-related fatigue, which is a chronic feeling of exhaustion experienced by many cancer patients due to the disease and its treatments, such as chemotherapy and radiation. It emphasizes that this fatigue is often more severe than typical fatigue and can significantly affect patients' quality of life, including their physical and social interactions. The purpose of the content is to raise awareness about the importance of recognizing and addressing cancer-related fatigue, encouraging patients to communicate with their healthcare team about their experiences and explore different management strategies. It also provides practical advice on coping with fatigue, including maintaining a healthy routine, physical activity, and open communication with loved ones.","cancer, breast, lung",rochepro.fr,All,0.377918686673953,medium,215,Disease Information
443,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-fibroscopie-bronchique-00003431-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_fibroscopie_bronchique_00003431_2_pdf.txt,200,pdf,Indexable,3,58,0,0,2,1,0.905660377358491,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-fibroscopie-bronchique-00003431-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-fibroscopie-bronchique-00003431-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-fibroscopie-bronchique-00003431-2.pdf.txt,[],Oncology-Hematology,France,Disease information,"bronchial fibroscopy, lung cancer, types of anesthesia, pain, risks, recovery",lung cancer,29.137346,-13.895156,12,"The content discusses the procedure and details surrounding bronchial fibroscopy, a medical examination that allows direct visualization of the trachea and bronchi to diagnose conditions such as lung cancer. It outlines pre-examination requirements, the steps of the procedure, types of anesthesia used, potential discomfort, and post-examination care. The purpose of this content is to inform patients about what to expect during the procedure, its significance in diagnosing and monitoring lung conditions, and to address common concerns regarding pain, risks, and recovery.","cancer, breast, lung",rochepro.fr,Flat,0.452816894716633,medium,36,Disease Information
444,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-hormonotherapie-effets-secondaires-00004457-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_hormonotherapie_effets_secondaires_00004457_2_pdf.txt,200,pdf,Indexable,3,94,0,0,2,1,0.906432748538012,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-hormonotherapie-effets-secondaires-00004457-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-hormonotherapie-effets-secondaires-00004457-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-hormonotherapie-effets-secondaires-00004457-2.pdf.txt,[],Oncology-Hematology,France,Medication information,"hormone therapy, breast cancer, anti-estrogens, aromatase inhibitors, side effects, physical activity",breast cancer,32.356174,-21.257486,12,"The content provides comprehensive information about hormone therapy for breast cancer, addressing its purpose, effectiveness, and associated side effects. It explains the different types of hormone therapies, including anti-estrogens and aromatase inhibitors, as well as their clinical applications, whether post-surgery, pre-surgery, or for metastatic cases. The content highlights the significance of monitoring side effects, which can affect patients' quality of life and treatment adherence, as many women discontinue therapy due to these issues. It also emphasizes the importance of communication between patients and healthcare providers and outlines potential solutions to manage side effects, including physical activity and other supportive measures. Overall, the content aims to inform both patients and healthcare professionals about the benefits and challenges of hormone therapy in breast cancer treatment.","cancer, breast, lung",rochepro.fr,All,0.287294318116666,medium,88,Disease Information
445,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-immunotherapie-effets-indesirables-00005101-3.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_immunotherapie_effets_indesirables_00005101_3_pdf.txt,200,pdf,Indexable,3,81,0,0,2,1,0.906432748538012,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-immunotherapie-effets-indesirables-00005101-3.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-immunotherapie-effets-indesirables-00005101-3.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-immunotherapie-effets-indesirables-00005101-3.pdf.txt,[],Oncology-Hematology,France,Disease information,"immunotherapy, cancer, chemotherapy, side effects, treatment",,30.957235,-19.105114,12,"The content discusses immunotherapy in oncology, focusing on its purpose, mechanism, benefits, and potential side effects. It explains how immunotherapy works by activating the immune system to fight cancer cells, contrasting it with traditional chemotherapy. The content also emphasizes the importance of monitoring for side effects, which can occur after starting treatment or even after it has concluded, and encourages patients to report any new symptoms to their healthcare team. It provides a detailed overview of possible adverse effects, their management, and the classification of severity. Overall, the content serves to inform patients about immunotherapy and prepare them for what to expect during treatment.","cancer, breast, lung",rochepro.fr,Rising,0.310708507063424,medium,301,Disease Information
446,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-leucemie-lymphoide-chronique-00003516-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_leucemie_lymphoide_chronique_00003516_2_pdf.txt,200,pdf,Indexable,3,75,0,0,2,1,0.903030303030303,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-leucemie-lymphoide-chronique-00003516-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-leucemie-lymphoide-chronique-00003516-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-leucemie-lymphoide-chronique-00003516-2.pdf.txt,"['B', 'CLL']",Oncology-Hematology,France,Disease information,"chronic lymphocytic leukemia (CLL), blood cancer, B lymphocytes, symptoms, lymphocyte levels, infections, anemia, clinical follow-up, hematologist","chronic lymphocytic leukemia, anemia",28.40147,-18.58507,12,"The content provides an overview of chronic lymphocytic leukemia (CLL), a type of blood cancer affecting B lymphocytes. It discusses the disease's characteristics, diagnostic procedures, and stages, emphasizing the slow evolution of CLL compared to other types of leukemia. The content also outlines common symptoms, the importance of monitoring lymphocyte levels, and potential complications such as infections and anemia. Additionally, it highlights the need for regular clinical follow-up with a hematologist to manage the disease effectively. Overall, the purpose is to educate readers about CLL, its diagnosis, management, and the importance of ongoing medical care.","cancer, breast, lung",rochepro.fr,Rising,0.85670301865709,medium,326,Disease Information
447,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-lymphome-non-hodgkinien-00000571-3.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_lymphome_non_hodgkinien_00000571_3_pdf.txt,200,pdf,Indexable,3,70,0,0,2,1,0.9,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-lymphome-non-hodgkinien-00000571-3.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-lymphome-non-hodgkinien-00000571-3.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-lymphome-non-hodgkinien-00000571-3.pdf.txt,"['NHL', 'Hodgkin']",Oncology-Hematology,France,Disease information,"non-Hodgkin lymphoma, NHL, biopsies, imaging tests, blood work, symptoms, treatments",non-Hodgkin lymphoma,28.120277,-18.178192,12,"The content discusses non-Hodgkin lymphoma (NHL), a type of cancer that affects the immune system, specifically the lymphatic system. It describes the diagnostic process, which includes biopsies, imaging tests, and blood work to determine the presence and extent of the disease. The classification and progression of NHL are explained, along with its symptoms and potential treatments, which can vary based on the type and stage of the lymphoma. The purpose of the content is to provide comprehensive information about NHL for patients and their families, aiming to improve understanding and management of the condition.","cancer, breast, lung",rochepro.fr,Falling,0.982400343617268,medium,178,Disease Information
448,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-mammographie-00003143-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_mammographie_00003143_2_pdf.txt,200,pdf,Indexable,3,59,0,0,2,1,0.906040268456376,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-mammographie-00003143-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-mammographie-00003143-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-mammographie-00003143-2.pdf.txt,[],Oncology-Hematology,France,Disease information,"mammography, breast cancer, early detection, screenings, double readings, overdiagnosis, recovery rates, national screening programs",breast cancer,33.404263,-10.966428,12,"The content discusses the process and importance of mammography, a medical examination used for the early detection of breast cancer. It outlines preparation guidelines for patients, the examination procedure, and the significance of participating in regular screenings, particularly for women aged 50 to 74. It emphasizes the need for a structured approach in analyzing mammogram results, including double readings by radiologists to enhance reliability. Additionally, the content also touches on the potential for overdiagnosis while underlining that early detection and treatment significantly improve recovery rates in breast cancer cases. The content aims to educate and inform women about breast cancer screening and encourage participation in national screening programs.","cancer, breast, lung",rochepro.fr,Flat,0.487115796626408,medium,112,Disease Information
449,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-melanome-00002917-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_melanome_00002917_2_pdf.txt,200,pdf,Indexable,3,60,0,0,2,1,0.903448275862069,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-melanome-00002917-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-melanome-00002917-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-melanome-00002917-2.pdf.txt,"['Diameter', 'Evolution', 'ABCDE', 'Color', 'France', 'Asymmetry', 'Border']",Oncology-Hematology,France,Disease information,"melanoma, ABCDE rule, surgery, immunotherapy, imaging tests",melanoma,33.048344,-13.03898,12,"The content discusses melanoma, a malignant skin cancer that primarily develops from pigment-producing cells (melanocytes). It outlines the diagnostic criteria using the ABCDE rule (Asymmetry, Border irregularity, Color variation, Diameter increase, and Evolution) to identify suspicious moles. The content emphasizes the importance of early medical consultation when signs of melanoma are observed, detailing the examination process by dermatologists and subsequent treatments that may include surgery, immunotherapy, and imaging tests to assess potential metastasis. Additionally, it highlights risk factors, types of melanoma, and the growth of melanoma cases in France, providing important information for patient education and awareness regarding skin cancer prevention, diagnosis, and treatment.","cancer, breast, lung",rochepro.fr,Flat,0.978480907216894,medium,260,Disease Information
450,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-mucites-traitement-cancer-00000128-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_mucites_traitement_cancer_00000128_2_pdf.txt,200,pdf,Indexable,3,44,0,0,2,1,0.901234567901235,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-mucites-traitement-cancer-00000128-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-mucites-traitement-cancer-00000128-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-mucites-traitement-cancer-00000128-2.pdf.txt,[],Oncology-Hematology,France,Disease information,"mucositis, chemotherapy, radiotherapy, dietary suggestions, oral care practices, therapeutic interventions",mucositis,26.124813,-20.225693,12,"The content discusses the topic of mucositis, a common side effect of chemotherapy and radiotherapy, particularly its causes, risk factors, and management strategies. It highlights that mucositis often results from the cytotoxic effects of certain medications and treatment methods that damage rapidly dividing cells, including those in the oral mucosa. The content emphasizes individual risk factors such as age, genetic predispositions, and the importance of dental hygiene in preventing mucositis. It also provides recommendations for managing and treating the condition, including dietary suggestions, oral care practices, and potential therapeutic interventions. The purpose of the content is to inform patients and healthcare professionals about mucositis and strategies to mitigate its effects during cancer treatment.","cancer, breast, lung",rochepro.fr,Flat,0.836323911708843,medium,321,Disease Information
451,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-perfusion-chimiotherapie-00000370-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_perfusion_chimiotherapie_00000370_2_pdf.txt,200,pdf,Indexable,3,77,0,0,2,1,0.906832298136646,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-perfusion-chimiotherapie-00000370-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-perfusion-chimiotherapie-00000370-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-perfusion-chimiotherapie-00000370-2.pdf.txt,[],Oncology-Hematology,France,Patient support,"chemotherapy, patient care, individualization of treatment, administration of chemotherapy, monitoring, adjusting treatment, communication, side effects, personalized support",,-19.607872,-9.046496,0,"The content discusses chemotherapy treatment protocols, specifically highlighting the patient care process provided by Roche. It covers various aspects such as the individualization of treatment based on the patient's medical condition, the administration of chemotherapy either in a hospital or at home, and the role of healthcare professionals in monitoring and adjusting treatment. The content also emphasizes the importance of communication between patients and the healthcare team to manage side effects and optimize care. Overall, the purpose is to educate patients on what to expect during chemotherapy and the level of personalized support they will receive throughout their treatment journey.","oncology, professionals, data",rochepro.fr,Rising,0.976157602505067,medium,93,General Offer Outline
452,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-perte-cheveux-traitement-cancer-00003082-3.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_perte_cheveux_traitement_cancer_00003082_3_pdf.txt,200,pdf,Indexable,3,73,0,0,2,1,0.898809523809524,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-perte-cheveux-traitement-cancer-00003082-3.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-perte-cheveux-traitement-cancer-00003082-3.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-perte-cheveux-traitement-cancer-00003082-3.pdf.txt,[],Oncology-Hematology,France,Patient support,"chemotherapy, alopecia, cooling cap, hair loss management","alopecia, cancer",28.148375,-19.775082,12,"The content discusses the impact of chemotherapy on hair loss, specifically focusing on alopecia, which is a common side effect of cancer treatments. It provides advice on minimizing hair loss, such as avoiding harsh hair treatments and using a cooling cap during chemotherapy sessions to reduce blood flow to hair follicles. The content emphasizes that hair loss can be a traumatic experience, affecting self-content, but reassures readers that hair typically regrows after treatment ends. It also offers information on wig options and financial assistance for patients seeking hair replacement solutions, encouraging proactive choices regarding hair loss management during cancer treatment.","cancer, breast, lung",rochepro.fr,Falling,0.392305892009272,medium,36,Disease Information
453,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-radiotherapie-cancer-00000363-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_radiotherapie_cancer_00000363_2_pdf.txt,200,pdf,Indexable,3,61,0,0,2,1,0.904458598726115,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-radiotherapie-cancer-00000363-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-radiotherapie-cancer-00000363-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-radiotherapie-cancer-00000363-2.pdf.txt,[],Oncology-Hematology,France,Disease information,"radiotherapy, cancer, tumor volume, radiotherapy mechanisms, external radiotherapy, internal radiotherapy, brachytherapy, cancer recurrence, cancer treatment",,32.184704,-17.956852,12,"The content discusses the use of radiotherapy as a treatment for cancer. It explains how radiotherapy aims to reduce tumor volume, facilitate surgical interventions, and minimize the risk of cancer recurrence. The content outlines the mechanisms of radiotherapy, such as how radiation destroys cancer cells by inhibiting their ability to multiply, while also potentially affecting healthy tissue, leading to side effects. It further details the types of radiotherapy, including external and internal (brachytherapy), and addresses the planning, administration, and follow-up of treatment, emphasizing its importance in the management of various cancer types. Overall, the content serves to educate readers about radiotherapy, its procedures, and its role in cancer treatment.","cancer, breast, lung",rochepro.fr,Falling,0.443682867884583,medium,386,Disease Information
454,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-resultats-biopsie-mammaire-00003144-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_resultats_biopsie_mammaire_00003144_2_pdf.txt,200,pdf,Indexable,3,80,0,0,2,1,0.901840490797546,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-resultats-biopsie-mammaire-00003144-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-resultats-biopsie-mammaire-00003144-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-resultats-biopsie-mammaire-00003144-2.pdf.txt,['MRI'],Oncology-Hematology,France,Disease information,"breast cancer, diagnostic techniques, mammography, ultrasound, MRI, breast biopsy, ductal carcinoma, lobular carcinoma, laboratory analysis, biopsy samples, cancer type, cancer grade, receptor status, treatment options","breast cancer, ductal carcinoma, lobular carcinoma",34.672955,-12.667729,12,"The content discusses breast cancer, focusing on diagnostic techniques such as mammography, ultrasound, and MRI, which help visualize potential tumors. It emphasizes the importance of breast biopsy for confirming cancer diagnosis and describes various types of breast cancer, including ductal and lobular carcinoma, highlighting their characteristics. The content explains the significance of laboratory analysis of biopsy samples for determining cancer type, grade, and receptor status, which inform treatment options. Additionally, it addresses the emotional concerns patients may have regarding biopsy procedures and the interpretation of test results. Overall, the purpose of the content is to provide information on breast cancer diagnosis and treatment, promoting awareness and understanding among patients.","cancer, breast, lung",rochepro.fr,All,0.7278738343053,medium,387,Disease Information
455,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-syndrome-main-pied-cancer-00003142-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_syndrome_main_pied_cancer_00003142_2_pdf.txt,200,pdf,Indexable,3,78,0,0,2,1,0.895061728395062,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-syndrome-main-pied-cancer-00003142-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-syndrome-main-pied-cancer-00003142-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-syndrome-main-pied-cancer-00003142-2.pdf.txt,[],Oncology-Hematology,France,Patient support,"hand-foot syndrome, chemotherapy, targeted therapy, symptoms, stages of severity, skincare, hydration, skin irritants, symptom management",hand-foot syndrome,25.716057,-0.689543,4,"The provided content discusses the management and treatment of hand-foot syndrome (syndrome main-pied), a side effect associated with certain chemotherapy and targeted therapy treatments. It outlines symptoms, stages of severity, and recommendations for prevention and relief. The purpose of the content is to offer guidance on skincare and practical measures for patients experiencing this condition, emphasizing the importance of hydration, avoiding skin irritants, and consulting healthcare providers for effective symptom management.","technologies, artificial, ai",rochepro.fr,Rising,0.0314369928533931,medium,247,Technology
456,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-traitements-cancer-00000229-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_traitements_cancer_00000229_2_pdf.txt,200,pdf,Indexable,3,77,0,0,2,1,0.903225806451613,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-traitements-cancer-00000229-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-traitements-cancer-00000229-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-traitements-cancer-00000229-2.pdf.txt,['Its'],Oncology-Hematology,France,Disease information,"chemotherapy, surgery, radiotherapy, hormone therapy, immunotherapy, targeted therapies, methods of administration, potential side effects",,30.999762,-19.56846,12,"The content discusses various cancer treatments, particularly chemotherapy, surgery, radiotherapy, hormone therapy, immunotherapy, and targeted therapies. Its purpose is to inform readers about the different types of treatments available for cancer, how they work, and their intended effects on cancer cells. It explains the methods of administration, potential side effects, and the ways these treatments can be combined. The focus is on providing an overview of how these treatments aim to eliminate cancer cells while considering the unique characteristics of each patient's condition.","cancer, breast, lung",rochepro.fr,Rising,0.24963416937184,medium,63,Disease Information
457,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/fiches-info-patients/fiche-info-tumeur-cerveau-glioblastome-00000525-3.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_fiches_info_patients_fiche_info_tumeur_cerveau_glioblastome_00000525_3_pdf.txt,200,pdf,Indexable,3,64,0,0,2,1,0.902439024390244,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-tumeur-cerveau-glioblastome-00000525-3.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-tumeur-cerveau-glioblastome-00000525-3.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_fiches-info-patients_fiche-info-tumeur-cerveau-glioblastome-00000525-3.pdf.txt,"['CT', 'MRI']",Oncology-Hematology,France,Disease information,"glioblastoma, MRI, CT scans, surgery, radiotherapy, chemotherapy",glioblastoma,20.9213,29.059805,4,"The content discusses the diagnosis and treatment of glioblastoma, a common and aggressive type of brain cancer. It outlines the crucial role of healthcare professionals, especially neurologists and neuro-oncologists, in guiding patients through the diagnostic process, which includes neurological examinations and imaging tests like MRI and CT scans. Furthermore, it describes the symptoms associated with glioblastoma, such as persistent headaches and coordination issues, and the multidisciplinary approach to treatment, which may involve surgery, radiotherapy, and chemotherapy. Overall, the content aims to inform readers about glioblastoma, its diagnosis, symptoms, and treatment options, highlighting the importance of a coordinated medical team in managing this serious condition.","technologies, artificial, ai",rochepro.fr,Flat,0.14880516974539,medium,401,Technology
458,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/had/pour-vos-patients/brochure-hospitalisation-domicile-00005842-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_had_pour_vos_patients_brochure_hospitalisation_domicile_00005842_1_pdf.txt,200,pdf,Non-Indexable,4,65,0,0,1,1,0.9125,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vos-patients_brochure-hospitalisation-domicile-00005842-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vos-patients_brochure-hospitalisation-domicile-00005842-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vos-patients_brochure-hospitalisation-domicile-00005842-1.pdf.txt,['HAD'],Other,France,Patient support,,,1.8772738,3.6126273,7,"The content discusses hospital-at-home (HAD) services provided by Roche, aimed at improving the quality of life for patients with serious or terminal illnesses. It outlines the benefits of HAD, including reduced hospital stays, minimal travel, personalized treatment plans, and continuous care. The content also addresses common misconceptions about HAD, emphasizing that it is available not just for palliative care but for various serious health conditions. The purpose of the content is to inform patients and their families about HAD services, eligibility criteria, and how to access them while encouraging communication with healthcare providers for more detailed information.","event, exclusive, website",rochepro.fr,Rising,0.226425516397732,medium,181,Events & Patient Care
459,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/had/pour-vous/hospitalisation-domicile-feuille-route-nationale-2021-2026-00003020-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_had_pour_vous_hospitalisation_domicile_feuille_route_nationale_2021_2026_00003020_1_pdf.txt,200,pdf,Non-Indexable,4,65,0,0,1,1,0.903954802259887,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-feuille-route-nationale-2021-2026-00003020-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-feuille-route-nationale-2021-2026-00003020-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-feuille-route-nationale-2021-2026-00003020-1.pdf.txt,"['HAD', 'Hospitalization', 'Home']",Other,France,Research,,,27.108646,13.979271,4,"The content discusses the role of Hospitalization at Home (HAD) services provided by healthcare professionals, highlighting their significance for patients of all ages who suffer from serious medical conditions that require hospital-level care without the need for traditional hospitalization. It outlines a national roadmap aimed at enhancing the awareness, attractiveness, and integration of HAD services within the healthcare system, focusing on various sectors such as obstetrics, pediatrics, and palliative care. The content also emphasizes the importance of collaboration across healthcare and social services, improving care quality, leveraging digital health technologies, engaging patients and their caregivers, and fostering research and innovation within HAD practices. Overall, the purpose of the content is to advocate for the development and enhancement of HAD services as a vital component of modern healthcare delivery.","technologies, artificial, ai",rochepro.fr,Falling,0.778890700581415,medium,152,Technology
460,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/had/pour-vous/hospitalisation-domicile-module-1-eligibilite-patients-00007399-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_had_pour_vous_hospitalisation_domicile_module_1_eligibilite_patients_00007399_1_pdf.txt,200,pdf,Non-Indexable,4,52,0,0,1,1,0.907514450867052,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-1-eligibilite-patients-00007399-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-1-eligibilite-patients-00007399-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-1-eligibilite-patients-00007399-1.pdf.txt,"['HAD', 'France', 'Hospitalization', 'Home']",Oncology-Hematology,France,Patient support,"Home Hospitalization, chemotherapy, oncological care, patient quality of life, patient admission examples",,19.841793,-15.84045,12,"The extracted content discusses the management of cancer treatment in France, specifically focusing on the role of Home Hospitalization (HAD) in administering chemotherapy and providing follow-up care. It outlines patient eligibility criteria based on various axes, including the patient's condition, their environment, and medical considerations. The purpose of the content is to provide a framework for integrating HAD into oncological care, emphasizing its benefits such as enhancing patient quality of life, reducing hospital visits, and ensuring coordinated care at home while meeting statutory regulations. The content also includes statistical data, patient admission examples, and addresses common questions regarding the administration of chemotherapy in a home setting.","cancer, breast, lung",rochepro.fr,Flat,0.185979434940378,medium,129,Disease Information
461,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/had/pour-vous/hospitalisation-domicile-module-2-enjeux-administratifs-financiers-00006650-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_had_pour_vous_hospitalisation_domicile_module_2_enjeux_administratifs_financiers_00006650_1_pdf.txt,200,pdf,Non-Indexable,4,55,0,0,1,1,0.908108108108108,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-2-enjeux-administratifs-financiers-00006650-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-2-enjeux-administratifs-financiers-00006650-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-2-enjeux-administratifs-financiers-00006650-1.pdf.txt,"['HAD', 'France', 'COVID', 'Hospitalization', 'Home']",Oncology-Hematology,France,Disease information,,,28.703802,10.860691,4,"The content discusses various aspects of Home Hospitalization (HAD) in France, particularly focusing on its application in cancer treatment. It outlines the context and importance of HAD, the financial implications, and the practical aspects of implementing these services. The content emphasizes the growing trend of providing healthcare at home, particularly in light of the pressures on hospitals due to COVID-19. It examines eligibility criteria, types of care available, and funding mechanisms, suggesting that HAD can enhance patient care while alleviating hospital strain. Additionally, it highlights experimental initiatives and international experiences with similar healthcare models to inform future developments in HAD practices.","technologies, artificial, ai",rochepro.fr,Flat,0.19432247189692,medium,349,Technology
462,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/had/pour-vous/hospitalisation-domicile-module-3-role-pds-00006575-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_had_pour_vous_hospitalisation_domicile_module_3_role_pds_00006575_1_pdf.txt,200,pdf,Non-Indexable,4,93,0,0,1,1,0.900621118012422,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-3-role-pds-00006575-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-3-role-pds-00006575-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-3-role-pds-00006575-1.pdf.txt,"['HDJ', 'HAD']",Other,France,Patient support,,,26.760464,9.937452,4,"The content outlines the organization and administration of complex injectable treatments in a home hospitalization setting (HAD) as an alternative to day hospitalizations (HDJ). It discusses the roles of various stakeholders, including prescribing doctors, coordinating nurses, and logistic personnel, in ensuring effective patient care. The content details the key steps in the patient journey, from prescription and preparation to administration and follow-up, emphasizing the importance of coordination and logistics in managing home-based treatments. Overall, the purpose of the content is to provide a comprehensive framework for implementing and optimizing complex injectable treatment pathways in home care settings.","technologies, artificial, ai",rochepro.fr,Rising,0.862666545429976,medium,464,Technology
463,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/had/pour-vous/hospitalisation-domicile-module-4-securiser-circuit-medicaments-00007626-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_had_pour_vous_hospitalisation_domicile_module_4_securiser_circuit_medicaments_00007626_1_pdf.txt,200,pdf,Non-Indexable,4,71,0,0,1,1,0.906593406593407,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-4-securiser-circuit-medicaments-00007626-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-4-securiser-circuit-medicaments-00007626-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-4-securiser-circuit-medicaments-00007626-1.pdf.txt,"['HAD', 'Hospital', 'Home']",Oncology-Hematology,France,Patient support,,,19.874916,-16.119013,12,"The content outlines the guidelines and protocols for managing at-home chemotherapy treatments through Hospital at Home (HAD) programs. It discusses the regulatory framework, the coordination of various healthcare professionals involved in the treatment, and the processes for medication circulation, administration, and waste management. The purpose of the content is to ensure the safe and effective delivery of chemotherapy in a home setting, emphasizing patient eligibility, treatment monitoring, and the roles of different actors within the healthcare system.","cancer, breast, lung",rochepro.fr,Rising,0.251940991523039,medium,436,Disease Information
464,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/had/pour-vous/hospitalisation-domicile-module-5-harmoniser-pratiques-HDJ-HAD-00007361-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_had_pour_vous_hospitalisation_domicile_module_5_harmoniser_pratiques_HDJ_HAD_00007361_1_pdf.txt,200,pdf,Non-Indexable,4,151,0,0,1,1,0.900552486187845,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-5-harmoniser-pratiques-HDJ-HAD-00007361-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-5-harmoniser-pratiques-HDJ-HAD-00007361-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-5-harmoniser-pratiques-HDJ-HAD-00007361-1.pdf.txt,"['HDJ', 'HAD', 'Paris', 'Publique', 'APHP', 'Assistance', 'IDE']",Oncology-Hematology,France,Technology,"anti-tumor treatments, home hospitalization, day hospital, cancer patients, injectable therapies",cancer,20.918783,-15.257192,12,"The content discusses the administration of complex injectable treatments in a home hospitalization setting (HAD) as an alternative to day hospital (HDJ) care, particularly focusing on the experiences and training initiatives at the Assistance Publique - Hôpitaux de Paris (APHP). It outlines specific competencies required for nurses (IDE) in managing anti-tumor treatments, emphasizes the importance of harmonizing practices between HAD and HDJ, and describes the materials and protocols used in these settings. Furthermore, it highlights the need for training programs to address the gaps in knowledge and skills among healthcare professionals involved in home care for cancer patients, ensuring safe and effective treatment administration. The content serves as a comprehensive guide aimed at improving nursing practices and patient care in the context of home-based injectable therapies.","cancer, breast, lung",rochepro.fr,Falling,0.790248063803641,medium,81,Disease Information
465,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/had/pour-vous/hospitalisation-domicile-module-6-organiser-partage-informations-00007627-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_had_pour_vous_hospitalisation_domicile_module_6_organiser_partage_informations_00007627_1_pdf.txt,200,pdf,Non-Indexable,4,102,0,0,1,1,0.907103825136612,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-6-organiser-partage-informations-00007627-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-6-organiser-partage-informations-00007627-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-module-6-organiser-partage-informations-00007627-1.pdf.txt,"['HAD', 'HOPEN', 'Domicile']",Other,France,Technology,,,26.168335,12.69318,4,"The content discusses the organizational specifics and operational procedures of ""Hôpital à Domicile"" (HAD), emphasizing the importance of effective information sharing and care coordination in a home healthcare setting. It highlights the need for secure electronic documentation, real-time communication, and regular training for healthcare professionals involved in patient care. Additionally, it outlines future developments such as patient self-assessment, telemonitoring, and improved treatment administration at home through the HOPEN program, which aims to modernize healthcare facilities and enhance patient outcomes through better information system interoperability.","technologies, artificial, ai",rochepro.fr,Falling,0.456437154876286,medium,202,Technology
466,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/had/pour-vous/hospitalisation-domicile-recommandations-immunotherapie-00002029-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_had_pour_vous_hospitalisation_domicile_recommandations_immunotherapie_00002029_1_pdf.txt,200,pdf,Non-Indexable,4,68,0,0,1,1,0.919540229885058,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-recommandations-immunotherapie-00002029-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-recommandations-immunotherapie-00002029-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_hospitalisation-domicile-recommandations-immunotherapie-00002029-1.pdf.txt,['HAD'],Oncology-Hematology,France,Patient support,"immunotherapy, cancer patients, checkpoint inhibitors, patient education, follow-up, side effects",,32.296726,-19.135725,12,"The extracted content discusses the organization and guidelines for administering immunotherapy at home (HAD) for cancer patients, particularly focusing on the use of checkpoint inhibitors. It outlines the rationale behind home administration, emphasizing improved patient quality of life and support from healthcare systems while addressing potential complications and the need for proper training for medical professionals. The content also details the eligibility criteria for patients, the necessary protocols for treatment, and the importance of patient education and follow-up to ensure safety and effective monitoring of side effects. Overall, it aims to provide structured recommendations for healthcare providers to facilitate safe and efficient home-based immunotherapy for cancer patients.","cancer, breast, lung",rochepro.fr,All,0.161122051480974,medium,322,Disease Information
467,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/had/pour-vous/module-introductif-hospitalisation-domicile-00006574-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_had_pour_vous_module_introductif_hospitalisation_domicile_00006574_1_pdf.txt,200,pdf,Non-Indexable,4,91,0,0,1,1,0.91358024691358,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_module-introductif-hospitalisation-domicile-00006574-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_module-introductif-hospitalisation-domicile-00006574-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_module-introductif-hospitalisation-domicile-00006574-1.pdf.txt,"['HDJ', 'HAD', 'COVID']",Other,France,Patient support,,,26.921358,11.212832,4,"The content discusses the establishment of a healthcare organization for administering complex injectable treatments at home (hospitalization at home or HAD) as an alternative to day hospital services (HDJ). It covers the types of treatments involved, eligibility criteria for patients, practical implementation, and the overall impact on the quality of life for patients receiving these treatments at home, particularly during the COVID-19 pandemic. It includes patients' testimonials, the organization of care teams, and a detailed analysis of the operational framework for integrating HAD into healthcare systems, emphasizing its benefits and the need for a collaborative approach among healthcare professionals. The content aims to provide insights for healthcare providers and decision-makers on implementing HAD effectively.","technologies, artificial, ai",rochepro.fr,Rising,0.881470143893553,medium,87,Technology
468,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/had/pour-vous/presentation-projet-hospitalisation-a-domicile-00006497-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_had_pour_vous_presentation_projet_hospitalisation_a_domicile_00006497_1_pdf.txt,200,pdf,Non-Indexable,4,118,0,0,1,1,0.909090909090909,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_presentation-projet-hospitalisation-a-domicile-00006497-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_presentation-projet-hospitalisation-a-domicile-00006497-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_presentation-projet-hospitalisation-a-domicile-00006497-1.pdf.txt,"['HDJ', 'HAD']",Oncology-Hematology,France,Other,,,26.296902,9.190743,4,"The content details a methodology for establishing a home hospitalization program (HAD) for administering complex injectable treatments as an alternative to day hospital (HDJ) care. It outlines the framework developed through expert consultations and meetings aimed at streamlining care for patients eligible for home treatment, primarily in oncology and hematology. The content serves as a guideline for healthcare professionals, emphasizing administrative, financial, and regulatory considerations necessary for implementing a successful HAD program. It also includes objectives and modules aimed at training staff, ensuring patient eligibility, and organizing treatment protocols.","technologies, artificial, ai",rochepro.fr,Falling,0.910292203738357,medium,364,Technology
469,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/had/pour-vous/rapport-activite-2019-2020-fnehad-00002777-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_had_pour_vous_rapport_activite_2019_2020_fnehad_00002777_1_pdf.txt,200,pdf,Non-Indexable,4,74,0,0,1,1,0.901315789473684,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_rapport-activite-2019-2020-fnehad-00002777-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_rapport-activite-2019-2020-fnehad-00002777-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_rapport-activite-2019-2020-fnehad-00002777-1.pdf.txt,"['FNEHAD', 'Federation', 'French', 'COVID', 'Hospitalization', 'National', 'Home']",Other,France,Research,,,27.474398,11.926898,4,"The content is an annual activity report from the French National Federation of Home Hospitalization (FNEHAD), focusing primarily on the impact of the COVID-19 pandemic on home hospitalization services from 2019 to 2020. It aims to analyze the organization's performance during an unprecedented health crisis, emphasizing the role of home healthcare in delivering patient care, adaptations made to facilitate patient management, and the overall evolution of the healthcare system in response to new challenges. The content highlights the increased need and utilization of home hospitalization, alongside discussions of reforms in healthcare financing and service delivery for an aging population. It serves both as an accountability report and a strategic content outlining future directions for the sector, calling for greater integration and collaboration among healthcare providers.","technologies, artificial, ai",rochepro.fr,Rising,0.495588033395622,medium,349,Technology
470,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/had/pour-vous/rapport-activite-2021-2022-fnehad-00002099-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_had_pour_vous_rapport_activite_2021_2022_fnehad_00002099_1_pdf.txt,200,pdf,Non-Indexable,4,56,0,0,1,1,0.901315789473684,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_rapport-activite-2021-2022-fnehad-00002099-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_rapport-activite-2021-2022-fnehad-00002099-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_had_pour-vous_rapport-activite-2021-2022-fnehad-00002099-1.pdf.txt,"['FNEHAD', 'HAD', 'Federation', 'France', 'French', 'COVID', 'Hospitalization', 'National', 'Home']",Other,France,Other,,,27.537615,11.828261,4,"The extracted content is a report from the French National Federation of Home Hospitalization (FNEHAD) covering its activities for the years 2021-2022. It outlines the organization's role in promoting home hospitalization (HAD) as a viable alternative to conventional hospital care. The report emphasizes FNEHAD's efforts to improve the recognition and operational capacity of HAD within France's healthcare system, supporting nearly 260 affiliated establishments. It addresses challenges faced during the COVID-19 pandemic, ongoing reforms, and the need for better regulatory frameworks, as well as statistics on HAD activities. The report serves as both a performance overview and a call to action for enhancing home hospitalization services across the nation.","technologies, artificial, ai",rochepro.fr,Flat,0.557084378353535,medium,97,Technology
471,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/immuno-oncologie/pour-vous/bilan-routine-traitement-immunotherapie-00002058-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_immuno_oncologie_pour_vous_bilan_routine_traitement_immunotherapie_00002058_1_pdf.txt,200,pdf,Non-Indexable,3,99,0,0,2,2,0.912280701754386,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_immuno-oncologie_pour-vous_bilan-routine-traitement-immunotherapie-00002058-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_immuno-oncologie_pour-vous_bilan-routine-traitement-immunotherapie-00002058-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_immuno-oncologie_pour-vous_bilan-routine-traitement-immunotherapie-00002058-1.pdf.txt,"['C', 'I', 'F']",Immunology,France,Patient support,,,1.0127485,-3.9471657,7,"The content is an informational flyer produced by Roche, focusing on routine assessments required before and during immunotherapy treatments. It emphasizes the importance of these evaluations and mentions collaboration with an associated organization, A.F.I.C. Additionally, it provides contact information and guidelines related to personal data management and patient rights. The design features supportive imagery that conveys a caring interaction between healthcare professionals and patients.","event, exclusive, website",rochepro.fr,Falling,0.605559586851571,medium,421,Events & Patient Care
472,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/immuno-oncologie/pour-vous/poster-immunotherapie-effets-indesirables-00008005-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_immuno_oncologie_pour_vous_poster_immunotherapie_effets_indesirables_00008005_1_pdf.txt,200,pdf,Non-Indexable,3,68,0,0,2,2,0.913294797687861,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_immuno-oncologie_pour-vous_poster-immunotherapie-effets-indesirables-00008005-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_immuno-oncologie_pour-vous_poster-immunotherapie-effets-indesirables-00008005-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_immuno-oncologie_pour-vous_poster-immunotherapie-effets-indesirables-00008005-1.pdf.txt,[],Immunology,France,Medication information,"immunotherapy, fatigue, gastrointestinal issues, dermatological conditions, endocrine disorders, management strategies, patient care, side effects",,9.76188,-31.782415,1,"The content is an infographic from Roche focused on managing adverse effects related to immunotherapy treatments. It categorizes various side effects, including fatigue, gastrointestinal issues, dermatological conditions, and endocrine disorders, providing guidance on their frequency and management strategies. The layout includes sections for specific effects and recommendations for patient care, aiming to support healthcare professionals in monitoring and addressing these side effects effectively. The overall purpose is to enhance understanding and improve patient outcomes in immunotherapy.","drug, reporting, adverse",rochepro.fr,Flat,0.274787701085677,medium,479,Drug Safety
473,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/infirmer-pratique-avancee/brochure-ipa-00008009-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_infirmer_pratique_avancee_brochure_ipa_00008009_1_pdf.txt,200,pdf,Non-Indexable,3,77,0,0,1,1,0.909090909090909,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_infirmer-pratique-avancee_brochure-ipa-00008009-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_infirmer-pratique-avancee_brochure-ipa-00008009-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_infirmer-pratique-avancee_brochure-ipa-00008009-1.pdf.txt,[],Other,France,Patient support,,,26.609417,12.225661,4,"The content discusses the role and responsibilities of advanced practice nurses (APNs) in healthcare, specifically within the context of patient care collaboration between nurses and doctors in various healthcare settings. It highlights improvements in patient access to care, diversified management paths, and enhanced collaboration between primary and hospital care. The content emphasizes the need for specialized training and expertise for APNs, outlining their contributions in patient assessment, clinical decision-making, and the management of complex health conditions, particularly in a multidisciplinary team environment. The purpose of the content is to advocate for the recognition and integration of APNs into the healthcare system, improving both patient outcomes and healthcare delivery efficiency.","technologies, artificial, ai",rochepro.fr,All,0.784239493233668,medium,113,Technology
474,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/onco-hematologie/pour-vous/brochure-ide-src-cadre-immunotherapie-engageant-lt-5-points-cles-00010674-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_onco_hematologie_pour_vous_brochure_ide_src_cadre_immunotherapie_engageant_lt_5_points_cles_00010674_1_pdf.txt,200,pdf,Non-Indexable,3,146,0,0,2,2,0.892857142857143,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_onco-hematologie_pour-vous_brochure-ide-src-cadre-immunotherapie-engageant-lt-5-points-cles-00010674-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_onco-hematologie_pour-vous_brochure-ide-src-cadre-immunotherapie-engageant-lt-5-points-cles-00010674-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_onco-hematologie_pour-vous_brochure-ide-src-cadre-immunotherapie-engageant-lt-5-points-cles-00010674-1.pdf.txt,"['CAR', 'Release', 'Syndrome', 'CRS', 'Cytokine', 'T']",Immunology,France,Disease information,"Cytokine Release Syndrome, CRS, immunotherapies, T lymphocytes, CAR T-cells, bispecific antibodies, symptoms, treatments, multi-organ failure, monitoring, education",Cytokine Release Syndrome,25.460466,-0.5823855,4,"The content discusses the Cytokine Release Syndrome (CRS), a systemic inflammatory reaction associated with certain immunotherapies, particularly those involving T lymphocytes such as CAR T-cells and bispecific antibodies. It outlines the pathophysiology, symptoms, and grading of CRS, emphasizing the importance of prompt identification and management to prevent severe cases, which may lead to multi-organ failure. The content recommends specific treatments based on the severity of the syndrome, and emphasizes the need for careful monitoring and education for patients and caregivers regarding symptoms and contact protocols. Overall, the purpose of the content is to provide healthcare professionals with guidance on understanding, diagnosing, and managing CRS in patients receiving immunotherapy.","technologies, artificial, ai",rochepro.fr,Flat,0.852813281814502,medium,130,Technology
475,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/analyse-interpretation/stat4all-retranscription-module-analyses-intermediaires-etudes-cliniques-00004713-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_analyse_interpretation_stat4all_retranscription_module_analyses_intermediaires_etudes_cliniques_00004713_1_pdf.txt,200,pdf,Non-Indexable,3,98,0,0,2,1,0.91866028708134,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_analyse-interpretation_stat4all-retranscription-module-analyses-intermediaires-etudes-cliniques-00004713-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_analyse-interpretation_stat4all-retranscription-module-analyses-intermediaires-etudes-cliniques-00004713-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_analyse-interpretation_stat4all-retranscription-module-analyses-intermediaires-etudes-cliniques-00004713-1.pdf.txt,"['IDMC', 'AI']",Other,France,Research,,,26.956364,-4.5694785,4,"The content discusses the concept and implementation of interim analyses (AI) in clinical trials, particularly within the context of evaluating the effectiveness and safety of new treatments. It emphasizes the ethical importance of timely communication of results, which can lead to quicker treatment for patients if a new therapy proves effective or reveal potential toxicity sooner, reducing patient exposure to risks. The content outlines various statistical methods for conducting interim analyses, detailing how to manage and control the overall risk of incorrect conclusions during these evaluations. It advocates for rigorous methodologies and proper monitoring, suggesting the involvement of an independent data monitoring committee (IDMC) to ensure decisions are well-founded and not solely reliant on statistical outcomes.","technologies, artificial, ai",rochepro.fr,Rising,0.071724892375397,medium,58,Technology
476,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/analyse-interpretation/stat4all-retranscription-module-analyses-sous-groupes-00005165-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_analyse_interpretation_stat4all_retranscription_module_analyses_sous_groupes_00005165_1_pdf.txt,200,pdf,Non-Indexable,3,73,0,0,2,1,0.915789473684211,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_analyse-interpretation_stat4all-retranscription-module-analyses-sous-groupes-00005165-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_analyse-interpretation_stat4all-retranscription-module-analyses-sous-groupes-00005165-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_analyse-interpretation_stat4all-retranscription-module-analyses-sous-groupes-00005165-1.pdf.txt,[],Other,France,Research,,,27.826632,-3.9407403,4,"The content discusses the importance of subgroup analysis in clinical trials, specifically in evaluating the effectiveness of treatments based on patient characteristics, such as the presence of biomarkers. It emphasizes that subgroup analyses should be predefined in the trial protocol to avoid bias, and outlines necessary considerations for conducting these analyses, such as the need for statistical power and controlling for multiple testing. The content concludes by advising that overall results from the main analysis should take precedence over subgroup findings, and that subgroup results should be interpreted cautiously and within the context of other available trials.","technologies, artificial, ai",rochepro.fr,Falling,0.958037370624291,medium,251,Technology
477,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/analyse-interpretation/stat4all-retranscription-module-hierarchisation-tests-00003963-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_analyse_interpretation_stat4all_retranscription_module_hierarchisation_tests_00003963_1_pdf.txt,200,pdf,Non-Indexable,3,74,0,0,2,1,0.921052631578947,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_analyse-interpretation_stat4all-retranscription-module-hierarchisation-tests-00003963-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_analyse-interpretation_stat4all-retranscription-module-hierarchisation-tests-00003963-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_analyse-interpretation_stat4all-retranscription-module-hierarchisation-tests-00003963-1.pdf.txt,"['Type', 'Bonferroni', 'Hochberg', 'I', 'Various']",Other,France,Research,,,27.831934,-3.5267088,4,"The content discusses the complexities and statistical challenges associated with conducting clinical trials, particularly when testing multiple hypotheses within a single study. It explains the concept of multiplicity, detailing how performing multiple statistical tests can inflate the risk of Type I errors (false positives) and the importance of controlling this risk. Various methods for adjusting the alpha risk, such as the Bonferroni and Hochberg approaches, are outlined, along with procedural strategies for conducting tests in a hierarchical manner. The content emphasizes the need for collaboration between clinicians and statisticians in designing studies and protocols to manage these risks effectively.","technologies, artificial, ai",rochepro.fr,All,0.455292162115865,medium,234,Technology
478,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/analyse-interpretation/stat4all-retranscription-module-meta-analyses-essais-randomises-00004576-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_analyse_interpretation_stat4all_retranscription_module_meta_analyses_essais_randomises_00004576_1_pdf.txt,200,pdf,Non-Indexable,3,83,0,0,2,1,0.915,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_analyse-interpretation_stat4all-retranscription-module-meta-analyses-essais-randomises-00004576-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_analyse-interpretation_stat4all-retranscription-module-meta-analyses-essais-randomises-00004576-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_analyse-interpretation_stat4all-retranscription-module-meta-analyses-essais-randomises-00004576-1.pdf.txt,[],Oncology-Hematology,France,Research,,,20.437803,-26.436392,1,"The content discusses the process and significance of conducting quantitative meta-analyses in clinical research, particularly in pharmacology and oncology. It emphasizes how systematic reviews and meta-analyses provide the highest level of evidence for evaluating the effectiveness of experimental treatments compared to reference treatments. The content outlines the different types of meta-analyses, the importance of individual patient data, and the need for a structured protocol to ensure data quality and reduce bias. Additionally, it highlights the challenges and methodologies involved in analyzing diverse clinical trial data, aiming to harmonize treatment effects and support clinical decision-making.","drug, reporting, adverse",rochepro.fr,All,0.0162042360176145,medium,146,Drug Safety
479,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/essentiels-conception/stat4all-retranscription-module-approche-bayesienne-00005330-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_essentiels_conception_stat4all_retranscription_module_approche_bayesienne_00005330_1_pdf.txt,200,pdf,Non-Indexable,3,66,0,0,2,1,0.919786096256685,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-approche-bayesienne-00005330-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-approche-bayesienne-00005330-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-approche-bayesienne-00005330-1.pdf.txt,['Bayesian'],Other,France,Research,,,26.994484,-4.311843,4,"The content discusses the Bayesian approach to clinical trials and monitoring treatment effects, particularly in rare diseases where limited data is available. It contrasts this method with classical frequentist approaches, explaining how Bayesian methods allow for continuous updating of probability distributions based on observed data. The content highlights the flexibility and intuitive nature of Bayesian analysis, which permits mid-study evaluations and adjustments based on interim findings, while also emphasizing the importance of pre-study planning and independent oversight to ensure robust decision-making.","technologies, artificial, ai",rochepro.fr,Flat,0.587085381298835,medium,426,Technology
480,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/essentiels-conception/stat4all-retranscription-module-bases-methodologies-projet-clinique-00002356-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_essentiels_conception_stat4all_retranscription_module_bases_methodologies_projet_clinique_00002356_1_pdf.txt,200,pdf,Non-Indexable,3,90,0,0,2,1,0.916256157635468,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-bases-methodologies-projet-clinique-00002356-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-bases-methodologies-projet-clinique-00002356-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-bases-methodologies-projet-clinique-00002356-1.pdf.txt,[],Other,France,Research,,,3.7198985,-31.26237,1,"The content discusses the systematic process of designing and implementing clinical studies in the pharmaceutical industry, specifically within the context of Roche. It emphasizes the importance of defining a clear medical question, establishing objectives, and selecting appropriate methodologies for data collection and analysis. The content outlines various study designs, including interventional and non-interventional studies, and highlights the significance of statistical hypotheses and the necessary considerations for ethical and practical feasibility. Additionally, it addresses the determination of primary and secondary endpoints and the relevance of robust data interpretation, including potential biases. Overall, the purpose of the content is to provide a comprehensive framework for conducting clinical research that can reliably respond to scientific questions related to treatment efficacy and patient care.","drug, reporting, adverse",rochepro.fr,All,0.830141961765515,medium,471,Drug Safety
481,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/essentiels-conception/stat4all-retranscription-module-criteres-evaluation-oncologie-hematologie-00006148-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_essentiels_conception_stat4all_retranscription_module_criteres_evaluation_oncologie_hematologie_00006148_1_pdf.txt,200,pdf,Non-Indexable,3,98,0,0,2,1,0.91866028708134,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-criteres-evaluation-oncologie-hematologie-00006148-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-criteres-evaluation-oncologie-hematologie-00006148-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-criteres-evaluation-oncologie-hematologie-00006148-1.pdf.txt,"['Disease', 'Free', 'OS', 'PFS', 'DFS', 'Progression', 'Survival']",Oncology-Hematology,France,Research,"Overall Survival, Progression-Free Survival, Disease-Free Survival, treatment efficacy, therapeutic strategies, treatment response, tolerance, quality of life, cancer",,30.505907,-20.445227,12,"The content discusses various evaluation criteria used in clinical studies, particularly in the context of assessing treatment efficacy in oncology. It explains key metrics such as Overall Survival (OS), Progression-Free Survival (PFS), and Disease-Free Survival (DFS), emphasizing their relevance in determining the benefits and risks of therapeutic strategies. The content highlights the importance of these criteria being clinically relevant, reproducible, and tailored to specific clinical scenarios. Additionally, it addresses the evaluation of treatment response and the necessity of considering factors such as tolerance and quality of life. Overall, the content serves to provide a standardized framework for assessing therapeutic outcomes in patients with cancer.","cancer, breast, lung",rochepro.fr,All,0.591285204986939,medium,434,Disease Information
482,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/essentiels-conception/stat4all-retranscription-module-methodes-analyse-survie-00007048-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_essentiels_conception_stat4all_retranscription_module_methodes_analyse_survie_00007048_1_pdf.txt,200,pdf,Non-Indexable,3,78,0,0,2,1,0.916230366492147,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-methodes-analyse-survie-00007048-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-methodes-analyse-survie-00007048-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-methodes-analyse-survie-00007048-1.pdf.txt,"['Meier', 'Cox', 'Kaplan']",Oncology-Hematology,France,Research,,,32.324963,-20.817886,12,"The content discusses statistical methods used to analyze survival data in clinical trials, particularly in oncology. It focuses on the concepts of censoring and event occurrence, explaining how survival probabilities can be estimated using the Kaplan-Meier estimator, which generates survival curves based on observed events and censored data. The content also mentions the log-rank test for comparing survival between groups and the Cox proportional hazards model for estimating treatment effects. Overall, the purpose is to outline methodologies for evaluating treatment benefits and risks in the presence of censored data.","cancer, breast, lung",rochepro.fr,Rising,0.115451027202687,medium,258,Disease Information
483,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/essentiels-conception/stat4all-retranscription-module-randomisation-00004187-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_essentiels_conception_stat4all_retranscription_module_randomisation_00004187_1_pdf.txt,200,pdf,Non-Indexable,3,78,0,0,2,1,0.922651933701657,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-randomisation-00004187-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-randomisation-00004187-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_essentiels-conception_stat4all-retranscription-module-randomisation-00004187-1.pdf.txt,[],Other,France,Research,,,27.708519,-3.8790135,4,"The content discusses key concepts related to clinical trials, specifically focusing on the processes of randomization and blinding to avoid bias when comparing different treatments. It outlines the importance of ensuring comparability between treatment groups to achieve valid results, describing methods such as stratified randomization and minimization to address potential imbalances in prognostic factors. Additionally, it explains the implications of using different randomization ratios and the necessity of double-blind trials to prevent evaluation biases. Overall, the purpose is to provide insights into designing clinical trials effectively to assess the efficacy of experimental treatments.","technologies, artificial, ai",rochepro.fr,Falling,0.866910475677113,medium,249,Technology
484,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/mise-en-oeuvre/stat4all-retranscription-module-etapes-reglementaires-00005510-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_mise_en_oeuvre_stat4all_retranscription_module_etapes_reglementaires_00005510_1_pdf.txt,200,pdf,Non-Indexable,3,91,0,0,2,1,0.912087912087912,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_mise-en-oeuvre_stat4all-retranscription-module-etapes-reglementaires-00005510-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_mise-en-oeuvre_stat4all-retranscription-module-etapes-reglementaires-00005510-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_mise-en-oeuvre_stat4all-retranscription-module-etapes-reglementaires-00005510-1.pdf.txt,"['Products', 'Safety', 'Committees', 'CPP', 'France', 'Medicines', 'ANSM', 'National', 'Ethics', 'Agency', 'Health']",Other,France,Research,,,17.421013,-36.143154,1,"The content discusses the regulatory framework for clinical research in France, specifically addressing the categorization of clinical studies (RIPH1, RIPH2, RIPH3), the roles of the National Agency for the Safety of Medicines and Health Products (ANSM), and the Ethics Committees (CPP) in approving and monitoring these research activities. It outlines the procedures for submitting clinical trial applications, including documentation requirements, evaluation timelines, and the necessary authorizations before a study can commence. The purpose of this content is to provide detailed guidance on the processes involved in conducting clinical research while ensuring the protection of patients and adherence to legal standards.","drug, reporting, adverse",rochepro.fr,All,0.942609073023205,medium,479,Drug Safety
485,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/specificites/stat4all-retranscription-module-criteres-substitution-oncologie-00003964-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_specificites_stat4all_retranscription_module_criteres_substitution_oncologie_00003964_1_pdf.txt,200,pdf,Non-Indexable,3,87,0,0,2,1,0.921052631578947,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-criteres-substitution-oncologie-00003964-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-criteres-substitution-oncologie-00003964-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-criteres-substitution-oncologie-00003964-1.pdf.txt,['Prentice'],Oncology-Hematology,France,Research,,,31.93051,-20.109146,12,"The content discusses the evaluation of new cancer therapies, focusing on how to assess their efficacy, tolerance, and impact on patients' quality of life. It highlights the importance of surrogate endpoints, which can potentially provide quicker insights into treatment benefits compared to traditional outcomes like overall survival, which requires extensive follow-up. The content details statistical methods for validating these surrogate endpoints, including the Prentice criteria and meta-analytic approaches, emphasizing that while a correlation between surrogate and final endpoints is necessary, it is not sufficient to establish validity without long-term survival data. The purpose of the content is to outline the methods for objectively assessing the value of innovative cancer treatments.","cancer, breast, lung",rochepro.fr,All,0.329831487030385,medium,377,Disease Information
486,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/specificites/stat4all-retranscription-module-designs-essais-phase-precoce-00004659-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_specificites_stat4all_retranscription_module_designs_essais_phase_precoce_00004659_1_pdf.txt,200,pdf,Non-Indexable,3,82,0,0,2,1,0.914438502673797,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-designs-essais-phase-precoce-00004659-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-designs-essais-phase-precoce-00004659-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-designs-essais-phase-precoce-00004659-1.pdf.txt,[],Other,France,Research,"immunotherapy, targeted treatments, dose escalation methods, 3+3 design, continuous evaluation methods, patient safety, biomarker identification",,21.439968,-30.718721,1,"The content discusses methodologies for early-phase clinical trials, particularly focusing on safety, toxicity profiles, and optimal dosing strategies for pharmaceuticals. It outlines the principles behind dose escalation methods, such as the commonly used 3+3 design, and alternative continuous evaluation methods that incorporate real-time patient data to refine dosing decisions. Additionally, it highlights the unique considerations for specific therapies like targeted treatments and immunotherapy, emphasizing the need for tailored evaluation criteria and biomarker identification. The purpose of the content is to detail the systematic approach to ensuring patient safety and efficacy in drug development, underscoring the importance of biostatistical involvement in modern clinical trial designs.","drug, reporting, adverse",rochepro.fr,All,0.910245268421767,medium,31,Drug Safety
487,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/specificites/stat4all-retranscription-module-designs-medecine-precision-00004885-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_specificites_stat4all_retranscription_module_designs_medecine_precision_00004885_1_pdf.txt,200,pdf,Non-Indexable,3,81,0,0,2,1,0.918918918918919,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-designs-medecine-precision-00004885-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-designs-medecine-precision-00004885-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-designs-medecine-precision-00004885-1.pdf.txt,['These'],Oncology-Hematology,France,Research,"precision medicine, cancer treatments, enrichment designs, basket designs, umbrella designs, platform designs, targeted therapies, personalized treatment approaches, oncology",,34.54781,-17.017088,12,"The content discusses advancements in precision medicine, specifically in clinical trial designs that aim to tailor cancer treatments based on individual patient and tumor characteristics. It outlines various trial designs, including enrichment designs, basket designs, umbrella designs, and platform designs, highlighting their flexibility and ability to adapt to genomic alterations across different cancers. These designs aim to optimize treatment efficacy and provide quicker insights into how specific populations respond to targeted therapies, thereby supporting personalized treatment approaches in oncology.","cancer, breast, lung",rochepro.fr,All,0.285476947975279,medium,353,Disease Information
488,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/specificites/stat4all-retranscription-module-donnees-vie-reelle-00005467-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_specificites_stat4all_retranscription_module_donnees_vie_reelle_00005467_1_pdf.txt,200,pdf,Non-Indexable,3,70,0,0,2,1,0.915254237288136,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-donnees-vie-reelle-00005467-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-donnees-vie-reelle-00005467-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-donnees-vie-reelle-00005467-1.pdf.txt,['RWE'],Other,France,Research,,,17.904892,-34.910362,1,"The content discusses the importance of real-world evidence (RWE) in evaluating therapeutic strategies for patients, highlighting its complementarity to clinical trial data. It outlines the strengths and limitations of RWE, including concerns around bias due to lack of randomization and standard tracking. The content emphasizes the need for robust study protocols, quality data collection, and transparency in reporting results. It also details various sources of RWE and their role throughout the medication development process, from understanding unmet medical needs to post-market drug safety surveillance. The aim is to inform decision-makers within the healthcare community using reliable data.","drug, reporting, adverse",rochepro.fr,Rising,0.2626887268429,medium,479,Drug Safety
489,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/specificites/stat4all-retranscription-module-intelligence-artificielle-recherche-clinique-00004358-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_specificites_stat4all_retranscription_module_intelligence_artificielle_recherche_clinique_00004358_1_pdf.txt,200,pdf,Non-Indexable,3,99,0,0,2,1,0.921182266009852,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-intelligence-artificielle-recherche-clinique-00004358-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-intelligence-artificielle-recherche-clinique-00004358-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-intelligence-artificielle-recherche-clinique-00004358-1.pdf.txt,[],Other,France,Technology,,,41.13618,13.785039,4,"The content discusses the application of machine learning in the healthcare sector, particularly in understanding complex biological mechanisms and improving diagnostic processes. It highlights two main categories of algorithms: unsupervised learning, which helps structure and visualize data without human influence, and supervised learning, which attempts to replicate human reasoning for specific tasks. The aim is to leverage large databases to enhance the quality of health data analysis, ultimately advancing personalized medicine and improving patient care. The content emphasizes the ongoing development in this field, alongside existing challenges, and underscores the significance of collaboration with experts in statistics and data science.","technologies, artificial, ai",rochepro.fr,Flat,0.521296882484702,medium,184,Technology
490,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/stat4all/specificites/stat4all-retranscription-module-prems-proms-00007910-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_stat4all_specificites_stat4all_retranscription_module_prems_proms_00007910_1_pdf.txt,200,pdf,Non-Indexable,3,67,0,0,2,1,0.917647058823529,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-prems-proms-00007910-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-prems-proms-00007910-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_stat4all_specificites_stat4all-retranscription-module-prems-proms-00007910-1.pdf.txt,['Ultimately'],Other,France,Research,,,21.736143,17.539036,4,"The content discusses the importance of public health and the role of patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) in evaluating individual and collective health. It explains the distinction between various types of questionnaires used to assess quality of life and the impact of specific diseases, as well as the significance of patients' perspectives on their treatment experiences. Furthermore, it emphasizes the need for valid and reliable measurement tools and the considerations required in developing and using these instruments. Ultimately, the content advocates for incorporating PROMs and PREMs in relevant projects to enhance health outcomes.","technologies, artificial, ai",rochepro.fr,All,0.138474691998929,medium,45,Technology
491,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/oncologie/virage-annonce-autrement/fiche-pratique-pds-annonce-maladie-grave-00007193-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_oncologie_virage_annonce_autrement_fiche_pratique_pds_annonce_maladie_grave_00007193_2_pdf.txt,200,pdf,Non-Indexable,3,82,0,0,1,1,0.9,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_virage-annonce-autrement_fiche-pratique-pds-annonce-maladie-grave-00007193-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_virage-annonce-autrement_fiche-pratique-pds-annonce-maladie-grave-00007193-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_oncologie_virage-annonce-autrement_fiche-pratique-pds-annonce-maladie-grave-00007193-2.pdf.txt,['Key'],Other,France,Patient support,,,21.926723,16.146173,4,"The content discusses the challenges healthcare professionals face when announcing a serious diagnosis to patients. It emphasizes the importance of empathy and human connection while managing the anxiety patients may feel regarding their diagnosis and treatment. Key points include the need for clear and reassuring communication, the proper timing and location for such announcements, and the involvement of family members in consultations. The content highlights the significance of building trust with patients and addressing their questions and emotional responses throughout the care process. Overall, it serves as a guide for healthcare providers on how to navigate these sensitive conversations effectively.","technologies, artificial, ai",rochepro.fr,Falling,0.594432457959774,medium,150,Technology
492,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/ophtalmologie/dmlan-omd/pour-vos-patients/comprendre-web-ethnographie-methodologie-00008055-2.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_ophtalmologie_dmlan_omd_pour_vos_patients_comprendre_web_ethnographie_methodologie_00008055_2_pdf.txt,200,pdf,Non-Indexable,3,50,0,0,3,2,0.909604519774011,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_ophtalmologie_dmlan-omd_pour-vos-patients_comprendre-web-ethnographie-methodologie-00008055-2.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_ophtalmologie_dmlan-omd_pour-vos-patients_comprendre-web-ethnographie-methodologie-00008055-2.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_ophtalmologie_dmlan-omd_pour-vos-patients_comprendre-web-ethnographie-methodologie-00008055-2.pdf.txt,"['AMD', 'Its', 'DME']",Ophthalmology,France,Research,"age-related macular degeneration, AMD, diabetic macular edema, DME","age-related macular degeneration, diabetic macular edema",27.642872,19.640049,4,"The content focuses on the experiences of patients suffering from age-related macular degeneration (AMD) or diabetic macular edema (DME) by analyzing conversations on social media platforms and forums. Its purpose is to explore the subjective experiences and unvoiced concerns of patients and their caregivers, revealing emotional responses and unresolved needs. The study involves a systematic collection and analysis of 1,408 conversations, leading to the identification of eight semantic categories related to the patients' and caregivers' perspectives on their conditions, ultimately aiming to enhance understanding and communication around these diseases.","technologies, artificial, ai",rochepro.fr,Rising,0.0445699198734072,medium,192,Technology
493,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/aires-therapeutiques/ophtalmologie/dmlan-omd/telechargez-commandez/parcours-omd-00005794-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires_therapeutiques_ophtalmologie_dmlan_omd_telechargez_commandez_parcours_omd_00005794_1_pdf.txt,200,pdf,Non-Indexable,3,32,0,0,1,1,0.915032679738562,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_ophtalmologie_dmlan-omd_telechargez-commandez_parcours-omd-00005794-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_ophtalmologie_dmlan-omd_telechargez-commandez_parcours-omd-00005794-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_aires-therapeutiques_ophtalmologie_dmlan-omd_telechargez-commandez_parcours-omd-00005794-1.pdf.txt,[],CVRM,France,Patient support,"diabetes, oral medication, insulin, self-monitoring of blood glucose levels, dietary adjustments, emotional impact, complications",diabetes,20.324852,17.086884,4,"The content discusses the management and treatment of diabetes, particularly focusing on the importance of maintaining regular consultations with healthcare professionals such as general practitioners, endocrinologists, and ophthalmologists. It emphasizes the need for self-monitoring of blood glucose levels, adherence to prescribed treatments (oral medication or insulin), and dietary adjustments. Additionally, it addresses the emotional impact of a diabetes diagnosis, the logistics of managing treatment alongside social and professional life, and the potential complications that can arise. The purpose of the content is to provide guidance and support for individuals living with diabetes, promoting proactive management of their condition and fostering collaboration between patients and healthcare providers.","technologies, artificial, ai",rochepro.fr,Rising,0.388681128554067,medium,489,Technology
494,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/cellcept/cellcept-formulaire-accord-soins-00010435-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_cellcept_cellcept_formulaire_accord_soins_00010435_1_pdf.txt,200,pdf,Non-Indexable,2,71,0,0,1,1,0.907801418439716,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_cellcept_cellcept-formulaire-accord-soins-00010435-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_cellcept_cellcept-formulaire-accord-soins-00010435-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_cellcept_cellcept-formulaire-accord-soins-00010435-1.pdf.txt,"['French', 'Its']",Other,France,Medication information,"mycophenolate, risks, miscarriages, congenital malformations, negative pregnancy tests, contraceptive methods, coordinated care, family planning, treatment adjustments, precautions",,21.789925,-34.651993,1,"The extracted content is a French content related to the pharmaceutical management of women of childbearing potential undergoing treatment with mycophenolate. Its main focus is to ensure that patients are fully informed about the risks associated with mycophenolate use during pregnancy, including increased chances of miscarriages and congenital malformations. The content outlines specific measures for risk reduction, such as the requirement for negative pregnancy tests and effective contraceptive methods before, during, and post-treatment. It emphasizes the importance of coordinated care between patients and their healthcare providers regarding family planning and treatment adjustments. The purpose is to protect patients and ensure they understand the necessary precautions while undergoing this medication regimen.","drug, reporting, adverse",rochepro.fr,Rising,0.819624838594826,medium,41,Drug Safety
495,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/cellcept/guide-patients-riques-grossesse-projet-conception-juin2018.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_cellcept_guide_patients_riques_grossesse_projet_conception_juin2018_pdf.txt,200,pdf,Non-Indexable,2,116,0,0,1,1,0.91025641025641,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_cellcept_guide-patients-riques-grossesse-projet-conception-juin2018.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_cellcept_guide-patients-riques-grossesse-projet-conception-juin2018.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_cellcept_guide-patients-riques-grossesse-projet-conception-juin2018.pdf.txt,['Its'],Immunology,France,Medication information,"mycophenolate, miscarriage, birth defects, contraception, adverse effects",,13.445149,-30.298985,1,"The content is a patient guide from Roche regarding the use of mycophenolate, a medication that poses risks of miscarriage and birth defects for individuals who are pregnant or may become pregnant. Its purpose is to inform patients—particularly women of childbearing potential and their partners—about these risks, the importance of contraception while on the medication, and the necessary precautions to take before and during treatment. It emphasizes the need for informed discussions with healthcare providers regarding family planning and alternative treatments, as well as procedures for reporting adverse effects.","drug, reporting, adverse",rochepro.fr,All,0.913354532645601,medium,109,Drug Safety
496,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/cellcept/guide-pds-riques-grossesse-projet-conception-fevrier2019.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_cellcept_guide_pds_riques_grossesse_projet_conception_fevrier2019_pdf.txt,200,pdf,Non-Indexable,2,131,0,0,1,1,0.909090909090909,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_cellcept_guide-pds-riques-grossesse-projet-conception-fevrier2019.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_cellcept_guide-pds-riques-grossesse-projet-conception-fevrier2019.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_cellcept_guide-pds-riques-grossesse-projet-conception-fevrier2019.pdf.txt,['Key'],Immunology,France,Medication information,"mycophenolate, teratogenic risks, congenital malformations, spontaneous abortions, contraception, pregnancy planning, pregnancy testing",,22.114786,-34.92596,1,"The content is a detailed guide on the risks associated with using mycophenolate, particularly focusing on teratogenic risks, congenital malformations, and spontaneous abortions. It aims to provide healthcare professionals with crucial information regarding recommendations for contraception and pregnancy planning for patients who may conceive while undergoing treatment with mycophenolate. Key aspects include the necessity of effective contraception, the importance of pregnancy testing, and guidelines for male patients whose partners might be pregnant. The guide emphasizes the serious risks associated with mycophenolate use during pregnancy and outlines measures to minimize these risks, ensuring that both patients and healthcare providers engage in informed discussions regarding reproductive health.","drug, reporting, adverse",rochepro.fr,Rising,0.798878984902641,medium,198,Drug Safety
497,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/columvi/columvi-carte-patient-00009150-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_columvi_columvi_carte_patient_00009150_1_pdf.txt,200,pdf,Non-Indexable,2,43,0,0,1,1,0.906976744186047,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_columvi_columvi-carte-patient-00009150-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_columvi_columvi-carte-patient-00009150-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_columvi_columvi-carte-patient-00009150-1.pdf.txt,"['Key', 'COLUMVI', 'ANSM', 'July']",Oncology-Hematology,France,Medication information,"COLUMVI, glofitamab, safety information, fever, rapid heartbeat, confusion, cytokine release syndrome, serious side effects",cytokine release syndrome,11.777273,-36.060654,1,"The content is a patient information card for COLUMVI® (glofitamab), produced by Roche. It outlines important safety information for patients undergoing treatment with this medication. The card advises patients to carry it at all times and shows health professionals in case of any issues related to the treatment. Key symptoms to watch for include fever, rapid heartbeat, and confusion, indicating potential serious side effects like cytokine release syndrome, which requires immediate medical attention. The content is versioned and dated July 2023, and authorized by ANSM.","drug, reporting, adverse",rochepro.fr,Falling,0.261862116983761,medium,293,Drug Safety
498,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/columvi/columvi-guide-professionnels-de-sante-00009151-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_columvi_columvi_guide_professionnels_de_sante_00009151_1_pdf.txt,200,pdf,Non-Indexable,2,71,0,0,1,1,0.903448275862069,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_columvi_columvi-guide-professionnels-de-sante-00009151-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_columvi_columvi-guide-professionnels-de-sante-00009151-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_columvi_columvi-guide-professionnels-de-sante-00009151-1.pdf.txt,"['COLUMVI', 'CRS', 'Its']",Oncology-Hematology,France,Medication information,"COLUMVI, glofitamab, bispecific monoclonal antibody, cancer treatment, tumor flare reactions, cytokine release syndrome (CRS), patient education, monitoring for adverse effects, proactive management strategies","tumor flare reactions, cytokine release syndrome",18.023106,-29.738165,1,"The content is a safety guide from Roche concerning the drug COLUMVI (glofitamab), a bispecific monoclonal antibody used in cancer treatment. Its purpose is to inform healthcare professionals about the potential risks associated with the treatment, specifically focusing on tumor flare reactions and cytokine release syndrome (CRS). The guide emphasizes the importance of patient education, monitoring for adverse effects, and proactive management strategies during treatment. Additionally, it outlines the necessary steps for prescribing COLUMVI, including the distribution of a patient card that contains crucial information for both patients and healthcare providers.","drug, reporting, adverse",rochepro.fr,Flat,0.33905859525644,medium,39,Drug Safety
499,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/enspryng/enspryng-carte-patient-00007371-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_enspryng_enspryng_carte_patient_00007371_1_pdf.txt,200,pdf,Non-Indexable,2,44,0,0,1,1,0.908396946564886,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_enspryng_enspryng-carte-patient-00007371-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_enspryng_enspryng-carte-patient-00007371-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_enspryng_enspryng-carte-patient-00007371-1.pdf.txt,['Enspryng'],Immunology,France,Medication information,"Enspryng, satralizumab, infections",,8.591416,-37.362648,1,"The content is a patient information card from Roche regarding the medication Enspryng (satralizumab). It outlines important safety information for patients receiving the drug, specifically warning that it may reduce their ability to fight infections. The card advises patients to call their doctor immediately if they experience symptoms of infection and explains the importance of showing this card to any healthcare professional involved in their care. Additionally, it highlights the potential necessity to postpone medication administration if an infection is present.","drug, reporting, adverse",rochepro.fr,All,0.685350275169498,medium,300,Drug Safety
500,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/erivedge/erivedge-ppg-carnet-patient-00003477-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_erivedge_erivedge_ppg_carnet_patient_00003477_1_pdf.txt,200,pdf,Non-Indexable,2,70,0,0,1,1,0.904411764705882,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_erivedge_erivedge-ppg-carnet-patient-00003477-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_erivedge_erivedge-ppg-carnet-patient-00003477-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_erivedge_erivedge-ppg-carnet-patient-00003477-1.pdf.txt,['Erivedge'],Oncology-Hematology,France,Medication information,"Erivedge, advanced basal cell carcinoma, side effects","advanced basal cell carcinoma, skin cancer",21.912832,-33.964558,1,"The content is a patient information brochure for the medication Erivedge, which is used to treat advanced basal cell carcinoma, a type of skin cancer. It outlines critical safety information regarding the drug, particularly the risks it poses to pregnant women and fetuses. The content emphasizes the necessity of strict contraception for both men and women undergoing treatment, detailed guidelines for pregnancy testing, and information on potential side effects. The purpose of this content is to ensure that patients are well-informed about the medication's risks, proper usage, and the importance of avoiding pregnancy during treatment. It is designed to guide healthcare providers and patients in managing the treatment safely and effectively.","drug, reporting, adverse",rochepro.fr,Rising,0.778501563375477,medium,449,Drug Safety
501,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/erivedge/erivedge-ppg-carte-medecins-pharmaciens-00003478-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_erivedge_erivedge_ppg_carte_medecins_pharmaciens_00003478_1_pdf.txt,200,pdf,Non-Indexable,2,55,0,0,1,1,0.905405405405405,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_erivedge_erivedge-ppg-carte-medecins-pharmaciens-00003478-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_erivedge_erivedge-ppg-carte-medecins-pharmaciens-00003478-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_erivedge_erivedge-ppg-carte-medecins-pharmaciens-00003478-1.pdf.txt,['Erivedge'],Other,France,Medication information,"Erivedge, teratogenic risks, contraception requirements, pregnancy testing, reporting pregnancies, adverse effects",,21.912086,-35.993813,1,"The content provides information about the safety precautions and guidelines for the use of the medication Erivedge, particularly concerning its teratogenic risks (the potential to cause developmental issues in a fetus). It emphasizes the importance of educating both healthcare professionals and patients about these risks, especially for women who are pregnant, breastfeeding, or capable of becoming pregnant. The content includes specifics on contraception requirements, the need for regular pregnancy testing, and the protocol for reporting pregnancies and adverse effects associated with Erivedge. The purpose of this content is to ensure the safe and responsible use of Erivedge while minimizing risks to patients and potential future offspring.","drug, reporting, adverse",rochepro.fr,All,0.915524435692514,medium,111,Drug Safety
502,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/erivedge/erivedge-ppg-formulaire-accord-soins-et-contraception-00003471-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_erivedge_erivedge_ppg_formulaire_accord_soins_et_contraception_00003471_1_pdf.txt,200,pdf,Non-Indexable,2,78,0,0,1,1,0.901234567901235,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_erivedge_erivedge-ppg-formulaire-accord-soins-et-contraception-00003471-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_erivedge_erivedge-ppg-formulaire-accord-soins-et-contraception-00003471-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_erivedge_erivedge-ppg-formulaire-accord-soins-et-contraception-00003471-1.pdf.txt,['Erivedge'],Oncology-Hematology,France,Medication information,"Erivedge, vismodegib, embryotoxic, teratogenic, contraception, pregnancy testing, safe sexual practices",,21.665829,-35.988544,1,"The content primarily discusses the risks and precautions associated with the use of the medication Erivedge (vismodegib), particularly for pregnant women and those who may become pregnant. It outlines the potential embryotoxic and teratogenic effects of the drug, emphasizing the need for contraception and regular pregnancy testing for women during treatment. Additionally, it provides guidelines for male patients regarding safe sexual practices and reporting pregnancies. The purpose of the content is to ensure patient understanding of the serious risks posed by Erivedge, thereby promoting safety during its use.","drug, reporting, adverse",rochepro.fr,Flat,0.316262491963559,medium,307,Drug Safety
503,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/esbriet/marr-esbriet-pirfenidone-carte-patient-00010602-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_esbriet_marr_esbriet_pirfenidone_carte_patient_00010602_1_pdf.txt,200,pdf,Non-Indexable,2,43,0,0,1,1,0.904109589041096,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_esbriet_marr-esbriet-pirfenidone-carte-patient-00010602-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_esbriet_marr-esbriet-pirfenidone-carte-patient-00010602-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_esbriet_marr-esbriet-pirfenidone-carte-patient-00010602-1.pdf.txt,"['ANSM', 'Esbriet']",Other,France,Medication information,"pirfenidone, Esbriet, generic alternatives, adverse effects, drug interactions",idiopathic pulmonary fibrosis,17.510954,-38.54913,1,"The content is a patient card regarding the treatment with pirfenidone, specifically mentioning the medication Esbriet and its generic alternatives. It informs patients that their pulmonologist has prescribed this treatment and provides a link to consult the product characteristics and patient information. The card encourages patients to inform their doctors or pharmacists about any adverse effects they may experience and suggests showing the card to any consulting physician to ensure they are aware of the treatment and potential drug interactions. The card is distributed by pharmaceutical companies authorized by the ANSM.","drug, reporting, adverse",rochepro.fr,Rising,0.636936273865795,medium,207,Drug Safety
504,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/esbriet/marr-esbriet-pirfenidone-fiche-info-securite-pds-00010604-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_esbriet_marr_esbriet_pirfenidone_fiche_info_securite_pds_00010604_1_pdf.txt,200,pdf,Non-Indexable,2,85,0,0,1,1,0.897435897435898,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_esbriet_marr-esbriet-pirfenidone-fiche-info-securite-pds-00010604-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_esbriet_marr-esbriet-pirfenidone-fiche-info-securite-pds-00010604-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_esbriet_marr-esbriet-pirfenidone-fiche-info-securite-pds-00010604-1.pdf.txt,[],Other,France,Medication information,"pirfenidone, drug-induced liver damage, photosensitivity reactions, liver function tests, adverse effects, sunlight exposure, serious side effects",,16.627115,-39.17981,1,"The content is a safety information content for healthcare professionals regarding the drug pirfenidone, used in the treatment of certain conditions. It outlines the risks associated with the medication, particularly the potential for drug-induced liver damage and photosensitivity reactions. The content emphasizes the importance of conducting liver function tests before and during treatment, monitoring for adverse effects, and communicating with patients about protective measures against sunlight exposure. It also instructs healthcare providers to report serious side effects to relevant health authorities and provides links for further information on the drug's characteristics. The purpose of this content is to ensure safe prescribing practices and patient awareness related to pirfenidone.","drug, reporting, adverse",rochepro.fr,Flat,0.172616493320336,medium,108,Drug Safety
505,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/hemlibra/hemlibra-carte-patient-00008240-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_hemlibra_hemlibra_carte_patient_00008240_1_pdf.txt,200,pdf,Non-Indexable,2,44,0,0,1,1,0.908396946564886,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_hemlibra_hemlibra-carte-patient-00008240-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_hemlibra_hemlibra-carte-patient-00008240-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_hemlibra_hemlibra-carte-patient-00008240-1.pdf.txt,['Hemlibra'],Oncology-Hematology,France,Medication information,"hemophilia, Hemlibra, emicizumab, adverse effects, coagulation tests, thromboembolic events",hemophilia,19.149315,-0.8445432,4,"The content provides important information regarding the treatment of hemophilia with the drug Hemlibra (emicizumab) produced by Roche. It serves as a patient information card that outlines the necessary precautions, potential adverse effects, and the importance of reporting any side effects experienced during treatment. Additionally, it emphasizes the need for careful monitoring of coagulation tests and highlights important warnings about the risk of serious thromboembolic events associated with the medication. The overall purpose is to ensure patient safety and promote informed communication between patients and healthcare providers regarding the use of Hemlibra.","technologies, artificial, ai",rochepro.fr,Falling,0.26803543721433,medium,139,Technology
506,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/hemlibra/hemlibra-guide-biologie-pds-00008241-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_hemlibra_hemlibra_guide_biologie_pds_00008241_1_pdf.txt,200,pdf,Non-Indexable,2,96,0,0,1,1,0.904411764705882,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_hemlibra_hemlibra-guide-biologie-pds-00008241-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_hemlibra_hemlibra-guide-biologie-pds-00008241-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_hemlibra_hemlibra-guide-biologie-pds-00008241-1.pdf.txt,['HEMLIBRA'],Oncology-Hematology,France,Medication information,"HEMLIBRA, emicizumab, coagulation tests, mechanism of action, laboratory coagulation tests, interferences",,18.977283,-2.04339,4,"The content is an informational guide from Roche regarding the medication HEMLIBRA (emicizumab), specifically aimed at healthcare professionals such as prescribers, biologists, and pharmacists. It outlines important considerations for coagulation tests conducted on patients undergoing treatment with HEMLIBRA. The content covers the drug's approval details, mechanism of action, and its effects on laboratory coagulation tests, emphasizing the potential interferences caused by emicizumab. The purpose of the content is to educate medical professionals on the proper interpretation of coagulation test results in patients treated with HEMLIBRA and to ensure safe and effective patient management.","technologies, artificial, ai",rochepro.fr,Rising,0.622352486933223,medium,492,Technology
507,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/hemlibra/hemlibra-guide-patients-aidants-00008239-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_hemlibra_hemlibra_guide_patients_aidants_00008239_1_pdf.txt,200,pdf,Non-Indexable,2,68,0,0,1,1,0.907142857142857,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_hemlibra_hemlibra-guide-patients-aidants-00008239-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_hemlibra_hemlibra-guide-patients-aidants-00008239-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_hemlibra_hemlibra-guide-patients-aidants-00008239-1.pdf.txt,"['Card', 'VIII', 'Hemophilia', 'HEMLIBRA', 'Patient']",Oncology-Hematology,France,Medication information,"HEMLIBRA, emicizumab, Hemophilia A, factor VIII",Hemophilia A,19.64525,0.027182369,4,"The content is a patient guide for HEMLIBRA (emicizumab), a medication used to treat patients with Hemophilia A, particularly those with severe deficiency of factor VIII or conditions where inhibitors against factor VIII are present. The guide provides crucial information on the medication's usage, safety precautions, how it functions, and instructions for patients and caregivers on administering the drug. It emphasizes the importance of communication with healthcare providers, maintaining a Patient Card for emergencies, and the need to report any adverse effects. The content serves to educate patients about their treatment and ensure safe and effective management of their condition.","technologies, artificial, ai",rochepro.fr,Rising,0.108798041696352,medium,367,Technology
508,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/hemlibra/hemlibra-guide-professionnels-sante-00008242-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_hemlibra_hemlibra_guide_professionnels_sante_00008242_1_pdf.txt,200,pdf,Non-Indexable,2,72,0,0,1,1,0.909722222222222,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_hemlibra_hemlibra-guide-professionnels-sante-00008242-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_hemlibra_hemlibra-guide-professionnels-sante-00008242-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_hemlibra_hemlibra-guide-professionnels-sante-00008242-1.pdf.txt,['HEMLIBRA'],Oncology-Hematology,France,Medication information,"HEMLIBRA, emicizumab, hemophilia A, activated prothrombin complex concentrates, aPCC, thromboembolic events, thrombotic microangiopathy","hemophilia A, thromboembolic events, thrombotic microangiopathy",20.023373,0.096659645,4,"The content provides crucial information regarding the use of HEMLIBRA (emicizumab) for the prophylaxis of bleeding episodes in patients with hemophilia A. It outlines potential risks associated with the concurrent use of HEMLIBRA and activated prothrombin complex concentrates (aPCC), emphasizing concerns about thromboembolic events and thrombotic microangiopathy. The content serves as a guideline for healthcare professionals and caregivers, detailing management strategies for these risks, laboratory test interferences caused by HEMLIBRA, and patient education requirements. It also includes recommendations for monitoring and communication among healthcare providers to ensure the safe and effective use of the treatment. Overall, the purpose of the content is to enhance patient safety and optimize treatment outcomes.","technologies, artificial, ai",rochepro.fr,All,0.349219234382855,medium,113,Technology
509,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/kadcyla/kadcyla-brochure-pds-00005651-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_kadcyla_kadcyla_brochure_pds_00005651_1_pdf.txt,200,pdf,Non-Indexable,2,62,0,0,1,1,0.90625,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_kadcyla_kadcyla-brochure-pds-00005651-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_kadcyla_kadcyla-brochure-pds-00005651-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_kadcyla_kadcyla-brochure-pds-00005651-1.pdf.txt,"['Herceptin', 'Enhertu', 'Kadcyla', 'Its']",Oncology-Hematology,France,Medication information,"Kadcyla, trastuzumab emtansine, Herceptin, Enhertu, dosages, administration guidelines",,15.408985,-39.492363,1,"The content is a brochure aimed at healthcare professionals, specifically doctors, pharmacists, and nurses involved in the prescription, preparation, or administration of the drug Kadcyla (trastuzumab emtansine). Its purpose is to highlight the risks of confusion between Kadcyla and other trastuzumab-containing medications like Herceptin and Enhertu, which can lead to overdosing or reduced efficacy. The brochure emphasizes the importance of using both the brand name and the full international nonproprietary name during all stages of drug handling to prevent medication errors. It also outlines the specific indications, dosages, and administration guidelines for Kadcyla, stressing that it is not interchangeable with other trastuzumab products.","drug, reporting, adverse",rochepro.fr,Flat,0.176975302607503,medium,474,Drug Safety
510,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/mabthera-iv/mabthera-iv-carte-surveillance-patient-d-141314.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_mabthera_iv_mabthera_iv_carte_surveillance_patient_d_141314_pdf.txt,200,pdf,Non-Indexable,2,85,0,0,1,1,0.898648648648649,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_mabthera-iv_mabthera-iv-carte-surveillance-patient-d-141314.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_mabthera-iv_mabthera-iv-carte-surveillance-patient-d-141314.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_mabthera-iv_mabthera-iv-carte-surveillance-patient-d-141314.pdf.txt,[],Immunology,France,Medication information,"MabThera, rituximab, non-oncological diseases",,10.705053,-35.06608,1,The content is a monitoring card produced for Roche regarding patients treated with MabThera (rituximab). It emphasizes the importance of surveillance for these patients in non-oncological diseases. The design is likely intended to provide essential information and guidelines for healthcare providers and patients about the treatment process with MabThera.,"drug, reporting, adverse",rochepro.fr,Rising,0.444122438826778,medium,81,Drug Safety
511,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/roactemra/roactemra-brochure-patients-parents-tuteurs-00006772-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_roactemra_roactemra_brochure_patients_parents_tuteurs_00006772_1_pdf.txt,200,pdf,Non-Indexable,2,68,0,0,1,1,0.908496732026144,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_roactemra_roactemra-brochure-patients-parents-tuteurs-00006772-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_roactemra_roactemra-brochure-patients-parents-tuteurs-00006772-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_roactemra_roactemra-brochure-patients-parents-tuteurs-00006772-1.pdf.txt,[],Immunology,France,Medication information,"RoActemra, tocilizumab, inflammatory diseases, side effects, treatment, infections, liver function",,19.38663,-40.75247,1,"The content is a brochure intended for patients and their caregivers regarding RoActemra (tocilizumab), a medication used for treating inflammatory diseases. It outlines important information about the medication, including its usage, potential side effects, and precautions that need to be considered before and during treatment. The brochure emphasizes consulting healthcare professionals for any questions or concerns and stresses the importance of monitoring for specific symptoms related to infections and liver function throughout the treatment process. The content aims to ensure patients are well-informed about their treatment and associated risks.","drug, reporting, adverse",rochepro.fr,All,0.473324212585612,medium,361,Drug Safety
512,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/roactemra/roactemra-brochure-pds-00006780-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_roactemra_roactemra_brochure_pds_00006780_1_pdf.txt,200,pdf,Non-Indexable,2,64,0,0,1,1,0.909090909090909,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_roactemra_roactemra-brochure-pds-00006780-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_roactemra_roactemra-brochure-pds-00006780-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_roactemra_roactemra-brochure-pds-00006780-1.pdf.txt,[],Immunology,France,Medication information,"RoActemra, tocilizumab, systemic juvenile idiopathic arthritis, severe infections, liver toxicity, gastrointestinal complications, treatment",systemic juvenile idiopathic arthritis,14.116655,-36.002434,1,"The extracted content is a detailed information brochure about RoActemra (tocilizumab), a medication produced by Roche. It is primarily aimed at healthcare professionals and caregivers, informing them about the necessary precautions, potential risks, and side effects associated with the medication, particularly in treating severe conditions like systemic juvenile idiopathic arthritis. The purpose of this content is to ensure that patients and their guardians are fully aware of the risks, including severe infections, liver toxicity, and gastrointestinal complications, and to instruct them on proper monitoring and response to adverse events associated with the treatment. It also provides guidelines for prescribing and managing the medication safely.","drug, reporting, adverse",rochepro.fr,Flat,0.0499226035048969,medium,234,Drug Safety
513,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/roactemra/roactemra-carte-surveillance-patient-00006772-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_roactemra_roactemra_carte_surveillance_patient_00006772_1_pdf.txt,200,pdf,Non-Indexable,2,61,0,0,1,1,0.910958904109589,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_roactemra_roactemra-carte-surveillance-patient-00006772-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_roactemra_roactemra-carte-surveillance-patient-00006772-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_roactemra_roactemra-carte-surveillance-patient-00006772-1.pdf.txt,[],Immunology,France,Medication information,"RoActemra, tocilizumab, side effects, infections, patient safety, treatment",,17.23428,-41.387478,1,"The content is a patient information leaflet related to RoActemra (tocilizumab), a medication developed by Roche. It is intended for patients and guardians of children receiving this treatment, providing essential information about its administration, potential side effects, and monitoring requirements. The content emphasizes the importance of reporting adverse effects, understanding risks associated with infections, and the necessity for specific medical evaluations before and during treatment. Overall, it serves the purpose of ensuring patient safety and enhancing awareness among users and their caregivers.","drug, reporting, adverse",rochepro.fr,Flat,0.395496892410586,medium,26,Drug Safety
514,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/roactemra/roactemra-sc-guide-administration-patients-parents-tuteurs-00006782-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_roactemra_roactemra_sc_guide_administration_patients_parents_tuteurs_00006782_1_pdf.txt,200,pdf,Non-Indexable,2,93,0,0,1,1,0.904761904761905,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_roactemra_roactemra-sc-guide-administration-patients-parents-tuteurs-00006782-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_roactemra_roactemra-sc-guide-administration-patients-parents-tuteurs-00006782-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_roactemra_roactemra-sc-guide-administration-patients-parents-tuteurs-00006782-1.pdf.txt,['Its'],Immunology,France,Medication information,"RoActemra, tocilizumab, subcutaneous injection, side effects, missed dose",,19.744726,-39.84661,1,"The content is an instructional guide for patients regarding the administration of RoActemra (tocilizumab), a medication used for specific medical conditions. Its purpose is to provide detailed step-by-step instructions for self-administration via subcutaneous injection, including necessary equipment, storage guidelines, injection techniques, and safety precautions. It emphasizes the importance of training from healthcare professionals, proper handling of the medication, and the disposal of used materials to minimize health risks. Additionally, the guide includes information on recognizing symptoms of potential side effects and the correct procedure in case of a missed dose.","drug, reporting, adverse",rochepro.fr,All,0.476032769659801,medium,106,Drug Safety
515,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/information-medicale/marr/tecentriq/tecentriq-carte-patient-00008720-1.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_information_medicale_marr_tecentriq_tecentriq_carte_patient_00008720_1_pdf.txt,200,pdf,Non-Indexable,2,45,0,0,1,1,0.909774436090226,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_tecentriq_tecentriq-carte-patient-00008720-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_tecentriq_tecentriq-carte-patient-00008720-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_information-medicale_marr_tecentriq_tecentriq-carte-patient-00008720-1.pdf.txt,['TECENTRIQ'],Oncology-Hematology,France,Medication information,"TECENTRIQ, atezolizumab, immune-mediated reactions",,17.773008,-30.503847,1,"The content focuses on the safety and management of the immunotherapy drug TECENTRIQ (atezolizumab), manufactured by Roche. It provides critical information for healthcare professionals regarding potential serious adverse effects associated with the medication, such as immune-mediated reactions that can impact various organs. The content emphasizes the importance of early diagnosis and appropriate management to mitigate these risks and highlights specific symptoms for patients to monitor. It also includes essential contact details for oncologists and Roche's medical information services, ensuring that patients receive timely support and care during their treatment.","drug, reporting, adverse",rochepro.fr,All,0.903348976935381,medium,203,Drug Safety
516,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/pharmaciens/expertise-pui/articles/012024/infographie-chiffres-cles-loi-financement-securite-sociale-2024-00010462-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise_pui_articles_012024_infographie_chiffres_cles_loi_financement_securite_sociale_2024_00010462_1_pdf.txt,200,pdf,Non-Indexable,,106,0,0,1,1,0.905027932960894,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_012024_infographie-chiffres-cles-loi-financement-securite-sociale-2024-00010462-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_012024_infographie-chiffres-cles-loi-financement-securite-sociale-2024-00010462-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_012024_infographie-chiffres-cles-loi-financement-securite-sociale-2024-00010462-1.pdf.txt,"['France', 'French']",Other,France,Other,,,13.299011,6.3092637,7,"The content presents key figures from the 2024 social security funding law in France, produced by Roche. It highlights a total social security budget of €640 billion, which exceeds the state's budget of €491 billion. The infographic details allocations, such as €385.1 billion for retirement and family support, and €254.9 billion for healthcare. It also mentions a 3.2% increase in spending targets compared to 2023 and breaks down spending across various sectors, including €1.25 billion for fraud prevention. Overall, it emphasizes the financial structure and priorities of the French social security system for 2024.","event, exclusive, website",rochepro.fr,Rising,0.0053133152739594,medium,150,Events & Patient Care
517,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/pharmaciens/expertise-pui/articles/012024/infographie-mesures-loi-financement-securite-sociale-2024-pharmaciens-00010462-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise_pui_articles_012024_infographie_mesures_loi_financement_securite_sociale_2024_pharmaciens_00010462_1_pdf.txt,200,pdf,Non-Indexable,,94,0,0,1,1,0.908108108108108,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_012024_infographie-mesures-loi-financement-securite-sociale-2024-pharmaciens-00010462-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_012024_infographie-mesures-loi-financement-securite-sociale-2024-pharmaciens-00010462-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_012024_infographie-mesures-loi-financement-securite-sociale-2024-pharmaciens-00010462-1.pdf.txt,"['Law', 'Specific', 'Financing', 'Security', 'LFSS', 'Social']",Other,France,Offer outline,,,-2.2374458,-36.608307,1,"The content is an infographic by Roche summarizing key measures from the LFSS 2024 (Social Security Financing Law) relevant for pharmacists. It outlines various topics, including medication shortages, access to innovation, medical devices, and responsibilities for pharmacists. Specific details include the ability for pharmacies to dispense special hospital preparations, adjustments in medication regulations, and enhancements to access innovative treatments and compassionate use programs. The infographic serves as a quick reference for pharmacists to understand new legislative changes impacting their practice.","drug, reporting, adverse",rochepro.fr,Rising,0.585775488652397,medium,134,Drug Safety
518,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/pharmaciens/expertise-pui/articles/032024/pil282-cyberattaque-infographie.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise_pui_articles_032024_pil282_cyberattaque_infographie_pdf.txt,200,pdf,Non-Indexable,,20,0,0,1,1,0.926470588235294,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_032024_pil282-cyberattaque-infographie.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_032024_pil282-cyberattaque-infographie.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_032024_pil282-cyberattaque-infographie.pdf.txt,"['Training', 'Focuses', 'Discusses', 'Reaction', 'IT', 'Describes', 'Highlights', 'Anticipation', 'Security']",Other,France,Technology,,,-3.6716459,-36.331528,1,"The content is an informative infographic produced by Roche, outlining strategies for pharmacies to prepare for and react to cyberattacks. It emphasizes four key areas:   1. **Training** - Highlights the importance of secure passwords, awareness of phishing techniques, and adopting good practices to reduce human error. 2. **Anticipation** - Discusses exercises for maintaining activity continuity, preparing for cross-departmental communication, and having paper-based communication kits for crises. 3. **Security** - Focuses on protecting digital tools, ensuring regular off-site backups, using web-safe equipment, and having a known data backup plan. 4. **Reaction** - Describes procedures for following IT instructions, engaging with crisis teams, and managing a return to normal operations.  Overall, the infographic is a guide for enhancing cybersecurity preparedness in pharmacy settings.","drug, reporting, adverse",rochepro.fr,All,0.908674524177467,medium,81,Drug Safety
519,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/pharmaciens/expertise-pui/articles/042024/pil285-acces-compassionnel.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise_pui_articles_042024_pil285_acces_compassionnel_pdf.txt,200,pdf,Non-Indexable,,21,0,0,1,1,0.923664122137405,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_042024_pil285-acces-compassionnel.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_042024_pil285-acces-compassionnel.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_042024_pil285-acces-compassionnel.pdf.txt,"['Products', 'Safety', 'France', 'Medicines', 'ANSM', 'National', 'Agency', 'Health']",Other,France,Offer outline,,,15.996242,-37.63857,1,"The content outlines the process for accessing compassionate use of medicines in France, specifically focusing on the procedures guided by the ANSM (National Agency for the Safety of Medicines and Health Products). It details the situations in which a medicine can be requested, including when it is not available or authorized in France. The flowchart illustrates the evaluation and decision-making process, leading to either approval or refusal for compassionate access. It also highlights the different frameworks for authorization, emphasizing the criteria needed for both compassionate use and off-label prescription. The purpose of this infographic is to inform healthcare professionals about the steps required to facilitate access to unapproved medications for patients in critical need.","drug, reporting, adverse",rochepro.fr,All,0.372521951127827,medium,414,Drug Safety
520,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/pharmaciens/expertise-pui/articles/042024/pil285-acces-precoce-pre-post-amm.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise_pui_articles_042024_pil285_acces_precoce_pre_post_amm_pdf.txt,200,pdf,Non-Indexable,,23,0,0,1,1,0.905797101449275,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_042024_pil285-acces-precoce-pre-post-amm.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_042024_pil285-acces-precoce-pre-post-amm.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_042024_pil285-acces-precoce-pre-post-amm.pdf.txt,"['Products', 'Authority', 'Safety', 'France', 'French', 'Medicines', 'Health', 'ANSM', 'National', 'HAS', 'Agency']",Other,France,Offer outline,,,-0.76520234,-36.361702,1,"This content presents a flowchart detailing the process for early access to medications in France, produced by Roche. It differentiates between pre-authorization and post-authorization stages, outlining the roles of the ANSM (French National Agency for the Safety of Medicines and Health Products) and HAS (French National Authority for Health). The flowchart highlights criteria for authorizations, timelines for medication availability, and guidelines for reimbursement requests, emphasizing the structured approach to facilitating patient access to innovative treatments.","drug, reporting, adverse",rochepro.fr,Rising,0.758853140677807,medium,234,Drug Safety
521,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/pharmaciens/expertise-pui/articles/112024/fiche-synthese-acces-direct.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise_pui_articles_112024_fiche_synthese_acces_direct_pdf.txt,200,pdf,Non-Indexable,2,43,0,0,1,1,0.916666666666667,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_112024_fiche-synthese-acces-direct.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_112024_fiche-synthese-acces-direct.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_112024_fiche-synthese-acces-direct.pdf.txt,"['Transparency', 'AMM', 'Commission', 'CT']",Other,France,Offer outline,,,-0.31050462,-36.197636,1,"The content outlines the steps involved in accessing reimbursement for pharmaceutical products in two scenarios: when reimbursement is approved and when it is not. It provides a flowchart detailing the processes, timelines, and required submissions, such as requests for market authorization (AMM) and opinions from the Transparency Commission (CT). The goal is to clarify the procedures for healthcare professionals and stakeholders regarding pricing and reimbursement status for medications. The infographic is produced for Roche, emphasizing the importance of understanding reimbursement pathways.","drug, reporting, adverse",rochepro.fr,Falling,0.960367191874195,medium,63,Drug Safety
522,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/pharmaciens/expertise-pui/articles/112024/fiche-synthese-acces-precoce.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise_pui_articles_112024_fiche_synthese_acces_precoce_pdf.txt,200,pdf,Non-Indexable,2,38,0,0,1,1,0.917293233082707,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_112024_fiche-synthese-acces-precoce.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_112024_fiche-synthese-acces-precoce.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_expertise-pui_articles_112024_fiche-synthese-acces-precoce.pdf.txt,"['France', 'ANSM', 'HAS']",Other,France,Offer outline,,,15.160013,-37.481663,1,"The content outlines the processes for early access to medications before and after marketing authorization in France, specifically focusing on the regulatory roles of ANSM and HAS. The top section details criteria for pre-authorization, emphasizing the conditions for favorable and unfavorable opinions, along with steps for drug availability. The bottom part highlights the procedures post-authorization, summarizing necessary evaluations and timelines for reimbursement requests. This infographic serves as a guide for pharmaceutical laboratories on navigating the early access process.","drug, reporting, adverse",rochepro.fr,All,0.345251073690756,medium,491,Drug Safety
523,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/pharmaciens/rupture-chaine-froid/formulaire-excursion-temperature-iis-srd-0100304-7.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_rupture_chaine_froid_formulaire_excursion_temperature_iis_srd_0100304_7_pdf.txt,200,pdf,Non-Indexable,3,87,0,0,1,1,0.897260273972603,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_rupture-chaine-froid_formulaire-excursion-temperature-iis-srd-0100304-7.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_rupture-chaine-froid_formulaire-excursion-temperature-iis-srd-0100304-7.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_rupture-chaine-froid_formulaire-excursion-temperature-iis-srd-0100304-7.pdf.txt,[],Other,France,Medication information,,,2.1066241,-37.17542,1,"The content is a formal content related to Roche, a pharmaceutical company, focusing on protocol for handling temperature deviations of products. It outlines the necessary information, including contact details, study descriptions, and specific conditions for temperature excursions that could affect product integrity. The purpose is to ensure compliance with guidelines for safety and management of pharmaceuticals affected by temperature changes, detailing responsibilities of both pharmacists and Roche in ensuring product usability and storage conditions.","drug, reporting, adverse",rochepro.fr,Rising,0.821127873429324,medium,22,Drug Safety
524,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/pharmaciens/rupture-chaine-froid/formulaire-signalement-excursion-temperature-acces-compassionnels-precoces-aac-aap-srd-0100303-6.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_rupture_chaine_froid_formulaire_signalement_excursion_temperature_acces_compassionnels_precoces_aac_aap_srd_0100303_6_pdf.txt,200,pdf,Non-Indexable,3,83,0,0,1,1,0.895833333333333,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_rupture-chaine-froid_formulaire-signalement-excursion-temperature-acces-compassionnels-precoces-aac-aap-srd-0100303-6.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_rupture-chaine-froid_formulaire-signalement-excursion-temperature-acces-compassionnels-precoces-aac-aap-srd-0100303-6.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_rupture-chaine-froid_formulaire-signalement-excursion-temperature-acces-compassionnels-precoces-aac-aap-srd-0100303-6.pdf.txt,"['Finally', 'Its']",Other,France,Medication information,,,2.0967476,-37.25344,1,"The content is a detailed instruction and reporting form related to temperature excursions for pharmaceutical products handled by Roche, specifically for compassionate access programs. Its purpose is to gather essential information from pharmacists regarding any deviations in temperature that could affect the integrity of these products, ensuring compliance with safety protocols. The content outlines the necessary steps pharmacists must take when reporting such deviations, including providing specific data about the incident and affirming their adherence to storage conditions. Finally, it describes Roche's evaluation process for determining the usability of the affected products, along with the responsibilities of both the pharmacist and Roche regarding product safety and handling.","drug, reporting, adverse",rochepro.fr,Flat,0.473119594384565,medium,289,Drug Safety
525,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/pharmaciens/rupture-chaine-froid/formulaire-signalement-excursion-temperature-medicament-commerciaux-gcp-for003824-9.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_rupture_chaine_froid_formulaire_signalement_excursion_temperature_medicament_commerciaux_gcp_for003824_9_pdf.txt,200,pdf,Non-Indexable,3,44,0,0,1,1,0.905027932960894,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_rupture-chaine-froid_formulaire-signalement-excursion-temperature-medicament-commerciaux-gcp-for003824-9.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_rupture-chaine-froid_formulaire-signalement-excursion-temperature-medicament-commerciaux-gcp-for003824-9.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_rupture-chaine-froid_formulaire-signalement-excursion-temperature-medicament-commerciaux-gcp-for003824-9.pdf.txt,['Its'],Other,France,Other,,,2.833259,-37.999557,1,"The content appears to be a form related to temperature excursion reporting for pharmaceutical products specifically for Roche. Its purpose is to gather detailed information about temperature deviations that may affect product quality, outlining the responsibilities of the pharmacist and Roche. It requires pharmacists to content and verify conditions and events related to products after experiencing temperature excursions, ensuring compliance and safety in pharmaceutical handling. The form includes sections for pharmacist attestation, product details, and conditions for stable storage.","drug, reporting, adverse",rochepro.fr,Rising,0.480002477745386,medium,278,Drug Safety
526,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/pharmaciens/signaler-defaut-qualite/formulaire-signalement-defaut-qualite-roche-SRD-0112220-7.pdf,6,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_signaler_defaut_qualite_formulaire_signalement_defaut_qualite_roche_SRD_0112220_7_pdf.txt,200,pdf,Indexable,2,63,0,0,1,1,0.897435897435898,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_signaler-defaut-qualite_formulaire-signalement-defaut-qualite-roche-SRD-0112220-7.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_signaler-defaut-qualite_formulaire-signalement-defaut-qualite-roche-SRD-0112220-7.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_pharmaciens_signaler-defaut-qualite_formulaire-signalement-defaut-qualite-roche-SRD-0112220-7.pdf.txt,[],Other,France,Offer outline,,,-4.144658,-25.850077,3,"The content is a quality defect reporting form from Roche, intended for health professionals to report issues with pharmaceutical products. It includes sections for the reporter's information, details about the concerned medication, and questions regarding the product's usage, defect discovery, and any adverse events. The form emphasizes the importance of documenting and addressing quality concerns for patient safety.","users, page, website",rochepro.fr,Rising,0.450674596629706,medium,274,Website Metadata
527,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/services/90-secondes/alimenter-profil-linkedin/que-partager-sur-linkedin-00000424-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90_secondes_alimenter_profil_linkedin_que_partager_sur_linkedin_00000424_1_pdf.txt,200,pdf,Non-Indexable,,59,0,0,1,1,0.897260273972603,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_alimenter-profil-linkedin_que-partager-sur-linkedin-00000424-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_alimenter-profil-linkedin_que-partager-sur-linkedin-00000424-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_alimenter-profil-linkedin_que-partager-sur-linkedin-00000424-1.pdf.txt,[],Other,France,Other,,,-1.5935583,-18.610525,3,"The content is a promotional infographic from Roche, aimed at encouraging professionals to engage on LinkedIn. It outlines three key types of content to share: press articles, studies and infographics, and personal opinions on current topics relevant to their profession. The title suggests a quick, 90-second read designed to provide valuable networking tips.","users, page, website",rochepro.fr,All,0.891131645716021,medium,253,Website Metadata
528,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/services/90-secondes/alimenter-profil-linkedin/qui-inviter-profil-linkedin-00000424-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90_secondes_alimenter_profil_linkedin_qui_inviter_profil_linkedin_00000424_1_pdf.txt,200,pdf,Non-Indexable,,73,0,0,1,1,0.898648648648649,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_alimenter-profil-linkedin_qui-inviter-profil-linkedin-00000424-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_alimenter-profil-linkedin_qui-inviter-profil-linkedin-00000424-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_alimenter-profil-linkedin_qui-inviter-profil-linkedin-00000424-1.pdf.txt,[],Other,France,Other,,,3.9473865,-0.9643522,7,"The content is an informative graphic produced by Roche for professional networking. It emphasizes the importance of connecting with various individuals on LinkedIn, including colleagues, supervisors, mentors, partners, and leading experts in one's specialty. The aim is to enhance professional relationships and network effectively in a concise, engaging format. The title suggests that the information can be absorbed quickly—within 90 seconds.","event, exclusive, website",rochepro.fr,Falling,0.998615590420967,medium,299,Events & Patient Care
529,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/services/90-secondes/animer-reseau-de-pairs/pourquoi-chercher-animer-reseau-00000424-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90_secondes_animer_reseau_de_pairs_pourquoi_chercher_animer_reseau_00000424_1_pdf.txt,200,pdf,Non-Indexable,,73,0,0,1,1,0.89261744966443,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_animer-reseau-de-pairs_pourquoi-chercher-animer-reseau-00000424-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_animer-reseau-de-pairs_pourquoi-chercher-animer-reseau-00000424-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_animer-reseau-de-pairs_pourquoi-chercher-animer-reseau-00000424-1.pdf.txt,[],Other,France,Other,,,3.6935408,-1.0445689,7,"The content is an informative infographic produced by Roche, focusing on the importance of engaging one's professional network. It outlines several key benefits of networking, such as expanding one's reach, saving time by attending online events, discovering new opportunities, and facilitating quick exchanges with peers. The design features a countdown timer and visually appealing icons to emphasize each point, underscoring the message of effective communication and connection in a professional context.","event, exclusive, website",rochepro.fr,All,0.129814381354116,medium,185,Events & Patient Care
530,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/services/90-secondes/animer-reseau-de-pairs/quoi-partager-quand-faire-00000424-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90_secondes_animer_reseau_de_pairs_quoi_partager_quand_faire_00000424_1_pdf.txt,200,pdf,Non-Indexable,,67,0,0,1,1,0.888111888111888,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_animer-reseau-de-pairs_quoi-partager-quand-faire-00000424-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_animer-reseau-de-pairs_quoi-partager-quand-faire-00000424-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_animer-reseau-de-pairs_quoi-partager-quand-faire-00000424-1.pdf.txt,"['Twitter', 'Difference', 'Seconds', 'Make']",Other,France,Offer outline,,,21.482819,12.708592,4,"The content is an infographic from Roche, titled ""90 Seconds That Make a Difference."" It outlines guidelines on what to share and when in a professional context. The content includes suggestions like sharing articles or publications relevant to practice, studies conducted or deemed pertinent, personal ideas or viewpoints, and advice on using Twitter and LinkedIn for effective communication. The aim is to encourage proactive sharing of valuable information within a professional setting.","technologies, artificial, ai",rochepro.fr,All,0.381925913478074,medium,41,Technology
531,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/services/90-secondes/consultation-distance/90-secondes-precautions-a-prendre-00005287-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90_secondes_consultation_distance_90_secondes_precautions_a_prendre_00005287_1_pdf.txt,200,pdf,Non-Indexable,,59,0,0,1,1,0.9,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_consultation-distance_90-secondes-precautions-a-prendre-00005287-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_consultation-distance_90-secondes-precautions-a-prendre-00005287-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_consultation-distance_90-secondes-precautions-a-prendre-00005287-1.pdf.txt,[],Other,France,Technology,,,7.472663,1.6492302,7,"The content is a visual message from RochePro outlining important precautions to consider during teleconsultations. It includes key points such as the importance of selecting appropriate operators, reading the terms of service, understanding responsibilities regarding remuneration, and emphasizing patient confidentiality. The overall purpose is to provide guidance for ensuring safe and effective teleconsultation practices.","event, exclusive, website",rochepro.fr,All,0.770504359702995,medium,353,Events & Patient Care
532,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/services/90-secondes/creer-profil-linkedin/bien-creer-profil-linkedin-00000424-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90_secondes_creer_profil_linkedin_bien_creer_profil_linkedin_00000424_1_pdf.txt,200,pdf,Non-Indexable,,64,0,0,1,1,0.895104895104895,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_creer-profil-linkedin_bien-creer-profil-linkedin-00000424-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_creer-profil-linkedin_bien-creer-profil-linkedin-00000424-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_creer-profil-linkedin_bien-creer-profil-linkedin-00000424-1.pdf.txt,[],Other,France,Other,,,-0.56101257,-20.429329,3,"The content is an infographic created by RochePro, focusing on how to effectively create a LinkedIn profile. It emphasizes the importance of using a clear photo for identification, avoiding pseudonyms to maintain authenticity, and providing precise information about education and career background. The content is designed to assist individuals in enhancing their professional presence on LinkedIn within a brief time frame.","users, page, website",rochepro.fr,Rising,0.335356158129786,medium,412,Website Metadata
533,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/services/90-secondes/creer-profil-linkedin/linkedin-un-clin-oeil-00000424-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90_secondes_creer_profil_linkedin_linkedin_un_clin_oeil_00000424_1_pdf.txt,200,pdf,Non-Indexable,,60,0,0,1,1,0.891304347826087,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_creer-profil-linkedin_linkedin-un-clin-oeil-00000424-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_creer-profil-linkedin_linkedin-un-clin-oeil-00000424-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_creer-profil-linkedin_linkedin-un-clin-oeil-00000424-1.pdf.txt,[],Other,France,Other,,,-0.6309844,-19.295538,3,"The content is an infographic produced for Roche that highlights key facts about LinkedIn. It emphasizes LinkedIn as a professional networking platform, noting it has nearly 546 million users and provides global visibility to one's professional activities. The design includes visual icons and a clear, concise layout, making the information easily digestible for the audience. The title suggests it aims to deliver useful insights quickly.","users, page, website",rochepro.fr,Rising,0.009390138405977,medium,182,Website Metadata
534,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/services/90-secondes/teleconsultation-nouvelle-relation-patient/ce-qui-change-patients-00005287-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90_secondes_teleconsultation_nouvelle_relation_patient_ce_qui_change_patients_00005287_1_pdf.txt,200,pdf,Non-Indexable,,65,0,0,1,1,0.9,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_teleconsultation-nouvelle-relation-patient_ce-qui-change-patients-00005287-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_teleconsultation-nouvelle-relation-patient_ce-qui-change-patients-00005287-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_teleconsultation-nouvelle-relation-patient_ce-qui-change-patients-00005287-1.pdf.txt,[],Other,France,Patient support,,,-25.779854,-23.035517,0,"The content is an informational poster produced by RochePro, highlighting changes that affect patients. It emphasizes that there will be no changes to pricing, reimbursement, or prescriptions. It also stresses the importance of maintaining a good patient-physician relationship and encourages healthcare providers to take time to explain changes to patients, helping them to adjust. The content is designed to assure patients and facilitate communication regarding healthcare updates.","oncology, professionals, data",rochepro.fr,Rising,0.227488838807111,medium,216,General Offer Outline
535,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/services/90-secondes/teleconsultation-ou-en-est-on/teleconsultation-definition-chiffres-00005287-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90_secondes_teleconsultation_ou_en_est_on_teleconsultation_definition_chiffres_00005287_1_pdf.txt,200,pdf,Non-Indexable,,78,0,0,1,1,0.900621118012422,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_teleconsultation-ou-en-est-on_teleconsultation-definition-chiffres-00005287-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_teleconsultation-ou-en-est-on_teleconsultation-definition-chiffres-00005287-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_teleconsultation-ou-en-est-on_teleconsultation-definition-chiffres-00005287-1.pdf.txt,"['France', 'April']",Other,France,Technology,,,23.981962,9.909575,4,"The content is an informational infographic produced by Roche focusing on teleconsultation. It defines teleconsultation as a remote medical consultation via videoconference and provides statistical data, indicating that since April 2020, there have been nearly one million teleconsultations per week in France, making up 27% of all medical consultations. The purpose of the infographic is to highlight the significance and impact of teleconsultation in healthcare.","technologies, artificial, ai",rochepro.fr,All,0.372654734474742,medium,420,Technology
536,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/services/90-secondes/teleconsultation-ou-en-est-on/teleconsultation-pour-quel-patient-00005287-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90_secondes_teleconsultation_ou_en_est_on_teleconsultation_pour_quel_patient_00005287_1_pdf.txt,200,pdf,Non-Indexable,,71,0,0,2,2,0.893081761006289,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_teleconsultation-ou-en-est-on_teleconsultation-pour-quel-patient-00005287-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_teleconsultation-ou-en-est-on_teleconsultation-pour-quel-patient-00005287-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_services_90-secondes_teleconsultation-ou-en-est-on_teleconsultation-pour-quel-patient-00005287-1.pdf.txt,[],Other,France,Technology,,,7.239596,1.9616575,7,"The content is an informational graphic by Roche focusing on teleconsultation in healthcare. It outlines the criteria for patients eligible for teleconsultation, emphasizing that patients must have been seen in-person at least once in the past year, adhere to their usual health management, and that no specific pathology prevents them from accessing these services. Additionally, it states that patients may be accompanied by a healthcare professional during the teleconsultation. The graphic aims to clarify guidelines for both patients and healthcare providers.","event, exclusive, website",rochepro.fr,Falling,0.373033557139826,medium,243,Events & Patient Care
537,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/visite/cancer-bronchique-therapie-ciblee/BD-CBNPC-mettre-toutes-les-chances-du-cote-de-votre-therapie-ciblee-00008042-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_cancer_bronchique_therapie_ciblee_BD_CBNPC_mettre_toutes_les_chances_du_cote_de_votre_therapie_ciblee_00008042_1_pdf.txt,200,pdf,Non-Indexable,,60,0,0,1,1,0.873626373626374,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_cancer-bronchique-therapie-ciblee_BD-CBNPC-mettre-toutes-les-chances-du-cote-de-votre-therapie-ciblee-00008042-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_cancer-bronchique-therapie-ciblee_BD-CBNPC-mettre-toutes-les-chances-du-cote-de-votre-therapie-ciblee-00008042-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_cancer-bronchique-therapie-ciblee_BD-CBNPC-mettre-toutes-les-chances-du-cote-de-votre-therapie-ciblee-00008042-1.pdf.txt,['NSCLC'],Oncology-Hematology,France,Patient support,"targeted therapy, non-small cell lung cancer (NSCLC), medication, cancer cells, resistance, complementary medicines, treatment efficacy, side effects",non-small cell lung cancer,29.784195,-19.36754,12,"The content discusses the importance of adhering to a targeted therapy regimen for patients with non-small cell lung cancer (NSCLC) caused by genetic mutations. It emphasizes the potential consequences of skipping medication, such as allowing cancer cells to proliferate and develop resistance. The content provides guidance on how to effectively integrate medication into daily routines, address interactions with other treatments, and maintain a healthy diet. Additionally, it cautions against complementary medicines, highlights the significance of regular communication with healthcare professionals, and outlines lifestyle factors that may affect treatment efficacy. Overall, the purpose of the content is to educate patients on maximizing the effectiveness of their cancer treatment while minimizing potential side effects.","cancer, breast, lung",rochepro.fr,Flat,0.934948384154427,medium,247,Disease Information
538,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/visite/suivi-cancer-bronchique/immunotherapie-bilan-routine-00002058-1.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_suivi_cancer_bronchique_immunotherapie_bilan_routine_00002058_1_pdf.txt,200,pdf,Non-Indexable,,64,0,0,1,1,0.902255639097744,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_suivi-cancer-bronchique_immunotherapie-bilan-routine-00002058-1.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_suivi-cancer-bronchique_immunotherapie-bilan-routine-00002058-1.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_suivi-cancer-bronchique_immunotherapie-bilan-routine-00002058-1.pdf.txt,"['C', 'I', 'F']",Immunology,France,Patient support,,,-18.796759,-10.650498,0,"The content is a brochure from Roche emphasizing the importance of routine assessments to be conducted before and during immunotherapy treatments. It features a supportive interaction between a healthcare professional and a patient, indicating a focus on patient care and communication. The brochure also outlines Roche's commitment to handling personal data responsibly in collaboration with A.F.I.C. Additionally, it provides contact information and resources for further details about patient data rights and treatment information.","oncology, professionals, data",rochepro.fr,Falling,0.463012249227413,medium,134,General Offer Outline
539,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/visite/wikiboop/wikiboop-affiche-d-20-0286.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_wikiboop_wikiboop_affiche_d_20_0286_pdf.txt,200,pdf,Non-Indexable,,28,0,0,1,1,0.895238095238095,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_wikiboop_wikiboop-affiche-d-20-0286.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_wikiboop_wikiboop-affiche-d-20-0286.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_wikiboop_wikiboop-affiche-d-20-0286.pdf.txt,"['QR', 'Wikiboop']",Oncology-Hematology,France,Technology,"Wikiboop, breast cancer",breast cancer,25.134777,-10.294993,12,"The content promotes a mobile application called ""Wikiboop,"" designed to support individuals on their personalized journey with breast cancer. It highlights features such as step-by-step guidance, clear information about breast cancer, and a compassionate environment for users. The app is free to download, and a QR code is provided for easy access. The design is colorful and inviting, aiming to foster a supportive community for users.","cancer, breast, lung",rochepro.fr,Rising,0.292994371122617,medium,462,Disease Information
540,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/visite/wikiboop/wikiboop-flyer-patiente-d-20-0435.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_wikiboop_wikiboop_flyer_patiente_d_20_0435_pdf.txt,200,pdf,Non-Indexable,,37,0,0,1,1,0.892857142857143,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_wikiboop_wikiboop-flyer-patiente-d-20-0435.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_wikiboop_wikiboop-flyer-patiente-d-20-0435.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_wikiboop_wikiboop-flyer-patiente-d-20-0435.pdf.txt,"['QR', 'Wikiboop', 'Play', 'Store', 'Google', 'App']",Oncology-Hematology,France,Patient support,"breast cancer, Wikiboop, emotional support, QR code, Google Play, App Store",breast cancer,25.454811,-9.969284,12,"The content promotes ""Wikiboop,"" an application designed to support individuals dealing with breast cancer throughout their care journey. It highlights the app's features, such as easy access to information and emotional support. The message encourages users to download the app via QR code, offering it on Google Play and the App Store. Overall, the purpose is to provide a comprehensive resource for those navigating breast cancer treatment.","cancer, breast, lung",rochepro.fr,Rising,0.797410095251647,medium,478,Disease Information
541,https://rochepro.fr/content/dam/nextgen/whitelabel/emea/fr/fr/visite/wikiboop/wikiboop-flyer-pds.pdf,5,rochepro_fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_wikiboop_wikiboop_flyer_pds_pdf.txt,200,pdf,Non-Indexable,,40,0,0,1,1,0.907216494845361,https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_wikiboop_wikiboop-flyer-pds.pdf,image/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_wikiboop_wikiboop-flyer-pds.pdf.png,text/https_rochepro.fr_content_dam_nextgen_whitelabel_emea_fr_fr_visite_wikiboop_wikiboop-flyer-pds.pdf.txt,['Wikiboop'],Oncology-Hematology,France,Patient support,,breast cancer,24.206644,-10.124909,12,"The content promotes ""Wikiboop,"" an application designed to support patients with breast cancer throughout their care journey. It is produced by Roche and emphasizes wellness and guidance for individuals facing this health challenge. The illustration features a serene outdoor scene, symbolizing support and positivity in the healing process.","cancer, breast, lung",rochepro.fr,Rising,0.431074502666583,medium,479,Disease Information
542,https://www.rocheplus.es/content/dam/hcp-portals/spain/documents/areas-terapeuticas/oncologia/medicina-de-precision/Roche_Informe__resumen_TTA_final.pdf,6,www_rocheplus_es_content_dam_hcp_portals_spain_documents_areas_terapeuticas_oncologia_medicina_de_precision_Roche_Informe__resumen_TTA_final_pdf.txt,200,pdf,Indexable,2,50,0,0,2,1,0.919463087248322,https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_areas-terapeuticas_oncologia_medicina-de-precision_Roche_Informe__resumen_TTA_final.pdf,image/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_areas-terapeuticas_oncologia_medicina-de-precision_Roche_Informe__resumen_TTA_final.pdf.png,text/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_areas-terapeuticas_oncologia_medicina-de-precision_Roche_Informe__resumen_TTA_final.pdf.txt,"['System', 'TTA', 'Spain', 'National', 'SNS', 'Health']",Oncology-Hematology,Spain,Research,"tumor-agnostic therapies, oncology treatment, cancer, genetic characteristics, molecular characteristics, challenges, access, funding, adapted methodologies, multidisciplinary scientific committee, innovative cancer treatments",,33.610085,-17.62149,12,"The content discusses tumor-agnostic therapies (TTA), which are a type of oncology treatment that targets cancer based on genetic and molecular characteristics rather than the tumor's location or histology. It highlights the challenges these therapies face within Spain's National Health System (SNS), particularly concerning access, funding, and the need for adapted methodologies. The goal of the project presented is to facilitate access to TTA in Spain through a multidisciplinary scientific committee that examines the current state of these therapies, identifies key challenges, and proposes solutions to ensure they are integrated into the healthcare system efficiently. The content underscores the importance of collaboration among stakeholders in addressing these issues while promoting patient access to innovative cancer treatments.","cancer, breast, lung",www.rocheplus.es,All,0.168415841429116,medium,140,Disease Information
543,https://www.rocheplus.es/content/dam/hcp-portals/spain/documents/areas-terapeuticas/oncologia/medicina-de-precision/tecnicas-diagnosticas/Roche_guia_diagnostico_fusiones_NTRK.pdf,0,www_rocheplus_es_content_dam_hcp_portals_spain_documents_areas_terapeuticas_oncologia_medicina_de_precision_tecnicas_diagnosticas_Roche_guia_diagnostico_fusiones_NTRK_pdf.txt,200,pdf,Indexable,3,0,0,0,1,1,0.925714285714286,https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_areas-terapeuticas_oncologia_medicina-de-precision_tecnicas-diagnosticas_Roche_guia_diagnostico_fusiones_NTRK.pdf,image/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_areas-terapeuticas_oncologia_medicina-de-precision_tecnicas-diagnosticas_Roche_guia_diagnostico_fusiones_NTRK.pdf.png,text/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_areas-terapeuticas_oncologia_medicina-de-precision_tecnicas-diagnosticas_Roche_guia_diagnostico_fusiones_NTRK.pdf.txt,"['FISH', 'IHC', 'NGS', 'NTRK']",Oncology-Hematology,Spain,Technology,"NTRK gene fusions, next-generation sequencing (NGS), immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), targeted therapies",,34.660633,-14.813459,12,"The content discusses the significance of actionable biomarkers, specifically NTRK gene fusions, in cancer diagnosis and treatment. It highlights the importance of high-quality molecular testing to identify patients with such fusions, which can lead to targeted therapies. The content outlines various diagnostic techniques such as next-generation sequencing (NGS), immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH), emphasizing their roles, advantages, limitations, and guidelines for detecting NTRK fusions. Overall, the purpose is to inform healthcare professionals about the methods and recommendations for identifying NTRK fusions to optimize patient care in oncology.","cancer, breast, lung",www.rocheplus.es,Flat,0.997023570633406,low,89,Disease Information
544,https://www.rocheplus.es/content/dam/hcp-portals/spain/documents/informacion-cientifica/Infografia_infocientifica_.pdf,1,www_rocheplus_es_content_dam_hcp_portals_spain_documents_informacion_cientifica_Infografia_infocientifica__pdf.txt,200,pdf,Indexable,2,0,0,0,3,2,0.91304347826087,https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_informacion-cientifica_Infografia_infocientifica_.pdf,image/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_informacion-cientifica_Infografia_infocientifica_.pdf.png,text/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_informacion-cientifica_Infografia_infocientifica_.pdf.txt,"['Europe', 'East', 'Middle']",Other,Spain,Metainformation,,,-24.778652,-19.293318,0,"The content is an informative infographic created by Roche, focusing on the scientific information available to healthcare professionals. It highlights the resources offered by Roche for inquiries about diseases and products, detailing that each country has a dedicated scientific information unit. The infographic includes contact information, including a web address, phone number, and email, as well as a map indicating Roche's presence across Europe and parts of the Middle East. Additionally, it categorizes services into areas like pharmaceutical consultations, full-content articles, congress communications, and bibliographic searches.","oncology, professionals, data",www.rocheplus.es,All,0.717115686818912,low,257,General Offer Outline
545,https://www.rocheplus.es/content/dam/hcp-portals/spain/documents/innovacion/articulos/6-Infografia._Rocheplus_Medicina_Regenerativa.pdf,0,www_rocheplus_es_content_dam_hcp_portals_spain_documents_innovacion_articulos_6_Infografia__Rocheplus_Medicina_Regenerativa_pdf.txt,200,pdf,Indexable,3,0,0,0,1,1,0.916666666666667,https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_6-Infografia._Rocheplus_Medicina_Regenerativa.pdf,image/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_6-Infografia._Rocheplus_Medicina_Regenerativa.pdf.png,text/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_6-Infografia._Rocheplus_Medicina_Regenerativa.pdf.txt,[],Other,Spain,Research,"regenerative medicine, stem cells, tissue regeneration, lung tissue destruction, cartilage regeneration, wound healing, renal regeneration, tissue engineering","lung tissue destruction, cartilage degeneration, wound healing, renal regeneration, tissue engineering",30.07644,0.41706836,4,"The content presents an infographic about regenerative medicine, focusing on its definition, benefits, and applications. It describes regenerative medicine as a therapy using stem cells for tissue regeneration and highlights benefits such as accelerated healing and contributions to personalized medicine. The applications listed include reducing lung tissue destruction, regenerating cartilage in knees, wound healing, renal regeneration, and tissue engineering, emphasizing Roche's involvement in these innovative medical solutions.","technologies, artificial, ai",www.rocheplus.es,Flat,0.773905762302871,low,195,Technology
546,https://www.rocheplus.es/content/dam/hcp-portals/spain/documents/innovacion/articulos/7-Infografia._Rocheplus_Objetivo_aumentar_la_natalidad.pdf,5,www_rocheplus_es_content_dam_hcp_portals_spain_documents_innovacion_articulos_7_Infografia__Rocheplus_Objetivo_aumentar_la_natalidad_pdf.txt,200,pdf,Indexable,3,23,0,0,1,1,0.921985815602837,https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_7-Infografia._Rocheplus_Objetivo_aumentar_la_natalidad.pdf,image/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_7-Infografia._Rocheplus_Objetivo_aumentar_la_natalidad.pdf.png,text/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_7-Infografia._Rocheplus_Objetivo_aumentar_la_natalidad.pdf.txt,"['Embryo', 'Lapse', 'Uteruses', 'AI', 'Monitoring', 'Technology', 'These', 'Artificial', 'Time', 'Bluetooth', 'Selection']",Other,Spain,Technology,"AI for Embryo Selection, Artificial Uteruses, Monitoring Technology, premature babies, infant mortality rates, prematurity",,12.685571,8.114755,7,The content presents an infographic by Roche focused on medical technologies aimed at increasing birth rates and improving outcomes for premature babies. It highlights three key innovations:   1. **AI for Embryo Selection**: The Time Lapse tool monitors embryo development using a camera in incubators. 2. **Artificial Uteruses**: These are designed to support the growth of premature infants outside the mother's womb and enhance their survival chances. 3. **Monitoring Technology**: A monitoring system utilizes transparent strips to transmit vital data of premature babies via Bluetooth.  The overall purpose is to showcase advancements in healthcare that could help reduce infant mortality rates due to prematurity.,"event, exclusive, website",www.rocheplus.es,All,0.303811686749835,medium,330,Events & Patient Care
547,https://www.rocheplus.es/content/dam/hcp-portals/spain/documents/innovacion/articulos/9._Infografia_La_revolucion_del_5G.pdf,0,www_rocheplus_es_content_dam_hcp_portals_spain_documents_innovacion_articulos_9__Infografia_La_revolucion_del_5G_pdf.txt,200,pdf,Indexable,3,0,0,0,1,1,0.917355371900827,https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_9._Infografia_La_revolucion_del_5G.pdf,image/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_9._Infografia_La_revolucion_del_5G.pdf.png,text/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_9._Infografia_La_revolucion_del_5G.pdf.txt,"['Teleconsultation', 'Surgery', 'Data', 'Wearable', 'Facilitating', 'Assisted', 'Analysis', 'Monitoring', 'Enabling', 'Enhancing', 'Improving', 'Storage']",Other,Spain,Technology,"5G technology, Teleconsultation, Data Storage and Analysis, Assisted Surgery, Wearable Monitoring",,30.741606,14.473928,4,"The content titled ""Tecnología 5G en medicina"" from Roche outlines the transformative impact of 5G technology in modern healthcare. It highlights four key areas of application:  1. **Teleconsultation** - Enhancing direct and reliable communication between doctors and patients. 2. **Data Storage and Analysis** - Facilitating the analysis and storage of medical data while preventing network failures that could slow down processes. 3. **Assisted Surgery** - Enabling remote collaboration and support among professionals with high-definition content and video sharing. 4. **Wearable Monitoring** - Improving the speed and efficiency of health data collection from wearable devices through reduced latency.  The overall purpose is to showcase how 5G can expand healthcare capabilities.","technologies, artificial, ai",www.rocheplus.es,All,0.0170372393295598,low,496,Technology
548,https://www.rocheplus.es/content/dam/hcp-portals/spain/documents/innovacion/articulos/Infografia_Roche-Hospitales_Inteligentes.pdf,5,www_rocheplus_es_content_dam_hcp_portals_spain_documents_innovacion_articulos_Infografia_Roche_Hospitales_Inteligentes_pdf.txt,200,pdf,Indexable,3,40,0,0,2,1,0.921259842519685,https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_Infografia_Roche-Hospitales_Inteligentes.pdf,image/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_Infografia_Roche-Hospitales_Inteligentes.pdf.png,text/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_Infografia_Roche-Hospitales_Inteligentes.pdf.txt,"['Hospitals', 'UV', 'Intelligent', 'Various']",Other,Spain,Technology,"artificial intelligence, robotics, augmented reality, centralized data, remote operations, tele-diagnostic robots, UV disinfection systems",,11.947651,9.847204,7,"The content is an infographic presented by Roche, focusing on the theme of ""Intelligent Hospitals"" and the technological advancements reshaping healthcare facilities. It highlights key concepts such as artificial intelligence, robotics, and augmented reality, illustrating how these technologies contribute to hospital operations. Various elements such as centralized data, remote operations, tele-diagnostic robots, and UV disinfection systems are depicted, emphasizing improvements in patient care and hospital efficiency. The overall message conveys a vision of a transformed healthcare environment through innovative technologies.","event, exclusive, website",www.rocheplus.es,Rising,0.906596403717361,medium,494,Events & Patient Care
549,https://www.rocheplus.es/content/dam/hcp-portals/spain/documents/innovacion/articulos/Infografia_Roche-tecnologia_Sensorial.pdf,5,www_rocheplus_es_content_dam_hcp_portals_spain_documents_innovacion_articulos_Infografia_Roche_tecnologia_Sensorial_pdf.txt,200,pdf,Indexable,3,37,0,0,2,1,0.919354838709677,https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_Infografia_Roche-tecnologia_Sensorial.pdf,image/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_Infografia_Roche-tecnologia_Sensorial.pdf.png,text/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_Infografia_Roche-tecnologia_Sensorial.pdf.txt,['LIDAR'],Other,Spain,Technology,"artificial intelligence, LIDAR sensors, particle sensors, light sensors, object recognition software, voice recognition, haptic technology",,37.165165,7.8493977,4,"The content titled ""Tecnologías sensoriales aplicadas a la robótica"" focuses on various sensory technologies utilized in robotics, highlighting their applications and functionalities. It features several technologies, including artificial intelligence, LIDAR sensors, particle sensors, light sensors, object recognition software, voice recognition, and haptic technology. The infographic aims to showcase how these innovations enhance robots' ability to understand and interact with their environment and humans, ultimately promoting the development and integration of smart robotic systems.","technologies, artificial, ai",www.rocheplus.es,Rising,0.579707493305028,medium,272,Technology
550,https://www.rocheplus.es/content/dam/hcp-portals/spain/documents/innovacion/articulos/Infografia_Rocheplus_COVID.pdf,0,www_rocheplus_es_content_dam_hcp_portals_spain_documents_innovacion_articulos_Infografia_Rocheplus_COVID_pdf.txt,200,pdf,Indexable,3,0,0,0,1,1,0.920353982300885,https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_Infografia_Rocheplus_COVID.pdf,image/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_Infografia_Rocheplus_COVID.pdf.png,text/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_Infografia_Rocheplus_COVID.pdf.txt,"['Advances', 'COVID', 'Pandemic', 'Technological', 'Combat']",Other,Spain,Technology,"COVID-19, genetic research, apps, chatbots, self-testing, diagnosis, artificial intelligence, diagnostics, infrared cameras, temperature measurements",,40.00495,12.167535,4,"The content is an infographic detailing ""7 Technological Advances to Combat the COVID-19 Pandemic,"" produced by Roche. It highlights various innovations such as genetic research against the virus, the use of apps and chatbots for self-testing and diagnosis, the application of artificial intelligence to improve diagnostics, and the implementation of infrared cameras for mass temperature measurements. The purpose of the infographic is to showcase how technology has played a crucial role in managing and mitigating the impact of the pandemic.","technologies, artificial, ai",www.rocheplus.es,All,0.630349010013825,low,11,Technology
551,https://www.rocheplus.es/content/dam/hcp-portals/spain/documents/innovacion/articulos/Infografia-tecnologias-emergencias.pdf,0,www_rocheplus_es_content_dam_hcp_portals_spain_documents_innovacion_articulos_Infografia_tecnologias_emergencias_pdf.txt,200,pdf,Indexable,3,0,0,0,1,1,0.909090909090909,https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_Infografia-tecnologias-emergencias.pdf,image/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_Infografia-tecnologias-emergencias.pdf.png,text/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_articulos_Infografia-tecnologias-emergencias.pdf.txt,"['Key', 'Gain', 'AI', 'Emergency', 'Time', 'Technologies']",Other,Spain,Technology,"AI, mobile apps, medical drones, portable diagnostic devices",,34.65536,14.134076,4,"The content presents an infographic titled ""Tecnologías para ganar al tiempo en una emergencia,"" which translates to ""Technologies to Gain Time in an Emergency."" It highlights various technological advancements aimed at improving emergency response and healthcare. Key topics include the use of AI for predicting emergencies, mobile apps for in-flight medical situations, medical drones for transporting supplies, and portable diagnostic devices for immediate patient care. This content is produced by the pharmaceutical company Roche and emphasizes innovative solutions for enhancing emergency healthcare efficiency.","technologies, artificial, ai",www.rocheplus.es,Flat,0.0465820277487652,low,94,Technology
552,https://www.rocheplus.es/content/dam/hcp-portals/spain/documents/innovacion/paradigma-financiacion/Infografia_Nuevos_horizontes.pdf,5,www_rocheplus_es_content_dam_hcp_portals_spain_documents_innovacion_paradigma_financiacion_Infografia_Nuevos_horizontes_pdf.txt,200,pdf,Indexable,3,75,0,0,0,0,0.921875,https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_paradigma-financiacion_Infografia_Nuevos_horizontes.pdf,image/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_paradigma-financiacion_Infografia_Nuevos_horizontes.pdf.png,text/https_www.rocheplus.es_content_dam_hcp-portals_spain_documents_innovacion_paradigma-financiacion_Infografia_Nuevos_horizontes.pdf.txt,"['R', 'D']",Other,Spain,Research,,,41.932102,10.227031,4,"The content discusses the role of the pharmaceutical and healthcare sector in fostering economic growth, highlighting various activities related to research, product development, production, and clinical trials. It emphasizes the importance of collaboration among pharmaceutical companies, hospitals, startups, and research institutions to enhance the impact of research and innovation (R&D). The content outlines pathways for obtaining public and private funding for R&D projects, including the criteria for successful applications, strategic planning, and the significance of societal impact. It also mentions various funding sources and examples of potential projects, emphasizing the need for technological innovation, digitalization, and the development of practical healthcare solutions.","technologies, artificial, ai",www.rocheplus.es,Rising,0.776017701108432,medium,397,Technology
553,https://rochepro.fr/,8,rochepro_fr_.txt,200,html,Indexable,0,7,0,1348,1549,640,0.888888888888889,rochepro_fr_.txt.txt,image/rochepro_fr_.txt.txt.png,text/rochepro_fr_.txt.txt.txt,[],Other,France,Offer outline,,,-26.258457,-18.389084,0,"The content focuses on providing resources and information for healthcare professionals regarding Roche's pharmaceutical products and services. It outlines various therapeutic areas such as oncology, neurology, and rare diseases, while offering options for physicians and pharmacists to connect with product specialists, access medical information, and report any issues related to products. The purpose is to create an interactive platform where professionals can inquire, schedule appointments, and gain insights into Roche's offerings, catering specifically to their medical and pharmaceutical needs.","oncology, professionals, data",rochepro.fr,Rising,0.150122516386026,high,462,General Offer Outline
554,https://rochepro.fr/aires-therapeutiques.html,8,rochepro_fr_aires_therapeutiques_html.txt,200,html,Indexable,1,20,0,838,773,640,1,rochepro_fr_aires_therapeutiques_html.txt,image/rochepro_fr_aires_therapeutiques_html.txt.png,text/rochepro_fr_aires_therapeutiques_html.txt.txt,"['Rare', 'Diseases', 'Hematology', 'Oncology']",Oncology-Hematology,France,Offer outline,,,-1.6638129,-6.553539,7,"The content features a section from RochePro, highlighting therapeutic areas relevant to healthcare professionals. It invites users to explore useful content related to their practice and patient care. The displayed categories include Oncology, Hematology, and Rare Diseases, with corresponding images suggesting active clinical or research environments. The overall purpose is to provide valuable resources for medical professionals.","event, exclusive, website",rochepro.fr,Falling,0.832133733286863,high,308,Events & Patient Care
555,https://rochepro.fr/aires-therapeutiques/maladies-rares/amyotrophie-spinale/telechargez-commandez.html,10,rochepro_fr_aires_therapeutiques_maladies_rares_amyotrophie_spinale_telechargez_commandez_html.txt,200,html,Indexable,2,60,99,1191,19,12,0.98,rochepro_fr_aires_therapeutiques_maladies_rares_amyotrophie_spinale_telechargez_commandez_html.txt.txt,image/rochepro_fr_aires_therapeutiques_maladies_rares_amyotrophie_spinale_telechargez_commandez_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_maladies_rares_amyotrophie_spinale_telechargez_commandez_html.txt.txt.txt,['SMA'],Other,France,Offer outline,"spinal muscular atrophy, hemophilia","spinal muscular atrophy, hemophilia",-33.415802,-11.493996,0,"The content outlines services and resources provided by Roche for healthcare professionals, specifically targeting physicians and pharmacists. It mentions various therapeutic areas, including rare diseases and specific conditions like spinal muscular atrophy (SMA) and hemophilia, and offers tools for patient management and access to specialist consultations. The content encourages healthcare professionals to inquire about Roche's products, participate in events, and utilize medical information services. Additionally, it emphasizes data protection and user rights regarding personal information collected by Roche. Overall, the content serves as a resource hub for professionals seeking information and support from Roche.","oncology, professionals, data",rochepro.fr,Falling,0.678468680274251,high,315,General Offer Outline
556,https://rochepro.fr/aires-therapeutiques/maladies-rares/hemophilie.html,10,rochepro_fr_aires_therapeutiques_maladies_rares_hemophilie_html.txt,200,html,Indexable,1,10,150,1164,40,27,0.971014492753623,rochepro_fr_aires_therapeutiques_maladies_rares_hemophilie_html.txt.txt,image/rochepro_fr_aires_therapeutiques_maladies_rares_hemophilie_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_maladies_rares_hemophilie_html.txt.txt.txt,"['France', 'Monaco']",Oncology-Hematology,France,Patient support,hemophilia,hemophilia,18.764277,0.69341516,4,"The content focuses on providing comprehensive information and resources related to various medical conditions, particularly hemophilia, for healthcare professionals in France and Monaco. It includes features like access to medications, consultations with product specialists, educational materials for patients and their families, and tools for pharmacists to aid in treatment delivery. The purpose is to enhance the knowledge and support available to healthcare providers, thereby improving patient care and outcomes in specialized therapeutic areas.","technologies, artificial, ai",rochepro.fr,Flat,0.567358184610537,high,371,Technology
557,https://rochepro.fr/aires-therapeutiques/neurologie/sclerose-en-plaques/evenements/forum-hdj-2023.html,10,rochepro_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_evenements_forum_hdj_2023_html.txt,200,html,Indexable,2,31,152,1128,26,15,0.98,rochepro_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_evenements_forum_hdj_2023_html.txt.txt,image/rochepro_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_evenements_forum_hdj_2023_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_evenements_forum_hdj_2023_html.txt.txt.txt,"['HDJ', 'Forum']",Neurology,France,Patient support,,,22.735569,22.730011,4,"The content showcases the ""Forum HDJ,"" which focuses on supporting neurology patients and facilitating discussions among healthcare professionals. It highlights significant moments from the neurology forum and encourages sharing insights on current issues related to day hospitals. Additionally, there are sections for downloading resources and accessing event replays. The overall purpose is to enhance patient care by fostering collaboration and information exchange among medical professionals.","technologies, artificial, ai",rochepro.fr,All,0.331425179591994,high,86,Technology
558,https://rochepro.fr/aires-therapeutiques/neurologie/sclerose-en-plaques/evenements/neuro-agora-2023.html,10,rochepro_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_evenements_neuro_agora_2023_html.txt,200,html,Indexable,2,33,157,1035,26,15,1,rochepro_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_evenements_neuro_agora_2023_html.txt,image/rochepro_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_evenements_neuro_agora_2023_html.txt.png,text/rochepro_fr_aires_therapeutiques_neurologie_sclerose_en_plaques_evenements_neuro_agora_2023_html.txt.txt,"['Agora', 'Neuro', 'SEP']",Neurology,France,Technology,"multiple sclerosis, neurological diseases, exoskeletons",multiple sclerosis,24.23638,24.571695,4,"The content of the content focuses on Neuro Agora, a platform designed to enhance knowledge in the field of neurology, specifically concerning multiple sclerosis (SEP) and other neurological diseases. The 2023 edition of Neuro Agora highlights advancements in neuroscience, including developments related to exoskeletons. Additionally, it offers resources for healthcare professionals, such as downloadable materials and information for patient engagement.","technologies, artificial, ai",rochepro.fr,Falling,0.690111923291527,high,36,Technology
559,https://rochepro.fr/aires-therapeutiques/oncologie/cahiers-creatifs.html,10,rochepro_fr_aires_therapeutiques_oncologie_cahiers_creatifs_html.txt,200,html,Indexable,2,16,127,1116,53,47,0.971428571428571,rochepro_fr_aires_therapeutiques_oncologie_cahiers_creatifs_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cahiers_creatifs_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cahiers_creatifs_html.txt.txt.txt,"['Notebooks', 'Creative', 'These', 'Cahiers']",Oncology-Hematology,France,Patient support,,,3.1443706,-8.430959,7,"The content presents Roche's resources for oncology, specifically highlighting ""Cahiers créatifs"" (Creative Notebooks). These materials are designed to support patients by providing them with a space to reflect and express their thoughts on various themes and challenges they face during treatment. The section also promotes specific creative exercises and offers contact information for medical inquiries.","event, exclusive, website",rochepro.fr,Rising,0.245988667834299,high,231,Events & Patient Care
560,https://rochepro.fr/aires-therapeutiques/oncologie/cancer-bronchique.html,10,rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_html.txt,200,html,Indexable,1,17,143,1079,41,32,1,rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_html.txt.txt,"['Bronchial', 'Cancer']",Oncology-Hematology,France,Disease information,"Bronchial Cancer, OnkoLung",Bronchial Cancer,3.0418713,-9.892988,7,"The content focuses on ""Bronchial Cancer"" within Roche's oncology section, targeting healthcare professionals. It highlights resources available for download and ordering, as well as a web application named ""OnkoLung,"" designed for improving patient care. The page includes contact information for medical inquiries, emphasizing Roche's commitment to support both healthcare providers and patients.","event, exclusive, website",rochepro.fr,All,0.884463641562654,high,178,Events & Patient Care
561,https://rochepro.fr/aires-therapeutiques/oncologie/cancer-bronchique/pour-vos-patients/expliquer-cancer-bronchique-patients-non-fumeurs.html,10,rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vos_patients_expliquer_cancer_bronchique_patients_non_fumeurs_html.txt,200,html,Indexable,2,77,147,1356,14,7,0.985507246376812,rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vos_patients_expliquer_cancer_bronchique_patients_non_fumeurs_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vos_patients_expliquer_cancer_bronchique_patients_non_fumeurs_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vos_patients_expliquer_cancer_bronchique_patients_non_fumeurs_html.txt.txt.txt,[],Oncology-Hematology,France,Offer outline,,lung cancer,-21.689066,-9.236729,0,"The content primarily serves as a resource hub for healthcare professionals interacting with Roche's products, covering various therapeutic areas such as oncology, neurology, and rare diseases. It offers information on medications, opportunities for consultations with product specialists, and tools for medical inquiries. Additionally, it facilitates access to patient resources, guides, and educational content on specific conditions like lung cancer. The purpose is to support healthcare professionals in their practice, enhance patient care, and improve understanding of cancer therapies and management.","oncology, professionals, data",rochepro.fr,Flat,0.181461538039611,high,157,General Offer Outline
562,https://rochepro.fr/aires-therapeutiques/oncologie/cancer-bronchique/pour-vos-patients.html,7,rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vos_patients_html.txt,200,html,Indexable,2,54,0,1001,10,6,1,rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vos_patients_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vos_patients_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vos_patients_html.txt.txt,[],Oncology-Hematology,France,Patient support,broncho-cancer,broncho-cancer,4.6775904,-8.924516,7,"The content focuses on broncho-cancer, providing resources aimed at patients and their families. It includes sections on explaining the disease, downloadable materials, and tools for communication with children about cancer. Additionally, there are contact details for medical inquiries, emphasizing Roche's support for patients and their support networks. The goal is to facilitate understanding and offer helpful resources regarding a serious health condition.","event, exclusive, website",rochepro.fr,Rising,0.0535941117641761,high,430,Events & Patient Care
563,https://rochepro.fr/aires-therapeutiques/oncologie/cancer-bronchique/pour-vous.html,10,rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vous_html.txt,200,html,Indexable,2,47,137,940,10,6,1,rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vous_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vous_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vous_html.txt.txt,[],Oncology-Hematology,France,Patient support,,bronchial cancer,2.0984933,-10.40323,7,"The content features a section from Roche's professional website focusing on bronchial cancer. It provides resources for healthcare professionals, including links for downloading and ordering materials. The page also emphasizes support for both practitioners and their patients, showcasing a focus on immuno-oncology. Additionally, contact information is available for medical inquiries, underlining Roche's commitment to addressing questions related to their products and services.","event, exclusive, website",rochepro.fr,All,0.924365733734336,high,27,Events & Patient Care
564,https://rochepro.fr/aires-therapeutiques/oncologie/cancer-bronchique/pour-vous/onkolung.html,10,rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vous_onkolung_html.txt,200,html,Indexable,2,28,138,1139,14,7,1,rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vous_onkolung_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vous_onkolung_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_pour_vous_onkolung_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,lung cancer,-19.642159,-5.94028,0,"The content provides a comprehensive overview of Roche's resources and services aimed at medical professionals, specifically focusing on various therapeutic areas such as oncology, neurology, and rare diseases. It highlights tools for physicians and pharmacists to access drug information, schedule consultations with specialists, and address medical inquiries. Additionally, it introduces the OnkoLung web application, designed to streamline the classification of lung cancer and associated treatments through interactive modules. The purpose of the content is to facilitate the daily practices of healthcare professionals by providing them with accessible information and support.","oncology, professionals, data",rochepro.fr,Falling,0.16685729330786,high,219,General Offer Outline
565,https://rochepro.fr/aires-therapeutiques/oncologie/cancer-bronchique/telechargez-commandez.html,10,rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_telechargez_commandez_html.txt,200,html,Indexable,2,44,94,1184,13,6,1,rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_telechargez_commandez_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_telechargez_commandez_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cancer_bronchique_telechargez_commandez_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-27.556194,-15.406234,0,"The content primarily provides information and resources for healthcare professionals regarding Roche's pharmaceutical products and services, focusing on areas like oncology, neurology, and rare diseases. It offers various functionalities such as scheduling appointments with product specialists, asking medical or pharmaceutical questions, and accessing educational materials for patients. The content emphasizes Roche's commitment to supporting medical professionals and improving patient care through accessible information, resources, and customer service.","oncology, professionals, data",rochepro.fr,Falling,0.117901150012817,high,38,General Offer Outline
566,https://rochepro.fr/aires-therapeutiques/oncologie/cancer-sein.html,10,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_html.txt,200,html,Indexable,1,14,162,1072,39,30,1,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_html.txt.txt,['Contact'],Oncology-Hematology,France,Patient support,breast cancer,breast cancer,1.0241014,-9.736028,7,"The content presents a dedicated section on Roche's professional website focusing on breast cancer. It features resources for healthcare providers, including downloadable materials and support tools. Additionally, there are sections aimed at both medical professionals and patients, highlighting Roche's commitment to providing information and assistance regarding cancer treatment. Contact details for inquiries are also included.","event, exclusive, website",rochepro.fr,Falling,0.344396667730404,high,319,Events & Patient Care
567,https://rochepro.fr/aires-therapeutiques/oncologie/cancer-sein/pour-vos-patients.html,10,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vos_patients_html.txt,200,html,Indexable,2,51,125,983,12,7,0.975903614457831,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vos_patients_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vos_patients_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vos_patients_html.txt.txt.txt,['Wikiboop'],Oncology-Hematology,France,Patient support,,breast cancer,1.1979744,-7.919667,7,"The content showcases a section of Roche's professional website focused on breast cancer resources for patients and their families. It highlights tools such as ""Wikiboop,"" aimed at providing educational support, and features an interactive application designed to facilitate discussions about cancer. Additionally, there are contact details provided for medical inquiries, reinforcing Roche's commitment to patient support.","event, exclusive, website",rochepro.fr,Falling,0.495059871744213,high,133,Events & Patient Care
568,https://rochepro.fr/aires-therapeutiques/oncologie/cancer-sein/pour-vos-patients/wikiboop.html,10,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vos_patients_wikiboop_html.txt,200,html,Indexable,2,25,147,1187,18,11,0.978260869565217,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vos_patients_wikiboop_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vos_patients_wikiboop_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vos_patients_wikiboop_html.txt.txt.txt,['Wikiboop'],Oncology-Hematology,France,Offer outline,"multiple sclerosis, hemophilia, oncology, breast cancer, Wikiboop application","multiple sclerosis, hemophilia, breast cancer",-2.66561,-4.177539,7,"The content provides information targeted at healthcare professionals, primarily focusing on Roche's offerings related to various medical conditions such as multiple sclerosis, hemophilia, and oncology, particularly breast cancer. It promotes resources like the Wikiboop application, which aims to support patients throughout their treatment journey by providing personalized information and answers to their questions. Additionally, the content details services available to physicians and pharmacists, such as consultations with product specialists and access to medical information. Overall, the purpose is to enhance patient care and provide support for healthcare providers through Roche's products and services.","event, exclusive, website",rochepro.fr,Falling,0.0379838676913245,high,198,Events & Patient Care
569,https://rochepro.fr/aires-therapeutiques/oncologie/cancer-sein/pour-vous.html,10,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vous_html.txt,200,html,Indexable,2,44,162,952,12,7,1,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vous_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vous_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vous_html.txt.txt,['Visual'],Oncology-Hematology,France,Patient support,,breast cancer,0.718131,-8.444458,7,"The content features RochePro's oncology section, specifically focused on breast cancer. It aims to provide healthcare professionals with resources and support tailored to their practice, encouraging downloads and orders related to cancer care. The page includes options for inquiries and assistance, highlighting Roche's commitment to addressing medical and pharmaceutical questions. Visual elements depict collaboration between healthcare professionals and patient support.","event, exclusive, website",rochepro.fr,Rising,0.315254193762574,high,337,Events & Patient Care
570,https://rochepro.fr/aires-therapeutiques/oncologie/cancer-sein/pour-vous/optimisation-parcours-soins.html,10,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vous_optimisation_parcours_soins_html.txt,200,html,Indexable,2,65,127,1108,15,7,1,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vous_optimisation_parcours_soins_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vous_optimisation_parcours_soins_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vous_optimisation_parcours_soins_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,breast cancer,-29.448303,0.42808884,0,"The content provides information meant for healthcare professionals regarding Roche's pharmaceutical products and services, specifically in the fields of oncology, neurology, and other areas. It outlines various initiatives aimed at improving patient care, particularly for breast cancer patients, including studies on care pathways and support services. The content also encourages professionals to engage with Roche specialists, access medical information, and report any quality defects or adverse effects related to Roche products. Overall, the purpose is to enhance collaboration between Roche and healthcare providers to optimize patient outcomes and care processes.","oncology, professionals, data",rochepro.fr,All,0.97909312833542,high,269,General Offer Outline
571,https://rochepro.fr/aires-therapeutiques/oncologie/cancer-sein/pour-vous/regards-croises.html,7,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vous_regards_croises_html.txt,200,html,Indexable,2,32,0,1247,15,7,1,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vous_regards_croises_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vous_regards_croises_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_pour_vous_regards_croises_html.txt.txt,['Its'],Oncology-Hematology,France,Offer outline,,,-25.591417,-8.672839,0,"The content focuses on the services and resources that Roche provides specifically for healthcare professionals, including physicians and pharmacists. Its purpose is to facilitate access to information on Roche's medications, enable appointment scheduling with product specialists, and address medical inquiries. Additionally, it highlights therapeutic areas such as oncology, and it emphasizes the ongoing evolution and personalization of cancer treatment pathways. The content is designed to support healthcare providers in optimizing patient care and staying informed about Roche’s offerings and advancements.","oncology, professionals, data",rochepro.fr,Rising,0.607902418696694,high,413,General Offer Outline
572,https://rochepro.fr/aires-therapeutiques/oncologie/cancer-sein/telechargez-commandez.html,10,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_telechargez_commandez_html.txt,200,html,Indexable,2,41,94,1119,14,7,1,rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_telechargez_commandez_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_telechargez_commandez_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_cancer_sein_telechargez_commandez_html.txt.txt,"['Pro', 'PDF', 'Two']",Oncology-Hematology,France,Patient support,"breast cancer, breast cancer studies, PDF format",breast cancer,0.168048,-9.414984,7,"The content depicts a webpage focused on breast cancer resources provided by Roche Pro. It features a section for downloading and ordering relevant materials with options for easy one-click downloads. Two specific documents related to breast cancer studies are highlighted, available in PDF format. Additionally, there is contact information for further inquiries related to medical and pharmaceutical questions, making it clear that the site serves as a professional resource for healthcare practitioners.","event, exclusive, website",rochepro.fr,All,0.370194512609241,high,304,Events & Patient Care
573,https://rochepro.fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire.html,10,rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_html.txt,200,html,Indexable,1,32,161,1029,40,32,0.975,rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_html.txt.txt.txt,['France'],Oncology-Hematology,France,Disease information,hepatocellular carcinoma,hepatocellular carcinoma,4.448492,-10.474415,7,"The content features a webpage dedicated to hepatocellular carcinoma, part of Roche's professional resources. It provides options for downloading and ordering documents, as well as information about improving patient care in France. Additionally, there are contact details for medical inquiries, emphasizing Roche's support for healthcare professionals and patients. The overall aim is to facilitate access to relevant information and resources for treating this specific cancer type.","event, exclusive, website",rochepro.fr,All,0.719690650367755,high,47,Events & Patient Care
574,https://rochepro.fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/pour-vos-patients.html,10,rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vos_patients_html.txt,200,html,Indexable,2,53,141,1418,12,7,1,rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vos_patients_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vos_patients_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vos_patients_html.txt.txt,[],Oncology-Hematology,France,Offer outline,"hepatocellular carcinoma, patient care, treatment",hepatocellular carcinoma,-25.08311,-11.8746605,0,"The content focuses on providing comprehensive information and resources for healthcare professionals regarding Roche's pharmaceutical products, particularly for conditions such as hepatocellular carcinoma and other related diseases. It emphasizes the availability of medical information, educational materials, and support tools for doctors, pharmacists, and patients, including brochures and guides that aid in patient care and treatment. The purpose of the content is to facilitate communication and collaboration among healthcare providers and to support patients throughout their treatment journey. Additionally, it includes contact information for inquiries related to medical and pharmaceutical questions.","oncology, professionals, data",rochepro.fr,Rising,0.498507556388729,high,10,General Offer Outline
575,https://rochepro.fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/pour-vous/ameliorer-parcours-soin-chc-france.html,10,rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_ameliorer_parcours_soin_chc_france_html.txt,200,html,Indexable,2,75,164,3263,14,6,0.984,rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_ameliorer_parcours_soin_chc_france_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_ameliorer_parcours_soin_chc_france_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_ameliorer_parcours_soin_chc_france_html.txt.txt.txt,"['France', 'HCC']",Oncology-Hematology,France,Offer outline,,hepatocellular carcinoma,-19.857075,-9.090412,0,"The content provides information targeted at healthcare professionals, specifically regarding Roche's pharmaceutical offerings and support services. It emphasizes resources for doctors and pharmacists, including details about medications, opportunities for scheduling consultations with product specialists, and avenues for medical inquiries. Additionally, it highlights Roche's commitment to improving patient care pathways, particularly in the context of hepatocellular carcinoma (HCC) in France, addressing challenges like timely diagnosis and treatment initiation. The content serves as both an informative guide and a resource hub for professionals seeking to enhance patient outcomes in various therapeutic areas.","oncology, professionals, data",rochepro.fr,All,0.737078363561163,high,400,General Offer Outline
576,https://rochepro.fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/pour-vous.html,10,rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_html.txt,200,html,Indexable,2,63,160,961,12,7,1,rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_html.txt.txt,[],Oncology-Hematology,France,Offer outline,"hepatocellular carcinoma, liver cancer","hepatocellular carcinoma, liver cancer",4.0864053,-11.176305,7,"The content presents a section of RochePro, focusing on hepatocellular carcinoma, a type of liver cancer. It aims to provide resources and information specifically for healthcare professionals, with options to download materials and make orders. The page also offers contact details for medical and pharmaceutical inquiries, illustrating Roche's commitment to supporting practitioners in their work.","event, exclusive, website",rochepro.fr,Falling,0.537441071550116,high,485,Events & Patient Care
577,https://rochepro.fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/pour-vous/pour-vous-infirmiers.html,10,rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_pour_vous_infirmiers_html.txt,200,html,Indexable,2,63,118,1844,14,6,1,rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_pour_vous_infirmiers_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_pour_vous_infirmiers_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_pour_vous_pour_vous_infirmiers_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,liver cancer,-23.861464,-8.7604885,0,"The content primarily provides information and resources for healthcare professionals about Roche's pharmaceutical products and services. It includes sections on various therapeutic areas such as oncology, neurology, and rare diseases, as well as educational programs and tools aimed at enhancing patient care, particularly focusing on liver cancer. There are opportunities for medical professionals to engage with specialists, access medical information, and report adverse effects. The purpose is to facilitate professional development, improve patient outcomes, and ensure safety and compliance in the use of Roche's products.","oncology, professionals, data",rochepro.fr,Falling,0.574709512096515,high,128,General Offer Outline
578,https://rochepro.fr/aires-therapeutiques/oncologie/carcinome-hepatocellulaire/telechargez-commandez.html,10,rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_telechargez_commandez_html.txt,200,html,Indexable,2,67,111,1579,13,6,1,rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_telechargez_commandez_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_telechargez_commandez_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_carcinome_hepatocellulaire_telechargez_commandez_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,liver diseases,-24.963543,-9.876974,0,"The content primarily outlines the services and resources offered by Roche, specifically aimed at healthcare professionals, including doctors and pharmacists. It provides information on various therapeutic areas, particularly focusing on oncology and liver diseases, detailing available medications, supportive materials, and patient resources. The purpose is to facilitate communication and collaboration among healthcare providers, enhance patient care, and promote access to Roche’s educational materials and services for professionals in the medical field.","oncology, professionals, data",rochepro.fr,All,0.64604535830187,high,333,General Offer Outline
579,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/alcool-cancer.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_alcool_cancer_html.txt,200,html,Indexable,2,62,141,1215,5,3,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_alcool_cancer_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_alcool_cancer_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_alcool_cancer_html.txt.txt,"['France', 'Monaco']",Oncology-Hematology,France,Patient support,,,-27.246277,-13.416505,0,"The content provides a resource for healthcare professionals in France and Monaco, offering a range of services and information related to Roche's pharmaceutical products. It includes sections for doctors and pharmacists to inquire about medications, schedule appointments with product specialists, and request medical or pharmaceutical information. Additionally, it addresses various therapeutic areas such as oncology, detailing patient information resources on topics like alcohol and cancer, chemotherapy administration, and radiation therapy. The purpose is to support medical professionals in patient care, enhance communication about treatments, and provide educational resources for both practitioners and patients.","oncology, professionals, data",rochepro.fr,Falling,0.132915924923827,high,128,General Offer Outline
580,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/anemie.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_anemie_html.txt,200,html,Indexable,2,62,160,1219,12,10,0.975308641975309,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_anemie_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_anemie_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_anemie_html.txt.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-26.383986,-5.0531645,0,"The content primarily serves as a resource for healthcare professionals, providing information on Roche's pharmaceutical products and therapeutic areas, including oncology, neurology, and rare diseases. It offers tools for medical inquiries, specialist appointments, and access to educational materials aimed at enhancing patient care. Additionally, it features patient information sheets on various cancers, reflecting Roche's commitment to supporting medical professionals in their practice. The site facilitates communication regarding product inquiries, adverse effects, and quality issues within Roche's offerings.","oncology, professionals, data",rochepro.fr,Flat,0.833651069185701,high,90,General Offer Outline
581,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/biopsie-mammaire.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_biopsie_mammaire_html.txt,200,html,Indexable,2,63,178,1208,8,6,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_biopsie_mammaire_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_biopsie_mammaire_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_biopsie_mammaire_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-28.9811,-4.561981,0,"The content primarily focuses on providing medical professionals, particularly doctors and pharmacists, with information about Roche's pharmaceutical products, services, and various therapeutic areas such as oncology and neurology. It offers resources for medical inquiries, includes patient information sheets about cancer procedures and treatments, and facilitates connections with specialists. The purpose of this content is to support healthcare providers with educational materials, enhance patient care, and address any medical or pharmaceutical questions related to Roche’s offerings.","oncology, professionals, data",rochepro.fr,Flat,0.758092656629084,high,23,General Offer Outline
582,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-bronchique-petites-cellules.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_bronchique_petites_cellules_html.txt,200,html,Indexable,2,79,159,1207,5,3,0.981651376146789,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_bronchique_petites_cellules_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_bronchique_petites_cellules_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_bronchique_petites_cellules_html.txt.txt.txt,[],Oncology-Hematology,France,Offer outline,"lung cancer, multiple sclerosis","lung cancer, multiple sclerosis",-32.855595,-1.9878731,0,"The content is an array of resources and services provided by Roche for healthcare professionals, including doctors and pharmacists. It emphasizes on various therapeutic areas such as oncology and neurology, specifically focusing on conditions like lung cancer and multiple sclerosis. The content also offers opportunities for professionals to inquire about medications, schedule meetings with product specialists, and access patient information materials. Additionally, it highlights Roche’s commitment to medical education, pharmacovigilance, and support for health care practitioners in managing patient care effectively.","oncology, professionals, data",rochepro.fr,Falling,0.910887562174672,high,395,General Offer Outline
583,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-carcinome-basocellulaire.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_carcinome_basocellulaire_html.txt,200,html,Indexable,2,66,238,1182,4,2,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_carcinome_basocellulaire_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_carcinome_basocellulaire_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_carcinome_basocellulaire_html.txt.txt,[],Oncology-Hematology,France,Offer outline,"basal cell carcinoma, melanoma","basal cell carcinoma, melanoma",-29.277784,-7.3140926,0,"The content serves as an informational resource for healthcare professionals, particularly doctors and pharmacists, focusing on Roche's pharmaceutical products and services. It encourages users to inquire about medications, schedule consultations with product specialists, and access various medical information related to specific therapeutic areas such as oncology and neurology. Additionally, it provides educational resources, including patient information sheets on conditions like basal cell carcinoma and melanoma, and emphasizes Roche's commitment to supporting healthcare providers in patient care and treatment management.","oncology, professionals, data",rochepro.fr,Flat,0.414647760507824,high,374,General Offer Outline
584,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-col-uterus.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_col_uterus_html.txt,200,html,Indexable,2,67,135,1225,14,12,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_col_uterus_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_col_uterus_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_col_uterus_html.txt.txt,[],Oncology-Hematology,France,Medication information,"oncology, neurology, hemophilia, cervical cancer, lung cancer","cervical cancer, lung cancer",-23.879791,-7.808774,0,"The content is a resource for healthcare professionals using Roche's services and products, focusing on various therapeutic areas such as oncology, neurology, and hemophilia. It provides information about medications, allows users to consult with specialists, and offers resources like patient information sheets regarding specific cancers, including cervical and lung cancer. The content highlights Roche's commitment to education, support, and pharmacovigilance, aiming to enhance patient care and facilitate healthcare providers' access to relevant information and tools.","oncology, professionals, data",rochepro.fr,Flat,0.973478195449884,high,234,General Offer Outline
585,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-colon-alimentation.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_colon_alimentation_html.txt,200,html,Indexable,2,53,166,1200,4,2,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_colon_alimentation_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_colon_alimentation_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_colon_alimentation_html.txt.txt,[],Oncology-Hematology,France,Offer outline,"colorectal cancer, oncology, neurology, rare diseases, nutritional considerations, adverse event reporting, ongoing education initiatives",colorectal cancer,-26.187973,-7.5300975,0,"The content provides detailed information aimed at healthcare professionals regarding Roche's pharmaceutical products and therapeutic areas, particularly focusing on oncology, neurology, and rare diseases. It emphasizes resources available for physicians and pharmacists, such as consultations with product specialists, medical inquiries, and educational materials for patients, specifically related to colorectal cancer and its nutritional considerations. Additionally, it includes services related to medical information, adverse event reporting, and ongoing education initiatives for both patients and healthcare providers. The overall purpose of the content is to promote Roche's commitment to supporting healthcare professionals and enhancing patient care through accessible information and resources.","oncology, professionals, data",rochepro.fr,All,0.832533202637806,high,102,General Offer Outline
586,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-colorectal-colon.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_colorectal_colon_html.txt,200,html,Indexable,2,59,191,1216,5,3,0.979591836734694,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_colorectal_colon_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_colorectal_colon_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_colorectal_colon_html.txt.txt.txt,['Its'],Oncology-Hematology,France,Offer outline,,"colorectal cancer, lung cancer, prostate cancer",-23.150898,-8.0172615,0,"The content appears to be a compilation of resources and services provided by Roche for healthcare professionals, including doctors and pharmacists. It covers various therapeutic areas such as oncology, neurology, and rare diseases, offering information on medications, recommendations for consultations with product specialists, and channels for asking medical or pharmaceutical questions. The content also highlights patient information resources, focusing on specific cancers like colorectal, lung, and prostate cancer, and mentions initiatives to support healthcare professionals in managing patient care. Its overall purpose is to assist medical professionals in their practice through access to relevant information and support services.","oncology, professionals, data",rochepro.fr,Flat,0.0907521384851113,high,58,General Offer Outline
587,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-ovaire.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_ovaire_html.txt,200,html,Indexable,2,60,124,1221,4,2,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_ovaire_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_ovaire_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_ovaire_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-24.793024,-8.838602,0,"The content provides information tailored for healthcare professionals, specifically regarding Roche's pharmaceutical products and services. It covers various therapeutic areas, including oncology, suggesting resources such as patient information leaflets on specific cancers, and details on medical assistance services. Additionally, it highlights opportunities for healthcare professionals to engage with product specialists, submit medical inquiries, and access tools for patient support. The overall purpose is to facilitate information exchange, promote Roche's offerings, and enhance patient care through professional resources.","oncology, professionals, data",rochepro.fr,Flat,0.356686596560191,high,78,General Offer Outline
588,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-poumon.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_poumon_html.txt,200,html,Indexable,2,59,118,1211,15,11,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_poumon_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_poumon_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_poumon_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,"lung cancer, other cancers",-28.650993,-5.9771867,0,"The content provides information about Roche's pharmaceutical offerings and services, particularly targeting healthcare professionals such as doctors and pharmacists. It highlights various therapeutic areas, including oncology and neurology, and details resources available for medical professionals to inquire about medications, schedule specialist appointments, and access patient information on conditions like lung cancer and other cancers. The content serves as a resource hub to support healthcare providers in their practice and enhance patient care through education and interaction with specialists.","oncology, professionals, data",rochepro.fr,Flat,0.288990418982342,high,226,General Offer Outline
589,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-prostate-dosage-psa.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_prostate_dosage_psa_html.txt,200,html,Indexable,2,74,111,1213,4,2,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_prostate_dosage_psa_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_prostate_dosage_psa_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_prostate_dosage_psa_html.txt.txt,[],Oncology-Hematology,France,Offer outline,"prostate cancer, oncology, neurology",prostate cancer,-28.188515,-4.150297,0,"The content provides a comprehensive overview of Roche's offerings for healthcare professionals, including medications, specialist consultations, and resources for medical inquiries. It emphasizes the importance of various therapeutic areas, such as oncology and neurology, and highlights specific diseases like prostate cancer. Additionally, it includes patient information resources, guidance for pharmacists, and tools for medical professionals to enhance their knowledge and patient care practices. The purpose is to ensure that healthcare providers have access to essential information and support related to Roche's products and services.","oncology, professionals, data",rochepro.fr,Rising,0.0895827773072337,high,80,General Offer Outline
590,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-prostate.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_prostate_html.txt,200,html,Indexable,2,63,197,1212,12,10,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_prostate_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_prostate_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_prostate_html.txt.txt,[],Other,France,Offer outline,,,-31.880512,-9.200757,0,"The content is focused on providing medical professionals, such as doctors and pharmacists, with resources and information related to Roche's pharmaceutical products and services. It highlights various therapeutic areas including oncology, neurology, and rare diseases, while also offering tools for medical inquiries, expert consultations, product information, and patient education materials. The purpose is to enhance healthcare providers' understanding of Roche's offerings and facilitate communication regarding medical and pharmaceutical questions. Additionally, it emphasizes support services such as pharmacovigilance and client assistance.","oncology, professionals, data",rochepro.fr,Falling,0.815994778976385,high,149,General Offer Outline
591,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-rein.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_rein_html.txt,200,html,Indexable,2,56,99,1218,5,3,0.976744186046512,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_rein_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_rein_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_rein_html.txt.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-28.84293,-4.9877014,0,"The content presents a range of resources and services offered by Roche specifically for healthcare professionals, including physicians and pharmacists. It highlights the company's therapeutic areas, such as oncology and neurology, and provides information about various medications, patient information sheets, and the ability to consult with specialists. Additionally, it emphasizes the importance of supporting patients during their treatment journeys, including managing side effects and facilitating conversations about cancer. The purpose of the content is to inform and assist healthcare professionals in their practice while promoting Roche's products and services within the medical community.","oncology, professionals, data",rochepro.fr,Falling,0.183127283239485,high,72,General Offer Outline
592,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-sein-statut-her2.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_sein_statut_her2_html.txt,200,html,Indexable,2,54,186,1214,8,6,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_sein_statut_her2_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_sein_statut_her2_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_sein_statut_her2_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-26.678188,-16.225338,0,"The content appears to be focused on providing medical professionals, including doctors and pharmacists, with detailed information about Roche's pharmaceuticals, particularly in areas such as oncology, neurology, and rare diseases. It offers resources like product information, patient guides, and support for managing patient care. The content emphasizes facilitating communication between healthcare providers and Roche's specialists, alongside access to educational materials about specific conditions, treatments, and patient support tools. Overall, the purpose is to enhance the knowledge and capabilities of healthcare professionals regarding Roche's products and services.","oncology, professionals, data",rochepro.fr,Falling,0.933407253814241,high,433,General Offer Outline
593,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-sein-triple-negatif.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_sein_triple_negatif_html.txt,200,html,Indexable,2,74,213,1261,10,8,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_sein_triple_negatif_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_sein_triple_negatif_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_sein_triple_negatif_html.txt.txt,[],Oncology-Hematology,France,Disease information,"triple-negative breast cancer, treatment options",triple-negative breast cancer,-25.23695,-7.9194365,0,"The content appears to be an informational resource for healthcare professionals concerning various medical conditions and Roche's pharmaceutical products. It provides guidance on topics like hematology, oncology, and neurology, enabling physicians and pharmacists to access product information, schedule consultations with specialists, and pose medical inquiries. Additionally, it discusses specific cancer types, such as triple-negative breast cancer, detailing treatment options and patient support materials. The content emphasizes Roche's role as a partner in healthcare through information dissemination and support resources for managing patient care.","oncology, professionals, data",rochepro.fr,All,0.0411573875259462,high,468,General Offer Outline
594,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-tete-cou.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_tete_cou_html.txt,200,html,Indexable,2,71,205,1236,6,4,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_tete_cou_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_tete_cou_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_tete_cou_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-25.319832,-10.783368,0,"The content primarily focuses on providing medical professionals with information and resources related to Roche's pharmaceutical products and services. It includes sections dedicated to various therapeutic areas such as oncology, neurology, and hematology, and offers tools like patient information sheets and guidelines for different cancer treatments. Additionally, it facilitates communication between healthcare providers and Roche through specialist consultations, customer service, and medical inquiries, aiming to support healthcare professionals in delivering patient care effectively.","oncology, professionals, data",rochepro.fr,Flat,0.628927829707747,high,452,General Offer Outline
595,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/cancer-vessie.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_vessie_html.txt,200,html,Indexable,2,61,128,1194,5,3,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_vessie_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_vessie_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_cancer_vessie_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-26.2438,-12.511236,0,"The content primarily serves as a professional resource for healthcare providers associated with Roche, outlining various therapeutic areas and providing tools and information relevant to doctors and pharmacists. It emphasizes services such as consultations with product specialists, medical inquiries, and access to patient information sheets on specific cancers and treatments. The content encourages healthcare professionals to engage with Roche's offerings, including educational resources and support for patient care. Additionally, it highlights services related to pharmacovigilance and reporting adverse effects. Overall, the purpose is to facilitate communication and dissemination of vital medical knowledge among professionals in the pharmaceutical sector.","oncology, professionals, data",rochepro.fr,Falling,0.689088841463279,high,213,General Offer Outline
596,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/carcinome-hepatocellulaire.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_carcinome_hepatocellulaire_html.txt,200,html,Indexable,2,68,143,1202,4,2,0.98019801980198,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_carcinome_hepatocellulaire_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_carcinome_hepatocellulaire_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_carcinome_hepatocellulaire_html.txt.txt.txt,[],Oncology-Hematology,France,Offer outline,,hepatocellular carcinoma,-26.17872,-9.077137,0,"The content outlines various resources and services offered by Roche for healthcare professionals, including physicians and pharmacists. It emphasizes the availability of information about Roche's medications, the ability to schedule appointments with product specialists, and the provision of medical and pharmaceutical queries. Additionally, it covers specific therapeutic areas such as oncology, detailing educational materials on diseases like hepatocellular carcinoma, the effects of alcohol on cancer risk, and different cancer treatment modalities. The overall purpose is to facilitate healthcare professionals' understanding of Roche's products and enhance patient care through accessible information and support services.","oncology, professionals, data",rochepro.fr,All,0.568230291825065,high,368,General Offer Outline
597,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/coloscopie.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_coloscopie_html.txt,200,html,Indexable,2,36,122,1206,6,4,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_coloscopie_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_coloscopie_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_coloscopie_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,"colorectal cancer, prostate cancer",-25.050943,-7.076657,0,"The content provides a range of resources and services offered by Roche for healthcare professionals, including information on medications, scheduling appointments with product specialists, and addressing medical inquiries. It highlights various therapeutic areas such as oncology, neurology, and rare diseases, and includes patient information sheets on topics like colorectal cancer and prostate cancer. Additionally, it mentions support tools for healthcare providers to assist patients, educational resources, and links to further medical information. The purpose is to facilitate healthcare professionals' access to Roche's products, support, and information.","oncology, professionals, data",rochepro.fr,Falling,0.972066933752277,high,140,General Offer Outline
598,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/comprendre-analyse-sang.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_comprendre_analyse_sang_html.txt,200,html,Indexable,2,68,177,1230,10,8,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_comprendre_analyse_sang_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_comprendre_analyse_sang_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_comprendre_analyse_sang_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-27.042458,-13.193687,0,"The content provides information targeted at healthcare professionals regarding Roche's pharmaceutical offerings. It outlines support services for doctors and pharmacists, such as access to medical information, consultations with product specialists, and a robust system for reporting medical inquiries and adverse effects. It also includes educational resources about specific health conditions, particularly cancers, emphasizing the importance of blood tests in monitoring treatment. The content serves as a comprehensive resource for medical professionals to enhance their understanding and management of patient care related to Roche's therapies.","oncology, professionals, data",rochepro.fr,Flat,0.538201640943924,high,496,General Offer Outline
599,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/diarrhee-chimiotherapie.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_diarrhee_chimiotherapie_html.txt,200,html,Indexable,2,59,189,1210,7,5,0.979591836734694,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_diarrhee_chimiotherapie_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_diarrhee_chimiotherapie_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_diarrhee_chimiotherapie_html.txt.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-30.509022,-0.47724804,0,"The content discusses Roche's offerings in the medical field, specifically targeting healthcare professionals such as doctors and pharmacists. It provides comprehensive information on various medical treatments, side effects of chemotherapy, and available resources for managing patient care. The purpose is to facilitate communication between Roche and healthcare providers, offering tools for inquiries, appointments with product specialists, and access to educational materials regarding therapeutic areas like oncology, neurology, and rare diseases. The site emphasizes Roche's commitment to supporting medical professionals through reliable information and assistance services.","oncology, professionals, data",rochepro.fr,Rising,0.880029212963451,high,11,General Offer Outline
600,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/effets-indesirables-peau-ongles.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_effets_indesirables_peau_ongles_html.txt,200,html,Indexable,2,70,179,1201,8,6,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_effets_indesirables_peau_ongles_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_effets_indesirables_peau_ongles_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_effets_indesirables_peau_ongles_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-26.95893,-10.246377,0,"The content provides detailed information and resources related to Roche's pharmaceutical offerings, specifically addressing healthcare professionals such as doctors and pharmacists. It covers various therapeutic areas, including oncology, and discusses potential side effects of treatments, emphasizing the importance of patient quality of life. The content encourages professionals to engage with Roche through appointments with specialists, access medical information, and download patient information sheets. The purpose of the content is to facilitate professional use of Roche's products and to support healthcare providers in addressing patient needs effectively.","oncology, professionals, data",rochepro.fr,Flat,0.014671977613584,high,310,General Offer Outline
601,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/effets-secondaires-chimiotherapie.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_effets_secondaires_chimiotherapie_html.txt,200,html,Indexable,2,66,121,1226,11,9,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_effets_secondaires_chimiotherapie_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_effets_secondaires_chimiotherapie_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_effets_secondaires_chimiotherapie_html.txt.txt,[],Other,France,Offer outline,,,-24.354042,-11.871106,0,"The content of the content focuses on providing information and resources related to Roche's pharmaceutical products and services for healthcare professionals, including doctors and pharmacists. It includes support for specific therapeutic areas such as oncology, neurology, and rare diseases, and offers tools for managing medical inquiries, safety reporting, and patient care. The content also highlights educational materials for managing chemotherapy side effects, such as fatigue and hair loss, and contains promotional aspects for scheduling consultations with specialists. Overall, the purpose is to facilitate communication, knowledge sharing, and support healthcare professionals in their practice.","oncology, professionals, data",rochepro.fr,Rising,0.189073223436476,high,104,General Offer Outline
602,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/fatigue-cancer.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_fatigue_cancer_html.txt,200,html,Indexable,2,64,200,1213,8,6,0.97752808988764,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_fatigue_cancer_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_fatigue_cancer_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_fatigue_cancer_html.txt.txt.txt,[],Oncology-Hematology,France,Offer outline,,cancer-related fatigue,-25.540003,-13.695579,0,"The content focuses on providing medical professionals, specifically doctors and pharmacists, with information about Roche’s pharmaceutical products and services. It includes resources for managing patient care, such as downloadable patient information sheets and guidelines on treatments for various conditions, including cancer-related fatigue and side effects of therapies. Additionally, it offers features like scheduling appointments with product specialists, asking medical questions, and accessing assistance for pharmaceutical issues. The purpose is to support healthcare professionals with reliable information and tools to enhance patient care.","oncology, professionals, data",rochepro.fr,Flat,0.947026051220946,high,495,General Offer Outline
603,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/fibroscopie-bronchique.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_fibroscopie_bronchique_html.txt,200,html,Indexable,2,48,180,1203,5,3,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_fibroscopie_bronchique_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_fibroscopie_bronchique_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_fibroscopie_bronchique_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-25.503193,-14.684505,0,"The content primarily serves as a resource hub for healthcare professionals, specifically targeting medical doctors and pharmacists associated with Roche. It outlines various therapeutic areas, such as oncology and rare diseases, while offering information on Roche's medications and their uses. The purpose is to facilitate professional engagement by allowing users to consult specialists, request articles, report adverse effects, and access educational materials for patient care. Additionally, it emphasizes the importance of communication, patient information, and support for medical practitioners in managing complex health conditions.","oncology, professionals, data",rochepro.fr,Rising,0.316567658844492,high,133,General Offer Outline
604,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/hormonotherapie-effets-secondaires.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_hormonotherapie_effets_secondaires_html.txt,200,html,Indexable,2,84,157,1247,6,4,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_hormonotherapie_effets_secondaires_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_hormonotherapie_effets_secondaires_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_hormonotherapie_effets_secondaires_html.txt.txt,[],Oncology-Hematology,France,Patient support,,,-23.186634,-12.492094,0,"The content guides healthcare professionals, including doctors and pharmacists, on Roche's pharmaceutical products and services. It emphasizes access to medical information, specialist consultations, patient education materials, and support for managing various health conditions, particularly focusing on oncology. The content also includes risk management measures, adverse effects of treatments, and available resources for healthcare providers, aiming to facilitate informed decision-making and enhance patient care.","oncology, professionals, data",rochepro.fr,Rising,0.141846688622426,high,294,General Offer Outline
605,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_html.txt,200,html,Indexable,2,20,145,2017,44,42,0.972972972972973,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_html.txt.txt.txt,['Fiches'],Oncology-Hematology,France,Patient support,,,2.0707705,-7.6774526,7,"The content features a section titled ""Fiches info patients"" under the oncology category on RochePro, aimed at providing information for patients. It includes three images that appear to depict individuals experiencing various health concerns. The purpose is to offer educational resources that assist patients in understanding their conditions or treatments better, emphasizing patient care and support in oncology.","event, exclusive, website",rochepro.fr,Rising,0.459184223564884,high,239,Events & Patient Care
606,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/immunotherapie-effets-indesirables.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_immunotherapie_effets_indesirables_html.txt,200,html,Indexable,2,70,139,1213,9,7,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_immunotherapie_effets_indesirables_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_immunotherapie_effets_indesirables_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_immunotherapie_effets_indesirables_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-25.167,-13.347127,0,"The content provides information aimed at healthcare professionals regarding Roche's medical products and services. It highlights areas such as oncological treatments, patient information brochures, and resources for pharmacists and physicians. The content encourages healthcare professionals to engage with specialists, ask medical or pharmaceutical questions, and access various tools for patient care, including downloadable materials and guidelines on managing side effects of treatments like immunotherapy. Additionally, it emphasizes Roche's commitment to supporting healthcare professionals in their roles through a variety of resources and services.","oncology, professionals, data",rochepro.fr,Flat,0.0033163358791286,high,169,General Offer Outline
607,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/leucemie-lymphoide-chronique.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_leucemie_lymphoide_chronique_html.txt,200,html,Indexable,2,65,152,1222,5,3,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_leucemie_lymphoide_chronique_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_leucemie_lymphoide_chronique_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_leucemie_lymphoide_chronique_html.txt.txt,"['France', 'Monaco']",Oncology-Hematology,France,Offer outline,"chronic lymphocytic leukemia, patient education materials, treatment protocols, patient communication, monitoring, patient support",chronic lymphocytic leukemia,-28.821415,-10.52941,0,"The content serves as a comprehensive informational resource for healthcare professionals regarding Roche's pharmaceutical offerings and services. It provides details on various therapeutic areas, patient education materials, and avenues for healthcare providers to engage with Roche specialists for inquiries about medications and treatment protocols. The content highlights specific illnesses such as chronic lymphocytic leukemia, offers educational tools for patient communication, and emphasizes the importance of monitoring and patient support throughout medical treatment. The overall purpose is to facilitate access to medical knowledge and promote Roche's commitment to healthcare professionals in France and Monaco.","oncology, professionals, data",rochepro.fr,Flat,0.116550352135324,high,343,General Offer Outline
608,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/lymphome-non-hodgkinien.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_lymphome_non_hodgkinien_html.txt,200,html,Indexable,2,60,121,1221,5,3,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_lymphome_non_hodgkinien_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_lymphome_non_hodgkinien_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_lymphome_non_hodgkinien_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,"lymphoma, cancer",-22.865637,-9.552802,0,"The content primarily addresses healthcare professionals, specifically targeting physicians and pharmacists, providing information about Roche's pharmaceutical products and services. It highlights various therapeutic areas, including oncology and treatments for specific conditions like lymphoma. The content encourages healthcare providers to engage with Roche specialists, access medical information, and utilize resources like patient information sheets and applications designed to aid patient dialogues about cancer. Overall, the purpose is to facilitate communication, education, and support for medical professionals in their practice regarding Roche's offerings.","oncology, professionals, data",rochepro.fr,All,0.0659856898236723,high,447,General Offer Outline
609,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/mammographie.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_mammographie_html.txt,200,html,Indexable,2,49,116,1214,5,3,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_mammographie_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_mammographie_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_mammographie_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,breast cancer,-22.358229,-12.792919,0,"The content is a resource aimed at healthcare professionals, specifically focusing on Roche's pharmaceutical offerings and services. It outlines various therapeutic areas such as oncology, neurology, and rare diseases, and provides information for doctors and pharmacists about their medications, how to schedule consultations with product specialists, and avenues for addressing medical queries. Additionally, the content includes patient information resources, particularly regarding breast cancer screening and biopsies, to aid in educating patients and facilitating communication about their health. Overall, the purpose is to support healthcare providers with relevant medical information and foster collaboration in patient care.","oncology, professionals, data",rochepro.fr,Falling,0.66872922312846,high,219,General Offer Outline
610,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/melanome.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_melanome_html.txt,200,html,Indexable,2,50,83,1258,8,6,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_melanome_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_melanome_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_melanome_html.txt.txt,[],Oncology-Hematology,France,Patient support,,,-26.489819,-17.181738,0,"The content on the website appears to be a resource for healthcare professionals, particularly focusing on Roche's pharmaceutical products and their therapeutic areas, including cancer, neurology, and rare diseases. It offers information about various medical conditions, drug inquiries, appointment scheduling with product specialists, and educational resources for both physicians and pharmacists. The purpose is to facilitate access to medical information, enhance understanding of specific health issues, and provide support services such as pharmacovigilance and quality reporting. Additionally, the site promotes engagement through downloadable patient information sheets and tools aimed at improving patient dialogue.","oncology, professionals, data",rochepro.fr,Falling,0.15769417077508,high,99,General Offer Outline
611,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/mucites-traitement-cancer.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_mucites_traitement_cancer_html.txt,200,html,Indexable,2,34,168,1178,5,3,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_mucites_traitement_cancer_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_mucites_traitement_cancer_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_mucites_traitement_cancer_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-27.53796,-9.261442,0,"The content provides information tailored for healthcare professionals regarding Roche's pharmaceutical products and services. It covers therapeutic areas such as oncology, neurology, and rare diseases, offering resources like patient information sheets, the option to consult specialists, and a platform for medical inquiries. Additionally, it highlights support services for pharmacists and addresses patient care strategies, particularly related to side effects of cancer treatments. The purpose is to facilitate communication and provide valuable resources for medical professionals to enhance patient care.","oncology, professionals, data",rochepro.fr,All,0.669872998588042,high,348,General Offer Outline
612,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/perfusion-chimiotherapie.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_perfusion_chimiotherapie_html.txt,200,html,Indexable,2,67,189,1187,11,9,0.97979797979798,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_perfusion_chimiotherapie_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_perfusion_chimiotherapie_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_perfusion_chimiotherapie_html.txt.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-30.717825,-2.6488695,0,"The content provides a comprehensive overview of Roche's offerings and services for healthcare professionals, particularly focusing on various therapeutic areas such as oncology and neurology. It outlines resources available for doctors and pharmacists, including drug information, appointment scheduling with product specialists, and avenues for addressing medical inquiries or reporting adverse drug effects. Additionally, it highlights educational materials geared towards patient care, such as informational leaflets about chemotherapy and radiation treatments. The purpose of this content is to facilitate professional engagement with Roche's products, enhance knowledge, and support medical practitioners in delivering patient care.","oncology, professionals, data",rochepro.fr,All,0.555122471988428,high,483,General Offer Outline
613,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/perte-cheveux-traitement-cancer.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_perte_cheveux_traitement_cancer_html.txt,200,html,Indexable,2,63,183,1203,7,5,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_perte_cheveux_traitement_cancer_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_perte_cheveux_traitement_cancer_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_perte_cheveux_traitement_cancer_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-26.726936,-10.874376,0,"The content of the content provides information and resources related to Roche's pharmaceutical products and services, specifically targeting healthcare professionals such as physicians and pharmacists. It outlines various therapeutic areas, including oncology, and offers support resources such as patient information sheets on chemotherapy side effects, consultations with product specialists, and ways to report adverse effects or quality issues. The purpose is to facilitate healthcare professionals in accessing essential medical information, managing patient care, and navigating Roche's offerings effectively.","oncology, professionals, data",rochepro.fr,Flat,0.308420829982221,high,327,General Offer Outline
614,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/radiotherapie-cancer.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_radiotherapie_cancer_html.txt,200,html,Indexable,2,51,166,1241,12,10,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_radiotherapie_cancer_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_radiotherapie_cancer_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_radiotherapie_cancer_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-27.756407,-14.743239,0,"The content primarily focuses on providing information and resources for healthcare professionals regarding Roche's pharmaceutical products and services. It includes sections on therapeutic areas such as oncology, neurology, and rare diseases, detailing various treatments like chemotherapy and radiotherapy. The purpose is to facilitate doctors and pharmacists in learning about medications, scheduling consultations with product specialists, and accessing medical information, while also offering educational resources for patient engagement and awareness.","oncology, professionals, data",rochepro.fr,All,0.003241315885707,high,259,General Offer Outline
615,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/resultats-biopsie-mammaire.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_resultats_biopsie_mammaire_html.txt,200,html,Indexable,2,66,94,1230,5,3,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_resultats_biopsie_mammaire_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_resultats_biopsie_mammaire_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_resultats_biopsie_mammaire_html.txt.txt,[],Oncology-Hematology,France,Offer outline,"breast cancer, oncology, neurology, treatment options",breast cancer,-29.286367,-7.341709,0,"The content serves as an informational resource for healthcare professionals regarding Roche's pharmaceutical products and services. It highlights various therapeutic areas, including oncology and neurology, and offers guidance on topics such as breast cancer diagnosis and treatment options. Furthermore, the content promotes interactions between healthcare providers and Roche, encouraging questions about medications and offering ways to schedule appointments with product specialists. Overall, the content aims to enhance understanding and collaboration in medical care, while providing essential resources for professionals in the field.","oncology, professionals, data",rochepro.fr,All,0.834285842664618,high,414,General Offer Outline
616,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/syndrome-main-pied-cancer.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_syndrome_main_pied_cancer_html.txt,200,html,Indexable,2,66,165,1224,6,4,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_syndrome_main_pied_cancer_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_syndrome_main_pied_cancer_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_syndrome_main_pied_cancer_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-26.12533,-12.8425665,0,"The content provides information targeted at healthcare professionals regarding Roche's pharmaceutical products and services. It highlights ways for doctors and pharmacists to engage with the company, including scheduling appointments with product specialists, asking medical or pharmaceutical questions, and accessing various therapeutic areas like oncology and neurology. Additionally, it offers resources for patient support, such as information sheets on managing side effects of cancer treatments, emphasizing patient care throughout the treatment journey. The overall purpose is to facilitate communication and support for healthcare professionals in managing patient care effectively.","oncology, professionals, data",rochepro.fr,Flat,0.030679346759699,high,207,General Offer Outline
617,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/traitements-cancer.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_traitements_cancer_html.txt,200,html,Indexable,2,67,187,1201,14,12,0.978494623655914,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_traitements_cancer_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_traitements_cancer_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_traitements_cancer_html.txt.txt.txt,[],Oncology-Hematology,France,Offer outline,"oncology, neurology, hematology, chemotherapy, radiotherapy",,-21.307537,-8.358336,0,"The content provides information about Roche's offerings for healthcare professionals, specifically targeting physicians and pharmacists. It outlines various therapeutic areas, including oncology, neurology, and hematology, while encouraging professionals to engage with their specialists, inquire about medications, and access medical resources. The content also includes practical information on treatment options for cancer, such as chemotherapy and radiotherapy, and highlights support tools for patient communication and education. Overall, the purpose of the content is to serve as a resource for healthcare professionals to enhance their knowledge and support their patients effectively.","oncology, professionals, data",rochepro.fr,Falling,0.889354519686697,high,255,General Offer Outline
618,https://rochepro.fr/aires-therapeutiques/oncologie/fiches-info-patients/tumeur-cerveau-glioblastome.html,10,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_tumeur_cerveau_glioblastome_html.txt,200,html,Indexable,2,54,192,1219,6,4,1,rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_tumeur_cerveau_glioblastome_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_tumeur_cerveau_glioblastome_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_fiches_info_patients_tumeur_cerveau_glioblastome_html.txt.txt,[],Oncology-Hematology,France,Offer outline,"glioblastoma, cancers of the head and neck, treatment options, apps, creative tools","glioblastoma, cancers of the head and neck",-19.913668,-4.089008,0,"The content of this content outlines the resources and services provided by Roche for healthcare professionals, specifically focusing on various medical conditions such as glioblastoma and cancers of the head and neck. It highlights opportunities for physicians and pharmacists to learn about medications, access medical information, schedule consultations with product specialists, and ask medical questions. Additionally, it features patient information materials, treatment options, and links to apps and creative tools designed to facilitate patient discussions regarding cancer diagnoses. Overall, the content serves as a comprehensive guide for medical professionals seeking support and information from Roche.","oncology, professionals, data",rochepro.fr,All,0.781161307237735,high,327,General Offer Outline
619,https://rochepro.fr/aires-therapeutiques/oncologie/hospitalisation-domicile.html,10,rochepro_fr_aires_therapeutiques_oncologie_hospitalisation_domicile_html.txt,200,html,Indexable,2,44,150,1077,14,9,1,rochepro_fr_aires_therapeutiques_oncologie_hospitalisation_domicile_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_hospitalisation_domicile_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_hospitalisation_domicile_html.txt.txt,"['Hospitalisation', 'HAD', 'Domicile']",Other,France,Offer outline,,,-31.261099,-15.735018,0,"The content is focused on providing resources and information tailored for healthcare professionals, specifically regarding Roche's pharmaceutical products and services. It highlights various therapeutic areas such as oncology, neurology, and rare diseases, and emphasizes the importance of home hospitalization (Hospitalisation à Domicile, HAD) as a care option. The site encourages physicians and pharmacists to learn about medications, schedule appointments with specialists, and inquire about medical or pharmaceutical questions. Additionally, it outlines support services, medical information access, and reporting mechanisms for adverse effects, showcasing Roche as a comprehensive partner in healthcare management.","oncology, professionals, data",rochepro.fr,Rising,0.646868017963427,high,186,General Offer Outline
620,https://rochepro.fr/aires-therapeutiques/oncologie/hospitalisation-domicile/pour-vos-patients.html,9,rochepro_fr_aires_therapeutiques_oncologie_hospitalisation_domicile_pour_vos_patients_html.txt,200,html,Indexable,3,46,226,1233,6,3,1,rochepro_fr_aires_therapeutiques_oncologie_hospitalisation_domicile_pour_vos_patients_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_hospitalisation_domicile_pour_vos_patients_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_hospitalisation_domicile_pour_vos_patients_html.txt.txt,"['HAD', 'COVID']",Other,France,Patient support,,,-18.687359,-21.748861,0,"The content of the content focuses on providing healthcare professionals, particularly doctors and pharmacists, with information about Roche’s medications and services, including details on specialized consultations, patient care information, and resources for home hospitalization (HAD). It addresses common misconceptions about home hospitalization, especially during the COVID-19 pandemic, and emphasizes the comfort and continuity of care it offers. Additionally, the content encourages healthcare professionals to engage with Roche for inquiries, support, and access to medical information, while also highlighting connections to various patient associations related to treatment experiences.","oncology, professionals, data",rochepro.fr,Falling,0.970219436438285,high,168,General Offer Outline
621,https://rochepro.fr/aires-therapeutiques/oncologie/hospitalisation-domicile/pour-vous.html,9,rochepro_fr_aires_therapeutiques_oncologie_hospitalisation_domicile_pour_vous_html.txt,200,html,Indexable,3,56,236,1577,6,3,1,rochepro_fr_aires_therapeutiques_oncologie_hospitalisation_domicile_pour_vous_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_hospitalisation_domicile_pour_vous_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_hospitalisation_domicile_pour_vous_html.txt.txt,['HAD'],Other,France,Patient support,,,-18.623165,-23.168415,0,"The content outlines the resources and support Roche provides for healthcare professionals, particularly focusing on medical information, product inquiries, and training for managing home hospitalization (HAD) for complex injectable treatments. It highlights access to specialists, valuable training modules for healthcare staff, and emphasizes the importance of quality care and regulatory compliance in home care settings. Additionally, it offers information and protocols to facilitate effective patient management and communication among healthcare providers. Overall, the content serves as a professional resource aimed at enhancing healthcare delivery related to Roche's therapeutic areas.","oncology, professionals, data",rochepro.fr,Rising,0.791421212130495,high,441,General Offer Outline
622,https://rochepro.fr/aires-therapeutiques/oncologie.html,10,rochepro_fr_aires_therapeutiques_oncologie_html.txt,200,html,Indexable,1,9,125,5308,725,640,1,rochepro_fr_aires_therapeutiques_oncologie_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_html.txt.txt,[],Oncology-Hematology,France,Disease information,"bronchial cancer, hepatocellular carcinoma, personalized cancer treatment, therapeutic management","bronchial cancer, hepatocellular carcinoma",2.8145468,-11.5358715,7,"The content focuses on oncology, highlighting Roche's 50 years of research and innovation aimed at personalized cancer treatment. It introduces various cancer pathologies, such as bronchial cancer and hepatocellular carcinoma, and emphasizes the availability of detailed information on these diseases and their therapeutic management. The layout suggests a professional audience, likely healthcare providers, seeking comprehensive resources in oncology.","event, exclusive, website",rochepro.fr,All,0.210957730583968,high,357,Events & Patient Care
623,https://rochepro.fr/aires-therapeutiques/oncologie/immuno-oncologie.html,10,rochepro_fr_aires_therapeutiques_oncologie_immuno_oncologie_html.txt,200,html,Indexable,1,16,85,909,40,32,1,rochepro_fr_aires_therapeutiques_oncologie_immuno_oncologie_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_immuno_oncologie_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_immuno_oncologie_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-1.3775741,-6.7752285,7,"The content displays a section of Roche's website dedicated to immuno-oncology, aimed at healthcare professionals. It allows users to download resources and place orders related to this therapeutic area. Additionally, there is contact information provided for inquiries, including a phone number and email address, emphasizing Roche’s support for medical and pharmaceutical questions. The design is clean and professional, reflecting the company's focus on providing valuable information to its users.","event, exclusive, website",rochepro.fr,Flat,0.58005644888693,high,430,Events & Patient Care
624,https://rochepro.fr/aires-therapeutiques/oncologie/immuno-oncologie/telechargez-commandez.html,10,rochepro_fr_aires_therapeutiques_oncologie_immuno_oncologie_telechargez_commandez_html.txt,200,html,Indexable,2,43,94,1096,10,3,0.978260869565217,rochepro_fr_aires_therapeutiques_oncologie_immuno_oncologie_telechargez_commandez_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_immuno_oncologie_telechargez_commandez_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_immuno_oncologie_telechargez_commandez_html.txt.txt.txt,['PDF'],Oncology-Hematology,France,Patient support,,,-16.010208,-2.7470996,0,"The content in the content focuses on immuno-oncology resources offered by Roche. It provides options for downloading documents related to routine assessments and patient follow-ups during immunotherapy, available in PDF format. The page encourages users to access these materials with a single click and offers a way to contact Roche for medical and pharmaceutical inquiries.","oncology, professionals, data",rochepro.fr,All,0.869904624875024,high,363,General Offer Outline
625,https://rochepro.fr/aires-therapeutiques/oncologie/infirmier-pratique-avancee.html,10,rochepro_fr_aires_therapeutiques_oncologie_infirmier_pratique_avancee_html.txt,200,html,Indexable,2,29,151,1107,5,3,1,rochepro_fr_aires_therapeutiques_oncologie_infirmier_pratique_avancee_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_infirmier_pratique_avancee_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_infirmier_pratique_avancee_html.txt.txt,"['Nurses', 'Practice', 'Advanced']",Oncology-Hematology,France,Offer outline,,,-19.151596,-11.637453,0,"The content primarily serves as an informational resource for healthcare professionals focusing on Roche's products and therapeutic areas, such as oncology, neurology, and rare diseases. It highlights services available to doctors and pharmacists, including scheduling consultations with product specialists, accessing medical information, and addressing drug-related inquiries. There is specific mention of the role of Advanced Practice Nurses (IPAs) in oncology care, emphasizing their importance in patient management and collaborative healthcare. The content aims to facilitate better patient care by providing tools and resources for healthcare professionals.","oncology, professionals, data",rochepro.fr,Rising,0.677586148523856,high,140,General Offer Outline
626,https://rochepro.fr/aires-therapeutiques/oncologie/onco-hematologie/evenements/hemopathies-malignes-annonce.html,10,rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_evenements_hemopathies_malignes_annonce_html.txt,200,html,Indexable,2,63,164,1140,13,6,1,rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_evenements_hemopathies_malignes_annonce_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_evenements_hemopathies_malignes_annonce_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_evenements_hemopathies_malignes_annonce_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-23.780298,-10.956057,0,"The content focuses on Roche's medical offerings and support for healthcare professionals, including physicians and pharmacists. It provides resources for understanding their medications, ways to schedule appointments with product specialists, and avenues to pose medical inquiries. The content highlights therapeutic areas such as oncology and hematology, emphasizing the importance of communicating medical diagnoses and its emotional impact on patients. Furthermore, it invites professionals to engage with Roche's events and information, promoting an environment of collaboration and knowledge sharing in clinical practice.","oncology, professionals, data",rochepro.fr,Rising,0.0945615875793782,high,362,General Offer Outline
627,https://rochepro.fr/aires-therapeutiques/oncologie/onco-hematologie/evenements.html,10,rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_evenements_html.txt,200,html,Indexable,2,40,163,922,11,7,1,rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_evenements_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_evenements_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_evenements_html.txt.txt,"['Events', 'Replays']",Oncology-Hematology,France,Events,,,-0.21464118,-6.759079,7,"The content features a section of the RochePro website dedicated to oncology and hematology events. It highlights ""Replays and Events,"" indicating resources related to past events and discussions in the field. The page aims to provide healthcare professionals with access to recorded content and additional information for improving their practice and patient care. There is also a contact option for medical inquiries.","event, exclusive, website",rochepro.fr,All,0.671035885126724,high,83,Events & Patient Care
628,https://rochepro.fr/aires-therapeutiques/oncologie/onco-hematologie.html,7,rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_html.txt,200,html,Indexable,1,16,0,1168,41,33,1,rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_html.txt.txt,[],Oncology-Hematology,France,Medication information,,,-21.576792,-11.639968,0,"The content primarily serves as a resource platform for healthcare professionals, including physicians and pharmacists, focusing on Roche's pharmaceutical offerings. It provides information on medications, therapeutic areas (like oncology and hematology), and tools for managing patient care, such as resources for understanding complex medical conditions and dialogues about cancer. The site highlights opportunities for healthcare professionals to engage with specialists, access educational materials, and obtain medical information, aiming to support both clinicians in their practice and patients in their healthcare journeys.","oncology, professionals, data",rochepro.fr,Falling,0.362154607781039,high,481,General Offer Outline
629,https://rochepro.fr/aires-therapeutiques/oncologie/onco-hematologie/pour-vos-patients.html,10,rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_pour_vos_patients_html.txt,200,html,Indexable,2,53,126,983,10,7,1,rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_pour_vos_patients_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_pour_vos_patients_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_pour_vos_patients_html.txt.txt,[],Oncology-Hematology,France,Patient support,,,-21.317293,-9.694782,0,"The content showcases a section of RochePro, specifically focusing on oncological and hematological care for patients and their families. It features resources designed to support patients, including downloadable materials and creative workbooks. Additionally, contact information is provided for medical and pharmaceutical inquiries, indicating a professional orientation towards facilitating dialogue and assistance for those affected by cancer.","oncology, professionals, data",rochepro.fr,All,0.621908008445161,high,271,General Offer Outline
630,https://rochepro.fr/aires-therapeutiques/oncologie/onco-hematologie/pour-vous.html,10,rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_pour_vous_html.txt,200,html,Indexable,2,46,94,1188,12,7,0.975,rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_pour_vous_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_pour_vous_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_pour_vous_html.txt.txt.txt,[],Oncology-Hematology,France,Offer outline,,cytokine release syndrome,-29.235075,-9.896083,0,"The content focuses on Roche's offerings and resources for healthcare professionals, including doctors and pharmacists. It highlights various therapeutic areas, particularly in oncology and hematology, and emphasizes the availability of specialized medications and support for patient care. The content provides educational resources, such as brochures on cytokine release syndrome and avenues for medical inquiries, while also outlining the company's commitment to ensuring quality and addressing healthcare needs through continuous communication and assistance. Overall, the purpose is to inform and facilitate healthcare professionals in their practice related to Roche's products and services.","oncology, professionals, data",rochepro.fr,Rising,0.230763522615778,high,471,General Offer Outline
631,https://rochepro.fr/aires-therapeutiques/oncologie/onco-hematologie/telechargez-commandez.html,10,rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_telechargez_commandez_html.txt,200,html,Indexable,2,43,94,999,14,7,0.978260869565217,rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_telechargez_commandez_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_telechargez_commandez_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_onco_hematologie_telechargez_commandez_html.txt.txt.txt,[],Oncology-Hematology,France,Patient support,,,-3.047899,-4.8933077,7,"The content showcases a section of Roche's professional website, specifically focused on oncology and hematology. It provides users with options to download materials related to cytokine release syndrome and allows for easy ordering of resources. There are features for immediate downloads and a contact section for medical inquiries, highlighting support for healthcare professionals and their patients.","event, exclusive, website",rochepro.fr,All,0.161416806694933,high,165,Events & Patient Care
632,https://rochepro.fr/aires-therapeutiques/oncologie/parler-cancer-avec-theo.html,10,rochepro_fr_aires_therapeutiques_oncologie_parler_cancer_avec_theo_html.txt,200,html,Indexable,2,26,88,1223,57,49,0.974025974025974,rochepro_fr_aires_therapeutiques_oncologie_parler_cancer_avec_theo_html.txt.txt,image/rochepro_fr_aires_therapeutiques_oncologie_parler_cancer_avec_theo_html.txt.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_parler_cancer_avec_theo_html.txt.txt.txt,[],Oncology-Hematology,France,Patient support,,,-22.500343,-8.794496,0,"The content provides comprehensive information for healthcare professionals regarding Roche's pharmaceutical products, including educational resources and tools specifically designed for patient engagement in oncology and other therapeutic areas. It outlines services available for both physicians and pharmacists, such as consultations with product specialists, access to medical information, and reporting mechanisms for quality defects or adverse effects. Additionally, it highlights interactive applications and creative resources aimed at aiding patients, particularly those with cancer, in navigating their treatment journeys. The overall purpose is to facilitate communication, education, and support within the healthcare community and enhance patient care.","oncology, professionals, data",rochepro.fr,All,0.286231370717539,high,408,General Offer Outline
633,https://rochepro.fr/aires-therapeutiques/oncologie/relation-medecin-patient-annonce-maladie-grave.html,10,rochepro_fr_aires_therapeutiques_oncologie_relation_medecin_patient_annonce_maladie_grave_html.txt,200,html,Indexable,2,28,179,1342,49,46,1,rochepro_fr_aires_therapeutiques_oncologie_relation_medecin_patient_annonce_maladie_grave_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_relation_medecin_patient_annonce_maladie_grave_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_relation_medecin_patient_annonce_maladie_grave_html.txt.txt,[],Oncology-Hematology,France,Patient support,,,-22.887852,-11.076395,0,"The content serves as a comprehensive resource for healthcare professionals regarding Roche's pharmaceutical products and services. It provides information on various therapeutic areas like oncology and hematology, emphasizing the importance of effectively communicating serious diagnoses to patients. The content includes invitations for consultations with product specialists, access to medical information, and support services for managing patient treatment journeys. Additionally, it highlights educational materials, such as videos addressing the emotional impacts of announcing a disease, and offers practical guidance for healthcare providers on how to navigate these sensitive conversations.","oncology, professionals, data",rochepro.fr,Falling,0.258586959166963,high,24,General Offer Outline
634,https://rochepro.fr/aires-therapeutiques/oncologie/stat4all.html,10,rochepro_fr_aires_therapeutiques_oncologie_stat4all_html.txt,200,html,Indexable,2,9,136,2539,44,6,1,rochepro_fr_aires_therapeutiques_oncologie_stat4all_html.txt,image/rochepro_fr_aires_therapeutiques_oncologie_stat4all_html.txt.png,text/rochepro_fr_aires_therapeutiques_oncologie_stat4all_html.txt.txt,[],Other,France,Offer outline,,,-31.392963,-4.1376796,0,"The content provides an overview of Roche's offerings and resources tailored for healthcare professionals, specifically focusing on medications for various therapeutic areas such as oncology, hematology, neurology, and rare diseases. It emphasizes engagement with healthcare providers, offering opportunities to schedule meetings with product specialists and access medical information. Additionally, it highlights the availability of educational materials through a series of online modules designed to enhance understanding of clinical research methodologies. Overall, the content aims to support medical professionals by facilitating access to knowledge, expertise, and Roche's products.","oncology, professionals, data",rochepro.fr,Falling,0.115174475189983,high,433,General Offer Outline
635,https://rochepro.fr/aires-therapeutiques/ophtalmologie/dmlan-omd.html,10,rochepro_fr_aires_therapeutiques_ophtalmologie_dmlan_omd_html.txt,200,html,Indexable,1,12,160,1204,29,15,1,rochepro_fr_aires_therapeutiques_ophtalmologie_dmlan_omd_html.txt,image/rochepro_fr_aires_therapeutiques_ophtalmologie_dmlan_omd_html.txt.png,text/rochepro_fr_aires_therapeutiques_ophtalmologie_dmlan_omd_html.txt.txt,[],Other,France,Offer outline,,,-34.307724,-11.068523,0,"The content primarily focuses on Roche's offerings and resources for healthcare professionals, emphasizing its therapeutic areas such as ophthalmology, neurology, and oncology. It provides information on various services available to doctors and pharmacists, including the ability to schedule consultations, ask medical questions, and access educational materials. Additionally, the content highlights Roche's commitment to understanding patient experiences through studies and ethnographic research, aiming to address unmet needs in treatment and enhance care pathways. Overall, the purpose is to support medical professionals in their practice and improve patient outcomes through Roche's products and insights.","oncology, professionals, data",rochepro.fr,Flat,0.805373426198538,high,199,General Offer Outline
636,https://rochepro.fr/confirmation-envoi-formulaire.html,6,rochepro_fr_confirmation_envoi_formulaire_html.txt,200,html,Indexable,,40,0,1605,1,1,1,rochepro_fr_confirmation_envoi_formulaire_html.txt,image/rochepro_fr_confirmation_envoi_formulaire_html.txt.png,text/rochepro_fr_confirmation_envoi_formulaire_html.txt.txt,"['Below', 'ONKO', 'Wikiboop', 'LUNG']",Oncology-Hematology,France,Patient support,"ONKO LUNG, Wikiboop, oncology, patient education",,1.0668557,-4.1071844,7,"The content conveys a confirmation message indicating that a request has been sent and will be addressed promptly. Below this message, there are resources available for healthcare professionals and their patients, suggesting a focus on providing helpful information or tools related to Roche’s offerings. The presence of specific resources, such as ""ONKO LUNG"" and ""Wikiboop,"" indicates specialized support related to oncology and patient education.","event, exclusive, website",rochepro.fr,Flat,0.377963683823248,medium,224,Events & Patient Care
637,https://rochepro.fr/contact.html,8,rochepro_fr_contact_html.txt,200,html,Indexable,1,21,0,995,1291,640,1,rochepro_fr_contact_html.txt,image/rochepro_fr_contact_html.txt.png,text/rochepro_fr_contact_html.txt.txt,"['Contact', 'Assistance']",Other,France,Patient support,,,-22.767708,-20.925404,0,"The content presents a ""Contact & Assistance"" section from Roche's professional website. It offers resources for inquiries related to their medications, allowing users to schedule appointments with product specialists and providing contact information for medical inquiries and pharmacovigilance. The layout emphasizes ease of access to support, catering specifically to healthcare professionals.","oncology, professionals, data",rochepro.fr,All,0.0054148448834269,high,232,General Offer Outline
638,https://rochepro.fr/contact/rdv-specialistes-produits.html,7,rochepro_fr_contact_rdv_specialistes_produits_html.txt,200,html,Indexable,1,60,0,846,650,640,1,rochepro_fr_contact_rdv_specialistes_produits_html.txt,image/rochepro_fr_contact_rdv_specialistes_produits_html.txt.png,text/rochepro_fr_contact_rdv_specialistes_produits_html.txt.txt,[],Ophthalmology,France,Patient support,,,-21.254168,-16.545084,0,"The content features a section from RochePro's website focused on contacting assistance and scheduling appointments with product specialists. It highlights various therapeutic areas, including rare diseases, ophthalmology, and neurology. The purpose is to facilitate inquiries and support for healthcare professionals regarding Roche's products and services.","oncology, professionals, data",rochepro.fr,Rising,0.406050100395719,high,229,General Offer Outline
639,https://rochepro.fr/example-global/product-landing-page.html,6,rochepro_fr_example_global_product_landing_page_html.txt,200,html,Non-Indexable,,20,0,907,1,1,0.96551724137931,rochepro_fr_example_global_product_landing_page_html.txt.txt,image/rochepro_fr_example_global_product_landing_page_html.txt.txt.png,text/rochepro_fr_example_global_product_landing_page_html.txt.txt.txt,"['Erivedge', 'Below', 'Phegso', 'All', 'Enspryng', 'Alecensa', 'Kadcyla', 'Tous']",Oncology-Hematology,France,Offer outline,"Erivedge, Enspryng, Alecensa, Phegso, Kadcyla",,4.8308463,-34.392662,1,"The content displays a professional website for Roche, focusing on their pharmaceutical products. It highlights featured products, specifically listing ""Erivedge"" capsules prominently. Below, there is a section titled ""Tous les produits"" (All products), which includes a dropdown menu for selecting therapeutic areas and a list of specific medications such as Enspryng, Alecensa, Phegso, and Kadcyla. The site appears designed for healthcare professionals, offering information on Roche's offerings in various therapeutic areas.","drug, reporting, adverse",rochepro.fr,Rising,0.935744926299131,medium,189,Drug Safety
640,https://rochepro.fr/information-medicale/aide-recherche-pubmed.html,10,rochepro_fr_information_medicale_aide_recherche_pubmed_html.txt,200,html,Indexable,2,49,214,1057,12,8,1,rochepro_fr_information_medicale_aide_recherche_pubmed_html.txt,image/rochepro_fr_information_medicale_aide_recherche_pubmed_html.txt.png,text/rochepro_fr_information_medicale_aide_recherche_pubmed_html.txt.txt,"['NCBI', 'Topics', 'My']",Other,France,Technology,,,22.134495,13.324863,4,"The content provides resources for medical professionals on how to effectively use PubMed, a widely used biomedical database. It includes a brief introduction highlighting PubMed's importance and offers access to a series of official videos aimed at enhancing users' research skills. Topics covered in the videos include understanding how PubMed works, utilizing its main search functionalities, saving searches, and personalizing user experience with My NCBI. The overall goal is to facilitate better access to bibliographic research.","technologies, artificial, ai",rochepro.fr,Rising,0.591270597170751,high,133,Technology
641,https://rochepro.fr/information-medicale/declarer-effet-indesirable/formulaire-declarer-effet-indesirable.html,7,rochepro_fr_information_medicale_declarer_effet_indesirable_formulaire_declarer_effet_indesirable_html.txt,200,html,Indexable,2,71,0,1497,4,2,0.981481481481482,rochepro_fr_information_medicale_declarer_effet_indesirable_formulaire_declarer_effet_indesirable_html.txt.txt,image/rochepro_fr_information_medicale_declarer_effet_indesirable_formulaire_declarer_effet_indesirable_html.txt.txt.png,text/rochepro_fr_information_medicale_declarer_effet_indesirable_formulaire_declarer_effet_indesirable_html.txt.txt.txt,[],Other,France,Offer outline,,,-27.270771,-27.213837,0,"The content appears to be a detailed overview of Roche's services and resources aimed at healthcare professionals, particularly focusing on the reporting and management of adverse drug reactions. It provides instructions for physicians and pharmacists on how to inquire about medications, schedule specialist consultations, ask medical or pharmaceutical questions, and declare any adverse effects associated with Roche products. Additionally, it outlines the company’s commitment to pharmacovigilance, explaining the process for reporting adverse events and handling personal data in compliance with legal obligations. Overall, the purpose is to facilitate communication and support for professionals in managing patient care and safety related to Roche's pharmaceuticals.","oncology, professionals, data",rochepro.fr,Falling,0.0155140976437876,high,96,General Offer Outline
642,https://rochepro.fr/information-medicale/declarer-effet-indesirable.html,7,rochepro_fr_information_medicale_declarer_effet_indesirable_html.txt,200,html,Indexable,1,52,0,1034,683,640,1,rochepro_fr_information_medicale_declarer_effet_indesirable_html.txt,image/rochepro_fr_information_medicale_declarer_effet_indesirable_html.txt.png,text/rochepro_fr_information_medicale_declarer_effet_indesirable_html.txt.txt,['Ultimately'],Other,France,Medication information,,,-22.765837,-24.114925,0,"The content primarily serves as a resource for healthcare professionals, particularly physicians and pharmacists, providing information about Roche's medications and services. It encourages engagement with specialists, facilitates inquiries about medical and pharmaceutical questions, and offers guidance on reporting adverse events related to medication use. Additionally, it includes instructions for accessing medical information, the importance of pharmacovigilance, and details regarding therapeutic areas such as oncology and neurology. Ultimately, the purpose is to enhance communication and support among healthcare practitioners while ensuring patient safety through effective reporting and information sharing.","oncology, professionals, data",rochepro.fr,All,0.44187598235795,high,303,General Offer Outline
643,https://rochepro.fr/information-medicale/demande-article.html,10,rochepro_fr_information_medicale_demande_article_html.txt,200,html,Indexable,2,63,176,1188,230,227,1,rochepro_fr_information_medicale_demande_article_html.txt,image/rochepro_fr_information_medicale_demande_article_html.txt.png,text/rochepro_fr_information_medicale_demande_article_html.txt.txt,[],Other,France,Patient support,,,-32.6069,-9.942443,0,"The content provides a comprehensive overview of Roche's support services and resources for healthcare professionals, including doctors and pharmacists. It outlines various ways these professionals can engage with the company, such as scheduling meetings with product specialists, asking medical or pharmaceutical questions, and accessing medications relevant to specific therapeutic areas like neurology and oncology. Additionally, the content mentions services related to research article requests, pharmacovigilance, and clinical updates. The overall purpose is to facilitate communication and resource access for healthcare professionals working with Roche's products and contribute to ongoing education and support within the healthcare system.","oncology, professionals, data",rochepro.fr,Falling,0.0540257073883013,high,166,General Offer Outline
644,https://rochepro.fr/information-medicale.html,11,rochepro_fr_information_medicale_html.txt,200,html,Indexable,1,20,197,1053,1548,640,0.953488372093023,rochepro_fr_information_medicale_html.txt.txt,image/rochepro_fr_information_medicale_html.txt.txt.png,text/rochepro_fr_information_medicale_html.txt.txt.txt,"['Information', 'Medical']",Other,France,Metainformation,,,-25.875776,-20.726967,0,"The content outlines the ""Medical Information"" section of RochePro, targeting healthcare professionals. It highlights a dedicated team providing personalized and updated medical and pharmaceutical information to benefit patients and ensure proper medication use. The section indicates that over 5,000 health professionals reached out in 2023 and offers personalized responses regarding Roche products and associated therapeutic areas. Additionally, it provides contact information for further inquiries and options for assistance, like asking medical questions or requesting bibliographic searches.","oncology, professionals, data",rochepro.fr,Rising,0.992588268012384,high,457,General Offer Outline
645,https://rochepro.fr/information-medicale/marr.html,7,rochepro_fr_information_medicale_marr_html.txt,200,html,Indexable,1,75,0,2623,651,640,1,rochepro_fr_information_medicale_marr_html.txt,image/rochepro_fr_information_medicale_marr_html.txt.png,text/rochepro_fr_information_medicale_marr_html.txt.txt,[],Other,France,Offer outline,,,-27.754406,-27.165194,0,"The content is oriented toward healthcare professionals, specifically focusing on Roche’s medications and services. It provides information about various therapeutic areas, medical resources, and support for physicians and pharmacists, including the ability to schedule consultations with product specialists and ask medical or pharmaceutical questions. Additionally, it discusses risk management measures for specific products, reporting adverse effects, and offers tools for healthcare professionals to access and manage relevant medical literature. Overall, the content serves as a comprehensive resource for professionals seeking information and support related to Roche’s pharmaceutical offerings.","oncology, professionals, data",rochepro.fr,Rising,0.409630169439456,high,483,General Offer Outline
646,https://rochepro.fr/information-medicale/question-medicale-pharmaceutique.html,7,rochepro_fr_information_medicale_question_medicale_pharmaceutique_html.txt,200,html,Indexable,2,64,0,1056,230,227,1,rochepro_fr_information_medicale_question_medicale_pharmaceutique_html.txt,image/rochepro_fr_information_medicale_question_medicale_pharmaceutique_html.txt.png,text/rochepro_fr_information_medicale_question_medicale_pharmaceutique_html.txt.txt,[],Other,France,Metainformation,,,-24.309683,-18.896471,0,"The content of the content pertains to a medical inquiry section of Roche's professional website. It enables users to submit questions related to Roche's medical or pharmaceutical products. The page emphasizes that only inquiries specifically tied to Roche’s products or therapeutic areas will be addressed. There are additional options for requesting bibliographic research, reporting adverse effects, and accessing PubMed assistance.","oncology, professionals, data",rochepro.fr,All,0.668172627575526,high,268,General Offer Outline
647,https://rochepro.fr/information-medicale/recherche-bibliographique.html,10,rochepro_fr_information_medicale_recherche_bibliographique_html.txt,200,html,Indexable,2,61,162,1105,259,256,1,rochepro_fr_information_medicale_recherche_bibliographique_html.txt,image/rochepro_fr_information_medicale_recherche_bibliographique_html.txt.png,text/rochepro_fr_information_medicale_recherche_bibliographique_html.txt.txt,"['France', 'Monaco']",Oncology-Hematology,France,Offer outline,,,-32.593018,-14.586622,0,"The content outlines resources and services offered by Roche for healthcare professionals in France and Monaco. It describes various therapeutic areas, such as oncology and neurology, and includes information on medication inquiries, specialist appointments, and medical questions. Additionally, it provides guidance on how to request bibliographic research related to Roche’s products while adhering to copyright regulations. The content emphasizes Roche's commitment to medical information and support for healthcare providers, as well as compliance with legal requirements regarding personal data.","oncology, professionals, data",rochepro.fr,Flat,0.0093413555257158,high,99,General Offer Outline
648,https://rochepro.fr/materiels-commandables/panier.html,7,rochepro_fr_materiels_commandables_panier_html.txt,200,html,Non-Indexable,1,17,0,1013,640,639,1,rochepro_fr_materiels_commandables_panier_html.txt,image/rochepro_fr_materiels_commandables_panier_html.txt.png,text/rochepro_fr_materiels_commandables_panier_html.txt.txt,[],Other,France,Other,,,-4.3748612,-24.862051,3,"The content displays a message indicating that the shopping cart is empty on RochePro's website. It informs users that they have not added any items to their cart and provides a button to return to the previous page. The interface is user-friendly, aimed at professionals navigating the site for Roche's pharmaceutical products and services.","users, page, website",rochepro.fr,Rising,0.943073094996216,high,451,Website Metadata
649,https://rochepro.fr/medecins.html,8,rochepro_fr_medecins_html.txt,200,html,Indexable,1,18,0,1511,650,640,0.935483870967742,rochepro_fr_medecins_html.txt.txt,image/rochepro_fr_medecins_html.txt.txt.png,text/rochepro_fr_medecins_html.txt.txt.txt,[],Other,France,Patient support,,,-31.522175,-12.549713,0,"The content outlines the services and resources provided by Roche for healthcare professionals, including doctors and pharmacists. It emphasizes the availability of information about Roche's medications, opportunities for appointments with product specialists, and options to ask medical or pharmaceutical questions. Additionally, it provides details about therapeutic areas such as oncology, neurology, and rare diseases, as well as support for patient care and resources for healthcare practitioners. The purpose is to facilitate access to medical information and support services, enhancing the collaboration between Roche and healthcare professionals.","oncology, professionals, data",rochepro.fr,Rising,0.301385895111557,high,224,General Offer Outline
650,https://rochepro.fr/nos-produits/alecensa.html,8,rochepro_fr_nos_produits_alecensa_html.txt,200,html,Non-Indexable,2,8,0,1016,7,3,1,rochepro_fr_nos_produits_alecensa_html.txt,image/rochepro_fr_nos_produits_alecensa_html.txt.png,text/rochepro_fr_nos_produits_alecensa_html.txt.txt,"['Alecensa', 'November']",Oncology-Hematology,France,Medication information,"Alecensa, alectinib, 150 mg capsules, oncology specialists, updated guidance",,12.849944,-28.359604,1,"The content provides information about Alecensa (alectinib), a medication produced by Roche. It includes details such as the dosage form (150 mg capsules), pricing, and regulations surrounding its prescription, which is restricted to oncology specialists. Additionally, it references relevant transparency notices and medical information, indicating updated guidance as of November 18, 2024. The content is tailored for professionals in the healthcare field.","drug, reporting, adverse",rochepro.fr,Rising,0.0856823461039722,high,125,Drug Safety
651,https://rochepro.fr/nos-produits/avastin.html,8,rochepro_fr_nos_produits_avastin_html.txt,200,html,Non-Indexable,2,7,0,1478,5,2,1,rochepro_fr_nos_produits_avastin_html.txt,image/rochepro_fr_nos_produits_avastin_html.txt.png,text/rochepro_fr_nos_produits_avastin_html.txt.txt,['Avastin'],Oncology-Hematology,France,Offer outline,"Avastin, oncology, neurology, rare diseases, indications, pricing, regulatory information, adverse effects",,-29.313736,-20.19493,0,"The content provides information targeted at healthcare professionals about Roche's products, specifically their medications and therapeutic areas such as oncology, neurology, and rare diseases. It offers details on how to engage with Roche, including scheduling appointments with product specialists, asking medical or pharmaceutical questions, and accessing medical information. Additionally, it includes specifics about a medication called Avastin, such as its indications, pricing, and regulatory information, as well as guidelines for reporting adverse effects. Overall, the content serves as a resource for medical professionals seeking to understand Roche's offerings and stay informed about their treatments.","oncology, professionals, data",rochepro.fr,Falling,0.867548959591395,high,42,General Offer Outline
652,https://rochepro.fr/nos-produits/cellcept.html,8,rochepro_fr_nos_produits_cellcept_html.txt,200,html,Non-Indexable,2,8,0,1262,6,2,1,rochepro_fr_nos_produits_cellcept_html.txt,image/rochepro_fr_nos_produits_cellcept_html.txt.png,text/rochepro_fr_nos_produits_cellcept_html.txt.txt,['Specific'],Other,France,Offer outline,,,-27.809927,-28.563318,0,"The content provides detailed information aimed at healthcare professionals regarding Roche's pharmaceutical products and services. It includes resources for doctors and pharmacists, such as medication information, appointment scheduling with product specialists, and a section for inquiries related to medical or pharmaceutical questions. Specific drugs are highlighted, including their formulations, pricing, and prescription guidelines, as well as relevant medical safety information. Overall, the purpose of this content is to facilitate access to Roche's products, support healthcare professionals in their practice, and ensure compliance with safety and regulatory measures.","oncology, professionals, data",rochepro.fr,Rising,0.647715310454224,high,69,General Offer Outline
653,https://rochepro.fr/nos-produits/columvi.html,8,rochepro_fr_nos_produits_columvi_html.txt,200,html,Non-Indexable,2,7,0,1001,4,2,1,rochepro_fr_nos_produits_columvi_html.txt,image/rochepro_fr_nos_produits_columvi_html.txt.png,text/rochepro_fr_nos_produits_columvi_html.txt.txt,"['Columvi', 'RCP']",Oncology-Hematology,France,Medication information,"Columvi, glofitamab, intravenous infusion, 2.5 mg, 10 mg, prescription conditions, safety monitoring",,19.941746,-38.862766,1,"The content provides details on the medication ""Columvi"" (glofitamab), specifically its formulations for intravenous infusion in two strengths (2.5 mg and 10 mg). It includes links to important documents such as common notices and regional product characteristics (RCP) for both strengths. The content also mentions prescription conditions, indicating that the medication is reserved for hospital use and requires specialist oversight in hematology. Additionally, there is a note about ongoing safety monitoring and contact information for medical inquiries.","drug, reporting, adverse",rochepro.fr,Falling,0.59991390285478,high,192,Drug Safety
654,https://rochepro.fr/nos-produits/cotellic.html,8,rochepro_fr_nos_produits_cotellic_html.txt,200,html,Non-Indexable,2,8,0,992,6,2,0.954545454545455,rochepro_fr_nos_produits_cotellic_html.txt.txt,image/rochepro_fr_nos_produits_cotellic_html.txt.txt.png,text/rochepro_fr_nos_produits_cotellic_html.txt.txt.txt,"['Cotellic', 'February']",Oncology-Hematology,France,Medication information,"Cotellic, cobimetinib, 20 mg, film-coated tablets, oncology",,16.594395,-32.393867,1,"The content provides information about Cotellic (cobimetinib), including its dosage (20 mg) and form (film-coated tablets). It outlines the product's price as of February 1, 2021, and indicates its prescription conditions, emphasizing that it's available only through hospital prescriptions to specialists in oncology. Additionally, it mentions the financial coverage conditions and provides links to relevant documentation for healthcare professionals, along with contact information for medical inquiries.","drug, reporting, adverse",rochepro.fr,Rising,0.529792225796154,high,241,Drug Safety
655,https://rochepro.fr/nos-produits/erivedge.html,8,rochepro_fr_nos_produits_erivedge_html.txt,200,html,Non-Indexable,2,8,0,1091,7,3,1,rochepro_fr_nos_produits_erivedge_html.txt,image/rochepro_fr_nos_produits_erivedge_html.txt.png,text/rochepro_fr_nos_produits_erivedge_html.txt.txt,"['Erivedge', 'December', 'February', 'Additional']",Oncology-Hematology,France,Medication information,"Erivedge, vismodegib, 150 mg capsules, prescription conditions, monitoring during treatment, women of childbearing potential",,16.029974,-33.132458,1,"The content presents information about Erivedge (vismodegib), a medication available from Roche. It details its dosage (150 mg capsules) and provides pricing information as of February 2023. Additional resources, such as the medication's information sheet and product summary, are linked. The content also outlines specific prescription conditions, including restrictions for oncology specialists and requirements for monitoring during treatment, especially for women of childbearing potential. The last update date is noted as December 21, 2023.","drug, reporting, adverse",rochepro.fr,Flat,0.950125898633813,high,266,Drug Safety
656,https://rochepro.fr/nos-produits/evrysdi.html,8,rochepro_fr_nos_produits_evrysdi_html.txt,200,html,Non-Indexable,2,7,0,1069,6,2,1,rochepro_fr_nos_produits_evrysdi_html.txt,image/rochepro_fr_nos_produits_evrysdi_html.txt.png,text/rochepro_fr_nos_produits_evrysdi_html.txt.txt,"['Evrysdi', 'April']",Other,France,Medication information,"Evrysdi, risdiplam, oral solution, monitoring, adverse effects",,20.783127,-37.800724,1,"The content features information about Evrysdi (risdiplam), a medication for specific medical conditions, including its formulation as a powder for oral solution. It provides details such as the public price as of April 2022, daily treatment costs, and mentions additional monitoring for safety and adverse effects. The page is dedicated to healthcare professionals, offering links to product information and guidelines, as well as areas regarding prescription requirements and official recommendations related to its use.","drug, reporting, adverse",rochepro.fr,Flat,0.341537844311056,high,411,Drug Safety
657,https://rochepro.fr/nos-produits/fuzeon.html,8,rochepro_fr_nos_produits_fuzeon_html.txt,200,html,Non-Indexable,2,6,0,1051,6,2,0.952380952380952,rochepro_fr_nos_produits_fuzeon_html.txt.txt,image/rochepro_fr_nos_produits_fuzeon_html.txt.txt.png,text/rochepro_fr_nos_produits_fuzeon_html.txt.txt.txt,"['February', 'Fuzeon']",Other,France,Medication information,"Fuzeon, enfuvirtide, pricing, prescription, delivery, drug use, administrative details",,17.753046,-37.756283,1,"The content provides information about Fuzeon (enfuvirtide), a medication available in a powder form for injectable solution. It includes details such as the product's pricing as of February 1, 2021, references for product information, and conditions for prescription and delivery. Additionally, it lists transparency notices from various health commissions and offers a contact option for medical inquiries. The page is designed for healthcare professionals to access specifics about the drug's use and administrative details.","drug, reporting, adverse",rochepro.fr,Rising,0.134347674657814,high,279,Drug Safety
658,https://rochepro.fr/nos-produits/gazyvaro.html,8,rochepro_fr_nos_produits_gazyvaro_html.txt,200,html,Non-Indexable,2,8,0,1057,5,2,0.954545454545455,rochepro_fr_nos_produits_gazyvaro_html.txt.txt,image/rochepro_fr_nos_produits_gazyvaro_html.txt.txt.png,text/rochepro_fr_nos_produits_gazyvaro_html.txt.txt.txt,"['Additional', 'Gazyvaro']",Oncology-Hematology,France,Medication information,"Gazyvaro, obinutuzumab, solution for infusion, administration conditions, monitoring, pricing, insurance coverage",,17.693516,-33.200928,1,"The content provides information about Gazyvaro (obinutuzumab), including its formulation as a 1000 mg solution for infusion. It outlines the administration conditions, indicating that it is reserved for hospital use and should only be prescribed by specialists in hematology or qualified physicians. Additional links are available for further documentation, such as a package insert and regulatory compliance information. The page highlights the importance of monitoring during treatment and includes details on pricing and insurance coverage.","drug, reporting, adverse",rochepro.fr,Flat,0.780496786640368,high,210,Drug Safety
659,https://rochepro.fr/nos-produits/herceptin/herceptin-iv.html,6,rochepro_fr_nos_produits_herceptin_herceptin_iv_html.txt,200,html,Non-Indexable,3,12,0,1214,5,2,1,rochepro_fr_nos_produits_herceptin_herceptin_iv_html.txt,image/rochepro_fr_nos_produits_herceptin_herceptin_iv_html.txt.png,text/rochepro_fr_nos_produits_herceptin_herceptin_iv_html.txt.txt,['Herceptin'],Oncology-Hematology,France,Offer outline,"Herceptin, oncology, neurology",,-32.130642,-16.286827,0,"The content provides a comprehensive overview of Roche's offerings and services tailored specifically for healthcare professionals, including physicians and pharmacists. It outlines various therapeutic areas such as oncology and neurology, lists medications like Herceptin along with administration and billing details, and offers resources for medical inquiries and pharmacovigilance. The purpose is to facilitate access to Roche's products, support professional education, and ensure proper medication management while streamlining communication with the company's medical information services.","oncology, professionals, data",rochepro.fr,All,0.674533646251348,medium,205,General Offer Outline
660,https://rochepro.fr/nos-produits/herceptin/herceptin-sc.html,6,rochepro_fr_nos_produits_herceptin_herceptin_sc_html.txt,200,html,Non-Indexable,3,12,0,1100,5,2,1,rochepro_fr_nos_produits_herceptin_herceptin_sc_html.txt,image/rochepro_fr_nos_produits_herceptin_herceptin_sc_html.txt.png,text/rochepro_fr_nos_produits_herceptin_herceptin_sc_html.txt.txt,['Herceptin'],Other,France,Offer outline,"Herceptin, oncology, neurology, rare diseases, adverse effects, regulatory compliance",,-29.092823,-20.30204,0,"The content appears to be a resource for healthcare professionals regarding Roche's pharmaceutical offerings and services. It provides information on various therapeutic areas such as oncology, neurology, and rare diseases, while also outlining procedures for medical inquiries, product appointments, and reporting adverse effects. Additionally, it includes specific details about Roche's medication, like Herceptin, and emphasizes regulatory compliance and guidelines for healthcare practitioners. The primary purpose of the content is to facilitate access to Roche's products and support for medical professionals in managing treatment and patient care.","oncology, professionals, data",rochepro.fr,All,0.0523825981747604,medium,59,General Offer Outline
661,https://rochepro.fr/nos-produits/herceptin.html,8,rochepro_fr_nos_produits_herceptin_html.txt,200,html,Non-Indexable,2,9,0,841,7,5,1,rochepro_fr_nos_produits_herceptin_html.txt,image/rochepro_fr_nos_produits_herceptin_html.txt.png,text/rochepro_fr_nos_produits_herceptin_html.txt.txt,"['SC', 'Herceptin', 'IV']",Oncology-Hematology,France,Medication information,"Herceptin, trastuzumab, Herceptin IV, Herceptin SC, oncology, neurology",,7.916516,-33.08286,1,"The content features a webpage related to Herceptin (trastuzumab), a medication provided by Roche. It allows users to select the mode of administration—either Herceptin IV or Herceptin SC—to access relevant legal information. The page also includes sections for contact and assistance, pharmacovigilance reporting, and lists various therapeutic areas such as oncology and neurology, aimed at healthcare professionals.","drug, reporting, adverse",rochepro.fr,Falling,0.39173452378233,high,59,Drug Safety
662,https://rochepro.fr/nos-produits.html,8,rochepro_fr_nos_produits_html.txt,200,html,Indexable,1,15,0,989,686,640,1,rochepro_fr_nos_produits_html.txt,image/rochepro_fr_nos_produits_html.txt.png,text/rochepro_fr_nos_produits_html.txt.txt,"['Alectinib', 'Glofitamab', 'Mycophenolate', 'Bevacizumab']",Oncology-Hematology,France,Medication information,"Alectinib, Bevacizumab, Mycophenolate mofetil, Glofitamab",,5.1394844,-35.277008,1,"The content displays a section of the RochePro website dedicated to pharmaceuticals, specifically listing various medications. It invites users to log in for access to detailed product information useful for their practice. The page features a selection of products, including names like Alectinib, Bevacizumab, Mycophenolate mofetil, and Glofitamab, categorized under therapeutic areas for easier navigation. The overall design emphasizes user accessibility and professional relevance.","drug, reporting, adverse",rochepro.fr,Falling,0.907014805599948,high,201,Drug Safety
663,https://rochepro.fr/nos-produits/kadcyla.html,8,rochepro_fr_nos_produits_kadcyla_html.txt,200,html,Non-Indexable,2,7,0,1231,6,3,1,rochepro_fr_nos_produits_kadcyla_html.txt,image/rochepro_fr_nos_produits_kadcyla_html.txt.png,text/rochepro_fr_nos_produits_kadcyla_html.txt.txt,"['France', 'Monaco', 'Kadcyla']",Oncology-Hematology,France,Offer outline,"Kadcyla, oncology, neurology, adverse effects, quality defects",,-30.036417,-22.508297,0,"The content primarily focuses on Roche's product offerings, including specific medications like Kadcyla, and provides information tailored for healthcare professionals such as doctors and pharmacists. It offers resources for medical inquiries, scheduling consultations with product specialists, and instructions for reporting adverse effects and quality defects. Additionally, it outlines therapeutic areas covered by Roche, including oncology and neurology, and emphasizes compliance with medical regulations and the support available for healthcare providers in France and Monaco. The overall purpose is to facilitate access to information and services related to Roche's pharmaceutical products while promoting medical safety and communication.","oncology, professionals, data",rochepro.fr,Flat,0.546965332952034,high,161,General Offer Outline
664,https://rochepro.fr/nos-produits/mabthera.html,8,rochepro_fr_nos_produits_mabthera_html.txt,200,html,Non-Indexable,2,8,0,840,7,5,0.954545454545455,rochepro_fr_nos_produits_mabthera_html.txt.txt,image/rochepro_fr_nos_produits_mabthera_html.txt.txt.png,text/rochepro_fr_nos_produits_mabthera_html.txt.txt.txt,"['SC', 'IV']",Oncology-Hematology,France,Medication information,"MabThera, rituximab, MabThera IV, MabThera SC, oncology, neurology",,5.093493,-31.947783,1,"The content features a section from RochePro's website dedicated to the drug MabThera (rituximab). It provides options for users to select the administration method—either MabThera IV or MabThera SC—to access relevant legal information. The page also includes contact and assistance resources, pharmacovigilance information, and lists therapeutic areas such as oncology and neurology. This content aims to serve healthcare professionals by providing essential information about Roche products and services.","drug, reporting, adverse",rochepro.fr,All,0.371547467358332,high,286,Drug Safety
665,https://rochepro.fr/nos-produits/mabthera/mabthera-iv.html,6,rochepro_fr_nos_produits_mabthera_mabthera_iv_html.txt,200,html,Non-Indexable,3,10,0,1323,5,2,1,rochepro_fr_nos_produits_mabthera_mabthera_iv_html.txt,image/rochepro_fr_nos_produits_mabthera_mabthera_iv_html.txt.png,text/rochepro_fr_nos_produits_mabthera_mabthera_iv_html.txt.txt,[],Other,France,Offer outline,"MabThera, drug prescriptions, adverse effects, drug pricing, insurance coverage, regulatory approvals",,-22.34374,-24.511583,0,"The content primarily serves as a resource for healthcare professionals, particularly doctors and pharmacists, providing detailed information about Roche's pharmaceutical products, specifically focusing on medications like MabThera. It outlines how to access medical information, schedule appointments with specialists, and manage inquiries related to drug prescriptions and adverse effects. Additionally, it includes details about drug pricing, insurance coverage, and regulatory approvals, reflecting the company's commitment to supporting medical practitioners and ensuring safe medication practices. Overall, the content is geared towards facilitating communication and providing essential resources for professionals in the healthcare field.","oncology, professionals, data",rochepro.fr,Rising,0.0274280090108469,medium,403,General Offer Outline
666,https://rochepro.fr/nos-produits/mabthera/mabthera-sc.html,6,rochepro_fr_nos_produits_mabthera_mabthera_sc_html.txt,200,html,Non-Indexable,3,11,0,1002,5,2,0.964285714285714,rochepro_fr_nos_produits_mabthera_mabthera_sc_html.txt.txt,image/rochepro_fr_nos_produits_mabthera_mabthera_sc_html.txt.txt.png,text/rochepro_fr_nos_produits_mabthera_mabthera_sc_html.txt.txt.txt,['SC'],Oncology-Hematology,France,Medication information,"MabThera SC, rituximab, subcutaneous injection, 1400 mg, prescription-only, specialists in hematology, special monitoring, first administration, hospital setting",,17.136435,-32.88891,1,"The content contains information about MabThera SC (rituximab), a medication manufactured by Roche. It highlights the specific form and dosage (1400 mg) intended for subcutaneous injection. The content includes links to detailed usage guidelines and regulatory information, emphasizing that the medication is prescription-only and intended for specialists in hematology or related fields. It also notes the need for special monitoring during treatment and specifies that the first administration should occur in a hospital setting. Additionally, there are references to pricing and health insurance coverage.","drug, reporting, adverse",rochepro.fr,Falling,0.243174743835649,medium,399,Drug Safety
667,https://rochepro.fr/nos-produits/mircera.html,8,rochepro_fr_nos_produits_mircera_html.txt,200,html,Non-Indexable,2,7,0,1348,6,2,1,rochepro_fr_nos_produits_mircera_html.txt,image/rochepro_fr_nos_produits_mircera_html.txt.png,text/rochepro_fr_nos_produits_mircera_html.txt.txt,['Mircera'],Other,France,Medication information,"Mircera, medication consultations, pricing, administration guidelines, reimbursement, adverse event reporting",,5.2456455,-32.734028,1,"The content appears to be a detailed overview of Roche's medical products and services, specifically focusing on their medication Mircera, which is used for treating certain medical conditions. It includes information for healthcare professionals such as doctors and pharmacists, providing details about medication consultations, the product's pricing, administration guidelines, and conditions regarding reimbursement. Additionally, it outlines resources for medical inquiries and adverse event reporting. The purpose is to facilitate access to Roche’s pharmaceutical offerings and support healthcare providers in their practice.","drug, reporting, adverse",rochepro.fr,Falling,0.686287962803773,high,42,Drug Safety
668,https://rochepro.fr/nos-produits/modopar.html,8,rochepro_fr_nos_produits_modopar_html.txt,200,html,Non-Indexable,2,7,0,1217,6,2,1,rochepro_fr_nos_produits_modopar_html.txt,image/rochepro_fr_nos_produits_modopar_html.txt.png,text/rochepro_fr_nos_produits_modopar_html.txt.txt,['Modopar'],Other,France,Offer outline,"Modopar, oncology, neurology, pharmacovigilance, therapeutic areas",,-31.09097,-16.29952,0,"The content provides a comprehensive overview of Roche's offerings for healthcare professionals, specifically targeting physicians and pharmacists. It includes information about medication inquiries, specialist appointments, and medical questions. Additionally, it details specific medications like Modopar, including their formulations, pricing, and regulatory approvals. The content emphasizes Roche's commitment to healthcare collaboration and information sharing, highlighting its support services, pharmacovigilance, and therapeutic areas such as oncology and neurology. Overall, the purpose is to serve as a resource hub for medical professionals engaging with Roche products and services.","oncology, professionals, data",rochepro.fr,Rising,0.793497818948741,high,416,General Offer Outline
669,https://rochepro.fr/nos-produits/neorecormon.html,8,rochepro_fr_nos_produits_neorecormon_html.txt,200,html,Non-Indexable,2,11,0,1381,7,3,0.957446808510638,rochepro_fr_nos_produits_neorecormon_html.txt.txt,image/rochepro_fr_nos_produits_neorecormon_html.txt.txt.png,text/rochepro_fr_nos_produits_neorecormon_html.txt.txt.txt,[],Other,France,Offer outline,"NeoRecormon, dosages, pricing, prescription conditions, pharmacovigilance, patient safety protocols",,-29.969908,-22.92034,0,"The content appears to focus on Roche's healthcare services and pharmaceutical products, particularly emphasizing resources available for medical professionals such as doctors and pharmacists. It provides information on medications, specifically highlighting NeoRecormon, its dosages, pricing, and prescription conditions. The content encourages professionals to engage with Roche for inquiries, appointments with specialists, and access to medical information, reflecting a commitment to support healthcare providers in managing patient care effectively. Additionally, it mentions services for pharmacovigilance and patient safety protocols. Overall, the content serves as a professional resource for the medical community regarding Roche's offerings and support systems.","oncology, professionals, data",rochepro.fr,Rising,0.599341380718257,high,321,General Offer Outline
670,https://rochepro.fr/nos-produits/ocrevus.html,8,rochepro_fr_nos_produits_ocrevus_html.txt,200,html,Non-Indexable,2,7,0,841,6,4,1,rochepro_fr_nos_produits_ocrevus_html.txt,image/rochepro_fr_nos_produits_ocrevus_html.txt.png,text/rochepro_fr_nos_produits_ocrevus_html.txt.txt,"['SC', 'Ocrevus', 'IV']",Neurology,France,Medication information,"Ocrevus, ocrelizumab, IV, SC, oncology, neurology",,10.082395,-32.222607,1,"The content displays content related to Ocrevus (ocrelizumab), a medication offered by Roche. It provides options for selecting the mode of administration—either IV (intravenous) or SC (subcutaneous). The page serves as a resource for healthcare professionals, with links for legal information, contact assistance, and additional therapeutic areas such as oncology and neurology. It emphasizes the supportive services available for medical inquiries and pharmacovigilance.","drug, reporting, adverse",rochepro.fr,Flat,0.496464140950447,high,65,Drug Safety
671,https://rochepro.fr/nos-produits/perjeta.html,8,rochepro_fr_nos_produits_perjeta_html.txt,200,html,Non-Indexable,2,7,0,1181,5,2,1,rochepro_fr_nos_produits_perjeta_html.txt,image/rochepro_fr_nos_produits_perjeta_html.txt.png,text/rochepro_fr_nos_produits_perjeta_html.txt.txt,"['December', 'Last', 'RCP', 'Perjeta']",Oncology-Hematology,France,Medication information,"Perjeta, pertuzumab, solution for infusion, pricing, reimbursement conditions, prescription requirements, oncology specialists",,20.217571,-35.31089,1,"The content features information about the pharmaceutical product Perjeta (pertuzumab), detailing its formulation as a 420 mg solution for infusion. It provides links to the product's notice and the summary of product characteristics (RCP). Additionally, it mentions the pricing and reimbursement conditions associated with the medication. Last updated on December 4, 2023, the page also outlines prescription requirements and notes that the medication is intended for hospital use under the supervision of oncology specialists.","drug, reporting, adverse",rochepro.fr,Falling,0.260883503686622,high,200,Drug Safety
672,https://rochepro.fr/nos-produits/phesgo.html,8,rochepro_fr_nos_produits_phesgo_html.txt,200,html,Non-Indexable,2,6,0,1101,6,3,0.952380952380952,rochepro_fr_nos_produits_phesgo_html.txt.txt,image/rochepro_fr_nos_produits_phesgo_html.txt.txt.png,text/rochepro_fr_nos_produits_phesgo_html.txt.txt.txt,"['October', 'Phesgo']",Oncology-Hematology,France,Medication information,"Phesgo, pertuzumab, trastuzumab, dosages, safety measures, specialist prescription, oncology, enhanced safety surveillance, transparency notices, updates",,19.47453,-32.778675,1,"The content displays information regarding a specific medication, Phesgo, which contains pertuzumab and trastuzumab. It outlines the available dosages (600 mg/600 mg and 1,200 mg/600 mg), provides links to common usage information and safety measures for each dosage, and highlights the need for specialist prescription in oncology. Additionally, it notes that the medication is subject to enhanced safety surveillance and includes references to official transparency notices and updates as of October 2024.","drug, reporting, adverse",rochepro.fr,Falling,0.167034256945087,high,70,Drug Safety
673,https://rochepro.fr/nos-produits/pulmozyme.html,8,rochepro_fr_nos_produits_pulmozyme_html.txt,200,html,Non-Indexable,2,9,0,1055,6,2,1,rochepro_fr_nos_produits_pulmozyme_html.txt,image/rochepro_fr_nos_produits_pulmozyme_html.txt.png,text/rochepro_fr_nos_produits_pulmozyme_html.txt.txt,['Pulmozyme'],Other,France,Medication information,"Pulmozyme, dornase-alfa, inhalation, nebulizer, prescription, reimbursement, transparency opinions",,17.836325,-38.490765,1,"The content provides information about Pulmozyme (dornase-alfa), specifically detailing its formulation for inhalation using a nebulizer. It includes pricing information, links to the product notice and health authority registration documentation, and outlines conditions for prescription and reimbursement. Additionally, it references transparency opinions related to the medication, indicating updates on its status and history in social security listings. This resource is aimed at healthcare professionals for informed prescribing and management of the medication.","drug, reporting, adverse",rochepro.fr,Flat,0.0227282855159991,high,391,Drug Safety
674,https://rochepro.fr/nos-produits/roactemra.html,8,rochepro_fr_nos_produits_roactemra_html.txt,200,html,Non-Indexable,2,9,0,841,6,4,0.955555555555556,rochepro_fr_nos_produits_roactemra_html.txt.txt,image/rochepro_fr_nos_produits_roactemra_html.txt.txt.png,text/rochepro_fr_nos_produits_roactemra_html.txt.txt.txt,"['SC', 'IV']",Other,France,Medication information,"RoActemra, tocilizumab, IV, SC, oncology, neurology",,8.139862,-35.107006,1,"The content displays a section from Roche's professional website, specifically about RoActemra (tocilizumab). It provides options for selecting the mode of administration (IV or SC) to access corresponding legal information. Additionally, it includes resources for contact and assistance, pharmacovigilance reporting, and highlights various therapeutic areas like oncology and neurology. The page is designed to support healthcare professionals by offering relevant product information and resources.","drug, reporting, adverse",rochepro.fr,All,0.0086994022599695,high,430,Drug Safety
675,https://rochepro.fr/nos-produits/rocephine.html,8,rochepro_fr_nos_produits_rocephine_html.txt,200,html,Non-Indexable,2,9,0,1145,6,2,1,rochepro_fr_nos_produits_rocephine_html.txt,image/rochepro_fr_nos_produits_rocephine_html.txt.png,text/rochepro_fr_nos_produits_rocephine_html.txt.txt,['Rocephine'],Other,France,Medication information,"Rocephin, reimbursement status, safety information, adverse effects, therapeutic areas",,-28.126143,-26.083103,0,"The content primarily serves as a resource for healthcare professionals, particularly doctors and pharmacists, offering information about Roche’s medications, including details on specific products like Rocephine and their reimbursement status. It encourages professionals to consult with product specialists, ask medical or pharmaceutical questions, and access educational resources. Additionally, the content includes safety information, guidelines for reporting adverse effects, and a range of therapeutic areas, reflecting Roche's commitment to supporting healthcare providers in patient care and medication management.","oncology, professionals, data",rochepro.fr,Falling,0.945135343949989,high,131,General Offer Outline
676,https://rochepro.fr/nos-produits/tarceva.html,8,rochepro_fr_nos_produits_tarceva_html.txt,200,html,Non-Indexable,2,7,0,1078,6,2,1,rochepro_fr_nos_produits_tarceva_html.txt,image/rochepro_fr_nos_produits_tarceva_html.txt.png,text/rochepro_fr_nos_produits_tarceva_html.txt.txt,"['Tarceva', 'May']",Oncology-Hematology,France,Medication information,"Tarceva, erlotinib, dosages, prescription conditions, oncology",,17.715532,-34.629055,1,"The content provides information about Tarceva (erlotinib), including its various dosages (100 mg, 150 mg, and 25 mg) and their associated prices. It includes links to the common notice and regulatory documentation for Tarceva, as well as a note about the prescription conditions, indicating that it is restricted to specialists in oncology and requires particular monitoring during treatment. The last update date is noted as May 4, 2023, highlighting the site's focus on providing up-to-date information for healthcare professionals.","drug, reporting, adverse",rochepro.fr,Falling,0.368827784282612,high,229,Drug Safety
677,https://rochepro.fr/nos-produits/tecentriq.html,8,rochepro_fr_nos_produits_tecentriq_html.txt,200,html,Non-Indexable,2,9,0,856,8,6,1,rochepro_fr_nos_produits_tecentriq_html.txt,image/rochepro_fr_nos_produits_tecentriq_html.txt.png,text/rochepro_fr_nos_produits_tecentriq_html.txt.txt,['Tecentriq'],Oncology-Hematology,France,Medication information,"Tecentriq, atezolizumab, administration methods, dosages, subcutaneous administration",,14.601514,-34.767384,1,"The content features a section dedicated to ""Tecentriq"" (atezolizumab), a medication by Roche. It includes different administration methods for the drug, highlighting options based on dosages (840 mg and 1200 mg) and a subcutaneous administration option. The page is designed for healthcare professionals, providing legal mentions related to the drug, as well as links for further assistance and information on pharmacovigilance.","drug, reporting, adverse",rochepro.fr,Falling,0.673334675410528,high,347,Drug Safety
678,https://rochepro.fr/nos-produits/tecentriq/tecentriq-1200.html,6,rochepro_fr_nos_produits_tecentriq_tecentriq_1200_html.txt,200,html,Non-Indexable,3,17,0,1611,5,2,1,rochepro_fr_nos_produits_tecentriq_tecentriq_1200_html.txt,image/rochepro_fr_nos_produits_tecentriq_tecentriq_1200_html.txt.png,text/rochepro_fr_nos_produits_tecentriq_tecentriq_1200_html.txt.txt,"['France', 'Tecentriq', 'Monaco']",Other,France,Offer outline,"Tecentriq, therapeutic areas, reimbursement, drug-related issues",,-25.139795,-27.47268,0,"The content serves as a resource for healthcare professionals in France and Monaco, detailing Roche's pharmaceutical offerings, including specific medications like Tecentriq. It provides information about medical consultations, services for pharmacists, and avenues for reporting drug-related issues. Additionally, it includes regulatory updates, conditions of reimbursement by health insurance, and various therapeutic areas, ensuring that stakeholders have access to essential medical information and assistance. The content emphasizes Roche’s commitment to supporting healthcare providers and facilitating effective patient care.","oncology, professionals, data",rochepro.fr,Flat,0.0962969569786477,medium,461,General Offer Outline
679,https://rochepro.fr/nos-produits/tecentriq/tecentriq-840.html,6,rochepro_fr_nos_produits_tecentriq_tecentriq_840_html.txt,200,html,Non-Indexable,3,15,0,1642,5,2,0.966101694915254,rochepro_fr_nos_produits_tecentriq_tecentriq_840_html.txt.txt,image/rochepro_fr_nos_produits_tecentriq_tecentriq_840_html.txt.txt.png,text/rochepro_fr_nos_produits_tecentriq_tecentriq_840_html.txt.txt.txt,['Tecentriq'],Oncology-Hematology,France,Offer outline,"Tecentriq, pharmacovigilance, drug use, patient care",,-26.496275,-26.792618,0,"The content provides information regarding Roche's pharmaceutical offerings targeted at healthcare professionals, specifically physicians and pharmacists. It outlines available medications, including detailed product data for Tecentriq, along with guidelines for prescription, medical inquiries, and support services. The content aims to facilitate communication and education among healthcare professionals about Roche's products, while also emphasizing the importance of pharmacovigilance and administrative procedures related to drug use and patient care.","oncology, professionals, data",rochepro.fr,Falling,0.460856440738466,medium,46,General Offer Outline
680,https://rochepro.fr/nos-produits/tecentriq/tecentriq-sc.html,6,rochepro_fr_nos_produits_tecentriq_tecentriq_sc_html.txt,200,html,Non-Indexable,3,12,0,1233,5,2,1,rochepro_fr_nos_produits_tecentriq_tecentriq_sc_html.txt,image/rochepro_fr_nos_produits_tecentriq_tecentriq_sc_html.txt.png,text/rochepro_fr_nos_produits_tecentriq_tecentriq_sc_html.txt.txt,"['SC', 'Tecentriq', 'Atezolizumab']",Oncology-Hematology,France,Medication information,"Tecentriq SC, Atezolizumab, injectable solution, prescription, dispensing, oncology",,15.347357,-33.77346,1,"The content provides information about Tecentriq SC (Atezolizumab), a 1,875 mg injectable solution produced by Roche. It includes links to the product's injectable notice and its summary of product characteristics. The content outlines the price responsibility and conditions for prescription and dispensing, indicating it is reserved for hospital use and requires a specialist's prescription in oncology. Additionally, it notes the latest update date and includes references to transparency and official journal listings relevant to the medication.","drug, reporting, adverse",rochepro.fr,Falling,0.944524898290659,medium,153,Drug Safety
681,https://rochepro.fr/nos-produits/vabysmo.html,8,rochepro_fr_nos_produits_vabysmo_html.txt,200,html,Non-Indexable,2,7,0,1058,6,3,1,rochepro_fr_nos_produits_vabysmo_html.txt,image/rochepro_fr_nos_produits_vabysmo_html.txt.png,text/rochepro_fr_nos_produits_vabysmo_html.txt.txt,['Vabysmo'],Ophthalmology,France,Medication information,"Vabysmo, faricimab, dosage concentration, safety monitoring",,20.258081,-37.293015,1,"The content displays information about Vabysmo (faricimab), an injectable solution used in medical treatment. It includes details such as the dosage concentration (120 mg/mL), pricing information, prescription guidelines, and notes on safety monitoring for the medication. Additionally, it provides links to relevant documentation for healthcare professionals, emphasizing its use under specific prescription conditions reserved for ophthalmology specialists. The content is aimed at medical professionals for informational and prescribing purposes.","drug, reporting, adverse",rochepro.fr,Flat,0.635097136860168,high,179,Drug Safety
682,https://rochepro.fr/nos-produits/zelboraf.html,8,rochepro_fr_nos_produits_zelboraf_html.txt,200,html,Non-Indexable,2,8,0,984,6,2,1,rochepro_fr_nos_produits_zelboraf_html.txt,image/rochepro_fr_nos_produits_zelboraf_html.txt.png,text/rochepro_fr_nos_produits_zelboraf_html.txt.txt,['Zelboraf'],Oncology-Hematology,France,Medication information,"Zelboraf, vemurafenib, oncology, treatment",,16.968805,-33.227745,1,"The content provides detailed information about the medication Zelboraf (vemurafenib), including its formulation, pricing, and relevant documentation for healthcare professionals. It outlines prescription conditions, indicating that it is reserved for specialists in oncology and requires specific monitoring during treatment. Additionally, the page contains links to medical information and support for inquiries related to the medication.","drug, reporting, adverse",rochepro.fr,Falling,0.054263404308262,high,248,Drug Safety
683,https://rochepro.fr/pharmaciens/expertise-pui/comite-experts.html,7,rochepro_fr_pharmaciens_expertise_pui_comite_experts_html.txt,200,html,Indexable,2,50,0,1293,199,100,1,rochepro_fr_pharmaciens_expertise_pui_comite_experts_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_comite_experts_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_comite_experts_html.txt.txt,[],Other,France,Research,,,-16.874485,-28.604403,0,"The content discusses the role of a scientific committee associated with Roche's professional platform, which focuses on independent editorial choices made by its members. It emphasizes the committee's efforts to provide relevant insights into various topics pertinent to hospital pharmacists, highlighting their expertise and the importance of informed decision-making in the pharmaceutical field. The page also features images of the committee members.","oncology, professionals, data",rochepro.fr,Rising,0.609567143636799,high,432,General Offer Outline
684,https://rochepro.fr/pharmaciens/expertise-pui/evenements.html,10,rochepro_fr_pharmaciens_expertise_pui_evenements_html.txt,200,html,Indexable,2,38,97,1270,108,100,1,rochepro_fr_pharmaciens_expertise_pui_evenements_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_evenements_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_evenements_html.txt.txt,"['PUI', 'Expertise']",Oncology-Hematology,France,Events,,,-11.392562,-20.296589,3,"The content presents a section of a professional website for Roche, specifically focused on ""Expertise PUI"" events. It highlights access to recorded sessions from past events related to this area of expertise. The content appears to be aimed at providing information and resources to pharmaceutical professionals, emphasizing collaboration and knowledge sharing in chemotherapy production and health economics.","users, page, website",rochepro.fr,Falling,0.784540197865446,high,91,Website Metadata
685,https://rochepro.fr/pharmaciens/expertise-pui/evenements/pepc-national-2023.html,9,rochepro_fr_pharmaciens_expertise_pui_evenements_pepc_national_2023_html.txt,200,html,Indexable,3,57,220,1219,6,4,0.974358974358974,rochepro_fr_pharmaciens_expertise_pui_evenements_pepc_national_2023_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_evenements_pepc_national_2023_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_evenements_pepc_national_2023_html.txt.txt.txt,"['National', 'PEPC']",Other,France,Events,,,6.417771,4.2057185,7,"The content presents information about the ""PEPC National 2023"" event hosted by Roche, highlighting its 15-year anniversary. It invites viewers to revisit the event through available replays. The content mentions key figures involved and outlines topics discussed, such as crisis management in healthcare systems and human resources challenges in hospital settings. This segment serves to engage healthcare professionals and provide access to valuable discussions from the event.","event, exclusive, website",rochepro.fr,Rising,0.773748509445633,high,53,Events & Patient Care
686,https://rochepro.fr/pharmaciens/expertise-pui/evenements/pepc-national-2024.html,10,rochepro_fr_pharmaciens_expertise_pui_evenements_pepc_national_2024_html.txt,200,html,Indexable,2,57,137,1265,12,5,1,rochepro_fr_pharmaciens_expertise_pui_evenements_pepc_national_2024_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_evenements_pepc_national_2024_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_evenements_pepc_national_2024_html.txt.txt,"['National', 'PEPC']",Oncology-Hematology,France,Offer outline,,,-24.817085,-27.644848,0,"The content provides information focused on Roche's pharmaceutical products and services for healthcare professionals, particularly targeting physicians and pharmacists. It outlines resources available for medical inquiries, appointments with product specialists, and updates about events such as the PEPC National 2024, highlighting themes like innovation in healthcare and good preparation practices. Additionally, it addresses important topics like pharmacovigilance, risk reduction measures, and the application of new guidelines in pediatric and oncology care, reflecting Roche's commitment to supporting healthcare professionals in delivering effective patient care.","oncology, professionals, data",rochepro.fr,Flat,0.530273711604817,high,217,General Offer Outline
687,https://rochepro.fr/pharmaciens/expertise-pui/evenements/pres-2023.html,9,rochepro_fr_pharmaciens_expertise_pui_evenements_pres_2023_html.txt,200,html,Indexable,3,48,124,1656,10,6,1,rochepro_fr_pharmaciens_expertise_pui_evenements_pres_2023_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_evenements_pres_2023_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_evenements_pres_2023_html.txt.txt,"['Economics', 'PRES', 'Paris', 'Program', 'April', 'Health']",Other,France,Events,,,8.551437,7.1161666,7,"The content focuses on the PRES 2023 event, which is part of Roche's Health Economics Program. It highlights a recap of the event that took place in Paris on April 5-6, 2023, where experts discussed access to therapeutic innovations, financing, and real-world data applications. The content aims to inform professionals about key discussions and insights from the event, emphasizing the importance of health economics in healthcare development.","event, exclusive, website",rochepro.fr,Falling,0.597555554213363,high,491,Events & Patient Care
688,https://rochepro.fr/pharmaciens/expertise-pui/evenements/pres-2024.html,10,rochepro_fr_pharmaciens_expertise_pui_evenements_pres_2024_html.txt,200,html,Indexable,2,48,124,1352,14,6,1,rochepro_fr_pharmaciens_expertise_pui_evenements_pres_2024_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_evenements_pres_2024_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_evenements_pres_2024_html.txt.txt,"['PRES', 'Paris', 'Scheduled', 'April']",Other,France,Events,,,8.372028,6.5712543,7,"The content provides information about ""PRES 2024,"" an event organized by Roche focused on health economics. Scheduled for April 2-3, 2024, in Paris, it aims to discuss topics like access to therapeutic innovations, healthcare transformation, and new evaluation methodologies for health products. The page highlights the significance of the event and offers options for accessing recorded sessions from the event.","event, exclusive, website",rochepro.fr,All,0.0359447063312869,high,73,Events & Patient Care
689,https://rochepro.fr/pharmaciens/expertise-pui.html,10,rochepro_fr_pharmaciens_expertise_pui_html.txt,200,html,Indexable,2,13,175,1278,205,103,1,rochepro_fr_pharmaciens_expertise_pui_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_html.txt.txt,"['PUI', 'Expertise']",Other,France,Offer outline,,,-17.535826,-28.560099,0,"The content features a section dedicated to ""Expertise PUI"" on Roche's professional website for pharmacists. It highlights recent updates and news relevant to pharmacy practice, including important developments in healthcare and medication access. There are links to articles and resources aimed at pharmacists, emphasizing Roche's commitment to providing expert information and support within the pharmaceutical sector.","oncology, professionals, data",rochepro.fr,Flat,0.580126700620493,high,295,General Offer Outline
690,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/20e-congres-sfpc-focus-conferences.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_20e_congres_sfpc_focus_conferences_html.txt,200,html,Indexable,,58,89,2165,3,1,0.97979797979798,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_20e_congres_sfpc_focus_conferences_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_20e_congres_sfpc_focus_conferences_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_20e_congres_sfpc_focus_conferences_html.txt.txt.txt,[],Other,France,Offer outline,,,-21.870043,-28.798468,0,"The content primarily serves as a comprehensive resource for healthcare professionals, particularly pharmacists and physicians, focusing on Roche's medicinal products and their therapeutic areas. It outlines various services available to medical professionals, including information on medications, opportunities to consult product specialists, and resources for medical inquiries. Additionally, it highlights Roche's participation in recent healthcare conferences, showcasing insights into clinical pharmacy practices, patient care innovations, and the integration of pharmacists in hospital settings. The purpose is to facilitate education, collaboration, and improved healthcare delivery through accessible information and support services tailored for professionals in the medical field.","oncology, professionals, data",rochepro.fr,Falling,0.263042421039859,high,177,General Offer Outline
691,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/acces-direct-experimentation-gagnant-gagnant.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_direct_experimentation_gagnant_gagnant_html.txt,200,html,Indexable,1,73,129,2272,101,97,0.981651376146789,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_direct_experimentation_gagnant_gagnant_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_direct_experimentation_gagnant_gagnant_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_direct_experimentation_gagnant_gagnant_html.txt.txt.txt,['France'],Other,France,Offer outline,,,-24.477247,-29.706732,0,"The content primarily focuses on Roche's pharmaceutical products and services, emphasizing information available for healthcare professionals, such as physicians and pharmacists. It outlines initiatives for direct market access to medications, eligibility criteria, and the processes involved in securing funding and reimbursement from health insurance systems in France. Additionally, it highlights Roche's commitment to ensuring patient care and the role of an expert committee in addressing pharmaceutical practices and regulations. The overall purpose is to provide healthcare professionals with relevant resources and support related to Roche's offerings and recent legislative changes.","oncology, professionals, data",rochepro.fr,Rising,0.0125787202911648,high,166,General Offer Outline
692,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/acces-precoce-compassionnel.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_precoce_compassionnel_html.txt,200,html,Indexable,,80,100,1575,3,1,0.978260869565217,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_precoce_compassionnel_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_precoce_compassionnel_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_precoce_compassionnel_html.txt.txt.txt,['France'],Other,France,Offer outline,,,-30.367579,-15.256764,0,"The content serves as a comprehensive resource for healthcare professionals, specifically doctors and pharmacists, detailing Roche's pharmaceutical offerings and services. It highlights various therapeutic areas such as neurology, oncology, and rare diseases, while providing information on medication access pathways like early access and compassionate use programs in France. Additionally, the content encourages engagement through the ability to book specialist appointments, ask medical questions, and stay updated via newsletters. Overall, the purpose is to facilitate healthcare professionals' access to essential information and support related to Roche's products and services.","oncology, professionals, data",rochepro.fr,All,0.971336034917271,high,110,General Offer Outline
693,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/acces-precoce-rappel-procedures-et-premier-bilan.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_precoce_rappel_procedures_et_premier_bilan_html.txt,200,html,Indexable,1,70,157,2229,6,4,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_precoce_rappel_procedures_et_premier_bilan_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_precoce_rappel_procedures_et_premier_bilan_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_precoce_rappel_procedures_et_premier_bilan_html.txt.txt,"['France', 'AMM']",Oncology-Hematology,France,Offer outline,,,-24.047838,-31.924053,0,"The content provides detailed information for healthcare professionals regarding Roche's pharmaceutical products and services, focusing on topics such as early access procedures for medications before and after market authorization (AMM) in France. It discusses the reforms implemented in 2021, the challenges faced by laboratories in navigating these access routes, and recent trends in acceptance rates for drug requests. The purpose of the content is to inform and support physicians and pharmacists with resources, updates on procedures, and provide avenues for inquiries related to medical and pharmaceutical questions. Additionally, it emphasizes the importance of data collection and compliance in managing early access programs for new medications, particularly in oncology.","oncology, professionals, data",rochepro.fr,All,0.754116033342943,high,36,General Offer Outline
694,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/acces-precoce-retour-experience.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_precoce_retour_experience_html.txt,200,html,Indexable,2,58,146,2069,4,2,0.979166666666667,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_precoce_retour_experience_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_precoce_retour_experience_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_acces_precoce_retour_experience_html.txt.txt.txt,['France'],Other,France,Offer outline,,,-24.465927,-30.01664,0,"The content provides information aimed at healthcare professionals about Roche's products and services, particularly focusing on recent reforms concerning early access to innovative medications in France. It discusses the implementation of these reforms, highlighting their benefits, such as increased access for patients and reduced delays, while also acknowledging ongoing challenges like administrative complexities and data collection issues. Additionally, the content emphasizes the company's commitment to supporting healthcare professionals through various resources, events, and expert consultations. Overall, the purpose is to enhance understanding and facilitate the use of Roche's offerings within the medical community.","oncology, professionals, data",rochepro.fr,All,0.549182348992915,high,217,General Offer Outline
695,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/agence-innovation-sante-liens-pharmaciens.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_agence_innovation_sante_liens_pharmaciens_html.txt,200,html,Indexable,,86,139,1599,3,1,0.981132075471698,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_agence_innovation_sante_liens_pharmaciens_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_agence_innovation_sante_liens_pharmaciens_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_agence_innovation_sante_liens_pharmaciens_html.txt.txt.txt,[],Other,France,Offer outline,,,-21.374084,-26.33856,0,"The content appears to be an informational resource aimed at healthcare professionals, particularly physicians and pharmacists, focusing on Roche's pharmaceutical products and services. It provides guidance on how practitioners can access medical information, schedule consultations with product specialists, pose medical queries, and manage pharmaceutical concerns such as drug quality or supply chain issues. Additionally, it covers Roche's involvement in healthcare innovation, detailing strategies to enhance patient care and integrate new medical solutions into practice. Overall, the content is designed to support healthcare providers in their ongoing professional development and patient care through Roche’s offerings.","oncology, professionals, data",rochepro.fr,Falling,0.690396503375997,high,299,General Offer Outline
696,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/agence-numerique-sante-accelerateur-institutionnel-numerique-sante.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_agence_numerique_sante_accelerateur_institutionnel_numerique_sante_html.txt,200,html,Indexable,2,98,142,1454,4,2,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_agence_numerique_sante_accelerateur_institutionnel_numerique_sante_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_agence_numerique_sante_accelerateur_institutionnel_numerique_sante_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_agence_numerique_sante_accelerateur_institutionnel_numerique_sante_html.txt.txt,[],Other,France,Offer outline,,,-37.555954,-10.453313,0,"The content is a comprehensive overview of Roche's resources and services tailored specifically for healthcare professionals, including doctors and pharmacists. It highlights various therapeutic areas such as neurology, oncology, and rare diseases, while also offering guidance on medication inquiries, specialist appointments, and selection of resources. Additionally, it addresses regulatory updates in digital health, emphasizing Roche's commitment to innovation and support in healthcare practices. The purpose is to facilitate access to information and services to enhance medical care and support professional development.","oncology, professionals, data",rochepro.fr,Flat,0.405440564762814,high,196,General Offer Outline
697,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/anticorps-bispecifiques-deux-bras-armes-immunotherapie.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_anticorps_bispecifiques_deux_bras_armes_immunotherapie_html.txt,200,html,Indexable,2,79,162,2185,4,2,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_anticorps_bispecifiques_deux_bras_armes_immunotherapie_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_anticorps_bispecifiques_deux_bras_armes_immunotherapie_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_anticorps_bispecifiques_deux_bras_armes_immunotherapie_html.txt.txt,[],Oncology-Hematology,France,Medication information,"bi-specific antibodies, immunotherapy, hematological cancers, multiple myeloma, leukemias, mechanism of action, indications, administration, potential complications","multiple myeloma, leukemias",-15.522167,8.128643,0,"The content focuses on Roche's therapeutic areas, specifically highlighting innovations in cancer treatment, particularly bi-specific antibodies used in immunotherapy for hematological cancers. It provides detailed information on the mechanism of action, indications, administration, and potential complications associated with these treatments, particularly for conditions like multiple myeloma and leukemias. The purpose of the content is to serve as a resource for healthcare professionals, offering insights into medication, scheduling appointments with specialists, and facilitating access to medical information and support services.","oncology, professionals, data",rochepro.fr,Falling,0.864278158699556,high,245,General Offer Outline
698,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/apport-ia-exercice-pharmaciens-hospitaliers.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_apport_ia_exercice_pharmaciens_hospitaliers_html.txt,200,html,Indexable,,74,149,1383,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_apport_ia_exercice_pharmaciens_hospitaliers_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_apport_ia_exercice_pharmaciens_hospitaliers_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_apport_ia_exercice_pharmaciens_hospitaliers_html.txt.txt,[],Other,France,Offer outline,,,-14.618272,-30.52971,0,"The content provides an overview of Roche's offerings and resources targeted at healthcare professionals, specifically physicians and pharmacists. It outlines various services such as scheduling specialist consultations, accessing medical information, and obtaining updates on pharmaceutical products. Additionally, the content highlights the role of artificial intelligence in enhancing the activities of hospital pharmacists and improving healthcare quality. It emphasizes Roche's commitment to supporting healthcare professionals through expert resources and customer service. Overall, the purpose of the content is to facilitate healthcare providers' access to relevant information and services related to Roche's pharmaceutical products.","oncology, professionals, data",rochepro.fr,Falling,0.685784342847197,high,75,General Offer Outline
699,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/arnm-medicaments-pas-comme-autres.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_arnm_medicaments_pas_comme_autres_html.txt,200,html,Indexable,,62,160,2449,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_arnm_medicaments_pas_comme_autres_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_arnm_medicaments_pas_comme_autres_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_arnm_medicaments_pas_comme_autres_html.txt.txt,"['States', 'United', 'Europe']",Oncology-Hematology,France,Offer outline,"mRNA-based treatments, mRNA technology, vaccination, cancer therapy, genetic disorders",,-10.3292055,0.01939069,0,"The content focuses on Roche's therapeutic innovations and pharmacological offerings, particularly emphasizing mRNA-based treatments. It highlights various applications of mRNA technology in vaccination, cancer therapy, and genetic disorders, explaining the regulatory frameworks surrounding these drugs in Europe compared to the United States. The purpose is to inform healthcare professionals—including doctors and pharmacists—about Roche's products, facilitate interactions with specialists, and provide guidelines for safe and effective use, thereby positioning Roche as a knowledgeable partner in medical care.","oncology, professionals, data",rochepro.fr,All,0.59779512885613,high,306,General Offer Outline
700,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/article-51-exemple-ako-dom-picto.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_article_51_exemple_ako_dom_picto_html.txt,200,html,Indexable,,54,138,2291,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_article_51_exemple_ako_dom_picto_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_article_51_exemple_ako_dom_picto_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_article_51_exemple_ako_dom_picto_html.txt.txt,[],Oncology-Hematology,France,Patient support,,,-19.21645,-11.565229,0,"The content focuses on Roche's initiatives and support for healthcare professionals, particularly in oncology. It outlines a specific program called AKOdomPICTO, aimed at improving treatment adherence and communication between patients, hospitals, and home care providers through personalized support pathways. The experimental program involves multidisciplinary collaboration, patient education, and the implementation of a monitoring platform across various healthcare facilities. The content emphasizes Roche’s commitment to enhancing patient care and facilitating professional exchanges in the healthcare community.","oncology, professionals, data",rochepro.fr,All,0.72516706993269,high,266,General Offer Outline
701,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/article-51-quel-bilan-5-ans.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_article_51_quel_bilan_5_ans_html.txt,200,html,Indexable,,49,149,2220,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_article_51_quel_bilan_5_ans_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_article_51_quel_bilan_5_ans_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_article_51_quel_bilan_5_ans_html.txt.txt,[],Other,France,Offer outline,,,-18.40598,-23.403208,0,"The content primarily addresses healthcare professionals, especially doctors and pharmacists, offering information about Roche's medications, therapeutic areas, and avenues for professional engagement. It promotes access to medical information, consultations with product specialists, and participation in ongoing health initiatives and experiments, particularly related to innovative healthcare financing models. The focus is on enhancing patient care through coordinated health management and experimental projects in line with public health objectives, with updates on recent programs and their outcomes. Overall, the content serves as a resource for healthcare professionals to facilitate improved patient outcomes and navigate Roche’s offerings.","oncology, professionals, data",rochepro.fr,Rising,0.133010647669202,high,484,General Offer Outline
702,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/bonnes-pratiques-preparation-application-cancerologie.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_bonnes_pratiques_preparation_application_cancerologie_html.txt,200,html,Indexable,3,88,171,2133,4,2,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_bonnes_pratiques_preparation_application_cancerologie_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_bonnes_pratiques_preparation_application_cancerologie_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_bonnes_pratiques_preparation_application_cancerologie_html.txt.txt,"['Practices', 'GPP', 'Good', 'Preparation']",Oncology-Hematology,France,Offer outline,,,-26.346107,-26.178474,0,"The content provides detailed information for healthcare professionals regarding Roche's medications and services, specifically focusing on guidelines for pharmacists and medical staff involved in oncology and pharmaceuticals. It covers updates to Good Preparation Practices (GPP) and includes directives concerning the handling of hazardous drugs, environmental safety, and staff training. The purpose of the content is to inform healthcare professionals about best practices, safety standards, and resources available for effective patient care and medication management. Additionally, it emphasizes Roche's commitment to supporting healthcare providers through expert-led guidance and resources.","oncology, professionals, data",rochepro.fr,All,0.252692094893395,high,198,General Offer Outline
703,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/bonnes-pratiques-preparation-application-pediatrie.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_bonnes_pratiques_preparation_application_pediatrie_html.txt,200,html,Indexable,3,89,171,2117,4,2,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_bonnes_pratiques_preparation_application_pediatrie_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_bonnes_pratiques_preparation_application_pediatrie_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_bonnes_pratiques_preparation_application_pediatrie_html.txt.txt,"['Practices', 'Good', 'BPP', 'Preparation']",Other,France,Offer outline,,,0.90781826,-35.455772,1,"The content primarily addresses medical professionals, particularly pharmacists, providing information on Roche’s pharmaceutical products, services, and recent updates in Good Preparation Practices (BPP) for pediatric formulations. It emphasizes the need for pharmacists to enhance their vigilance and reassess preparation processes in light of new regulations, particularly concerning pediatric medicines. The content serves as an educational resource, aiming to facilitate better patient care through improved practices and the establishment of formalized preparation documentation. It also encourages engagement with Roche specialists for further support and information.","drug, reporting, adverse",rochepro.fr,Falling,0.821141110479403,high,310,Drug Safety
704,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/bonnes-pratiques-preparation-importance-methodologie-analyse-risques.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_bonnes_pratiques_preparation_importance_methodologie_analyse_risques_html.txt,200,html,Indexable,,105,122,2380,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_bonnes_pratiques_preparation_importance_methodologie_analyse_risques_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_bonnes_pratiques_preparation_importance_methodologie_analyse_risques_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_bonnes_pratiques_preparation_importance_methodologie_analyse_risques_html.txt.txt,['French'],Other,France,Offer outline,,,0.7223877,-35.42473,1,"The content contains information aimed at healthcare professionals, particularly focusing on Roche's pharmaceutical offerings and support services. It highlights resources available for physicians and pharmacists, such as the ability to schedule consultations with product specialists, inquire about medications, and download relevant materials. Additionally, it discusses the importance of risk management in pharmaceutical preparations, detailing updates on good preparation practices (BPPs) introduced by the French drug safety agency. The content emphasizes the necessity for pharmacists to understand and implement risk management methodologies to ensure medication safety and compliance with recent regulations. It also notes the various training opportunities available for pharmacists to enhance their capabilities in this area. Overall, the content serves to educate healthcare professionals on Roche’s products, support, and regulatory obligations in pharmaceutical practices.","drug, reporting, adverse",rochepro.fr,Falling,0.79776557317263,high,126,Drug Safety
705,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/certification-periodique-pharmaciens.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_certification_periodique_pharmaciens_html.txt,200,html,Indexable,,75,168,2095,3,1,0.98019801980198,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_certification_periodique_pharmaciens_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_certification_periodique_pharmaciens_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_certification_periodique_pharmaciens_html.txt.txt.txt,[],Other,France,Offer outline,,,-24.314573,-28.684341,0,"The content appears to provide comprehensive information targeted at medical professionals, particularly pharmacists and physicians, regarding Roche's pharmaceuticals and services. It discusses certification requirements for healthcare professionals, emphasizing the importance of continuous education, quality of practice, and keeping up-to-date with medical advancements. The content includes details about updates in healthcare regulations, opportunities for professional development, and support services offered by Roche, such as consultations and technical assistance. The purpose is to enhance collaboration between Roche and healthcare providers while ensuring compliance with evolving standards in the medical field.","oncology, professionals, data",rochepro.fr,Rising,0.788563828095654,high,182,General Offer Outline
706,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/chaire-industrielle-e-lodi-reflexion-usage-nouvelles-technologies-pharmaceutiques-etablissement-sante.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_chaire_industrielle_e_lodi_reflexion_usage_nouvelles_technologies_pharmaceutiques_etablissement_sante_html.txt,200,html,Indexable,2,132,174,2114,4,2,0.987951807228916,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_chaire_industrielle_e_lodi_reflexion_usage_nouvelles_technologies_pharmaceutiques_etablissement_sante_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_chaire_industrielle_e_lodi_reflexion_usage_nouvelles_technologies_pharmaceutiques_etablissement_sante_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_chaire_industrielle_e_lodi_reflexion_usage_nouvelles_technologies_pharmaceutiques_etablissement_sante_html.txt.txt.txt,[],Other,France,Technology,,,-15.968063,-30.485498,0,"The content focuses on Roche's commitment to advancing healthcare through innovation and collaboration in pharmaceutical practices. It highlights various initiatives such as the industrial chair ELoDi, which aims to integrate new technologies in healthcare, particularly in medication production and logistics. The content targets healthcare professionals, offering resources like expert consultations, informative articles, and tools for optimizing health product distribution. Overall, the purpose is to foster knowledge sharing and improve the efficiency of therapeutic procedures in healthcare settings.","oncology, professionals, data",rochepro.fr,Flat,0.728027226687288,high,461,General Offer Outline
707,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/chimiotherapies-injectables-tout-comprendre-fondation-sante-service.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_chimiotherapies_injectables_tout_comprendre_fondation_sante_service_html.txt,200,html,Indexable,2,114,152,2194,4,2,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_chimiotherapies_injectables_tout_comprendre_fondation_sante_service_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_chimiotherapies_injectables_tout_comprendre_fondation_sante_service_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_chimiotherapies_injectables_tout_comprendre_fondation_sante_service_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-31.077389,-17.49197,0,"The content primarily outlines Roche's services for medical professionals, specifically focusing on their products related to various medical conditions, including cancers and neurological disorders. It provides information on how healthcare providers can inquire about medications, schedule consultations with product specialists, and access medical updates. Additionally, it highlights Roche's operational processes concerning injectable chemotherapies, including their preparation, delivery, and management of patient care at home. The purpose is to facilitate communication and support for healthcare professionals, ensuring they have the necessary resources and information to provide effective patient care.","oncology, professionals, data",rochepro.fr,Falling,0.345098263363679,high,478,General Offer Outline
708,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/congres-sfpc-optimisation-therapeutique-deprescription.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_congres_sfpc_optimisation_therapeutique_deprescription_html.txt,200,html,Indexable,,98,235,2227,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_congres_sfpc_optimisation_therapeutique_deprescription_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_congres_sfpc_optimisation_therapeutique_deprescription_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_congres_sfpc_optimisation_therapeutique_deprescription_html.txt.txt,[],Other,France,Patient support,,,-19.873827,-31.497969,0,"The content primarily discusses Roche's commitment to supporting healthcare professionals, particularly pharmacists and physicians, in optimizing pharmaceutical care. It emphasizes the importance of therapeutic optimization, deprescribing strategies, and the role of pharmacists in managing polypharmacy, particularly for elderly patients. The content encourages professional collaboration and offers resources such as articles and newsletters aimed at improving medication management and patient outcomes. It also addresses challenges in deprescribing and provides insights into ongoing education and support for healthcare providers. Overall, the purpose is to foster better medication practices and enhance patient care through informed collaboration among health professionals.","oncology, professionals, data",rochepro.fr,All,0.234076253800481,high,158,General Offer Outline
709,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/contamination-environnementale-cytotoxiques-hexagone-etudes-significatives.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_contamination_environnementale_cytotoxiques_hexagone_etudes_significatives_html.txt,200,html,Indexable,2,68,199,2810,4,2,0.985611510791367,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_contamination_environnementale_cytotoxiques_hexagone_etudes_significatives_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_contamination_environnementale_cytotoxiques_hexagone_etudes_significatives_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_contamination_environnementale_cytotoxiques_hexagone_etudes_significatives_html.txt.txt.txt,[],Oncology-Hematology,France,Research,,,-0.48341435,-36.94192,1,"The content provides an overview of Roche's resources and services aimed at healthcare professionals, particularly focusing on topics related to pharmaceuticals and drug safety. It discusses issues related to environmental contamination by cytotoxic drugs in hospital settings, emphasizing the importance of monitoring and research to establish standards and guidelines for exposure limits. The content highlights ongoing studies, collaborations, and methodologies designed to evaluate contamination levels, aiming to improve safety for healthcare workers while addressing regulatory gaps. Additionally, it encourages professionals to access specialized information, participate in events, and engage with experts in the field.","drug, reporting, adverse",rochepro.fr,Rising,0.367829502451485,high,164,Drug Safety
710,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/crise-en-sortir-bonnes-pratiques.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_crise_en_sortir_bonnes_pratiques_html.txt,200,html,Indexable,,61,394,2415,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_crise_en_sortir_bonnes_pratiques_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_crise_en_sortir_bonnes_pratiques_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_crise_en_sortir_bonnes_pratiques_html.txt.txt,[],Other,France,Patient support,,,-18.864483,-27.200027,0,"The content is focused on Roche's commitment to healthcare professionals, particularly pharmacists and doctors. It provides resources for medical inquiries, drug information, and crisis management in healthcare settings. The content emphasizes the importance of effective communication, crisis response strategies, and the role of expert panels in optimizing healthcare practices. It also mentions tools for managing drug quality issues and offers support for decision-making during emergencies. The overarching purpose is to facilitate medical professionals' access to essential information and strategies that enhance patient care and organizational efficiency in healthcare environments.","oncology, professionals, data",rochepro.fr,Flat,0.294508598700991,high,77,General Offer Outline
711,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/cyberattaque-eviter-catastrophe.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cyberattaque_eviter_catastrophe_html.txt,200,html,Indexable,,52,184,2424,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cyberattaque_eviter_catastrophe_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cyberattaque_eviter_catastrophe_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cyberattaque_eviter_catastrophe_html.txt.txt,[],Other,France,Offer outline,,,-16.670425,-29.554241,0,"The content outlines various services and resources offered by Roche specifically for healthcare professionals, including doctors and pharmacists. It emphasizes areas such as pharmacological consultation, scheduling appointments with product specialists, medical information, and safety procedures in response to critical incidents like cyberattacks. The latter part of the content describes a specific cyberattack on a hospital, detailing the crisis management, the response strategies employed by healthcare staff, and lessons learned for improving future cybersecurity and operational resilience. Overall, the purpose is to inform healthcare professionals about Roche's support services and share insights on handling emergencies in a medical context.","oncology, professionals, data",rochepro.fr,All,0.54486273781576,high,369,General Offer Outline
712,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/cyberattaques-retours-experience-deux-pui.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cyberattaques_retours_experience_deux_pui_html.txt,200,html,Indexable,,64,134,2909,3,1,0.981132075471698,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cyberattaques_retours_experience_deux_pui_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cyberattaques_retours_experience_deux_pui_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cyberattaques_retours_experience_deux_pui_html.txt.txt.txt,"['Francilien', 'Versailles', 'Hospitalier', 'Centre', 'Sud', 'CH']",Other,France,Patient support,,,-16.914736,-30.076527,0,"The content focuses on Roche's support for healthcare professionals, particularly in dealing with challenges like cyberattacks on hospitals. It discusses the operational disruptions caused by these attacks at the Centre Hospitalier de Versailles and CH Sud Francilien, detailing the emergency response and adaptation strategies implemented by pharmacy teams. The content emphasizes the importance of crisis management, data security, and the necessity for healthcare institutions to prepare for potential future incidents. It aims to provide medical professionals with insights, practical guidance, and updates regarding Roche's therapeutic areas and services.","oncology, professionals, data",rochepro.fr,Falling,0.672033582865482,high,275,General Offer Outline
713,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/cybersecurite-enjeu-etablissements-hospitaliers.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cybersecurite_enjeu_etablissements_hospitaliers_html.txt,200,html,Indexable,,79,172,1322,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cybersecurite_enjeu_etablissements_hospitaliers_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cybersecurite_enjeu_etablissements_hospitaliers_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cybersecurite_enjeu_etablissements_hospitaliers_html.txt.txt,"['Pro', 'PUI', 'Expertise']",Other,France,Technology,,,29.804882,8.103237,4,"The content focuses on a section titled ""Expertise PUI"" from Roche Pro, discussing the issue of cyberattacks targeting healthcare establishments. It highlights the risks associated with the extensive health data collected and the growing threat from cybercriminals. The article emphasizes the role of hospital pharmacists in preventing such attacks and protecting data, featuring insights from an expert in digital health security. The content is designed to inform professionals in the healthcare sector about cybersecurity challenges and prevention strategies.","technologies, artificial, ai",rochepro.fr,Flat,0.676765361108728,high,42,Technology
714,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/cytotoxiques-analyse-pui-taux-contamination.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cytotoxiques_analyse_pui_taux_contamination_html.txt,200,html,Indexable,,92,143,2030,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cytotoxiques_analyse_pui_taux_contamination_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cytotoxiques_analyse_pui_taux_contamination_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_cytotoxiques_analyse_pui_taux_contamination_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-25.213144,-26.039894,0,"The content focuses on Roche's commitments to healthcare professionals, highlighting the company's medications, services, and expertise in areas like oncology and hematology. It offers physicians and pharmacists opportunities to inquire about products, schedule consultations with product specialists, and access medical information. The content also emphasizes the role of Roche in addressing environmental contamination from cytotoxic agents within hospitals, detailing diagnostics and safety measures for healthcare workers. Overall, the purpose is to provide comprehensive support and resources for medical professionals, enhancing patient care and safety practices in healthcare settings.","oncology, professionals, data",rochepro.fr,Flat,0.912303388328053,high,156,General Offer Outline
715,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/data-analyste-ingenieur-financier-nouveaux-metiers-pui.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_data_analyste_ingenieur_financier_nouveaux_metiers_pui_html.txt,200,html,Indexable,1,94,331,2427,5,3,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_data_analyste_ingenieur_financier_nouveaux_metiers_pui_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_data_analyste_ingenieur_financier_nouveaux_metiers_pui_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_data_analyste_ingenieur_financier_nouveaux_metiers_pui_html.txt.txt,"['Hospital', 'Units', 'France', 'Pharmacy', 'PUI']",Other,France,Technology,,,28.304783,8.730127,4,"The content primarily discusses the evolving roles and responsibilities within Hospital Pharmacy Units (PUI) in France, addressing the challenges of hyper-specialization and the need for multidisciplinary collaboration in healthcare settings. It highlights the necessity for pharmacists to adapt and expand their skill sets in response to technological advancements and evolving healthcare demands, such as data management and automation. Additionally, it explores the recruitment of new profiles like data analysts and engineers to enhance operational efficiency, while also noting the tension between integrating these roles with traditional pharmacy practices. The purpose of this content is to inform and guide healthcare professionals about trends and strategies for improving pharmacy operations in hospitals.","technologies, artificial, ai",rochepro.fr,Rising,0.646580992044143,high,366,Technology
716,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/dispositifs-medicaux-avancees-ue.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_dispositifs_medicaux_avancees_ue_html.txt,200,html,Indexable,,77,162,1391,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_dispositifs_medicaux_avancees_ue_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_dispositifs_medicaux_avancees_ue_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_dispositifs_medicaux_avancees_ue_html.txt.txt,[],Other,France,Offer outline,,,-25.462143,-29.055826,0,"The content provides information and resources for healthcare professionals regarding Roche's pharmaceutical products and services. It offers avenues for physicians and pharmacists to inquire about medications, schedule appointments with specialists, and access medical information. The content emphasizes the importance of regulatory compliance, particularly concerning medical devices, and highlights Roche's commitment to supporting healthcare professionals through updates, expert committees, and educational materials. Additionally, it details procedures for reporting quality defects and adverse effects, underscoring Roche's focus on patient safety and healthcare continuity.","oncology, professionals, data",rochepro.fr,Rising,0.590125748256825,high,330,General Offer Outline
717,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/donnees-vie-reelle-usages.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_donnees_vie_reelle_usages_html.txt,200,html,Indexable,,54,157,2072,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_donnees_vie_reelle_usages_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_donnees_vie_reelle_usages_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_donnees_vie_reelle_usages_html.txt.txt,[],Other,France,Offer outline,,,-30.170094,-20.751549,0,"The content serves as a resource for medical professionals, specifically focusing on Roche's pharmaceutical offerings and related services. It provides guidance for healthcare providers, including physicians and pharmacists, on how to access information about Roche's medications, engage with specialists, and address medical inquiries. The content highlights the importance of real-world data in evaluating drug efficacy and safety, as well as the complexities surrounding data access and patient confidentiality within the healthcare system. Additionally, it outlines Roche's therapeutic areas, such as oncology and neurology, and offers a platform for professionals to connect with Roche's resources.","oncology, professionals, data",rochepro.fr,All,0.541099660254538,high,298,General Offer Outline
718,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/emission-deux-value-programme-roche-vbhc.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_emission_deux_value_programme_roche_vbhc_html.txt,200,html,Indexable,,73,132,1749,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_emission_deux_value_programme_roche_vbhc_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_emission_deux_value_programme_roche_vbhc_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_emission_deux_value_programme_roche_vbhc_html.txt.txt,"['VBHC', 'VALUE', 'Based', 'Value', 'Care', 'Health']",Other,France,Offer outline,,,-16.86612,-22.96313,0,"The content provides an overview of Roche's offerings and initiatives aimed at healthcare professionals, particularly physicians and pharmacists. It emphasizes the company’s commitment to Value Based Health Care (VBHC), detailing a program called VALUE that includes educational resources and web series focused on VBHC principles. This approach seeks to improve patient outcomes while optimizing healthcare resources. Additionally, the content encourages professionals to engage with Roche through consultations, educational events, and the sharing of medical information, reflecting the company’s focus on collaboration and support within the healthcare system.","oncology, professionals, data",rochepro.fr,Falling,0.865483131900856,high,297,General Offer Outline
719,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/enjeux-acces-innovation.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_enjeux_acces_innovation_html.txt,200,html,Indexable,,52,168,1427,3,1,0.977272727272727,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_enjeux_acces_innovation_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_enjeux_acces_innovation_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_enjeux_acces_innovation_html.txt.txt.txt,[],Other,France,Offer outline,,,-19.292728,-24.71596,0,"The content outlines services and resources offered by Roche specifically for healthcare professionals, including physicians and pharmacists. It emphasizes support in areas such as medical information, product inquiries, and expert consultations. Additionally, it mentions Roche's commitment to innovation in healthcare access, highlighting discussions with industry experts about ongoing health economic initiatives. The content serves to inform and engage medical professionals, facilitating their interaction with Roche's offerings in pharmaceuticals and diagnostics.","oncology, professionals, data",rochepro.fr,Flat,0.211086204104417,high,251,General Offer Outline
720,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/evaluation-medicaments-evolution-doctrine-has.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_evaluation_medicaments_evolution_doctrine_has_html.txt,200,html,Indexable,,76,151,2302,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_evaluation_medicaments_evolution_doctrine_has_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_evaluation_medicaments_evolution_doctrine_has_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_evaluation_medicaments_evolution_doctrine_has_html.txt.txt,"['French', 'HAS']",Other,France,Offer outline,,,-25.815567,-29.066984,0,"The content primarily focuses on Roche's pharmaceutical offerings, providing information tailored for healthcare professionals, including physicians and pharmacists. It outlines various services available, such as scheduling appointments with specialists, addressing medical inquiries, and accessing resources about medications and therapeutic areas. Additionally, it details updates related to the evaluation and reimbursement processes of medications as governed by the French health authority (HAS), emphasizing the need for transparency and robustness in clinical data. The overarching purpose is to support medical professionals in understanding Roche's products while ensuring adherence to evolving health regulations and standards.","oncology, professionals, data",rochepro.fr,Flat,0.223123663890375,high,157,General Offer Outline
721,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/expertise-pui-nouveau-media-pharmaciens-hospitaliers.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_expertise_pui_nouveau_media_pharmaciens_hospitaliers_html.txt,200,html,Indexable,3,96,121,1704,3,1,0.982905982905983,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_expertise_pui_nouveau_media_pharmaciens_hospitaliers_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_expertise_pui_nouveau_media_pharmaciens_hospitaliers_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_expertise_pui_nouveau_media_pharmaciens_hospitaliers_html.txt.txt.txt,"['PUI', 'Expertise', 'Pharminlink']",Other,France,Offer outline,,,-17.522003,-25.963419,0,"The content serves as a comprehensive resource for healthcare professionals, specifically addressing physicians and pharmacists associated with Roche. It outlines various services such as obtaining medication information, scheduling consultations with product specialists, and asking medical questions. The content emphasizes Roche's commitment to supporting healthcare practitioners through updates about their products, therapeutic areas, and an initiative to enhance accessibility and content diversity on their platform. It also highlights the rebranding of a communication outlet, Pharminlink, to Expertise PUI, aimed at providing tailored, expert-driven content that addresses the specific needs and challenges faced by hospital pharmacists. Overall, the purpose is to facilitate better information access and enhance professional practice within the medical community.","oncology, professionals, data",rochepro.fr,Flat,0.099043074080751,high,16,General Offer Outline
722,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/ght-49-deploiement-outil-coordination-conciliation-medicamenteuse.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_ght_49_deploiement_outil_coordination_conciliation_medicamenteuse_html.txt,200,html,Indexable,2,93,167,2261,4,2,0.984615384615385,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_ght_49_deploiement_outil_coordination_conciliation_medicamenteuse_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_ght_49_deploiement_outil_coordination_conciliation_medicamenteuse_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_ght_49_deploiement_outil_coordination_conciliation_medicamenteuse_html.txt.txt.txt,"['GHT', 'Partage']",Other,France,Patient support,,,-18.730984,-28.049513,0,"The content of the content focuses on Roche's collaboration with healthcare professionals, particularly pharmacists and hospital staff, to enhance pharmaceutical care and improve medication management for patients. It discusses initiatives like the ""Partage GHT 49"" project, which aims to improve communication and coordination between hospitals and pharmacies, especially during medication reconciliation for elderly, polymedicated patients. The content emphasizes the importance of professional relationships, the integration of clinical pharmacy practices, and the ongoing efforts to secure funding and expand the project's reach while measuring its clinical impact. Overall, it serves to inform healthcare providers about Roche's resources and initiatives in supporting patient care through better pharmaceutical management.","oncology, professionals, data",rochepro.fr,Falling,0.127896072947584,high,91,General Offer Outline
723,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/gustave-roussy-experimente-imprimante-3d.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_gustave_roussy_experimente_imprimante_3d_html.txt,200,html,Indexable,,60,134,1375,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_gustave_roussy_experimente_imprimante_3d_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_gustave_roussy_experimente_imprimante_3d_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_gustave_roussy_experimente_imprimante_3d_html.txt.txt,[],Other,France,Offer outline,,,-32.09958,-15.810573,0,"The content provides information targeted at healthcare professionals, specifically physicians and pharmacists, regarding Roche's pharmaceutical products and services. It outlines resources available for medical inquiries, appointment scheduling with product specialists, and information about therapeutic areas such as oncology and neurology. Additionally, it highlights Roche's partnerships in innovative drug manufacturing, emphasizing advancements in patient care, adherence, and the personalization of treatments. The overall purpose is to support professionals in their practice and enhance patient care through Roche's offerings.","oncology, professionals, data",rochepro.fr,Falling,0.678030776349818,high,284,General Offer Outline
724,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/hopipharm-congres-pharmacie-hospitaliere-riche-enseignements.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopipharm_congres_pharmacie_hospitaliere_riche_enseignements_html.txt,200,html,Indexable,2,71,107,2389,4,2,0.984,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopipharm_congres_pharmacie_hospitaliere_riche_enseignements_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopipharm_congres_pharmacie_hospitaliere_riche_enseignements_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopipharm_congres_pharmacie_hospitaliere_riche_enseignements_html.txt.txt.txt,[],Other,France,Offer outline,,,-16.016275,-24.700773,0,"The content primarily focuses on Roche's offerings for medical professionals, particularly pharmacists and doctors, emphasizing its pharmaceuticals and support services. It discusses participation in healthcare conferences, the importance of continuing education, and collaborative approaches in hospital pharmacy practices. The content also highlights the integration of digital solutions in healthcare, such as telepharmacy and data sharing, while addressing challenges like environmental sustainability and crisis management in hospitals. Overall, the content serves as a resource and communication platform for Roche to educate and engage with healthcare professionals about its products and services.","oncology, professionals, data",rochepro.fr,All,0.489204898128938,high,202,General Offer Outline
725,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/hopital-foch-devient-structure-magnetique.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopital_foch_devient_structure_magnetique_html.txt,200,html,Indexable,,67,191,2020,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopital_foch_devient_structure_magnetique_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopital_foch_devient_structure_magnetique_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopital_foch_devient_structure_magnetique_html.txt.txt,"['Foch', 'Hospital']",Other,France,Patient support,,,-18.064901,-24.898932,0,"The content provides various resources and services offered by Roche for healthcare professionals, specifically targeting physicians and pharmacists. It includes information on accessing medical products, scheduling appointments with specialists, and posing medical or pharmaceutical inquiries. Additionally, it discusses Roche's commitment to improving hospital environments, particularly in terms of attracting staff and enhancing the quality of patient care at the Hospital Foch, outlining initiatives focused on professional development, management practices, workplace quality, and employee benefits. Overall, the content aims to support healthcare professionals in their roles and improve healthcare service delivery.","oncology, professionals, data",rochepro.fr,Rising,0.72054210763845,high,12,General Offer Outline
726,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/hopital-foch-escape-game-pharmaciens.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopital_foch_escape_game_pharmaciens_html.txt,200,html,Indexable,,71,149,1364,3,1,0.98019801980198,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopital_foch_escape_game_pharmaciens_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopital_foch_escape_game_pharmaciens_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopital_foch_escape_game_pharmaciens_html.txt.txt.txt,"['Eve', 'Antoine', 'Foch', 'Faucheron', 'Camps']",Other,France,Technology,,,25.700914,11.960104,4,"The content discusses an innovative training program implemented at Hôpital Foch, led by pharmacists Eve Camps and Antoine Faucheron. The program features an escape game designed to improve practices related to medication management among hospital staff. It highlights a hands-on approach to training, fostering engagement through themed scenarios while also emphasizing debriefing sessions for participants to enhance learning outcomes.","technologies, artificial, ai",rochepro.fr,Flat,0.431718384293319,high,212,Technology
727,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/hopital-henri-mondor-nouvelle-unite-pharmaceutique-preparation-controle-avenir.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopital_henri_mondor_nouvelle_unite_pharmaceutique_preparation_controle_avenir_html.txt,200,html,Indexable,1,78,159,1583,101,97,0.986013986013986,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopital_henri_mondor_nouvelle_unite_pharmaceutique_preparation_controle_avenir_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopital_henri_mondor_nouvelle_unite_pharmaceutique_preparation_controle_avenir_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopital_henri_mondor_nouvelle_unite_pharmaceutique_preparation_controle_avenir_html.txt.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-26.517227,-9.335808,0,"The content provides detailed information for healthcare professionals, particularly doctors and pharmacists, regarding Roche's pharmaceutical products and services. It emphasizes the company's commitment to enhancing patient care through innovative therapies, specifically in oncology and other therapeutic areas. The content also promotes resources such as specialist consultations, medical inquiries, and updates on pharmaceutical preparations, particularly within a new unit designed to meet regulatory demands and improve cancer treatment pathways. Furthermore, it highlights opportunities for professionals to stay informed through newsletters and expert insights.","oncology, professionals, data",rochepro.fr,Falling,0.781663731187258,high,433,General Offer Outline
728,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/hopitaux-proximite-circuit-medicament-labellisation.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopitaux_proximite_circuit_medicament_labellisation_html.txt,200,html,Indexable,,92,181,2313,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopitaux_proximite_circuit_medicament_labellisation_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopitaux_proximite_circuit_medicament_labellisation_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_hopitaux_proximite_circuit_medicament_labellisation_html.txt.txt,[],Other,France,Offer outline,,,-21.77279,-30.005121,0,"The content primarily focuses on providing information for healthcare professionals, particularly physicians and pharmacists, about Roche’s pharmaceutical products and services. It outlines various therapeutic areas addressed by Roche, encourages consultations with product specialists, and facilitates medical inquiries. Additionally, it discusses organizational changes in drug management within hospital settings, highlighting contractual agreements between hospitals to improve medication logistics and security. The purpose is to enhance collaboration among healthcare providers and streamline medication administration processes, ultimately aiming to improve patient care and support for healthcare professionals.","oncology, professionals, data",rochepro.fr,Falling,0.148456154323924,high,212,General Offer Outline
729,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite.html,7,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_html.txt,200,html,Indexable,1,57,0,2417,201,101,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_html.txt.txt,[],Other,France,Offer outline,,,-19.942978,-28.982208,0,"The content presents a section of Roche's professional platform, focusing on the latest news and developments relevant to hospital pharmacists. It highlights categories related to expertise, including management, health economics, and scientific advancements. The overarching aim is to provide professionals with updated information and resources that support their work in hospital settings. The featured content emphasizes Roche's commitment to the pharmaceutical industry and the enhancement of patient care.","oncology, professionals, data",rochepro.fr,Falling,0.173518753264687,high,23,General Offer Outline
730,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/ia-optimisation-conciliation-medicamenteuse.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_ia_optimisation_conciliation_medicamenteuse_html.txt,200,html,Indexable,,60,164,2223,3,1,0.981481481481482,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_ia_optimisation_conciliation_medicamenteuse_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_ia_optimisation_conciliation_medicamenteuse_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_ia_optimisation_conciliation_medicamenteuse_html.txt.txt.txt,['Synapse'],Other,France,Technology,,,-14.683086,-30.811068,0,"The content discusses Roche's commitment to improving the medication reconciliation process within healthcare settings, particularly through the use of digital tools and artificial intelligence. It highlights a partnership with Synapse to enhance efficiency and accuracy in this process by enabling healthcare professionals to gather and analyze patient medication information seamlessly at the bedside. The purpose is to streamline workflows, reduce errors, and provide better patient care through a more effective integration of data management and clinical pharmacy practices. Additionally, it looks forward to further developments in linking hospital and outpatient pharmacy services for improved patient follow-up and safety.","oncology, professionals, data",rochepro.fr,Falling,0.918158215385895,high,173,General Offer Outline
731,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/inhibiteurs-tyrosine-kinase-gestion-variabilite-inter-individuelle.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_inhibiteurs_tyrosine_kinase_gestion_variabilite_inter_individuelle_html.txt,200,html,Indexable,,88,146,2272,3,1,0.984732824427481,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_inhibiteurs_tyrosine_kinase_gestion_variabilite_inter_individuelle_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_inhibiteurs_tyrosine_kinase_gestion_variabilite_inter_individuelle_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_inhibiteurs_tyrosine_kinase_gestion_variabilite_inter_individuelle_html.txt.txt.txt,[],Oncology-Hematology,France,Offer outline,"tyrosine kinase inhibitors (TKIs), cancers, pharmacokinetic monitoring, therapeutic monitoring",,-11.027489,-0.9054083,0,"The content provides detailed information on Roche's pharmaceutical offerings, particularly focusing on targeted therapies such as tyrosine kinase inhibitors (TKIs). It discusses their mechanisms, applications in treating various cancers, and the importance of pharmacokinetic monitoring to address individual variability in treatment response. The content aims to educate healthcare professionals, including doctors and pharmacists, on Roche's products and therapeutic approaches, promoting informed communication and optimizing patient care within the oncology field. Additionally, it emphasizes the need for appropriate therapeutic monitoring to personalize treatment regimens effectively.","oncology, professionals, data",rochepro.fr,Falling,0.216637638550719,high,27,General Offer Outline
732,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/institut-montaigne-recommandations-parcours-patient.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_institut_montaigne_recommandations_parcours_patient_html.txt,200,html,Indexable,,88,154,2317,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_institut_montaigne_recommandations_parcours_patient_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_institut_montaigne_recommandations_parcours_patient_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_institut_montaigne_recommandations_parcours_patient_html.txt.txt,[],Other,France,Patient support,,,-16.894648,-23.158419,0,"The content provides a detailed overview of Roche's commitment to healthcare professionals, emphasizing support and resources for physicians and pharmacists. It highlights programs for improving patient care pathways, addressing the challenges faced by patients in navigating the healthcare system, especially for chronic illnesses. The content aims to inform health professionals about Roche's products, services, and initiatives, including the incorporation of digital tools to enhance patient engagement and care coordination. It underscores the importance of collaboration among healthcare providers and the integration of patient voices in quality improvement efforts.","oncology, professionals, data",rochepro.fr,Flat,0.480266341306544,high,381,General Offer Outline
733,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/lfss-2022-changement-paradigme-pour-medicaments.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_lfss_2022_changement_paradigme_pour_medicaments_html.txt,200,html,Indexable,,68,157,2400,3,1,0.982142857142857,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_lfss_2022_changement_paradigme_pour_medicaments_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_lfss_2022_changement_paradigme_pour_medicaments_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_lfss_2022_changement_paradigme_pour_medicaments_html.txt.txt.txt,"['Law', 'Financing', 'Security', 'Social']",Other,France,Offer outline,,,-26.046679,-29.87095,0,"The content provides detailed information intended for healthcare professionals regarding Roche's pharmaceutical offerings and services. It discusses various therapeutic areas, allows physicians and pharmacists to inquire about medications, consult with product specialists, and access medical information. The content also addresses recent legislative changes affecting medication pricing and reimbursement, highlighting new regulations introduced under the 2022 Social Security Financing Law. Additionally, it informs readers about healthcare events and provides resources for managing issues like drug shortages and quality defects, thereby positioning Roche as a supportive partner in medical care and pharmaceutical innovation.","oncology, professionals, data",rochepro.fr,Flat,0.224366336999369,high,92,General Offer Outline
734,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/lfss-2024-impacts-pharmaciens.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_lfss_2024_impacts_pharmaciens_html.txt,200,html,Indexable,,77,170,2809,4,2,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_lfss_2024_impacts_pharmaciens_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_lfss_2024_impacts_pharmaciens_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_lfss_2024_impacts_pharmaciens_html.txt.txt,"['France', 'LFSS']",Other,France,Offer outline,,,-24.396193,-28.80267,0,"The content provides detailed information aimed at medical professionals, specifically focusing on Roche's pharmaceutical products and services. It outlines various therapeutic areas, resources for healthcare providers, and updates related to drug regulation and healthcare financing, particularly in the context of France's 2024 social security budget law (LFSS). The content serves to inform doctors and pharmacists about medication inquiries, specialist appointments, new regulations, and healthcare strategies to enhance patient care and manage drug supply shortages. Overall, the content emphasizes Roche's commitment to supporting healthcare professionals in delivering quality care through accessible medical information and resources.","oncology, professionals, data",rochepro.fr,Flat,0.454464214036577,high,393,General Offer Outline
735,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/lfss-concentre-prevention.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_lfss_concentre_prevention_html.txt,200,html,Indexable,,54,128,2395,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_lfss_concentre_prevention_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_lfss_concentre_prevention_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_lfss_concentre_prevention_html.txt.txt,['France'],Other,France,Offer outline,,,-22.181437,-27.076458,0,"The content provides information targeted at healthcare professionals, including pharmacists and doctors, about Roche's pharmaceutical products and services. It outlines resources for learning about medications, scheduling consultations with product specialists, and asking medical or pharmaceutical questions. Additionally, it discusses recent developments in health legislation in France, emphasizing preventive health measures, access to care, and medication regulation. The content aims to support healthcare providers in staying informed and managing patient care effectively through Roche's offerings and ongoing educational initiatives.","oncology, professionals, data",rochepro.fr,Flat,0.38655432368147,high,12,General Offer Outline
736,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/logiciels-gestion-pui-aide-activite-pharmaciens.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_logiciels_gestion_pui_aide_activite_pharmaciens_html.txt,200,html,Indexable,,83,344,2408,3,1,0.982142857142857,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_logiciels_gestion_pui_aide_activite_pharmaciens_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_logiciels_gestion_pui_aide_activite_pharmaciens_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_logiciels_gestion_pui_aide_activite_pharmaciens_html.txt.txt.txt,[],Other,France,Offer outline,,,-20.487705,-28.631187,0,"The content outlines Roche’s commitment to providing support and resources for healthcare professionals, including doctors and pharmacists. It discusses their product information, medical inquiries, and specialist consultations. Additionally, it highlights Roche's initiatives in improving stock management and logistics within hospitals, tackling challenges such as inventory control and medication supply. The content also emphasizes the importance of tailored software solutions for healthcare settings and the ongoing collaboration with health organizations to enhance pharmacy operations and patient care. Overall, it serves as a resource for professionals seeking guidance on Roche's offerings and industry solutions.","oncology, professionals, data",rochepro.fr,Falling,0.292644392089469,high,149,General Offer Outline
737,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/mediation-solution-reglement-differends-entre-agents.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_mediation_solution_reglement_differends_entre_agents_html.txt,200,html,Indexable,,82,130,3059,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_mediation_solution_reglement_differends_entre_agents_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_mediation_solution_reglement_differends_entre_agents_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_mediation_solution_reglement_differends_entre_agents_html.txt.txt,[],Other,France,Patient support,,,-18.503084,-26.652908,0,"The content appears to focus on the resources and support available for healthcare professionals, particularly in the context of Roche's pharmaceutical products and services. It provides information regarding medications for various health conditions, facilitating appointments with product specialists, and addressing medical and pharmaceutical inquiries. Additionally, it discusses the mediation process in public health institutions to resolve conflicts among healthcare personnel, outlining its principles and mechanisms. The purpose is to enhance communication, troubleshoot issues within healthcare teams, and provide structured support to professionals engaged with Roche's offerings.","oncology, professionals, data",rochepro.fr,Rising,0.280662884645559,high,47,General Offer Outline
738,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/mission-borne-criteres-financement-regulation-produits-sante-plus-vert.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_mission_borne_criteres_financement_regulation_produits_sante_plus_vert_html.txt,200,html,Indexable,,110,181,2433,3,1,0.985185185185185,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_mission_borne_criteres_financement_regulation_produits_sante_plus_vert_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_mission_borne_criteres_financement_regulation_produits_sante_plus_vert_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_mission_borne_criteres_financement_regulation_produits_sante_plus_vert_html.txt.txt.txt,[],Other,France,Offer outline,,,-23.502792,-29.239017,0,"The content discusses various resources and services that Roche provides for healthcare professionals, specifically targeting physicians and pharmacists. It covers topics such as accessing medical information, booking appointments with product specialists, and inquiring about medicines. Additionally, it addresses current healthcare policies related to financing and regulation of health products, emphasizing the importance of sustainable practices and efficient prescriptions. The content aims to facilitate communication and enhance understanding between Roche and healthcare professionals regarding their products and services while reflecting the company’s commitment to innovation and quality in healthcare delivery.","oncology, professionals, data",rochepro.fr,All,0.615606156068422,high,151,General Offer Outline
739,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/nouveau-statut-preparations-hospitalieres-speciales.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_nouveau_statut_preparations_hospitalieres_speciales_html.txt,200,html,Indexable,,79,159,2190,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_nouveau_statut_preparations_hospitalieres_speciales_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_nouveau_statut_preparations_hospitalieres_speciales_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_nouveau_statut_preparations_hospitalieres_speciales_html.txt.txt,['COVID'],Other,France,Offer outline,,,-22.50691,-28.448515,0,"The content provides detailed information targeting healthcare professionals, particularly physicians and pharmacists, regarding Roche's pharmaceutical products and services. It discusses topics such as the management of medication shortages during health crises—specifically related to the production of specialized hospital preparations. The content emphasizes Roche's commitment to supporting healthcare providers with medical information, specialist consultations, and updates on regulations and practices, particularly in the context of recent challenges faced during the COVID-19 pandemic. Overall, the purpose of the content is to enhance collaboration between Roche and healthcare professionals while ensuring continuity of care for patients amid pharmaceutical supply issues.","oncology, professionals, data",rochepro.fr,All,0.471517885968505,high,295,General Offer Outline
740,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/nouvel-arrete-tracabilite-dmi.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_nouvel_arrete_tracabilite_dmi_html.txt,200,html,Indexable,,59,163,2428,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_nouvel_arrete_tracabilite_dmi_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_nouvel_arrete_tracabilite_dmi_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_nouvel_arrete_tracabilite_dmi_html.txt.txt,"['DMI', 'European']",Other,France,Offer outline,,,-23.515629,-32.769314,0,"The content primarily focuses on Roche's pharmaceutical products and services tailored for healthcare professionals, particularly pharmacists and doctors. It provides guidance on medication inquiries, scheduling appointments with product specialists, and asking medical or pharmaceutical questions. Additionally, it highlights regulatory updates regarding medical devices, specifically the traceability obligations for implantable medical devices (DMI), ensuring compliance with European regulations. The content emphasizes the importance of quality management and risk management in healthcare settings, reflecting Roche's commitment to patient safety and professional support in the medical community.","oncology, professionals, data",rochepro.fr,All,0.907583067127104,high,229,General Offer Outline
741,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/nouvelle-radiopharmacie-gustave-roussy.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_nouvelle_radiopharmacie_gustave_roussy_html.txt,200,html,Indexable,,60,141,1984,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_nouvelle_radiopharmacie_gustave_roussy_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_nouvelle_radiopharmacie_gustave_roussy_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_nouvelle_radiopharmacie_gustave_roussy_html.txt.txt,"['Roussy', 'Gustave']",Other,France,Offer outline,,,-23.42589,-28.227566,0,"The content provides information about Roche's pharmaceutical products and services, specifically targeting medical professionals and pharmacists. It outlines opportunities for professionals to learn about medications, schedule consultations with product specialists, and ask medical or pharmaceutical questions. Additionally, it highlights the opening of a new radiopharmacy unit at Gustave Roussy, detailing its design, the technology involved, and the benefits it brings for patient care and compliance with health regulations. The emphasis is on enhancing healthcare delivery through improved facilities and collaborative efforts in medical practice.","oncology, professionals, data",rochepro.fr,Rising,0.650231894429462,high,468,General Offer Outline
742,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/numerique-sante-pui-concernees.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_numerique_sante_pui_concernees_html.txt,200,html,Indexable,,55,175,1394,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_numerique_sante_pui_concernees_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_numerique_sante_pui_concernees_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_numerique_sante_pui_concernees_html.txt.txt,[],Other,France,Offer outline,,,-16.249092,-21.152643,0,"The content provides an overview of Roche's resources and support for healthcare professionals, particularly focusing on the information and services available to doctors and pharmacists. It highlights various therapeutic areas such as neurology, oncology, and rare diseases, as well as the importance of digital health data sharing and interoperability among healthcare providers. The content aims to facilitate communication, improve patient care, and offer assistance with Roche’s medicinal products, including addressing quality issues and adverse effects. Additionally, it emphasizes the role of an expert committee in creating relevant content and keeping professionals updated on health economics and innovations in digital healthcare.","oncology, professionals, data",rochepro.fr,Falling,0.770155994142876,high,466,General Offer Outline
743,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/pannes-informatiques-en-milieu-hospitalier-retour-experience.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pannes_informatiques_en_milieu_hospitalier_retour_experience_html.txt,200,html,Indexable,,84,186,2236,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pannes_informatiques_en_milieu_hospitalier_retour_experience_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pannes_informatiques_en_milieu_hospitalier_retour_experience_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pannes_informatiques_en_milieu_hospitalier_retour_experience_html.txt.txt,[],Oncology-Hematology,France,Patient support,,,-20.52245,-27.329178,0,"The content focuses on Roche's support and resources for healthcare professionals, particularly pharmacists and doctors. It outlines the process for obtaining information about Roche's medications, scheduling appointments with product specialists, and addressing medical or pharmaceutical inquiries. Additionally, it discusses recent challenges faced by a hospital during a software malfunction related to chemotherapy prescriptions, detailing the team’s response and problem-solving strategies used to manage the situation. The goal is to enhance communication, provide expertise, and assist healthcare professionals in their clinical practices while ensuring patient care continuity.","oncology, professionals, data",rochepro.fr,Flat,0.588630986625595,high,54,General Offer Outline
744,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/patchs-nouvelle-methode-vaccination-sans-aiguille.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_patchs_nouvelle_methode_vaccination_sans_aiguille_html.txt,200,html,Indexable,,78,124,2342,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_patchs_nouvelle_methode_vaccination_sans_aiguille_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_patchs_nouvelle_methode_vaccination_sans_aiguille_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_patchs_nouvelle_methode_vaccination_sans_aiguille_html.txt.txt,[],Immunology,France,Technology,"needle-free approach, patches, vaccines, dermal layer, immune response, intramuscular injections, vaccination technologies",,33.951817,1.3571475,4,"The content discusses developments in vaccination methods, particularly focusing on a new needle-free approach using patches. It explains the advantages of delivering vaccines through the skin, targeting the dermal layer for better immune response while addressing logistical challenges and patient acceptance. The article outlines various techniques and research related to these innovations, along with the potential benefits and limitations in comparison to traditional intramuscular injections. This content is aimed at healthcare professionals, providing insights into emerging vaccination technologies and fostering discussions about advancements in medical practice.","technologies, artificial, ai",rochepro.fr,Rising,0.225415118899796,high,266,Technology
745,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/personnalisation-medicaments-revolution-imprimante-3d.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_personnalisation_medicaments_revolution_imprimante_3d_html.txt,200,html,Indexable,2,101,159,2142,4,2,0.983050847457627,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_personnalisation_medicaments_revolution_imprimante_3d_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_personnalisation_medicaments_revolution_imprimante_3d_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_personnalisation_medicaments_revolution_imprimante_3d_html.txt.txt.txt,[],Other,France,Technology,,,-1.4653225,-36.45807,1,"The content discusses Roche's initiatives tailored for healthcare professionals, particularly pharmacists and doctors. It focuses on innovations like the use of 3D printing technology to produce personalized medications, especially for pediatric and geriatric patients. The content highlights the challenges of traditional formulations in these populations and how custom solutions improve patient adherence and treatment effectiveness. It also outlines regulatory aspects, ongoing clinical trials, and the financial implications of this technology for healthcare institutions. Overall, the content aims to inform medical professionals about Roche’s commitment to personalized healthcare and advanced pharmaceutical practices.","drug, reporting, adverse",rochepro.fr,All,0.369249741316562,high,436,Drug Safety
746,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/pharmacie-hospitaliere-problematiques-recrutement.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmacie_hospitaliere_problematiques_recrutement_html.txt,200,html,Indexable,,74,168,2102,3,1,0.982456140350877,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmacie_hospitaliere_problematiques_recrutement_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmacie_hospitaliere_problematiques_recrutement_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmacie_hospitaliere_problematiques_recrutement_html.txt.txt.txt,[],Other,France,Offer outline,,,-19.1013,-29.024128,0,"The content discusses various medical and professional services provided by Roche for healthcare professionals, emphasizing support for physicians and pharmacists. It covers topics such as medication inquiries, specialist appointments, and medical information services. Additionally, it addresses challenges in hospital pharmacy, particularly the shortage of pharmacy staff and the impact on healthcare delivery. The content highlights efforts to improve hospital attractiveness amid competition from private clinics, as well as the ongoing strategies to address recruitment difficulties and enhance organizational efficiency within the hospital pharmacy system.","oncology, professionals, data",rochepro.fr,Rising,0.397348502888046,high,167,General Offer Outline
747,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/pharmacie-humanitaire-internationale-aide-demunis.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmacie_humanitaire_internationale_aide_demunis_html.txt,200,html,Indexable,,85,158,2420,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmacie_humanitaire_internationale_aide_demunis_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmacie_humanitaire_internationale_aide_demunis_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmacie_humanitaire_internationale_aide_demunis_html.txt.txt,"['Internationale', 'Humanitaire', 'France', 'Pharmacie', 'PHI']",Other,France,Offer outline,,,-19.90979,-27.975977,0,"The content discusses Roche and its commitment to supporting healthcare professionals, including doctors and pharmacists, by providing access to information about its medications and services. It emphasizes Roche's therapeutic areas, the facilitation of consultations with product specialists, and medical inquiries. Additionally, it highlights the role of humanitarian organizations like Pharmacie Humanitaire Internationale (PHI) in delivering medical aid to underprivileged populations, both locally in France and internationally. The content serves as a resource for healthcare professionals seeking knowledge and support in their practice, while also reflecting Roche's corporate social responsibility initiatives.","oncology, professionals, data",rochepro.fr,All,0.641919295311591,high,296,General Offer Outline
748,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/pharmacie-officine-transformation-numerique.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmacie_officine_transformation_numerique_html.txt,200,html,Indexable,,85,161,2379,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmacie_officine_transformation_numerique_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmacie_officine_transformation_numerique_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmacie_officine_transformation_numerique_html.txt.txt,[],Other,France,Offer outline,,,-19.677483,-23.767588,0,"The content provides extensive information about Roche's pharmaceutical products and services aimed specifically at healthcare professionals, including doctors and pharmacists. It highlights various therapeutic areas such as neurology, oncology, and hematology, and offers resources for specialists, detailing how to inquire about medications, schedule appointments, and access medical information. Additionally, it discusses the digital transformation and regulatory changes taking place within the healthcare system, particularly concerning the integration of digital tools in pharmacy practices. The purpose is to assist healthcare professionals in improving patient care through enhanced information sharing and access to Roche's offerings.","oncology, professionals, data",rochepro.fr,Rising,0.825578615598128,high,235,General Offer Outline
749,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/pharmaciens-au-coeur-experimentation-usage-cannabis-therapeutique.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmaciens_au_coeur_experimentation_usage_cannabis_therapeutique_html.txt,200,html,Indexable,,98,142,2701,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmaciens_au_coeur_experimentation_usage_cannabis_therapeutique_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmaciens_au_coeur_experimentation_usage_cannabis_therapeutique_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmaciens_au_coeur_experimentation_usage_cannabis_therapeutique_html.txt.txt,['French'],Other,France,Offer outline,,,-30.968296,-18.257769,0,"The content provides detailed information about Roche's pharmaceutical offerings and services tailored for healthcare professionals, particularly focusing on medical cannabis as an emerging treatment. It discusses the ongoing experimentation with therapeutic cannabis under the supervision of the French health authority, including its indications, patient inclusion criteria, and outcomes from the trial. The communication emphasizes the importance of education and collaboration among healthcare providers, particularly pharmacists, in managing and administering these new treatments. The purpose of this content is to inform and engage medical professionals about Roche's role in advancing patient care through innovative therapies and to provide support in navigating these developments.","oncology, professionals, data",rochepro.fr,All,0.0662080665130096,high,55,General Offer Outline
750,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/pharmaciens-manquent-appel.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmaciens_manquent_appel_html.txt,200,html,Indexable,,50,162,2355,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmaciens_manquent_appel_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmaciens_manquent_appel_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmaciens_manquent_appel_html.txt.txt,[],Other,France,Offer outline,,,-20.27433,-26.002851,0,"The content provides detailed information aimed at healthcare professionals, specifically focusing on Roche's therapeutic areas and resources for doctors and pharmacists. It highlights the availability of medications, expert consultations, and medical inquiries, as well as addressing workforce challenges in the pharmacy sector. The content indicates a concern about pharmacist vacancies and recruitment issues that could impact patient care, while also discussing initiatives to improve visibility and accessibility of pharmacy education. Overall, the purpose of the content is to facilitate support and engagement between Roche and healthcare providers, ensuring they have necessary resources and information to enhance patient care.","oncology, professionals, data",rochepro.fr,All,0.838698284284694,high,153,General Offer Outline
751,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/pharmaciens-officine-substituer-biosimilaires.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmaciens_officine_substituer_biosimilaires_html.txt,200,html,Indexable,,79,161,2360,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmaciens_officine_substituer_biosimilaires_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmaciens_officine_substituer_biosimilaires_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmaciens_officine_substituer_biosimilaires_html.txt.txt,['France'],Other,France,Offer outline,,,-1.5000793,-37.10597,1,"The content focuses on Roche's pharmaceuticals and the recent legislative changes regarding the substitution of biosimilars by pharmacists in France. It discusses the implications of a law allowing pharmacists to dispense biosimilars instead of prescribed biological medicines under certain conditions. The content aims to inform medical professionals, particularly pharmacists, about these changes, their rationale, and the impact on patient care and the healthcare system. Additionally, it highlights the burden and responsibilities pharmacists carry in ensuring proper medication management while addressing economic factors and healthcare access related to biosimilars.","drug, reporting, adverse",rochepro.fr,Rising,0.833166756572646,high,91,Drug Safety
752,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/pharmamobile-dispositif-formation-innovant.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmamobile_dispositif_formation_innovant_html.txt,200,html,Indexable,,65,167,1939,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmamobile_dispositif_formation_innovant_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmamobile_dispositif_formation_innovant_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pharmamobile_dispositif_formation_innovant_html.txt.txt,['Pharmamobile'],Other,France,Offer outline,,,-18.693937,-21.661377,0,"The content provides detailed information about Roche's initiatives and services tailored for medical professionals, particularly focusing on a project called Pharmamobile. This innovative training program aims to enhance the education of healthcare professionals through a blended learning approach, combining traditional in-person lectures with e-learning modules. It emphasizes practical skills and active learning, targeting not only healthcare providers but also patients suffering from chronic conditions. The content also mentions various resources, support services, and opportunities for further inquiry related to Roche's pharmaceutical products and practices.","oncology, professionals, data",rochepro.fr,Flat,0.879736419913168,high,358,General Offer Outline
753,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/politique-rse-engagements-pharmaciens.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_politique_rse_engagements_pharmaciens_html.txt,200,html,Indexable,,72,141,1341,3,1,0.980392156862745,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_politique_rse_engagements_pharmaciens_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_politique_rse_engagements_pharmaciens_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_politique_rse_engagements_pharmaciens_html.txt.txt.txt,"['Corporate', 'Responsibility', 'CSR', 'Social']",Other,France,Patient support,,,-4.180907,-36.0153,1,"The content presents a segment from RochePro, focusing on the topic of Corporate Social Responsibility (CSR) and its commitments for pharmacists. It discusses various aspects of CSR relevant to community pharmacies, such as air quality, water consumption, energy use, and medical waste management. The content aims to inform pharmacists about their responsibilities and the importance of sustainable practices in their work. It also features an expert perspective, likely intended to guide pharmacists in implementing these practices effectively.","drug, reporting, adverse",rochepro.fr,Flat,0.606674641259502,high,83,Drug Safety
754,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/pui-ghef-meaux-robotisation-respect-obligation-serialisation.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pui_ghef_meaux_robotisation_respect_obligation_serialisation_html.txt,200,html,Indexable,,101,178,1636,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pui_ghef_meaux_robotisation_respect_obligation_serialisation_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pui_ghef_meaux_robotisation_respect_obligation_serialisation_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_pui_ghef_meaux_robotisation_respect_obligation_serialisation_html.txt.txt,['European'],Other,France,Offer outline,,,-23.56786,-32.321865,0,"The content focuses on Roche's services and resources tailored for medical professionals, including doctors and pharmacists. It provides information about medications, specialist consultations, and medical inquiries while highlighting Roche’s commitment to compliance with European regulations on drug serialization to prevent counterfeit products. Additionally, it discusses the implementation of automation in hospitals to meet these serialization requirements. The purpose of the content is to inform healthcare professionals about Roche's offerings, facilitate communication, and ensure adherence to regulatory standards in the pharmaceutical industry.","oncology, professionals, data",rochepro.fr,Falling,0.0100684074955266,high,272,General Offer Outline
755,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/radiopharmacie-bonnes-pratiques-professionnelles-detaillees.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_radiopharmacie_bonnes_pratiques_professionnelles_detaillees_html.txt,200,html,Indexable,2,70,203,2285,4,2,0.983870967741936,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_radiopharmacie_bonnes_pratiques_professionnelles_detaillees_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_radiopharmacie_bonnes_pratiques_professionnelles_detaillees_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_radiopharmacie_bonnes_pratiques_professionnelles_detaillees_html.txt.txt.txt,['BPP'],Other,France,Offer outline,,,-24.614378,-30.679956,0,"The content focuses on Roche's commitment to providing extensive information and resources for healthcare professionals, particularly pharmacists and physicians. It emphasizes the company's pharmaceutical products, ongoing developments in radiopharmacy, and updates to good manufacturing practices (BPP) that ensure quality and safety in medication preparation. Additionally, it details the new guidelines and requirements for handling radiopharmaceuticals, aimed at enhancing operational standards and protecting health professionals while ensuring efficient preparation processes. The purpose is to facilitate collaboration, enhance knowledge sharing, and promote adherence to regulatory standards among healthcare practitioners.","oncology, professionals, data",rochepro.fr,Flat,0.853104810795366,high,52,General Offer Outline
756,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/reactivite-scientifique-coeur-crise-sanitaire.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_reactivite_scientifique_coeur_crise_sanitaire_html.txt,200,html,Indexable,,72,119,2301,3,1,0.981818181818182,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_reactivite_scientifique_coeur_crise_sanitaire_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_reactivite_scientifique_coeur_crise_sanitaire_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_reactivite_scientifique_coeur_crise_sanitaire_html.txt.txt.txt,['COVID'],Other,France,Offer outline,,,-16.483812,-23.194967,0,"The content focuses on Roche's support and resources for healthcare professionals, particularly emphasizing collaborations and advancements in medical practices brought on by the COVID-19 pandemic. It discusses the accelerated scientific responsiveness and streamlined communication among various healthcare stakeholders, such as pharmacists, physicians, and researchers. The content also highlights Roche's offerings, including access to medications, specialist consultations, and information-sharing platforms for professionals, while advocating for ongoing collaborative practices and the importance of digital tools in the healthcare sector.","oncology, professionals, data",rochepro.fr,All,0.48406713075878,high,233,General Offer Outline
757,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/reforme-3-eme-cycle-pharmacie-bilan-positif-5-ans.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_reforme_3_eme_cycle_pharmacie_bilan_positif_5_ans_html.txt,200,html,Indexable,2,82,176,2414,4,2,0.982456140350877,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_reforme_3_eme_cycle_pharmacie_bilan_positif_5_ans_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_reforme_3_eme_cycle_pharmacie_bilan_positif_5_ans_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_reforme_3_eme_cycle_pharmacie_bilan_positif_5_ans_html.txt.txt.txt,[],Other,France,Offer outline,,,-22.688759,-27.855213,0,"The content provides detailed information on Roche's pharmaceutical offerings, primarily aimed at healthcare professionals such as doctors and pharmacists. It highlights various therapeutic areas, ongoing medical education, and information services available to these professionals, including the ability to consult with product specialists and access medical articles. Additionally, it discusses recent reforms in pharmacy education, focusing on the structured training programs for pharmacy interns and the introduction of specialized training courses to enhance their expertise. The overall purpose is to support healthcare providers in their professional development and ensure they are well-informed about Roche's products and relevant pharmaceutical practices.","oncology, professionals, data",rochepro.fr,Falling,0.498716656139835,high,424,General Offer Outline
758,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/reforme-internat-pharmacie.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_reforme_internat_pharmacie_html.txt,200,html,Indexable,,53,145,2131,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_reforme_internat_pharmacie_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_reforme_internat_pharmacie_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_reforme_internat_pharmacie_html.txt.txt,['France'],Other,France,Offer outline,,,-21.539867,-28.26602,0,"The content provides detailed information directed towards medical professionals, specifically focusing on Roche's pharmaceutical products and services. It outlines resources available to doctors and pharmacists, such as consultations with product specialists and access to medical information. Additionally, it discusses recent reforms in pharmacy internships in France, emphasizing changes in training structures, stages, and the introduction of specialized training paths. The purpose of this content is to educate healthcare professionals about Roche's offerings while addressing the evolving landscape of pharmaceutical education and practice.","oncology, professionals, data",rochepro.fr,Flat,0.161414757980983,high,398,General Offer Outline
759,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/renouvellement-adaptation-prescriptions.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_renouvellement_adaptation_prescriptions_html.txt,200,html,Indexable,,90,161,2555,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_renouvellement_adaptation_prescriptions_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_renouvellement_adaptation_prescriptions_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_renouvellement_adaptation_prescriptions_html.txt.txt,[],Other,France,Offer outline,,,-21.3891,-29.944233,0,"The content primarily focuses on providing information and resources for healthcare professionals, specifically physicians and pharmacists, regarding Roche's medications and services. It discusses new regulations that empower hospital pharmacists to autonomously renew and adapt medical prescriptions, emphasizing collaboration with physicians to improve patient outcomes. Additionally, the content outlines the responsibilities and protocols for pharmacists within clinical settings, changes in their roles, and how to manage pharmaceutical practices effectively. Overall, the purpose is to inform and support healthcare professionals in utilizing Roche's products and optimizing patient care through enhanced pharmacy practices.","oncology, professionals, data",rochepro.fr,Falling,0.658817573150944,high,41,General Offer Outline
760,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/retour-cinq-interventions-retenir-csh-2024.html,10,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_retour_cinq_interventions_retenir_csh_2024_html.txt,200,html,Indexable,1,67,152,3140,99,96,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_retour_cinq_interventions_retenir_csh_2024_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_retour_cinq_interventions_retenir_csh_2024_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_retour_cinq_interventions_retenir_csh_2024_html.txt.txt,['AI'],Oncology-Hematology,France,Research,,,8.131919,9.486781,7,"The content is a comprehensive resource focused on Roche's pharmaceutical advancements, specifically in oncology and patient care. It highlights recent conferences that addressed topics such as the integration of artificial intelligence in healthcare, innovative cancer treatment approaches, and the evolving role of hospital pharmacists. The content provides medical professionals, particularly pharmacists and doctors, with insights into Roche's products and services, encourages engagement with specialists, and emphasizes the importance of collaboration in improving patient outcomes. It also touches on ethical considerations in using AI for medical decision-making and the importance of human oversight in healthcare delivery.","event, exclusive, website",rochepro.fr,Flat,0.441614634217117,high,180,Events & Patient Care
761,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/revivez-interventions-inspirantes-pepc-2024.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_revivez_interventions_inspirantes_pepc_2024_html.txt,200,html,Indexable,,52,224,2136,3,1,0.981481481481482,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_revivez_interventions_inspirantes_pepc_2024_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_revivez_interventions_inspirantes_pepc_2024_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_revivez_interventions_inspirantes_pepc_2024_html.txt.txt.txt,['PEPC'],Other,France,Offer outline,,,-17.655008,-25.25469,0,"The content primarily focuses on Roche's initiatives and offerings aimed at healthcare professionals, particularly pharmacists. It highlights various therapeutic areas, training events like the PEPC conference, and the importance of innovation and management in hospital pharmacy practice. The content encourages pharmacists to engage with Roche's resources for medical information, participate in specialist consultations, and stay updated with innovations that can enhance patient care. It also emphasizes community building and knowledge sharing among healthcare professionals.","oncology, professionals, data",rochepro.fr,Falling,0.114786096831616,high,392,General Offer Outline
762,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/sante-durable-vbhc-enjeux-cancerologie.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_sante_durable_vbhc_enjeux_cancerologie_html.txt,200,html,Indexable,,66,158,1645,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_sante_durable_vbhc_enjeux_cancerologie_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_sante_durable_vbhc_enjeux_cancerologie_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_sante_durable_vbhc_enjeux_cancerologie_html.txt.txt,['VBHC'],Oncology-Hematology,France,Offer outline,,,-20.018873,-12.878556,0,"The content primarily focuses on Roche's commitment to providing medical professionals with access to information about its pharmaceutical products and services. It outlines various resources available for both doctors and pharmacists, including opportunities for consultations with specialists, the ability to ask medical and pharmaceutical questions, and access to publications related to value-based healthcare (VBHC). Additionally, it highlights Roche's educational initiatives, specifically a web series aimed at improving understanding of healthcare economics and sustainable health systems within oncology. The overall purpose is to enhance collaboration and knowledge-sharing among healthcare professionals while emphasizing the importance of value and outcomes in patient care.","oncology, professionals, data",rochepro.fr,Flat,0.404487786493329,high,179,General Offer Outline
763,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/securisation-organisation-activite-radiopharmacie.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_securisation_organisation_activite_radiopharmacie_html.txt,200,html,Indexable,,76,188,2093,1,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_securisation_organisation_activite_radiopharmacie_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_securisation_organisation_activite_radiopharmacie_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_securisation_organisation_activite_radiopharmacie_html.txt.txt,['Anap'],Other,France,Offer outline,,,-19.052479,-26.773792,0,"The content serves as a professional resource for healthcare providers, particularly pharmacists and doctors, offering information about Roche's pharmaceutical products, services, and support systems. It includes guidance on accessing medication, connecting with product specialists, and managing medical or pharmaceutical inquiries. Additionally, it discusses the evolving regulations in radiopharmacy, the need for training and tools for safe practice, and highlights collaborative efforts with healthcare agencies like Anap. The content emphasizes optimizing patient care through improved organization and resources within the healthcare system.","oncology, professionals, data",rochepro.fr,Rising,0.633787092082946,high,252,General Offer Outline
764,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/serialisation-obligation-pui.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_serialisation_obligation_pui_html.txt,200,html,Indexable,,61,147,2487,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_serialisation_obligation_pui_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_serialisation_obligation_pui_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_serialisation_obligation_pui_html.txt.txt,[],Other,France,Offer outline,,,-24.20615,-31.471981,0,"The content primarily describes Roche's offerings and services tailored for healthcare professionals, including physicians and pharmacists. It highlights features such as product information, scheduling appointments with specialists, medical inquiries, and updates on therapeutic areas. Additionally, it covers the implementation and importance of serialization in the pharmaceutical supply chain to combat counterfeit drugs and enhance safety. The purpose of the content is to inform and assist healthcare professionals in navigating Roche's products and the regulatory requirements affecting their practice.","oncology, professionals, data",rochepro.fr,All,0.0903343331794755,high,305,General Offer Outline
765,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/sujets-pres-2024.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_sujets_pres_2024_html.txt,200,html,Indexable,,79,156,2496,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_sujets_pres_2024_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_sujets_pres_2024_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_sujets_pres_2024_html.txt.txt,['PRES'],Other,France,Offer outline,,,-24.043222,-27.632177,0,"The content focuses on Roche's offerings for healthcare professionals, particularly pharmacists and physicians. It provides information about Roche's medications, upcoming events, and educational opportunities, such as the PRES event, which addresses health economy and pharmaceutical practices. The content emphasizes collaboration among healthcare professionals, updates on legislative measures regarding drug financing, and discussions on real-world data analysis in clinical research. Additionally, it invites professionals to engage with Roche's resources and services, aiming to enhance knowledge and practice in the pharmaceutical field.","oncology, professionals, data",rochepro.fr,Falling,0.271168136078354,high,279,General Offer Outline
766,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/systeme-sante-promouvoir-virages-ambulatoire-domiciliaire.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_systeme_sante_promouvoir_virages_ambulatoire_domiciliaire_html.txt,200,html,Indexable,,85,162,2192,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_systeme_sante_promouvoir_virages_ambulatoire_domiciliaire_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_systeme_sante_promouvoir_virages_ambulatoire_domiciliaire_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_systeme_sante_promouvoir_virages_ambulatoire_domiciliaire_html.txt.txt,[],Other,France,Offer outline,,,-17.545023,-24.624744,0,"The content focuses on Roche's commitment to healthcare professionals, specifically targeting physicians and pharmacists. It highlights the company's offerings, including medical information, product consultations, and resources for managing patient care. Additionally, it discusses broader healthcare themes like the shift towards outpatient and home care, emphasizing the importance of coordination among healthcare providers. The content is aimed at supporting healthcare professionals with tools and information to enhance patient care and streamline processes within the evolving health system.","oncology, professionals, data",rochepro.fr,Falling,0.268608152192775,high,191,General Offer Outline
767,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/systemes-information-pui.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_systemes_information_pui_html.txt,200,html,Indexable,,69,158,2109,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_systemes_information_pui_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_systemes_information_pui_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_systemes_information_pui_html.txt.txt,['IT'],Other,France,Offer outline,,,-18.105368,-29.294024,0,"The content primarily focuses on providing information and resources for healthcare professionals, specifically pharmacists and doctors, regarding Roche's pharmaceutical products and services. It offers guidance on various therapeutic areas, tools for managing medication information, and support for navigating challenges associated with healthcare systems and information technology. Moreover, it highlights initiatives aimed at improving the interoperability of healthcare systems, increasing the efficiency of pharmacy operations, and facilitating communication between pharmacists and IT departments. The overall purpose is to enhance the collaboration and effectiveness of healthcare practitioners in their daily practices.","oncology, professionals, data",rochepro.fr,Falling,0.256919086030009,high,251,General Offer Outline
768,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/tests-sequencages-enjeu-accessibilite-financiere.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_tests_sequencages_enjeu_accessibilite_financiere_html.txt,200,html,Indexable,,74,172,2192,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_tests_sequencages_enjeu_accessibilite_financiere_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_tests_sequencages_enjeu_accessibilite_financiere_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_tests_sequencages_enjeu_accessibilite_financiere_html.txt.txt,['France'],Oncology-Hematology,France,Technology,,,-8.775192,-3.476232,0,"The content discusses Roche's ongoing contributions to personalized medicine, particularly through advancements in genomic sequencing and its applications in oncology. It addresses the challenges and methodologies involved in implementing genetic tests for patient treatment and diagnosis, highlighting the importance of collaboration among healthcare professionals. Additionally, the content touches upon the complexities of funding and accessibility for genomic testing in France, emphasizing the need for reform to enhance patient access to personalized therapies. The overall purpose is to inform healthcare professionals about Roche's products and services while facilitating a dialogue around innovations and issues in the health sector.","oncology, professionals, data",rochepro.fr,Flat,0.214513694773034,high,180,General Offer Outline
769,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/therapie-cellulaire-installation-nouvelles-generations.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_therapie_cellulaire_installation_nouvelles_generations_html.txt,200,html,Indexable,,76,142,2398,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_therapie_cellulaire_installation_nouvelles_generations_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_therapie_cellulaire_installation_nouvelles_generations_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_therapie_cellulaire_installation_nouvelles_generations_html.txt.txt,"['Europe', 'T']",Oncology-Hematology,France,Technology,"cell therapy, gene therapy, genetically modified T cells, tumor-infiltrating lymphocytes",,-11.065438,3.9484334,0,"The content discusses Roche's focus on advanced therapies, particularly in the field of cell therapy and gene therapy. It highlights the evolution of these therapeutic approaches, including the development of genetically modified T cells and tumor-infiltrating lymphocytes, while emphasizing their clinical applications and the regulatory framework governing them in Europe. The purpose of the content is to provide medical professionals with information regarding Roche's products, facilitate consultations with specialists, and keep them informed about innovations and best practices in patient care. Additionally, it stresses the importance of compliance with production standards and the challenges associated with these therapeutic advancements.","oncology, professionals, data",rochepro.fr,Rising,0.359503455395316,high,17,General Offer Outline
770,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/therapie-orale-cancerologie-experimentations-en-cours.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_therapie_orale_cancerologie_experimentations_en_cours_html.txt,200,html,Indexable,,78,184,1441,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_therapie_orale_cancerologie_experimentations_en_cours_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_therapie_orale_cancerologie_experimentations_en_cours_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_therapie_orale_cancerologie_experimentations_en_cours_html.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-31.760475,-11.584184,0,"The content outlines various services and resources offered by Roche for healthcare professionals, specifically targeting doctors and pharmacists. It includes information about Roche's medications, opportunities to meet with product specialists, and answers to medical or pharmaceutical queries. Additionally, it discusses therapeutic areas such as oncology, hematology, and neurology. The content aims to facilitate communication and collaboration among healthcare providers, enhance patient care, and keep professionals informed about the latest developments within Roche's offerings.","oncology, professionals, data",rochepro.fr,Rising,0.186917291125429,high,100,General Offer Outline
771,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/tracabilite-securisation-administration-chimiotherapies-pompe-connectee.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_tracabilite_securisation_administration_chimiotherapies_pompe_connectee_html.txt,200,html,Indexable,,103,221,1409,3,1,0.985294117647059,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_tracabilite_securisation_administration_chimiotherapies_pompe_connectee_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_tracabilite_securisation_administration_chimiotherapies_pompe_connectee_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_tracabilite_securisation_administration_chimiotherapies_pompe_connectee_html.txt.txt.txt,[],Oncology-Hematology,France,Offer outline,,,-21.919666,-13.620095,0,"The content primarily focuses on providing pharmaceutical professionals, particularly doctors and pharmacists, with information about Roche's medications and services. It encourages users to engage with specialists, ask medical or pharmaceutical questions, and access resources related to Roche's therapeutic areas. The content features updates on the use of connected pumps to enhance chemotherapy administration safety, a newsletter subscription option, and highlights the expert committee involved in creating content tailored for healthcare professionals. Overall, the purpose is to facilitate knowledge exchange and support the healthcare community in improving patient care.","oncology, professionals, data",rochepro.fr,Falling,0.986587583700061,high,305,General Offer Outline
772,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/tracabilite-systeme-rfid-preparations-chimiotherapies.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_tracabilite_systeme_rfid_preparations_chimiotherapies_html.txt,200,html,Indexable,,83,863,1436,3,1,0.983050847457627,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_tracabilite_systeme_rfid_preparations_chimiotherapies_html.txt.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_tracabilite_systeme_rfid_preparations_chimiotherapies_html.txt.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_tracabilite_systeme_rfid_preparations_chimiotherapies_html.txt.txt.txt,['RFID'],Other,France,Offer outline,,,-23.688955,-26.38841,0,"The content provides information tailored for healthcare professionals about Roche's medications and services, emphasizing support for physicians and pharmacists. It outlines various resources available for medical inquiries, appointment scheduling with specialists, and updates on therapeutic areas such as neurology and oncology. Additionally, it discusses the implementation of RFID technology in chemotherapy preparations to enhance efficiency and safety in hospital settings. The content serves as a platform for medical professionals to access critical information, participate in healthcare advancements, and stay updated on Roche’s products and initiatives.","oncology, professionals, data",rochepro.fr,Rising,0.27581291151781,high,306,General Offer Outline
773,https://rochepro.fr/pharmaciens/expertise-pui/toute-actualite/trois-experimentations-innovation-organisationnelle.html,9,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_trois_experimentations_innovation_organisationnelle_html.txt,200,html,Indexable,,74,161,1447,3,1,1,rochepro_fr_pharmaciens_expertise_pui_toute_actualite_trois_experimentations_innovation_organisationnelle_html.txt,image/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_trois_experimentations_innovation_organisationnelle_html.txt.png,text/rochepro_fr_pharmaciens_expertise_pui_toute_actualite_trois_experimentations_innovation_organisationnelle_html.txt.txt,[],Other,France,Offer outline,,,-22.182287,-21.771297,0,"The content primarily focuses on providing resources and support for healthcare professionals, particularly pharmacists and physicians, in relation to Roche's pharmaceutical products and services. It includes information about requesting medical literature, consulting specialists, and staying updated on Roche's therapeutic areas, including recent innovations in pharmaceutical organization. The purpose of the content is to facilitate communication and professional development among healthcare providers, ensuring they have access to the latest information and assistance related to Roche's offerings.","oncology, professionals, data",rochepro.fr,All,0.462958651527808,high,33,General Offer Outline
774,https://rochepro.fr/pharmaciens.html,8,rochepro_fr_pharmaciens_html.txt,200,html,Indexable,1,21,0,1473,752,640,1,rochepro_fr_pharmaciens_html.txt,image/rochepro_fr_pharmaciens_html.txt.png,text/rochepro_fr_pharmaciens_html.txt.txt,[],Other,France,Offer outline,,,-30.734938,-14.68614,0,"The content outlines various services and resources offered by Roche for healthcare professionals, particularly physicians and pharmacists. It provides information on medications, medical inquiries, scheduling appointments with product specialists, and access to therapeutic areas such as oncology and neurology. The purpose is to assist professionals in their daily practices, offering support through expert guidance, updates on events, and contact information for customer service and technical assistance. Additionally, it encourages communication regarding product quality and adverse effects to enhance safety and efficacy in healthcare.","oncology, professionals, data",rochepro.fr,Rising,0.767290563440045,high,14,General Offer Outline
775,https://rochepro.fr/pharmaciens/rupture-chaine-froid.html,10,rochepro_fr_pharmaciens_rupture_chaine_froid_html.txt,200,html,Indexable,2,53,354,1099,104,101,1,rochepro_fr_pharmaciens_rupture_chaine_froid_html.txt,image/rochepro_fr_pharmaciens_rupture_chaine_froid_html.txt.png,text/rochepro_fr_pharmaciens_rupture_chaine_froid_html.txt.txt,"['France', 'Monaco']",Other,France,Offer outline,,,-26.123426,-28.428268,0,"The content serves as a comprehensive guide for healthcare professionals, particularly doctors and pharmacists, regarding Roche’s pharmaceutical products and services. It provides resources for learning about medications, scheduling appointments with product specialists, and addressing medical or pharmaceutical inquiries. The content also outlines protocols for managing issues like cold chain breaks and reporting quality defects or adverse effects. Additionally, it emphasizes ongoing communication and support through their customer service and medical information departments, reinforcing Roche's commitment to healthcare professionals in France and Monaco.","oncology, professionals, data",rochepro.fr,All,0.884956378737685,high,357,General Offer Outline
776,https://rochepro.fr/pharmaciens/signaler-defaut-qualite.html,7,rochepro_fr_pharmaciens_signaler_defaut_qualite_html.txt,200,html,Indexable,1,56,0,916,134,131,0.96551724137931,rochepro_fr_pharmaciens_signaler_defaut_qualite_html.txt.txt,image/rochepro_fr_pharmaciens_signaler_defaut_qualite_html.txt.txt.png,text/rochepro_fr_pharmaciens_signaler_defaut_qualite_html.txt.txt.txt,[],Other,France,Offer outline,,,-0.434397,-31.1603,1,"The content highlights a section on Roche's professional website aimed at pharmacists, focusing on reporting quality issues with Roche products. It provides instructions for downloading and filling out a quality defect report form, which can be sent via email or fax to Roche's quality unit. Additionally, contact information for further inquiries is available, ensuring pharmacists have the necessary resources for addressing product-related concerns.","drug, reporting, adverse",rochepro.fr,All,0.341690721619373,high,399,Drug Safety
777,https://rochepro.fr/search.html,7,rochepro_fr_search_html.txt,200,html,Non-Indexable,,19,0,814,1,1,1,rochepro_fr_search_html.txt,image/rochepro_fr_search_html.txt.png,text/rochepro_fr_search_html.txt.txt,[],Other,France,Metainformation,,,-4.494297,-24.217016,3,"The content displays a search results page from the RochePro website, indicating that no results were found for the search query entered. The message suggests checking the spelling or trying different keywords. This page likely serves healthcare professionals looking for specific information about Roche's products or services.","users, page, website",rochepro.fr,All,0.495361622420487,high,17,Website Metadata
778,https://rochepro.fr/services-transverses/90-secondes/alimenter-profil-linkedin.html,9,rochepro_fr_services_transverses_90_secondes_alimenter_profil_linkedin_html.txt,200,html,Indexable,,29,126,1199,6,4,1,rochepro_fr_services_transverses_90_secondes_alimenter_profil_linkedin_html.txt,image/rochepro_fr_services_transverses_90_secondes_alimenter_profil_linkedin_html.txt.png,text/rochepro_fr_services_transverses_90_secondes_alimenter_profil_linkedin_html.txt.txt,[],Other,France,Offer outline,,,-27.08877,-17.677202,0,"The content appears to be a resource for healthcare professionals regarding Roche's pharmaceutical products and services. It provides information on various therapeutic areas such as neurology, hematology, and oncology, and offers opportunities for medical professionals, including scheduling consultations with product specialists and asking medical or pharmaceutical questions. Additionally, it includes guidance on utilizing LinkedIn effectively for professional networking and engagement. Overall, the purpose is to support healthcare professionals in accessing information and enhancing their professional presence while facilitating communication with Roche.","oncology, professionals, data",rochepro.fr,Falling,0.615254312021036,high,484,General Offer Outline
779,https://rochepro.fr/services-transverses/90-secondes/animer-reseau-de-pairs.html,9,rochepro_fr_services_transverses_90_secondes_animer_reseau_de_pairs_html.txt,200,html,Indexable,,62,131,1206,6,4,1,rochepro_fr_services_transverses_90_secondes_animer_reseau_de_pairs_html.txt,image/rochepro_fr_services_transverses_90_secondes_animer_reseau_de_pairs_html.txt.png,text/rochepro_fr_services_transverses_90_secondes_animer_reseau_de_pairs_html.txt.txt,[],Other,France,Offer outline,,,-11.234335,-18.128828,3,"The content primarily targets healthcare professionals, including physicians and pharmacists, providing resources related to Roche's pharmaceutical products and services. It emphasizes the importance of building professional networks, leveraging social media, and encourages engagement through consultations with specialists, medical inquiries, and updates on therapeutic areas. The content also outlines company support for healthcare professionals, including customer service and pharmacovigilance. Overall, it serves as a platform for education, collaboration, and professional development within the medical community.","users, page, website",rochepro.fr,Rising,0.795508970150637,high,438,Website Metadata
780,https://rochepro.fr/services-transverses/90-secondes/comment-organiser-veille-scientifique-medecine.html,9,rochepro_fr_services_transverses_90_secondes_comment_organiser_veille_scientifique_medecine_html.txt,200,html,Indexable,,43,107,2526,7,5,1,rochepro_fr_services_transverses_90_secondes_comment_organiser_veille_scientifique_medecine_html.txt,image/rochepro_fr_services_transverses_90_secondes_comment_organiser_veille_scientifique_medecine_html.txt.png,text/rochepro_fr_services_transverses_90_secondes_comment_organiser_veille_scientifique_medecine_html.txt.txt,['COVID'],Other,France,Offer outline,,,1.9992079,3.223457,7,"The content outlines various strategies and resources for medical professionals to effectively engage in scientific literature surveillance, particularly in the context of rapidly changing medical information due to recent trends like the COVID-19 pandemic. It highlights automated subscription options, participation in expert-led reviews, engagement with peers, social media involvement, and collaboration in scientific journals as key practices for staying informed. The purpose is to assist healthcare providers in enhancing their professional development and ensuring they can navigate and utilize the wealth of medical literature available to them efficiently. Additionally, it emphasizes Roche's commitment to supporting medical professionals through various channels, including specialist consultations and pharmaceutical inquiries.","event, exclusive, website",rochepro.fr,Falling,0.88164849432159,high,415,Events & Patient Care
781,https://rochepro.fr/services-transverses/90-secondes/consultation-distance-etes-vous-bien-proteges.html,9,rochepro_fr_services_transverses_90_secondes_consultation_distance_etes_vous_bien_proteges_html.txt,200,html,Indexable,,43,159,1197,4,2,1,rochepro_fr_services_transverses_90_secondes_consultation_distance_etes_vous_bien_proteges_html.txt,image/rochepro_fr_services_transverses_90_secondes_consultation_distance_etes_vous_bien_proteges_html.txt.png,text/rochepro_fr_services_transverses_90_secondes_consultation_distance_etes_vous_bien_proteges_html.txt.txt,[],Other,France,Offer outline,,,-21.024908,-22.722744,0,"The content primarily focuses on providing medical professionals, specifically physicians and pharmacists, with information about Roche's pharmaceutical products and services. It outlines a variety of resources available for inquiry, including scheduling meetings with product specialists, asking medical questions, and accessing medical information. Additionally, it emphasizes teleconsultation practices, offering guidelines on maintaining confidentiality during virtual consultations. Overall, the content serves as a comprehensive resource for healthcare professionals engaging with Roche, ensuring they have the necessary support and information related to their therapeutic areas and services.","oncology, professionals, data",rochepro.fr,Falling,0.398474692835282,high,290,General Offer Outline
782,https://rochepro.fr/services-transverses/90-secondes/creer-profil-linkedin.html,9,rochepro_fr_services_transverses_90_secondes_creer_profil_linkedin_html.txt,200,html,Indexable,,62,151,1170,6,4,1,rochepro_fr_services_transverses_90_secondes_creer_profil_linkedin_html.txt,image/rochepro_fr_services_transverses_90_secondes_creer_profil_linkedin_html.txt.png,text/rochepro_fr_services_transverses_90_secondes_creer_profil_linkedin_html.txt.txt,[],Other,France,Offer outline,,,-21.331121,-21.874413,0,"The content outlines resources and services offered by Roche for healthcare professionals, including doctors and pharmacists. It emphasizes the company's commitment to providing medical information, facilitating appointments with product specialists, and addressing pharmaceutical inquiries. Additionally, it highlights the importance of networking and professional development on platforms like LinkedIn, offering guidance on creating an effective profile. Overall, the purpose is to support healthcare professionals in accessing Roche's products and services while fostering community engagement and ongoing education in the medical field.","oncology, professionals, data",rochepro.fr,Flat,0.49006521060667,high,174,General Offer Outline
783,https://rochepro.fr/services-transverses/90-secondes.html,6,rochepro_fr_services_transverses_90_secondes_html.txt,200,html,Indexable,,53,0,1710,16,14,1,rochepro_fr_services_transverses_90_secondes_html.txt,image/rochepro_fr_services_transverses_90_secondes_html.txt.png,text/rochepro_fr_services_transverses_90_secondes_html.txt.txt,['Featured'],Other,France,Technology,,,22.813921,13.871075,4,"The content highlights a section titled ""90 seconds: the minute 30 that makes a difference,"" aimed at providing quick insights for healthcare professionals. It emphasizes digital tools and solutions for scientific engagement and networking. Featured topics include scientific vigilance solutions and tips for enhancing LinkedIn profiles to connect with peers in the health sector. The content seems geared toward facilitating professional development and improving communication in the medical field.","technologies, artificial, ai",rochepro.fr,Rising,0.0143897982955707,medium,191,Technology
784,https://rochepro.fr/services-transverses/90-secondes/prerequis-reunion-en-ligne-efficace.html,9,rochepro_fr_services_transverses_90_secondes_prerequis_reunion_en_ligne_efficace_html.txt,200,html,Indexable,,34,138,1039,4,2,0.978021978021978,rochepro_fr_services_transverses_90_secondes_prerequis_reunion_en_ligne_efficace_html.txt.txt,image/rochepro_fr_services_transverses_90_secondes_prerequis_reunion_en_ligne_efficace_html.txt.txt.png,text/rochepro_fr_services_transverses_90_secondes_prerequis_reunion_en_ligne_efficace_html.txt.txt.txt,[],Other,France,Other,,,24.526684,14.56554,4,"The content discusses the prerequisites for conducting effective online meetings, specifically in the context of videoconferencing. It emphasizes the importance of preparation for smooth execution, addressing both technical and organizational aspects. The content serves as a resource for professionals to enhance their virtual meeting skills. Additionally, there are contact details for inquiries related to medical and pharmaceutical questions.","technologies, artificial, ai",rochepro.fr,Falling,0.745928210107566,high,461,Technology
785,https://rochepro.fr/services-transverses/90-secondes/teleconsultation-mode-emploi.html,9,rochepro_fr_services_transverses_90_secondes_teleconsultation_mode_emploi_html.txt,200,html,Indexable,,38,156,1286,6,4,1,rochepro_fr_services_transverses_90_secondes_teleconsultation_mode_emploi_html.txt,image/rochepro_fr_services_transverses_90_secondes_teleconsultation_mode_emploi_html.txt.png,text/rochepro_fr_services_transverses_90_secondes_teleconsultation_mode_emploi_html.txt.txt,"['Specifically', 'Laurent', 'COVID', 'Zelek', 'Professor']",Oncology-Hematology,France,Technology,"teleconsultation, cancer, chronic conditions","cancer, chronic conditions",28.374384,12.718493,4,"The content focuses on the topic of teleconsultation, sharing insights and experiences from a healthcare professional about its implementation during and after the COVID-19 pandemic. Specifically, it features a testimonial from Professor Laurent Zelek, an oncologist, who discusses the impact of teleconsultation on patient care, especially for those with cancer or chronic conditions. The page aims to inform healthcare professionals about the value of teleconsultation in modern medical practice.","technologies, artificial, ai",rochepro.fr,Rising,0.923672116663266,high,45,Technology
786,https://rochepro.fr/services-transverses/90-secondes/teleconsultation-nouvelle-relation-patient.html,9,rochepro_fr_services_transverses_90_secondes_teleconsultation_nouvelle_relation_patient_html.txt,200,html,Indexable,,47,128,1191,5,3,1,rochepro_fr_services_transverses_90_secondes_teleconsultation_nouvelle_relation_patient_html.txt,image/rochepro_fr_services_transverses_90_secondes_teleconsultation_nouvelle_relation_patient_html.txt.png,text/rochepro_fr_services_transverses_90_secondes_teleconsultation_nouvelle_relation_patient_html.txt.txt,[],Other,France,Patient support,,,-18.306164,-20.395264,0,"The content outlines the services and resources available from Roche for healthcare professionals, particularly focusing on medications and support for various therapeutic areas such as neurology, oncology, and hematology. It emphasizes the importance of maintaining communication between physicians and patients through teleconsultation and provides avenues for healthcare professionals to ask questions, schedule specialist meetings, and access medical information. Additionally, it mentions support services like pharmacovigilance and the management of cold chain disruptions, highlighting Roche’s commitment to patient care and professional assistance in the medical field.","oncology, professionals, data",rochepro.fr,Rising,0.0815402304907756,high,225,General Offer Outline
787,https://rochepro.fr/services-transverses/90-secondes/teleconsultation-ou-en-est-on.html,9,rochepro_fr_services_transverses_90_secondes_teleconsultation_ou_en_est_on_html.txt,200,html,Indexable,,68,156,1416,7,5,1,rochepro_fr_services_transverses_90_secondes_teleconsultation_ou_en_est_on_html.txt,image/rochepro_fr_services_transverses_90_secondes_teleconsultation_ou_en_est_on_html.txt.png,text/rochepro_fr_services_transverses_90_secondes_teleconsultation_ou_en_est_on_html.txt.txt,['COVID'],Other,France,Offer outline,,,-28.446718,-1.3766145,0,"The content provides an overview of Roche's services and resources tailored for healthcare professionals, particularly focusing on therapeutic areas such as neurology, oncology, and rare diseases. It emphasizes the availability of medications, the option for physicians and pharmacists to consult specialists, and resources for medical inquiries. Additionally, it discusses the rise of teleconsultation practices during the COVID-19 pandemic, outlining its implementation, benefits, and requirements for reimbursement. The purpose of the content is to assist healthcare providers in accessing crucial information and support related to Roche's pharmaceutical offerings and services.","oncology, professionals, data",rochepro.fr,Rising,0.455860112494722,high,138,General Offer Outline
788,https://rochepro.fr/services-transverses/90-secondes/teleconsultation-quelle-plateforme-utiliser.html,9,rochepro_fr_services_transverses_90_secondes_teleconsultation_quelle_plateforme_utiliser_html.txt,200,html,Indexable,,60,164,1187,6,4,1,rochepro_fr_services_transverses_90_secondes_teleconsultation_quelle_plateforme_utiliser_html.txt,image/rochepro_fr_services_transverses_90_secondes_teleconsultation_quelle_plateforme_utiliser_html.txt.png,text/rochepro_fr_services_transverses_90_secondes_teleconsultation_quelle_plateforme_utiliser_html.txt.txt,[],Other,France,Patient support,,,-18.300224,-22.340837,0,"The content of the content is focused on providing various resources and services for healthcare professionals regarding Roche's pharmaceuticals. It offers information on specific medical conditions, guidance for both physicians and pharmacists, opportunities to consult with product specialists, and support for teleconsultation practices. The content also emphasizes Roche's commitment to addressing medical inquiries, providing quality assurance, and facilitating access to therapies across different medical fields, such as oncology and neurology. Additionally, it includes practical details for engaging in telemedicine, underscoring its growing importance in healthcare delivery.","oncology, professionals, data",rochepro.fr,Flat,0.0987911845695357,high,390,General Offer Outline
789,https://rochepro.fr/services-transverses/90-secondes/tout-savoir-veille-scientifique-medecine.html,9,rochepro_fr_services_transverses_90_secondes_tout_savoir_veille_scientifique_medecine_html.txt,200,html,Indexable,,38,157,2340,6,4,1,rochepro_fr_services_transverses_90_secondes_tout_savoir_veille_scientifique_medecine_html.txt,image/rochepro_fr_services_transverses_90_secondes_tout_savoir_veille_scientifique_medecine_html.txt.png,text/rochepro_fr_services_transverses_90_secondes_tout_savoir_veille_scientifique_medecine_html.txt.txt,[],Other,France,Technology,,,1.5970658,2.6353745,7,"The content primarily discusses the importance of scientific vigilance in the medical field, focusing on the continuous surveillance of medical literature and innovations for healthcare professionals. It outlines the challenges faced by doctors in keeping up with the rapidly expanding medical knowledge and emphasizes the need for effective strategies and automated tools to facilitate this ongoing education. The content also promotes Roche's services and support for healthcare professionals, including direct access to product specialists, medical information resources, and tools to enhance their practice. Overall, the purpose of the content is to inform and assist medical practitioners in improving patient care through better access to and understanding of scientific research and developments.","event, exclusive, website",rochepro.fr,All,0.650158418283441,high,410,Events & Patient Care
790,https://rochepro.fr/services-transverses/90-secondes/veille-medicale-six-solutions-innovantes-pratiques.html,9,rochepro_fr_services_transverses_90_secondes_veille_medicale_six_solutions_innovantes_pratiques_html.txt,200,html,Indexable,,30,126,2001,7,5,0.981132075471698,rochepro_fr_services_transverses_90_secondes_veille_medicale_six_solutions_innovantes_pratiques_html.txt.txt,image/rochepro_fr_services_transverses_90_secondes_veille_medicale_six_solutions_innovantes_pratiques_html.txt.txt.png,text/rochepro_fr_services_transverses_90_secondes_veille_medicale_six_solutions_innovantes_pratiques_html.txt.txt.txt,"['Medscape', 'Juisci']",Other,France,Offer outline,,,-26.998232,-18.699457,0,"The content primarily serves as an informational resource for healthcare professionals, particularly focusing on Roche's pharmaceutical offerings and support services. It provides insights into various therapeutic areas and highlights tools and solutions for medical professionals, such as Medscape and Juisci, that assist in scientific literature monitoring. The content emphasizes Roche's commitment to providing medical information, facilitating contact with specialists, and supporting practitioners in their daily clinical decisions and research needs. Additionally, it encourages users to engage with resources for improving their scientific vigilance in medicine.","oncology, professionals, data",rochepro.fr,Rising,0.850165934749215,high,104,General Offer Outline
791,https://rochepro.fr/services-transverses/90-secondes/veille-scientifique-conseils-pro.html,9,rochepro_fr_services_transverses_90_secondes_veille_scientifique_conseils_pro_html.txt,200,html,Indexable,,36,133,1189,7,5,1,rochepro_fr_services_transverses_90_secondes_veille_scientifique_conseils_pro_html.txt,image/rochepro_fr_services_transverses_90_secondes_veille_scientifique_conseils_pro_html.txt.png,text/rochepro_fr_services_transverses_90_secondes_veille_scientifique_conseils_pro_html.txt.txt,[],Other,France,Offer outline,,,-25.445686,-21.2119,0,"The content is centered around Roche's offerings for healthcare professionals, particularly focusing on their medical and pharmaceutical products. It emphasizes the support provided to both physicians and pharmacists, including resources for medical inquiries, scheduling consultations with product specialists, and updates on therapeutic areas. The content also highlights Roche's commitment to facilitating scientific vigilance and efficient informational practices through various digital solutions. Overall, the purpose is to serve as a resource hub for healthcare professionals, enhancing their engagement with Roche’s products and therapeutic solutions.","oncology, professionals, data",rochepro.fr,Falling,0.916046328656737,high,332,General Offer Outline
792,https://rochepro.fr/services-transverses/iis.html,7,rochepro_fr_services_transverses_iis_html.txt,200,html,Indexable,,43,0,1291,3,1,1,rochepro_fr_services_transverses_iis_html.txt,image/rochepro_fr_services_transverses_iis_html.txt.png,text/rochepro_fr_services_transverses_iis_html.txt.txt,['IIS'],Other,France,Offer outline,,,-27.227446,-20.139572,0,"The content outlines services and information offered by Roche, specifically targeted at healthcare professionals such as physicians and pharmacists. It covers various aspects, including access to medications, interactions with product specialists, and the processes for submitting investigator-initiated studies (IIS) related to Roche's products. The content emphasizes Roche's commitment to supporting research that enhances the understanding and use of its therapies, as well as providing necessary information and assistance for medical inquiries and pharmacovigilance. The content serves to engage medical professionals by offering resources and facilitating communication with Roche's support teams.","oncology, professionals, data",rochepro.fr,Rising,0.447701242888585,high,484,General Offer Outline
793,https://rochepro.fr/services-transverses/voix-des-patients.html,6,rochepro_fr_services_transverses_voix_des_patients_html.txt,200,html,Indexable,,17,0,1427,3,1,1,rochepro_fr_services_transverses_voix_des_patients_html.txt,image/rochepro_fr_services_transverses_voix_des_patients_html.txt.png,text/rochepro_fr_services_transverses_voix_des_patients_html.txt.txt,"['Patients', 'Voix']",Other,France,Patient support,,,-20.103998,-23.18719,0,"The content primarily focuses on providing medical professionals and pharmacists with resources related to Roche's medicinal products and services. It emphasizes information about specific therapeutic areas, the role of Roche in patient care, and communication platforms like ""Voix des Patients,"" which facilitates patient engagement and support for those with chronic diseases. Additionally, it offers services such as scheduling consultations, posing medical questions, and maintaining quality assurance in pharmaceuticals. The overall purpose is to enhance collaboration between Roche, healthcare providers, and patients while promoting access to critical health-related information.","oncology, professionals, data",rochepro.fr,All,0.49474626684731,medium,208,General Offer Outline
794,https://rochepro.fr/termes-et-conditions.html,8,rochepro_fr_termes_et_conditions_html.txt,200,html,Indexable,1,34,0,3433,643,640,0.953488372093023,rochepro_fr_termes_et_conditions_html.txt.txt,image/rochepro_fr_termes_et_conditions_html.txt.txt.png,text/rochepro_fr_termes_et_conditions_html.txt.txt.txt,"['France', 'Monaco']",Other,France,Metainformation,,,-8.729632,-23.095293,3,"The content primarily outlines the purpose and regulations of a website operated by Roche, aimed at healthcare professionals in France and Monaco. It details various sections of the site including information about Roche's medications, guidelines for engaging with specialists, the process for reporting adverse effects, and the site's policies concerning data protection and intellectual property. The purpose of this content is to inform healthcare providers about Roche's pharmaceutical offerings while ensuring compliance with legal and regulatory standards in health communication and advertising. Additionally, it outlines user responsibilities and the interface's accessibility, emphasizing that it is not a substitute for professional medical advice.","users, page, website",rochepro.fr,All,0.538666603028124,high,42,Website Metadata
795,https://rochepro.fr/visite/digital-business-card.html,6,rochepro_fr_visite_digital_business_card_html.txt,200,html,Non-Indexable,,21,0,803,1,1,1,rochepro_fr_visite_digital_business_card_html.txt,image/rochepro_fr_visite_digital_business_card_html.txt.png,text/rochepro_fr_visite_digital_business_card_html.txt.txt,"['Contact', 'France', 'Assistance']",Other,France,Offer outline,,,-21.288305,-16.699194,0,"The content showcases a section of the RochePro website, focusing on a ""dematerialized business card."" It offers various professional resources related to Roche's pharmaceuticals and services, including ""Contact & Assistance"" for medical information, customer service, and pharmacovigilance for reporting adverse effects. Additionally, it highlights therapeutic areas such as ophthalmology, oncology, and neurology, along with Roche’s operations in France. The content aims to facilitate access to essential information and support for healthcare professionals.","oncology, professionals, data",rochepro.fr,All,0.495706832417926,medium,472,General Offer Outline
796,https://rochepro.fr/visite/suivi-cancer-bronchique.html,6,rochepro_fr_visite_suivi_cancer_bronchique_html.txt,200,html,Non-Indexable,,78,0,924,1,1,1,rochepro_fr_visite_suivi_cancer_bronchique_html.txt,image/rochepro_fr_visite_suivi_cancer_bronchique_html.txt.png,text/rochepro_fr_visite_suivi_cancer_bronchique_html.txt.txt,['These'],Immunology,France,Patient support,,,26.980778,0.76362586,4,"The content presents resources aimed at healthcare professionals for monitoring patients undergoing immunotherapy. It features downloadable documents, including a routine assessment guide and a follow-up questionnaire. These tools are designed to assist in identifying necessary examinations before and during treatment, as well as managing potential side effects effectively. The materials emphasize improving patient care through structured monitoring frameworks.","technologies, artificial, ai",rochepro.fr,Falling,0.663705821382894,medium,327,Technology
797,https://rochepro.fr/visite/tecentriq-mecanisme-action.html,6,rochepro_fr_visite_tecentriq_mecanisme_action_html.txt,200,html,Non-Indexable,,30,0,803,1,1,1,rochepro_fr_visite_tecentriq_mecanisme_action_html.txt,image/rochepro_fr_visite_tecentriq_mecanisme_action_html.txt.png,text/rochepro_fr_visite_tecentriq_mecanisme_action_html.txt.txt,['Tecentriq'],Oncology-Hematology,France,Medication information,"Tecentriq, hepatocarcinoma, mechanism of action","hepatocarcinoma, liver cancer",14.75418,-24.67969,1,"The content features a section about Tecentriq®, a medication by Roche, specifically focused on its application for hepatocarcinoma (liver cancer). It highlights the ""mechanism of action"" of Tecentriq®, suggesting that there is a video available for further explanation. The content is designed for healthcare professionals seeking detailed information on this treatment option.","drug, reporting, adverse",rochepro.fr,Falling,0.360665668803306,medium,280,Drug Safety
798,https://rochepro.fr/visite/wikiboop.html,7,rochepro_fr_visite_wikiboop_html.txt,200,html,Non-Indexable,,8,0,843,1,1,0.947368421052632,rochepro_fr_visite_wikiboop_html.txt.txt,image/rochepro_fr_visite_wikiboop_html.txt.txt.png,text/rochepro_fr_visite_wikiboop_html.txt.txt.txt,['Wikiboop'],Oncology-Hematology,France,Patient support,"breast cancer, Wikiboop, downloadable materials, promotional flyers, treatment process",breast cancer,2.5570567,-6.3792872,7,"The content presents a section of Roche's professional website dedicated to a tool called ""Wikiboop,"" which appears to assist breast cancer patients in managing their healthcare journey. It offers various downloadable materials, including promotional flyers for healthcare professionals and patients, as well as a video introduction. The content focuses on providing information and resources to support patients in navigating their treatment process effectively.","event, exclusive, website",rochepro.fr,Rising,0.207113523983033,high,91,Events & Patient Care
799,https://www.rocheplus.es/?namespace=s7viewers,11,www_rocheplus_es__namespace_s7viewers.txt,200,,Non-Indexable,1,49,131,1931,31,1,1,www_rocheplus_es__namespace_s7viewers.txt,image/www_rocheplus_es__namespace_s7viewers.txt.png,text/www_rocheplus_es__namespace_s7viewers.txt.txt,[],Other,Spain,Technology,,,-26.679642,-19.15428,0,"The content presents Roche's online portal for healthcare professionals, emphasizing access to exclusive and updated information on pharmaceuticals, medical conditions, and professional resources. It highlights various features, including new product launches, live events, webinars, and a dedicated app for easy access to information. The portal aims to foster innovation and education in precision medicine, showcasing studies related to various health issues and offering specialized courses for healthcare professionals. Additionally, it indicates Roche's commitment to providing scientific answers and insights into therapeutic areas, ultimately enhancing patient care and treatment options.","oncology, professionals, data",www.rocheplus.es,Falling,0.537114260857541,high,401,General Offer Outline
800,https://www.rocheplus.es/,11,www_rocheplus_es_.txt,200,,Indexable,0,49,131,1931,1672,410,1,www_rocheplus_es_.txt,image/www_rocheplus_es_.txt.png,text/www_rocheplus_es_.txt.txt,[],Oncology-Hematology,Spain,Offer outline,,,-24.774338,-5.9645705,0,"The content provides an overview of Roche's online portal specifically designed for healthcare professionals. It highlights various resources available, including information on new drug launches, cancer research, webinars, and other educational materials. The portal emphasizes Roche's focus on precision medicine and ongoing innovation in healthcare, while also featuring sections on specific therapeutic areas and opportunities for professional collaboration and training. The purpose is to equip healthcare professionals with the latest scientific knowledge and tools to enhance patient care.","oncology, professionals, data",www.rocheplus.es,Rising,0.97968438262194,high,163,General Offer Outline
801,https://www.rocheplus.es/app-roche.html,11,www_rocheplus_es_app_roche_html.txt,200,,Non-Indexable,1,10,154,958,16,6,0.945945945945946,www_rocheplus_es_app_roche_html.txt.txt,image/www_rocheplus_es_app_roche_html.txt.txt.png,text/www_rocheplus_es_app_roche_html.txt.txt.txt,[],Other,Spain,Technology,,,-6.1249704,-16.101637,3,"The content presents an overview of the Roche+ app designed for healthcare professionals. It emphasizes accessibility and direct contact with Roche's services, offering a platform for updates and educational resources. The app features sections for training and events, allowing users to access a variety of formatted content and participate in webinars tailored to their specialties. A prompt to download the app and register for exclusive content is prominently displayed.","users, page, website",www.rocheplus.es,All,0.0699287721635316,high,228,Website Metadata
802,https://www.rocheplus.es/areas-terapeuticas/covid-19.html,10,www_rocheplus_es_areas_terapeuticas_covid_19_html.txt,200,,Indexable,1,38,147,921,937,410,1,www_rocheplus_es_areas_terapeuticas_covid_19_html.txt,image/www_rocheplus_es_areas_terapeuticas_covid_19_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_covid_19_html.txt.txt,['COVID'],Other,Spain,Research,,,-11.560483,-11.2708845,0,"The content of the content focuses on Roche's commitment to addressing COVID-19. It emphasizes the company's efforts during the pandemic to minimize the impact on affected individuals and support healthcare professionals. The content highlights initiatives related to research, diagnostics, treatments, and vaccine development, showcasing Roche's role in combating the virus and facilitating access to scientific resources and support.","oncology, professionals, data",www.rocheplus.es,Flat,0.431301770457263,high,84,General Offer Outline
803,https://www.rocheplus.es/areas-terapeuticas/covid-19/patologia.html,10,www_rocheplus_es_areas_terapeuticas_covid_19_patologia_html.txt,200,,Indexable,1,20,148,2321,902,410,1,www_rocheplus_es_areas_terapeuticas_covid_19_patologia_html.txt,image/www_rocheplus_es_areas_terapeuticas_covid_19_patologia_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_covid_19_patologia_html.txt.txt,"['COVID', 'SARS']",Other,Spain,Disease information,"COVID-19, SARS-CoV-2, quarantine, asymptomatic cases, symptomatic cases",COVID-19,27.638393,-0.32247064,4,"The content provides an in-depth overview of COVID-19, detailing the virus responsible (SARS-CoV-2), its origins, transmission methods, incubation period, symptoms, and the evolution of the disease. It highlights the implications for public health, such as the need for quarantine and the characteristics of both asymptomatic and symptomatic cases. The content is geared towards healthcare professionals, aiming to inform them about the clinical aspects and epidemiological data related to COVID-19, while also referencing scientific studies and statistics to support the findings.","technologies, artificial, ai",www.rocheplus.es,Rising,0.635160600395836,high,23,Technology
804,https://www.rocheplus.es/areas-terapeuticas/covid-19/variantes.html,10,www_rocheplus_es_areas_terapeuticas_covid_19_variantes_html.txt,200,,Indexable,1,20,146,3085,902,410,1,www_rocheplus_es_areas_terapeuticas_covid_19_variantes_html.txt,image/www_rocheplus_es_areas_terapeuticas_covid_19_variantes_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_covid_19_variantes_html.txt.txt,"['COVID', 'SARS']",Other,Spain,Disease information,"COVID-19 variants, genomic sequencing, SARS-CoV-2",,29.14778,-2.0129325,4,"The content discusses various COVID-19 variants, particularly focusing on their characteristics, impact on public health, and the importance of genomic sequencing for monitoring these mutations. It details how different variants might affect transmissibility, severity, vaccine efficacy, and treatment responses. Moreover, it classifies variants into categories based on their potential health impact and suggests public health actions for surveillance and containment. Overall, the content aims to inform health professionals about the evolving nature of SARS-CoV-2 and the implications for public health strategies.","technologies, artificial, ai",www.rocheplus.es,Falling,0.0749892760356213,high,450,Technology
805,https://www.rocheplus.es/areas-terapeuticas/farmacia-hospitalaria.html?namespace=s7viewers,7,www_rocheplus_es_areas_terapeuticas_farmacia_hospitalaria_html_namespace_s7viewers.txt,200,,Non-Indexable,2,21,0,1021,2,1,0.977272727272727,www_rocheplus_es_areas_terapeuticas_farmacia_hospitalaria_html_namespace_s7viewers.txt.txt,image/www_rocheplus_es_areas_terapeuticas_farmacia_hospitalaria_html_namespace_s7viewers.txt.txt.png,text/www_rocheplus_es_areas_terapeuticas_farmacia_hospitalaria_html_namespace_s7viewers.txt.txt.txt,"['Farma', 'Various']",Other,Spain,Offer outline,,,-9.2778225,-20.088774,3,"The content features a section of Roche's website aimed at healthcare professionals, highlighting ""Farma+"", a dedicated space for hospital pharmacy. It emphasizes Roche's services and resources for health practitioners, inviting them to register for exclusive content. The design includes images of two professionals, reinforcing the focus on pharmacy and healthcare collaboration. Various therapeutic areas are also listed, indicating the breadth of Roche's offerings in the pharmaceutical sector.","users, page, website",www.rocheplus.es,Falling,0.947997646949771,high,485,Website Metadata
806,https://www.rocheplus.es/areas-terapeuticas/farmacia-hospitalaria.html,7,www_rocheplus_es_areas_terapeuticas_farmacia_hospitalaria_html.txt,200,,Non-Indexable,1,21,0,1021,921,410,1,www_rocheplus_es_areas_terapeuticas_farmacia_hospitalaria_html.txt,image/www_rocheplus_es_areas_terapeuticas_farmacia_hospitalaria_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_farmacia_hospitalaria_html.txt.txt,['Farma'],Other,Spain,Offer outline,,,-9.276165,-19.9485,3,"The content features a section of Roche's website designed for healthcare professionals, specifically focused on hospital pharmacy. It highlights ""Farma+"", a dedicated space for resources and information tailored to hospital pharmacists. The visual elements, including images of two professionals, emphasize a modern and approachable design. The page also invites users to register for exclusive content related to Roche's services and therapeutic areas.","users, page, website",www.rocheplus.es,All,0.0268947379386296,high,424,Website Metadata
807,https://www.rocheplus.es/areas-terapeuticas/farmacia-hospitalaria/informacion_medica_fh.html,7,www_rocheplus_es_areas_terapeuticas_farmacia_hospitalaria_informacion_medica_fh_html.txt,200,,Non-Indexable,2,18,0,884,71,34,0.977777777777778,www_rocheplus_es_areas_terapeuticas_farmacia_hospitalaria_informacion_medica_fh_html.txt.txt,image/www_rocheplus_es_areas_terapeuticas_farmacia_hospitalaria_informacion_medica_fh_html.txt.txt.png,text/www_rocheplus_es_areas_terapeuticas_farmacia_hospitalaria_informacion_medica_fh_html.txt.txt.txt,[],Other,Spain,Offer outline,,,-9.167813,-19.210913,3,"The content features a section of Roche’s website aimed at healthcare professionals. It invites users to register for access to exclusive medical information and resources related to hospital pharmacy. The content emphasizes the importance of registration to view comprehensive materials, highlighting a professional focus and encouraging engagement with their services.","users, page, website",www.rocheplus.es,Flat,0.6349241566126,high,467,Website Metadata
808,https://www.rocheplus.es/areas-terapeuticas/hematologia/hemofilia.html,7,www_rocheplus_es_areas_terapeuticas_hematologia_hemofilia_html.txt,200,,Non-Indexable,1,44,0,996,889,410,1,www_rocheplus_es_areas_terapeuticas_hematologia_hemofilia_html.txt,image/www_rocheplus_es_areas_terapeuticas_hematologia_hemofilia_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_hematologia_hemofilia_html.txt.txt,"['Hemophilia', 'VIII']",Oncology-Hematology,Spain,Disease information,"Hemophilia A, F8 gene, factor VIII, blood coagulation, hemostasis",Hemophilia A,22.04257,-0.047720823,4,"The content features a webpage from Roche that focuses on Hemophilia A, providing information about this genetic bleeding disorder caused by mutations in the F8 gene, which affects factor VIII production. It explains the implications of Hemophilia A on blood coagulation and hemostasis, emphasizing its effects on the body’s ability to form clots and manage bleeding. The content is aimed at healthcare professionals, inviting them to register for exclusive access to further resources.","technologies, artificial, ai",www.rocheplus.es,Rising,0.964043067876705,high,90,Technology
809,https://www.rocheplus.es/areas-terapeuticas.html,11,www_rocheplus_es_areas_terapeuticas_html.txt,200,,Non-Indexable,1,27,147,1005,1354,410,0.956521739130435,www_rocheplus_es_areas_terapeuticas_html.txt.txt,image/www_rocheplus_es_areas_terapeuticas_html.txt.txt.png,text/www_rocheplus_es_areas_terapeuticas_html.txt.txt.txt,['COVID'],Other,Spain,Offer outline,,,-35.49967,-10.576904,0,"The content features Roche's professional portal, specifically highlighting various therapeutic areas such as oncology, neurology, hematology, ophthalmology, and rheumatology. It aims to provide healthcare professionals with comprehensive information and resources related to these specialties. Additionally, it includes sections on COVID-19 and hospital pharmacy, emphasizing the company's commitment to supporting healthcare providers with relevant tools and knowledge for patient care.","oncology, professionals, data",www.rocheplus.es,Falling,0.109300363630378,high,337,General Offer Outline
810,https://www.rocheplus.es/areas-terapeuticas/neumologia/fibrosis-pulmonar-idiopatica.html,7,www_rocheplus_es_areas_terapeuticas_neumologia_fibrosis_pulmonar_idiopatica_html.txt,200,,Non-Indexable,1,62,0,798,894,410,0.976744186046512,www_rocheplus_es_areas_terapeuticas_neumologia_fibrosis_pulmonar_idiopatica_html.txt.txt,image/www_rocheplus_es_areas_terapeuticas_neumologia_fibrosis_pulmonar_idiopatica_html.txt.txt.png,text/www_rocheplus_es_areas_terapeuticas_neumologia_fibrosis_pulmonar_idiopatica_html.txt.txt.txt,['FPI'],Other,Spain,Disease information,"idiopathic pulmonary fibrosis, symptoms, diagnostic methods, cancer",idiopathic pulmonary fibrosis,23.876205,-9.232298,12,"The content features a section focused on idiopathic pulmonary fibrosis (FPI) from Roche's professional healthcare website. It serves to educate healthcare professionals about the condition, including its definition, symptoms, diagnostic methods, and comparisons with cancer. The design includes visual elements depicting the lungs, promoting a deeper understanding of the disease's impact, and offers further information through a dedicated link for more resources.","cancer, breast, lung",www.rocheplus.es,Falling,0.494168373694642,high,309,Disease Information
811,https://www.rocheplus.es/areas-terapeuticas/neumologia.html,7,www_rocheplus_es_areas_terapeuticas_neumologia_html.txt,200,,Non-Indexable,1,40,0,987,934,410,1,www_rocheplus_es_areas_terapeuticas_neumologia_html.txt,image/www_rocheplus_es_areas_terapeuticas_neumologia_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_neumologia_html.txt.txt,[],Other,Spain,Offer outline,,,-6.2211037,-14.963628,3,"The content highlights Roche's commitment to patients and the field of pulmonology. It serves as a gateway for healthcare professionals, emphasizing the need for registration to access exclusive content related to therapeutic areas, particularly in respiratory health. The design combines informative content with a visual representation of care, promoting engagement with medical resources and events offered by Roche.","users, page, website",www.rocheplus.es,Flat,0.584422952234971,high,350,Website Metadata
812,https://www.rocheplus.es/areas-terapeuticas/neurologia/neurodegeneracion/enfermedad-de-alzheimer.html,10,www_rocheplus_es_areas_terapeuticas_neurologia_neurodegeneracion_enfermedad_de_alzheimer_html.txt,200,,Non-Indexable,1,57,201,1012,825,410,1,www_rocheplus_es_areas_terapeuticas_neurologia_neurodegeneracion_enfermedad_de_alzheimer_html.txt,image/www_rocheplus_es_areas_terapeuticas_neurologia_neurodegeneracion_enfermedad_de_alzheimer_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_neurologia_neurodegeneracion_enfermedad_de_alzheimer_html.txt.txt,['Alzheimer'],Neurology,Spain,Disease information,"Alzheimer's disease, neurodegenerative dementia, amyloid-beta plaques, neurofibrillary tangles, pathological tau",Alzheimer's disease,23.001925,26.956657,4,"The content focuses on Alzheimer's disease, describing it as a cerebral disorder characterized by memory deterioration, language issues, and changes in mood and behavior. It notes that Alzheimer's is the most common cause of neurodegenerative dementia in developed countries, with prevalence increasing with age. The content also highlights key characteristics of the disease, including the presence of amyloid-beta plaques and neurofibrillary tangles of pathological tau in the brain. This information appears to be part of a resource aimed at healthcare professionals.","technologies, artificial, ai",www.rocheplus.es,All,0.473426503325598,high,495,Technology
813,https://www.rocheplus.es/areas-terapeuticas/oncologia/abordaje-tumor-agnostico/consenso-ntrk-seom-seap-sehop.html,10,www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_consenso_ntrk_seom_seap_sehop_html.txt,200,,Non-Indexable,2,52,132,1138,61,12,0.981981981981982,www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_consenso_ntrk_seom_seap_sehop_html.txt.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_consenso_ntrk_seom_seap_sehop_html.txt.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_consenso_ntrk_seom_seap_sehop_html.txt.txt.txt,['NTRK'],Oncology-Hematology,Spain,Offer outline,,,26.542126,-11.545905,12,"The content features content aimed at healthcare professionals regarding the detection of NTRK gene alterations in solid tumors. It emphasizes the importance of understanding, identifying, and treating these specific tumor fusions. There are calls to action for professionals to register for exclusive content and access resources related to the topic. The design includes visual elements like illustrations of hands and healthcare professionals, highlighting a supportive and informative approach.","cancer, breast, lung",www.rocheplus.es,Rising,0.736549809613679,high,128,Disease Information
814,https://www.rocheplus.es/areas-terapeuticas/oncologia/abordaje-tumor-agnostico.html,10,www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_html.txt,200,,Indexable,1,57,175,1152,932,410,0.975308641975309,www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_html.txt.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_html.txt.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_html.txt.txt.txt,"['System', 'Spanish', 'National', 'Health']",Oncology-Hematology,Spain,Research,"precision medicine, tumor-agnostic therapies, oncology, molecular diagnostic techniques, next-generation sequencing, genomic alterations, targeted treatments",,35.65166,-16.59208,12,"The content discusses the advancements in precision medicine and tumor-agnostic therapies within oncology, emphasizing the shift in cancer treatment paradigms. It highlights the role of molecular diagnostic techniques, such as next-generation sequencing, in identifying specific genomic alterations that can guide targeted treatments regardless of tumor type or location. The purpose is to raise awareness among healthcare professionals about the challenges and opportunities presented by these innovative therapies in the Spanish National Health System. The content also promotes resources, expert insights, and subscription options for further updates in this evolving field.","cancer, breast, lung",www.rocheplus.es,All,0.994830345543089,high,316,Disease Information
815,https://www.rocheplus.es/areas-terapeuticas/oncologia/abordaje-tumor-agnostico/mas-informacion.html,10,www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_mas_informacion_html.txt,200,,Indexable,2,46,134,828,58,13,1,www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_mas_informacion_html.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_mas_informacion_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_mas_informacion_html.txt.txt,['Encuentrk'],Oncology-Hematology,Spain,Offer outline,,,0.930196,-4.623596,7,"The content features a section from Roche's professional healthcare website, emphasizing their commitment to precision medicine. It highlights a program called ""Encuentrk"" and invites healthcare professionals to register for access to exclusive content and expert consultations. The layout includes options for accessing existing accounts or creating new ones, as well as links to therapeutic areas and diagnostic information relevant to oncology. The overall aim is to facilitate communication and information sharing among medical professionals.","event, exclusive, website",www.rocheplus.es,Rising,0.813494892030293,high,101,Events & Patient Care
816,https://www.rocheplus.es/areas-terapeuticas/oncologia/abordaje-tumor-agnostico/ta-explained.html,7,www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_ta_explained_html.txt,200,,Indexable,2,21,0,1013,71,2,0.978723404255319,www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_ta_explained_html.txt.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_ta_explained_html.txt.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_ta_explained_html.txt.txt.txt,"['TA', 'Foncillas', 'Explained', 'Dr']",Oncology-Hematology,Spain,Research,,,35.15227,-17.232765,12,"The content presents content related to ""TA Explained,"" a segment focusing on precision oncology. It features insights from Dr. Jesús García-Foncillas on the importance of molecular diagnostics and agnostic tumor approaches, as well as their impact on clinical practices and future developments in oncology. The information is aimed at healthcare professionals, highlighting advancements in cancer treatment and research, and includes video resources for deeper understanding.","cancer, breast, lung",www.rocheplus.es,Rising,0.416410374614898,high,443,Disease Information
817,https://www.rocheplus.es/areas-terapeuticas/oncologia/abordaje-tumor-agnostico/tecnicas-diagnosticas.html,10,www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_tecnicas_diagnosticas_html.txt,200,,Indexable,2,60,155,1995,73,13,0.980582524271845,www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_tecnicas_diagnosticas_html.txt.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_tecnicas_diagnosticas_html.txt.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_abordaje_tumor_agnostico_tecnicas_diagnosticas_html.txt.txt.txt,"['NGS', 'NTRK']",Oncology-Hematology,Spain,Technology,"precision medicine, cancer management, next-generation sequencing, NTRK fusion genes, molecular tests, personalized oncology",,35.707317,-15.697101,12,"The content focuses on precision medicine and cancer management, highlighting the importance of identifying genetic and molecular characteristics in patients to provide tailored treatment options. It discusses advanced diagnostic techniques, particularly next-generation sequencing (NGS), and their role in detecting significant genetic alterations associated with cancers, including NTRK fusion genes. Additionally, it compares traditional molecular tests and outlines the advantages and disadvantages of various diagnostic methods, emphasizing their impact on personalized oncology. The purpose of this content is to inform healthcare professionals about the latest advancements in cancer diagnostics and treatment strategies, encouraging them to employ precision medicine in their practice.","cancer, breast, lung",www.rocheplus.es,Falling,0.588883934912533,high,223,Disease Information
818,https://www.rocheplus.es/areas-terapeuticas/oncologia/cancer-de-mama.html,7,www_rocheplus_es_areas_terapeuticas_oncologia_cancer_de_mama_html.txt,200,,Non-Indexable,1,47,0,891,887,410,1,www_rocheplus_es_areas_terapeuticas_oncologia_cancer_de_mama_html.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_cancer_de_mama_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_cancer_de_mama_html.txt.txt,[],Oncology-Hematology,Spain,Research,"breast cancer, oncology",breast cancer,1.3048619,-9.29138,7,"The content features a section from Roche's website focused on breast cancer. It offers healthcare professionals access to resources, tools, and updated information regarding breast cancer studies. The content emphasizes providing valuable insights and educational material to enhance professional knowledge in oncology, facilitating better patient care.","event, exclusive, website",www.rocheplus.es,Flat,0.107024363838972,high,245,Events & Patient Care
819,https://www.rocheplus.es/areas-terapeuticas/oncologia/cancer-genitourinario.html,7,www_rocheplus_es_areas_terapeuticas_oncologia_cancer_genitourinario_html.txt,200,,Non-Indexable,1,54,0,1171,898,410,1,www_rocheplus_es_areas_terapeuticas_oncologia_cancer_genitourinario_html.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_cancer_genitourinario_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_cancer_genitourinario_html.txt.txt,"['GU', 'Discover']",Oncology-Hematology,Spain,Disease information,"genitourinary cancers, renal cancer, bladder cancer, prostate cancer","renal cancer, bladder cancer, prostate cancer",7.2001977,-6.4801955,7,"The content features a section of Roche's website aimed at healthcare professionals. It highlights the ""GU Discover"" initiative, which focuses on information related to genitourinary cancers, including renal, bladder, and prostate cancer. The content emphasizes the availability of resources and exclusive access for registered professionals, promoting a comprehensive hub for education and insight into these specific cancer types. Additionally, the design incorporates visual elements that enhance navigation and engagement.","event, exclusive, website",www.rocheplus.es,Flat,0.327948527086918,high,23,Events & Patient Care
820,https://www.rocheplus.es/areas-terapeuticas/oncologia/cancer-pulmon.html,7,www_rocheplus_es_areas_terapeuticas_oncologia_cancer_pulmon_html.txt,200,,Non-Indexable,1,28,0,861,901,410,0.971428571428571,www_rocheplus_es_areas_terapeuticas_oncologia_cancer_pulmon_html.txt.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_cancer_pulmon_html.txt.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_cancer_pulmon_html.txt.txt.txt,[],Oncology-Hematology,Spain,Offer outline,,lung cancer,1.9655162,-10.129199,7,"The content showcases a section of Roche's professional website focused on lung cancer. It emphasizes the availability of comprehensive information and services related to lung cancer management and treatment. The content appears to target healthcare professionals, inviting them to register for exclusive access to further resources and details about their offerings in oncology.","event, exclusive, website",www.rocheplus.es,Falling,0.819504497792614,high,96,Events & Patient Care
821,https://www.rocheplus.es/areas-terapeuticas/oncologia/hepatocarcinoma.html,7,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_html.txt,200,,Indexable,1,27,0,803,909,410,0.972222222222222,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_html.txt.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_html.txt.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_html.txt.txt.txt,"['LIVER', 'CORNER']",Oncology-Hematology,Spain,Patient support,hepatocellular carcinoma,"hepatocellular carcinoma, liver cancer",4.8789945,-6.6613173,7,"The content features a section of a professional website dedicated to Roche, focusing on hepatocellular carcinoma. It includes a prominent title ""LIVER CORNER,"" indicating resources and connections for healthcare professionals dealing with liver cancer. The site offers access to a blog, a library, and a forum dedicated to liver-related topics, suggesting a network for sharing knowledge and best practices among professionals in the oncology field. Overall, the content promotes engagement and education regarding hepatocellular carcinoma.","event, exclusive, website",www.rocheplus.es,Rising,0.311857163826484,high,301,Events & Patient Care
822,https://www.rocheplus.es/areas-terapeuticas/oncologia/hepatocarcinoma/liver-forum/como-las-nuevas-tecnologias-ayudan-al-manejo-del-hepatocarcinoma.html,6,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_como_las_nuevas_tecnologias_ayudan_al_manejo_del_hepatocarcinoma_html.txt,200,,Non-Indexable,3,67,0,873,18,3,1,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_como_las_nuevas_tecnologias_ayudan_al_manejo_del_hepatocarcinoma_html.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_como_las_nuevas_tecnologias_ayudan_al_manejo_del_hepatocarcinoma_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_como_las_nuevas_tecnologias_ayudan_al_manejo_del_hepatocarcinoma_html.txt.txt,"['Liver', 'Forum']",Oncology-Hematology,Spain,Technology,,hepatocellular carcinoma,3.3817472,-5.975192,7,"The content features a section of Roche's professional website focusing on the ""Liver Forum."" It highlights the use of new technologies in managing hepatocellular carcinoma. The main elements include a registration prompt for healthcare professionals to access exclusive content and a video related to the topic. The page also lists various therapeutic areas, emphasizing Roche's commitment to providing resources for medical professionals.","event, exclusive, website",www.rocheplus.es,Falling,0.546757676124592,medium,451,Events & Patient Care
823,https://www.rocheplus.es/areas-terapeuticas/oncologia/hepatocarcinoma/liver-forum/cuales-son-los-retos-y-oportunidades-en-hcc.html,6,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_cuales_son_los_retos_y_oportunidades_en_hcc_html.txt,200,,Non-Indexable,3,45,0,910,20,3,0.984375,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_cuales_son_los_retos_y_oportunidades_en_hcc_html.txt.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_cuales_son_los_retos_y_oportunidades_en_hcc_html.txt.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_cuales_son_los_retos_y_oportunidades_en_hcc_html.txt.txt.txt,"['Liver', 'Forum', 'HCC']",Oncology-Hematology,Spain,Patient support,hepatocellular carcinoma (HCC),hepatocellular carcinoma,4.626127,-5.6702123,7,"The content features a section of a website dedicated to Roche, highlighting the ""Liver Forum."" This forum focuses on resources and discussions related to hepatocellular carcinoma (HCC), addressing challenges and opportunities in the field. Additionally, there are video resources available for registered healthcare professionals. The site emphasizes engagement with its audience by encouraging professionals to register for exclusive content.","event, exclusive, website",www.rocheplus.es,Falling,0.508539576464374,medium,358,Events & Patient Care
824,https://www.rocheplus.es/areas-terapeuticas/oncologia/hepatocarcinoma/liver-forum.html?namespace=s7viewers,6,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_html_namespace_s7viewers.txt,200,,Non-Indexable,3,11,0,942,2,1,1,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_html_namespace_s7viewers.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_html_namespace_s7viewers.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_html_namespace_s7viewers.txt.txt,"['FORUM', 'Pepe', 'LIVER', 'Ribagorda']",Other,Spain,Other,,,3.8795404,-3.4550111,7,"The content features Roche's website targeting healthcare professionals. It highlights a project called ""LIVER FORUM"" led by an individual named Pepe Ribagorda. The content likely aims to engage medical professionals with exclusive resources and information about liver-related healthcare initiatives. A video play option suggests multimedia content related to the project is available for viewing.","event, exclusive, website",www.rocheplus.es,Flat,0.249048587031155,medium,371,Events & Patient Care
825,https://www.rocheplus.es/areas-terapeuticas/oncologia/hepatocarcinoma/liver-forum.html,7,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_html.txt,200,,Indexable,2,11,0,942,9,5,1,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_html.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_html.txt.txt,"['FORUM', 'Pepe', 'LIVER', 'Ribagorda']",Other,Spain,Events,,,3.9021666,-3.249084,7,"The content features a section from Roche's professional website, highlighting a project called ""LIVER FORUM"" led by Pepe Ribagorda. The content seems designed for healthcare professionals, promoting access to exclusive resources and events related to liver health. There is also a call to action encouraging user registration for further content access. Overall, the focus is on specialized information and initiatives in the field of healthcare.","event, exclusive, website",www.rocheplus.es,Falling,0.282321821149321,high,135,Events & Patient Care
826,https://www.rocheplus.es/areas-terapeuticas/oncologia/hepatocarcinoma/liver-forum/que-hace-diferente-al-hepatocarcinoma.html,6,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_que_hace_diferente_al_hepatocarcinoma_html.txt,200,,Non-Indexable,3,39,0,841,16,3,1,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_que_hace_diferente_al_hepatocarcinoma_html.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_que_hace_diferente_al_hepatocarcinoma_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_liver_forum_que_hace_diferente_al_hepatocarcinoma_html.txt.txt,"['Liver', 'Forum']",Oncology-Hematology,Spain,Events,"hapatocarcinoma, oncology",hepatocarcinoma,4.7495112,-4.986175,7,"The content features a webpage on Roche's platform aimed at healthcare professionals, highlighting the ""Liver Forum."" This section focuses on videos related to hepatocarcinoma, addressing topics such as distinguishing features of the disease. The page encourages professional registration for access to exclusive content, reinforcing its commitment to providing educational resources in therapeutic areas like oncology.","event, exclusive, website",www.rocheplus.es,Falling,0.609688382457703,medium,50,Events & Patient Care
827,https://www.rocheplus.es/areas-terapeuticas/oncologia/hepatocarcinoma/now-and-next.html,7,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_now_and_next_html.txt,200,,Non-Indexable,2,39,0,852,14,2,1,www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_now_and_next_html.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_now_and_next_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_hepatocarcinoma_now_and_next_html.txt.txt,"['Hospital', 'Barcelona', 'Pau', 'Sant']",Oncology-Hematology,Spain,Disease information,"liver cancer, hepatocarcinoma, treatment",liver cancer,4.7197604,-9.667207,7,"The content showcases a section of Roche's website dedicated to oncology, specifically focusing on liver cancer (hepatocarcinoma). It highlights the establishment of a multidisciplinary unit at the Hospital Sant Pau in Barcelona aimed at comprehensive management of liver cancer treatment. The content emphasizes collaboration among specialists to address the complexities of both cancer and related liver diseases, and includes a video presentation related to these efforts.","event, exclusive, website",www.rocheplus.es,All,0.749942011365854,high,129,Events & Patient Care
828,https://www.rocheplus.es/areas-terapeuticas/oncologia.html,10,www_rocheplus_es_areas_terapeuticas_oncologia_html.txt,200,,Non-Indexable,1,39,113,1217,944,410,0.964285714285714,www_rocheplus_es_areas_terapeuticas_oncologia_html.txt.txt,image/www_rocheplus_es_areas_terapeuticas_oncologia_html.txt.txt.png,text/www_rocheplus_es_areas_terapeuticas_oncologia_html.txt.txt.txt,[],Oncology-Hematology,Spain,Disease information,"immunotherapy, hepatocellular carcinoma, breast cancer, lung cancer, precision medicine","hepatocellular carcinoma, breast cancer, lung cancer",-16.084978,-5.9272585,0,"The content focuses on oncology, detailing Roche's commitment to advancing cancer treatment through innovative drugs and medical education. It outlines various aspects of oncology, including different cancer types (like hepatocellular carcinoma, breast cancer, and lung cancer) and treatment approaches such as immunotherapy and precision medicine. The content emphasizes the need for healthcare professionals to register on Roche's platform to access exclusive content, including virtual events, training programs, and resources for improving patient care. Additionally, it highlights Roche's efforts in supporting healthcare providers with the latest scientific updates and fostering communication through newsletters and contact resources.","oncology, professionals, data",www.rocheplus.es,Flat,0.441477228691312,high,277,General Offer Outline
829,https://www.rocheplus.es/areas-terapeuticas/reumatologia.html,7,www_rocheplus_es_areas_terapeuticas_reumatologia_html.txt,200,,Non-Indexable,1,42,0,991,922,410,1,www_rocheplus_es_areas_terapeuticas_reumatologia_html.txt,image/www_rocheplus_es_areas_terapeuticas_reumatologia_html.txt.png,text/www_rocheplus_es_areas_terapeuticas_reumatologia_html.txt.txt,[],Other,Spain,Offer outline,,,-3.6387436,-15.897972,3,"The content focuses on the rheumatology section of Roche's professional healthcare website. It invites healthcare professionals to register for access to exclusive medical content related to rheumatology, highlighting the importance of user registration for further information. The design features an illustration of a healthcare provider assisting a patient, reflecting the focus on patient care within the rheumatology field.","users, page, website",www.rocheplus.es,Flat,0.528124365754209,high,127,Website Metadata
830,https://www.rocheplus.es/aviso-legal-y-politica-de-privacidad.html,10,www_rocheplus_es_aviso_legal_y_politica_de_privacidad_html.txt,200,,Indexable,1,36,36,8860,428,410,1,www_rocheplus_es_aviso_legal_y_politica_de_privacidad_html.txt,image/www_rocheplus_es_aviso_legal_y_politica_de_privacidad_html.txt.png,text/www_rocheplus_es_aviso_legal_y_politica_de_privacidad_html.txt.txt,[],Other,Spain,Metainformation,,,-6.877577,-25.762665,3,"The content outlines Roche's legal disclaimers, privacy policies, and practices regarding the collection and handling of personal data. It emphasizes the company's commitment to data protection in accordance with relevant laws and describes the types of personal information Roche may collect, such as contact details, professional information, and interaction records. Additionally, it details how this data may be used, the legal bases for processing it, and the rights individuals have concerning their personal information. The primary purpose of the content is to inform users, particularly healthcare professionals and business partners, about their rights and Roche's obligations regarding data privacy and security.","users, page, website",www.rocheplus.es,All,0.620216017405911,high,168,Website Metadata
831,https://www.rocheplus.es/campaign/erivedge.html,7,www_rocheplus_es_campaign_erivedge_html.txt,200,,Indexable,,8,0,844,1,1,1,www_rocheplus_es_campaign_erivedge_html.txt,image/www_rocheplus_es_campaign_erivedge_html.txt.png,text/www_rocheplus_es_campaign_erivedge_html.txt.txt,['Erivedge'],Oncology-Hematology,Spain,Medication information,"Erivedge, vismodegib",,10.590924,-36.946358,1,"The content features information about ""Erivedge"" (vismodegib), highlighting its relevance within Roche's product offerings. It includes a prompt for healthcare professionals to register for exclusive content. Additionally, there is a visual element, likely a map, suggesting further information on publications related to Erivedge. The overall focus appears to be on providing resources and updates for medical professionals regarding this specific medication.","drug, reporting, adverse",www.rocheplus.es,Rising,0.964088130361071,high,195,Drug Safety
832,https://www.rocheplus.es/campaign/guspot.html?namespace=s7viewers,9,www_rocheplus_es_campaign_guspot_html_namespace_s7viewers.txt,200,,Non-Indexable,,49,174,1630,65,1,0.968253968253968,www_rocheplus_es_campaign_guspot_html_namespace_s7viewers.txt.txt,image/www_rocheplus_es_campaign_guspot_html_namespace_s7viewers.txt.txt.png,text/www_rocheplus_es_campaign_guspot_html_namespace_s7viewers.txt.txt.txt,"['La', 'GU', 'SPOT', 'Hospital', 'Paz', 'Madrid', 'PINTO', 'Pinto', 'Medical', 'University', 'Service', 'Oncology']",Oncology-Hematology,Spain,Offer outline,"genitourinary cancer, GU SPOT project",genitourinary cancer,26.827187,-10.775635,12,"The content features a segment highlighting ÁLVARO PINTO and the GU SPOT project, aimed at addressing genitourinary cancer. It indicates that Pinto is an associate doctor in the Medical Oncology Service at La Paz University Hospital in Madrid. The website encourages healthcare professionals to register for exclusive content related to this project and other medical resources, underscoring its focus on professional engagement and education in the pharmaceutical field.","cancer, breast, lung",www.rocheplus.es,Falling,0.755066827641145,high,294,Disease Information
833,https://www.rocheplus.es/campaign/guspot.html,10,www_rocheplus_es_campaign_guspot_html.txt,200,,Indexable,,49,174,1635,79,8,1,www_rocheplus_es_campaign_guspot_html.txt,image/www_rocheplus_es_campaign_guspot_html.txt.png,text/www_rocheplus_es_campaign_guspot_html.txt.txt,"['La', 'GU', 'SPOT', 'Hospital', 'Paz', 'Pinto', 'Dr', 'University']",Oncology-Hematology,Spain,Events,,,6.8887634,-6.323699,7,"The content features a section of Roche's professional website, highlighting a video about ""GU SPOT,"" a project led by Dr. Álvaro Pinto, an oncology specialist at La Paz University Hospital. The content aims to engage healthcare professionals by offering insights into developments related to genitourinary cancer. The site encourages registration for accessing exclusive content, emphasizing its focus on medical innovation and collaboration in the healthcare sector.","event, exclusive, website",www.rocheplus.es,Rising,0.95402280235045,high,236,Events & Patient Care
834,https://www.rocheplus.es/campaign/guspot/inteligencia-artificial.html,6,www_rocheplus_es_campaign_guspot_inteligencia_artificial_html.txt,200,,Indexable,,23,0,955,17,3,1,www_rocheplus_es_campaign_guspot_inteligencia_artificial_html.txt,image/www_rocheplus_es_campaign_guspot_inteligencia_artificial_html.txt.png,text/www_rocheplus_es_campaign_guspot_inteligencia_artificial_html.txt.txt,"['GU', 'SPOT', 'Guerra', 'Dr', 'Donas']",Oncology-Hematology,Spain,Technology,,urological cancer,9.794702,-6.2642736,7,"The content features a segment from Roche's website aimed at healthcare professionals, introducing a discussion platform called ""GU- SPOT."" This platform focuses on urological cancer, with a promotional highlight of a conversation between experts Dr. Jesús García-Donas and Néstor Guerra. It emphasizes the use of artificial intelligence in the context of urological health. The content aims to facilitate knowledge sharing and engagement among healthcare practitioners.","event, exclusive, website",www.rocheplus.es,All,0.347944552829085,medium,200,Events & Patient Care
835,https://www.rocheplus.es/campaign/guspot/nutricion-ejercicio.html,6,www_rocheplus_es_campaign_guspot_nutricion_ejercicio_html.txt,200,,Indexable,,21,0,959,17,3,0.968253968253968,www_rocheplus_es_campaign_guspot_nutricion_ejercicio_html.txt.txt,image/www_rocheplus_es_campaign_guspot_nutricion_ejercicio_html.txt.txt.png,text/www_rocheplus_es_campaign_guspot_nutricion_ejercicio_html.txt.txt.txt,"['GU', 'SPOT']",Oncology-Hematology,Spain,Patient support,,genitourinary cancer,6.285868,-6.363614,7,"The content features content from Roche focused on a platform called ""GU SPOT,"" which serves as a hub for discussions related to genitourinary cancer. The specific segment highlighted appears to cover topics such as nutrition and exercise. Additionally, it encourages healthcare professionals to register for exclusive content, indicating the platform's aim to provide targeted resources and engagement for medical practitioners.","event, exclusive, website",www.rocheplus.es,Flat,0.0817423558934252,medium,179,Events & Patient Care
836,https://www.rocheplus.es/campaign/guspot/oncogeriatria.html,6,www_rocheplus_es_campaign_guspot_oncogeriatria_html.txt,200,,Indexable,,13,0,930,17,3,1,www_rocheplus_es_campaign_guspot_oncogeriatria_html.txt,image/www_rocheplus_es_campaign_guspot_oncogeriatria_html.txt.png,text/www_rocheplus_es_campaign_guspot_oncogeriatria_html.txt.txt,"['Spot', 'GU']",Oncology-Hematology,Spain,Offer outline,,,7.0342155,-7.284247,7,"The content features a segment of Roche's professional platform focusing on genitourinary oncology, branded as ""GU Spot."" It invites healthcare professionals to register for access to exclusive content related to this specialized field. The visual includes a video interface and emphasizes collaboration and information exchange among medical experts. Overall, the content serves as a resource for professionals seeking insights and advancements in genitourinary cancer care.","event, exclusive, website",www.rocheplus.es,Flat,0.587277923870144,medium,196,Events & Patient Care
837,https://www.rocheplus.es/campaign/guspot/psicooncologia.html,6,www_rocheplus_es_campaign_guspot_psicooncologia_html.txt,200,,Indexable,,14,0,940,17,3,1,www_rocheplus_es_campaign_guspot_psicooncologia_html.txt,image/www_rocheplus_es_campaign_guspot_psicooncologia_html.txt.png,text/www_rocheplus_es_campaign_guspot_psicooncologia_html.txt.txt,"['GU', 'SPOT']",Oncology-Hematology,Spain,Patient support,,genitourinary cancer,6.09155,-7.6415653,7,"The content features a professional platform from Roche, highlighting a section called ""GU SPOT,"" which focuses on genitourinary cancer. It appears to provide a space for healthcare professionals to engage with expert content, specifically in the realm of psycho-oncology. The content is likely designed to foster discussion and share insights on the psychological aspects of cancer care. A registration prompt suggests that access to additional exclusive content is available for professionals.","event, exclusive, website",www.rocheplus.es,Falling,0.915147214211757,medium,483,Events & Patient Care
838,https://www.rocheplus.es/campaign/guspot-temporada-1/avances-tecnologicos.html,6,www_rocheplus_es_campaign_guspot_temporada_1_avances_tecnologicos_html.txt,200,,Non-Indexable,,20,0,1001,14,3,1,www_rocheplus_es_campaign_guspot_temporada_1_avances_tecnologicos_html.txt,image/www_rocheplus_es_campaign_guspot_temporada_1_avances_tecnologicos_html.txt.png,text/www_rocheplus_es_campaign_guspot_temporada_1_avances_tecnologicos_html.txt.txt,"['Spot', 'GU']",Oncology-Hematology,Spain,Technology,,genitourinary cancer,24.641037,-9.938183,12,"The content features a segment titled ""GU Spot,"" which serves as a meeting point for healthcare professionals to discuss advancements related to genitourinary cancer. It encourages professionals to register for exclusive content and highlights technological innovations within the field. The interface includes a video element, suggesting a multimedia approach to disseminate information. Overall, the content aims to foster engagement and provide valuable resources for medical professionals.","cancer, breast, lung",www.rocheplus.es,Falling,0.670712950919552,medium,162,Disease Information
839,https://www.rocheplus.es/campaign/guspot-temporada-1/el-papel-de-los-biomarcadores.html,6,www_rocheplus_es_campaign_guspot_temporada_1_el_papel_de_los_biomarcadores_html.txt,200,,Non-Indexable,,29,0,967,16,3,0.976470588235294,www_rocheplus_es_campaign_guspot_temporada_1_el_papel_de_los_biomarcadores_html.txt.txt,image/www_rocheplus_es_campaign_guspot_temporada_1_el_papel_de_los_biomarcadores_html.txt.txt.png,text/www_rocheplus_es_campaign_guspot_temporada_1_el_papel_de_los_biomarcadores_html.txt.txt.txt,"['Spot', 'GU']",Oncology-Hematology,Spain,Offer outline,,genitourinary cancer,6.9784226,-5.9635663,7,"The content features a section of Roche's website aimed at healthcare professionals. It promotes ""GU-Spot,"" a platform focused on topics related to genitourinary cancer. The content encourages professionals to register for exclusive material and highlights a discussion on the role of biomarkers, illustrated by a video featuring two individuals in a conversational setting. The design emphasizes interaction and access to specialized knowledge in the medical field.","event, exclusive, website",www.rocheplus.es,Falling,0.923618300953963,medium,269,Events & Patient Care
840,https://www.rocheplus.es/campaign/guspot-temporada-1/ensayos-clinicos.html,6,www_rocheplus_es_campaign_guspot_temporada_1_ensayos_clinicos_html.txt,200,,Non-Indexable,,16,0,960,16,3,1,www_rocheplus_es_campaign_guspot_temporada_1_ensayos_clinicos_html.txt,image/www_rocheplus_es_campaign_guspot_temporada_1_ensayos_clinicos_html.txt.png,text/www_rocheplus_es_campaign_guspot_temporada_1_ensayos_clinicos_html.txt.txt,"['Spot', 'GU']",Oncology-Hematology,Spain,Offer outline,,,5.5848927,-4.7096086,7,"The content highlights a section of Roche's website aimed at healthcare professionals, presenting a dedicated platform called ""GU Spot"" focused on urological cancer. It features a call to action inviting registration for exclusive content, and includes a visual element suggesting multimedia resources, such as interviews or discussions related to clinical trials in this area. The design emphasizes interactivity and provides a space for professional engagement on relevant topics.","event, exclusive, website",www.rocheplus.es,Flat,0.650459240167072,medium,153,Events & Patient Care
841,https://www.rocheplus.es/campaign/guspot-temporada-1.html?namespace=s7viewers,6,www_rocheplus_es_campaign_guspot_temporada_1_html_namespace_s7viewers.txt,200,,Non-Indexable,,49,0,1691,29,1,1,www_rocheplus_es_campaign_guspot_temporada_1_html_namespace_s7viewers.txt,image/www_rocheplus_es_campaign_guspot_temporada_1_html_namespace_s7viewers.txt.png,text/www_rocheplus_es_campaign_guspot_temporada_1_html_namespace_s7viewers.txt.txt,"['GU', 'SPOT', 'Pinto', 'Dr']",Oncology-Hematology,Spain,Events,,,7.188118,-7.09919,7,"The content highlights a feature on Roche's professional website, introducing Dr. Álvaro Pinto and the GU SPOT project, which focuses on genitourinary cancer. It emphasizes the project's aim as a meeting point for healthcare professionals to engage with updates and information related to this specific area of oncology. The design encourages professionals to register for access to exclusive content.","event, exclusive, website",www.rocheplus.es,Flat,0.62887119256003,medium,332,Events & Patient Care
842,https://www.rocheplus.es/campaign/guspot-temporada-1.html,6,www_rocheplus_es_campaign_guspot_temporada_1_html.txt,200,,Indexable,,49,0,1691,47,9,1,www_rocheplus_es_campaign_guspot_temporada_1_html.txt,image/www_rocheplus_es_campaign_guspot_temporada_1_html.txt.png,text/www_rocheplus_es_campaign_guspot_temporada_1_html.txt.txt,"['La', 'Universitario', 'GU', 'SPOT', 'Hospital', 'Paz', 'Madrid', 'Pinto']",Oncology-Hematology,Spain,Events,,,25.898102,-10.716952,12,"The content features a promotional section highlighting a project called ""GU SPOT,"" presented by Álvaro Pinto, an oncologist from the Hospital Universitario La Paz de Madrid. The purpose is to serve as a meeting point for discussions around genitourinary cancer. The design is aimed at healthcare professionals, inviting them to learn more about this initiative and its associated resources.","cancer, breast, lung",www.rocheplus.es,Flat,0.538455149907905,medium,119,Disease Information
843,https://www.rocheplus.es/campaign/guspot-temporada-1/trabajo-multidisciplinar.html,6,www_rocheplus_es_campaign_guspot_temporada_1_trabajo_multidisciplinar_html.txt,200,,Non-Indexable,,24,0,984,14,3,1,www_rocheplus_es_campaign_guspot_temporada_1_trabajo_multidisciplinar_html.txt,image/www_rocheplus_es_campaign_guspot_temporada_1_trabajo_multidisciplinar_html.txt.png,text/www_rocheplus_es_campaign_guspot_temporada_1_trabajo_multidisciplinar_html.txt.txt,"['Spot', 'Trabajo', 'Multidisciplinary', 'GU', 'Work']",Oncology-Hematology,Spain,Other,,genitourinary cancer,5.051739,-4.333037,7,"The content displays a section of Roche's professional platform, focusing on GU Spot, a resource dedicated to genitourinary cancer. It invites healthcare professionals to register for access to exclusive content. A video segment labeled ""Trabajo multidisciplinar"" (Multidisciplinary Work) is featured, likely discussing collaborative approaches in treating this type of cancer. The design suggests an engaging multimedia experience aimed at healthcare education and information sharing.","event, exclusive, website",www.rocheplus.es,All,0.832709988931972,medium,207,Events & Patient Care
844,https://www.rocheplus.es/campaign.html,7,www_rocheplus_es_campaign_html.txt,200,,Non-Indexable,,8,0,709,13,13,1,www_rocheplus_es_campaign_html.txt,image/www_rocheplus_es_campaign_html.txt.png,text/www_rocheplus_es_campaign_html.txt.txt,['Spain'],Other,Spain,Offer outline,,,-8.204795,-23.116,3,"The content contains information aimed at healthcare professionals regarding Roche. It invites users to register for access to exclusive content and highlights that the website is tailored for those who prescribe or dispense medications in Spain. The interface includes options for accessing various services and resources, along with legal disclaimers and privacy policies.","users, page, website",www.rocheplus.es,Flat,0.938752427163187,high,331,Website Metadata
845,https://www.rocheplus.es/campaign/IMCompass.html,7,www_rocheplus_es_campaign_IMCompass_html.txt,200,,Indexable,,9,0,741,5,1,1,www_rocheplus_es_campaign_IMCompass_html.txt,image/www_rocheplus_es_campaign_IMCompass_html.txt.png,text/www_rocheplus_es_campaign_IMCompass_html.txt.txt,['Spain'],Oncology-Hematology,Spain,Research,"atezolizumab, locally advanced urothelial carcinoma, metastatic urothelial carcinoma, compassionate use program",urothelial carcinoma,14.506266,-24.319847,1,"The content features content related to Roche's campaign called ""IMCompass,"" focusing on atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma within a compassionate use program in Spain. It likely discusses the study's objectives and protocols while targeting healthcare professionals, as indicated by the call for registration to access exclusive content. The visual elements emphasize a medical theme, aligning with the pharmaceutical context.","drug, reporting, adverse",www.rocheplus.es,Flat,0.116686886836282,high,496,Drug Safety
846,https://www.rocheplus.es/campaign/imvigor211.html,7,www_rocheplus_es_campaign_imvigor211_html.txt,200,,Indexable,,10,0,752,5,1,0.957446808510638,www_rocheplus_es_campaign_imvigor211_html.txt.txt,image/www_rocheplus_es_campaign_imvigor211_html.txt.txt.png,text/www_rocheplus_es_campaign_imvigor211_html.txt.txt.txt,['Atezolizumab'],Oncology-Hematology,Spain,Research,"Atezolizumab, chemotherapy, urothelial carcinoma",urothelial carcinoma,29.262074,-20.90713,12,"The content presents information about the IMvigor211 clinical trial, focusing on the comparison of Atezolizumab to chemotherapy for patients with platinum-treated locally advanced or metastatic urothelial carcinoma. It highlights a long-term overall survival and safety update related to this study. Additionally, there is an invitation for healthcare professionals to register for exclusive content, indicating that the site is tailored for medical professionals.","cancer, breast, lung",www.rocheplus.es,Flat,0.10890342287349,high,322,Disease Information
847,https://www.rocheplus.es/campaign/ntrk.html,7,www_rocheplus_es_campaign_ntrk_html.txt,200,,Indexable,,4,0,797,5,1,0.951219512195122,www_rocheplus_es_campaign_ntrk_html.txt.txt,image/www_rocheplus_es_campaign_ntrk_html.txt.txt.png,text/www_rocheplus_es_campaign_ntrk_html.txt.txt.txt,['NTRK'],Oncology-Hematology,Spain,Offer outline,"NTRK fusion tumors, precision medicine, diagnostic techniques, guidelines for NTRK, treatment of NTRK-related conditions",NTRK fusion tumors,27.037565,-11.8907995,12,"The content displays a webpage aimed at healthcare professionals, focusing on the topic of NTRK fusion tumors. It invites users to register for access to exclusive content and provides various sections related to precision medicine, diagnostic techniques, and guidelines for NTRK, emphasizing the identification and treatment of these tumors. The overall purpose is to educate and support professionals in managing NTRK-related conditions.","cancer, breast, lung",www.rocheplus.es,Falling,0.862000613014155,high,321,Disease Information
848,https://www.rocheplus.es/campaign/pulmon-estadios-iniciales.html,6,www_rocheplus_es_campaign_pulmon_estadios_iniciales_html.txt,200,,Indexable,,25,0,1044,1,1,0.967741935483871,www_rocheplus_es_campaign_pulmon_estadios_iniciales_html.txt.txt,image/www_rocheplus_es_campaign_pulmon_estadios_iniciales_html.txt.txt.png,text/www_rocheplus_es_campaign_pulmon_estadios_iniciales_html.txt.txt.txt,['Spain'],Oncology-Hematology,Spain,Disease information,lung cancer,lung cancer,25.902567,-14.436739,12,"The content focuses on lung cancer, highlighting its prevalence and the importance of early diagnosis. It emphasizes that timely intervention can significantly alter patient outcomes, given that many patients in Spain are diagnosed at an advanced stage. Additionally, the message encourages awareness and proactive measures in addressing this health issue, suggesting that early action can lead to better histories for patients. The graphic elements, including illustrations, support the theme of change and awareness.","cancer, breast, lung",www.rocheplus.es,Falling,0.50678522875361,medium,76,Disease Information
849,https://www.rocheplus.es/campaign/SAUL.html,7,www_rocheplus_es_campaign_SAUL_html.txt,200,,Indexable,,4,0,746,5,1,0.951219512195122,www_rocheplus_es_campaign_SAUL_html.txt.txt,image/www_rocheplus_es_campaign_SAUL_html.txt.txt.png,text/www_rocheplus_es_campaign_SAUL_html.txt.txt.txt,['SAUL'],Oncology-Hematology,Spain,Research,"atezolizumab, urinary tract carcinoma",urothelial carcinoma,28.286913,-21.797377,12,"The content focuses on the findings from the SAUL study, which is an international real-world investigation of atezolizumab treatment in 1,004 patients with previously treated locally advanced or metastatic urinary tract carcinoma. The page aims to provide healthcare professionals with insights into the study's results, promoting access to specialized medical information. It includes a call to action for professionals to register for exclusive content.","cancer, breast, lung",www.rocheplus.es,All,0.115661796522607,high,230,Disease Information
850,https://www.rocheplus.es/congresos-eventos/congresos-destacados/aacr-2023.html,7,www_rocheplus_es_congresos_eventos_congresos_destacados_aacr_2023_html.txt,200,,Non-Indexable,2,9,0,720,3,3,1,www_rocheplus_es_congresos_eventos_congresos_destacados_aacr_2023_html.txt,image/www_rocheplus_es_congresos_eventos_congresos_destacados_aacr_2023_html.txt.png,text/www_rocheplus_es_congresos_eventos_congresos_destacados_aacr_2023_html.txt.txt,"['AACR', 'USA', 'April', 'Orlando']",Other,Spain,Events,,,9.048123,3.5248156,7,"The content features information about the AACR 2023 event hosted by Roche, taking place from April 14 to April 19 in Orlando, USA. It invites healthcare professionals to register for exclusive content related to the event. The site highlights its focus on events for professionals, reflecting Roche's commitment to engaging with the medical community.","event, exclusive, website",www.rocheplus.es,All,0.882181830859831,high,287,Events & Patient Care
851,https://www.rocheplus.es/congresos-eventos/congresos-destacados/asco-gi-2023.html,7,www_rocheplus_es_congresos_eventos_congresos_destacados_asco_gi_2023_html.txt,200,,Non-Indexable,2,12,0,725,3,3,1,www_rocheplus_es_congresos_eventos_congresos_destacados_asco_gi_2023_html.txt,image/www_rocheplus_es_congresos_eventos_congresos_destacados_asco_gi_2023_html.txt.png,text/www_rocheplus_es_congresos_eventos_congresos_destacados_asco_gi_2023_html.txt.txt,"['Meeting', 'Annual', 'USA', 'ASCO', 'June', 'Chicago', 'Genentech']",Oncology-Hematology,Spain,Events,,,7.91889,2.755517,7,"The content highlights Roche and Genentech's participation in the 2023 ASCO Annual Meeting, scheduled from June 2 to June 6 in Chicago, USA. It serves as a professional platform, indicating the focus on healthcare professionals and the exclusivity of the content available through registration. The overall purpose is to provide information about their involvement in key industry events and to connect with healthcare practitioners.","event, exclusive, website",www.rocheplus.es,Flat,2.50200767913933E-05,high,153,Events & Patient Care
852,https://www.rocheplus.es/congresos-eventos/congresos-destacados/asco-gu-2023.html,7,www_rocheplus_es_congresos_eventos_congresos_destacados_asco_gu_2023_html.txt,200,,Non-Indexable,2,12,0,725,3,3,0.974683544303797,www_rocheplus_es_congresos_eventos_congresos_destacados_asco_gu_2023_html.txt.txt,image/www_rocheplus_es_congresos_eventos_congresos_destacados_asco_gu_2023_html.txt.txt.png,text/www_rocheplus_es_congresos_eventos_congresos_destacados_asco_gu_2023_html.txt.txt.txt,"['Meeting', 'Annual', 'USA', 'ASCO', 'June', 'Chicago', 'Genentech']",Other,Spain,Events,,,8.470853,2.73855,7,"The content focuses on Roche and Genentech's participation in the 2023 ASCO Annual Meeting, scheduled for June 2 to June 6 in Chicago, USA. It targets healthcare professionals, inviting them to register for access to exclusive content related to the event. The website emphasizes its role in providing information tailored for medical professionals.","event, exclusive, website",www.rocheplus.es,Rising,0.62571167882817,high,112,Events & Patient Care
853,https://www.rocheplus.es/congresos-eventos/congresos-destacados/ash-2024.html,7,www_rocheplus_es_congresos_eventos_congresos_destacados_ash_2024_html.txt,200,,Non-Indexable,2,17,0,769,7,3,1,www_rocheplus_es_congresos_eventos_congresos_destacados_ash_2024_html.txt,image/www_rocheplus_es_congresos_eventos_congresos_destacados_ash_2024_html.txt.png,text/www_rocheplus_es_congresos_eventos_congresos_destacados_ash_2024_html.txt.txt,"['ASH', 'California', 'December', 'Diego', 'American', 'Society', 'San', 'Hematology']",Oncology-Hematology,Spain,Events,,,9.319118,0.90651447,7,"The content focuses on the ASH 2024 event, organized by the American Society of Hematology, taking place from December 7-10 in San Diego, California. It emphasizes Roche's commitment to innovation in hematology and encourages healthcare professionals to register for exclusive content related to the event. The design highlights a sense of urgency and importance regarding the event and Roche's involvement in it.","event, exclusive, website",www.rocheplus.es,Rising,0.60051098580933,high,491,Events & Patient Care
854,https://www.rocheplus.es/congresos-eventos/congresos-destacados/congreso-asco-mama-2024.html,7,www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_asco_mama_2024_html.txt,200,,Non-Indexable,2,38,0,784,7,3,1,www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_asco_mama_2024_html.txt,image/www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_asco_mama_2024_html.txt.png,text/www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_asco_mama_2024_html.txt.txt,"['May', 'USA', 'ASCO', 'June', 'Chicago']",Oncology-Hematology,Spain,Events,,breast cancer,24.967644,-12.12748,12,"The content features information about the ASCO 2024 event, focusing on breast cancer highlights. It provides details such as the event dates (May 31 - June 04) and the location (Chicago, USA, with a hybrid format). The content encourages healthcare professionals to register to access exclusive content related to the conference. Overall, it serves as a promotional tool for an important medical event in the oncology field.","cancer, breast, lung",www.rocheplus.es,Rising,0.461147923266135,high,131,Disease Information
855,https://www.rocheplus.es/congresos-eventos/congresos-destacados/congreso-eahad-2024.html,7,www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_eahad_2024_html.txt,200,,Non-Indexable,2,10,0,743,8,4,1,www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_eahad_2024_html.txt,image/www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_eahad_2024_html.txt.png,text/www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_eahad_2024_html.txt.txt,"['EAHAD', 'February', 'Germany', 'Frankfurt']",Other,Spain,Events,,,9.521546,3.7163131,7,"The content features information about the EAHAD 2024 event, taking place in Frankfurt, Germany, from February 6 to February 9. It invites healthcare professionals to register for exclusive content related to the event, suggesting a focus on networking and knowledge sharing within the healthcare community. The layout promotes Roche's involvement, emphasizing its commitment to professionals in the industry.","event, exclusive, website",www.rocheplus.es,All,0.621487538856526,high,132,Events & Patient Care
856,https://www.rocheplus.es/congresos-eventos/congresos-destacados/congreso-eha-2024.html,7,www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_eha_2024_html.txt,200,,Non-Indexable,2,8,0,794,8,4,1,www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_eha_2024_html.txt,image/www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_eha_2024_html.txt.png,text/www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_eha_2024_html.txt.txt,"['Association', 'European', 'EHA', 'Madrid', 'June', 'Hematology']",Oncology-Hematology,Spain,Events,,,8.650453,1.1091161,7,"The content highlights the EHA 2024 event organized by Roche, focusing on the European Hematology Association conference taking place in Madrid from June 13 to June 16. It invites healthcare professionals to register for access to exclusive content related to the event and encourages them to consult published materials connected to the conference. The layout emphasizes professional engagement and information sharing within the pharmaceutical and medical communities.","event, exclusive, website",www.rocheplus.es,Falling,0.179544975560518,high,226,Events & Patient Care
857,https://www.rocheplus.es/congresos-eventos/congresos-destacados/congreso-isth-2024.html,7,www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_isth_2024_html.txt,200,,Non-Indexable,2,9,0,780,7,3,1,www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_isth_2024_html.txt,image/www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_isth_2024_html.txt.png,text/www_rocheplus_es_congresos_eventos_congresos_destacados_congreso_isth_2024_html.txt.txt,"['Bangkok', 'ISTH', 'June']",Other,Spain,Events,,,32.969063,9.93176,4,"The content highlights the upcoming ISTH 2024 event, scheduled to take place in Bangkok from June 22 to June 26. It targets healthcare professionals, encouraging them to register for exclusive access to related content. The content also features options for accessing additional information or registration services.","technologies, artificial, ai",www.rocheplus.es,Falling,0.065595279811734,high,184,Technology
858,https://www.rocheplus.es/congresos-eventos/congresos-destacados/congresoectrims24.html,7,www_rocheplus_es_congresos_eventos_congresos_destacados_congresoectrims24_html.txt,200,,Non-Indexable,2,12,0,790,7,3,0.976190476190476,www_rocheplus_es_congresos_eventos_congresos_destacados_congresoectrims24_html.txt.txt,image/www_rocheplus_es_congresos_eventos_congresos_destacados_congresoectrims24_html.txt.txt.png,text/www_rocheplus_es_congresos_eventos_congresos_destacados_congresoectrims24_html.txt.txt.txt,"['Copenhagen', 'September', 'ECTRIMS']",Other,Spain,Events,,,8.4120455,3.9812393,7,"The content highlights the ECTRIMS 2024 event organized by Roche, aimed at healthcare professionals. It invites users to register for access to exclusive content related to the forum. The event is set to take place in Copenhagen on September 19 and emphasizes the importance of registration for participation. The overall focus is on promoting professional engagement and information sharing within the healthcare community.","event, exclusive, website",www.rocheplus.es,All,0.852609644534221,high,281,Events & Patient Care
859,https://www.rocheplus.es/congresos-eventos/congresos-destacados/esmo-2024.html,7,www_rocheplus_es_congresos_eventos_congresos_destacados_esmo_2024_html.txt,200,,Non-Indexable,2,9,0,1167,7,3,0.973684210526316,www_rocheplus_es_congresos_eventos_congresos_destacados_esmo_2024_html.txt.txt,image/www_rocheplus_es_congresos_eventos_congresos_destacados_esmo_2024_html.txt.txt.png,text/www_rocheplus_es_congresos_eventos_congresos_destacados_esmo_2024_html.txt.txt.txt,['ESMO'],Oncology-Hematology,Spain,Events,,,-12.765451,2.1872141,0,"The content primarily serves as an announcement and informational resource regarding Roche's participation in the ESMO 2024 conference. It invites healthcare professionals to register to access exclusive content related to Roche's communications and studies presented at the event. The content lists various therapeutic areas and titles of articles showcasing research on cancers, highlighting specific studies and updates on treatment efficacy and genetic profiling. The purpose is to engage healthcare professionals and provide them with valuable research insights relevant to oncology.","oncology, professionals, data",www.rocheplus.es,Flat,0.685945359472948,high,328,General Offer Outline
860,https://www.rocheplus.es/congresos-eventos/congresos-destacados/euretina-2024.html,7,www_rocheplus_es_congresos_eventos_congresos_destacados_euretina_2024_html.txt,200,,Non-Indexable,2,13,0,856,15,3,0.975,www_rocheplus_es_congresos_eventos_congresos_destacados_euretina_2024_html.txt.txt,image/www_rocheplus_es_congresos_eventos_congresos_destacados_euretina_2024_html.txt.txt.png,text/www_rocheplus_es_congresos_eventos_congresos_destacados_euretina_2024_html.txt.txt.txt,"['September', 'Barcelona', 'Congress', 'EURETINA', 'Spain']",Ophthalmology,Spain,Events,,,8.147702,2.447169,7,"The content highlights the upcoming EURETINA Congress 2024, scheduled for September 19-22 in Barcelona, Spain. It promotes Roche's participation in the event by emphasizing exciting live symposiums and invites healthcare professionals to access additional exclusive content related to Roche's offerings at the congress. The focus is on engagement and information-sharing within the professional healthcare community.","event, exclusive, website",www.rocheplus.es,All,0.913061227762398,high,372,Events & Patient Care
861,https://www.rocheplus.es/congresos-eventos/eventos/biomarkers-on-tour.html,7,www_rocheplus_es_congresos_eventos_eventos_biomarkers_on_tour_html.txt,200,,Non-Indexable,2,18,0,867,30,5,0.972222222222222,www_rocheplus_es_congresos_eventos_eventos_biomarkers_on_tour_html.txt.txt,image/www_rocheplus_es_congresos_eventos_eventos_biomarkers_on_tour_html.txt.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_biomarkers_on_tour_html.txt.txt.txt,"['PD', 'September', 'Biomarkers', 'Lara', 'Tour', 'Pijuan']",Other,Spain,Events,,,9.179318,-5.24274,7,"The content features a section of Roche's website focused on a series of events titled ""Biomarkers on Tour."" This initiative appears to be aimed at healthcare professionals, inviting them to register for exclusive content. The page highlights a specific event related to the biomarker PD-L1, conducted by Lara Pijuan on September 14, 2022, and includes a video presentation. Overall, it serves to educate and engage professionals in the field regarding biomarker-related information and discussions.","event, exclusive, website",www.rocheplus.es,All,0.467225712258983,high,276,Events & Patient Care
862,https://www.rocheplus.es/congresos-eventos/eventos/farmatalks.html,10,www_rocheplus_es_congresos_eventos_eventos_farmatalks_html.txt,200,,Non-Indexable,2,11,109,778,7,3,1,www_rocheplus_es_congresos_eventos_eventos_farmatalks_html.txt,image/www_rocheplus_es_congresos_eventos_eventos_farmatalks_html.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_farmatalks_html.txt.txt,"['Farma', 'Talks']",Oncology-Hematology,Spain,Events,,,1.9052596,-5.6165295,7,"The content features content about a Roche event called ""Farma Talks,"" which focuses on personalized medicine in oncology and key techniques in molecular diagnostics. It highlights the necessity for healthcare professionals to register for access to exclusive content and to view the event. The overall purpose is to inform and engage healthcare professionals regarding upcoming discussions and information on innovative pharmaceutical practices.","event, exclusive, website",www.rocheplus.es,Falling,0.590688815838362,high,476,Events & Patient Care
863,https://www.rocheplus.es/congresos-eventos/eventos/fundamentales.html,7,www_rocheplus_es_congresos_eventos_eventos_fundamentales_html.txt,200,,Non-Indexable,2,46,0,909,49,3,1,www_rocheplus_es_congresos_eventos_eventos_fundamentales_html.txt,image/www_rocheplus_es_congresos_eventos_eventos_fundamentales_html.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_fundamentales_html.txt.txt,[],Other,Spain,Events,,,-3.049419,-14.72148,3,"The content appears to showcase a webpage dedicated to a professional event organized by Roche, focusing on pediatric rehabilitation. It invites healthcare professionals to register for exclusive content related to this specific field. The page features video presentations on topics like multidisciplinary approaches and patient evaluation, emphasizing educational resources for professionals engaged in pediatric care.","users, page, website",www.rocheplus.es,All,0.65386577395855,high,282,Website Metadata
864,https://www.rocheplus.es/congresos-eventos/eventos/historico-eventos-virtuales-roche.html,7,www_rocheplus_es_congresos_eventos_eventos_historico_eventos_virtuales_roche_html.txt,200,,Non-Indexable,2,24,0,1569,7,3,1,www_rocheplus_es_congresos_eventos_eventos_historico_eventos_virtuales_roche_html.txt,image/www_rocheplus_es_congresos_eventos_eventos_historico_eventos_virtuales_roche_html.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_historico_eventos_virtuales_roche_html.txt.txt,[],Other,Spain,Events,,,-10.144202,-9.753506,0,"The content primarily provides an overview of Roche's virtual events related to various therapeutic areas and personalized medicine. It includes a historical list of past events with details such as dates and topics covered, focusing on advanced treatments, diagnostics, and the integration of digital health. The purpose is to inform healthcare professionals about Roche's commitment to ongoing education and collaboration in the pharmaceutical sector, emphasizing the importance of personalized medicine and the use of technology in healthcare.","oncology, professionals, data",www.rocheplus.es,Rising,0.678611367922202,high,188,General Offer Outline
865,https://www.rocheplus.es/congresos-eventos/eventos/I-jornada-enfermeria-oncologica-noreste.html,7,www_rocheplus_es_congresos_eventos_eventos_I_jornada_enfermeria_oncologica_noreste_html.txt,200,,Non-Indexable,2,76,0,1049,6,2,1,www_rocheplus_es_congresos_eventos_eventos_I_jornada_enfermeria_oncologica_noreste_html.txt,image/www_rocheplus_es_congresos_eventos_eventos_I_jornada_enfermeria_oncologica_noreste_html.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_I_jornada_enfermeria_oncologica_noreste_html.txt.txt,[],Oncology-Hematology,Spain,Events,breast cancer,breast cancer,3.659671,-6.827606,7,"The content highlights an event hosted by Roche focused on advancements in oncology nursing, specifically regarding breast cancer. It informs healthcare professionals about the opportunity to register for the event and access exclusive content. The page encourages participants to log in if they are already registered or to register if they haven’t done so yet, promoting engagement and ongoing education in the healthcare field.","event, exclusive, website",www.rocheplus.es,Rising,0.559377819916123,high,30,Events & Patient Care
866,https://www.rocheplus.es/congresos-eventos/eventos/liver-talks.html,7,www_rocheplus_es_congresos_eventos_eventos_liver_talks_html.txt,200,,Non-Indexable,2,20,0,847,6,2,1,www_rocheplus_es_congresos_eventos_eventos_liver_talks_html.txt,image/www_rocheplus_es_congresos_eventos_eventos_liver_talks_html.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_liver_talks_html.txt.txt,"['Liver', 'Talks']",Oncology-Hematology,Spain,Events,,hepatocellular carcinoma,4.7589846,-5.432819,7,"The content features a section from Roche's website promoting ""Liver Talks,"" designed for healthcare professionals. It invites users to register in order to access exclusive content related to experiences in hepatocellular carcinoma. The message emphasizes the importance of attending these events and provides a call-to-action for registration. Overall, the focus is on sharing knowledge and insights within the medical community.","event, exclusive, website",www.rocheplus.es,Rising,0.0165374038881293,high,10,Events & Patient Care
867,https://www.rocheplus.es/congresos-eventos/eventos/meet-expert-ngs.html,7,www_rocheplus_es_congresos_eventos_eventos_meet_expert_ngs_html.txt,200,,Non-Indexable,2,33,0,825,16,4,1,www_rocheplus_es_congresos_eventos_eventos_meet_expert_ngs_html.txt,image/www_rocheplus_es_congresos_eventos_eventos_meet_expert_ngs_html.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_meet_expert_ngs_html.txt.txt,"['Farma', 'Meet', 'NGS', 'Spain']",Oncology-Hematology,Spain,Events,,,9.84856,-6.3926053,7,"The content presents information about an event titled ""Meet the expert NGS 4.0."" It highlights a gathering of over 35 experts in precision oncology from northern Spain, which is organized by Roche Farma. The event aims to address the challenges of personalized cancer treatment. An invitation to register for accessing exclusive content is also mentioned, targeting healthcare professionals.","event, exclusive, website",www.rocheplus.es,Falling,0.836873527460974,high,40,Events & Patient Care
868,https://www.rocheplus.es/congresos-eventos/eventos/phc-summit.html,10,www_rocheplus_es_congresos_eventos_eventos_phc_summit_html.txt,200,,Indexable,1,19,230,837,456,410,0.96875,www_rocheplus_es_congresos_eventos_eventos_phc_summit_html.txt.txt,image/www_rocheplus_es_congresos_eventos_eventos_phc_summit_html.txt.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_phc_summit_html.txt.txt.txt,"['PHC', 'Summit', 'July']",Other,Spain,Events,,,23.160482,13.272051,4,"The content features a webpage promoting the PHC Summit 2021, an event focused on personalized medicine, specifically designed for healthcare professionals. It invites them to register for access to exclusive content and highlights virtual sessions scheduled from July 12 to July 14, including video recaps from each day of the event. The layout emphasizes the importance of participation and ongoing education in the field of personalized medicine.","technologies, artificial, ai",www.rocheplus.es,Rising,0.163576332094412,high,168,Technology
869,https://www.rocheplus.es/congresos-eventos/eventos/phc-summit/revive-la-jornada/12-julio.html,10,www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_12_julio_html.txt,200,,Indexable,2,50,174,752,27,5,0.978021978021978,www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_12_julio_html.txt.txt,image/www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_12_julio_html.txt.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_12_julio_html.txt.txt.txt,"['PHC', 'Summit', 'July']",Other,Spain,Events,,,22.600208,13.7016945,4,"The content promotes an event called the ""PHC Summit,"" focused on personalized medicine. It invites healthcare professionals to register for virtual sessions held on July 12, 13, and 14. The content emphasizes exclusive access to related information and includes a video feature that likely summarizes or highlights key aspects of the event. The design is aimed at engaging professionals in the healthcare field.","technologies, artificial, ai",www.rocheplus.es,Flat,0.908166145131955,high,377,Technology
870,https://www.rocheplus.es/congresos-eventos/eventos/phc-summit/revive-la-jornada/13-julio.html,10,www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_13_julio_html.txt,200,,Indexable,2,50,158,752,27,5,1,www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_13_julio_html.txt,image/www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_13_julio_html.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_13_julio_html.txt.txt,"['PHC', 'Summit', 'July']",Other,Spain,Events,,,23.375242,13.033575,4,"The content features information about a virtual event called the ""PHC Summit,"" focused on personalized medicine. It invites healthcare professionals to register for exclusive content and highlights specific dates for the summit events, taking place from July 12 to July 14. Additionally, there's an option to revisit previous sessions from the event. The overall aim is to engage medical professionals in discussions and knowledge-sharing related to personalized healthcare.","technologies, artificial, ai",www.rocheplus.es,Falling,0.457021231957343,high,384,Technology
871,https://www.rocheplus.es/congresos-eventos/eventos/phc-summit/revive-la-jornada/14-julio.html,10,www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_14_julio_html.txt,200,,Indexable,2,50,144,751,27,5,1,www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_14_julio_html.txt,image/www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_14_julio_html.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_14_julio_html.txt.txt,"['PHC', 'July', 'Summit', 'Jornadas', 'I', 'Medicina', 'Personalizada']",Other,Spain,Events,,,23.76181,13.217022,4,"The content highlights an upcoming virtual event titled ""I Jornadas de Medicina Personalizada"" as part of the PHC Summit 2021, designed for healthcare professionals. The event is scheduled for July 12-14 and encourages registration for exclusive content. It emphasizes the theme of personalized medicine and includes a section for viewing recorded sessions. The layout suggests a focus on engaging professionals in discussions about new developments in healthcare.","technologies, artificial, ai",www.rocheplus.es,Flat,0.0461655537951377,high,383,Technology
872,https://www.rocheplus.es/congresos-eventos/eventos/phc-summit/revive-la-jornada.html,10,www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_html.txt,200,,Indexable,2,39,184,733,24,5,1,www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_html.txt,image/www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_html.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_phc_summit_revive_la_jornada_html.txt.txt,"['July', 'Jornadas', 'I', 'Medicina', 'Personalizada']",Other,Spain,Events,,,5.574334,2.5473237,7,"The content features a promotional layout for a series of virtual events hosted by Roche, specifically the ""I Jornadas de Medicina Personalizada."" It invites healthcare professionals to register and participate, highlighting event dates on July 12, 13, and 14. The content emphasizes personalized medicine and offers access to exclusive materials for registered participants.","event, exclusive, website",www.rocheplus.es,All,0.728623900596307,high,378,Events & Patient Care
873,https://www.rocheplus.es/congresos-eventos/eventos/retos-tratamiento-ame.html,7,www_rocheplus_es_congresos_eventos_eventos_retos_tratamiento_ame_html.txt,200,,Non-Indexable,2,77,0,935,41,5,1,www_rocheplus_es_congresos_eventos_eventos_retos_tratamiento_ame_html.txt,image/www_rocheplus_es_congresos_eventos_eventos_retos_tratamiento_ame_html.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_retos_tratamiento_ame_html.txt.txt,[],Other,Spain,Events,,,-4.5428357,-15.868311,3,"The content highlights a section of Roche's website focused on a healthcare-related event, specifically addressing challenges in the treatment of a medical condition in adult and pediatric patients. It invites healthcare professionals to register for exclusive content and to access past events. The layout features visual elements aimed at engaging medical professionals, with options for further registration and event participation.","users, page, website",www.rocheplus.es,Flat,0.468632182761637,high,310,Website Metadata
874,https://www.rocheplus.es/congresos-eventos/eventos/sarcomas-multidisciplinar.html,10,www_rocheplus_es_congresos_eventos_eventos_sarcomas_multidisciplinar_html.txt,200,,Non-Indexable,1,56,100,1043,832,410,0.974683544303797,www_rocheplus_es_congresos_eventos_eventos_sarcomas_multidisciplinar_html.txt.txt,image/www_rocheplus_es_congresos_eventos_eventos_sarcomas_multidisciplinar_html.txt.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_sarcomas_multidisciplinar_html.txt.txt.txt,[],Oncology-Hematology,Spain,Events,,,23.602545,-9.7388935,12,"The content promotes an online event centered on the multidisciplinary impact on the quality of pathological diagnoses related to sarcomas. It invites healthcare professionals to register for exclusive content and access the virtual event, providing details on how to join if they are already registered. The focus is on enhancing understanding and collaboration in the field of pathology.","cancer, breast, lung",www.rocheplus.es,Flat,0.261560494583272,high,432,Disease Information
875,https://www.rocheplus.es/congresos-eventos/eventos/traspasando-fronteras.html,10,www_rocheplus_es_congresos_eventos_eventos_traspasando_fronteras_html.txt,200,,Non-Indexable,2,26,161,1275,4,4,1,www_rocheplus_es_congresos_eventos_eventos_traspasando_fronteras_html.txt,image/www_rocheplus_es_congresos_eventos_eventos_traspasando_fronteras_html.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_traspasando_fronteras_html.txt.txt,"['Fronteras', 'Traspasando']",Other,Spain,Events,,,-2.1820846,-17.66252,3,"The content presents a welcome page for healthcare professionals visiting Roche's events section. It emphasizes registration for exclusive content, hinting at a specific event titled ""Traspasando Fronteras 2021."" The page aims to engage users by inviting them to sign in or register to access event details and related resources. The overall design is welcoming and geared towards professionals in the healthcare field.","users, page, website",www.rocheplus.es,Falling,0.950073402394811,high,268,Website Metadata
876,https://www.rocheplus.es/congresos-eventos/eventos/xii-revision-de-congresos-de-patologia-y-oncologia.html,7,www_rocheplus_es_congresos_eventos_eventos_xii_revision_de_congresos_de_patologia_y_oncologia_html.txt,200,,Non-Indexable,2,59,0,797,9,5,1,www_rocheplus_es_congresos_eventos_eventos_xii_revision_de_congresos_de_patologia_y_oncologia_html.txt,image/www_rocheplus_es_congresos_eventos_eventos_xii_revision_de_congresos_de_patologia_y_oncologia_html.txt.png,text/www_rocheplus_es_congresos_eventos_eventos_xii_revision_de_congresos_de_patologia_y_oncologia_html.txt.txt,"['Pathology', 'Congresses', 'Review', 'XII', 'Oncology']",Oncology-Hematology,Spain,Events,,,5.0216904,-8.65404,7,"The content highlights the ""XII Review of Pathology and Oncology Congresses"" hosted by Roche. It invites healthcare professionals to register for exclusive content and emphasizes the importance of registration to access the event. The interface appears user-friendly, with options for registration and accessing previous event materials, aimed at facilitating continued professional education in the fields of pathology and oncology.","event, exclusive, website",www.rocheplus.es,Flat,0.66422147611046,high,143,Events & Patient Care
877,https://www.rocheplus.es/congresos-eventos.html,11,www_rocheplus_es_congresos_eventos_html.txt,200,,Indexable,1,28,252,903,1269,410,0.955555555555556,www_rocheplus_es_congresos_eventos_html.txt.txt,image/www_rocheplus_es_congresos_eventos_html.txt.txt.png,text/www_rocheplus_es_congresos_eventos_html.txt.txt.txt,"['Events', 'Congresses']",Other,Spain,Events,,,-7.0031815,-16.423431,3,"The content features a section from Roche's professional website focused on ""Congresses & Events."" It highlights virtual events such as live webinars that provide updates on scientific advances. Additionally, it offers access to the latest oral presentations made by Roche at international congresses. This platform aims to engage healthcare professionals by providing valuable resources and information.","users, page, website",www.rocheplus.es,Flat,0.0574348285116944,high,446,Website Metadata
878,https://www.rocheplus.es/contacto.html,11,www_rocheplus_es_contacto_html.txt,200,,Non-Indexable,1,17,129,3311,1246,410,1,www_rocheplus_es_contacto_html.txt,image/www_rocheplus_es_contacto_html.txt.png,text/www_rocheplus_es_contacto_html.txt.txt,"['Contact', 'Additional']",Other,Spain,Metainformation,,,-23.912157,-20.372927,0,"The content presents a ""Contact"" section for Roche, aimed at healthcare professionals seeking medical information. It emphasizes the procedure for inquiries and highlights that personal medical consultations should be directed to a physician, rather than through the form. There are also provisions regarding data privacy and the treatment of personal information. Additional navigation options for general information, products, and medical details are available, along with a registration prompt for exclusive content.","oncology, professionals, data",www.rocheplus.es,Rising,0.727283489776908,high,283,General Offer Outline
879,https://www.rocheplus.es/formacion/amazonas.html,8,www_rocheplus_es_formacion_amazonas_html.txt,200,,Non-Indexable,1,36,0,1370,877,410,1,www_rocheplus_es_formacion_amazonas_html.txt,image/www_rocheplus_es_formacion_amazonas_html.txt.png,text/www_rocheplus_es_formacion_amazonas_html.txt.txt,[],Oncology-Hematology,Spain,Patient support,"lung cancer, diagnosis, treatment options, patient associations",lung cancer,23.651686,-14.714159,12,"The content presents the #PulmónAmazonas initiative, which focuses on medical education for lung cancer patients, facilitated by other patients. It highlights a welcoming message and outlines key topics such as the types of lung cancer, diagnosis, treatment options, and the role of patient associations. Additionally, it features a video resource aimed at educating viewers about lung cancer from a patient-to-patient perspective, promoting accessible information and support.","cancer, breast, lung",www.rocheplus.es,All,0.386143456765076,high,327,Disease Information
880,https://www.rocheplus.es/formacion/breast-link.html,10,www_rocheplus_es_formacion_breast_link_html.txt,200,,Non-Indexable,1,30,214,786,832,410,0.959183673469388,www_rocheplus_es_formacion_breast_link_html.txt.txt,image/www_rocheplus_es_formacion_breast_link_html.txt.txt.png,text/www_rocheplus_es_formacion_breast_link_html.txt.txt.txt,"['Link', 'Breast']",Oncology-Hematology,Spain,Patient support,breast cancer,breast cancer,7.589371,-6.811226,7,"The content features a section from Roche's website dedicated to ""Breast Link,"" a platform for healthcare professionals focused on updates and resources related to breast cancer. It invites professionals to register for access to exclusive content, including tools and information derived from relevant studies. There is an emphasis on keeping up-to-date with scientific news and approaches to breast cancer.","event, exclusive, website",www.rocheplus.es,All,0.912791614773048,high,473,Events & Patient Care
881,https://www.rocheplus.es/formacion/competencias-interaccion-paciente.html,10,www_rocheplus_es_formacion_competencias_interaccion_paciente_html.txt,200,,Non-Indexable,1,67,96,856,864,410,0.971830985915493,www_rocheplus_es_formacion_competencias_interaccion_paciente_html.txt.txt,image/www_rocheplus_es_formacion_competencias_interaccion_paciente_html.txt.txt.png,text/www_rocheplus_es_formacion_competencias_interaccion_paciente_html.txt.txt.txt,[],Neurology,Spain,Offer outline,,,6.1008897,8.317529,7,"The content of the content focuses on a training program offered by Roche, aimed at healthcare professionals. It emphasizes competencies related to patient interactions, particularly in the context of using artificial intelligence in neuromuscular health care. The page provides information about accessing specific training sections, encouraging users to register for Roche+ to gain access to exclusive content and resources.","event, exclusive, website",www.rocheplus.es,Rising,0.877954598474581,high,327,Events & Patient Care
882,https://www.rocheplus.es/formacion/curso-athenea.html,10,www_rocheplus_es_formacion_curso_athenea_html.txt,200,,Non-Indexable,1,32,73,1172,832,410,0.96078431372549,www_rocheplus_es_formacion_curso_athenea_html.txt.txt,image/www_rocheplus_es_formacion_curso_athenea_html.txt.txt.png,text/www_rocheplus_es_formacion_curso_athenea_html.txt.txt.txt,"['Curso', 'Athenea']",Oncology-Hematology,Spain,Offer outline,,,21.576488,-15.153286,12,"The content presents an online training course, ""Curso Athenea,"" aimed at oncology and hematology nurses. It emphasizes the need for continuous education due to the complexity of oncology patients and the evolving therapies used in clinical practice. The course covers vital aspects of oncology and hematology treatment, including drug toxicity management, nursing consultation importance, and the organization of day hospitals. It is designed to bolster practical knowledge and improve patient care, aligning with evidence-based practices. Additionally, the content provides information about course duration, objectives, faculty, and accreditation details, ensuring it caters specifically to healthcare professionals.","cancer, breast, lung",www.rocheplus.es,Falling,0.170719484434483,high,390,Disease Information
883,https://www.rocheplus.es/formacion/curso-neuroiag.html,7,www_rocheplus_es_formacion_curso_neuroiag_html.txt,200,,Non-Indexable,1,86,0,1087,866,410,1,www_rocheplus_es_formacion_curso_neuroiag_html.txt,image/www_rocheplus_es_formacion_curso_neuroiag_html.txt.png,text/www_rocheplus_es_formacion_curso_neuroiag_html.txt.txt,['AI'],Neurology,Spain,Technology,,,13.676069,11.568817,7,"The content features a section of Roche's professional platform focused on a training program called ""NeuroIA."" This program emphasizes the integration of artificial intelligence in neuromuscular health care. The content is targeted toward healthcare professionals, encouraging them to register for exclusive access to course materials. It highlights the benefits of using AI in everyday medical practices.","event, exclusive, website",www.rocheplus.es,Falling,0.736118941431789,high,143,Events & Patient Care
884,https://www.rocheplus.es/formacion/curso-SEEOne.html,7,www_rocheplus_es_formacion_curso_SEEOne_html.txt,200,,Non-Indexable,1,24,0,1086,845,410,1,www_rocheplus_es_formacion_curso_SEEOne_html.txt,image/www_rocheplus_es_formacion_curso_SEEOne_html.txt.png,text/www_rocheplus_es_formacion_curso_SEEOne_html.txt.txt,"['SEEO', 'Nursing', 'Spanish', 'Society', 'Oncology']",Oncology-Hematology,Spain,Patient support,,,4.3877034,-7.9471445,7,"The content showcases a section from Roche's website dedicated to a training project called ""SEEOne,"" which focuses on enhancing oncology care through educational content. The initiative aims to support oncology nursing professionals by emphasizing their essential role in patient care. It is developed in collaboration with the Spanish Society of Oncology Nursing (SEEO) and includes details about the project's online format, duration, and start date, highlighting its goal of improving the quality of cancer care.","event, exclusive, website",www.rocheplus.es,Flat,0.119229026788018,high,328,Events & Patient Care
885,https://www.rocheplus.es/formacion.html,11,www_rocheplus_es_formacion_html.txt,200,,Indexable,1,18,149,2545,1285,410,0.945945945945946,www_rocheplus_es_formacion_html.txt.txt,image/www_rocheplus_es_formacion_html.txt.txt.png,text/www_rocheplus_es_formacion_html.txt.txt.txt,[],Other,Spain,Technology,,,5.1644063,7.9465604,7,"The content outlines Roche's online training platform, designed for healthcare professionals to enhance their skills and knowledge in various specialties. It emphasizes the availability of specialized courses related to oncology, neurology, immunotherapy, and more, integrating modern themes such as artificial intelligence in healthcare. Additionally, the content promotes registration for access to exclusive educational resources and highlights user testimonials praising the practical nature and informative quality of the courses. Overall, the purpose is to support continuous professional development for healthcare providers through tailored educational offerings.","event, exclusive, website",www.rocheplus.es,Flat,0.322196209815195,high,416,Events & Patient Care
886,https://www.rocheplus.es/formacion/ia-boot-camp.html?namespace=s7viewers,7,www_rocheplus_es_formacion_ia_boot_camp_html_namespace_s7viewers.txt,200,,Non-Indexable,2,53,0,1377,10,1,1,www_rocheplus_es_formacion_ia_boot_camp_html_namespace_s7viewers.txt,image/www_rocheplus_es_formacion_ia_boot_camp_html_namespace_s7viewers.txt.png,text/www_rocheplus_es_formacion_ia_boot_camp_html_namespace_s7viewers.txt.txt,"['AI', 'Bootcamp']",Other,Spain,Technology,,,10.322391,8.224651,7,"The content features a promotional section for Roche's AI Bootcamp, aimed at healthcare professionals. It highlights a course focused on artificial intelligence, inviting attendees to learn about its current applications and future potential in the healthcare sector. There is an encouraging message to register for exclusive content, emphasizing accessibility to further resources on the subject.","event, exclusive, website",www.rocheplus.es,Falling,0.717263584851605,high,85,Events & Patient Care
887,https://www.rocheplus.es/formacion/ia-boot-camp.html,7,www_rocheplus_es_formacion_ia_boot_camp_html.txt,200,,Non-Indexable,1,53,0,1377,833,410,0.96,www_rocheplus_es_formacion_ia_boot_camp_html.txt.txt,image/www_rocheplus_es_formacion_ia_boot_camp_html.txt.txt.png,text/www_rocheplus_es_formacion_ia_boot_camp_html.txt.txt.txt,"['AI', 'Bootcamp']",Other,Spain,Events,,,9.42481,7.930175,7,"The content features a promotional section for an AI Bootcamp hosted by Roche, targeting healthcare professionals. It highlights an educational initiative focused on artificial intelligence in the medical field, inviting participants to discover future advancements. The content encourages registration to access exclusive materials, emphasizing the company's commitment to professional training and innovation in healthcare.","event, exclusive, website",www.rocheplus.es,Flat,0.605958707659865,high,279,Events & Patient Care
888,https://www.rocheplus.es/formacion/introduccion-a-la-genomica.html,7,www_rocheplus_es_formacion_introduccion_a_la_genomica_html.txt,200,,Non-Indexable,1,45,0,1531,839,410,1,www_rocheplus_es_formacion_introduccion_a_la_genomica_html.txt,image/www_rocheplus_es_formacion_introduccion_a_la_genomica_html.txt.png,text/www_rocheplus_es_formacion_introduccion_a_la_genomica_html.txt.txt,"['Introduction', 'Genomics']",Oncology-Hematology,Spain,Events,,,26.42675,-13.704643,12,"The content highlights an online course titled ""Introduction to Genomics,"" aimed at healthcare professionals, particularly oncologists, who need to understand genomic concepts to enhance personalized medicine approaches in cancer treatment. It outlines the course content, objectives, and key instructors, emphasizing the importance of genomic knowledge in interpreting molecular data and collaborating effectively within multidisciplinary teams. The course aims to provide foundational knowledge and clinical applications of genomics, particularly related to cancer, thus enhancing treatment personalization for patients.","cancer, breast, lung",www.rocheplus.es,All,0.712202222934117,high,173,Disease Information
889,https://www.rocheplus.es/formacion/lung-link.html,11,www_rocheplus_es_formacion_lung_link_html.txt,200,,Non-Indexable,1,28,150,1278,832,410,1,www_rocheplus_es_formacion_lung_link_html.txt,image/www_rocheplus_es_formacion_lung_link_html.txt.png,text/www_rocheplus_es_formacion_lung_link_html.txt.txt,"['Link', 'Lung']",Oncology-Hematology,Spain,Metainformation,,lung cancer,23.997694,-11.154259,12,"The content features a welcome message for ""Lung Link,"" a new section dedicated to updates on lung cancer. It's aimed at healthcare professionals, providing resources and information related to the disease. The site encourages user registration for exclusive content and highlights the continuous updates available in this area of oncology. Additionally, there are options for accessing and navigating the website.","cancer, breast, lung",www.rocheplus.es,All,0.755626509899919,high,358,Disease Information
890,https://www.rocheplus.es/formacion/ngstalks.html,8,www_rocheplus_es_formacion_ngstalks_html.txt,200,,Non-Indexable,1,9,0,719,834,410,1,www_rocheplus_es_formacion_ngstalks_html.txt,image/www_rocheplus_es_formacion_ngstalks_html.txt.png,text/www_rocheplus_es_formacion_ngstalks_html.txt.txt,"['Talks', 'NGS']",Neurology,Spain,Events,,,25.783388,20.62059,4,"The content features information about ""NGS Talks 2023,"" which comprises monthly virtual discussions lasting 45 minutes aimed at healthcare professionals. The talks focus on integrating artificial intelligence in neuromuscular health care. Additionally, there is an option to view all past sessions for those who missed them. The overall purpose is to provide ongoing education and updates in the medical field.","technologies, artificial, ai",www.rocheplus.es,Falling,0.189351735618576,high,127,Technology
891,https://www.rocheplus.es/formacion/solicita-informacion-error.html,6,www_rocheplus_es_formacion_solicita_informacion_error_html.txt,200,,Indexable,,38,0,735,1,1,1,www_rocheplus_es_formacion_solicita_informacion_error_html.txt,image/www_rocheplus_es_formacion_solicita_informacion_error_html.txt.png,text/www_rocheplus_es_formacion_solicita_informacion_error_html.txt.txt,[],Other,Spain,Metainformation,,,-1.2596145,-19.13968,3,"The content displays an error message related to a request for training information on the Roche website. It indicates that there was an issue with submitting the request and prompts the user to return in order to complete the registration process. The content is directed towards healthcare professionals, emphasizing exclusive access to training resources and courses.","users, page, website",www.rocheplus.es,Flat,0.797699201608177,medium,205,Website Metadata
892,https://www.rocheplus.es/informacion-medica.html,11,www_rocheplus_es_informacion_medica_html.txt,200,,Indexable,1,27,154,941,2078,410,1,www_rocheplus_es_informacion_medica_html.txt,image/www_rocheplus_es_informacion_medica_html.txt.png,text/www_rocheplus_es_informacion_medica_html.txt.txt,[],Other,Spain,Offer outline,,,-24.434734,-20.372234,0,"The content focuses on providing medical information for healthcare professionals. It emphasizes Roche's commitment to offering objective and high-quality scientific answers regarding their pharmaceutical products and therapeutic areas. Additionally, there is a visual element suggesting interactive features, including a video that aims to address relevant health-related questions. The overall purpose appears to be supporting professionals with reliable information and resources.","oncology, professionals, data",www.rocheplus.es,Falling,0.669969106452039,high,339,General Offer Outline
893,https://www.rocheplus.es/innovacion/estilo-de-vida/app-p4p.html,10,www_rocheplus_es_innovacion_estilo_de_vida_app_p4p_html.txt,200,,Indexable,2,76,118,4264,114,16,1,www_rocheplus_es_innovacion_estilo_de_vida_app_p4p_html.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_app_p4p_html.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_app_p4p_html.txt.txt,"['Plan', 'Professionals', 'Spain']",Other,Spain,Technology,,,28.320988,14.186576,4,"The content discusses the launch of an application called ""Plan for Professionals"" (P4P), designed to improve the management of healthcare personnel in Spain. It addresses the challenges posed by labor shortages and outdated manual processes in the healthcare sector, emphasizing the need for digital tools to enhance scheduling and organization. The P4P platform aims to facilitate real-time planning of shifts and services for medical staff, ultimately improving efficiency and the quality of care provided in healthcare facilities. The content serves to inform healthcare professionals about new innovations aimed at addressing staffing and operational challenges within the industry.","technologies, artificial, ai",www.rocheplus.es,Rising,0.353689501499316,high,106,Technology
894,https://www.rocheplus.es/innovacion/estilo-de-vida/Apps-relajacion.html,10,www_rocheplus_es_innovacion_estilo_de_vida_Apps_relajacion_html.txt,200,,Indexable,2,42,123,2333,52,15,1,www_rocheplus_es_innovacion_estilo_de_vida_Apps_relajacion_html.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_Apps_relajacion_html.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_Apps_relajacion_html.txt.txt,['COVID'],Other,Spain,Technology,,,23.741255,19.04416,4,"The content discusses various relaxation and meditation apps aimed at helping healthcare professionals manage stress, particularly in the context of the pressures faced during the COVID-19 pandemic. It highlights the importance of mental health strategies such as mindfulness and meditation, introducing specific applications that can assist users in achieving a state of calm and improving their overall well-being. The purpose is to provide valuable resources for medical professionals seeking to alleviate stress through technology, encouraging them to incorporate these tools into their daily routines.","technologies, artificial, ai",www.rocheplus.es,Rising,0.363344739473417,high,159,Technology
895,https://www.rocheplus.es/innovacion/estilo-de-vida/chaterapia-el-movil-como-herramienta-de-atencion-psicologica.html,10,www_rocheplus_es_innovacion_estilo_de_vida_chaterapia_el_movil_como_herramienta_de_atencion_psicologica_html.txt,200,,Indexable,2,57,124,2257,80,15,0.982456140350877,www_rocheplus_es_innovacion_estilo_de_vida_chaterapia_el_movil_como_herramienta_de_atencion_psicologica_html.txt.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_chaterapia_el_movil_como_herramienta_de_atencion_psicologica_html.txt.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_chaterapia_el_movil_como_herramienta_de_atencion_psicologica_html.txt.txt.txt,['Chaterapia'],Other,Spain,Technology,,,24.278032,18.688606,4,"The content discusses the concept of ""Chaterapia,"" a digital platform utilizing mobile chat as a means for psychological support and mental health management. It highlights a study that demonstrates the effectiveness of this approach for aiding patients with mental health disorders, emphasizing the importance of accessible psychological care. Additionally, it touches on the role of artificial intelligence in detecting mental health issues through vocal analysis and other innovative technologies aimed at enhancing patient care, particularly in remote or underserved areas. The overall purpose is to inform healthcare professionals about advancements in mental health treatment and the integration of technology to improve access and support for patients.","technologies, artificial, ai",www.rocheplus.es,All,0.0542214418028152,high,182,Technology
896,https://www.rocheplus.es/innovacion/estilo-de-vida/cibercondria.html,10,www_rocheplus_es_innovacion_estilo_de_vida_cibercondria_html.txt,200,,Indexable,2,52,149,4508,114,16,1,www_rocheplus_es_innovacion_estilo_de_vida_cibercondria_html.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_cibercondria_html.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_cibercondria_html.txt.txt,"['COVID', 'Spain']",Other,Spain,Patient support,,,23.127312,14.972715,4,"The content discusses the phenomenon of ""cyberchondria,"" where individuals excessively seek health information online, often leading to anxiety and misdiagnosis. It highlights the growing tendency of people in Spain to use search engines for medical queries rather than consulting healthcare professionals, particularly during the COVID-19 pandemic. The article emphasizes the importance of utilizing reliable medical sources, understanding the risks of self-diagnosis, and considering the internet as a supplement to professional healthcare rather than a substitute. Additionally, it suggests psychological support for those experiencing severe anxiety related to health concerns. The overall purpose is to raise awareness about the challenges of seeking health information online and to promote safer practices when doing so.","technologies, artificial, ai",www.rocheplus.es,Rising,0.131072974189988,high,66,Technology
897,https://www.rocheplus.es/innovacion/estilo-de-vida/claves-wearable.html,10,www_rocheplus_es_innovacion_estilo_de_vida_claves_wearable_html.txt,200,,Indexable,2,57,155,2376,52,15,0.971014492753623,www_rocheplus_es_innovacion_estilo_de_vida_claves_wearable_html.txt.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_claves_wearable_html.txt.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_claves_wearable_html.txt.txt.txt,['COVID'],Other,Spain,Technology,,,35.20823,10.454259,4,"The content discusses the growing market for wearable health devices, emphasizing their increasing importance in managing personal health, particularly in the context of the COVID-19 pandemic. It outlines key factors to consider when selecting wearables, including regulatory compliance, technical features, user experience, and compatibility with smartphones. The article provides insights on the expected market growth and highlights the need for consumers to choose devices wisely to ensure they meet their health monitoring needs effectively. The purpose is to inform healthcare professionals about wearable technology and assist them in making informed recommendations to patients.","technologies, artificial, ai",www.rocheplus.es,Falling,0.490599957011652,high,248,Technology
898,https://www.rocheplus.es/innovacion/estilo-de-vida/combatir-la-obesidad.html,10,www_rocheplus_es_innovacion_estilo_de_vida_combatir_la_obesidad_html.txt,200,,Indexable,2,58,154,2527,53,16,0.972972972972973,www_rocheplus_es_innovacion_estilo_de_vida_combatir_la_obesidad_html.txt.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_combatir_la_obesidad_html.txt.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_combatir_la_obesidad_html.txt.txt.txt,[],CVRM,Spain,Technology,"obesity, optogenetics, vagus nerve, intragastric balloon, capsule-based balloon delivery system",obesity,34.826656,4.2112527,4,"The content discusses innovative medical techniques and devices aimed at combating obesity, an escalating public health issue. It highlights various approaches, including a breakthrough device that employs optogenetics to stimulate the vagus nerve and create a sensation of fullness, as well as less invasive options like the intragastric balloon and a new capsule-based balloon delivery system. The purpose of the content is to inform healthcare professionals about advancements in obesity treatment methods, addressing the urgency of tackling this significant health epidemic.","technologies, artificial, ai",www.rocheplus.es,Rising,0.207484405007259,high,385,Technology
899,https://www.rocheplus.es/innovacion/estilo-de-vida/crowdfunding.html,10,www_rocheplus_es_innovacion_estilo_de_vida_crowdfunding_html.txt,200,,Indexable,2,56,139,2457,52,15,0.96969696969697,www_rocheplus_es_innovacion_estilo_de_vida_crowdfunding_html.txt.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_crowdfunding_html.txt.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_crowdfunding_html.txt.txt.txt,"['Parkinson', 'Aarn']",Other,Spain,Research,"Parkinson's, pill dispenser, respiratory diseases","Parkinson's disease, respiratory diseases",30.383562,11.47201,4,"The content discusses the role of crowdfunding and crowdsourcing in the medical field, emphasizing their effectiveness in financing new therapies and enhancing patient quality of life. It highlights various examples, such as Aarn's case, where collective efforts helped raise funds for his medical needs. Additionally, it touches on innovations, like a pill dispenser for Parkinson's patients developed through TikTok collaboration, and ongoing research collaborations aimed at studying respiratory diseases. The content aims to inform healthcare professionals about the impact of collective financial efforts and technological innovations in improving healthcare outcomes.","technologies, artificial, ai",www.rocheplus.es,All,0.0061608344415276,high,359,Technology
900,https://www.rocheplus.es/innovacion/estilo-de-vida/generacion-recetas-medicas-tecnologia-bitcoin.html,10,www_rocheplus_es_innovacion_estilo_de_vida_generacion_recetas_medicas_tecnologia_bitcoin_html.txt,200,,Indexable,2,60,114,2277,52,15,1,www_rocheplus_es_innovacion_estilo_de_vida_generacion_recetas_medicas_tecnologia_bitcoin_html.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_generacion_recetas_medicas_tecnologia_bitcoin_html.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_generacion_recetas_medicas_tecnologia_bitcoin_html.txt.txt,"['Prescrypto', 'Bitcoin']",Other,Spain,Technology,"blockchain technology, cryptocurrencies, Bitcoin, Prescrypto, MedBlockChain, artificial intelligence, medication dosages",,42.760693,9.503223,4,"The content discusses the intersection of healthcare and technology, particularly focusing on how blockchain technology and cryptocurrencies like Bitcoin are set to revolutionize the process of prescribing medications. It highlights new applications and initiatives, such as Prescrypto and MedBlockChain, which aim to enhance the traceability and security of electronic prescriptions while improving efficiencies in medication dispensation. Additionally, it touches on the potential use of artificial intelligence to determine personalized medication dosages. Overall, the content serves to inform healthcare professionals about innovative developments within the pharmaceutical industry that leverage emerging technologies for better patient care.","technologies, artificial, ai",www.rocheplus.es,All,0.754902366835428,high,167,Technology
901,https://www.rocheplus.es/innovacion/estilo-de-vida/herramientas-digitales-para-sanitarios.html,10,www_rocheplus_es_innovacion_estilo_de_vida_herramientas_digitales_para_sanitarios_html.txt,200,,Indexable,2,61,156,2448,52,15,1,www_rocheplus_es_innovacion_estilo_de_vida_herramientas_digitales_para_sanitarios_html.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_herramientas_digitales_para_sanitarios_html.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_herramientas_digitales_para_sanitarios_html.txt.txt,"['Teams', 'Trello', 'Asana', 'Slack', 'Microsoft']",Other,Spain,Technology,,,26.33197,13.043061,4,"The content discusses collaborative tools designed for healthcare professionals, emphasizing their importance in enhancing communication and project management within medical teams. It highlights various platforms such as Microsoft Teams, Slack, and project management tools like Trello and Asana, which facilitate efficient collaboration and information sharing among doctors, nurses, and pharmacists. The content serves to inform healthcare professionals about the benefits and functionalities of these digital tools, ultimately aiming to improve patient care and operational efficiency in the medical field.","technologies, artificial, ai",www.rocheplus.es,Falling,0.700686038795538,high,134,Technology
902,https://www.rocheplus.es/innovacion/estilo-de-vida/hospitales-del-futuro.html,10,www_rocheplus_es_innovacion_estilo_de_vida_hospitales_del_futuro_html.txt,200,,Indexable,2,60,168,4643,142,16,0.973333333333333,www_rocheplus_es_innovacion_estilo_de_vida_hospitales_del_futuro_html.txt.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_hospitales_del_futuro_html.txt.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_hospitales_del_futuro_html.txt.txt.txt,['AI'],Other,Spain,Technology,,,34.98877,16.884396,4,"The content outlines the technological advancements shaping the future of hospitals, emphasizing the role of digitalization, artificial intelligence, and innovative medical technologies. It discusses the transition towards paperless environments, the integration of telemedicine, and the implementation of AI to enhance patient management and treatment efficiency. Additionally, it highlights the emergence of smart hospital rooms equipped with advanced communication systems and automation to improve patient care and experiences. The overall purpose is to inform healthcare professionals about the ongoing trends and innovations in the healthcare sector.","technologies, artificial, ai",www.rocheplus.es,Rising,0.76319563799388,high,286,Technology
903,https://www.rocheplus.es/innovacion/estilo-de-vida.html,10,www_rocheplus_es_innovacion_estilo_de_vida_html.txt,200,,Indexable,1,36,122,1519,1591,410,1,www_rocheplus_es_innovacion_estilo_de_vida_html.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_html.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_html.txt.txt,[],Other,Spain,Other,,,5.571288,6.875171,7,"The content provides an overview of a professional platform dedicated to healthcare professionals, focusing on Roche's innovative projects, research, and articles. It highlights various topics relevant to the medical community, such as technology in healthcare, artificial intelligence, and alternative therapies. The purpose is to engage healthcare professionals by offering exclusive content, fostering collaboration, and promoting advancements in medical practice and patient care through accessible digital tools and resources.","event, exclusive, website",www.rocheplus.es,Flat,0.748674911602213,high,459,Events & Patient Care
904,https://www.rocheplus.es/innovacion/estilo-de-vida/influencers-y-medicina.html,10,www_rocheplus_es_innovacion_estilo_de_vida_influencers_y_medicina_html.txt,200,,Indexable,2,60,141,2372,59,15,1,www_rocheplus_es_innovacion_estilo_de_vida_influencers_y_medicina_html.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_influencers_y_medicina_html.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_influencers_y_medicina_html.txt.txt,['Spain'],Other,Spain,Technology,,,24.506454,13.066353,4,"The content discusses the emergence of influencers in the healthcare field, highlighting their role as educators and communicators rather than traditional marketers. It emphasizes the legal restrictions on advertising prescription medications in Spain and differentiates between general influencers and those in the health sector, who primarily focus on health education. The article provides examples of notable health influencers, detailing their backgrounds and contributions to health education through various social media platforms. Overall, the purpose is to inform healthcare professionals about the growing influence of digital communication in medicine and the specific responsibilities of health influencers.","technologies, artificial, ai",www.rocheplus.es,Rising,0.0269693934701158,high,29,Technology
905,https://www.rocheplus.es/innovacion/estilo-de-vida/lectores-rss-contra-las-fake-news-sanitarias.html,10,www_rocheplus_es_innovacion_estilo_de_vida_lectores_rss_contra_las_fake_news_sanitarias_html.txt,200,,Indexable,2,55,169,2131,52,15,1,www_rocheplus_es_innovacion_estilo_de_vida_lectores_rss_contra_las_fake_news_sanitarias_html.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_lectores_rss_contra_las_fake_news_sanitarias_html.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_lectores_rss_contra_las_fake_news_sanitarias_html.txt.txt,"['Flipboard', 'RSS', 'Feedly', 'Republic', 'Winds', 'News', 'Various']",Other,Spain,Technology,,,22.866898,14.509029,4,"The content discusses the importance of reliable information sources in healthcare, particularly in light of the spread of fake news. It introduces RSS feed readers as tools for filtering and accessing credible content from reputable medical sources, journals, and blogs efficiently. Various RSS readers are highlighted, including News Republic, Feedly, Winds, and Flipboard, each offering unique features to optimize information retrieval for users. The overall purpose is to inform healthcare professionals about resources that help navigate the deluge of information online, ensuring they stay informed with trustworthy data while avoiding misinformation.","technologies, artificial, ai",www.rocheplus.es,Falling,0.871338082435057,high,163,Technology
906,https://www.rocheplus.es/innovacion/estilo-de-vida/mundo-salud-evolucion.html,10,www_rocheplus_es_innovacion_estilo_de_vida_mundo_salud_evolucion_html.txt,200,,Indexable,2,34,141,4232,114,16,1,www_rocheplus_es_innovacion_estilo_de_vida_mundo_salud_evolucion_html.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_mundo_salud_evolucion_html.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_mundo_salud_evolucion_html.txt.txt,"['Neurology', 'Hematology', 'Oncology']",Other,Spain,Technology,,,5.1434155,4.001476,7,"The content highlights Roche's mobile application, which serves as a key educational tool for healthcare professionals. It offers specialized training content, including online courses across various medical specialties such as Hematology, Neurology, and Oncology, as well as virtual talks led by experts. The app emphasizes the importance of continuous education in adapting to advancements in healthcare technology, particularly the integration of digital tools in healthcare practice (referred to as eHealth). It aims to support professionals in staying updated on trends and improving patient care through innovative resources and organizational tools.","event, exclusive, website",www.rocheplus.es,All,0.416490533714684,high,55,Events & Patient Care
907,https://www.rocheplus.es/innovacion/estilo-de-vida/ozonoterapia-tratamiento-heridas.html,10,www_rocheplus_es_innovacion_estilo_de_vida_ozonoterapia_tratamiento_heridas_html.txt,200,,Indexable,2,67,148,2108,52,15,0.976744186046512,www_rocheplus_es_innovacion_estilo_de_vida_ozonoterapia_tratamiento_heridas_html.txt.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_ozonoterapia_tratamiento_heridas_html.txt.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_ozonoterapia_tratamiento_heridas_html.txt.txt.txt,"['Purdue', 'University']",Other,Spain,Technology,"ozonotherapy, wound healing, antimicrobial properties, portable solution, chronic wounds",,31.202587,2.2706287,4,"The content discusses the innovative medical technique of ozonotherapy, highlighting its benefits in wound healing, particularly for chronic wounds. It emphasizes how this method not only speeds up recovery but also offers antimicrobial properties through a portable solution developed by Purdue University, which allows patients to treat wounds at home. The content positions ozonotherapy as a significant advancement in medical treatments, aiming to alleviate the burden on healthcare systems. Additionally, it mentions broader themes of medical innovation, such as the integration of technology and self-care in healthcare practices. Overall, the purpose of the content is to inform healthcare professionals about the advantages and applications of ozonotherapy in modern medicine.","technologies, artificial, ai",www.rocheplus.es,Flat,0.774541996182234,high,166,Technology
908,https://www.rocheplus.es/innovacion/estilo-de-vida/pildoras-inteligentes.html,10,www_rocheplus_es_innovacion_estilo_de_vida_pildoras_inteligentes_html.txt,200,,Indexable,2,65,157,2295,52,15,0.973333333333333,www_rocheplus_es_innovacion_estilo_de_vida_pildoras_inteligentes_html.txt.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_pildoras_inteligentes_html.txt.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_pildoras_inteligentes_html.txt.txt.txt,[],Other,Spain,Technology,"digital pills, electronic circuits, medication adherence, psychiatric patients, smartphones, wearable devices, treatment outcomes, patient care",,42.825024,9.0076885,4,"The content discusses the emerging technology of digital pills, which are integrated with electronic circuits to monitor medication adherence, particularly in psychiatric patients. It describes how these pills can interact with smartphones and wearable devices to provide real-time data on patient health, facilitating better medication management and potentially improving treatment outcomes. The article emphasizes the innovation behind these digital medications, highlighting their development for specific treatments and addressing challenges like privacy concerns and the need for precise tracking of the pills within the patient's body. Overall, it illustrates the intersection of medicine and technology in enhancing patient care.","technologies, artificial, ai",www.rocheplus.es,Rising,0.982023044859175,high,476,Technology
909,https://www.rocheplus.es/innovacion/estilo-de-vida/quirofanos-hibridos-la-revolucion-de-la-cirugia-smart.html,10,www_rocheplus_es_innovacion_estilo_de_vida_quirofanos_hibridos_la_revolucion_de_la_cirugia_smart_html.txt,200,,Indexable,2,65,152,2217,52,15,1,www_rocheplus_es_innovacion_estilo_de_vida_quirofanos_hibridos_la_revolucion_de_la_cirugia_smart_html.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_quirofanos_hibridos_la_revolucion_de_la_cirugia_smart_html.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_quirofanos_hibridos_la_revolucion_de_la_cirugia_smart_html.txt.txt,[],Other,Spain,Technology,,,38.17492,3.3301039,4,"The content discusses the advancements in hybrid operating rooms, which integrate the latest medical technologies to enhance surgical procedures. It highlights the benefits of these smart operating rooms, including real-time imaging capabilities, improved precision, and the ability to conduct multiple diagnostic procedures during surgery. The content aims to inform healthcare professionals about the innovative potential of these technologies to increase surgical efficiency and patient safety, while also emphasizing the shift from traditional surgical practices to more integrated, multidisciplinary approaches.","technologies, artificial, ai",www.rocheplus.es,Falling,0.900244067362974,high,248,Technology
910,https://www.rocheplus.es/innovacion/estilo-de-vida/radar-covid.html,10,www_rocheplus_es_innovacion_estilo_de_vida_radar_covid_html.txt,200,,Indexable,2,55,138,2095,52,15,0.969230769230769,www_rocheplus_es_innovacion_estilo_de_vida_radar_covid_html.txt.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_radar_covid_html.txt.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_radar_covid_html.txt.txt.txt,"['COVID', 'Radar', 'Spanish', 'Bluetooth']",Other,Spain,Technology,"COVID Radar, COVID-19, Bluetooth technology, potential exposure",,33.516335,10.670073,4,"The content discusses the development and functionality of the COVID Radar mobile application, which was created by the Spanish government to track potential COVID-19 exposures. The app uses Bluetooth technology to anonymously record interactions with individuals who may have tested positive for the virus, aiming to help prevent further transmission. It explains the process of how the app collects data and notifies users of potential exposure while encouraging them to follow local health guidelines. The content serves to inform healthcare professionals about technological advancements in pandemic management and the use of innovative tools in public health initiatives.","technologies, artificial, ai",www.rocheplus.es,All,0.545038254375344,high,268,Technology
911,https://www.rocheplus.es/innovacion/estilo-de-vida/terapias-alterantivas-saludables.html,10,www_rocheplus_es_innovacion_estilo_de_vida_terapias_alterantivas_saludables_html.txt,200,,Indexable,2,51,154,4457,115,17,0.976744186046512,www_rocheplus_es_innovacion_estilo_de_vida_terapias_alterantivas_saludables_html.txt.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_terapias_alterantivas_saludables_html.txt.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_terapias_alterantivas_saludables_html.txt.txt.txt,[],Other,Spain,Patient support,"music therapy, animal-assisted therapy, equine therapy, canine therapy, hydrotherapy, laughter therapy, mental health, physical rehabilitation",,19.719486,20.975557,4,"The content discusses various alternative therapies that, despite lacking a scientific foundation, have been shown to improve the quality of life for patients with specific conditions. It highlights the benefits of music therapy, animal-assisted therapy (specifically equine and canine), hydrotherapy, and laughter therapy, detailing their effects on mental health and physical rehabilitation. The purpose of the content is to inform healthcare professionals about these therapeutic options that could complement traditional medical treatments and to promote a holistic approach to patient care.","technologies, artificial, ai",www.rocheplus.es,Rising,0.807066299890895,high,409,Technology
912,https://www.rocheplus.es/innovacion/estilo-de-vida/werables-para-ver-y-dormir.html,10,www_rocheplus_es_innovacion_estilo_de_vida_werables_para_ver_y_dormir_html.txt,200,,Indexable,2,62,159,2403,52,15,1,www_rocheplus_es_innovacion_estilo_de_vida_werables_para_ver_y_dormir_html.txt,image/www_rocheplus_es_innovacion_estilo_de_vida_werables_para_ver_y_dormir_html.txt.png,text/www_rocheplus_es_innovacion_estilo_de_vida_werables_para_ver_y_dormir_html.txt.txt,['COVID'],Other,Spain,Technology,"smart mask, air quality, smart lenses, vision enhancement, bra, breast cancer, biosensors, COVID-19",breast cancer,37.54487,5.9630165,4,"The content discusses various innovations in wearable technology that enhance health monitoring and treatment capabilities. It highlights multiple examples, such as a smart mask that can disinfect itself and monitor air quality, smart lenses for vision enhancement, and a bra designed to detect breast cancer through biosensors. The overall purpose is to illustrate the advancements in wearable devices and their potential to improve quality of life and medical diagnostics, particularly in the context of ongoing health challenges like COVID-19. The content is tailored for healthcare professionals, emphasizing the intersection of technology and medicine.","technologies, artificial, ai",www.rocheplus.es,All,0.924135916701441,high,269,Technology
913,https://www.rocheplus.es/innovacion.html,11,www_rocheplus_es_innovacion_html.txt,200,,Indexable,1,19,154,1386,2212,410,1,www_rocheplus_es_innovacion_html.txt,image/www_rocheplus_es_innovacion_html.txt.png,text/www_rocheplus_es_innovacion_html.txt.txt,[],Oncology-Hematology,Spain,Research,"melatonin, age-related macular degeneration, cancer prediction, stem cell research, leukemia treatment","age-related macular degeneration, leukemia",35.58604,0.9186807,4,"The content outlines a range of recent scientific and technological advancements relevant to healthcare professionals. It covers various topics, including studies on melatonin for age-related macular degeneration, innovative cancer prediction methods, and breakthroughs in stem cell research for leukemia treatment. The content encourages registration for access to exclusive materials, promoting active participation in a scientific community focused on medical innovation. The articles highlight cutting-edge research and potential applications in clinical settings, catering specifically to medical professionals such as doctors, nurses, and pharmacists.","technologies, artificial, ai",www.rocheplus.es,Flat,0.0319606048540205,high,453,Technology
914,https://www.rocheplus.es/innovacion/infografias/ciberseguridad-ambito-medico.html,10,www_rocheplus_es_innovacion_infografias_ciberseguridad_ambito_medico_html.txt,200,,Indexable,2,54,154,2061,34,11,0.974683544303797,www_rocheplus_es_innovacion_infografias_ciberseguridad_ambito_medico_html.txt.txt,image/www_rocheplus_es_innovacion_infografias_ciberseguridad_ambito_medico_html.txt.txt.png,text/www_rocheplus_es_innovacion_infografias_ciberseguridad_ambito_medico_html.txt.txt.txt,[],Other,Spain,Technology,,,33.926395,13.08528,4,"The content discusses important aspects of cybersecurity specifically related to the healthcare sector, emphasizing the need for robust data protection measures to safeguard sensitive medical information amid increasing digitalization and the rise of telemedicine. It outlines various precautions healthcare professionals and organizations should take, such as data encryption, use of strong passwords, installation of antivirus software, regular data backups, secure deletion practices, and ensuring secure internet connections. The purpose is to inform and provide actionable guidelines for medical professionals to enhance the security of patient data and comply with legal confidentiality requirements.","technologies, artificial, ai",www.rocheplus.es,Falling,0.365757763080424,high,111,Technology
915,https://www.rocheplus.es/innovacion/infografias/hospitales-inteligentes.html,10,www_rocheplus_es_innovacion_infografias_hospitales_inteligentes_html.txt,200,,Indexable,2,54,141,1121,32,10,1,www_rocheplus_es_innovacion_infografias_hospitales_inteligentes_html.txt,image/www_rocheplus_es_innovacion_infografias_hospitales_inteligentes_html.txt.png,text/www_rocheplus_es_innovacion_infografias_hospitales_inteligentes_html.txt.txt,"['Smart', 'Hospitals']",Other,Spain,Technology,,,33.799892,17.230907,4,"The content focuses on the concept of ""Smart Hospitals,"" highlighting the role of artificial intelligence, robotics, and augmented reality in transforming healthcare facilities. It presents the idea that these technological advancements will significantly enhance the functioning of hospitals as we know them. The content aims to engage healthcare professionals, emphasizing innovation in medical services and inviting them to access exclusive resources. Additionally, there is an infographic available for download, which likely elaborates on these topics.","technologies, artificial, ai",www.rocheplus.es,Flat,0.645329248863095,high,204,Technology
916,https://www.rocheplus.es/innovacion/infografias.html,10,www_rocheplus_es_innovacion_infografias_html.txt,200,,Indexable,1,33,120,1182,1564,410,0.96,www_rocheplus_es_innovacion_infografias_html.txt.txt,image/www_rocheplus_es_innovacion_infografias_html.txt.txt.png,text/www_rocheplus_es_innovacion_infografias_html.txt.txt.txt,[],Other,Spain,Technology,"5G, surgery, cybersecurity, regenerative medicine, technologies, care of premature infants",,30.91087,14.024805,4,"The content focuses on providing exclusive resources and infographics related to medical innovation, research, and healthcare advancements for professionals in the pharmaceutical and healthcare sectors. It highlights various topics such as the impact of 5G on surgery, cybersecurity for medical data, regenerative medicine, and technologies that aid in the care of premature infants. The purpose is to educate and engage healthcare professionals by offering insights into recent trends and developments in medicine and technology, fostering a community for scientific collaboration and knowledge sharing.","technologies, artificial, ai",www.rocheplus.es,All,0.236461197299828,high,411,Technology
917,https://www.rocheplus.es/innovacion/infografias/medicina-regenerativa.html,10,www_rocheplus_es_innovacion_infografias_medicina_regenerativa_html.txt,200,,Indexable,2,66,150,1898,34,11,1,www_rocheplus_es_innovacion_infografias_medicina_regenerativa_html.txt,image/www_rocheplus_es_innovacion_infografias_medicina_regenerativa_html.txt.png,text/www_rocheplus_es_innovacion_infografias_medicina_regenerativa_html.txt.txt,['COVID'],Other,Spain,Research,"stem cells, amniotic fluid, lung tissue recovery, COVID-19, cartilage regeneration, knee injuries, wound healing, kidney regeneration","COVID-19, knee injuries",31.384298,-0.16281231,4,"The content focuses on advancements in regenerative medicine, particularly the use of stem cells derived from amniotic fluid and their potential applications in treating various medical conditions. It highlights significant breakthroughs, such as improving lung tissue recovery in COVID-19 patients and facilitating cartilage regeneration in knee injuries. The content discusses ongoing research in regenerative treatments, including the development of new therapies for wound healing and kidney regeneration. Overall, the purpose is to inform healthcare professionals about these innovations and their implications for future medical practices.","technologies, artificial, ai",www.rocheplus.es,Falling,0.0977633712815981,high,492,Technology
918,https://www.rocheplus.es/innovacion/infografias/objetivo-aumentar-natalidad.html,10,www_rocheplus_es_innovacion_infografias_objetivo_aumentar_natalidad_html.txt,200,,Indexable,2,53,142,2098,32,10,1,www_rocheplus_es_innovacion_infografias_objetivo_aumentar_natalidad_html.txt,image/www_rocheplus_es_innovacion_infografias_objetivo_aumentar_natalidad_html.txt.png,text/www_rocheplus_es_innovacion_infografias_objetivo_aumentar_natalidad_html.txt.txt,[],Other,Spain,Technology,"artificial intelligence, embryo selection, artificial wombs, neonatal mortality, monitoring systems, reproductive health",,40.303635,16.19872,4,"The content discusses innovative medical technologies developed to address declining birth rates and neonatal mortality. It highlights the collaboration between artificial intelligence and medicine in areas such as embryo selection, the creation of artificial wombs for premature infants, and monitoring systems to improve care for newborns. The purpose is to inform healthcare professionals about these advancements that aim to enhance reproductive health and support families in raising healthy children, thereby contributing to demographic sustainability.","technologies, artificial, ai",www.rocheplus.es,Flat,0.708972303275992,high,326,Technology
919,https://www.rocheplus.es/innovacion/infografias/revolucion-5g.html,10,www_rocheplus_es_innovacion_infografias_revolucion_5g_html.txt,200,,Indexable,2,41,154,2075,52,11,1,www_rocheplus_es_innovacion_infografias_revolucion_5g_html.txt,image/www_rocheplus_es_innovacion_infografias_revolucion_5g_html.txt.png,text/www_rocheplus_es_innovacion_infografias_revolucion_5g_html.txt.txt,[],Other,Spain,Technology,"5G technology, telemedicine, remote surgeries, real-time patient monitoring, teleconsultations, wearables",,30.774862,15.712518,4,"The content primarily discusses the transformative potential of 5G technology in the field of medicine, highlighting its implications for telemedicine, remote surgeries, and real-time patient monitoring. It emphasizes how 5G can significantly reduce latency, enhance communication reliability, and facilitate the transmission of large data sets, all of which can lead to improved healthcare delivery and research capabilities. Additionally, the content points out various applications of 5G in medical settings, such as teleconsultations and the use of wearables, positioning the technology as a key driver of future medical innovations. The overall purpose is to inform healthcare professionals about advancements and the potential impact of these technologies on patient care and medical practice.","technologies, artificial, ai",www.rocheplus.es,Falling,0.82771200886804,high,102,Technology
920,https://www.rocheplus.es/innovacion/infografias/tecnologia-anti-covid.html,10,www_rocheplus_es_innovacion_infografias_tecnologia_anti_covid_html.txt,200,,Indexable,2,64,155,1942,32,10,0.972222222222222,www_rocheplus_es_innovacion_infografias_tecnologia_anti_covid_html.txt.txt,image/www_rocheplus_es_innovacion_infografias_tecnologia_anti_covid_html.txt.txt.png,text/www_rocheplus_es_innovacion_infografias_tecnologia_anti_covid_html.txt.txt.txt,"['COVID', 'Its']",Other,Spain,Technology,,COVID-19,8.458274,8.4915905,7,"The content discusses Roche's initiatives and innovations aimed at combating the COVID-19 pandemic. It highlights various technological advancements and research efforts, such as the development of vaccines, artificial intelligence for diagnostics, and data analysis tools to track the virus's spread. The content emphasizes the collaboration between researchers, laboratories, and governments in the global effort to mitigate the effects of the pandemic. Its purpose is to inform healthcare professionals about Roche's contributions and the broader technological landscape responding to COVID-19 challenges.","event, exclusive, website",www.rocheplus.es,Flat,0.993156563141896,high,306,Events & Patient Care
921,https://www.rocheplus.es/innovacion/infografias/tecnologia-emergencias.html,10,www_rocheplus_es_innovacion_infografias_tecnologia_emergencias_html.txt,200,,Indexable,2,59,150,2045,32,10,0.972602739726027,www_rocheplus_es_innovacion_infografias_tecnologia_emergencias_html.txt.txt,image/www_rocheplus_es_innovacion_infografias_tecnologia_emergencias_html.txt.txt.png,text/www_rocheplus_es_innovacion_infografias_tecnologia_emergencias_html.txt.txt.txt,[],Other,Spain,Technology,"artificial intelligence, mobile applications, drones, emergency care, response times, patient outcomes",,34.93094,14.826517,4,"The content discusses the role of innovation and technology in enhancing emergency medical response. It highlights various advancements, such as artificial intelligence for predicting emergencies, mobile applications tailored for medical emergencies during flights, and the use of drones for rapid medical supply delivery. It emphasizes the critical importance of timely intervention in life-threatening situations and outlines how these technological tools are transforming emergency care, ultimately aiming to reduce response times and improve patient outcomes. The content is primarily targeted at healthcare professionals, showcasing Roche's commitment to leveraging technology in medical situations.","technologies, artificial, ai",www.rocheplus.es,Falling,0.815340537064804,high,373,Technology
922,https://www.rocheplus.es/innovacion/infografias/tecnologia-fisioterapia-rehabilitacion.html,10,www_rocheplus_es_innovacion_infografias_tecnologia_fisioterapia_rehabilitacion_html.txt,200,,Indexable,2,73,148,2107,32,10,1,www_rocheplus_es_innovacion_infografias_tecnologia_fisioterapia_rehabilitacion_html.txt,image/www_rocheplus_es_innovacion_infografias_tecnologia_fisioterapia_rehabilitacion_html.txt.png,text/www_rocheplus_es_innovacion_infografias_tecnologia_fisioterapia_rehabilitacion_html.txt.txt,[],Neurology,Spain,Technology,"wearables, robotics, virtual reality, rehabilitation technologies, mobility disabilities",,26.659084,21.794474,4,"The content focuses on innovative rehabilitation technologies and their importance in aiding recovery for individuals with physical or neurological injuries. It discusses various advanced tools such as wearables, robotics, and virtual reality, which enhance the rehabilitation process and help individuals regain lost functionalities, particularly for those facing mobility disabilities. The purpose of the content is to inform healthcare professionals about these technological advancements and their applications in rehabilitation, ultimately emphasizing the significance of these innovations in improving patient outcomes.","technologies, artificial, ai",www.rocheplus.es,Flat,0.0987479404530661,high,202,Technology
923,https://www.rocheplus.es/innovacion/infografias/tecnologia-sensorial.html,10,www_rocheplus_es_innovacion_infografias_tecnologia_sensorial_html.txt,200,,Indexable,2,29,76,1121,50,10,0.971830985915493,www_rocheplus_es_innovacion_infografias_tecnologia_sensorial_html.txt.txt,image/www_rocheplus_es_innovacion_infografias_tecnologia_sensorial_html.txt.txt.png,text/www_rocheplus_es_innovacion_infografias_tecnologia_sensorial_html.txt.txt.txt,['LIDAR'],Other,Spain,Technology,,,10.783348,5.6403756,7,"The content showcases information related to sensory technologies applied in robotics, presented by Roche. It emphasizes various sensor types and their applications, such as LIDAR and particle sensors, alongside features like object recognition and haptic technology. The content serves to inform healthcare professionals about innovative developments in robotics that could enhance medical practices. There is also a call to action for professionals to register for access to exclusive content.","event, exclusive, website",www.rocheplus.es,All,0.063218448220019,high,352,Events & Patient Care
924,https://www.rocheplus.es/innovacion/inteligencia-artificial/algoritmos-de-ia.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_algoritmos_de_ia_html.txt,200,,Indexable,2,66,154,3782,187,62,0.974683544303797,www_rocheplus_es_innovacion_inteligencia_artificial_algoritmos_de_ia_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_algoritmos_de_ia_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_algoritmos_de_ia_html.txt.txt.txt,['AI'],Other,Spain,Technology,"artificial intelligence, heart attacks, skin cancer, suicide risks","heart attacks, skin cancer, suicide risks",40.483604,15.43445,4,"The content discusses the potential applications of artificial intelligence (AI) in medicine, emphasizing its benefits in improving diagnostics and predictive capabilities for various health conditions, such as heart attacks, skin cancer, and suicide risks. It highlights research and technological advancements that demonstrate how AI can enhance medical decision-making and patient care, while also acknowledging the need for appropriate regulation of this technology. The content serves to inform healthcare professionals about innovative AI tools and their implications in the medical field.","technologies, artificial, ai",www.rocheplus.es,Falling,0.826986687075042,high,88,Technology
925,https://www.rocheplus.es/innovacion/inteligencia-artificial/aliados-tecnologicos-piel.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_aliados_tecnologicos_piel_html.txt,200,,Indexable,2,57,149,3770,187,62,0.977272727272727,www_rocheplus_es_innovacion_inteligencia_artificial_aliados_tecnologicos_piel_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_aliados_tecnologicos_piel_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_aliados_tecnologicos_piel_html.txt.txt.txt,['AI'],Oncology-Hematology,Spain,Technology,"AI, skin diseases, skin cancer, self-diagnosis apps, robotic explorations, 3D bioprinting, tissue regeneration, wearable technologies, sun exposure",skin cancer,39.93801,-3.5767858,12,"The content focuses on the advancements in dermatology driven by technology and artificial intelligence (AI) at Roche. It discusses how AI tools and deep learning algorithms enhance the diagnosis and treatment of skin diseases, particularly skin cancer, and highlights various innovations such as self-diagnosis apps and robotic explorations for accurate skin assessments. Additionally, it touches on emerging techniques like 3D bioprinting for tissue regeneration and wearable technologies that monitor sun exposure. The purpose is to inform healthcare professionals about cutting-edge solutions and research in dermatology that can improve patient outcomes.","cancer, breast, lung",www.rocheplus.es,Falling,0.687899733478962,high,421,Disease Information
926,https://www.rocheplus.es/innovacion/inteligencia-artificial/app_detectar_autismo.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_app_detectar_autismo_html.txt,200,,Indexable,2,47,109,3614,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_app_detectar_autismo_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_app_detectar_autismo_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_app_detectar_autismo_html.txt.txt,"['University', 'Duke']",Other,Spain,Technology,"SenseToKnow, autism, artificial intelligence, early detection, behavioral indicators, facial expressions, gaze patterns, head movements, blinking frequency, early intervention, behavioral markers",autism,29.517023,26.389877,4,"The content discusses a new mobile application named ""SenseToKnow,"" developed by researchers at Duke University, designed for early detection of autism in children using artificial intelligence. The app analyzes various behavioral indicators, including facial expressions, gaze patterns, head movements, and blinking frequency, to assess the likelihood of a child being on the autism spectrum. It aims to enhance early intervention, providing therapists with detailed insights into specific behavioral markers. The content serves as an informative piece for healthcare professionals, highlighting innovative technological advancements in autism detection and the potential benefits for patient care.","technologies, artificial, ai",www.rocheplus.es,Flat,0.386361182369792,high,205,Technology
927,https://www.rocheplus.es/innovacion/inteligencia-artificial/armas-contra-epilepsia.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_armas_contra_epilepsia_html.txt,200,,Indexable,2,51,148,3925,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_armas_contra_epilepsia_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_armas_contra_epilepsia_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_armas_contra_epilepsia_html.txt.txt,[],Neurology,Spain,Technology,"wearable devices, apps, artificial intelligence tools, epilepsy",epilepsy,28.427744,24.049871,4,"The content discusses the technological advancements and innovations aimed at improving the management of epilepsy, focusing on the development of wearable devices, apps, and artificial intelligence tools. It highlights the challenges faced by patients, such as societal stigma and the unpredictability of seizures, while emphasizing the importance of creating solutions that can predict seizures and enhance patients' quality of life. The content also details specific technological products, their functionalities, and potential benefits, aimed at healthcare professionals interested in epilepsy management. The overarching purpose is to inform and inspire advancements in epilepsy care through innovative technology.","technologies, artificial, ai",www.rocheplus.es,Rising,0.759421489399496,high,332,Technology
928,https://www.rocheplus.es/innovacion/inteligencia-artificial/big-data.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_big_data_html.txt,200,,Indexable,2,41,185,3870,194,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_big_data_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_big_data_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_big_data_html.txt.txt,"['Data', 'Big']",Other,Spain,Technology,,,41.4677,13.107891,4,"The content discusses the role of Big Data and artificial intelligence in the advancement of medicine in the 21st century. It highlights how data analysis can lead to better diagnostics, personalized treatment plans, and disease prevention, particularly through genomics and wearable technology. Additionally, it emphasizes the significance of data in various medical fields, including precision medicine and epidemiology, showcasing specific projects that utilize Big Data for predicting epidemics and improving healthcare outcomes. Overall, the purpose of the content is to inform healthcare professionals about the transformative potential of data-driven approaches in the pharmaceutical and medical sectors.","technologies, artificial, ai",www.rocheplus.es,Flat,0.475449027628065,high,170,Technology
929,https://www.rocheplus.es/innovacion/inteligencia-artificial/cancer-genitourinario.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_cancer_genitourinario_html.txt,200,,Indexable,2,62,109,3676,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_cancer_genitourinario_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_cancer_genitourinario_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_cancer_genitourinario_html.txt.txt,"['AI', 'UK']",Oncology-Hematology,Spain,Research,"artificial intelligence, prostate cancer, genomic analysis, personalized treatment approaches, genetic tests, prognostic accuracy",prostate cancer,39.503098,-9.377184,12,"The content discusses recent advancements in prostate cancer research, particularly the identification of two distinct types of prostate cancer using artificial intelligence (AI). A UK research team discovered that classifying tumors based on their evolutionary pathways could enhance diagnosis and treatment efficacy, moving beyond reliance on individual genetic mutations. The findings, driven by comprehensive genomic analysis and AI neural networks, aim to support personalized treatment approaches for patients. Additionally, the content emphasizes collaboration between various research institutions to develop genetic tests for improved prognostic accuracy in prostate cancer management.","cancer, breast, lung",www.rocheplus.es,All,0.781894627956804,high,287,Disease Information
930,https://www.rocheplus.es/innovacion/inteligencia-artificial/caries-dental.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_caries_dental_html.txt,200,,Indexable,2,60,142,3787,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_caries_dental_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_caries_dental_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_caries_dental_html.txt.txt,['AI'],Other,Spain,Technology,"optical devices, artificial intelligence, dental caries, acidity in dental plaque",,37.608612,6.92389,4,"The content discusses innovative technologies for detecting dental caries, with a focus on the potential of optical devices and artificial intelligence. It highlights a prototype optical device that measures acidity in dental plaque, which can help dentists identify areas at risk for caries. Additionally, it mentions research using AI to diagnose caries more accurately than traditional methods, analyzing images and radiographs. The overall purpose is to inform healthcare professionals about advancements in dental technology that aim to improve early detection and prevention of caries.","technologies, artificial, ai",www.rocheplus.es,Falling,0.234298139591573,high,111,Technology
931,https://www.rocheplus.es/innovacion/inteligencia-artificial/cefaleas.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_cefaleas_html.txt,200,,Indexable,2,57,156,3727,187,62,0.971830985915493,www_rocheplus_es_innovacion_inteligencia_artificial_cefaleas_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_cefaleas_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_cefaleas_html.txt.txt.txt,"['AI', 'These', 'Spain']",Neurology,Spain,Technology,"artificial intelligence, migraines, wearables, electrical stimulation, migraine management",migraines,30.606888,24.505781,4,"The content discusses innovative technologies and devices designed to combat migraines, emphasizing the role of artificial intelligence (AI) in their development. It highlights the prevalence of headaches and migraines in Spain, particularly among women, and presents various technological solutions such as wearables and devices that utilize electrical stimulation to alleviate pain. These innovations aim to predict and treat migraines effectively, demonstrating a shift from traditional pharmacological remedies to more advanced technological approaches. The overarching purpose is to inform healthcare professionals about the latest advancements in migraine management.","technologies, artificial, ai",www.rocheplus.es,Falling,0.617168134034164,high,101,Technology
932,https://www.rocheplus.es/innovacion/inteligencia-artificial/ces-2024.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_ces_2024_html.txt,200,,Indexable,2,86,112,4011,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_ces_2024_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_ces_2024_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_ces_2024_html.txt.txt,"['Parkinson', 'CES']",Other,Spain,Technology,"artificial intelligence, smart rings, health monitors, virtual biopsies, assistive technologies, Parkinson’s disease, visual impairments","Parkinson’s disease, visual impairments",37.1291,20.091825,4,"The content details innovations presented at CES 2024, focusing on advancements in health technology powered by artificial intelligence. It highlights the latest devices aimed at enhancing personal health and well-being, including smart rings, health monitors, virtual biopsies, and assistive technologies for conditions like Parkinson’s disease and visual impairments. The purpose of the content is to inform healthcare professionals about cutting-edge solutions that may improve patient care and health management. Additionally, it encourages readers to register for exclusive content related to these innovations.","technologies, artificial, ai",www.rocheplus.es,Falling,0.871754842356111,high,179,Technology
933,https://www.rocheplus.es/innovacion/inteligencia-artificial/chatbots-medicina.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_chatbots_medicina_html.txt,200,,Indexable,2,60,149,3933,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_chatbots_medicina_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_chatbots_medicina_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_chatbots_medicina_html.txt.txt,"['Youper', 'AI', 'IMPAI']",Other,Spain,Technology,,,35.52018,17.912199,4,"The content discusses the emerging role of health chatbots in primary care, emphasizing their potential to alleviate the workload of healthcare services. It outlines various chatbots, like IMPAI and Youper, that utilize artificial intelligence to assist patients in basic medical inquiries and symptom evaluation. The purpose is to highlight innovative technological solutions that can streamline healthcare processes, enhance patient interactions, and serve as initial points of contact before escalating cases to human professionals, showcasing a shift towards integrating AI in medical support systems.","technologies, artificial, ai",www.rocheplus.es,All,0.729136369282581,high,149,Technology
934,https://www.rocheplus.es/innovacion/inteligencia-artificial/cloud-e-ia.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_cloud_e_ia_html.txt,200,,Indexable,2,80,154,3662,194,62,0.972602739726027,www_rocheplus_es_innovacion_inteligencia_artificial_cloud_e_ia_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_cloud_e_ia_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_cloud_e_ia_html.txt.txt.txt,"['AI', 'Africa']",Other,Spain,Technology,,,37.304306,16.42191,4,"The content discusses the integration of cloud technology and artificial intelligence (AI) in revolutionizing the healthcare sector. It highlights how these technologies can enhance access to medical treatments and data, making advanced healthcare more widely available, particularly in underserved regions like Africa. The content emphasizes the potential of cloud computing to support AI applications in diagnostics and treatment without requiring expensive infrastructure, thus promoting remote healthcare services. Additionally, it mentions ongoing projects and collaborations that demonstrate the practical implications of these technological advancements in medicine.","technologies, artificial, ai",www.rocheplus.es,Flat,0.107913187574263,high,186,Technology
935,https://www.rocheplus.es/innovacion/inteligencia-artificial/contra-cancer-mama.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_contra_cancer_mama_html.txt,200,,Indexable,2,57,103,3843,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_contra_cancer_mama_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_contra_cancer_mama_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_contra_cancer_mama_html.txt.txt,['MIT'],Oncology-Hematology,Spain,Technology,"artificial intelligence, breast cancer, 3D digital mammography, risk assessment models, early detection, personalize treatment strategies",breast cancer,40.006287,-8.212555,12,"The content discusses technological innovations aimed at combating breast cancer, emphasizing the role of artificial intelligence and cutting-edge diagnostic tools. It highlights advancements such as 3D digital mammography, risk assessment models developed by institutions like MIT, and projects that enhance early detection and personalize treatment strategies. The purpose is to inform healthcare professionals about these innovations and their impact on improving survival rates and diagnosis accuracy for breast cancer patients.","cancer, breast, lung",www.rocheplus.es,All,0.100087132512774,high,104,Disease Information
936,https://www.rocheplus.es/innovacion/inteligencia-artificial/contra-trastornos-mentales.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_contra_trastornos_mentales_html.txt,200,,Indexable,2,53,138,3951,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_contra_trastornos_mentales_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_contra_trastornos_mentales_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_contra_trastornos_mentales_html.txt.txt,"['AI', 'COVID']",Other,Spain,Technology,"artificial intelligence, bipolar disorder, schizophrenia, texting intervention, virtual reality platform, suicide prevention, AI to detect suicidal behaviors","bipolar disorder, schizophrenia",37.653023,19.18831,4,"The content discusses advancements in technology, particularly artificial intelligence (AI), aimed at addressing mental health issues and preventing suicide, exacerbated by the COVID-19 pandemic. It highlights various innovative approaches, such as a texting intervention for patients with bipolar disorder and schizophrenia, and a virtual reality platform designed to support clinical practices for mental health professionals. The content also critiques the effectiveness of existing mobile apps for suicide prevention and presents a project that uses AI to detect suicidal behaviors on social media. Overall, the content serves to inform healthcare professionals about emerging technologies and their potential impact on mental health treatment.","technologies, artificial, ai",www.rocheplus.es,Falling,0.551687245797394,high,117,Technology
937,https://www.rocheplus.es/innovacion/inteligencia-artificial/diagnostico-por-voz.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_diagnostico_por_voz_html.txt,200,,Indexable,2,60,156,3889,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_diagnostico_por_voz_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_diagnostico_por_voz_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_diagnostico_por_voz_html.txt.txt,"['Parkinson', 'AI']",CVRM,Spain,Technology,"voice biomarkers, artificial intelligence, cardiovascular diseases, pulmonary issues, Parkinson’s disease, mental health disorders, telemedicine, voice analysis technology","cardiovascular diseases, pulmonary issues, Parkinson's disease, mental health disorders",38.50617,18.8122,4,"The content discusses the innovative use of voice biomarkers in remote diagnostics, particularly in relation to artificial intelligence (AI). It highlights ongoing research efforts to utilize voice characteristics for detecting various medical conditions, including cardiovascular diseases, pulmonary issues, Parkinson’s disease, and mental health disorders. The potential for these technologies to enhance telemedicine by providing non-invasive diagnostic tools that improve patient care and expedite the identification of at-risk individuals is emphasized, as well as collaborations between medical institutions and technology companies. Overall, the content aims to inform healthcare professionals about the advancements in voice analysis technology and its applications in modern medicine.","technologies, artificial, ai",www.rocheplus.es,Rising,0.668697959104519,high,55,Technology
938,https://www.rocheplus.es/innovacion/inteligencia-artificial/ecografia-bolsillo-ia-diagnostico-precoz.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_ecografia_bolsillo_ia_diagnostico_precoz_html.txt,200,,Indexable,2,84,150,3861,188,63,0.980582524271845,www_rocheplus_es_innovacion_inteligencia_artificial_ecografia_bolsillo_ia_diagnostico_precoz_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_ecografia_bolsillo_ia_diagnostico_precoz_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_ecografia_bolsillo_ia_diagnostico_precoz_html.txt.txt.txt,"['IQ', 'COVID', 'Butterfly']",Other,Spain,Technology,"artificial intelligence, COVID-19, Butterfly IQ, portable ultrasound technology, telemedicine",COVID-19,39.43494,16.130066,4,"The content discusses the integration of artificial intelligence and portable ultrasound technology in healthcare, particularly for early diagnosis of diseases like COVID-19. It highlights innovations such as the Butterfly IQ, a portable ultrasound device that allows medical professionals to conduct quick assessments, even in resource-limited settings. The content emphasizes the role of these advanced tools in enhancing diagnostic capabilities, facilitating telemedicine, and improving patient management during challenging times, including a pandemic. Overall, it aims to inform healthcare professionals about the latest technological advancements and their practical applications in modern medicine.","technologies, artificial, ai",www.rocheplus.es,Flat,0.531311621835874,high,74,Technology
939,https://www.rocheplus.es/innovacion/inteligencia-artificial/el-ojo.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_el_ojo_html.txt,200,,Indexable,2,55,108,3777,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_el_ojo_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_el_ojo_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_el_ojo_html.txt.txt,"['AI', 'Alzheimer']",CVRM,Spain,Technology,"artificial intelligence, cardiovascular diseases, heart attacks, neurological disorders, Alzheimer’s, mobile applications","cardiovascular diseases, heart attacks, Alzheimer’s disease",32.166805,22.611254,4,"The content discusses the innovative use of artificial intelligence (AI) in detecting various health conditions through eye examinations. It highlights research on AI tools designed to analyze retinal scans for early diagnosis of cardiovascular diseases, such as heart attacks, and neurological disorders like Alzheimer’s. The content emphasizes the potential of these technologies to provide quick, non-invasive, and cost-effective assessments, thereby revolutionizing disease prevention and management. Additionally, it mentions the development of mobile applications that facilitate this diagnostic process. Overall, the purpose is to inform healthcare professionals about advancements in medical technology and their applications in early disease detection.","technologies, artificial, ai",www.rocheplus.es,Falling,0.806903296259499,high,242,Technology
940,https://www.rocheplus.es/innovacion/inteligencia-artificial/electroencefalograma-ela.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_electroencefalograma_ela_html.txt,200,,Indexable,2,72,142,3726,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_electroencefalograma_ela_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_electroencefalograma_ela_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_electroencefalograma_ela_html.txt.txt,"['Amyotrophic', 'Sclerosis', 'Lateral', 'France', 'EEG', 'Researchers', 'ALS']",Neurology,Spain,Research,"electroencephalography, EEG, Amyotrophic Lateral Sclerosis, ALS, brain wave patterns, neuronal activity, therapeutic interventions",Amyotrophic Lateral Sclerosis,25.925287,27.92616,4,"The content discusses a promising new application of electroencephalography (EEG) in detecting Amyotrophic Lateral Sclerosis (ALS), a serious neurodegenerative disease. Researchers in France have identified a specific profile of brain wave patterns that may help in the early diagnosis of ALS, offering a cost-effective and minimally invasive alternative compared to existing methods. The study indicates that EEG can reveal imbalances in neuronal activity associated with the disease, potentially facilitating timely therapeutic interventions. The content aims to inform healthcare professionals about advancements in ALS research and the role of innovative diagnostic tools.","technologies, artificial, ai",www.rocheplus.es,Flat,0.827614950563649,high,241,Technology
941,https://www.rocheplus.es/innovacion/inteligencia-artificial/electroestimulacion-contra-paraplejia.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_electroestimulacion_contra_paraplejia_html.txt,200,,Indexable,2,61,120,3825,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_electroestimulacion_contra_paraplejia_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_electroestimulacion_contra_paraplejia_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_electroestimulacion_contra_paraplejia_html.txt.txt,"['Tailor', 'Swiss']",Neurology,Spain,Technology,"neural electrostimulation, spinal cord injuries, paraplegia, Tailor, rehabilitation, robotic technologies, muscle activation","spinal cord injuries, paraplegia",25.69966,24.519815,4,"The content focuses on advancements in the use of neural electrostimulation as a therapeutic approach for spinal cord injuries. It discusses a Swiss research project that aims to restore motor functions in individuals with paraplegia through electrical stimulation, highlighting its clinical trials and positive outcomes. Additionally, it covers the development of a hybrid exoskeleton, known as Tailor, designed to enhance rehabilitation through robotic technologies and muscle activation. The article serves to inform healthcare professionals about innovative treatments and technologies aimed at improving mobility and independence for those with spinal injuries.","technologies, artificial, ai",www.rocheplus.es,Rising,0.563986642184444,high,441,Technology
942,https://www.rocheplus.es/innovacion/inteligencia-artificial/enfermedades-congenitas-bebes.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_enfermedades_congenitas_bebes_html.txt,200,,Indexable,2,60,150,3847,187,62,0.978260869565217,www_rocheplus_es_innovacion_inteligencia_artificial_enfermedades_congenitas_bebes_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_enfermedades_congenitas_bebes_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_enfermedades_congenitas_bebes_html.txt.txt.txt,"['III', 'Hospital', 'Madrid', 'Universidad', 'Carlos', 'Gregorio']",Other,Spain,Research,"craniosynostosis, spina bifida, surgical navigation system, augmented reality, 3D imaging, robotic exoskeleton, artificial intelligence, congenital disorders","craniosynostosis, spina bifida",30.957409,22.635935,4,"The content discusses innovative research and technological advancements aimed at addressing congenital malformations in children, particularly focusing on craniosynostosis and spina bifida. It highlights a collaboration between the Universidad Carlos III de Madrid and the Hospital Gregorio Marañón to develop a pioneering surgical navigation system enhanced with augmented reality and detailed 3D imaging, which improves the precision of surgeries for craniosynostosis. Additionally, it mentions the creation of a flexible, low-cost robotic exoskeleton for the rehabilitation of infants with spina bifida. The role of artificial intelligence in early detection of congenital disorders during pregnancy is also emphasized, indicating its potential to significantly enhance maternal and child health outcomes. Overall, the purpose of the content is to inform healthcare professionals about cutting-edge solutions in pediatric medicine and the importance of interdisciplinary collaboration in improving treatment methods.","technologies, artificial, ai",www.rocheplus.es,Rising,0.879264082770682,high,479,Technology
943,https://www.rocheplus.es/innovacion/inteligencia-artificial/enfermedades-reumaticas.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_enfermedades_reumaticas_html.txt,200,,Indexable,2,83,164,3594,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_enfermedades_reumaticas_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_enfermedades_reumaticas_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_enfermedades_reumaticas_html.txt.txt,['Europe'],Other,Spain,Technology,"artificial intelligence, biomarker research, rheumatoid arthritis, gout, osteoarthritis, early-stage biomarkers, clinical guidelines, mobile applications, rheumatology","rheumatoid arthritis, gout, osteoarthritis",30.557701,24.609076,4,"The content discusses the innovative use of artificial intelligence and biomarker research in diagnosing and treating rheumatic diseases, particularly focusing on early detection methods for conditions like rheumatoid arthritis, gout, and osteoarthritis. It highlights ongoing projects and collaborations in Europe aimed at identifying early-stage biomarkers, which could lead to better treatment outcomes. Additionally, the content emphasizes the development of practical clinical guidelines and mobile applications to enhance healthcare quality and patient management for professionals dealing with these conditions. Overall, the purpose is to inform healthcare professionals about advancements in rheumatology and support patient care through scientific research and technological innovations.","technologies, artificial, ai",www.rocheplus.es,Falling,0.203354143001783,high,242,Technology
944,https://www.rocheplus.es/innovacion/inteligencia-artificial/escritura-con-la-mente.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_escritura_con_la_mente_html.txt,200,,Indexable,2,69,164,3634,188,63,1,www_rocheplus_es_innovacion_inteligencia_artificial_escritura_con_la_mente_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_escritura_con_la_mente_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_escritura_con_la_mente_html.txt.txt,"['Stanford', 'University']",Other,Spain,Technology,"tetraplegia, brain-computer interfaces, mental writing systems, eye-tracking apps, assistive technologies",tetraplegia,24.755247,23.015549,4,"The content discusses advancements in communication technology for individuals with tetraplegia, focusing on mental writing systems that utilize brain-computer interfaces. It highlights innovative research from Stanford University, which enables patients to convert neural activity associated with imagined writing into content, achieving speeds comparable to typical smartphone users. Additionally, the content mentions other assistive technologies, such as eye-tracking apps, that help those with mobility impairments communicate. The overall purpose is to inform healthcare professionals about these breakthroughs and their potential to enhance the quality of life for people with severe communication challenges.","technologies, artificial, ai",www.rocheplus.es,Flat,0.5773629731803,high,363,Technology
945,https://www.rocheplus.es/innovacion/inteligencia-artificial/eye-tracking.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_eye_tracking_html.txt,200,,Indexable,2,70,151,3988,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_eye_tracking_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_eye_tracking_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_eye_tracking_html.txt.txt,"['TALLK', 'Amyotrophic', 'Sclerosis', 'Lateral', 'Stentrode', 'ALS']",Neurology,Spain,Technology,"ALS, TALLK app, eye-tracking technology, Stentrode device, brain signals",Amyotrophic Lateral Sclerosis,26.00701,24.235418,4,"The content discusses advancements in technology and research aimed at improving the quality of life for patients with Amyotrophic Lateral Sclerosis (ALS). It highlights innovations such as the TALLK app, which uses eye-tracking technology to enable communication for patients with mobility impairments, and the Stentrode device, which provides a wireless interface for patients to control computers directly using brain signals. The article emphasizes the importance of both technology and ongoing research in finding effective treatments and enhancing patient autonomy and communication capabilities. Overall, the purpose is to inform healthcare professionals of these developments and their potential impact on ALS patient care.","technologies, artificial, ai",www.rocheplus.es,All,0.420334644252761,high,191,Technology
946,https://www.rocheplus.es/innovacion/inteligencia-artificial/farmacos-del-futuro.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_farmacos_del_futuro_html.txt,200,,Indexable,2,62,154,3774,187,62,0.975609756097561,www_rocheplus_es_innovacion_inteligencia_artificial_farmacos_del_futuro_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_farmacos_del_futuro_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_farmacos_del_futuro_html.txt.txt.txt,[],Other,Spain,Technology,"artificial intelligence, virtual reality, 3D printing, personalized medicine, digestible sensors, smart pills, in silico trials, augmented reality",,41.303223,10.021834,4,"The content discusses innovative trends in pharmaceutical development, focusing on the integration of advanced technologies such as artificial intelligence, virtual reality, and 3D printing in creating future medications. It highlights the shift towards personalized medicine, the use of digestible sensors and smart pills, in silico trials, and the application of augmented reality to improve user experience. The content aims to inform healthcare professionals about these advancements, which promise to enhance patient outcomes and revolutionize drug development processes.","technologies, artificial, ai",www.rocheplus.es,Falling,0.430091691972397,high,392,Technology
947,https://www.rocheplus.es/innovacion/inteligencia-artificial/florence-pahola.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_florence_pahola_html.txt,200,,Indexable,2,71,110,3848,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_florence_pahola_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_florence_pahola_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_florence_pahola_html.txt.txt,"['Pahola', 'Together', 'Florence', 'AI', 'COVID', 'World', 'Organization', 'Health']",Other,Spain,Technology,"artificial intelligence, mental health issues, addiction, smoking cessation, stress management, COVID-19, alcohol consumption, drinking habits, mental health disorders","mental health issues, addiction, alcohol consumption",35.78008,18.309286,4,"The content discusses the use of artificial intelligence (AI) in the development of virtual assistants, specifically Florence and Pahola, aimed at supporting individuals in managing mental health issues, addiction, and promoting healthy lifestyles. Florence, backed by the World Health Organization, provides resources and interactive advice on topics such as smoking cessation, stress management, and the impact of COVID-19 on mental health. Pahola focuses on alcohol consumption and offers assessments related to drinking habits. Together, these platforms aim to democratize access to healthcare information and support users in making healthier choices without a judgmental approach. The content highlights the importance of these tools in addressing the increased prevalence of mental health disorders during the pandemic.","technologies, artificial, ai",www.rocheplus.es,Flat,0.945673302043633,high,312,Technology
948,https://www.rocheplus.es/innovacion/inteligencia-artificial/foodtech.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_foodtech_html.txt,200,,Indexable,2,81,123,3821,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_foodtech_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_foodtech_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_foodtech_html.txt.txt,['AI'],Other,Spain,Technology,,,38.02668,7.788513,4,"The content focuses on innovative trends in food technology, particularly the intersection of artificial intelligence and sustainable food production. It discusses solutions for addressing global food security challenges posed by population growth and environmental concerns, highlighting advancements such as personalized diets through AI, 3D food printing, and alternative protein sources derived from microorganisms. The purpose of the content is to inform health professionals about emerging technologies that can enhance nutrition and sustainability in food systems while fostering a better understanding of the relationship between diet and health.","technologies, artificial, ai",www.rocheplus.es,Rising,0.158602582491081,high,386,Technology
949,https://www.rocheplus.es/innovacion/inteligencia-artificial/ganara-la-IA-y-el-aprendizaje-de-maquinas-la-batalla-contra-el-cancer.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_ganara_la_IA_y_el_aprendizaje_de_maquinas_la_batalla_contra_el_cancer_html.txt,200,,Indexable,2,80,163,3833,188,63,1,www_rocheplus_es_innovacion_inteligencia_artificial_ganara_la_IA_y_el_aprendizaje_de_maquinas_la_batalla_contra_el_cancer_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_ganara_la_IA_y_el_aprendizaje_de_maquinas_la_batalla_contra_el_cancer_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_ganara_la_IA_y_el_aprendizaje_de_maquinas_la_batalla_contra_el_cancer_html.txt.txt,"['Watson', 'IBM', 'AI', 'Health']",Oncology-Hematology,Spain,Technology,"artificial intelligence, machine learning, cancer, early detection, personalized treatment strategies, deep learning, IBM Watson Health",,40.96474,-8.900718,12,"The content discusses the advancements in artificial intelligence (AI) and machine learning in the fight against cancer, highlighting their role in improving early detection and personalized treatment strategies. It emphasizes the potential of AI technologies, such as deep learning, to analyze vast datasets for more accurate diagnoses and treatment recommendations. Additionally, it presents real-world applications, like IBM Watson Health and projects from academic institutions, which have begun to successfully implement these technologies in clinical settings. The overall purpose is to inform healthcare professionals about the transformative impact of AI on cancer diagnostics and treatment.","cancer, breast, lung",www.rocheplus.es,Flat,0.731312929100313,high,443,Disease Information
950,https://www.rocheplus.es/innovacion/inteligencia-artificial/guante-exoesqueleto.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_guante_exoesqueleto_html.txt,200,,Indexable,2,56,89,3652,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_guante_exoesqueleto_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_guante_exoesqueleto_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_guante_exoesqueleto_html.txt.txt,"['Florida', 'University', 'Atlantic']",Neurology,Spain,Technology,"robotic glove, stroke, artificial intelligence, soft robotics, pneumatic actuators, tactile feedback, rehabilitation, mobility impairments",stroke,26.640112,23.64714,4,"The content discusses an innovative robotic glove developed by researchers at Florida Atlantic University, designed to assist stroke patients in regaining hand mobility and dexterity through the use of artificial intelligence. The glove, which is lightweight and flexible, utilizes soft robotics and features pneumatic actuators and sensors to enable precise finger movement and tactile feedback. The main goal is to help users perform complex tasks, such as playing the piano, thereby enhancing their rehabilitation process. Additionally, the article highlights the broader implications of such technology in improving the quality of life for individuals affected by similar mobility impairments.","technologies, artificial, ai",www.rocheplus.es,Flat,0.399376278914213,high,406,Technology
951,https://www.rocheplus.es/innovacion/inteligencia-artificial/hospitales-inteligentes.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_hospitales_inteligentes_html.txt,200,,Indexable,2,55,123,3940,187,62,0.976744186046512,www_rocheplus_es_innovacion_inteligencia_artificial_hospitales_inteligentes_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_hospitales_inteligentes_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_hospitales_inteligentes_html.txt.txt.txt,[],Other,Spain,Technology,,,34.05328,17.074476,4,"The content discusses the concept of ""smart hospitals"" and the integration of advanced technologies like IoT, 5G, and artificial intelligence in healthcare. It describes a fictional patient's experience in a technologically advanced hospital, illustrating how digital tools and robotic systems enhance medical procedures, patient monitoring, and overall care. The content emphasizes the potential for improved efficiency, safety, and personalized treatment through the adoption of these innovations. The purpose is to highlight the ongoing transformation in healthcare and to inform healthcare professionals about the latest advancements in the industry.","technologies, artificial, ai",www.rocheplus.es,Rising,0.448679042722221,high,320,Technology
952,https://www.rocheplus.es/innovacion/inteligencia-artificial.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_html.txt,200,,Indexable,1,45,122,2757,1673,410,1,www_rocheplus_es_innovacion_inteligencia_artificial_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_html.txt.txt,['AI'],Other,Spain,Technology,,,37.949734,17.014574,4,"The content primarily focuses on advancements in artificial intelligence (AI) and technology within the healthcare sector, showcasing various innovative applications related to diagnostics, treatment, and patient care. It highlights numerous research projects, tools, and methodologies designed to enhance medical practices, improve early detection of diseases, and facilitate personalized medicine. Additionally, it serves as a platform for healthcare professionals to engage with exclusive content, including podcasts and specialized articles. The overall purpose is to inform and connect professionals involved in the scientific community, particularly those in health-related fields, to share insights and developments in medical technology and AI.","technologies, artificial, ai",www.rocheplus.es,Flat,0.346647669584189,high,472,Technology
953,https://www.rocheplus.es/innovacion/inteligencia-artificial/ia-autismo.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_ia_autismo_html.txt,200,,Indexable,2,52,119,3448,312,64,1,www_rocheplus_es_innovacion_inteligencia_artificial_ia_autismo_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_ia_autismo_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_ia_autismo_html.txt.txt,"['Karolinska', 'Institute', 'Sweden']",Other,Spain,Technology,"AutMedAI, autism",autism,29.799656,26.800182,4,"The content discusses the development of AutMedAI, an artificial intelligence model designed to facilitate early detection of autism in children as young as two years old. It highlights the importance of early diagnosis for effective intervention and improved outcomes, noting the existing limitations of traditional detection methods. The study, conducted by researchers at the Karolinska Institute in Sweden, involved a significant dataset and demonstrated that AutMedAI can accurately identify autism in a high percentage of cases. The purpose of the content is to inform healthcare professionals about advancements in autism detection technology and its impact on personalized medicine.","technologies, artificial, ai",www.rocheplus.es,All,0.345191799224625,high,143,Technology
954,https://www.rocheplus.es/innovacion/inteligencia-artificial/ia-cancer-mama.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_ia_cancer_mama_html.txt,200,,Indexable,2,58,124,3552,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_ia_cancer_mama_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_ia_cancer_mama_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_ia_cancer_mama_html.txt.txt,"['AI', 'Sweden']",Oncology-Hematology,Spain,Technology,"artificial intelligence, breast cancer, cancer detection rate, false positive rates",breast cancer,40.176067,-7.474838,12,"The content discusses the application of artificial intelligence (AI) in breast cancer screening, highlighting a recent study conducted in Sweden that involved over 58,000 women. It emphasizes the findings that AI improved the cancer detection rate by over 4% compared to traditional methods, while also reducing false positive rates. The study advocates for the incorporation of AI alongside human radiologists to enhance diagnostic accuracy. Furthermore, it aims to inform healthcare professionals about the potential benefits and implications of integrating AI in clinical settings for more effective breast cancer screening.","cancer, breast, lung",www.rocheplus.es,Rising,0.699338175136329,high,173,Disease Information
955,https://www.rocheplus.es/innovacion/inteligencia-artificial/ia-contra-cancer.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_ia_contra_cancer_html.txt,200,,Indexable,2,61,111,3662,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_ia_contra_cancer_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_ia_contra_cancer_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_ia_contra_cancer_html.txt.txt,"['CUP', 'AI']",Oncology-Hematology,Spain,Technology,"AI, unknown primary origin (CUP), machine learning, tumors, cancer diagnosis, cancer treatment",unknown primary origin,39.85982,-10.16767,12,"The content discusses a new artificial intelligence tool developed to identify the origins of tumors, especially those of unknown primary origin (CUP), which affect around 3-7% of cancer patients. It highlights the complexities that arise when such cancers manifest metastatically, making treatment decisions challenging. The AI tool utilizes machine learning to analyze genetic sequences from tumors, showing promising results in classifying these unknown tumors, which could potentially increase the number of patients eligible for more precise and effective treatments. The overall purpose is to inform healthcare professionals about advancements in cancer research and the role of AI in enhancing cancer diagnosis and treatment.","cancer, breast, lung",www.rocheplus.es,Flat,0.418928660534291,high,150,Disease Information
956,https://www.rocheplus.es/innovacion/inteligencia-artificial/ia-contra-el-insomnio.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_ia_contra_el_insomnio_html.txt,200,,Indexable,2,74,144,3854,187,62,0.976190476190476,www_rocheplus_es_innovacion_inteligencia_artificial_ia_contra_el_insomnio_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_ia_contra_el_insomnio_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_ia_contra_el_insomnio_html.txt.txt.txt,"['California', 'Technion', 'AI', 'Bryte', 'Israel', 'University', 'MIT']",Other,Spain,Technology,"artificial intelligence, sleep disorders, insomnia, obstructive sleep apnea, wireless sensors, diagnostic methods, smart beds","insomnia, obstructive sleep apnea",40.03212,16.741375,4,"The content discusses the role of artificial intelligence (AI) in addressing sleep disorders, particularly insomnia and obstructive sleep apnea, which affect a significant portion of the global population. It highlights various innovative projects and technologies designed to monitor sleep patterns and enhance sleep quality, including wireless sensors developed by MIT, diagnostic methods from Technion in Israel, and smart beds created by Bryte in collaboration with the University of California. The purpose of the content is to inform healthcare professionals about advancements in AI that can improve patient care related to sleep health.","technologies, artificial, ai",www.rocheplus.es,Falling,0.799070744371726,high,458,Technology
957,https://www.rocheplus.es/innovacion/inteligencia-artificial/ia-contra-pandemias.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_ia_contra_pandemias_html.txt,200,,Indexable,2,65,150,3843,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_ia_contra_pandemias_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_ia_contra_pandemias_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_ia_contra_pandemias_html.txt.txt,"['EPIFOR', 'Russian', 'AI', 'European', 'COVID', 'University', 'Metabiota', 'Petersburg', 'St']",Other,Spain,Technology,"artificial intelligence, COVID-19, BlueDot, Metabiota, European EPIFOR project, computational epidemiology, vaccine development",,40.318718,13.650206,4,"The content focuses on the role of artificial intelligence (AI) in predicting and preventing epidemics, particularly in light of the COVID-19 pandemic. It discusses various AI-driven projects, like BlueDot and Metabiota, that have been developed to identify patterns and anticipate the spread of infectious diseases. The article highlights specific research and models, such as the European EPIFOR project and a Russian model from St. Petersburg University, which aim to improve epidemic response through computational epidemiology. It emphasizes the importance of human involvement in refining AI algorithms and analyses while showcasing ongoing efforts to combat viral mutations and enhance vaccine development. The purpose is to inform healthcare professionals about innovative approaches and technologies in epidemic prediction and management.","technologies, artificial, ai",www.rocheplus.es,Falling,0.345371957747118,high,341,Technology
958,https://www.rocheplus.es/innovacion/inteligencia-artificial/ia-diagnostico-deterioro-cognitivo.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_ia_diagnostico_deterioro_cognitivo_html.txt,200,,Indexable,2,70,86,3720,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_ia_diagnostico_deterioro_cognitivo_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_ia_diagnostico_deterioro_cognitivo_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_ia_diagnostico_deterioro_cognitivo_html.txt.txt,"['PET', 'AI', 'Alzheimer', 'Canadian', 'Californian']",Neurology,Spain,Technology,"artificial intelligence, machine learning, early diagnosis, Alzheimer's disease, neuroimaging techniques, PET scans, cognitive decline",Alzheimer's disease,29.287035,27.669973,4,"The content discusses advancements in artificial intelligence (AI) and machine learning for the early diagnosis of Alzheimer's disease. It highlights research conducted by Canadian and Californian scientists who have developed software capable of detecting early symptoms through neuroimaging techniques, such as PET scans. The article emphasizes the importance of early detection in Alzheimer's, noting that AI can recognize subtle cognitive decline patterns long before traditional methods, potentially enabling diagnosis up to six years earlier. The overall purpose of the content is to inform healthcare professionals about innovative diagnostic tools that leverage technology to enhance patient outcomes in cognitive healthcare.","technologies, artificial, ai",www.rocheplus.es,All,0.228376301492961,high,222,Technology
959,https://www.rocheplus.es/innovacion/inteligencia-artificial/ia-diagnostico-medico.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_ia_diagnostico_medico_html.txt,200,,Indexable,2,68,159,3698,187,62,0.976190476190476,www_rocheplus_es_innovacion_inteligencia_artificial_ia_diagnostico_medico_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_ia_diagnostico_medico_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_ia_diagnostico_medico_html.txt.txt.txt,"['AI', 'MIT']",Other,Spain,Technology,,,38.546947,16.906902,4,"The content discusses the advancements of artificial intelligence (AI) in medical diagnostics, emphasizing its potential to enhance efficiency and accuracy in patient care. It highlights a study from MIT that illustrates how AI can assist healthcare professionals by sorting through vast amounts of clinical data to determine the necessity for expert intervention, ultimately allowing doctors to focus on complex cases. The content aims to educate healthcare professionals about the integration of AI in medicine, dispelling fears and promoting the idea of AI as a supportive ally rather than a replacement for human expertise. Additionally, it underscores the importance of utilizing AI to improve health outcomes, especially in contexts that may require social distancing.","technologies, artificial, ai",www.rocheplus.es,Flat,0.682950641699792,high,310,Technology
960,https://www.rocheplus.es/innovacion/inteligencia-artificial/ia-diseno-de-farmacos.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_ia_diseno_de_farmacos_html.txt,200,,Indexable,2,70,101,3530,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_ia_diseno_de_farmacos_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_ia_diseno_de_farmacos_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_ia_diseno_de_farmacos_html.txt.txt,"['AI', 'Swiss']",Other,Spain,Technology,,,43.28148,10.298706,4,"The content discusses the application of artificial intelligence (AI) in drug development, specifically highlighting a system developed by Swiss researchers that streamlines the process of synthesizing drug molecules. It describes how AI helps predict the best synthesis methods and assess the likelihood of success, significantly reducing the number of laboratory experiments traditionally required. The piece emphasizes the complexity of drug development, the potential for increased efficiency and sustainability, and how this innovative approach could enhance the creation of new and effective medications. The content is aimed at professionals in the pharmaceutical field, providing insights into the intersection of AI and pharmaceutical research.","technologies, artificial, ai",www.rocheplus.es,Rising,0.200328235249155,high,492,Technology
961,https://www.rocheplus.es/innovacion/inteligencia-artificial/ia-para-cancer-pulmon.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_ia_para_cancer_pulmon_html.txt,200,,Indexable,2,68,124,3496,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_ia_para_cancer_pulmon_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_ia_para_cancer_pulmon_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_ia_para_cancer_pulmon_html.txt.txt,"['AI', 'By', 'Anorak']",Oncology-Hematology,Spain,Technology,"Anorak, lung adenocarcinoma, deep learning, pixel-scale content analysis, tumor classification, prognosis","lung adenocarcinoma, lung cancer",40.36268,-10.02438,12,"The content discusses the development of an artificial intelligence (AI) model called Anorak, designed to analyze growth patterns of lung adenocarcinoma, the most common lung cancer subtype. It highlights the challenges posed by the cancer's complex morphology and intratumoral heterogeneity, which complicate accurate prognosis by pathologists. By utilizing deep learning and pixel-scale content analysis, the Anorak model enhances tumor classification and prognosis, especially in early-stage cases, showcasing a significant advancement in cancer research and diagnostics through AI technology. The content aims to inform healthcare professionals about innovative approaches in cancer treatment and diagnosis using AI.","cancer, breast, lung",www.rocheplus.es,Falling,0.403924906481566,high,147,Disease Information
962,https://www.rocheplus.es/innovacion/inteligencia-artificial/IA-para-detectar-enfermedades-raras.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_IA_para_detectar_enfermedades_raras_html.txt,200,,Indexable,2,77,168,3648,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_IA_para_detectar_enfermedades_raras_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_IA_para_detectar_enfermedades_raras_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_IA_para_detectar_enfermedades_raras_html.txt.txt,"['IDCV', 'UCLA', 'Specifically', 'AI']",Immunology,Spain,Technology,"artificial intelligence, early diagnosis, rare diseases, PheNet, electronic health records, genetic disorders, common variable immunodeficiency disease, IDCV",common variable immunodeficiency disease,41.031883,14.430526,4,"The content discusses advancements in using artificial intelligence (AI) to facilitate the early diagnosis of rare diseases. Specifically, it highlights a tool named PheNet developed by researchers at UCLA, which compares electronic health records of undiagnosed patients with those known to have specific genetic disorders. This AI algorithm has shown promise in identifying patients with common variable immunodeficiency disease (IDCV) potentially years before traditional methods would have. The article emphasizes the significance of early diagnosis in improving patient outcomes, reducing healthcare costs, and alleviating the psychological burden associated with delayed treatment. Overall, the purpose is to inform healthcare professionals about innovative uses of technology in rare disease diagnosis and management.","technologies, artificial, ai",www.rocheplus.es,Falling,0.53811955981046,high,449,Technology
963,https://www.rocheplus.es/innovacion/inteligencia-artificial/ictus.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_ictus_html.txt,200,,Indexable,2,69,154,3770,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_ictus_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_ictus_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_ictus_html.txt.txt,"['Basque', 'Cognition', 'Language', 'Brain', 'Center', 'Examples']",Neurology,Spain,Technology,"aphasia, artificial intelligence, machine learning, rehabilitation technologies, Basque Center on Cognition Brain and Language, VerbalizApp",aphasia,25.414448,23.486584,4,"The content discusses innovative technological tools designed to improve the diagnosis and treatment of aphasia, particularly in the context of stroke survivors. It highlights various applications that utilize artificial intelligence and machine learning to enhance communication for patients with this language disorder. Examples of these tools include an app developed by the Basque Center on Cognition Brain and Language to assess linguistic deficits, and VerbalizApp, which aids communication through personalized content use. The overall purpose is to inform healthcare professionals about advancements in rehabilitation technologies aimed at improving the quality of life for patients suffering from aphasia.","technologies, artificial, ai",www.rocheplus.es,Falling,0.215558418733927,high,262,Technology
964,https://www.rocheplus.es/innovacion/inteligencia-artificial/innovacion-en-pediatria.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_innovacion_en_pediatria_html.txt,200,,Indexable,2,105,130,3638,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_innovacion_en_pediatria_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_innovacion_en_pediatria_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_innovacion_en_pediatria_html.txt.txt,[],Other,Spain,Technology,"saliva-based diagnostic candy, gamification tools for speech therapy, advanced ultrasound devices, meningitis detection, proton therapy, cancer treatment, molecular diagnostics, artificial intelligence","meningitis, cancer",37.401833,0.56915754,4,"The content discusses innovative pediatric technologies and initiatives aimed at improving the diagnosis and treatment of diseases in children. It highlights several innovative projects, including a saliva-based diagnostic candy, gamification tools for speech therapy, and advanced ultrasound devices for meningitis detection, all designed to enhance the healthcare experience for pediatric patients. Additionally, it mentions advances in proton therapy for cancer treatment and molecular diagnostics, emphasizing the importance of non-invasive methods and the integration of artificial intelligence in healthcare solutions for children. The content primarily serves to inform healthcare professionals about developments in pediatric care and promote Roche’s commitment to innovation in this field.","technologies, artificial, ai",www.rocheplus.es,Falling,0.524915153958776,high,12,Technology
965,https://www.rocheplus.es/innovacion/inteligencia-artificial/inteligencia-artificial.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_inteligencia_artificial_html.txt,200,,Indexable,2,112,117,3736,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_inteligencia_artificial_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_inteligencia_artificial_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_inteligencia_artificial_html.txt.txt,"['X', 'AI', 'European', 'USA', 'Europe', 'Oxipit', 'Lithuanian']",Other,Spain,Technology,"artificial intelligence, ChestLink, X-ray images, medical imaging",,41.359608,15.948779,4,"The content discusses the growing role of artificial intelligence (AI) in the medical field, particularly highlighting the first European-certified AI tool for medical imaging, ChestLink by the Lithuanian company Oxipit. It outlines the tool's capabilities in analyzing X-ray images for medical issues autonomously, without human oversight, and the stringent regulatory requirements it met to receive certification. The piece contrasts the regulatory landscape in Europe with the USA, noting the advanced approval of numerous algorithms in the latter. Overall, the content serves to inform healthcare professionals about innovations in medical technology, emphasizing the impact of AI on diagnostics and healthcare delivery.","technologies, artificial, ai",www.rocheplus.es,Flat,0.646993565815457,high,88,Technology
966,https://www.rocheplus.es/innovacion/inteligencia-artificial/marcius.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_marcius_html.txt,200,,Indexable,2,84,136,3598,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_marcius_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_marcius_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_marcius_html.txt.txt,"['AI', 'European', 'MARCIUS']",CVRM,Spain,Technology,"cardiovascular diseases, artificial intelligence, machine learning, heart function assessments, diagnostic tools",,40.117012,15.403106,4,"The content discusses the MARCIUS project, a European initiative aimed at improving the diagnosis of cardiovascular diseases through artificial intelligence (AI) and machine learning techniques. It highlights the project's objectives to enhance diagnostic speed and accuracy for heart function assessments by utilizing patient data and virtual patient models. The content emphasizes the potential to reduce healthcare costs while advancing research and training in this medical field. Additionally, it points out the significance of combining real clinical data with virtual simulations to develop better diagnostic tools for cardiologists.","technologies, artificial, ai",www.rocheplus.es,Rising,0.301965247142111,high,142,Technology
967,https://www.rocheplus.es/innovacion/inteligencia-artificial/medicina-deportiva.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_medicina_deportiva_html.txt,200,,Indexable,2,58,156,3912,187,62,0.975308641975309,www_rocheplus_es_innovacion_inteligencia_artificial_medicina_deportiva_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_medicina_deportiva_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_medicina_deportiva_html.txt.txt.txt,['Spain'],Other,Spain,Technology,"artificial intelligence, virtual reality, augmented reality, infrared thermography",,36.425686,10.799167,4,"The content discusses recent advancements in sports medicine, particularly the innovative technologies aimed at preventing and treating injuries in athletes. It highlights how artificial intelligence, virtual and augmented reality, and infrared thermography are being utilized to enhance recovery processes and reduce injury risks. The content is tailored for medical professionals, emphasizing the importance of these technologies in improving the health and safety of athletes, as well as the broader significance of the sports industry in Spain's economy. The purpose is to inform healthcare providers about the latest developments in sports medicine technology and encourage engagement with these innovations.","technologies, artificial, ai",www.rocheplus.es,Falling,0.458078120597705,high,53,Technology
968,https://www.rocheplus.es/innovacion/inteligencia-artificial/melanoma.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_melanoma_html.txt,200,,Indexable,2,63,95,3634,187,62,0.971830985915493,www_rocheplus_es_innovacion_inteligencia_artificial_melanoma_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_melanoma_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_melanoma_html.txt.txt.txt,"['Spain', 'Johns', 'University', 'Hopkins']",Oncology-Hematology,Spain,Research,"computer vision technology, early detection, melanoma, artificial intelligence",melanoma,39.752888,-4.5570745,12,"The content discusses a groundbreaking method developed by researchers at Johns Hopkins University that utilizes computer vision technology for the early detection of melanoma, the most severe type of skin cancer. This innovative approach involves scanning the skin across multiple visits to track changes over time, enabling more accurate identification of lesions that may be overlooked by the human eye. The content highlights advancements in artificial intelligence and emphasizes the importance of early detection and monitoring in the fight against increasing melanoma rates in Spain. It also reflects on the conference where this research was presented, showcasing Roche's commitment to supporting medical innovation and research.","cancer, breast, lung",www.rocheplus.es,Flat,0.934764614328141,high,371,Disease Information
969,https://www.rocheplus.es/innovacion/inteligencia-artificial/metaverso.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_metaverso_html.txt,200,,Indexable,2,58,154,3800,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_metaverso_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_metaverso_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_metaverso_html.txt.txt,"['Zaragoza', 'Hospital', 'Juan', 'San', 'Dios', 'Privacy']",Other,Spain,Technology,,,32.47515,16.632349,4,"The content discusses the emerging potential of the metaverse in healthcare, highlighting its ability to create virtual environments for patient consultations and care. It emphasizes innovations such as avatars that carry patients' clinical data, which could enhance treatment effectiveness through the integration of artificial intelligence and machine learning. Privacy concerns surrounding personal data in such digital environments are noted as significant challenges. The content illustrates ongoing efforts, such as those by the Hospital San Juan de Dios in Zaragoza, to develop virtual healthcare solutions and hints at the future possibilities enabled by advancements like 5G technology. Overall, the content aims to inform healthcare professionals about the transformative role of technology in medical services and patient care.","technologies, artificial, ai",www.rocheplus.es,Flat,0.331319927529458,high,370,Technology
970,https://www.rocheplus.es/innovacion/inteligencia-artificial/mia-para-cancer-mama.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_mia_para_cancer_mama_html.txt,200,,Indexable,2,72,118,3589,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_mia_para_cancer_mama_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_mia_para_cancer_mama_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_mia_para_cancer_mama_html.txt.txt,"['MIA', 'AI', 'Hungary', 'UK']",Oncology-Hematology,Spain,Technology,"MIA, breast cancer, artificial intelligence, oncology, breast cancer screening",breast cancer,40.26968,-7.859555,12,"The content discusses the introduction of ""MIA,"" a new AI software developed for the early detection of breast cancer. It highlights MIA's effectiveness in increasing detection rates by 13%, reducing false positives, and minimizing additional patient evaluations, thereby alleviating healthcare professionals' workload. The content also mentions successful trials in Hungary and the UK, during which MIA aims to expedite diagnoses and improve patient outcomes. Overall, it showcases advancements in artificial intelligence and its potential impact on oncology, specifically breast cancer screening, targeting healthcare professionals interested in innovative medical solutions.","cancer, breast, lung",www.rocheplus.es,Falling,0.689543982882113,high,433,Disease Information
971,https://www.rocheplus.es/innovacion/inteligencia-artificial/microrobots.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_microrobots_html.txt,200,,Indexable,2,57,147,3705,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_microrobots_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_microrobots_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_microrobots_html.txt.txt,['Its'],Oncology-Hematology,Spain,Technology,"nanotechnology, microrobotics, targeted drug delivery, bone repair, cancer cell elimination, artificial intelligence",,40.096626,-2.5636806,12,"The content discusses advancements in nanotechnology and microrobotics within the field of medicine, highlighting innovative applications such as targeted drug delivery, bone repair, and cancer cell elimination. It details recent research efforts, including the development of microrobots that navigate bodily fluids using artificial intelligence and materials engineered for specific medical functions. The content emphasizes the transformative potential of these technologies in improving treatment outcomes and the ongoing evolution of research in this area. Its purpose is to inform healthcare professionals about the latest innovations and research tied to Roche's contributions to the medical field.","cancer, breast, lung",www.rocheplus.es,Flat,0.420711227183267,high,371,Disease Information
972,https://www.rocheplus.es/innovacion/inteligencia-artificial/mobile-world-congress-2023.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_mobile_world_congress_2023_html.txt,200,,Indexable,2,79,133,3905,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_mobile_world_congress_2023_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_mobile_world_congress_2023_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_mobile_world_congress_2023_html.txt.txt,"['World', 'Congress', 'Mediktor', 'Mobile']",Other,Spain,Technology,"artificial intelligence, robotic surgery, modular surgical robot, Mediktor, non-invasive imaging systems, cardiac monitoring",,38.199863,15.057649,4,"The content discusses innovative medical technologies showcased at the 2023 Mobile World Congress, emphasizing advancements in artificial intelligence and robotic surgery. It highlights several notable products, including a modular surgical robot, Mediktor for patient triage, and non-invasive imaging systems for cardiac monitoring, aimed at improving healthcare delivery and patient outcomes. The purpose is to inform healthcare professionals about cutting-edge solutions that enhance medical practices and overall health management.","technologies, artificial, ai",www.rocheplus.es,Flat,0.343319818413812,high,404,Technology
973,https://www.rocheplus.es/innovacion/inteligencia-artificial/mobile-world-congress.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_mobile_world_congress_html.txt,200,,Indexable,2,63,150,3645,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_mobile_world_congress_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_mobile_world_congress_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_mobile_world_congress_html.txt.txt,"['MWC', 'Parkinson', 'World', 'Congress', 'Mobile']",Oncology-Hematology,Spain,Technology,"artificial intelligence, telemedicine, remote patient monitoring, smart devices, mental health assessment, diagnostic equipment, cancer care, Parkinson's disease, dermatological issues",Parkinson's disease,36.23466,20.680582,4,"The content discusses the recent innovations in healthcare showcased at the Mobile World Congress (MWC), focusing on advancements in artificial intelligence and telemedicine that aim to improve patient care. It highlights various technologies, such as tools for remote patient monitoring, smart devices for mental health assessment, and diagnostic equipment for cancer care, specifically targeting conditions like Parkinson's disease and dermatological issues. The purpose of the content is to inform healthcare professionals about the latest trends and tools in digital health, emphasizing Roche's role in fostering these innovations.","technologies, artificial, ai",www.rocheplus.es,All,0.780777109647786,high,382,Technology
974,https://www.rocheplus.es/innovacion/inteligencia-artificial/pacientes-virtuales.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_pacientes_virtuales_html.txt,200,,Indexable,2,75,189,3760,196,63,1,www_rocheplus_es_innovacion_inteligencia_artificial_pacientes_virtuales_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_pacientes_virtuales_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_pacientes_virtuales_html.txt.txt,[],Other,Spain,Technology,"in silico medicine, virtual patients, vaccines, treatments, cardiology, oncology, artificial intelligence, simulation technologies",,36.300095,14.933693,4,"The content discusses the concept of ""in silico"" medicine, particularly focusing on the use of virtual patients—computer-generated avatars that simulate real clinical cases. It highlights how these virtual patients allow healthcare professionals to safely train, diagnose, and test vaccines or treatments without risking patient safety. The content illustrates the applications of this technology in various medical fields, such as cardiology and oncology, and emphasizes ongoing developments aimed at enhancing medical data and refining virtual models. The purpose of the content is to inform medical professionals about innovative advancements in medicine facilitated by artificial intelligence and simulation technologies.","technologies, artificial, ai",www.rocheplus.es,Rising,0.493884242517503,high,482,Technology
975,https://www.rocheplus.es/innovacion/inteligencia-artificial/redes-neuronales-radiografias-torax.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_redes_neuronales_radiografias_torax_html.txt,200,,Indexable,2,80,149,3669,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_redes_neuronales_radiografias_torax_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_redes_neuronales_radiografias_torax_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_redes_neuronales_radiografias_torax_html.txt.txt,"['British', 'X', 'AI']",Other,Spain,Technology,"artificial intelligence, X-ray, XRaydar, deep learning algorithms, abnormalities, diagnostic accuracy, diagnostic efficiency",,39.312244,-2.904421,12,"The content discusses the advancement of artificial intelligence (AI) in radiology, specifically its application in the automatic interpretation of chest X-rays. It highlights a project called XRaydar, developed by British researchers, which utilizes deep learning algorithms to detect 37 types of abnormalities in X-ray images with a high diagnostic accuracy. The system aims to enhance diagnostic efficiency, particularly in healthcare settings with a shortage of radiologists. It emphasizes the importance of making such AI tools freely accessible for medical professionals and researchers, ultimately improving diagnostic standards and speeding up treatment processes.","cancer, breast, lung",www.rocheplus.es,Falling,0.544963426499002,high,251,Disease Information
976,https://www.rocheplus.es/innovacion/inteligencia-artificial/retos-investigacion-medica.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_retos_investigacion_medica_html.txt,200,,Indexable,2,70,148,3748,187,62,0.97752808988764,www_rocheplus_es_innovacion_inteligencia_artificial_retos_investigacion_medica_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_retos_investigacion_medica_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_retos_investigacion_medica_html.txt.txt.txt,"['CRISPR', 'AI']",Oncology-Hematology,Spain,Research,"artificial intelligence, gene therapy, precision diagnostics, biobanks, data democratization, genetic biomarkers, CRISPR-Cas9, chronic diseases, cancer, patient care, personalized medicine",,41.385765,-8.2441025,12,"The content discusses the future challenges and innovations in medical research, particularly focusing on artificial intelligence (AI), gene therapy, precision diagnostics, biobanks, and data democratization. It highlights how advancements in genetic biomarkers and technologies like CRISPR-Cas9 are transforming treatments for chronic diseases, including cancer. The importance of managing medical data ethically and efficiently is emphasized, along with the role of biobanks in accelerating research. Overall, the content aims to inform healthcare professionals about cutting-edge developments in pharmaceuticals and research that can enhance patient care and personalized medicine.","cancer, breast, lung",www.rocheplus.es,Flat,0.175277519556801,high,337,Disease Information
977,https://www.rocheplus.es/innovacion/inteligencia-artificial/tecnologia-dentista.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_tecnologia_dentista_html.txt,200,,Indexable,2,57,144,3808,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_tecnologia_dentista_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_tecnologia_dentista_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_tecnologia_dentista_html.txt.txt,['AI'],Other,Spain,Technology,"artificial intelligence, tele-dentistry, 3D printing, dental care, diagnostics",,37.55118,13.537748,4,"The content discusses the impact of new technologies, particularly artificial intelligence (AI), tele-dentistry, and 3D printing, on dental care and the dentist-patient relationship. It highlights how these innovations are transforming traditional dental practices, making procedures less stressful for patients and enhancing diagnostic accuracy. The content aims to inform healthcare professionals about advancements in dental technology, emphasizing the benefits and potential changes these tools bring to patient care and engagement in dentistry. Additionally, it touches on the challenges related to data privacy in leveraging AI for diagnostics.","technologies, artificial, ai",www.rocheplus.es,Rising,0.910852379385278,high,490,Technology
978,https://www.rocheplus.es/innovacion/inteligencia-artificial/telemetria_medica_y_monitorizacion_remota.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_telemetria_medica_y_monitorizacion_remota_html.txt,200,,Indexable,2,58,118,3748,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_telemetria_medica_y_monitorizacion_remota_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_telemetria_medica_y_monitorizacion_remota_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_telemetria_medica_y_monitorizacion_remota_html.txt.txt,[],CVRM,Spain,Technology,,,12.309449,7.874827,7,"The content discusses the advancements in health monitoring technologies, particularly focusing on smartwatches and smart patches, as part of Roche's commitment to innovation in healthcare. It highlights how these devices have transformed remote health monitoring, with an emphasis on features like heart rate monitoring and blood pressure tracking, aided by artificial intelligence and advanced sensors. The content serves to inform healthcare professionals about the growing market for wearable tech, its applications in disease prevention, and how these innovations can improve patient care and monitoring. Overall, the purpose is to showcase Roche's involvement in and support for cutting-edge health technology developments.","event, exclusive, website",www.rocheplus.es,All,0.68952293366224,high,413,Events & Patient Care
979,https://www.rocheplus.es/innovacion/inteligencia-artificial/telerehabilitacion.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_telerehabilitacion_html.txt,200,,Indexable,2,75,152,3587,188,63,1,www_rocheplus_es_innovacion_inteligencia_artificial_telerehabilitacion_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_telerehabilitacion_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_telerehabilitacion_html.txt.txt,"['AI', 'COVID', 'Trak']",Other,Spain,Technology,"artificial intelligence, tele-rehabilitation, COVID-19, Trak, ReHub, personalized rehabilitation programs, post-COVID, muscle deterioration",,37.086773,18.958294,4,"The content discusses the integration of artificial intelligence (AI) in tele-rehabilitation services, particularly in response to challenges posed by the COVID-19 pandemic. It outlines innovative platforms like Trak and ReHub, which enable remote monitoring and personalized rehabilitation programs for patients, helping to reduce dropout rates in therapy. Additionally, it highlights ongoing projects aimed at supporting post-COVID patients experiencing muscle deterioration. The purpose of the content is to inform healthcare professionals about advancements in telemedicine and AI, enhancing patient care and treatment efficacy.","technologies, artificial, ai",www.rocheplus.es,Falling,0.146069665326751,high,235,Technology
980,https://www.rocheplus.es/innovacion/inteligencia-artificial/terapia-digital.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_terapia_digital_html.txt,200,,Indexable,2,61,139,3858,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_terapia_digital_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_terapia_digital_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_terapia_digital_html.txt.txt,"['Ultimately', 'ADHD', 'COVID']",Other,Spain,Technology,"digital therapies, artificial intelligence, prevention, treatment, COVID-19, diabetes, cancer, ADHD","diabetes, cancer, ADHD",38.277428,17.97251,4,"The content discusses the role of digital therapies, particularly those enhanced by artificial intelligence, in the prevention and treatment of various diseases. It highlights recent technological advancements in healthcare that have emerged, especially during the COVID-19 pandemic, such as applications designed to manage conditions like diabetes, cancer, and ADHD. It also mentions the importance of compliance with regulatory standards and patient privacy concerns. Ultimately, the content aims to inform healthcare professionals about innovative digital solutions that can improve patient care while acknowledging the limitations and challenges associated with their implementation.","technologies, artificial, ai",www.rocheplus.es,All,0.352099210643419,high,309,Technology
981,https://www.rocheplus.es/innovacion/inteligencia-artificial/trombosis.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_trombosis_html.txt,200,,Indexable,2,55,84,3693,187,62,0.972222222222222,www_rocheplus_es_innovacion_inteligencia_artificial_trombosis_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_trombosis_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_trombosis_html.txt.txt.txt,"['AI', 'DVT']",Other,Spain,Technology,"thrombosis, deep vein thrombosis (DVT), microfluidic device, AI algorithm, blood coagulation, mobile applications, thromboembolic risks, diagnosis, patient monitoring",deep vein thrombosis,38.99461,5.3452225,4,"The content highlights technological advancements and innovations in the diagnosis and prevention of thrombosis, particularly deep vein thrombosis (DVT) and its related health risks. It details the development of a microfluidic device and an AI algorithm designed to effectively analyze blood coagulation levels and detect DVT cases, improving patient management and outcomes. Additionally, it discusses mobile applications that support healthcare providers and patients in managing thromboembolic risks, emphasizing the importance of accurate diagnosis and ongoing patient monitoring. The purpose of the content is to inform healthcare professionals about the latest tools and strategies in thrombosis management.","technologies, artificial, ai",www.rocheplus.es,Flat,0.152970333187275,high,28,Technology
982,https://www.rocheplus.es/innovacion/inteligencia-artificial/un-estetoscopio-tuneado-con-inteligencia-artificial-detectara-los-problemas-cardiacos.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_un_estetoscopio_tuneado_con_inteligencia_artificial_detectara_los_problemas_cardiacos_html.txt,200,,Indexable,2,94,90,3614,309,62,0.986486486486487,www_rocheplus_es_innovacion_inteligencia_artificial_un_estetoscopio_tuneado_con_inteligencia_artificial_detectara_los_problemas_cardiacos_html.txt.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_un_estetoscopio_tuneado_con_inteligencia_artificial_detectara_los_problemas_cardiacos_html.txt.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_un_estetoscopio_tuneado_con_inteligencia_artificial_detectara_los_problemas_cardiacos_html.txt.txt.txt,['AI'],CVRM,Spain,Technology,"artificial intelligence, AI-enhanced digital stethoscopes, cardiac issues, aortic stenosis, machine learning algorithms, heart sounds, respiratory conditions",aortic stenosis,40.618546,17.128996,4,"The content discusses advancements in the use of artificial intelligence (AI) in medical diagnostics, particularly focusing on AI-enhanced digital stethoscopes that can detect cardiac issues, such as aortic stenosis, with high precision. It covers a study that applied machine learning algorithms to recorded heart sounds, achieving a detection rate of 97.2%. The article highlights the potential of these technologies to improve early diagnosis and reduce the need for expensive procedures. Additionally, it mentions ongoing research into using AI for detecting respiratory conditions, emphasizing the goal of making these innovations accessible for both healthcare professionals and patients at home.","technologies, artificial, ai",www.rocheplus.es,Flat,0.735552010524381,high,10,Technology
983,https://www.rocheplus.es/innovacion/inteligencia-artificial/vr-para-formacion-medica.html,10,www_rocheplus_es_innovacion_inteligencia_artificial_vr_para_formacion_medica_html.txt,200,,Indexable,2,70,146,3695,187,62,1,www_rocheplus_es_innovacion_inteligencia_artificial_vr_para_formacion_medica_html.txt,image/www_rocheplus_es_innovacion_inteligencia_artificial_vr_para_formacion_medica_html.txt.png,text/www_rocheplus_es_innovacion_inteligencia_artificial_vr_para_formacion_medica_html.txt.txt,['COVID'],Other,Spain,Technology,"virtual reality, augmented reality, simulation platforms, VirtaMed, HoloAnatomy, surgical procedures, anatomy education, skill acquisition, clinical preparedness",,29.655268,17.066616,4,"The content focuses on the integration of virtual and augmented reality technologies in medical education, particularly in response to challenges posed by the COVID-19 pandemic. It discusses various immersive tools, such as simulation platforms and applications like VirtaMed and HoloAnatomy, that are being utilized to enhance the training of medical students and professionals in surgical procedures and anatomy education. The purpose of the content is to highlight innovative educational solutions that compensate for practical training limitations, thereby improving skill acquisition and clinical preparedness in healthcare education.","technologies, artificial, ai",www.rocheplus.es,Falling,0.864557189870579,high,88,Technology
984,https://www.rocheplus.es/innovacion/investigacion-ciencia/alergia-alimentaria.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_alergia_alimentaria_html.txt,200,,Indexable,2,86,122,1620,93,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_alergia_alimentaria_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_alergia_alimentaria_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_alergia_alimentaria_html.txt.txt,"['Spanish', 'Researchers']",Other,Spain,Technology,"food allergens, allergen detection",,34.128,6.4011292,4,"This content discusses the development of a portable prototype designed to detect food allergens quickly and economically using a smartphone. Researchers from Spanish institutions have created a testing strip that allows users to identify and quantify allergen levels in food within five minutes, addressing a significant public health issue as food allergies affect millions worldwide. The content highlights the innovation in allergen detection, emphasizing its accessibility and ease of use, and ultimately aims to enhance safety for individuals with food allergies.","technologies, artificial, ai",www.rocheplus.es,Flat,0.39898194866771,high,494,Technology
985,https://www.rocheplus.es/innovacion/investigacion-ciencia/amplificador-nervios-permitira-control-protesis-roboticas.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_amplificador_nervios_permitira_control_protesis_roboticas_html.txt,200,,Indexable,2,72,121,3669,207,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_amplificador_nervios_permitira_control_protesis_roboticas_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_amplificador_nervios_permitira_control_protesis_roboticas_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_amplificador_nervios_permitira_control_protesis_roboticas_html.txt.txt,"['Michigan', 'University']",Other,Spain,Technology,"robotic prosthetics, neural amplifier, muscle implants, electrodes, artificial intelligence",,29.865923,23.542852,4,"The content discusses advancements in technology related to robotic prosthetics, focusing particularly on a neural amplifier that allows for better control of these devices through nerve signals. It highlights research from the University of Michigan that combines muscle implants with electrodes to enhance signal reception, facilitating more precise movement control for patients who have undergone amputations. Additionally, the article touches on the integration of artificial intelligence to translate these signals into movements, marking significant progress in the field. Overall, the purpose of the content is to inform healthcare professionals about innovative developments in robotic prosthetics and their potential benefits for patients.","technologies, artificial, ai",www.rocheplus.es,Rising,0.288113335225998,high,455,Technology
986,https://www.rocheplus.es/innovacion/investigacion-ciencia/bcg-cancer-pulmon.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_bcg_cancer_pulmon_html.txt,200,,Indexable,2,97,156,3856,157,46,0.974358974358974,www_rocheplus_es_innovacion_investigacion_ciencia_bcg_cancer_pulmon_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_bcg_cancer_pulmon_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_bcg_cancer_pulmon_html.txt.txt.txt,"['Zaragoza', 'University', 'BCG']",Oncology-Hematology,Spain,Research,"tuberculosis, BCG, lung cancer, immunotherapy, intravenous administration, tumor resistance, traditional treatments","tuberculosis, lung cancer",33.333675,-18.01971,12,"The content discusses a recent research study conducted by scientists at the University of Zaragoza regarding the potential use of the tuberculosis vaccine (BCG) as a treatment for lung cancer. The study found that administering BCG intravenously, in combination with immunotherapy, significantly improved survival rates in mice with lung cancer, achieving a 50% cure rate in certain cases. The research also suggests that this new approach may help overcome tumor resistance to traditional treatments. The content serves to inform healthcare professionals about innovative therapeutic strategies in the ongoing battle against lung cancer, highlighting the relevance of combining established treatments with new methodologies.","cancer, breast, lung",www.rocheplus.es,Rising,0.719639459662449,high,217,Disease Information
987,https://www.rocheplus.es/innovacion/investigacion-ciencia/biopsia-liquida-cancer-mama.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_biopsia_liquida_cancer_mama_html.txt,200,,Indexable,2,60,106,1827,93,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_biopsia_liquida_cancer_mama_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_biopsia_liquida_cancer_mama_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_biopsia_liquida_cancer_mama_html.txt.txt,['Spanish'],Oncology-Hematology,Spain,Research,"liquid biopsy, non-invasive cancer diagnostics, breast cancer, genomic sequencing, blood samples, protein variations, early detection, traditional tissue biopsies, personalized treatment, monitoring disease progression",breast cancer,36.230865,-11.791542,12,"The content discusses advancements in liquid biopsy techniques for non-invasive cancer diagnostics, particularly focusing on breast cancer. It highlights research conducted by Spanish scientists who have developed a method that enables early detection of breast tumors through blood analysis, which is less invasive than traditional tissue biopsies. The content outlines the significance of genomic sequencing from blood samples, identifies specific protein variations that could predict breast cancer, and underscores the potential of these methodologies in personalizing treatment and monitoring disease progression. The overarching purpose of the content is to inform healthcare professionals about innovative diagnostic tools and their implications for cancer management.","cancer, breast, lung",www.rocheplus.es,Rising,0.362066583317316,high,363,Disease Information
988,https://www.rocheplus.es/innovacion/investigacion-ciencia/camisetas-inteligentes-de-control-para-pacientes-cronicos.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_camisetas_inteligentes_de_control_para_pacientes_cronicos_html.txt,200,,Indexable,2,66,160,3634,196,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_camisetas_inteligentes_de_control_para_pacientes_cronicos_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_camisetas_inteligentes_de_control_para_pacientes_cronicos_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_camisetas_inteligentes_de_control_para_pacientes_cronicos_html.txt.txt,['ECG'],CVRM,Spain,Technology,"smart t-shirts, sensors, chronic disease management, ECG, respiratory rate, body temperature, neuromorphic engineering, artificial intelligence, cardiology, acute heart failure, pulmonary congestion, digital health technologies",acute heart failure,39.285316,17.993437,4,"The content discusses innovative patient monitoring technologies, specifically smart t-shirts equipped with sensors for chronic disease management. It details how these garments can continuously track vital signs such as ECG, respiratory rate, and body temperature, allowing healthcare professionals to remotely monitor patients’ health status. The content emphasizes the integration of neuromorphic engineering and artificial intelligence to enhance data analysis and improve treatment outcomes. Additionally, it illustrates the potential of such technologies in cardiology, particularly for patients with acute heart failure, showcasing how they can detect pulmonary congestion without invasive procedures. Overall, the purpose is to highlight advancements in digital health technologies that can improve patient care and quality of life.","technologies, artificial, ai",www.rocheplus.es,Flat,0.156306261932379,high,437,Technology
989,https://www.rocheplus.es/innovacion/investigacion-ciencia/cancer-mama.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_cancer_mama_html.txt,200,,Indexable,2,58,127,3634,157,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_cancer_mama_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_cancer_mama_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_cancer_mama_html.txt.txt,[],Oncology-Hematology,Spain,Research,"breast cancer, saliva, disposable test strips, HER2, CA153, cancer diagnostics, early detection",breast cancer,36.978325,-11.301532,12,"The content discusses a groundbreaking innovation in breast cancer detection involving the use of saliva. It outlines a research group's development of disposable test strips capable of identifying two key biomarkers, HER2 and CA153, associated with breast cancer. This non-invasive method presents advantages over traditional imaging techniques and biopsies, such as lower cost, improved accessibility, and faster results within a minute. The purpose of the content is to highlight advancements in cancer diagnostics that may enhance early detection and improve patient outcomes.","cancer, breast, lung",www.rocheplus.es,All,0.116547925537444,high,487,Disease Information
990,https://www.rocheplus.es/innovacion/investigacion-ciencia/cancer-pulmon.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_cancer_pulmon_html.txt,200,,Indexable,2,90,123,3711,157,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_cancer_pulmon_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_cancer_pulmon_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_cancer_pulmon_html.txt.txt,"['MIT', 'Researchers']",Oncology-Hematology,Spain,Technology,"inhalable nanosensors, lung cancer, early diagnosis, diagnostic particles, urine, computerized tomography, lung cancer screening",lung cancer,37.383606,-9.6078615,12,"The content discusses innovative developments in lung cancer detection, specifically focusing on the use of inhalable nanosensors that offer a significant advancement in early diagnosis. Researchers from MIT have created diagnostic particles that, when inhaled, release a substance detectable in urine, eliminating many risks associated with traditional imaging methods such as computerized tomography. The article emphasizes the accessibility, speed, and cost-effectiveness of this new method, which could revolutionize lung cancer screening, particularly in low-resource settings. It also mentions the ongoing research and testing phases to ensure the method's efficacy for human use.","cancer, breast, lung",www.rocheplus.es,Rising,0.006419846536894,high,408,Disease Information
991,https://www.rocheplus.es/innovacion/investigacion-ciencia/celulas-madre-sanguineas.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_celulas_madre_sanguineas_html.txt,200,,Indexable,1,86,184,3555,207,88,1,www_rocheplus_es_innovacion_investigacion_ciencia_celulas_madre_sanguineas_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_celulas_madre_sanguineas_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_celulas_madre_sanguineas_html.txt.txt,['Australian'],Oncology-Hematology,Spain,Research,"blood stem cells, childhood leukemia, bone marrow disorders, transplants, personalized treatment options","childhood leukemia, bone marrow disorders",31.5109,-0.23144802,4,"The content discusses a significant breakthrough in medical research, highlighting the creation of laboratory-derived blood stem cells by Australian researchers. This innovation has the potential to advance treatments for childhood leukemia and bone marrow disorders by overcoming challenges related to donor compatibility. The study demonstrates the successful transformation of ordinary patient cells into functional blood stem cells that can be used in transplants, addressing the limitations of current therapies. This research could facilitate personalized treatment options and contributes to understanding blood cell development, benefiting the scientific community and healthcare practices.","technologies, artificial, ai",www.rocheplus.es,Flat,0.164454607716101,high,257,Technology
992,https://www.rocheplus.es/innovacion/investigacion-ciencia/ChatGPT.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_ChatGPT_html.txt,200,,Indexable,2,59,100,1798,93,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_ChatGPT_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_ChatGPT_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_ChatGPT_html.txt.txt,"['AI', 'Alzheimer']",Neurology,Spain,Technology,"ChatGPT, AI, early detection, Alzheimer’s, speech analysis, patient triage, virtual health assistant, remote consultations",Alzheimer's disease,36.052856,19.11893,4,"The content discusses the potential applications of ChatGPT, an AI tool created by OpenAI, in the medical field. It explores how this conversational AI can assist in areas like early detection of Alzheimer’s through speech analysis, patient triage in emergency settings, and as a virtual health assistant for remote consultations. The article emphasizes the tool's capabilities while cautioning that it should not replace medical professionals. It highlights the ongoing exploration of AI in healthcare and provides insights into its promising yet nascent role in improving medical practices.","technologies, artificial, ai",www.rocheplus.es,Falling,0.669131715148668,high,80,Technology
993,https://www.rocheplus.es/innovacion/investigacion-ciencia/cirujanos-roboticos.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_cirujanos_roboticos_html.txt,200,,Indexable,2,71,129,3734,156,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_cirujanos_roboticos_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_cirujanos_roboticos_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_cirujanos_roboticos_html.txt.txt,"['Smart', 'Element', 'Robot', 'Tissue', 'Da', 'Fifth', 'Vinci', 'Prometheus', 'Star', 'Wars', 'Autonomous']",Other,Spain,Technology,"Da Vinci system, Smart Tissue Autonomous Robot",,37.461266,10.805891,4,"The content discusses the portrayal of robotic surgeons in science fiction films, highlighting notable examples like ""Prometheus,"" ""Star Wars,"" and ""The Fifth Element."" It compares these fictional depictions with current advancements in surgical robotics, such as the Da Vinci system and the Smart Tissue Autonomous Robot. The purpose of the article is to engage healthcare professionals by exploring the intersection of technology and medicine while reflecting on the gap between cinematic imagination and real-world capabilities in surgical robotics.","technologies, artificial, ai",www.rocheplus.es,All,0.205009155322384,high,291,Technology
994,https://www.rocheplus.es/innovacion/investigacion-ciencia/corazon-artificial-completo.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_corazon_artificial_completo_html.txt,200,,Indexable,2,72,130,3686,157,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_corazon_artificial_completo_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_corazon_artificial_completo_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_corazon_artificial_completo_html.txt.txt,"['French', 'Carmat']",CVRM,Spain,Technology,"artificial heart technology, severe heart failure, complete artificial heart, Carmat, cardiac health innovations, heart treatment options",,37.076836,5.0376797,4,"The content discusses recent advancements in artificial heart technology as a potential solution for patients with severe heart failure while they await transplants. It highlights the development of a complete artificial heart by the French company Carmat, which can temporarily replace a damaged heart muscle for a limited time. The article addresses the challenges and limitations of existing solutions and emphasizes ongoing research in cardiac health innovations. Overall, the purpose is to inform healthcare professionals about cutting-edge developments in heart treatment options and the implications for patient care.","technologies, artificial, ai",www.rocheplus.es,Rising,0.521196207257361,high,19,Technology
995,https://www.rocheplus.es/innovacion/investigacion-ciencia/detector-de-falsificaciones.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_detector_de_falsificaciones_html.txt,200,,Indexable,2,53,116,3677,156,46,0.977272727272727,www_rocheplus_es_innovacion_investigacion_ciencia_detector_de_falsificaciones_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_detector_de_falsificaciones_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_detector_de_falsificaciones_html.txt.txt.txt,"['Device', 'PAD', 'Paper', 'World', 'Analytical', 'Organization', 'Health']",Other,Spain,Technology,"Paper Analytical Device (PAD), counterfeit medications, machine learning, pharmaceuticals, counterfeit drugs",,43.731403,9.74211,4,"The content discusses a technological innovation called the Paper Analytical Device (PAD), which is designed to detect counterfeit medications using machine learning. It highlights the alarming statistics from the World Health Organization regarding the prevalence of fake drugs in developing countries and the potential health risks associated with them. The PAD combines a physical card that tests pharmaceuticals with a mobile app to improve detection accuracy. The article aims to inform healthcare professionals about advancements in combating medication fraud and the serious implications of counterfeit drugs on public health.","technologies, artificial, ai",www.rocheplus.es,Rising,0.220336813267304,high,62,Technology
996,https://www.rocheplus.es/innovacion/investigacion-ciencia/diagnostico-cancer-endometrio.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_diagnostico_cancer_endometrio_html.txt,200,,Indexable,2,67,102,3630,157,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_diagnostico_cancer_endometrio_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_diagnostico_cancer_endometrio_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_diagnostico_cancer_endometrio_html.txt.txt,['Catalan'],Oncology-Hematology,Spain,Research,"non-invasive diagnostic methods, endometrial cancer, urine, cytology, self-obtained vaginal samples, biopsy procedures, cancer detection",endometrial cancer,34.986645,-11.631826,12,"The content discusses the advancements in non-invasive diagnostic methods for endometrial cancer, highlighting research conducted by various Catalan institutions. It details the use of urine, cytology, and self-obtained vaginal samples as alternatives to traditional, more painful biopsy procedures. The aim is to improve the accuracy and speed of cancer detection, which is crucial for enhancing patient outcomes and treatment effectiveness. The article emphasizes the research collaboration among healthcare professionals and the need for further studies to validate these promising findings.","cancer, breast, lung",www.rocheplus.es,Falling,0.57333132500124,high,36,Disease Information
997,https://www.rocheplus.es/innovacion/investigacion-ciencia/dispositivos-alzheimer.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_dispositivos_alzheimer_html.txt,200,,Indexable,2,50,151,3682,156,46,0.975903614457831,www_rocheplus_es_innovacion_investigacion_ciencia_dispositivos_alzheimer_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_dispositivos_alzheimer_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_dispositivos_alzheimer_html.txt.txt.txt,"['Europe', 'Alzheimer']",Neurology,Spain,Research,"transcranial magnetic stimulation, cognitive exercises, artificial neurons, diagnostic tools, cognitive gaming, NeuroAD, non-invasive therapy, Alzheimer's disease",Alzheimer's disease,25.695894,27.950089,4,"The content discusses innovative approaches to treating Alzheimer's disease, including the use of transcranial magnetic stimulation combined with cognitive exercises, as well as the development of artificial neurons on silicon chips. It outlines recent developments in research, including diagnostic tools and methods to delay symptoms through cognitive gaming. The article highlights a device called NeuroAD, approved in Europe, which aims to improve cognitive function through non-invasive therapy. It emphasizes the collaboration between technology and medicine in addressing Alzheimer's, an incurable disease, while providing insights into ongoing research and clinical studies related to these innovations.","technologies, artificial, ai",www.rocheplus.es,Falling,0.975427766574505,high,228,Technology
998,https://www.rocheplus.es/innovacion/investigacion-ciencia/enfermedades_raras.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_enfermedades_raras_html.txt,200,,Indexable,2,82,141,3657,158,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_enfermedades_raras_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_enfermedades_raras_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_enfermedades_raras_html.txt.txt,"['CHARM', 'DNA']",Other,Spain,Research,,"hereditary prion diseases, fatal familial insomnia, prion disease",28.795376,-2.2787306,4,"The content discusses a recent breakthrough in genetic research aimed at combating hereditary prion diseases, specifically through a tool called CHARM, which functions as a genetic silencer. It highlights the innovative approach of this epigenetic solution, which deactivates the prion protein gene without altering the underlying DNA, thereby potentially preventing diseases like fatal familial insomnia. The narrative also includes the personal story of a researcher motivated by her mother's death from a prion disease, emphasizing the urgency and emotional drive behind this research. The article serves to inform healthcare professionals about advancements in medical science related to genetic therapy and prion diseases.","technologies, artificial, ai",www.rocheplus.es,All,0.838825349420481,high,238,Technology
999,https://www.rocheplus.es/innovacion/investigacion-ciencia/entrenar-voluntad.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_entrenar_voluntad_html.txt,200,,Indexable,2,60,121,1653,48,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_entrenar_voluntad_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_entrenar_voluntad_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_entrenar_voluntad_html.txt.txt,[],Neurology,Spain,Research,"self-control, smoking cessation, obesity management, training program, application, addiction-related stimuli, video game, addiction treatment",,22.539818,19.75366,4,"The content discusses a new method for treating addictions through self-control, highlighting a research study that focuses on activating and strengthening the brain's self-regulatory capabilities. It explains the development of a training program aimed at improving self-control, particularly in areas like smoking cessation and obesity management. The study seeks to provide a free application that helps individuals enhance their self-regulation by using specific tasks to divert their attention from addiction-related stimuli. Additionally, it mentions the positive outcomes observed in participants after using a targeted video game designed to increase self-control. Overall, the purpose is to inform healthcare professionals about innovative approaches in addiction treatment backed by research findings.","technologies, artificial, ai",www.rocheplus.es,Flat,0.818710961576157,high,298,Technology
1000,https://www.rocheplus.es/innovacion/investigacion-ciencia/experimentacion-animal.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_experimentacion_animal_html.txt,200,,Indexable,2,44,150,3768,156,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_experimentacion_animal_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_experimentacion_animal_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_experimentacion_animal_html.txt.txt,[],Other,Spain,Research,"regenerative medicine, transplantation, genetically modified pig heart, regeneration, rabbit cartilage, electrical impulses, organ shortages, degenerative conditions, osteoarthritis",osteoarthritis,35.984676,1.2116693,4,"The content discusses recent advancements in regenerative medicine, particularly focusing on groundbreaking procedures such as the first successful transplantation of a genetically modified pig heart into a human patient and the regeneration of rabbit cartilage using electrical impulses. It highlights the significance of animal experimentation in medical research, addressing ethical debates while emphasizing the potential for these innovations to address organ shortages and treat degenerative conditions like osteoarthritis. Moreover, it outlines the experimental techniques and their implications for future human applications in regenerative health care.","technologies, artificial, ai",www.rocheplus.es,Falling,0.198998319044841,high,249,Technology
1001,https://www.rocheplus.es/innovacion/investigacion-ciencia/fibrosis-quistica.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_fibrosis_quistica_html.txt,200,,Indexable,2,75,203,3613,157,46,0.974358974358974,www_rocheplus_es_innovacion_investigacion_ciencia_fibrosis_quistica_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_fibrosis_quistica_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_fibrosis_quistica_html.txt.txt.txt,"['European', 'May']",Other,Spain,Research,"cystic fibrosis, inhalable light sources, drug-resistant bacterial lung infections, Light4Lungs, photosensitizers, reactive oxygen species, photonics",cystic fibrosis,32.434315,0.17111172,4,"The content discusses a novel treatment approach for cystic fibrosis, focusing on the development of inhalable light sources designed to combat drug-resistant bacterial lung infections. It highlights a European project named Light4Lungs, which aims to utilize photosensitizers to produce reactive oxygen species that can kill pathogens while minimizing damage to patient tissues. The project, underway since late 2019 and set to conclude in May 2024, aims to redefine infection treatments by integrating photonics with medicine. The article also outlines the research objectives, progress made, and implications for various medical fields. The purpose is to inform healthcare professionals about innovative research efforts and advancements in treating serious genetic diseases.","technologies, artificial, ai",www.rocheplus.es,Flat,0.324333852597478,high,238,Technology
1002,https://www.rocheplus.es/innovacion/investigacion-ciencia.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_html.txt,200,,Indexable,1,45,121,2789,1676,410,0.966666666666667,www_rocheplus_es_innovacion_investigacion_ciencia_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_html.txt.txt.txt,[],Oncology-Hematology,Spain,Research,,,-7.886734,-8.295567,0,"The content focuses on Roche’s commitment to scientific innovation and research, providing exclusive access to articles, podcasts, and projects aimed at healthcare professionals such as doctors, nurses, and pharmacists. It highlights various advancements in medical research, particularly in areas like cancer treatment, ophthalmology, and artificial intelligence in healthcare. The purpose is to foster a community centered on scientific inquiry and to disseminate the latest developments in medical technology and treatments, positioning Roche as a leader in pharmaceutical innovation.","oncology, professionals, data",www.rocheplus.es,Falling,0.663924855615735,high,459,General Offer Outline
1003,https://www.rocheplus.es/innovacion/investigacion-ciencia/ia-cancer-de-pulmon.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_ia_cancer_de_pulmon_html.txt,200,,Indexable,2,82,135,3584,158,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_ia_cancer_de_pulmon_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_ia_cancer_de_pulmon_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_ia_cancer_de_pulmon_html.txt.txt,"['Glasgow', 'Langone', 'AI', 'Researchers', 'University', 'NYU', 'Health']",Oncology-Hematology,Spain,Technology,"self-learning artificial intelligence, lung cancer, cancer recurrence",lung cancer,40.52748,-9.657909,12,"The content discusses the innovative use of self-learning artificial intelligence (AI) in oncology, specifically for predicting lung cancer recurrence. Researchers from NYU Langone Health and the University of Glasgow developed an AI system that accurately predicts the likelihood and timing of cancer reappearing after treatment by analyzing microscopic images of lung cancer samples. The system demonstrated a 72% accuracy in forecasts, surpassing the traditional methods used by pathologists. Furthermore, the researchers aim to expand the algorithm's application to other cancer types and incorporate additional medical data to enhance its predictive capabilities. The purpose of the content is to inform healthcare professionals about advancements in cancer research and the role of AI in improving patient outcomes.","cancer, breast, lung",www.rocheplus.es,Rising,0.398468498716021,high,273,Disease Information
1004,https://www.rocheplus.es/innovacion/investigacion-ciencia/investigacion-contra-las-alergias.html?namespace=s7viewers,9,www_rocheplus_es_innovacion_investigacion_ciencia_investigacion_contra_las_alergias_html_namespace_s7viewers.txt,200,,Non-Indexable,3,63,154,3904,65,1,1,www_rocheplus_es_innovacion_investigacion_ciencia_investigacion_contra_las_alergias_html_namespace_s7viewers.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_investigacion_contra_las_alergias_html_namespace_s7viewers.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_investigacion_contra_las_alergias_html_namespace_s7viewers.txt.txt,[],Immunology,Spain,Research,"allergies, microRNAs, allergic inflammation, immunotherapy, dust mites, milk, diagnostics, treatment efficacy, microbiome, food allergies","allergies, food allergies",30.084448,-2.7275655,4,"The content discusses ongoing research and advancements in allergy treatments, highlighting the increasing prevalence of allergies as a significant public health issue. It covers various studies, including the role of microRNAs in allergic inflammation and innovative immunotherapy approaches aimed at treating common allergens like dust mites and milk. The objective is to understand the mechanisms behind allergic reactions to enhance diagnostics and treatment efficacy. Additionally, it emphasizes the importance of integrating insights from microbiome research in developing potential therapies for food allergies. The content is targeted at healthcare professionals to inform them about new scientific findings relevant to their practice.","technologies, artificial, ai",www.rocheplus.es,Flat,0.456876867885373,high,16,Technology
1005,https://www.rocheplus.es/innovacion/investigacion-ciencia/investigacion-contra-las-alergias.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_investigacion_contra_las_alergias_html.txt,200,,Indexable,2,63,154,3899,156,46,0.978723404255319,www_rocheplus_es_innovacion_investigacion_ciencia_investigacion_contra_las_alergias_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_investigacion_contra_las_alergias_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_investigacion_contra_las_alergias_html.txt.txt.txt,[],Immunology,Spain,Research,"allergy, allergic conditions, microRNAs, allergic inflammation, immunotherapy, common allergens",,29.447699,-1.8877447,4,"The content discusses recent advancements in allergy research and therapies, emphasizing ongoing studies and innovations aimed at understanding and treating allergic conditions. It highlights various research initiatives, including the role of microRNAs in allergic inflammation and the development of new immunotherapy approaches for common allergens. The anticipated increase in allergy prevalence by 2050 is noted, raising concerns about public health implications. The intention is to inform healthcare professionals about cutting-edge developments in allergy treatment and the broader implications of emerging therapies.","technologies, artificial, ai",www.rocheplus.es,Falling,0.387572384068073,high,190,Technology
1006,https://www.rocheplus.es/innovacion/investigacion-ciencia/la-realidad-virtual-entra-en-la-consulta.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_la_realidad_virtual_entra_en_la_consulta_html.txt,200,,Indexable,2,49,147,3718,156,46,0.98019801980198,www_rocheplus_es_innovacion_investigacion_ciencia_la_realidad_virtual_entra_en_la_consulta_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_la_realidad_virtual_entra_en_la_consulta_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_la_realidad_virtual_entra_en_la_consulta_html.txt.txt.txt,"['VR', 'AR']",Other,Spain,Technology,,,26.460773,21.265251,4,"The content focuses on the application of immersive technologies, specifically virtual reality (VR) and augmented reality (AR), in the fields of healthcare and medicine. It discusses the potential benefits these technologies can bring to various medical specializations, including surgery, psychology, psychiatry, and neurology, by enhancing precision, improving patient treatment, and aiding in cognitive rehabilitation. The purpose of the content is to inform healthcare professionals about innovative technological advancements that can significantly impact patient care and treatment outcomes, while also encouraging engagement with exclusive resources on the topic.","technologies, artificial, ai",www.rocheplus.es,All,0.064709934576793,high,354,Technology
1007,https://www.rocheplus.es/innovacion/investigacion-ciencia/maquina-higados-vivos.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_maquina_higados_vivos_html.txt,200,,Indexable,2,59,66,3422,156,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_maquina_higados_vivos_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_maquina_higados_vivos_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_maquina_higados_vivos_html.txt.txt,"['Zurich', 'Hospital', 'University']",Other,Spain,Technology,"organ transplantation, organ preservation machine, liver organs",,37.130234,3.5782921,4,"The content discusses recent advancements in medical technology specifically related to organ transplantation, highlighting a new organ preservation machine developed by researchers at the University Hospital of Zurich. This device significantly extends the viability of liver organs for transplant by allowing them to remain metabolically active for a week, compared to the previous one-day preservation limit. The content emphasizes the collaboration between engineering and medicine to improve transplantation outcomes and suggests future applications for preserving other organs. Additionally, it encourages professionals to register for access to exclusive content and provides insights into ongoing innovations in healthcare technology.","technologies, artificial, ai",www.rocheplus.es,All,0.146118162364373,high,495,Technology
1008,https://www.rocheplus.es/innovacion/investigacion-ciencia/mascarillas-inteligentes.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_mascarillas_inteligentes_html.txt,200,,Indexable,2,59,159,1584,93,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_mascarillas_inteligentes_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_mascarillas_inteligentes_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_mascarillas_inteligentes_html.txt.txt,"['UV', 'COVID']",Other,Spain,Technology,"COVID-19, smart masks, self-cleaning capabilities, transparent designs, UV light",COVID-19,37.88574,5.1799364,4,"The content discusses innovative developments in smart masks designed to combat COVID-19, highlighting technological advancements that enhance both safety and functionality. It details several types of smart masks, including those with self-cleaning capabilities, transparent designs to aid communication for the hearing impaired, and masks that use UV light to neutralize viruses. The overarching theme is the intersection of technology and health, showcasing how these innovations contribute to public safety and inclusivity during the pandemic. The content is geared towards healthcare professionals, emphasizing ongoing research and development in the pharmaceutical sector.","technologies, artificial, ai",www.rocheplus.es,Falling,0.616648951230263,high,331,Technology
1009,https://www.rocheplus.es/innovacion/investigacion-ciencia/materiales-biocompatibles.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_materiales_biocompatibles_html.txt,200,,Indexable,2,68,142,3626,112,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_materiales_biocompatibles_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_materiales_biocompatibles_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_materiales_biocompatibles_html.txt.txt,['Danish'],Other,Spain,Technology,,,34.800255,5.4227586,4,"The content discusses advancements in biocompatible materials for medical devices, focusing on research from a Danish team developing cerium oxide-based materials that are safe for implantation in the human body. It highlights the importance of these materials in the creation of smart medical devices that can monitor health and deliver medication efficiently, addressing the growing demand due to an aging population. The project, named BioWings, aims to enhance the functionality of microelectromechanical systems, crucial in biomedical research and clinical practice, while also emphasizing the environmental safety and reduced toxicity of these new materials. The content serves to inform healthcare professionals about innovative developments in biomedicine and the potential impact on future medical devices.","technologies, artificial, ai",www.rocheplus.es,All,0.591173270414006,high,345,Technology
1010,https://www.rocheplus.es/innovacion/investigacion-ciencia/materiales-magneticos.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_materiales_magneticos_html.txt,200,,Indexable,2,75,107,3485,156,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_materiales_magneticos_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_materiales_magneticos_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_materiales_magneticos_html.txt.txt,"['III', 'Madrid', 'University', 'Carlos']",Other,Spain,Research,"magnetotherapy, wound healing, magnetoactive polymers, cancer, artificial muscles, nanorobots",cancer,34.799397,2.0495782,4,"The content discusses the advancements in magnetotherapy and the development of smart materials for wound healing, primarily focusing on a research project led by the Carlos III University of Madrid (UC3M). It explores the use of magnetoactive polymers that can be manipulated externally to enhance cellular performance in healing wounds and combating cancer. The ultimate aim is to create methodologies that help understand cellular systems and improve therapies through innovative materials, including artificial muscles and nanorobots. The content is targeted at healthcare professionals, emphasizing the applications and implications of this research in medical practice and patient care.","technologies, artificial, ai",www.rocheplus.es,Flat,0.263885950932242,high,182,Technology
1011,https://www.rocheplus.es/innovacion/investigacion-ciencia/medidor-de-tumores.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_medidor_de_tumores_html.txt,200,,Indexable,2,83,99,1708,93,47,0.974683544303797,www_rocheplus_es_innovacion_investigacion_ciencia_medidor_de_tumores_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_medidor_de_tumores_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_medidor_de_tumores_html.txt.txt.txt,"['Stanford', 'University', 'By']",Oncology-Hematology,Spain,Technology,"tumor progression, portable electronic strain sensor, cancer treatment, non-invasive monitoring, tumor size changes",,38.832714,-10.025059,12,"The content focuses on a pioneering device developed by researchers at Stanford University, designed to monitor tumor progression in real-time using a portable electronic strain sensor. This innovation aims to enhance the efficiency of cancer treatment evaluations by providing continuous, automated, and non-invasive monitoring of tumor size changes. By addressing the limitations of traditional methods, the device could significantly reduce the time and costs involved in developing new cancer therapies. The article emphasizes the potential impact of this technology on pharmaceutical and oncology research, facilitating faster identification of effective treatments.","cancer, breast, lung",www.rocheplus.es,Rising,0.46439257971991,high,203,Disease Information
1012,https://www.rocheplus.es/innovacion/investigacion-ciencia/microrobots-header.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_microrobots_header_html.txt,200,,Indexable,2,83,140,3760,156,46,0.974683544303797,www_rocheplus_es_innovacion_investigacion_ciencia_microrobots_header_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_microrobots_header_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_microrobots_header_html.txt.txt.txt,[],Oncology-Hematology,Spain,Technology,"micro and nanorobots, therapeutic applications, locating lesions, administering medications, cancer treatment, kidney stone removal, surgical procedures","cancer, kidney stones",38.00001,0.82184124,4,"The content discusses advancements in medical technology, particularly focusing on the development of micro and nanorobots for therapeutic applications within the human body. It highlights groundbreaking innovations that allow these microscopic devices to perform tasks such as locating lesions, conducting surgeries, administering medications, and improving diagnostics. The aim is to enhance treatment efficacy and quality of life for patients by using minimally invasive solutions. The article emphasizes research findings and ongoing studies that explore the potential of these technologies in areas like cancer treatment, kidney stone removal, and surgical procedures. Overall, the content serves to inform healthcare professionals about cutting-edge developments in medical technologies.","technologies, artificial, ai",www.rocheplus.es,All,0.407671461545841,high,304,Technology
1013,https://www.rocheplus.es/innovacion/investigacion-ciencia/neumonia-bacteriana.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_neumonia_bacteriana_html.txt,200,,Indexable,2,66,144,3544,158,47,0.975,www_rocheplus_es_innovacion_investigacion_ciencia_neumonia_bacteriana_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_neumonia_bacteriana_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_neumonia_bacteriana_html.txt.txt.txt,"['FAIR', 'European']",Immunology,Spain,Research,"immunomodulator, flagellin, antibiotics, bacterial pneumonia, nebulization, antibiotic resistance, respiratory infections",bacterial pneumonia,28.94443,1.8483262,4,"The content discusses a new treatment approach for bacterial pneumonia, focusing on the use of an immunomodulator called flagellin in conjunction with antibiotics. It highlights the European project FAIR, which aims to improve the distribution method of flagellin through nebulization to enhance respiratory defenses and combat antibiotic resistance. The article underscores the significance of this research in providing new treatment options, increasing safety and effectiveness, and ultimately improving patient outcomes in respiratory infections. The content serves to inform healthcare professionals about advancements in pneumonia treatment and ongoing clinical research.","technologies, artificial, ai",www.rocheplus.es,Falling,0.464646939826141,high,192,Technology
1014,https://www.rocheplus.es/innovacion/investigacion-ciencia/neumonia-mortalidad-infantil.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_neumonia_mortalidad_infantil_html.txt,200,,Indexable,2,64,165,3683,157,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_neumonia_mortalidad_infantil_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_neumonia_mortalidad_infantil_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_neumonia_mortalidad_infantil_html.txt.txt,['European'],Other,Spain,Research,"diagnostic techniques, childhood pneumonia, microorganisms, nasal sampling, disease transmission, immunity, new therapies, pneumonia management",pneumonia,31.539488,1.360041,4,"The content discusses a European research initiative aimed at improving diagnostic techniques for childhood pneumonia by studying the role of microorganisms in the upper respiratory tract. It highlights the significant mortality caused by pneumonia in children and outlines the project's focus on enhancing nasal sampling methods to better understand disease transmission and immunity. The research seeks to develop new therapies and improve public health predictions regarding pathogen spread. Overall, the content serves to inform healthcare professionals about ongoing innovative research that could impact pediatric care and pneumonia management.","technologies, artificial, ai",www.rocheplus.es,Rising,0.906025013983685,high,257,Technology
1015,https://www.rocheplus.es/innovacion/investigacion-ciencia/neurologia.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_neurologia_html.txt,200,,Indexable,2,90,129,3731,157,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_neurologia_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_neurologia_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_neurologia_html.txt.txt,['Alzheimer'],Neurology,Spain,Research,"blood tests, early detection, Alzheimer's disease, biomarkers, phosphorylated tau protein, diagnostic accuracy, lumbar punctures, brain scans",Alzheimer’s disease,24.165403,28.071835,4,"The content discusses a study highlighting the potential of blood tests as an effective and economical alternative for early detection of Alzheimer’s disease. It details research focused on identifying specific biomarkers in blood, particularly the phosphorylated tau protein, which correlates with brain protein accumulations indicative of the disease. The findings suggest that blood analysis can achieve diagnostic accuracy comparable to standard methods like lumbar punctures or brain scans. The purpose of the content is to inform healthcare professionals about innovative diagnostic approaches in Alzheimer's research, emphasizing the importance of early detection for patient management.","technologies, artificial, ai",www.rocheplus.es,All,0.167813011959134,high,361,Technology
1016,https://www.rocheplus.es/innovacion/investigacion-ciencia/operaciones-realidad-aumentada.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_operaciones_realidad_aumentada_html.txt,200,,Indexable,2,40,34,3780,156,46,0.978021978021978,www_rocheplus_es_innovacion_investigacion_ciencia_operaciones_realidad_aumentada_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_operaciones_realidad_aumentada_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_operaciones_realidad_aumentada_html.txt.txt.txt,"['AR', 'Microsoft']",Other,Spain,Technology,"augmented reality, HoloLens, surgical procedures, 3D models, virtual reality, mixed reality",,30.068083,16.8719,4,"The content discusses the transformative impact of augmented reality (AR) technology on surgery and medical training. It highlights how devices like Microsoft's HoloLens enhance surgical procedures by overlaying vital information and 3D models in real-time, thereby improving decision-making and patient outcomes. The article also explains the distinction between virtual reality, augmented reality, and mixed reality, and references various companies and initiatives that are pioneering the integration of AR into surgical practices. Overall, the purpose is to inform healthcare professionals about cutting-edge innovations that are set to revolutionize the medical field.","technologies, artificial, ai",www.rocheplus.es,All,0.202813551751163,high,41,Technology
1017,https://www.rocheplus.es/innovacion/investigacion-ciencia/piel-artificial.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_piel_artificial_html.txt,200,,Indexable,2,35,134,1627,93,47,0.973684210526316,www_rocheplus_es_innovacion_investigacion_ciencia_piel_artificial_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_piel_artificial_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_piel_artificial_html.txt.txt.txt,[],Other,Spain,Technology,"SmartCore, external stimuli, temperature, pressure, humidity, tactile sensitivity, advanced robotics, human-robot interfaces, biotechnology",,36.657757,7.04208,4,"The content discusses the development of an innovative artificial skin, named SmartCore, designed to detect external stimuli such as temperature, pressure, and humidity. This project aims to closely replicate the sensory functions of human skin, utilizing advanced materials that respond to environmental changes and can also deliver medications. It highlights researchers' efforts to enhance tactile sensitivity and expand the applicability of this technology in advanced robotics, creating more interactive human-robot interfaces. The content serves to inform healthcare professionals about cutting-edge advancements in biotechnology and their potential applications.","technologies, artificial, ai",www.rocheplus.es,All,0.178449071795573,high,470,Technology
1018,https://www.rocheplus.es/innovacion/investigacion-ciencia/proteinas-cancer.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_proteinas_cancer_html.txt,200,,Indexable,2,85,182,3648,157,46,0.974025974025974,www_rocheplus_es_innovacion_investigacion_ciencia_proteinas_cancer_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_proteinas_cancer_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_proteinas_cancer_html.txt.txt.txt,"['Biobank', 'University', 'UK', 'Oxford']",Oncology-Hematology,Spain,Research,,,35.326023,-13.057021,12,"The content discusses a groundbreaking study conducted by researchers at the University of Oxford, which has identified over 100 proteins that can predict cancer risk up to seven years before diagnosis. It elaborates on the methodology, which involved analyzing proteins in relation to various cancer types and subtypes using data from the UK Biobank. The findings suggest significant potential for these proteins as biomarkers for early cancer detection, with numerous associations identified between blood proteins and different cancers. The content aims to inform healthcare professionals about recent scientific advancements in cancer research and highlights the importance of further study in this area.","cancer, breast, lung",www.rocheplus.es,Falling,0.855135652578302,high,106,Disease Information
1019,https://www.rocheplus.es/innovacion/investigacion-ciencia/proteinas-musicales.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_proteinas_musicales_html.txt,200,,Indexable,2,56,164,3748,156,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_proteinas_musicales_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_proteinas_musicales_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_proteinas_musicales_html.txt.txt,"['They', 'Chi', 'J', 'Yu', 'Hua', 'MIT', 'Buehler', 'Markus']",Other,Spain,Research,,,30.3126,-3.5279248,4,"The content discusses an innovative research project by MIT scientists Chi-Hua Yu and Markus J. Buehler, which examines the intersection of music and protein synthesis. They have developed a method to translate the structures of proteins into musical compositions, enabling the creation of entirely new proteins by manipulating musical notes analogous to amino acid sequences. This interdisciplinary approach aims to enhance our understanding of protein structures and potentially lead to sustainable biological materials, such as extending the shelf-life of perishable foods. The findings suggest that music can serve not only as an art form but also as a scientific tool for exploring the intricacies of molecular biology. The content highlights the potential implications of this research for both science and music.","technologies, artificial, ai",www.rocheplus.es,Rising,0.322140640178844,high,453,Technology
1020,https://www.rocheplus.es/innovacion/investigacion-ciencia/reconocimiento-facial.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_reconocimiento_facial_html.txt,200,,Indexable,2,65,131,1801,93,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_reconocimiento_facial_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_reconocimiento_facial_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_reconocimiento_facial_html.txt.txt,"['Ultimately', 'AI']",Other,Spain,Technology,"facial recognition technology, genetic disorders, Face2Gene, AI, algorithms, diagnostic technology",rare genetic disorders,38.812603,0.3159303,4,"The content discusses the innovative use of facial recognition technology in the medical field, specifically for identifying rare genetic disorders through an application called Face2Gene. It describes how this AI-powered tool analyzes facial features using a database of images to assist healthcare professionals in making more accurate diagnoses. The article examines the training of the underlying algorithms, the success stories, and the ongoing need for diverse data to enhance the tool's effectiveness. Ultimately, the content aims to inform healthcare professionals about advancements in diagnostic technology, emphasizing the significant potential of integrating AI in medicine.","technologies, artificial, ai",www.rocheplus.es,Flat,0.567176311797147,high,98,Technology
1021,https://www.rocheplus.es/innovacion/investigacion-ciencia/relojes-y-pulseras-inteligentes-nuevas-herramientas-de-diagnostico-del-covid19.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_relojes_y_pulseras_inteligentes_nuevas_herramientas_de_diagnostico_del_covid19_html.txt,200,,Indexable,2,66,132,3722,156,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_relojes_y_pulseras_inteligentes_nuevas_herramientas_de_diagnostico_del_covid19_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_relojes_y_pulseras_inteligentes_nuevas_herramientas_de_diagnostico_del_covid19_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_relojes_y_pulseras_inteligentes_nuevas_herramientas_de_diagnostico_del_covid19_html.txt.txt,"['Fitbit', 'AI', 'COVID', 'Apple', 'Alzheimer']",Other,Spain,Technology,"wearable technology, smartwatches, fitness bands, COVID-19, biometric measurements, predictive algorithms, cognitive impairments, Alzheimer's disease","COVID-19, Alzheimer's disease",29.789259,25.894377,4,"The content discusses the integration of wearable technology, such as smartwatches and fitness bands, in the early diagnosis of COVID-19 and other diseases. It highlights how biometric measurements from these devices can help detect health issues before symptoms appear, potentially improving diagnostic timelines. The article also references studies and initiatives involving companies like Fitbit and Apple, emphasizing the growing importance of technology in healthcare. Additionally, it notes ongoing research aimed at developing predictive algorithms for various medical conditions, including cognitive impairments like Alzheimer's disease. Overall, the purpose of the content is to inform healthcare professionals about advancements in diagnostic technology leveraging AI and wearables.","technologies, artificial, ai",www.rocheplus.es,Falling,0.706902353784615,high,111,Technology
1022,https://www.rocheplus.es/innovacion/investigacion-ciencia/rinones-bioartificiales.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_rinones_bioartificiales_html.txt,200,,Indexable,2,96,123,1652,93,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_rinones_bioartificiales_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_rinones_bioartificiales_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_rinones_bioartificiales_html.txt.txt,"['Disease', 'California', 'Kidney', 'Researchers', 'Chronic', 'University', 'CKD', 'San', 'Francisco', 'Spain']",CVRM,Spain,Research,"bioartificial kidneys, Chronic Kidney Disease, dialysis, transplantation, advanced filtration technology, renal health, therapeutic options",Chronic Kidney Disease,36.219334,2.8872542,4,"The content discusses the development of bioartificial kidneys as a groundbreaking alternative for patients with Chronic Kidney Disease (CKD), which is a significant public health issue in Spain. Researchers from the University of California, San Francisco have designed an implantable bioartificial kidney that functions autonomously, potentially eliminating the need for dialysis and transplantation. The article highlights the device's innovative design, which uses advanced filtration technology to improve waste removal while minimizing the risk of immune rejection. This research represents a hopeful advancement in renal health, as the bioartificial kidney is currently in preclinical trials. The purpose of the content is to inform healthcare professionals about new therapeutic options and innovations in kidney disease treatment.","technologies, artificial, ai",www.rocheplus.es,Rising,0.241699766605546,high,397,Technology
1023,https://www.rocheplus.es/innovacion/investigacion-ciencia/risa-parkinson.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_risa_parkinson_html.txt,200,,Indexable,2,72,133,1914,93,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_risa_parkinson_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_risa_parkinson_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_risa_parkinson_html.txt.txt,"['Spanish', 'Parkinson']",Neurology,Spain,Research,"Parkinson's disease, artificial intelligence, laughter patterns, vocal analysis, advanced imaging techniques, early intervention",Parkinson's disease,27.003506,27.232086,4,"The content discusses innovative research focusing on the early detection of Parkinson's disease through the analysis of laughter. Spanish researchers have developed an artificial intelligence system that can identify the disease by analyzing laughter patterns, achieving an accuracy rate of 83% from a database of recorded laughs. The article highlights the health benefits of laughter and its potential role in diagnosing neurodegenerative conditions, showcasing various detection methods, including vocal analysis and advanced imaging techniques. Overall, the content serves to inform healthcare professionals about emerging diagnostic technologies and the importance of early intervention for Parkinson's disease.","technologies, artificial, ai",www.rocheplus.es,Rising,0.616112798559907,high,262,Technology
1024,https://www.rocheplus.es/innovacion/investigacion-ciencia/sangre-artificial.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_sangre_artificial_html.txt,200,,Indexable,2,52,154,1903,93,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_sangre_artificial_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_sangre_artificial_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_sangre_artificial_html.txt.txt,"['European', 'Spanish', 'UK', 'CSIC']",Oncology-Hematology,Spain,Research,"artificial blood, synthetic red blood cells, clinical trials, lab-grown red blood cells, drug delivery, cellular therapies",,32.784775,1.0768034,4,"The content focuses on the advancements in artificial blood research, particularly highlighting the efforts of Spanish researchers from the CSIC in a European project aimed at creating synthetic red blood cells. It addresses the global shortage of blood donations, the significance of blood for medical needs, and ongoing clinical trials in the UK involving lab-grown red blood cells. The purpose of the content is to inform healthcare professionals about innovative solutions to blood supply issues that could mitigate dependencies on traditional blood donations and improve treatment for patients with rare blood types. Additionally, it hints at the broader potential of artificial blood technology in drug delivery and cellular therapies.","technologies, artificial, ai",www.rocheplus.es,All,0.325994439593669,high,253,Technology
1025,https://www.rocheplus.es/innovacion/investigacion-ciencia/seguimiento_de_implantes.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_seguimiento_de_implantes_html.txt,200,,Indexable,2,58,117,1661,93,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_seguimiento_de_implantes_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_seguimiento_de_implantes_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_seguimiento_de_implantes_html.txt.txt,['French'],Other,Spain,Technology,"BoneImplant, prosthetic implants, dental applications, hip applications, computer modeling, ultrasound technology, healing, implant stability, advanced measurement techniques, orthopedic procedures, dental procedures",,35.891567,5.4994044,4,"The content discusses a project called BoneImplant, developed by French researchers to minimize the risk of rejection in prosthetic implants, particularly in dental and hip applications. It emphasizes innovations in monitoring the relationship between bone and implants, using computer modeling, and ultrasound technology. The project aims to enhance healing and implant stability via advanced measurement techniques, yielding two spinoff companies focused on improving patient care. The article underlines the intersection of medical research, technology, and patient outcomes in the field of orthopedic and dental procedures.","technologies, artificial, ai",www.rocheplus.es,Flat,0.388036986525132,high,123,Technology
1026,https://www.rocheplus.es/innovacion/investigacion-ciencia/startups-atencion-medica.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_startups_atencion_medica_html.txt,200,,Indexable,2,70,128,3674,156,46,0.976470588235294,www_rocheplus_es_innovacion_investigacion_ciencia_startups_atencion_medica_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_startups_atencion_medica_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_startups_atencion_medica_html.txt.txt.txt,['European'],Other,Spain,Technology,,"diabetes, cancer, autoimmune disease",39.31521,11.284089,4,"The content discusses the role of European startups in advancing the medical field through innovative technologies. It highlights various startups that are making significant contributions, including developments in orthopedics, diabetes management, cancer diagnosis, and autoimmune disease forecasting. The narrative emphasizes how these small companies are transforming health care by providing solutions that improve patients' well-being and ultimately revolutionize traditional medical approaches. The purpose of the content is to inform professionals in the health sector about groundbreaking initiatives and encourage the integration of startup innovations into the medical landscape.","technologies, artificial, ai",www.rocheplus.es,Flat,0.582165313364925,high,90,Technology
1027,https://www.rocheplus.es/innovacion/investigacion-ciencia/supervivencia-cancer-pulmon.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_supervivencia_cancer_pulmon_html.txt,200,,Indexable,2,90,147,3617,158,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_supervivencia_cancer_pulmon_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_supervivencia_cancer_pulmon_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_supervivencia_cancer_pulmon_html.txt.txt,"['Citing', 'Spain']",Oncology-Hematology,Spain,Research,"circadian rhythms, lung adenocarcinoma, biomarkers, treatment strategies, lung cancer, precision oncology","lung adenocarcinoma, lung cancer",34.095924,-15.842603,12,"The content discusses a pioneering study that investigates the relationship between circadian rhythms and lung adenocarcinoma survival rates. It highlights the identification of eight circadian-related genes that can serve as biomarkers for predicting patient outcomes and optimizing personalized treatment strategies. Citing statistical data on lung cancer's impact in Spain, the article underscores the urgency of improving treatment approaches given advances in understanding cancer biology linked to circadian disruptions. The primary purpose of this content is to inform healthcare professionals about significant research advancements relevant to precision oncology and patient care.","cancer, breast, lung",www.rocheplus.es,Flat,0.62759876610177,high,417,Disease Information
1028,https://www.rocheplus.es/innovacion/investigacion-ciencia/tejidos-bio.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_tejidos_bio_html.txt,200,,Indexable,2,77,131,1796,93,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_tejidos_bio_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_tejidos_bio_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_tejidos_bio_html.txt.txt,"['California', 'Munich', 'Technical', 'University']",Other,Spain,Technology,"biomaterials, wound healing, biomolecular film, active pharmaceutical ingredients, BioBandage",,32.21119,2.8993363,4,"The content discusses innovative biomaterials developed for wound healing, focusing on a biomolecular film designed by researchers from the Technical University of Munich. This film not only protects wounds but also releases active pharmaceutical ingredients, enhances healing, and biodegrades without leaving residues. It responds to challenges in medical care by adhering to wet tissues without causing damage. Additionally, the article mentions the creation of a sustainable BioBandage by students at the University of California, which aims to replace traditional adhesive bandages with more eco-friendly options. The overall purpose is to highlight advancements in biomaterials that improve medical treatments and promote sustainability in healthcare practices.","technologies, artificial, ai",www.rocheplus.es,Rising,0.722466958472899,high,284,Technology
1029,https://www.rocheplus.es/innovacion/investigacion-ciencia/tinte-celulas-cancerosas.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_tinte_celulas_cancerosas_html.txt,200,,Indexable,2,66,160,3746,158,47,1,www_rocheplus_es_innovacion_investigacion_ciencia_tinte_celulas_cancerosas_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_tinte_celulas_cancerosas_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_tinte_celulas_cancerosas_html.txt.txt,"['University', 'Oxford']",Oncology-Hematology,Spain,Research,"fluorescent dye, prostate cancer, robotic-assisted surgeries, tumor removal, cancer treatment technology",prostate cancer,36.354015,-9.815285,12,"The content discusses a groundbreaking study conducted by researchers at Oxford University, focusing on the use of a fluorescent dye to enhance the surgical removal of prostate cancer cells. This innovative approach aids surgeons by helping them visualize cancerous tissues in real time during robotic-assisted surgeries, potentially improving the precision of tumor removal and reducing the risk of recurrence. The content is aimed at healthcare professionals, highlighting advancements in cancer treatment technology and the importance of maintaining healthy surrounding tissues during surgery. It also touches on the dye's future applications in other cancers and emphasizes the study's promising results.","cancer, breast, lung",www.rocheplus.es,All,0.322305783984522,high,373,Disease Information
1030,https://www.rocheplus.es/innovacion/investigacion-ciencia/transporte-oxigeno-a-tumores.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_transporte_oxigeno_a_tumores_html.txt,200,,Indexable,2,52,126,1573,93,47,0.97752808988764,www_rocheplus_es_innovacion_investigacion_ciencia_transporte_oxigeno_a_tumores_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_transporte_oxigeno_a_tumores_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_transporte_oxigeno_a_tumores_html.txt.txt.txt,"['European', 'Spanish', 'Oxigenated']",Oncology-Hematology,Spain,Research,"nanocarriers, photodynamic therapy, cancer treatment, reactive oxygen species, hemoglobin-based nanoparticles, chemotherapy","tumor tissues, photodynamic therapy, cancer, chemotherapy",30.081299,-11.767121,12,"The content discusses an innovative European project called ""Oxigenated,"" which focuses on developing nanocarriers to deliver oxygen directly to tumor tissues to enhance the efficacy of photodynamic therapy in cancer treatment. It highlights the importance of oxygen in generating reactive oxygen species that can effectively target and destroy cancer cells. The project, coordinated by Spanish researchers, aims to create hemoglobin-based nanoparticles that improve oxygen availability in tumors, potentially offering a less aggressive alternative to traditional chemotherapy. The article emphasizes ongoing research efforts and their potential implications for more effective cancer therapies.","cancer, breast, lung",www.rocheplus.es,All,0.144365233692944,high,78,Disease Information
1031,https://www.rocheplus.es/innovacion/investigacion-ciencia/unidad-funcional-hepatocarcinoma.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_unidad_funcional_hepatocarcinoma_html.txt,200,,Indexable,2,70,160,1923,57,48,1,www_rocheplus_es_innovacion_investigacion_ciencia_unidad_funcional_hepatocarcinoma_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_unidad_funcional_hepatocarcinoma_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_unidad_funcional_hepatocarcinoma_html.txt.txt,"['Hospital', 'Barcelona', 'Pau', 'Sant', 'HCC']",Oncology-Hematology,Spain,Research,"hepatocellular carcinoma, HCC, immunotherapy",hepatocellular carcinoma,23.193121,-14.647353,12,"The content discusses the establishment of a new functional unit at the Hospital Sant Pau in Barcelona, aimed at providing a multidisciplinary approach to the systemic treatment of hepatocellular carcinoma (HCC). It highlights the collaboration between hepatologists and oncologists, emphasizing the importance of integrated care for patients with complex health issues. The article also addresses the benefits of innovative therapies, like immunotherapy, and outlines the unit’s goals of improving patient care, facilitating decision-making, and fostering research and education among healthcare professionals. Overall, it underscores the significance of coordinated efforts in managing this prevalent and often severe cancer.","cancer, breast, lung",www.rocheplus.es,Flat,0.724264011944791,high,394,Disease Information
1032,https://www.rocheplus.es/innovacion/investigacion-ciencia/videojuegos-para-la-salud.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_videojuegos_para_la_salud_html.txt,200,,Indexable,2,33,152,3877,163,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_videojuegos_para_la_salud_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_videojuegos_para_la_salud_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_videojuegos_para_la_salud_html.txt.txt,['Alzheimer'],Neurology,Spain,Research,"dyslexia, depression, autism, Alzheimer's disease, video games, cognitive functioning, attention, social skills, clinical trials","dyslexia, depression, autism, Alzheimer's disease",22.843132,25.109661,4,"The content discusses the therapeutic use of video games as an innovative approach to combat various neurological disorders, such as dyslexia, depression, autism, and Alzheimer's disease. It highlights research studies that demonstrate the effectiveness of engaging video games in improving cognitive functioning, attention, and social skills among affected individuals. Furthermore, it showcases specific video games designed for therapeutic purposes, noting significant benefits observed in clinical trials. The overall purpose is to inform professionals in the healthcare field about the potential of video games in medical therapy and research.","technologies, artificial, ai",www.rocheplus.es,All,0.65244224604296,high,233,Technology
1033,https://www.rocheplus.es/innovacion/investigacion-ciencia/wearable-cancer-mama.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_wearable_cancer_mama_html.txt,200,,Indexable,2,55,98,3871,112,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_wearable_cancer_mama_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_wearable_cancer_mama_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_wearable_cancer_mama_html.txt.txt,['MIT'],Oncology-Hematology,Spain,Technology,"wearable technology, breast cancer, portable ultrasound imaging, miniaturization, 3D printing, artificial intelligence, diagnostic accuracy",breast cancer,39.487274,-6.2568417,12,"The content discusses a novel wearable technology developed by researchers at MIT aimed at early detection of breast cancer. The device, designed to fit into a brassiere, utilizes portable ultrasound imaging tailored for individuals at high risk of developing the disease. It highlights the importance of early detection, which significantly enhances survival rates. The article emphasizes the device's innovative features, such as miniaturization through 3D printing and integration with artificial intelligence for improved diagnostic accuracy. Overall, it portrays a significant advancement in breast cancer screening technology and aims to raise awareness among healthcare professionals about its potential impact in clinical settings.","cancer, breast, lung",www.rocheplus.es,Falling,0.787212015085086,high,199,Disease Information
1034,https://www.rocheplus.es/innovacion/investigacion-ciencia/werable-sudor-detectar-enfermedades.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_werable_sudor_detectar_enfermedades_html.txt,200,,Indexable,2,61,113,3643,156,46,1,www_rocheplus_es_innovacion_investigacion_ciencia_werable_sudor_detectar_enfermedades_html.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_werable_sudor_detectar_enfermedades_html.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_werable_sudor_detectar_enfermedades_html.txt.txt,[],CVRM,Spain,Technology,"wearable device, sweat composition, diabetes, non-invasive alternative, blood tests, biofluid, diagnostic technology, health monitoring",diabetes,35.187027,6.5527477,4,"The content discusses an innovative wearable device that analyzes sweat composition to monitor health and detect diseases. It highlights how this technology can provide real-time data on hydration, electrolyte levels, and potential health issues like diabetes, offering a non-invasive alternative to traditional blood tests. The article emphasizes the importance of sweat as a valuable biofluid in medical diagnostics, showcasing advancements in health technology and how they can improve patient care while alleviating issues like needle anxiety. The purpose is to inform healthcare professionals about this breakthrough in diagnostic technology and its implications for health monitoring.","technologies, artificial, ai",www.rocheplus.es,All,0.0703183417396555,high,397,Technology
1035,https://www.rocheplus.es/innovacion/investigacion-ciencia/xenoinjertos-cancer-mama.html,10,www_rocheplus_es_innovacion_investigacion_ciencia_xenoinjertos_cancer_mama_html.txt,200,,Indexable,1,86,150,3600,207,88,0.976470588235294,www_rocheplus_es_innovacion_investigacion_ciencia_xenoinjertos_cancer_mama_html.txt.txt,image/www_rocheplus_es_innovacion_investigacion_ciencia_xenoinjertos_cancer_mama_html.txt.txt.png,text/www_rocheplus_es_innovacion_investigacion_ciencia_xenoinjertos_cancer_mama_html.txt.txt.txt,"['University', 'Utah']",Oncology-Hematology,Spain,Research,"triple-negative breast cancer, xenografts, tumor biopsies, personalized medicine, targeted cancer treatments",triple-negative breast cancer,36.175243,-14.993216,12,"The content discusses an innovative approach developed by researchers at the University of Utah for predicting the aggressiveness of triple-negative breast cancer using xenografts. It highlights the significant challenge this cancer type poses due to its heterogeneous cells and resistance to conventional treatments. The researchers have created a technique involving the transplantation of human tumor biopsies into mice, which allows for faster and more accurate predictions regarding the tumor's behavior and likelihood of recurrence. The content aims to inform healthcare professionals about advancements in personalized medicine and the potential for more targeted cancer treatments based on the individual risks assessed through this new method.","cancer, breast, lung",www.rocheplus.es,Rising,0.511854124535241,high,96,Disease Information
1036,https://www.rocheplus.es/innovacion/paradigna-financiacion.html,7,www_rocheplus_es_innovacion_paradigna_financiacion_html.txt,200,,Non-Indexable,2,68,0,840,727,239,0.967213114754098,www_rocheplus_es_innovacion_paradigna_financiacion_html.txt.txt,image/www_rocheplus_es_innovacion_paradigna_financiacion_html.txt.txt.png,text/www_rocheplus_es_innovacion_paradigna_financiacion_html.txt.txt.txt,[],Other,Spain,Technology,,,5.829938,4.7347536,7,"The content highlights a section of Roche's professional website focusing on innovations in healthcare financing. It poses a question about understanding the public-private financing paradigm within the health ecosystem and encourages registration for further exclusive content. The main objective is to inform and engage healthcare professionals about this financing framework, indicating a focus on collaboration in healthcare advancements.","event, exclusive, website",www.rocheplus.es,Flat,0.910443005387451,high,277,Events & Patient Care
1037,https://www.rocheplus.es/innovacion/proyectos/historias-de-vocacion.html,10,www_rocheplus_es_innovacion_proyectos_historias_de_vocacion_html.txt,200,,Non-Indexable,2,21,184,839,512,243,1,www_rocheplus_es_innovacion_proyectos_historias_de_vocacion_html.txt,image/www_rocheplus_es_innovacion_proyectos_historias_de_vocacion_html.txt.png,text/www_rocheplus_es_innovacion_proyectos_historias_de_vocacion_html.txt.txt,"['Stories', 'Vocational']",Other,Spain,Other,,,-4.3067737,-14.837239,3,"The content features a section of a professional website for Roche, focusing on the theme of ""Vocational Stories."" It invites healthcare professionals to explore narratives that highlight experiences and insights in the medical field. The content aims to engage users by sharing personal stories that may resonate with professionals in the healthcare sector, encouraging them to register for access to exclusive content.","users, page, website",www.rocheplus.es,Falling,0.707858904389436,high,128,Website Metadata
1038,https://www.rocheplus.es/innovacion/proyectos/hospitales-humanos.html,10,www_rocheplus_es_innovacion_proyectos_hospitales_humanos_html.txt,200,,Non-Indexable,2,18,169,868,506,243,1,www_rocheplus_es_innovacion_proyectos_hospitales_humanos_html.txt,image/www_rocheplus_es_innovacion_proyectos_hospitales_humanos_html.txt.png,text/www_rocheplus_es_innovacion_proyectos_hospitales_humanos_html.txt.txt,"['Hospitales', 'Hospitals', 'Human', 'Humanos']",Other,Spain,Patient support,,,27.986004,15.020392,4,"The content highlights a project called ""Hospitales Humanos"" (Human Hospitals), which is an initiative aimed at transforming the healthcare experience through humanization within the healthcare system. It emphasizes a revolutionary approach to healthcare focused on understanding and addressing the needs of patients and healthcare professionals. The page likely encourages healthcare professionals to engage with the movement and provides insight into various projects designed with a human-centered perspective in mind.","technologies, artificial, ai",www.rocheplus.es,All,0.642046170400955,high,70,Technology
1039,https://www.rocheplus.es/innovacion/proyectos.html,10,www_rocheplus_es_innovacion_proyectos_html.txt,200,,Non-Indexable,1,9,35,815,1557,410,0.958333333333333,www_rocheplus_es_innovacion_proyectos_html.txt.txt,image/www_rocheplus_es_innovacion_proyectos_html.txt.txt.png,text/www_rocheplus_es_innovacion_proyectos_html.txt.txt.txt,"['Hospitals', 'Zinkinn', 'Projects', 'Human']",Other,Spain,Technology,,,5.891532,5.1717067,7,"The content presents a section focused on ""Projects"" related to innovation within healthcare by Roche. It highlights various initiatives aimed at improving health outcomes and patient care, such as the ""Zinkinn"" platform and ""Human Hospitals."" Additionally, it promotes a virtual project collecting testimonials from healthcare professionals. The content is tailored for healthcare professionals, encouraging them to register for exclusive access to resources and information.","event, exclusive, website",www.rocheplus.es,Falling,0.873647546179645,high,426,Events & Patient Care
1040,https://www.rocheplus.es/innovacion/proyectos/zinkinn.html,10,www_rocheplus_es_innovacion_proyectos_zinkinn_html.txt,200,,Non-Indexable,1,7,222,831,1326,410,0.964285714285714,www_rocheplus_es_innovacion_proyectos_zinkinn_html.txt.txt,image/www_rocheplus_es_innovacion_proyectos_zinkinn_html.txt.txt.png,text/www_rocheplus_es_innovacion_proyectos_zinkinn_html.txt.txt.txt,['Zinkinn'],Other,Spain,Technology,,,7.218029,4.839793,7,"The content presents a section of Roche's website focused on innovation within healthcare. It highlights ""Zinkinn,"" a platform aimed at fostering collaboration around health innovation projects. The content suggests that the platform is dedicated to improving health and quality of life through innovative initiatives. It also invites healthcare professionals to register for exclusive content, emphasizing engagement and participation in the innovation process.","event, exclusive, website",www.rocheplus.es,All,0.944063532677269,high,126,Events & Patient Care
1041,https://www.rocheplus.es/innovacion/tecnologia/3D-fistulas-Crohn.html,10,www_rocheplus_es_innovacion_tecnologia_3D_fistulas_Crohn_html.txt,200,,Indexable,2,60,122,1665,101,51,0.970149253731343,www_rocheplus_es_innovacion_tecnologia_3D_fistulas_Crohn_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_3D_fistulas_Crohn_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_3D_fistulas_Crohn_html.txt.txt.txt,['Crohn'],Immunology,Spain,Technology,"3D technology, 3D imaging, artificial intelligence, Crohn’s disease, perianal fistulas, surgical planning","Crohn's disease, perianal fistulas",37.80466,2.519038,4,"The content discusses the advancements of 3D technology in the medical field, particularly its application in enhancing the surgical planning for patients with Crohn’s disease. It highlights a study demonstrating how 3D imaging, coupled with artificial intelligence algorithms, improves the precision of diagnosing and planning surgeries for complex perianal fistulas associated with Crohn's disease. The content emphasizes the benefits of using 3D reconstructions over traditional imaging methods, ultimately aiming to improve patient outcomes and quality of life. The purpose is to inform healthcare professionals about innovative technologies that can advance surgical practices in treating Crohn’s disease.","technologies, artificial, ai",www.rocheplus.es,Falling,0.625399978807339,high,257,Technology
1042,https://www.rocheplus.es/innovacion/tecnologia/6podcast-salud.html,10,www_rocheplus_es_innovacion_tecnologia_6podcast_salud_html.txt,200,,Indexable,2,60,154,4469,184,50,0.96875,www_rocheplus_es_innovacion_tecnologia_6podcast_salud_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_6podcast_salud_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_6podcast_salud_html.txt.txt.txt,[],Other,Spain,Technology,,,21.468704,15.226462,4,"The content outlines various resources geared toward healthcare professionals, particularly focusing on audio content such as podcasts and playlists that provide specialized information about health and medicine. It discusses the increasing popularity of on-demand audio formats and highlights specific health-related podcasts, offering listeners insights on topics ranging from nutrition to psychological well-being. Additionally, it features curated playlists designed to enhance focus and relaxation for medical professionals during their work. The purpose of this content is to engage and educate healthcare workers through innovative and accessible media.","technologies, artificial, ai",www.rocheplus.es,All,0.0154178722079786,high,57,Technology
1043,https://www.rocheplus.es/innovacion/tecnologia/algoritmo-contra-el-cancer-de-pulmon.html,10,www_rocheplus_es_innovacion_tecnologia_algoritmo_contra_el_cancer_de_pulmon_html.txt,200,,Indexable,2,76,115,4274,184,50,1,www_rocheplus_es_innovacion_tecnologia_algoritmo_contra_el_cancer_de_pulmon_html.txt,image/www_rocheplus_es_innovacion_tecnologia_algoritmo_contra_el_cancer_de_pulmon_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_algoritmo_contra_el_cancer_de_pulmon_html.txt.txt,"['POLYGON', 'AI']",Oncology-Hematology,Spain,Technology,"artificial intelligence, lung cancer, POLYGON, machine learning algorithms, drug combinations, therapeutic outcomes",lung cancer,41.56749,-8.614011,12,"The content discusses the innovative use of artificial intelligence (AI) in developing new treatments for lung cancer. It highlights the POLYGON platform, which utilizes machine learning algorithms to predict effective drug combinations and synthesize potential new medications. The article emphasizes the advantages of AI in expediting drug discovery processes and improving therapeutic outcomes with fewer side effects. Additionally, it refers to related technological advancements and research projects aimed at enhancing cancer diagnosis and treatment. The overall purpose is to inform healthcare professionals about cutting-edge developments in pharmaceutical research and technology.","cancer, breast, lung",www.rocheplus.es,Rising,0.861805794110428,high,93,Disease Information
1044,https://www.rocheplus.es/innovacion/tecnologia/anestesia-a-la-carta.html,10,www_rocheplus_es_innovacion_tecnologia_anestesia_a_la_carta_html.txt,200,,Indexable,2,84,127,4211,184,50,1,www_rocheplus_es_innovacion_tecnologia_anestesia_a_la_carta_html.txt,image/www_rocheplus_es_innovacion_tecnologia_anestesia_a_la_carta_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_anestesia_a_la_carta_html.txt.txt,"['Hospital', 'General', 'EEG', 'Massachusetts', 'MIT']",Other,Spain,Technology,"closed-loop anesthesia system, anesthesia, anesthetic, EEG data",,28.350626,24.240614,4,"The content discusses an innovative closed-loop anesthesia system designed by researchers from MIT and Massachusetts General Hospital, aimed at improving the accuracy of anesthesia administration during surgical procedures. The system monitors brain activity to deliver precise dosages of anesthetic every 20 seconds, allowing for better control of unconsciousness compared to traditional methods. It highlights the challenges anesthetists face in maintaining patient stability and minimizing cognitive side effects during and after anesthesia. Additionally, the content notes that this system is still in the testing phase, with future plans to integrate human EEG data for further development.","technologies, artificial, ai",www.rocheplus.es,Falling,0.128649497010867,high,285,Technology
1045,https://www.rocheplus.es/innovacion/tecnologia/anticonceptivos.html,10,www_rocheplus_es_innovacion_tecnologia_anticonceptivos_html.txt,200,,Indexable,2,70,107,1979,101,51,0.969230769230769,www_rocheplus_es_innovacion_tecnologia_anticonceptivos_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_anticonceptivos_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_anticonceptivos_html.txt.txt.txt,[],Other,Spain,Research,"voice-assisted device, ultrasound, sperm production, subdermal implants, contraceptive protection, hormonal load, contraceptive options",,33.23466,4.5307584,4,"The content discusses advancements in contraceptive technologies, highlighting innovative methods under development, such as a voice-assisted device utilizing ultrasound to temporarily halt sperm production in men and subdermal implants for women that provide long-lasting contraceptive protection with reduced hormonal load. It outlines the ongoing research efforts and clinical trials related to these innovations, emphasizing the potential benefits of more user-friendly and effective contraceptive options. The content targets healthcare professionals by providing insights into emerging contraceptive solutions and ongoing clinical research, aiming to stimulate interest and discussion regarding the future of contraceptive methods.","technologies, artificial, ai",www.rocheplus.es,Flat,0.631279102105748,high,214,Technology
1046,https://www.rocheplus.es/innovacion/tecnologia/aplicaciones-del-laser.html,10,www_rocheplus_es_innovacion_tecnologia_aplicaciones_del_laser_html.txt,200,,Indexable,2,48,144,4477,184,50,1,www_rocheplus_es_innovacion_tecnologia_aplicaciones_del_laser_html.txt,image/www_rocheplus_es_innovacion_tecnologia_aplicaciones_del_laser_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_aplicaciones_del_laser_html.txt.txt,[],Other,Spain,Technology,"laser technology, benign prostatic hyperplasia, hemorrhoids, cancer, aesthetic medicine","benign prostatic hyperplasia, hemorrhoids",32.52209,-0.7656542,4,"The content discusses the revolutionary impact of laser technology in the medical field, highlighting its various applications and advantages over conventional surgical methods. It details how lasers are utilized in procedures for treating conditions like benign prostatic hyperplasia, hemorrhoids, and in dentistry, emphasizing their minimally invasive nature, reduced recovery times, and effectiveness. Additionally, it touches upon advancements in cancer research and aesthetic medicine facilitated by laser technology. The overall purpose of the content is to inform healthcare professionals about the innovative uses of laser technology in improving patient care and outcomes.","technologies, artificial, ai",www.rocheplus.es,Flat,0.740821168162532,high,482,Technology
1047,https://www.rocheplus.es/innovacion/tecnologia/apnea-sueno.html,10,www_rocheplus_es_innovacion_tecnologia_apnea_sueno_html.txt,200,,Indexable,2,101,136,4420,184,50,1,www_rocheplus_es_innovacion_tecnologia_apnea_sueno_html.txt,image/www_rocheplus_es_innovacion_tecnologia_apnea_sueno_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_apnea_sueno_html.txt.txt,"['Revolution', 'Sleep', 'Spain']",Other,Spain,Research,"obstructive sleep apnea, machine learning, wearable technology, diagnostic algorithms, digital platform, data integration, treatment options",obstructive sleep apnea,39.50098,13.948425,4,"The content discusses a project called ""The Sleep Revolution,"" aimed at improving the diagnosis and treatment of obstructive sleep apnea, a condition affecting approximately 2 million people in Spain, of whom only 10% are properly diagnosed and treated. The initiative seeks to leverage machine learning and wearable technology to enhance sleep studies and provide personalized healthcare solutions. It involves collaboration among over 30 sleep centers and aims to develop accurate diagnostic algorithms and a digital platform to facilitate data integration among researchers, patients, and healthcare professionals. The project is significant in its scale and funding, highlighting the need for better diagnostic methods and treatment options for this common but often misdiagnosed disorder.","technologies, artificial, ai",www.rocheplus.es,Falling,0.940778335315116,high,43,Technology
1048,https://www.rocheplus.es/innovacion/tecnologia/apps-dejar-de-fumar.html,10,www_rocheplus_es_innovacion_tecnologia_apps_dejar_de_fumar_html.txt,200,,Indexable,2,45,149,4524,184,50,0.971014492753623,www_rocheplus_es_innovacion_tecnologia_apps_dejar_de_fumar_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_apps_dejar_de_fumar_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_apps_dejar_de_fumar_html.txt.txt.txt,"['Spanish', 'Ultimately']",Other,Spain,Technology,,,32.39187,9.038414,4,"The content discusses various smartphone apps and technologies designed to assist individuals in quitting smoking in 2021. It highlights the significant health risks associated with tobacco addiction and presents statistical insights into smoking cessation efforts among the Spanish population. The article emphasizes the role of technology, including specific apps and wearables, in supporting individuals to quit smoking by tracking habits, providing motivational tools, and creating personalized quitting plans. Ultimately, it serves to inform healthcare professionals and the general public about innovative solutions available for smoking cessation.","technologies, artificial, ai",www.rocheplus.es,Rising,0.469063203650901,high,66,Technology
1049,https://www.rocheplus.es/innovacion/tecnologia/Apps-medicas.html,10,www_rocheplus_es_innovacion_tecnologia_Apps_medicas_html.txt,200,,Indexable,2,54,181,4788,186,51,1,www_rocheplus_es_innovacion_tecnologia_Apps_medicas_html.txt,image/www_rocheplus_es_innovacion_tecnologia_Apps_medicas_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_Apps_medicas_html.txt.txt,"['Parkinson', 'Its']",Other,Spain,Technology,,"Parkinson's disease, multiple sclerosis",26.198172,16.243301,4,"The content primarily discusses various medical applications designed to enhance healthcare delivery through mobile technology. It details specific apps that assist with tasks like monitoring scars, conducting home urine analysis, managing medication schedules, and tracking chronic conditions such as Parkinson's and multiple sclerosis. The content emphasizes the innovative use of technology in medical practice while cautioning that these apps do not replace professional medical advice. Its purpose is to inform healthcare professionals about useful mobile applications that can improve patient care and streamline medical processes.","technologies, artificial, ai",www.rocheplus.es,All,0.123568542501802,high,169,Technology
1050,https://www.rocheplus.es/innovacion/tecnologia/apps-moviles-al-servicio-de-la-medicina.html,10,www_rocheplus_es_innovacion_tecnologia_apps_moviles_al_servicio_de_la_medicina_html.txt,200,,Indexable,2,64,155,4368,184,50,1,www_rocheplus_es_innovacion_tecnologia_apps_moviles_al_servicio_de_la_medicina_html.txt,image/www_rocheplus_es_innovacion_tecnologia_apps_moviles_al_servicio_de_la_medicina_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_apps_moviles_al_servicio_de_la_medicina_html.txt.txt,"['Several', 'Medscape']",Other,Spain,Technology,,,26.285858,15.715307,4,"The content discusses the growing field of mobile health (mHealth) and the various applications designed to assist medical professionals in their daily practice. It highlights the lack of specific regulations governing these health apps despite their adoption by healthcare practitioners for facilitating diagnoses and enhancing patient care. Several examples of medical applications, such as Medscape and iDoctus, are provided, emphasizing their functionalities and benefits in the medical field. The overall purpose is to inform healthcare professionals about innovative tools available to improve their practice and patient outcomes, while also noting the challenges related to regulation and safety.","technologies, artificial, ai",www.rocheplus.es,Rising,0.0672275266279312,high,313,Technology
1051,https://www.rocheplus.es/innovacion/tecnologia/apps-paciente-oncologicos.html,10,www_rocheplus_es_innovacion_tecnologia_apps_paciente_oncologicos_html.txt,200,,Indexable,2,61,145,4474,184,50,1,www_rocheplus_es_innovacion_tecnologia_apps_paciente_oncologicos_html.txt,image/www_rocheplus_es_innovacion_tecnologia_apps_paciente_oncologicos_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_apps_paciente_oncologicos_html.txt.txt,"['Diana', 'Specific']",Oncology-Hematology,Spain,Technology,"breast cancer, Diana, Close2U, digital health tools",breast cancer,23.079994,-12.975187,12,"The content provides an overview of mobile applications developed to support cancer patients in their treatment journey. It highlights innovations in technology and research aimed at enhancing patient care and quality of life. Specific apps are described, such as ""Diana,"" which offers comprehensive support for breast cancer patients by tracking treatment, managing schedules, and providing emotional assistance, and ""Close2U,"" which allows patients to record their symptoms and treatment progress to receive personalized advice. The purpose of the content is to promote these digital health tools as valuable resources for cancer patients, emphasizing the importance of innovation in healthcare.","cancer, breast, lung",www.rocheplus.es,All,0.415348489737366,high,50,Disease Information
1052,https://www.rocheplus.es/innovacion/tecnologia/asistentes-de-voz.html,10,www_rocheplus_es_innovacion_tecnologia_asistentes_de_voz_html.txt,200,,Indexable,2,61,139,1908,101,51,1,www_rocheplus_es_innovacion_tecnologia_asistentes_de_voz_html.txt,image/www_rocheplus_es_innovacion_tecnologia_asistentes_de_voz_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_asistentes_de_voz_html.txt.txt,"['Service', 'Alexa', 'Google', 'National', 'UK', 'Home', 'Health']",Other,Spain,Technology,,,35.695087,18.520266,4,"The content discusses the integration of voice assistants, such as Alexa and Google Home, into the healthcare sector, highlighting their potential to revolutionize medical diagnostics and assist both patients and healthcare professionals. It outlines various applications of these technologies, including symptom assessment tools for patients and support systems designed for the elderly, as well as examples of collaborations between tech companies and health services, such as the UK's National Health Service. The purpose of the content is to inform healthcare professionals about emerging technologies that can enhance patient care and streamline medical processes.","technologies, artificial, ai",www.rocheplus.es,Rising,0.375742738528854,high,309,Technology
1053,https://www.rocheplus.es/innovacion/tecnologia/bioimpresion.html,10,www_rocheplus_es_innovacion_tecnologia_bioimpresion_html.txt,200,,Indexable,2,57,79,4450,193,51,1,www_rocheplus_es_innovacion_tecnologia_bioimpresion_html.txt,image/www_rocheplus_es_innovacion_tecnologia_bioimpresion_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_bioimpresion_html.txt.txt,[],Other,Spain,Technology,"3D bioprinting, prosthetics, artificial artery, biotints, living cells, surgical outcomes, bioprinting technology",,37.241917,6.4429336,4,"The content discusses advancements in 3D bioprinting technology and its applications in personalized medicine. It explains how bioprinting can create biological structures, such as prosthetics and new organs, using biotints that incorporate living cells. The content highlights specific innovations, including an artificial artery developed by researchers, which reacts to electrical pulses, potentially improving surgical outcomes. Additionally, it underscores the growing market for bioprinting technology, projected to reach significant financial values, and emphasizes its transformative impact on healthcare. The overall purpose is to inform healthcare professionals about the latest developments and potential benefits of bioprinting in medical treatments.","technologies, artificial, ai",www.rocheplus.es,Falling,0.835528533139743,high,370,Technology
1054,https://www.rocheplus.es/innovacion/tecnologia/cardiopatia-isquemica.html,10,www_rocheplus_es_innovacion_tecnologia_cardiopatia_isquemica_html.txt,200,,Indexable,2,61,148,4281,184,50,0.971830985915493,www_rocheplus_es_innovacion_tecnologia_cardiopatia_isquemica_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_cardiopatia_isquemica_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_cardiopatia_isquemica_html.txt.txt.txt,"['European', 'Navarra', 'BRAV', 'Clinic', 'Europe', 'University']",CVRM,Spain,Research,"ischemic heart disease, BioVAD, advanced tissue engineering, 3D printing, stem cells, computational modeling, regenerative medicine",ischemic heart disease,37.636616,2.3199003,4,"The content discusses the BRAV project, a European initiative led by the University Clinic of Navarra aimed at cardiac regeneration to address ischemic heart disease, which is a leading cause of cardiovascular mortality. It outlines the project's goal to develop a biological device named BioVAD, employing advanced tissue engineering, 3D printing, stem cells, and computational modeling to enhance heart function. The content emphasizes the potential impact on regenerative medicine and the collaboration between various institutions across Europe to facilitate this innovative approach to heart repair.","technologies, artificial, ai",www.rocheplus.es,Flat,0.246026764478468,high,34,Technology
1055,https://www.rocheplus.es/innovacion/tecnologia/catalogo-oms.html,10,www_rocheplus_es_innovacion_tecnologia_catalogo_oms_html.txt,200,,Indexable,2,51,150,1669,101,51,0.967741935483871,www_rocheplus_es_innovacion_tecnologia_catalogo_oms_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_catalogo_oms_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_catalogo_oms_html.txt.txt.txt,"['Health', 'WHO', 'World', 'Organization']",Other,Spain,Technology,,,36.79549,13.037576,4,"The content discusses recent innovations in healthcare technologies approved by the World Health Organization (WHO), focusing on solutions that can enhance the quality of care, particularly in underserved areas. It highlights various medical devices and technologies aimed at addressing immediate health challenges, including monitoring newborns' heart rates, detecting communicable diseases, and providing oxygen supply without electrical infrastructure. Additionally, the piece emphasizes the role of technological advancement amidst rapid digitalization in healthcare, while also referencing the challenges of regulatory validation before market release. The overarching purpose is to inform healthcare professionals about noteworthy innovations that can significantly impact patient care.","technologies, artificial, ai",www.rocheplus.es,Flat,0.867665446308159,high,445,Technology
1056,https://www.rocheplus.es/innovacion/tecnologia/ces-2023.html,10,www_rocheplus_es_innovacion_tecnologia_ces_2023_html.txt,200,,Indexable,2,62,127,1725,101,51,1,www_rocheplus_es_innovacion_tecnologia_ces_2023_html.txt,image/www_rocheplus_es_innovacion_tecnologia_ces_2023_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_ces_2023_html.txt.txt,"['AI', 'CES', 'Alzheimer']",Other,Spain,Technology,,,39.808445,17.930767,4,"The content provides an overview of the latest innovations in digital health showcased at CES 2023, focusing on the integration of artificial intelligence in medical technologies. It highlights various products, including AI-powered devices for virus detection, home urine analysis, gut health monitoring, hydration tracking for athletes, early Alzheimer's detection, safety features for wheelchairs, and health assessments through imaging. The article serves to inform healthcare professionals about advancements in digital health solutions that may enhance patient care and medical practices.","technologies, artificial, ai",www.rocheplus.es,All,0.0774123254045044,high,278,Technology
1057,https://www.rocheplus.es/innovacion/tecnologia/CES.html,10,www_rocheplus_es_innovacion_tecnologia_CES_html.txt,200,,Indexable,2,64,156,1781,101,51,1,www_rocheplus_es_innovacion_tecnologia_CES_html.txt,image/www_rocheplus_es_innovacion_tecnologia_CES_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_CES_html.txt.txt,['CES'],Other,Spain,Technology,"wearable devices, monitoring body temperature, sleep patterns, vital signs, artificial intelligence, health assessments",,13.071114,9.087456,7,"The content discusses the highlights of digital health innovations presented at CES 2022, showcasing various technological advancements aimed at improving health and wellness. It details several innovative products, including wearable devices for monitoring body temperature, sleep patterns, and vital signs, as well as tools utilizing artificial intelligence for health assessments. The content serves to inform healthcare professionals about new technologies that could enhance patient care and outcomes, aligning with Roche's commitment to advancing healthcare through innovation.","event, exclusive, website",www.rocheplus.es,Flat,0.785883563326463,high,90,Events & Patient Care
1058,https://www.rocheplus.es/innovacion/tecnologia/deteccion-cancer-mama.html,10,www_rocheplus_es_innovacion_tecnologia_deteccion_cancer_mama_html.txt,200,,Indexable,2,86,163,4388,203,68,1,www_rocheplus_es_innovacion_tecnologia_deteccion_cancer_mama_html.txt,image/www_rocheplus_es_innovacion_tecnologia_deteccion_cancer_mama_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_deteccion_cancer_mama_html.txt.txt,"['X', 'Qustom']",Oncology-Hematology,Spain,Technology,"Qustom project, breast cancer, 3D ultrasound imaging, high-performance computing, detailed 3D images, traditional mammograms, breast tumors, dense breast tissue, radiation-free alternatives",breast cancer,37.245903,-9.982647,12,"The content discusses a groundbreaking initiative called the Qustom project, which aims to enhance breast cancer diagnosis through the use of high-resolution 3D ultrasound imaging. It describes how this innovative technology integrates high-performance computing with advanced ultrasound data acquisition to produce detailed 3D images, potentially replacing traditional mammograms and eliminating the need for X-rays. The content emphasizes the significance of accurate imaging in identifying breast tumors, especially in women with dense breast tissue. Additionally, it outlines the project's technical advancements, safety tests, and the overall objective of revolutionizing breast cancer screening methods with radiation-free alternatives. The target audience appears to be healthcare professionals and stakeholders interested in medical advancements and cancer diagnostics.","cancer, breast, lung",www.rocheplus.es,Flat,0.0846274855855772,high,224,Disease Information
1059,https://www.rocheplus.es/innovacion/tecnologia/deteccion-precoz-cancer-mama.html,10,www_rocheplus_es_innovacion_tecnologia_deteccion_precoz_cancer_mama_html.txt,200,,Indexable,2,53,117,4277,184,50,1,www_rocheplus_es_innovacion_tecnologia_deteccion_precoz_cancer_mama_html.txt,image/www_rocheplus_es_innovacion_tecnologia_deteccion_precoz_cancer_mama_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_deteccion_precoz_cancer_mama_html.txt.txt,"['Salamanca', 'University', 'CSIC']",Oncology-Hematology,Spain,Technology,"breast cancer, intelligent risk predictor, machine learning, genetic markers, survival, prognosis, early detection, treatment strategies, numerical risk scale, diagnostic precision, biomarkers, clinical oncology practices",breast cancer,38.292713,-11.314143,12,"The content discusses a newly developed intelligent risk predictor for breast cancer, created by researchers from the CSIC and the University of Salamanca. This predictive tool utilizes machine learning techniques to analyze genetic markers associated with survival and prognosis, aiming to improve early detection and treatment strategies. The platform offers a numerical risk scale, enhancing diagnostic precision by evaluating various biomarkers. It emphasizes the importance of early cancer detection and the potential advancement in clinical oncology practices, providing evidence that the new system could significantly impact treatment decisions while maintaining similar costs to existing commercial tests.","cancer, breast, lung",www.rocheplus.es,Flat,0.960459733662555,high,437,Disease Information
1060,https://www.rocheplus.es/innovacion/tecnologia/discapacidad.html,10,www_rocheplus_es_innovacion_tecnologia_discapacidad_html.txt,200,,Indexable,2,59,141,2061,101,51,0.967741935483871,www_rocheplus_es_innovacion_tecnologia_discapacidad_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_discapacidad_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_discapacidad_html.txt.txt.txt,"['Toronto', 'California', 'Sidewalk', 'Labs', 'Netherlands']",Other,Spain,Technology,,"autism, dementia",28.085108,20.774744,4,"The content discusses the integration of technology into urban environments to support people with disabilities, highlighting the growing global population of approximately 650 million individuals with various disabilities. It emphasizes the need for smart city initiatives that foster accessibility, referencing projects like Toronto's Sidewalk Labs and various technological aids such as apps for visually impaired individuals and wheelchair navigation. The content also notes innovative living arrangements tailored for people with autism and dementia, such as specialized residential communities in California and the Netherlands. Overall, the purpose is to inform professionals about advancements in smart cities and technology aimed at improving the quality of life for disabled individuals.","technologies, artificial, ai",www.rocheplus.es,All,0.888867996435258,high,325,Technology
1061,https://www.rocheplus.es/innovacion/tecnologia/dispositivos-hipertension.html,10,www_rocheplus_es_innovacion_tecnologia_dispositivos_hipertension_html.txt,200,,Indexable,2,76,126,4435,184,50,1,www_rocheplus_es_innovacion_tecnologia_dispositivos_hipertension_html.txt,image/www_rocheplus_es_innovacion_tecnologia_dispositivos_hipertension_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_dispositivos_hipertension_html.txt.txt,[],CVRM,Spain,Technology,"hypertension, portable devices, blood pressure, continuous monitoring",hypertension,36.192123,7.9858985,4,"The content discusses advancements in technology for detecting and managing hypertension, a significant global health issue affecting approximately 1.28 billion people. It highlights innovative portable devices that allow for easy and precise monitoring of blood pressure and overall health, essential for combating undiagnosed cases of hypertension. The content serves as a resource for healthcare professionals, providing insights into new technologies, including various device functionalities, their applications, and the importance of continuous monitoring. Additionally, it emphasizes the goal of reducing the global incidence of hypertension by 25% by 2030.","technologies, artificial, ai",www.rocheplus.es,All,0.8171667908127,high,147,Technology
1062,https://www.rocheplus.es/innovacion/tecnologia/dispositivos-silver-atencion-personas-mayores.html,10,www_rocheplus_es_innovacion_tecnologia_dispositivos_silver_atencion_personas_mayores_html.txt,200,,Indexable,2,56,140,4530,184,50,1,www_rocheplus_es_innovacion_tecnologia_dispositivos_silver_atencion_personas_mayores_html.txt,image/www_rocheplus_es_innovacion_tecnologia_dispositivos_silver_atencion_personas_mayores_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_dispositivos_silver_atencion_personas_mayores_html.txt.txt,['Spain'],Other,Spain,Technology,,,36.437817,12.2835245,4,"The content discusses the increasing need for technology designed to support elderly individuals, particularly in light of Spain's aging population. It highlights various innovations, including IoT devices, artificial intelligence, and smart wearables, all aimed at enhancing the autonomy and overall quality of life for older adults. The content serves to inform healthcare professionals about these technological advancements, emphasizing their potential to facilitate independent living and improve care for the elderly.","technologies, artificial, ai",www.rocheplus.es,Falling,0.837267218121959,high,373,Technology
1063,https://www.rocheplus.es/innovacion/tecnologia/doctor-gadget.html,10,www_rocheplus_es_innovacion_tecnologia_doctor_gadget_html.txt,200,,Indexable,2,53,152,4449,184,50,1,www_rocheplus_es_innovacion_tecnologia_doctor_gadget_html.txt,image/www_rocheplus_es_innovacion_tecnologia_doctor_gadget_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_doctor_gadget_html.txt.txt,[],Other,Spain,Technology,"digital devices, technology, portable medical devices, digital stethoscopes, portable ultrasound machines, drones, defibrillators, telemedicine",,36.35878,13.220199,4,"The content discusses the integration of modern digital devices and technology in healthcare, focusing on innovations that enhance medical treatment and diagnostics in the 21st century. It highlights various portable medical devices, such as digital stethoscopes, portable ultrasound machines, and drones equipped with defibrillators, that improve accessibility to healthcare and facilitate remote medical care through telemedicine. The purpose of the content is to inform healthcare professionals about these advancements and encourage the adoption of digital tools in their practice.","technologies, artificial, ai",www.rocheplus.es,Rising,0.106958402963022,high,353,Technology
1064,https://www.rocheplus.es/innovacion/tecnologia/drones-emergencias-cardiacas.html,10,www_rocheplus_es_innovacion_tecnologia_drones_emergencias_cardiacas_html.txt,200,,Indexable,2,39,158,4298,184,50,1,www_rocheplus_es_innovacion_tecnologia_drones_emergencias_cardiacas_html.txt,image/www_rocheplus_es_innovacion_tecnologia_drones_emergencias_cardiacas_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_drones_emergencias_cardiacas_html.txt.txt,['Sweden'],CVRM,Spain,Technology,"drones, automatic external defibrillators, out-of-hospital cardiac arrests, defibrillators, survival rates",out-of-hospital cardiac arrests,35.95971,13.214968,4,"The content discusses a study conducted in Sweden that evaluated the effectiveness of drones in delivering automatic external defibrillators (AEDs) for responding to out-of-hospital cardiac arrests. The results indicated that drones were able to arrive 67% faster than ambulances, providing a potentially life-saving advantage in emergencies. The study highlights the importance of quick access to defibrillators, as timely intervention can significantly improve survival rates. The article is part of a larger content aimed at healthcare professionals, emphasizing innovation in medical technology and emergency response systems.","technologies, artificial, ai",www.rocheplus.es,All,0.475987160170217,high,290,Technology
1065,https://www.rocheplus.es/innovacion/tecnologia/enfermeria-asistencia.html,10,www_rocheplus_es_innovacion_tecnologia_enfermeria_asistencia_html.txt,200,,Indexable,2,46,131,4433,184,50,0.971830985915493,www_rocheplus_es_innovacion_tecnologia_enfermeria_asistencia_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_enfermeria_asistencia_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_enfermeria_asistencia_html.txt.txt.txt,"['Veebot', 'COVID']",Other,Spain,Technology,"Veebot, telemedicine, remote triage, virtual reality, automated solutions, autonomous robots",,36.891594,17.837238,4,"The content discusses innovations in nursing technology, particularly in response to the challenges posed by the COVID-19 pandemic. It highlights automated solutions such as the Veebot for needle insertion, autonomous robots for medication transport, and virtual reality for training and reducing stress in clinical settings. It also mentions advancements in telemedicine and remote triage capabilities, which have evolved significantly during the pandemic. The overall purpose is to showcase how technological advancements can enhance the efficiency and safety of nursing practices while alleviating the burdens faced by healthcare professionals.","technologies, artificial, ai",www.rocheplus.es,Falling,0.882757455845432,high,151,Technology
1066,https://www.rocheplus.es/innovacion/tecnologia/espacio-y-hologramas.html,10,www_rocheplus_es_innovacion_tecnologia_espacio_y_hologramas_html.txt,200,,Indexable,2,47,146,1651,141,51,1,www_rocheplus_es_innovacion_tecnologia_espacio_y_hologramas_html.txt,image/www_rocheplus_es_innovacion_tecnologia_espacio_y_hologramas_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_espacio_y_hologramas_html.txt.txt,"['International', 'NASA', 'ISS', 'Station', 'Earth', 'Space']",Other,Spain,Technology,"holographic technology, telemedicine, remote medical assistance, psychological support, mixed-reality systems",,29.46294,17.277853,4,"The content focuses on the innovative use of holographic technology in medical care, particularly in remote locations such as the International Space Station (ISS). It highlights a significant achievement by NASA, where real-time holographic communication was established between Earth-based researchers and an astronaut, paving the way for new telemedicine applications. The content discusses practical implications, including remote medical assistance, psychological support, and training applications. Additionally, it reflects on the rapid advancements in telemedicine during the pandemic and emphasizes the potential of mixed-reality systems to enhance healthcare delivery. Overall, the purpose is to inform professionals about cutting-edge technologies that can improve patient care and medical training.","technologies, artificial, ai",www.rocheplus.es,All,0.0430999166161401,high,472,Technology
1067,https://www.rocheplus.es/innovacion/tecnologia/estimulacion-cerebral-profunda.html,10,www_rocheplus_es_innovacion_tecnologia_estimulacion_cerebral_profunda_html.txt,200,,Indexable,2,113,116,4250,203,68,1,www_rocheplus_es_innovacion_tecnologia_estimulacion_cerebral_profunda_html.txt,image/www_rocheplus_es_innovacion_tecnologia_estimulacion_cerebral_profunda_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_estimulacion_cerebral_profunda_html.txt.txt,"['Parkinson', 'MIT', 'DBS']",Neurology,Spain,Technology,"deep brain stimulation, DBS, Parkinson's disease, ultrasound, neurodegenerative diseases, neurological treatments",Parkinson's disease,25.270899,28.834713,4,"The content discusses an innovative approach to deep brain stimulation (DBS) for treating Parkinson's disease, developed by researchers at MIT. It highlights a new system that uses ultrasound instead of electrical impulses to stimulate brain regions, thereby minimizing risks associated with traditional electrode-based methods. This approach aims to provide a safer and less invasive alternative for patients with neurodegenerative diseases. The content is primarily intended for healthcare professionals, emphasizing advancements in medical technology and research related to neurological treatments.","technologies, artificial, ai",www.rocheplus.es,Rising,0.793761545047486,high,454,Technology
1068,https://www.rocheplus.es/innovacion/tecnologia/exoesqueleto-pediatrico.html,10,www_rocheplus_es_innovacion_tecnologia_exoesqueleto_pediatrico_html.txt,200,,Indexable,2,54,147,4363,185,51,0.972602739726027,www_rocheplus_es_innovacion_tecnologia_exoesqueleto_pediatrico_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_exoesqueleto_pediatrico_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_exoesqueleto_pediatrico_html.txt.txt.txt,['ATLAS'],Other,Spain,Technology,"ATLAS 2030, pediatric exoskeleton, spinal muscular atrophy, cerebral palsy, 3D printing, affordable prosthetics, lightweight prosthetics","spinal muscular atrophy, cerebral palsy",28.153894,21.81163,4,"The content primarily discusses the development of ATLAS 2030, the world's first pediatric exoskeleton designed to assist children with spinal muscular atrophy and cerebral palsy. It highlights the innovative features of the exoskeleton, including its ability to adapt to the child's movements and provide therapeutic benefits. The content emphasizes advancements in technology, such as 3D printing, that have made affordable and lightweight prosthetics possible for children. The purpose of the content is to inform healthcare professionals and stakeholders about these technological innovations that cater to children’s needs, improving their mobility and quality of life.","technologies, artificial, ai",www.rocheplus.es,Rising,0.2389639750367,high,70,Technology
1069,https://www.rocheplus.es/innovacion/tecnologia/felipe-villacampa.html,10,www_rocheplus_es_innovacion_tecnologia_felipe_villacampa_html.txt,200,,Indexable,2,77,142,1775,110,52,1,www_rocheplus_es_innovacion_tecnologia_felipe_villacampa_html.txt,image/www_rocheplus_es_innovacion_tecnologia_felipe_villacampa_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_felipe_villacampa_html.txt.txt,"['Expert', 'Dr', 'Felipe', 'Villacampa']",Oncology-Hematology,Spain,Technology,"bladder cancer, DaVinci robotic system, radical cystectomy, chemotherapy, immunotherapy",bladder cancer,37.794743,-0.11553168,4,"The content primarily discusses advancements in robotic surgery, specifically the use of the DaVinci robotic system for bladder cancer interventions. It highlights the role of robotics in enhancing surgical precision, reducing recovery time, and improving patient outcomes during complex procedures like radical cystectomy. Expert insights from Dr. Felipe Villacampa detail how robotic surgery not only minimizes patient trauma but also facilitates subsequent treatments such as chemotherapy and immunotherapy. Additionally, the content outlines the operational aspects of the DaVinci system and emphasizes the importance of training for surgeons to effectively use this technology. Overall, the purpose of the content is to inform healthcare professionals about innovative surgical techniques and the potential benefits of robotic assistance in oncology.","technologies, artificial, ai",www.rocheplus.es,Falling,0.629438630244821,high,374,Technology
1070,https://www.rocheplus.es/innovacion/tecnologia/femtech.html,10,www_rocheplus_es_innovacion_tecnologia_femtech_html.txt,200,,Indexable,2,55,156,1739,101,51,1,www_rocheplus_es_innovacion_tecnologia_femtech_html.txt,image/www_rocheplus_es_innovacion_tecnologia_femtech_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_femtech_html.txt.txt,"['Clue', 'Femtech']",Other,Spain,Technology,"Clue app, LactApp, Femtech",,32.93693,7.1757846,4,"The content discusses the growing phenomenon of Femtech, which refers to health technology specifically designed to empower women and address their health needs. It highlights various applications and tools that support women's health, such as the Clue app for menstrual tracking and the LactApp for lactation monitoring. The content emphasizes the rise of Femtech as a significant business trend, projecting significant revenue growth in the coming years, while also underscoring the importance of leveraging technology to enhance women's health and well-being. The overall purpose is to inform healthcare professionals about innovative solutions available for women's health, encouraging their engagement with these resources.","technologies, artificial, ai",www.rocheplus.es,Flat,0.0508389914092793,high,481,Technology
1071,https://www.rocheplus.es/innovacion/tecnologia/gadget-salud-trendy-2021.html,10,www_rocheplus_es_innovacion_tecnologia_gadget_salud_trendy_2021_html.txt,200,,Indexable,2,62,112,4503,184,50,1,www_rocheplus_es_innovacion_tecnologia_gadget_salud_trendy_2021_html.txt,image/www_rocheplus_es_innovacion_tecnologia_gadget_salud_trendy_2021_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_gadget_salud_trendy_2021_html.txt.txt,"['COVID', 'CES']",Other,Spain,Technology,"none-invasive glucose monitoring, smart masks, air quality sensors, smart mirror, health checks",,36.58214,10.195582,4,"The content discusses the latest trends in health technology showcased during CES 2021, highlighting innovative devices designed to improve health monitoring and personal care amidst the ongoing COVID-19 pandemic. It includes descriptions of various products, such as a smartwatch for non-invasive glucose monitoring, smart masks with air quality sensors, and a smart mirror that conducts basic health checks. The purpose of the content is to inform healthcare professionals about advancements in health technology and their potential applications to enhance patient care and monitoring.","technologies, artificial, ai",www.rocheplus.es,Flat,0.853345833530844,high,318,Technology
1072,https://www.rocheplus.es/innovacion/tecnologia/gadgets-post-covid.html,10,www_rocheplus_es_innovacion_tecnologia_gadgets_post_covid_html.txt,200,,Indexable,2,32,144,4347,184,50,1,www_rocheplus_es_innovacion_tecnologia_gadgets_post_covid_html.txt,image/www_rocheplus_es_innovacion_tecnologia_gadgets_post_covid_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_gadgets_post_covid_html.txt.txt,"['Pro', 'Muse', 'COVID', 'S']",Other,Spain,Technology,"COVID-19, meditation gadgets, Muse S headband, BrainLink Pro, brain activity monitoring, mental well-being, mental health challenges",,23.468979,20.52686,4,"The content focuses on the emotional impacts of the COVID-19 pandemic and highlights technological solutions, such as meditation gadgets, that can assist individuals in coping with stress and anxiety. It discusses various products like the Muse S headband and BrainLink Pro, which utilize brain activity monitoring to enhance meditation experiences. The purpose is to inform healthcare professionals and the public about innovative tools that leverage technology for mental well-being, while also addressing the broader context of mental health challenges during and following the pandemic.","technologies, artificial, ai",www.rocheplus.es,All,0.409634293202193,high,47,Technology
1073,https://www.rocheplus.es/innovacion/tecnologia/gigantes-tecnologicos.html,10,www_rocheplus_es_innovacion_tecnologia_gigantes_tecnologicos_html.txt,200,,Indexable,2,59,148,1601,101,51,1,www_rocheplus_es_innovacion_tecnologia_gigantes_tecnologicos_html.txt,image/www_rocheplus_es_innovacion_tecnologia_gigantes_tecnologicos_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_gigantes_tecnologicos_html.txt.txt,"['Cloud', 'Healthcare', 'Google', 'Care', 'Apple', 'Amazon', 'Microsoft']",Other,Spain,Technology,,,33.36356,16.472218,4,"The content discusses the increasing involvement of major technology companies like Amazon, Microsoft, Apple, and Google in the digital health sector, especially in response to the rising demand for remote healthcare services due to the pandemic. It highlights various initiatives, such as Microsoft Cloud for Healthcare aimed at enhancing patient experiences and Amazon Care providing telehealth consultations. Additionally, it touches on the successes and challenges faced by these companies in implementing health technologies and forming partnerships to improve healthcare delivery. The overall purpose is to inform healthcare professionals about the evolving landscape of digital health solutions offered by tech giants.","technologies, artificial, ai",www.rocheplus.es,Falling,0.669773498757703,high,17,Technology
1074,https://www.rocheplus.es/innovacion/tecnologia/glosario-medico.html,10,www_rocheplus_es_innovacion_tecnologia_glosario_medico_html.txt,200,,Indexable,2,57,141,1840,101,51,1,www_rocheplus_es_innovacion_tecnologia_glosario_medico_html.txt,image/www_rocheplus_es_innovacion_tecnologia_glosario_medico_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_glosario_medico_html.txt.txt,['Each'],Other,Spain,Technology,"artificial intelligence, digital twins, 3D printing, biomarkers, wearables, virtual reality, augmented reality, nanomedicine",,37.555416,15.629539,4,"The content focuses on the rapid advancements in medical technology and the importance of familiarizing oneself with key concepts in this evolving field. It presents an innovative glossary that outlines eight critical areas, including artificial intelligence, digital twins, 3D printing, biomarkers, wearables, virtual and augmented reality, and nanomedicine. Each concept emphasizes its significance and application in improving medical practices, diagnostics, and patient care. The purpose of the content is to educate healthcare professionals about the transformative impact of technology on medicine, enabling them to navigate the complexities of the medical innovation ecosystem.","technologies, artificial, ai",www.rocheplus.es,Flat,0.27415343117417,high,345,Technology
1075,https://www.rocheplus.es/innovacion/tecnologia/gominolas-medicina-3D.html,10,www_rocheplus_es_innovacion_tecnologia_gominolas_medicina_3D_html.txt,200,,Indexable,2,96,119,1634,151,76,0.971830985915493,www_rocheplus_es_innovacion_tecnologia_gominolas_medicina_3D_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_gominolas_medicina_3D_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_gominolas_medicina_3D_html.txt.txt.txt,"['Aimed', 'Vall', 'Hospital', 'Hebron', 'Spain']",Other,Spain,Research,"3D-printed medications, gummy candies, personalized medicine, 3D printing technology",,31.53776,4.2772903,4,"The content discusses a clinical trial conducted by Vall d'Hebron Hospital in Spain, focusing on the development of 3D-printed medications designed to resemble gummy candies. Aimed at improving the experience of administering medication to children with chronic conditions, this innovative approach targets issues related to the unpleasantness of traditional forms like pills and syrups. The content emphasizes the role of 3D printing technology in creating personalized, palatable, and effective medications for pediatric patients, while also highlighting the potential expansion of this strategy to adult patients facing similar challenges. Overall, it illustrates advancements in personalized medicine and the emerging intersection of technology and healthcare.","technologies, artificial, ai",www.rocheplus.es,Falling,0.748937512588292,high,108,Technology
1076,https://www.rocheplus.es/innovacion/tecnologia/hacia-farmacia-4-0.html,10,www_rocheplus_es_innovacion_tecnologia_hacia_farmacia_4_0_html.txt,200,,Indexable,2,48,124,1818,102,52,1,www_rocheplus_es_innovacion_tecnologia_hacia_farmacia_4_0_html.txt,image/www_rocheplus_es_innovacion_tecnologia_hacia_farmacia_4_0_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_hacia_farmacia_4_0_html.txt.txt,"['Farmacia', 'COVID']",Other,Spain,Technology,,,28.327862,8.768741,4,"The content discusses the evolving role of pharmacies in the context of technological advancements, particularly during and after the COVID-19 pandemic. It explores concepts like telemedicine, health consultations, and innovative healthcare solutions, highlighting how pharmacies could transition into more advanced healthcare hubs, referred to as ""Farmacia 4.0."" The purpose is to inform healthcare professionals about potential future developments in pharmacy practice, emphasizing the integration of technology and healthcare services to improve patient accessibility and care. The article also touches on the need for pharmacies to adapt and overcome regulatory challenges in order to fully realize these advancements.","technologies, artificial, ai",www.rocheplus.es,Falling,0.869059042315053,high,414,Technology
1077,https://www.rocheplus.es/innovacion/tecnologia/heridas-cronicas.html,10,www_rocheplus_es_innovacion_tecnologia_heridas_cronicas_html.txt,200,,Indexable,2,73,147,1722,101,51,0.96969696969697,www_rocheplus_es_innovacion_tecnologia_heridas_cronicas_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_heridas_cronicas_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_heridas_cronicas_html.txt.txt.txt,"['Singapore', 'University', 'National']",Other,Spain,Technology,"smart bandage, chronic wounds, diabetic foot, venous ulcers, VeCare platform, portable sensor, mobile app, temperature, pH, bacterial presence, wound assessment, real-time monitoring","diabetic foot, venous ulcers",34.694923,8.979868,4,"The content discusses an innovative smart bandage designed for the monitoring and healing of chronic wounds, particularly highlighting its significance for the aging population susceptible to conditions like diabetic foot and venous ulcers. It outlines the development of the VeCare platform by researchers at the National University of Singapore, which utilizes a portable sensor and mobile app to evaluate wound conditions rapidly by measuring factors such as temperature, pH, and bacterial presence. This technology aims to improve the traditional wound assessment process, reducing the need for multiple hospital visits and allowing for real-time monitoring by healthcare providers. The purpose of the content is to inform healthcare professionals about advancements in chronic wound care technology and its potential benefits for patient management.","technologies, artificial, ai",www.rocheplus.es,Falling,0.104153573170913,high,44,Technology
1078,https://www.rocheplus.es/innovacion/tecnologia/herramienta_sinestesia_infantil.html,10,www_rocheplus_es_innovacion_tecnologia_herramienta_sinestesia_infantil_html.txt,200,,Indexable,2,62,112,4337,184,50,0.975308641975309,www_rocheplus_es_innovacion_tecnologia_herramienta_sinestesia_infantil_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_herramienta_sinestesia_infantil_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_herramienta_sinestesia_infantil_html.txt.txt.txt,"['European', 'Funded', 'SYNTOOLKIT']",Neurology,Spain,Technology,"synesthesia, SYNTOOLKIT",synesthesia,24.085133,27.567171,4,"The content discusses an innovative app developed for diagnosing childhood synesthesia, a neurological phenomenon that intertwines the senses. Funded by European grants, the app aims to facilitate the identification of synesthesia in children by using simple tests that assess their ability to associate numbers with colors and personality traits. It highlights the significance of early detection, linking synesthesia with various developmental differences, potentially impacting children's educational experiences. The project, known as SYNTOOLKIT, has garnered attention for its potential to improve understanding and support for affected children and their families.","technologies, artificial, ai",www.rocheplus.es,Rising,0.265370339530278,high,184,Technology
1079,https://www.rocheplus.es/innovacion/tecnologia.html,10,www_rocheplus_es_innovacion_tecnologia_html.txt,200,,Indexable,1,32,108,3383,1714,410,1,www_rocheplus_es_innovacion_tecnologia_html.txt,image/www_rocheplus_es_innovacion_tecnologia_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_html.txt.txt,[],Other,Spain,Technology,,,9.484651,8.621241,7,"The content outlines a variety of innovative medical technologies and research initiatives spearheaded by Roche and related projects, aimed at healthcare professionals. It covers advancements in fields such as artificial intelligence, robotics, imaging techniques, and patient monitoring devices, highlighting their potential to enhance diagnostics, treatments, and overall patient care. The content serves as a resource for medical professionals to learn about emerging technologies and practices that could transform their work and improve patient outcomes.","event, exclusive, website",www.rocheplus.es,All,0.780400149291568,high,476,Events & Patient Care
1080,https://www.rocheplus.es/innovacion/tecnologia/ictus.html,10,www_rocheplus_es_innovacion_tecnologia_ictus_html.txt,200,,Indexable,2,61,147,4411,185,51,1,www_rocheplus_es_innovacion_tecnologia_ictus_html.txt,image/www_rocheplus_es_innovacion_tecnologia_ictus_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_ictus_html.txt.txt,['Spain'],Neurology,Spain,Technology,"stroke, smart wearables, arrhythmias, big data-driven project",stroke,28.895765,21.994162,4,"The content discusses advancements in technology aimed at preventing and diagnosing stroke, a leading cause of death and disability in Spain. It highlights the seriousness of stroke as a public health issue, particularly among women, and describes innovative solutions such as smart wearables that detect arrhythmias and a big data-driven project for early diagnosis. Additionally, the content aims to raise awareness about stroke symptoms and the importance of rapid intervention, targeting medical professionals to improve patient outcomes.","technologies, artificial, ai",www.rocheplus.es,Falling,0.774305824053168,high,291,Technology
1081,https://www.rocheplus.es/innovacion/tecnologia/lanzamiento-app.html,10,www_rocheplus_es_innovacion_tecnologia_lanzamiento_app_html.txt,200,,Indexable,2,58,147,1386,101,51,0.969230769230769,www_rocheplus_es_innovacion_tecnologia_lanzamiento_app_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_lanzamiento_app_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_lanzamiento_app_html.txt.txt.txt,[],Other,Spain,Technology,,,4.5482574,4.8121495,7,"The content outlines the launch of Roche's new app designed specifically for healthcare professionals. It serves as a comprehensive tool that provides access to various features such as training resources, live events, and a calendar for managing notifications related to webinars. The app facilitates continuous communication between Roche and healthcare professionals through direct contact options, while also offering relevant information on advances in medical technology. Overall, its purpose is to enhance the professional development and connectivity of users in the medical field, supporting their needs and interests effectively.","event, exclusive, website",www.rocheplus.es,All,0.847030212207955,high,182,Events & Patient Care
1082,https://www.rocheplus.es/innovacion/tecnologia/medicina-estetica.html,10,www_rocheplus_es_innovacion_tecnologia_medicina_estetica_html.txt,200,,Indexable,2,52,150,4482,184,50,1,www_rocheplus_es_innovacion_tecnologia_medicina_estetica_html.txt,image/www_rocheplus_es_innovacion_tecnologia_medicina_estetica_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_medicina_estetica_html.txt.txt,['Spain'],Other,Spain,Technology,"ultrasound, cryolipolysis, fat reduction, skin rejuvenation",,33.078907,-0.29296798,4,"The content focuses on the evolving field of aesthetic medicine in Spain, highlighting its significant growth and the increasing acceptance of various cosmetic treatments among younger populations, driven by social media and a desire for physical enhancement. It emphasizes innovation in treatment technologies, such as ultrasound and cryolipolysis, which offer non-invasive options for fat reduction and skin rejuvenation. Additionally, the article discusses the importance of continuous advancements in aesthetic procedures to maintain effectiveness and cater to a growing clientele. Overall, the purpose is to inform healthcare professionals about trends, innovations, and statistics related to aesthetic medicine, reinforcing its relevance in the contemporary health landscape.","technologies, artificial, ai",www.rocheplus.es,All,0.610446980662491,high,307,Technology
1083,https://www.rocheplus.es/innovacion/tecnologia/modelos-mamarios-3d.html,10,www_rocheplus_es_innovacion_tecnologia_modelos_mamarios_3d_html.txt,200,,Indexable,2,78,136,4309,203,68,1,www_rocheplus_es_innovacion_tecnologia_modelos_mamarios_3d_html.txt,image/www_rocheplus_es_innovacion_tecnologia_modelos_mamarios_3d_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_modelos_mamarios_3d_html.txt.txt,"['AI', 'European', 'Phenomeno', 'MRI']",Oncology-Hematology,Spain,Technology,"3D breast models, AI, MRI technology, breast cancer, early detection, treatment outcomes, 3D technology",breast cancer,39.440163,-8.238183,12,"The content discusses the European project Phenomeno, which focuses on creating 3D breast models using AI and MRI technology to enhance breast cancer research and clinical training. It emphasizes the importance of developing accurate anthropomorphic models to improve early detection and treatment outcomes for breast cancer. The initiative aims to foster international collaboration among experts in anatomy, imaging, and engineering to overcome existing limitations in 3D technology. Overall, the content serves to inform healthcare professionals about advancements in breast cancer detection and research methods.","cancer, breast, lung",www.rocheplus.es,Falling,0.0459118732189704,high,443,Disease Information
1084,https://www.rocheplus.es/innovacion/tecnologia/mordedura-smart.html,10,www_rocheplus_es_innovacion_tecnologia_mordedura_smart_html.txt,200,,Indexable,2,78,152,1715,101,51,1,www_rocheplus_es_innovacion_tecnologia_mordedura_smart_html.txt,image/www_rocheplus_es_innovacion_tecnologia_mordedura_smart_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_mordedura_smart_html.txt.txt,"['Singapore', 'University', 'National']",Other,Spain,Technology,,,34.636654,10.260326,4,"The content discusses a revolutionary smart mouthguard developed by researchers at the National University of Singapore, designed to aid individuals with mobility and communication challenges. This innovative device translates bite patterns into commands for controlling various electronic devices, offering a more precise and less invasive alternative compared to existing assistive technologies. It highlights the mouthguard's advantages over voice recognition and other technologies, emphasizing its potential to enhance autonomy for users without requiring extensive training or additional equipment. The content serves to inform healthcare professionals about advancements in assistive technology that could improve patient outcomes.","technologies, artificial, ai",www.rocheplus.es,Flat,0.660070219395711,high,352,Technology
1085,https://www.rocheplus.es/innovacion/tecnologia/mujeres-embarazadas.html,10,www_rocheplus_es_innovacion_tecnologia_mujeres_embarazadas_html.txt,200,,Indexable,2,59,100,1640,101,51,0.971014492753623,www_rocheplus_es_innovacion_tecnologia_mujeres_embarazadas_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_mujeres_embarazadas_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_mujeres_embarazadas_html.txt.txt.txt,"['Invu', 'Bloomlife', 'Babypod']",Other,Spain,Technology,"Babypod, Bloomlife, Invu, vital signs, fetal development",,33.928234,7.5415673,4,"The content discusses essential wearables for pregnant women, highlighting how technology can enhance prenatal care and the connection between mother and fetus. It presents various gadgets and applications, such as Babypod, Bloomlife, and Invu, that monitor vital signs, track fetal development, and assist mothers in managing their health during pregnancy. The purpose is to inform healthcare professionals and expectant mothers about innovative tools that complement medical examinations and improve the overall pregnancy experience. Additionally, it emphasizes the importance of consulting medical professionals despite the utility of these technologies.","technologies, artificial, ai",www.rocheplus.es,Flat,0.0480751498512817,high,51,Technology
1086,https://www.rocheplus.es/innovacion/tecnologia/nueva-tecnologia-vision.html,10,www_rocheplus_es_innovacion_tecnologia_nueva_tecnologia_vision_html.txt,200,,Indexable,2,77,114,4398,184,50,1,www_rocheplus_es_innovacion_tecnologia_nueva_tecnologia_vision_html.txt,image/www_rocheplus_es_innovacion_tecnologia_nueva_tecnologia_vision_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_nueva_tecnologia_vision_html.txt.txt,"['Segmentation', 'Austrian', 'Information', 'LIONESS', 'Nanoscopy', 'Enabling', 'Optimized', 'Live', 'Saturated']",Neurology,Spain,Technology,"LIONESS, imaging technology, neurological disorders, high-resolution views, cellular interactions",,26.672369,28.666628,4,"The content discusses a breakthrough technology developed by Austrian researchers that enables real-time imaging of brain tissue without damaging the living sample. The system, named LIONESS (Live Information Optimized Nanoscopy Enabling Saturated Segmentation), utilizes advanced imaging and virtual reconstruction techniques, offering unprecedented high-resolution views of brain dynamics. This innovation could significantly enhance the understanding of neurological disorders and overall brain function by capturing detailed cellular interactions as they occur. The article serves to inform healthcare professionals about the potential applications and implications of this new imaging technology in medical research and treatment.","technologies, artificial, ai",www.rocheplus.es,All,0.609235778613155,high,338,Technology
1087,https://www.rocheplus.es/innovacion/tecnologia/parches-all-in-one.html,10,www_rocheplus_es_innovacion_tecnologia_parches_all_in_one_html.txt,200,,Indexable,2,58,153,4484,184,50,1,www_rocheplus_es_innovacion_tecnologia_parches_all_in_one_html.txt,image/www_rocheplus_es_innovacion_tecnologia_parches_all_in_one_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_parches_all_in_one_html.txt.txt,[],CVRM,Spain,Technology,"insulin, diabetes, blood pressure, glucose, hydration, wearable technology, smart patches",diabetes,35.64375,8.589778,4,"The content discusses the advancements in wearable technology, specifically smart patches designed for health monitoring and management. It highlights various innovative applications, such as patches that can administer insulin for diabetics, monitor blood pressure and glucose levels, and analyze sweat for hydration needs in athletes. The content emphasizes the effectiveness and practicality of these wearable devices in improving patient quality of life and preventing diseases through continuous physiological monitoring. Overall, the purpose is to inform healthcare professionals about the latest developments in health technology and its potential impact on patient care.","technologies, artificial, ai",www.rocheplus.es,All,0.905643712722577,high,318,Technology
1088,https://www.rocheplus.es/innovacion/tecnologia/parches-con-ultrasonidos.html,10,www_rocheplus_es_innovacion_tecnologia_parches_con_ultrasonidos_html.txt,200,,Indexable,2,59,121,1604,101,51,0.972972972972973,www_rocheplus_es_innovacion_tecnologia_parches_con_ultrasonidos_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_parches_con_ultrasonidos_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_parches_con_ultrasonidos_html.txt.txt.txt,['MIT'],Other,Spain,Technology,,,32.54738,2.9384944,4,"The content discusses an innovative drug delivery method using ultrasound technology, developed by scientists at MIT. It highlights a wearable device that employs sonophoresis to create small channels in the skin for painless drug administration, potentially improving treatment options for various conditions while enhancing patient comfort. The content targets healthcare professionals by providing insights into advancements in pharmaceutical delivery systems and emphasizes the importance of reducing invasive procedures in modern medicine.","technologies, artificial, ai",www.rocheplus.es,Rising,0.373542682451492,high,442,Technology
1089,https://www.rocheplus.es/innovacion/tecnologia/parkinson-tecnologia.html,10,www_rocheplus_es_innovacion_tecnologia_parkinson_tecnologia_html.txt,200,,Indexable,2,62,155,4352,185,51,1,www_rocheplus_es_innovacion_tecnologia_parkinson_tecnologia_html.txt,image/www_rocheplus_es_innovacion_tecnologia_parkinson_tecnologia_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_parkinson_tecnologia_html.txt.txt,"['Parkinson', 'Hospital', 'HIFU', 'Sur', 'Conducted', 'University', 'Puerta', 'HM']",Neurology,Spain,Research,"Parkinson's disease, high-intensity focused ultrasound (HIFU), motor symptoms, tremors, rigidity, traditional surgical methods",Parkinson's disease,23.315575,28.446497,4,"The content discusses innovative non-invasive treatment options for Parkinson's disease, specifically focusing on a clinical trial involving high-intensity focused ultrasound (HIFU). Conducted at the HM Puerta del Sur University Hospital, the trial demonstrated the safety and efficacy of HIFU for alleviating motor symptoms of Parkinson's, such as tremors and rigidity, compared to traditional surgical methods. The content serves to inform healthcare professionals about cutting-edge research and developments in Parkinson's treatment, emphasizing advancements that minimize risks and recovery time for patients.","technologies, artificial, ai",www.rocheplus.es,Rising,0.487844883346679,high,296,Technology
1090,https://www.rocheplus.es/innovacion/tecnologia/pegamentofugasanastomoticas.html,10,www_rocheplus_es_innovacion_tecnologia_pegamentofugasanastomoticas_html.txt,200,,Indexable,2,75,122,4214,184,50,1,www_rocheplus_es_innovacion_tecnologia_pegamentofugasanastomoticas_html.txt,image/www_rocheplus_es_innovacion_tecnologia_pegamentofugasanastomoticas_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_pegamentofugasanastomoticas_html.txt.txt,['European'],Other,Spain,Technology,"sFilmFS2, anastomotic leaks, gastrointestinal surgeries, surgical technology",,32.472122,2.4063833,4,"The content discusses a new biocompatible and bioabsorbable adhesive developed by a European company, designed to prevent anastomotic leaks during gastrointestinal surgeries. It highlights the product, sFilmFS2, which is currently in the validation phase, and aims to improve surgical outcomes by controlling bleeding when standard methods fail. The article emphasizes the importance of addressing anastomotic leaks, a significant surgical complication, and outlines the product's features, safety, and effectiveness based on animal trials, as well as the expected benefits for surgical teams and patient recovery. The content serves to inform healthcare professionals about innovative advancements in surgical technology and its implications for patient care.","technologies, artificial, ai",www.rocheplus.es,Rising,0.520079753155966,high,69,Technology
1091,https://www.rocheplus.es/innovacion/tecnologia/peliculas-anticiparon-futuro-tecnologico.html,10,www_rocheplus_es_innovacion_tecnologia_peliculas_anticiparon_futuro_tecnologico_html.txt,200,,Indexable,2,56,156,4052,164,52,0.977777777777778,www_rocheplus_es_innovacion_tecnologia_peliculas_anticiparon_futuro_tecnologico_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_peliculas_anticiparon_futuro_tecnologico_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_peliculas_anticiparon_futuro_tecnologico_html.txt.txt.txt,[],Other,Spain,Technology,,,9.696324,6.8989396,7,"The content discusses the intersection of science fiction and real-world technological advancements, highlighting films that have predicted or inspired current technologies such as video conferencing, smart homes, and advanced medical devices. It explores how concepts introduced in popular films have become part of modern life, often with a focus on innovations that Roche is involved with or relevant to the healthcare sector. The purpose is to engage healthcare professionals by showcasing how fictional narratives can reflect and inspire actual scientific progress, while also promoting Roche's commitment to innovation in health technology.","event, exclusive, website",www.rocheplus.es,Rising,0.464700785089942,high,165,Events & Patient Care
1092,https://www.rocheplus.es/innovacion/tecnologia/productos-farmaceuticos-via-dron.html,10,www_rocheplus_es_innovacion_tecnologia_productos_farmaceuticos_via_dron_html.txt,200,,Indexable,2,41,116,4378,184,50,1,www_rocheplus_es_innovacion_tecnologia_productos_farmaceuticos_via_dron_html.txt,image/www_rocheplus_es_innovacion_tecnologia_productos_farmaceuticos_via_dron_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_productos_farmaceuticos_via_dron_html.txt.txt,"['U', 'S', 'Europe', 'Spain']",Other,Spain,Technology,,,41.077045,8.713384,4,"The content focuses on the innovative use of drone technology for delivering medications, emphasizing its potential benefits for improving access to pharmaceuticals, particularly in rural areas and during emergencies. It discusses a pilot program implemented in Spain, the regulatory challenges faced by such delivery systems, and the comparison between drone use in Europe and the U.S. The overall purpose is to inform healthcare professionals about the advancements in medication delivery that could enhance patient access and efficiency, while also highlighting the future implications of this technology in the pharmaceutical sector.","technologies, artificial, ai",www.rocheplus.es,Flat,0.137860666206155,high,55,Technology
1093,https://www.rocheplus.es/innovacion/tecnologia/profesionales-de-futuro.html,10,www_rocheplus_es_innovacion_tecnologia_profesionales_de_futuro_html.txt,200,,Indexable,2,50,139,4536,184,50,1,www_rocheplus_es_innovacion_tecnologia_profesionales_de_futuro_html.txt,image/www_rocheplus_es_innovacion_tecnologia_profesionales_de_futuro_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_profesionales_de_futuro_html.txt.txt,[],Other,Spain,Technology,"nanomedicine, bioinformatics, virtual reality therapy, big data analytics, bio-printing",,34.309,16.15413,4,"The content discusses the future of medical professions influenced by advancements in technology, particularly in the context of digitalization and innovations in healthcare. It highlights several emerging fields, such as nanomedicine, bioinformatics, virtual reality therapy, big data analytics, and bio-printing, emphasizing their significance in transforming medical treatments and improving patient care. The purpose is to inform healthcare professionals about the evolving landscape of medical careers and the educational opportunities available in these cutting-edge specialties, underscoring the integration of technology in advancing healthcare outcomes.","technologies, artificial, ai",www.rocheplus.es,Rising,0.112559117363309,high,196,Technology
1094,https://www.rocheplus.es/innovacion/tecnologia/proyecto-neurologico.html,10,www_rocheplus_es_innovacion_tecnologia_proyecto_neurologico_html.txt,200,,Indexable,2,106,142,4231,184,50,0.971428571428571,www_rocheplus_es_innovacion_tecnologia_proyecto_neurologico_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_proyecto_neurologico_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_proyecto_neurologico_html.txt.txt.txt,"['Parkinson', 'Union', 'European']",Neurology,Spain,Research,"MetaBrain, non-invasive ultrasound brain stimulation, stroke, epilepsy, depression, Parkinson's disease, brain injuries, nanotechnology, microelectronics, computational modeling, therapeutic technologies, neural activity, recovery","stroke, epilepsy, depression, Parkinson's disease, brain injuries",25.493029,28.424997,4,"The content discusses an innovative European project called MetaBrain, which aims to develop non-invasive ultrasound brain stimulation techniques to treat neurological disorders such as stroke, epilepsy, depression, Parkinson's disease, and brain injuries. It highlights the significant global prevalence of neurological conditions and the urgent need for effective treatments. The project, funded by the European Union, combines advanced nanotechnology, microelectronics, and computational modeling to improve control over brain activity. The ultimate goal is to create therapeutic technologies that can precisely modulate neural activity and potentially facilitate recovery for affected patients.","technologies, artificial, ai",www.rocheplus.es,Rising,0.26539204513644,high,443,Technology
1095,https://www.rocheplus.es/innovacion/tecnologia/puente-digital-contra-paraplejia.html,10,www_rocheplus_es_innovacion_tecnologia_puente_digital_contra_paraplejia_html.txt,200,,Indexable,2,74,133,1959,101,51,1,www_rocheplus_es_innovacion_tecnologia_puente_digital_contra_paraplejia_html.txt,image/www_rocheplus_es_innovacion_tecnologia_puente_digital_contra_paraplejia_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_puente_digital_contra_paraplejia_html.txt.txt,['Swiss'],Neurology,Spain,Technology,"spinal cord injuries, paraplegia, digital interface, implanted devices, artificial intelligence, restoring function","spinal cord injuries, paraplegia",26.82862,23.576233,4,"The content discusses a groundbreaking innovation developed by Swiss scientists that aims to improve mobility for individuals with spinal cord injuries, specifically targeting paraplegia. It describes a digital interface that establishes communication between the brain and the spinal cord through implanted devices, allowing a paraplegic patient to regain control of their leg movements and walk naturally. The article highlights advances in technology and artificial intelligence that contribute to this research and outlines the potential applications for restoring function in other parts of the body, such as arms and hands, in the future. The content is aimed at healthcare professionals, focusing on the latest developments in medical research and technology related to mobility recovery.","technologies, artificial, ai",www.rocheplus.es,All,0.278081402537058,high,304,Technology
1096,https://www.rocheplus.es/innovacion/tecnologia/realidad-aumentada.html,10,www_rocheplus_es_innovacion_tecnologia_realidad_aumentada_html.txt,200,,Indexable,2,61,156,1661,101,51,1,www_rocheplus_es_innovacion_tecnologia_realidad_aumentada_html.txt,image/www_rocheplus_es_innovacion_tecnologia_realidad_aumentada_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_realidad_aumentada_html.txt.txt,['AR'],Other,Spain,Technology,"augmented reality, surgical precision, visual impairments, treatment for mental disorders",,28.476343,20.140194,4,"The content discusses the applications of augmented reality (AR) in the medical field, highlighting nine real-world uses that demonstrate its effectiveness. It outlines various innovative uses of AR technology, such as improving surgical precision, aiding patients with visual impairments, and enhancing treatment for mental disorders. The article aims to inform healthcare professionals about the transformative potential of AR in medicine and encourages further exploration of these technologies to improve patient care and medical education.","technologies, artificial, ai",www.rocheplus.es,Flat,0.21316379719607,high,453,Technology
1097,https://www.rocheplus.es/innovacion/tecnologia/realidad-virtual-contra-obesidad.html,10,www_rocheplus_es_innovacion_tecnologia_realidad_virtual_contra_obesidad_html.txt,200,,Indexable,2,42,122,1770,101,51,1,www_rocheplus_es_innovacion_tecnologia_realidad_virtual_contra_obesidad_html.txt,image/www_rocheplus_es_innovacion_tecnologia_realidad_virtual_contra_obesidad_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_realidad_virtual_contra_obesidad_html.txt.txt,"['VR', 'Scrates']",CVRM,Spain,Technology,"""Scrates, virtual reality, obesity""",obesity,26.297945,17.037043,4,"The content discusses an innovative project called Scrates, which utilizes virtual reality (VR) to address obesity by allowing patients to interact with digital avatars of themselves. This approach aims to help individuals confront the root causes of their obesity and encourage self-therapy, leading to healthier lifestyle changes. The initiative involves collaboration among various institutions and aims to empower patients to take control of their health. The content highlights the potential of VR technology in treating obesity and notes the project's funding and expected clinical evaluations. Overall, the purpose is to inform healthcare professionals about advancements in utilizing technology for obesity management.","technologies, artificial, ai",www.rocheplus.es,Rising,0.142181342589871,high,341,Technology
1098,https://www.rocheplus.es/innovacion/tecnologia/resumen-2021.html,10,www_rocheplus_es_innovacion_tecnologia_resumen_2021_html.txt,200,,Indexable,2,61,152,1592,101,51,1,www_rocheplus_es_innovacion_tecnologia_resumen_2021_html.txt,image/www_rocheplus_es_innovacion_tecnologia_resumen_2021_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_resumen_2021_html.txt.txt,[],Other,Spain,Technology,"pediatric exoskeleton, artificial hearts, brain-computer interfaces, remote rehabilitation, artificial intelligence, electrostimulation suits, neurological conditions",,13.576903,11.432873,7,"The content provides an overview of significant technological innovations in digital health from 2021, highlighting key advancements in medical technology that emerged throughout the year. It discusses various applications such as the first pediatric exoskeleton, artificial hearts, brain-computer interfaces for communication, remote rehabilitation using artificial intelligence, and electrostimulation suits for neurological conditions. The aim is to inform healthcare professionals about these innovations and their potential impact on patient care while promoting Roche's commitment to healthcare advancements. Additionally, the content invites readers to engage with exclusive content on the Roche platform.","event, exclusive, website",www.rocheplus.es,All,0.51511439462538,high,195,Events & Patient Care
1099,https://www.rocheplus.es/innovacion/tecnologia/robot-cancer-mama.html,10,www_rocheplus_es_innovacion_tecnologia_robot_cancer_mama_html.txt,200,,Indexable,2,67,129,4372,184,50,1,www_rocheplus_es_innovacion_tecnologia_robot_cancer_mama_html.txt,image/www_rocheplus_es_innovacion_tecnologia_robot_cancer_mama_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_robot_cancer_mama_html.txt.txt,"['IRIS', 'University', 'Bristol']",Oncology-Hematology,Spain,Technology,"IRIS robotic device, breast cancer, automated examinations, sensors, early diagnosis, diagnostic tool",breast cancer,39.606754,-5.0112348,12,"The content discusses the introduction of the IRIS robotic device developed by researchers at the University of Bristol, which aims to enhance the early detection of breast cancer through automated examinations. The robot utilizes sensors to perform breast explorations with greater precision than traditional manual exams, making it a potentially valuable diagnostic tool available in pharmacies and health centers. The purpose of this content is to inform healthcare professionals about advancements in cancer detection technology, emphasizing the importance of early diagnosis, especially in younger women, and the potential for improved patient outcomes through innovative solutions.","cancer, breast, lung",www.rocheplus.es,Flat,0.668887632490516,high,451,Disease Information
1100,https://www.rocheplus.es/innovacion/tecnologia/robot-trastornos-neurologicos.html,10,www_rocheplus_es_innovacion_tecnologia_robot_trastornos_neurologicos_html.txt,200,,Indexable,2,76,180,4204,310,72,1,www_rocheplus_es_innovacion_tecnologia_robot_trastornos_neurologicos_html.txt,image/www_rocheplus_es_innovacion_tecnologia_robot_trastornos_neurologicos_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_robot_trastornos_neurologicos_html.txt.txt,"['Parkinson', 'European', 'By', 'Alzheimer']",Neurology,Spain,Research,"SoftReach, minimally invasive robotic device, Parkinson's, Alzheimer's, epilepsy, stroke, real-time magnetic resonance feedback, localized therapy delivery","Parkinson's disease, Alzheimer’s disease, epilepsy, stroke",25.182724,29.507795,4,"The content discusses Roche's innovative project called SoftReach, which aims to revolutionize the treatment of neurological disorders through a minimally invasive robotic device. This device is designed to deliver therapies directly into deep brain regions affected by conditions such as Parkinson's, Alzheimer’s, epilepsy, and stroke. By utilizing real-time magnetic resonance feedback and synthetic materials that emulate plant growth, the project hopes to improve the efficacy of treatments while reducing side effects. The research is part of a European initiative backed by substantial funding and involves collaboration among several reputable institutions. The overall goal is to enhance localized therapy delivery, ultimately transforming clinical practices for neurological disorders lacking effective treatments.","technologies, artificial, ai",www.rocheplus.es,Falling,0.942850445760594,high,132,Technology
1101,https://www.rocheplus.es/innovacion/tecnologia/robotica-ginecologia.html,10,www_rocheplus_es_innovacion_tecnologia_robotica_ginecologia_html.txt,200,,Indexable,2,74,144,1640,101,51,1,www_rocheplus_es_innovacion_tecnologia_robotica_ginecologia_html.txt,image/www_rocheplus_es_innovacion_tecnologia_robotica_ginecologia_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_robotica_ginecologia_html.txt.txt,[],Other,Spain,Technology,"robotic surgery, advanced ultrasound techniques, laser treatments",,37.223335,3.1399794,4,"The content focuses on advancements in gynecological technology aimed at improving women's health and well-being. It discusses robotic surgery, advanced ultrasound techniques, and laser treatments, highlighting their precision and benefits for patients. The content is intended to inform healthcare professionals about innovative approaches in gynecological care, emphasizing the role of technology in enhancing diagnosis and treatment outcomes.","technologies, artificial, ai",www.rocheplus.es,Flat,0.019463252925532,high,415,Technology
1102,https://www.rocheplus.es/innovacion/tecnologia/robots-recuperacion-infantil.html,10,www_rocheplus_es_innovacion_tecnologia_robots_recuperacion_infantil_html.txt,200,,Indexable,2,68,119,4404,184,50,1,www_rocheplus_es_innovacion_tecnologia_robots_recuperacion_infantil_html.txt,image/www_rocheplus_es_innovacion_tecnologia_robots_recuperacion_infantil_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_robots_recuperacion_infantil_html.txt.txt,"['Duck', 'Haru', 'My', 'Aflac', 'Hero', 'Special', 'Spain']",Oncology-Hematology,Spain,Technology,"cancer, Haru, cognitive rehabilitation, Hero, language recovery, My Special Aflac Duck, treatment routines",pediatric cancer,37.329613,-0.9052874,4,"The content discusses innovative robotic technologies designed to assist children undergoing cancer treatment in Spain. It highlights three specific robots: Haru, which supports cognitive rehabilitation through interactive play; Hero, which aids in language and cognitive recovery during hospitalization; and My Special Aflac Duck, a plush robot that helps children express their feelings and familiarize themselves with treatment routines. The purpose of this content is to inform healthcare professionals about these technological advancements aimed at enhancing the pediatric cancer care experience and improving the quality of life for young patients.","technologies, artificial, ai",www.rocheplus.es,All,0.68133843651972,high,25,Technology
1103,https://www.rocheplus.es/innovacion/tecnologia/sistema-de-escucha-fisiologico.html,10,www_rocheplus_es_innovacion_tecnologia_sistema_de_escucha_fisiologico_html.txt,200,,Indexable,2,90,126,4327,184,50,1,www_rocheplus_es_innovacion_tecnologia_sistema_de_escucha_fisiologico_html.txt,image/www_rocheplus_es_innovacion_tecnologia_sistema_de_escucha_fisiologico_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_sistema_de_escucha_fisiologico_html.txt.txt,"['University', 'Unlike', 'Northwestern']",Other,Spain,Technology,,,35.74032,10.253738,4,"The content discusses an advanced acoustic-mechanical detection system developed by researchers at Northwestern University, designed to continuously monitor the body’s internal sounds for physiological health indications. This wireless system is particularly beneficial for newborns and patients undergoing thoracic surgery, as it accurately tracks respiratory and gastrointestinal functions. Unlike traditional stethoscopes, this portable device allows for remote monitoring, providing real-time data on various bodily processes, which can help in diagnosing and managing health conditions. The content aims to inform healthcare professionals about innovative monitoring technologies that enhance patient care.","technologies, artificial, ai",www.rocheplus.es,Falling,0.1709528597543,high,295,Technology
1104,https://www.rocheplus.es/innovacion/tecnologia/sistema-imagen-contracciones.html,10,www_rocheplus_es_innovacion_tecnologia_sistema_imagen_contracciones_html.txt,200,,Indexable,2,73,115,1675,101,51,1,www_rocheplus_es_innovacion_tecnologia_sistema_imagen_contracciones_html.txt,image/www_rocheplus_es_innovacion_tecnologia_sistema_imagen_contracciones_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_sistema_imagen_contracciones_html.txt.txt,"['Louis', 'Washington', 'University', 'St']",Other,Spain,Technology,"4D imaging technology, uterine contractions, high-risk pregnancies, preterm births, cesarean sections, endometriosis, painful menstruation, maternal safety, neonatal safety, complications associated with preterm births","endometriosis, painful menstruation",34.98956,7.4317064,4,"The content discusses a novel 4D imaging technology developed by researchers at Washington University in St. Louis, aimed at monitoring uterine contractions during pregnancy and labor. This non-invasive system is intended to improve the management of high-risk pregnancies, reduce preterm births, and minimize cesarean sections by providing real-time analysis of contractions. Additionally, the technology could aid in studying conditions like endometriosis and painful menstruation. The article emphasizes the importance of this advancement in enhancing maternal and neonatal safety while also addressing complications associated with preterm births. It is tailored for healthcare professionals, highlighting ongoing research and the potential for practical applications in obstetrics.","technologies, artificial, ai",www.rocheplus.es,All,0.504183740413788,high,57,Technology
1105,https://www.rocheplus.es/innovacion/tecnologia/startups.html,10,www_rocheplus_es_innovacion_tecnologia_startups_html.txt,200,,Indexable,2,85,110,2026,101,51,1,www_rocheplus_es_innovacion_tecnologia_startups_html.txt,image/www_rocheplus_es_innovacion_tecnologia_startups_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_startups_html.txt.txt,"['Mowoot', 'AI', 'Idoven']",Other,Spain,Technology,"artificial intelligence, Idoven, cardiac diagnostics, Mowoot, non-invasive treatment, chronic constipation",chronic constipation,37.72719,16.68805,4,"The content focuses on innovative technological solutions in the healthcare sector, particularly emphasizing the role of startups leveraging artificial intelligence and digital technology. It highlights several specific startups and their contributions, such as Idoven's AI-driven cardiac diagnostics and Mowoot's non-invasive treatment for chronic constipation, among others. The purpose of the content is to inform healthcare professionals about emerging technologies and innovations that aim to improve diagnostics, treatments, and overall patient care in the healthcare landscape.","technologies, artificial, ai",www.rocheplus.es,Rising,0.332352296796053,high,238,Technology
1106,https://www.rocheplus.es/innovacion/tecnologia/tattoo-salud.html,10,www_rocheplus_es_innovacion_tecnologia_tattoo_salud_html.txt,200,,Indexable,2,54,146,1933,101,51,1,www_rocheplus_es_innovacion_tecnologia_tattoo_salud_html.txt,image/www_rocheplus_es_innovacion_tecnologia_tattoo_salud_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_tattoo_salud_html.txt.txt,"['Austin', 'Technology', 'Institute', 'Harvard', 'School', 'Texas', 'Medical', 'Korea', 'Science', 'University', 'Advanced']",Other,Spain,Technology,,,34.987087,7.2599306,4,"The content discusses innovative developments in health-monitoring tattoos, highlighting research advancements from various institutions, including the Korea Advanced Institute of Science and Technology, Harvard Medical School, and the University of Texas at Austin. It describes the creation of biosensitive inks and electronic tattoos designed to monitor vital signs such as heart rate, blood pressure, and glucose levels, surpassing traditional wearable devices. The content emphasizes both the technological and medical implications of these advancements, indicating a shift in the perception of tattoos from mere aesthetic markers to functional health monitoring tools. The purpose is to inform healthcare professionals about cutting-edge technologies that may enhance patient care and monitoring.","technologies, artificial, ai",www.rocheplus.es,Rising,0.343539864010421,high,11,Technology
1107,https://www.rocheplus.es/innovacion/tecnologia/tecnologia-al-servicio-de-la-salud-de-la-mujer.html,10,www_rocheplus_es_innovacion_tecnologia_tecnologia_al_servicio_de_la_salud_de_la_mujer_html.txt,200,,Indexable,2,71,107,4334,242,50,0.979166666666667,www_rocheplus_es_innovacion_tecnologia_tecnologia_al_servicio_de_la_salud_de_la_mujer_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_tecnologia_al_servicio_de_la_salud_de_la_mujer_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_tecnologia_al_servicio_de_la_salud_de_la_mujer_html.txt.txt.txt,"['Cycles', 'Mira', 'Women', 'Ava', 'Care', 'Natural']",Other,Spain,Technology,"Natural Cycles, Ava Women, Mira Care, hormonal changes, menstrual cycles, fertility, contraceptive methods",,33.797108,6.199544,4,"The content emphasizes innovations in femtech, particularly focusing on devices that help women track their fertility cycles. It outlines the significant growth in investment within the femtech sector, projecting its market value to reach $50 billion by 2025. The article details various technological solutions like Natural Cycles, Ava Women, and Mira Care, which utilize advanced algorithms and sensors to monitor hormonal changes, menstrual cycles, and fertility, all aimed at enhancing women's health and providing non-invasive, effective alternatives to traditional contraceptive methods. Additionally, the content serves to inform healthcare professionals about emerging technologies that could support women's reproductive health.","technologies, artificial, ai",www.rocheplus.es,Falling,0.601998682733451,high,350,Technology
1108,https://www.rocheplus.es/innovacion/tecnologia/tecnologia-alimentos.html,10,www_rocheplus_es_innovacion_tecnologia_tecnologia_alimentos_html.txt,200,,Indexable,2,62,156,1925,101,51,1,www_rocheplus_es_innovacion_tecnologia_tecnologia_alimentos_html.txt,image/www_rocheplus_es_innovacion_tecnologia_tecnologia_alimentos_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_tecnologia_alimentos_html.txt.txt,['Spain'],CVRM,Spain,Technology,,,33.152924,7.7428393,4,"The content discusses the increasing role of technology in promoting healthy eating habits and combating issues like obesity and food allergies, particularly in Spain. It highlights various technological devices and mobile applications designed to assist individuals in monitoring their food intake, managing dietary habits, and improving overall health. The aim is to improve quality of life through innovative solutions, citing examples such as fitness trackers, smart utensils, and nutrition assessment apps. The content serves to inform healthcare professionals about these advancements and their potential benefits for patient health management.","technologies, artificial, ai",www.rocheplus.es,All,0.716274890398772,high,289,Technology
1109,https://www.rocheplus.es/innovacion/tecnologia/tecnologia-contra-adicciones.html,10,www_rocheplus_es_innovacion_tecnologia_tecnologia_contra_adicciones_html.txt,200,,Indexable,2,58,147,1710,101,51,1,www_rocheplus_es_innovacion_tecnologia_tecnologia_contra_adicciones_html.txt,image/www_rocheplus_es_innovacion_tecnologia_tecnologia_contra_adicciones_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_tecnologia_contra_adicciones_html.txt.txt,"['Transcranial', 'Stimulation', 'TMS', 'SIDEAL', 'Magnetic', 'Spain']",Other,Spain,Technology,"alcohol abuse, cocaine abuse, SIDEAL app, Transcranial Magnetic Stimulation, cocaine addiction, non-pharmacological treatment","alcohol abuse, cocaine addiction",22.020193,20.755182,4,"The content discusses innovative technologies and approaches in combating addiction, particularly focusing on alcohol and cocaine abuse in Spain. It highlights the use of digital tools, such as the SIDEAL app, designed to help individuals monitor and manage their alcohol consumption, emphasizing its integration within therapeutic contexts and the importance of professional supervision. Additionally, it presents Transcranial Magnetic Stimulation (TMS) as a non-pharmacological treatment for cocaine addiction, discussing its potential effectiveness and the current lack of clear protocols for its use. Overall, the content aims to inform healthcare professionals about new resources and treatment methods available to support individuals struggling with addiction.","technologies, artificial, ai",www.rocheplus.es,Rising,0.470196586515298,high,45,Technology
1110,https://www.rocheplus.es/innovacion/tecnologia/tecnologia-digitalizacion-medico.html,10,www_rocheplus_es_innovacion_tecnologia_tecnologia_digitalizacion_medico_html.txt,200,,Indexable,2,89,137,1653,101,51,1,www_rocheplus_es_innovacion_tecnologia_tecnologia_digitalizacion_medico_html.txt,image/www_rocheplus_es_innovacion_tecnologia_tecnologia_digitalizacion_medico_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_tecnologia_digitalizacion_medico_html.txt.txt,[],Other,Spain,Technology,"digital stethoscopes, portable ultrasound devices, smart otoscopes, diagnostic capabilities, patient care",,37.15698,11.192012,4,"The content focuses on advancements in medical technology and digitalization that enhance the efficiency of healthcare professionals in the 21st century. It discusses various innovative tools such as digital stethoscopes, portable ultrasound devices, and smart otoscopes, detailing their functionalities and benefits in both clinical and telemedicine settings. The purpose is to inform healthcare professionals about the latest technological developments that improve diagnostic capabilities and patient care, ultimately promoting a more streamlined medical practice.","technologies, artificial, ai",www.rocheplus.es,Rising,0.0384903340028284,high,87,Technology
1111,https://www.rocheplus.es/innovacion/tecnologia/tecnologia-y-espacio.html,10,www_rocheplus_es_innovacion_tecnologia_tecnologia_y_espacio_html.txt,200,,Indexable,2,64,154,1787,101,51,1,www_rocheplus_es_innovacion_tecnologia_tecnologia_y_espacio_html.txt,image/www_rocheplus_es_innovacion_tecnologia_tecnologia_y_espacio_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_tecnologia_y_espacio_html.txt.txt,"['International', 'ISS', 'Mars', 'Station', 'Space']",Other,Spain,Technology,,,30.143217,16.109396,4,"The content discusses the challenges and advancements in medical technology for space travel, particularly focusing on the medical needs of astronauts on missions like those to the International Space Station (ISS) and potential missions to Mars. It highlights the importance of telemedicine, training programs for astronauts, and the limitations of current medical technologies, especially in surgical procedures under microgravity conditions. The article emphasizes the necessity for thorough planning to anticipate medical emergencies and the evolution of remote medical assistance for long-duration space missions, revealing that the relationship between space exploration and medical technology is still in its early stages. The content is intended for healthcare professionals interested in the intersection of medicine and space travel.","technologies, artificial, ai",www.rocheplus.es,Falling,0.612814045023973,high,388,Technology
1112,https://www.rocheplus.es/innovacion/tecnologia/tecnologias-contra-enfermedades-autoinmunes.html,10,www_rocheplus_es_innovacion_tecnologia_tecnologias_contra_enfermedades_autoinmunes_html.txt,200,,Indexable,2,62,141,1614,101,51,0.978494623655914,www_rocheplus_es_innovacion_tecnologia_tecnologias_contra_enfermedades_autoinmunes_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_tecnologias_contra_enfermedades_autoinmunes_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_tecnologias_contra_enfermedades_autoinmunes_html.txt.txt.txt,['Spanish'],Immunology,Spain,Technology,"autoimmune diseases, virtual reality, artificial intelligence, chronic pain, symptom management, patient support",,28.141438,22.833364,4,"The content discusses technological solutions and innovations aimed at alleviating symptoms associated with autoimmune diseases, which affect a significant portion of the Spanish population. It highlights various technologies, such as virtual reality and artificial intelligence tools, that help manage chronic pain and improve patients' quality of life. The content emphasizes that while these technological advancements do not cure the underlying conditions, they can significantly enhance patient support and symptom management, with an important note on the necessity of medical diagnosis and oversight.","technologies, artificial, ai",www.rocheplus.es,All,0.407020553982056,high,408,Technology
1113,https://www.rocheplus.es/innovacion/tecnologia/tecnologias-tratamiento-diagnostico-cancer.html,10,www_rocheplus_es_innovacion_tecnologia_tecnologias_tratamiento_diagnostico_cancer_html.txt,200,,Indexable,2,67,156,4418,184,50,1,www_rocheplus_es_innovacion_tecnologia_tecnologias_tratamiento_diagnostico_cancer_html.txt,image/www_rocheplus_es_innovacion_tecnologia_tecnologias_tratamiento_diagnostico_cancer_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_tecnologias_tratamiento_diagnostico_cancer_html.txt.txt,"['DNA', 'Key']",Oncology-Hematology,Spain,Technology,"biomarker identification, real-time cancer diagnostics, in silico trials, DNA cages, targeted drug delivery, at-home biomarker testing, pain management technologies",,39.83836,-11.080806,12,"The content primarily discusses innovative technologies and advancements aimed at combating cancer at various stages. It highlights the growing burden of cancer, its associated costs, and emotional impact on patients, while emphasizing the importance of ongoing medical research. Key topics include early detection through biomarker identification, real-time cancer diagnostics, in silico trials, DNA cages for targeted drug delivery, at-home biomarker testing, and pain management technologies. The article underscores the continuous efforts in medical research to enhance cancer treatment and improve patients' quality of life.","cancer, breast, lung",www.rocheplus.es,Rising,0.816439086731864,high,312,Disease Information
1114,https://www.rocheplus.es/innovacion/tecnologia/tendencia-sector-farmaceutico.html,10,www_rocheplus_es_innovacion_tecnologia_tendencia_sector_farmaceutico_html.txt,200,,Indexable,2,68,163,1711,101,51,1,www_rocheplus_es_innovacion_tecnologia_tendencia_sector_farmaceutico_html.txt,image/www_rocheplus_es_innovacion_tecnologia_tendencia_sector_farmaceutico_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_tendencia_sector_farmaceutico_html.txt.txt,[],Other,Spain,Technology,"digital therapeutics, artificial intelligence, drug discovery, personalized medicine, 3D printing, virtual reality, drug research",,41.55096,10.433343,4,"The content discusses four key trends that are set to shape the future of the pharmaceutical industry, emphasizing the impact of digital transformation and technology on research, product development, and patient engagement. It highlights the rise of digital therapeutics, the role of artificial intelligence in drug discovery, advancements in personalized medicine through 3D printing, and the use of virtual reality for drug research. The purpose of the content is to inform healthcare professionals about these innovative trends and their potential to revolutionize pharmaceutical practices, ultimately improving patient outcomes.","technologies, artificial, ai",www.rocheplus.es,Flat,0.913328117860528,high,15,Technology
1115,https://www.rocheplus.es/innovacion/tecnologia/tendencias-2024.html,10,www_rocheplus_es_innovacion_tecnologia_tendencias_2024_html.txt,200,,Indexable,2,52,146,4748,184,50,1,www_rocheplus_es_innovacion_tecnologia_tendencias_2024_html.txt,image/www_rocheplus_es_innovacion_tecnologia_tendencias_2024_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_tendencias_2024_html.txt.txt,"['AI', 'Google']",Other,Spain,Technology,"artificial intelligence, digital twins, digital therapies, minimally invasive blood analysis techniques, generative AI, MedPalm2",,38.45836,16.346262,4,"The content discusses upcoming medical innovations anticipated for 2024, emphasizing advancements in artificial intelligence, digital twins, digital therapies, and minimally invasive blood analysis techniques. It highlights how technologies like generative AI, exemplified by Google's MedPalm2, can transform healthcare by enhancing diagnostics and patient communication. Additionally, the content details the growing potential of digital twins to personalize treatment plans and mentions various digital therapy solutions that support chronic condition management. The overarching purpose is to inform healthcare professionals about these emerging trends and their implications for the future of medicine.","technologies, artificial, ai",www.rocheplus.es,Falling,0.922339138227249,high,256,Technology
1116,https://www.rocheplus.es/innovacion/tecnologia/traje-electroestimulacion.html,10,www_rocheplus_es_innovacion_tecnologia_traje_electroestimulacion_html.txt,200,,Indexable,2,65,151,1471,102,52,1,www_rocheplus_es_innovacion_tecnologia_traje_electroestimulacion_html.txt,image/www_rocheplus_es_innovacion_tecnologia_traje_electroestimulacion_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_traje_electroestimulacion_html.txt.txt,"['Parkinson', 'Suit', 'Exopulse', 'Mollii']",Neurology,Spain,Technology,"Exopulse Mollii Suit, neurological disorders, Parkinson's disease, cerebral palsy, multiple sclerosis, electrostimulation technology, chronic pain, spasms, non-invasive methods, physical therapy, treatment options","Parkinson's disease, cerebral palsy, multiple sclerosis",25.266712,25.169565,4,"The content discusses the Exopulse Mollii Suit, a novel device designed for patients suffering from neurological disorders such as Parkinson's disease, cerebral palsy, and multiple sclerosis. It uses electrostimulation technology to alleviate chronic pain and spasms by activating weak muscles and relaxing spastic ones. The suit is innovative as it applies non-invasive methods without pharmaceuticals and aims to improve patients' daily lives by reducing pain and enhancing mobility. The content also emphasizes ongoing clinical studies and the potential benefits of combining the suit with physical therapy. It targets healthcare professionals, presenting advancements in treatment options for neurological conditions.","technologies, artificial, ai",www.rocheplus.es,Flat,0.978912803943903,high,486,Technology
1117,https://www.rocheplus.es/innovacion/tecnologia/varices.html,10,www_rocheplus_es_innovacion_tecnologia_varices_html.txt,200,,Indexable,2,67,138,1551,101,51,1,www_rocheplus_es_innovacion_tecnologia_varices_html.txt,image/www_rocheplus_es_innovacion_tecnologia_varices_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_varices_html.txt.txt,"['Intensity', 'Spanish', 'HIFU', 'Ultrasound', 'High', 'Focused']",CVRM,Spain,Technology,"varicose veins, chronic venous insufficiency, High-Intensity Focused Ultrasound, HIFU, biocompatible cyanoacrylate glue, pharmacological treatments, surgical treatments","varicose veins, chronic venous insufficiency",31.998545,1.153392,4,"The content discusses innovative techniques for treating varicose veins, particularly focusing on chronic venous insufficiency, which affects a significant portion of the Spanish population. It highlights non-invasive methods such as High-Intensity Focused Ultrasound (HIFU) and biocompatible cyanoacrylate glue, noting their advantages over traditional pharmacological and surgical treatments. The article aims to inform healthcare professionals about these advanced options to enhance patient care and treatment outcomes in managing varicose veins. It also includes references to related technological advancements in various medical fields.","technologies, artificial, ai",www.rocheplus.es,Rising,0.905362893823236,high,164,Technology
1118,https://www.rocheplus.es/innovacion/tecnologia/vendajes-inteligentes.html,10,www_rocheplus_es_innovacion_tecnologia_vendajes_inteligentes_html.txt,200,,Indexable,2,61,103,1698,101,51,1,www_rocheplus_es_innovacion_tecnologia_vendajes_inteligentes_html.txt,image/www_rocheplus_es_innovacion_tecnologia_vendajes_inteligentes_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_vendajes_inteligentes_html.txt.txt,[],CVRM,Spain,Technology,"electrotherapy, diabetic wounds, biodegradable bandage, healing, diabetes, amputations, small electrodes, wireless communication system","diabetic wounds, diabetes",34.36774,9.128214,4,"The content discusses the innovative use of electrotherapy in treating diabetic wounds, highlighting a newly developed biodegradable bandage that accelerates healing by 30% and monitors the healing process in real-time. It outlines the challenges posed by diabetes, particularly the increased risk of severe complications like amputations due to poorly healing wounds. The bandage's design incorporates small electrodes and a wireless communication system to facilitate effective treatment. Overall, the content aims to inform healthcare professionals about advancements in diabetes management and urges them to consider these new technologies in their practices.","technologies, artificial, ai",www.rocheplus.es,All,0.791478000807645,high,280,Technology
1119,https://www.rocheplus.es/innovacion/tecnologia/victimas-colaterales-pandemia.html,10,www_rocheplus_es_innovacion_tecnologia_victimas_colaterales_pandemia_html.txt,200,,Indexable,2,60,153,4457,184,50,0.974683544303797,www_rocheplus_es_innovacion_tecnologia_victimas_colaterales_pandemia_html.txt.txt,image/www_rocheplus_es_innovacion_tecnologia_victimas_colaterales_pandemia_html.txt.txt.png,text/www_rocheplus_es_innovacion_tecnologia_victimas_colaterales_pandemia_html.txt.txt.txt,['COVID'],Other,Spain,Technology,"COVID-19, anxiety, depression, musculoskeletal disorders, relaxation apps, electrostimulation devices","anxiety, depression, musculoskeletal disorders",23.422768,20.096725,4,"The content discusses the collateral effects of the COVID-19 pandemic, particularly focusing on physical and psychological issues that have emerged due to social restrictions and lockdowns. It highlights an increase in mental health problems, such as anxiety and depression, as well as musculoskeletal disorders resulting from reduced physical activity. The content also mentions various technological solutions, such as relaxation apps and electrostimulation devices, that can help alleviate these issues. The overarching purpose of the content is to inform healthcare professionals about these challenges and potential technological interventions to improve patient wellbeing during and after the pandemic.","technologies, artificial, ai",www.rocheplus.es,Flat,0.135745635139068,high,132,Technology
1120,https://www.rocheplus.es/innovacion/tecnologia/wearables-para-bebes.html,10,www_rocheplus_es_innovacion_tecnologia_wearables_para_bebes_html.txt,200,,Indexable,2,49,159,4693,191,50,1,www_rocheplus_es_innovacion_tecnologia_wearables_para_bebes_html.txt,image/www_rocheplus_es_innovacion_tecnologia_wearables_para_bebes_html.txt.png,text/www_rocheplus_es_innovacion_tecnologia_wearables_para_bebes_html.txt.txt,[],Other,Spain,Technology,,"premature birth, perinatal asphyxia",35.624344,9.287703,4,"The content focuses on innovative technologies designed to enhance neonatal care and reduce infant mortality, particularly addressing issues like premature birth and perinatal asphyxia. It highlights advancements such as real-time monitoring systems for childbirth, ultrasonic devices to predict preterm labor, and smart wearable devices like intelligent pacifiers and socks that track vital health parameters in newborns. The purpose of the content is to inform healthcare professionals about these technological developments and their potential impact on improving the safety and health of infants.","technologies, artificial, ai",www.rocheplus.es,Falling,0.402600854366418,high,417,Technology
1121,https://www.rocheplus.es/medicina-personalizada/consenso-seap-seom.html,7,www_rocheplus_es_medicina_personalizada_consenso_seap_seom_html.txt,200,,Non-Indexable,1,18,0,1553,870,410,1,www_rocheplus_es_medicina_personalizada_consenso_seap_seom_html.txt,image/www_rocheplus_es_medicina_personalizada_consenso_seap_seom_html.txt.png,text/www_rocheplus_es_medicina_personalizada_consenso_seap_seom_html.txt.txt,"['Generation', 'KRAS', 'BRAF', 'Sequencing', 'NGS', 'Next', 'EGFR', 'NSCLC']",Oncology-Hematology,Spain,Research,"non-small cell lung cancer (NSCLC), predictive biomarker detection, personalized medicine, critical mutations, biomarkers, EGFR, BRAF, KRAS, PDL1, Next Generation Sequencing (NGS)",non-small cell lung cancer,35.163185,-15.330081,12,"The content focuses on a consensus content related to predictive biomarker detection in non-small cell lung cancer (NSCLC), emphasizing the importance of personalized medicine and collaboration among specialists. It outlines current recommendations for identifying critical mutations and biomarkers, including EGFR, BRAF, KRAS, and PDL1, and discusses the significance of techniques like Next Generation Sequencing (NGS). The purpose of the content is to provide healthcare professionals with updated insights and guidelines to enhance the diagnosis and treatment of NSCLC through the integration of advanced biomarkers in clinical practice.","cancer, breast, lung",www.rocheplus.es,All,0.437547686331227,high,499,Disease Information
1122,https://www.rocheplus.es/medicina-personalizada/dialogos-phc/aspectos-etico-legales-de-la-explotacion-y-manejo-del-big-data.html,10,www_rocheplus_es_medicina_personalizada_dialogos_phc_aspectos_etico_legales_de_la_explotacion_y_manejo_del_big_data_html.txt,200,,Indexable,1,77,332,2064,861,410,1,www_rocheplus_es_medicina_personalizada_dialogos_phc_aspectos_etico_legales_de_la_explotacion_y_manejo_del_big_data_html.txt,image/www_rocheplus_es_medicina_personalizada_dialogos_phc_aspectos_etico_legales_de_la_explotacion_y_manejo_del_big_data_html.txt.png,text/www_rocheplus_es_medicina_personalizada_dialogos_phc_aspectos_etico_legales_de_la_explotacion_y_manejo_del_big_data_html.txt.txt,"['Puente', 'Data', 'Nicols', 'Big', 'Management', 'Pilar', 'Aspects', 'Experts', 'Legal', 'Use']",Other,Spain,Events,,,31.850307,11.187885,4,"The content discusses the implications of big data in personalized medicine, highlighting a dialogue event titled ""Legal Aspects of Big Data Use and Management."" It emphasizes the role of big data in developing precise and effective therapies while acknowledging legal challenges related to data privacy and protection. Experts in the field, Pilar Nicols Jiménez and Agustín Puente, are introduced, outlining their credentials and contributions to biomedical law. The purpose of the content is to promote the event and address the intersection of technology, law, and healthcare advancements.","technologies, artificial, ai",www.rocheplus.es,Rising,0.0386692317171298,high,474,Technology
1123,https://www.rocheplus.es/medicina-personalizada/dialogos-phc/buscando-el-mejor-tratamiento-para-cada-paciente.html,10,www_rocheplus_es_medicina_personalizada_dialogos_phc_buscando_el_mejor_tratamiento_para_cada_paciente_html.txt,200,,Non-Indexable,1,63,295,1826,861,410,1,www_rocheplus_es_medicina_personalizada_dialogos_phc_buscando_el_mejor_tratamiento_para_cada_paciente_html.txt,image/www_rocheplus_es_medicina_personalizada_dialogos_phc_buscando_el_mejor_tratamiento_para_cada_paciente_html.txt.png,text/www_rocheplus_es_medicina_personalizada_dialogos_phc_buscando_el_mejor_tratamiento_para_cada_paciente_html.txt.txt,"['PHC', 'October', 'COVID', 'Dilogos']",Other,Spain,Events,,,29.526999,11.260943,4,"The content discusses a specialized dialogue series titled ""Dilogos PHC,"" focusing on personalized medicine and contemporary challenges in clinical research, particularly in light of the COVID-19 pandemic. It highlights changes in biomedical research, such as the adoption of digital tools, telemedicine, and reduced bureaucracy, to improve patient access to new treatments. The featured speakers include prominent medical professionals who will address the implications of these advancements and the changing landscape of therapeutic innovation on October 15. The overall purpose is to inform healthcare professionals about emerging trends and challenges in personalized medicine and clinical trials.","technologies, artificial, ai",www.rocheplus.es,Flat,0.852661673471811,high,459,Technology
1124,https://www.rocheplus.es/medicina-personalizada/dialogos-phc/charlas-dialogosphc.html,10,www_rocheplus_es_medicina_personalizada_dialogos_phc_charlas_dialogosphc_html.txt,200,,Indexable,1,20,325,1946,99,16,1,www_rocheplus_es_medicina_personalizada_dialogos_phc_charlas_dialogosphc_html.txt,image/www_rocheplus_es_medicina_personalizada_dialogos_phc_charlas_dialogosphc_html.txt.png,text/www_rocheplus_es_medicina_personalizada_dialogos_phc_charlas_dialogosphc_html.txt.txt,['COVID'],Other,Spain,Events,,,7.8221955,7.35085,7,"The content outlines various discussions and seminars related to personalized medicine and digital health, hosted by Roche. It features an array of topics including the integration of big data in healthcare, advancements in telemedicine due to the COVID-19 pandemic, and the implications of genomic technologies. The content is aimed at healthcare professionals, providing insights into current trends, challenges, and innovations in patient care and precision medicine. Overall, the purpose is to foster knowledge exchange and keep professionals informed about developments in the field.","event, exclusive, website",www.rocheplus.es,Rising,0.56881032302252,high,219,Events & Patient Care
1125,https://www.rocheplus.es/medicina-personalizada/dialogos-phc/dato-a-dato-en-el-seguimiento-del-paciente.html,10,www_rocheplus_es_medicina_personalizada_dialogos_phc_dato_a_dato_en_el_seguimiento_del_paciente_html.txt,200,,Indexable,1,57,282,1871,861,410,1,www_rocheplus_es_medicina_personalizada_dialogos_phc_dato_a_dato_en_el_seguimiento_del_paciente_html.txt,image/www_rocheplus_es_medicina_personalizada_dialogos_phc_dato_a_dato_en_el_seguimiento_del_paciente_html.txt.png,text/www_rocheplus_es_medicina_personalizada_dialogos_phc_dato_a_dato_en_el_seguimiento_del_paciente_html.txt.txt,['Dato'],Other,Spain,Technology,,,33.079685,14.318548,4,"The content focuses on the advancements in personalized medicine and the integration of digital technologies in healthcare, particularly the use of big data and artificial intelligence for patient monitoring and treatment. It promotes a discussion event titled ""Dato a dato en el seguimiento del paciente,"" featuring experts who will explore the implications of real-world data and digital tools in enhancing health care. Additionally, it reflects on the challenges and questions surrounding the effective management of patient data gathered outside clinical settings. The overall purpose is to inform healthcare professionals about innovations in patient care and encourage professional discourse in the field.","technologies, artificial, ai",www.rocheplus.es,Falling,0.763870867664234,high,293,Technology
1126,https://www.rocheplus.es/medicina-personalizada/dialogos-phc/el-big-bang-del-big-data-a-traves-del-covid-190.html,10,www_rocheplus_es_medicina_personalizada_dialogos_phc_el_big_bang_del_big_data_a_traves_del_covid_190_html.txt,200,,Indexable,1,61,399,2128,861,410,0.981981981981982,www_rocheplus_es_medicina_personalizada_dialogos_phc_el_big_bang_del_big_data_a_traves_del_covid_190_html.txt.txt,image/www_rocheplus_es_medicina_personalizada_dialogos_phc_el_big_bang_del_big_data_a_traves_del_covid_190_html.txt.txt.png,text/www_rocheplus_es_medicina_personalizada_dialogos_phc_el_big_bang_del_big_data_a_traves_del_covid_190_html.txt.txt.txt,"['Cruz', 'They', 'Trilla', 'COVID', 'Cigudosa', 'Dr', 'Juan', 'Antoni']",Other,Spain,Events,,,32.278175,12.83716,4,"The content discusses a panel discussion on the integration of big data in biomedical contexts since the COVID-19 pandemic. It highlights opportunities and challenges in leveraging vast amounts of clinical data for healthcare improvements. The discussion features prominent speakers, Dr. Juan Cruz Cigudosa and Dr. Antoni Trilla, who are experts in their respective fields. They will address essential questions related to data anonymity, legal implications, and the potential impact of real-world data in advancing healthcare practices. The overarching purpose is to promote dialogue among healthcare professionals about modern data utilization strategies in patient care and research.","technologies, artificial, ai",www.rocheplus.es,Rising,0.213209571850015,high,241,Technology
1127,https://www.rocheplus.es/medicina-personalizada/dialogos-phc.html,10,www_rocheplus_es_medicina_personalizada_dialogos_phc_html.txt,200,,Indexable,1,21,325,1552,1262,410,0.968253968253968,www_rocheplus_es_medicina_personalizada_dialogos_phc_html.txt.txt,image/www_rocheplus_es_medicina_personalizada_dialogos_phc_html.txt.txt.png,text/www_rocheplus_es_medicina_personalizada_dialogos_phc_html.txt.txt.txt,['PHC'],Other,Spain,Technology,,,4.76821,3.6862812,7,"The content features a section dedicated to ""Diálogos PHC,"" an initiative by Roche that focuses on personalized medicine. It highlights the importance of advancements in omics sciences and the digitalization of healthcare. The program aims to address current and future healthcare challenges through discussions led by experts, conducted in a virtual format. Additionally, it invites healthcare professionals to register for exclusive content and access to past talks, reinforcing its objective of ongoing education and transformation in healthcare practices.","event, exclusive, website",www.rocheplus.es,Rising,0.906349132883071,high,243,Events & Patient Care
1128,https://www.rocheplus.es/medicina-personalizada/dialogos-phc/la-vision-desde-los-medios-de-comunicacion.html,10,www_rocheplus_es_medicina_personalizada_dialogos_phc_la_vision_desde_los_medios_de_comunicacion_html.txt,200,,Indexable,1,57,446,1927,861,410,1,www_rocheplus_es_medicina_personalizada_dialogos_phc_la_vision_desde_los_medios_de_comunicacion_html.txt,image/www_rocheplus_es_medicina_personalizada_dialogos_phc_la_vision_desde_los_medios_de_comunicacion_html.txt.png,text/www_rocheplus_es_medicina_personalizada_dialogos_phc_la_vision_desde_los_medios_de_comunicacion_html.txt.txt,['COVID'],Other,Spain,Events,,,31.5157,11.378219,4,"The content focuses on the advancements in personalized medicine, particularly in the context of digital health, genomics, and medical technology. It discusses the increasing relevance of personalized medicine, especially following the COVID-19 pandemic, and addresses how media outlets are covering these developments, including their associated benefits and risks. The content outlines an upcoming discussion featuring two prominent health journalists who will explore these topics, aiming to improve public understanding of personalized medicine and its challenges. The purpose is to engage healthcare professionals in conversations about the communication of personalized medicine and to share insights on its evolving role in healthcare.","technologies, artificial, ai",www.rocheplus.es,Falling,0.874328094908838,high,300,Technology
1129,https://www.rocheplus.es/medicina-personalizada/dialogos-phc/medicina-personalizada-desde-el-epicentro-pacientes.html,10,www_rocheplus_es_medicina_personalizada_dialogos_phc_medicina_personalizada_desde_el_epicentro_pacientes_html.txt,200,,Indexable,1,67,333,1959,874,410,1,www_rocheplus_es_medicina_personalizada_dialogos_phc_medicina_personalizada_desde_el_epicentro_pacientes_html.txt,image/www_rocheplus_es_medicina_personalizada_dialogos_phc_medicina_personalizada_desde_el_epicentro_pacientes_html.txt.png,text/www_rocheplus_es_medicina_personalizada_dialogos_phc_medicina_personalizada_desde_el_epicentro_pacientes_html.txt.txt,"['Casanovas', 'PHC', 'Teresa', 'Pedro', 'Carrascal', 'Dilogos']",Neurology,Spain,Research,"personalized medicine, precision medicine, neurological diseases, hepatic diseases, genomic sequencing, directed therapies, big data",,30.032286,11.018371,4,"The content focuses on personalized medicine and highlights discussions held during the ""Dilogos PHC"" series, which addresses various aspects and future challenges of precision medicine from the patient's perspective. The content emphasizes the importance of patient-centered approaches, showcasing speakers like Pedro Carrascal and Teresa Casanovas, who represent patient organizations related to neurological and hepatic diseases. Additionally, it mentions topics such as genomic sequencing, directed therapies, and the role of big data in enhancing patient care. Overall, the content serves to inform healthcare professionals about ongoing dialogues and explorations in personalized medicine, encouraging engagement with patient viewpoints and their implications for treatment strategies.","technologies, artificial, ai",www.rocheplus.es,Falling,0.913289245382035,high,475,Technology
1130,https://www.rocheplus.es/medicina-personalizada/dialogos-phc/ni-antes-ni-despues--en-el-momento-adecuado.html,10,www_rocheplus_es_medicina_personalizada_dialogos_phc_ni_antes_ni_despues__en_el_momento_adecuado_html.txt,200,,Indexable,1,58,371,1999,861,410,1,www_rocheplus_es_medicina_personalizada_dialogos_phc_ni_antes_ni_despues__en_el_momento_adecuado_html.txt,image/www_rocheplus_es_medicina_personalizada_dialogos_phc_ni_antes_ni_despues__en_el_momento_adecuado_html.txt.png,text/www_rocheplus_es_medicina_personalizada_dialogos_phc_ni_antes_ni_despues__en_el_momento_adecuado_html.txt.txt,"['Products', 'Medicines', 'Spanish', 'Agency', 'Health']",Other,Spain,Research,,,42.13406,9.801211,4,"The content focuses on the evolving landscape of personalized medicine, emphasizing the significance of timely access to effective treatments for patients. It discusses the implications of digitalization on healthcare, including the roles of healthcare authorities and the pharmaceutical industry in implementing innovative therapies. The content also highlights a scheduled discussion featuring experts from the Spanish Agency of Medicines and Health Products, aiming to address challenges related to the regulation of human medicines and the integration of precision diagnostics with therapies. Overall, it serves to inform healthcare professionals about advancements and discussions in the field of personalized medicine and healthcare innovation.","technologies, artificial, ai",www.rocheplus.es,Flat,0.179139597231141,high,429,Technology
1131,https://www.rocheplus.es/medicina-personalizada/dialogos-phc/paciente-vs-telemedicina.html,10,www_rocheplus_es_medicina_personalizada_dialogos_phc_paciente_vs_telemedicina_html.txt,200,,Indexable,1,39,403,1975,861,410,1,www_rocheplus_es_medicina_personalizada_dialogos_phc_paciente_vs_telemedicina_html.txt,image/www_rocheplus_es_medicina_personalizada_dialogos_phc_paciente_vs_telemedicina_html.txt.png,text/www_rocheplus_es_medicina_personalizada_dialogos_phc_paciente_vs_telemedicina_html.txt.txt,['COVID'],Other,Spain,Technology,,,27.44516,12.524365,4,"The content discusses the role of telemedicine, especially in the context of the COVID-19 pandemic, emphasizing its importance in the healthcare system. It outlines how telemedicine has evolved beyond basic consultations to include diagnostics, pharmacy services, and patient monitoring, positioning it as a critical component of personalized medicine. The content aims to engage healthcare professionals in dialogue about the future of telemedicine, featuring expert speakers who will address the current challenges and advancements in the field. It highlights the necessity for patient education and adaptation to ensure the successful integration of telemedicine into healthcare practices.","technologies, artificial, ai",www.rocheplus.es,Flat,0.266473979361749,high,141,Technology
1132,https://www.rocheplus.es/medicina-personalizada/dialogos-phc/phc--presente-y-retos-de-futuro.html,10,www_rocheplus_es_medicina_personalizada_dialogos_phc_phc__presente_y_retos_de_futuro_html.txt,200,,Indexable,1,41,404,1712,874,410,0.978947368421053,www_rocheplus_es_medicina_personalizada_dialogos_phc_phc__presente_y_retos_de_futuro_html.txt.txt,image/www_rocheplus_es_medicina_personalizada_dialogos_phc_phc__presente_y_retos_de_futuro_html.txt.txt.png,text/www_rocheplus_es_medicina_personalizada_dialogos_phc_phc__presente_y_retos_de_futuro_html.txt.txt.txt,"['Barrio', 'PHC', 'Teresa', 'Ramos', 'Dilogos', 'Jaime']",Other,Spain,Technology,,,32.879955,14.279425,4,"The content focuses on the transformation of healthcare through personalized medicine, highlighting the impact of technologies such as artificial intelligence, big data, and genomic sequencing. It outlines a dialogue series, ""Dilogos PHC,"" featuring speakers Jaime del Barrio and Teresa Ramos, who discuss current practices and future challenges in personalized healthcare. The content aims to engage healthcare professionals by providing insights on innovative strategies and advancements in the medical field, emphasizing the importance of integrating digital tools in patient care and research.","technologies, artificial, ai",www.rocheplus.es,Flat,0.904732677493806,high,404,Technology
1133,https://www.rocheplus.es/medicina-personalizada/dialogos-phc/preguntas-y-respuestas-sobre-el-diagnostico-del-cancer.html,10,www_rocheplus_es_medicina_personalizada_dialogos_phc_preguntas_y_respuestas_sobre_el_diagnostico_del_cancer_html.txt,200,,Indexable,1,69,413,1870,861,410,1,www_rocheplus_es_medicina_personalizada_dialogos_phc_preguntas_y_respuestas_sobre_el_diagnostico_del_cancer_html.txt,image/www_rocheplus_es_medicina_personalizada_dialogos_phc_preguntas_y_respuestas_sobre_el_diagnostico_del_cancer_html.txt.png,text/www_rocheplus_es_medicina_personalizada_dialogos_phc_preguntas_y_respuestas_sobre_el_diagnostico_del_cancer_html.txt.txt,"['Rojo', 'September', 'Federico', 'Scheduled', 'Dopazo', 'Spain']",Oncology-Hematology,Spain,Events,,,38.26309,-10.325112,12,"The content outlines a virtual event focused on precision diagnostics in cancer, emphasizing the importance of personalized medicine. Scheduled for September 17, 2020, the discussion will feature experts Federico Rojo and Joaquín Dopazo, who will address relevant questions about the future of precision diagnostics, the necessity of a national strategy in Spain, and advancements in diagnostic tools. The overall purpose of the content is to inform healthcare professionals about evolving diagnostic approaches and encourage discourse regarding the integration of personalized medicine in clinical practice, supported by technological advancements like genomic sequencing and biomarker utilization.","cancer, breast, lung",www.rocheplus.es,Falling,0.0479099174417726,high,58,Disease Information
1134,https://www.rocheplus.es/medicina-personalizada/dialogos-phc/salud-digital-tecnologia-que-cuida-del-paciente.html,7,www_rocheplus_es_medicina_personalizada_dialogos_phc_salud_digital_tecnologia_que_cuida_del_paciente_html.txt,200,,Indexable,1,63,3,2014,861,410,0.981981981981982,www_rocheplus_es_medicina_personalizada_dialogos_phc_salud_digital_tecnologia_que_cuida_del_paciente_html.txt.txt,image/www_rocheplus_es_medicina_personalizada_dialogos_phc_salud_digital_tecnologia_que_cuida_del_paciente_html.txt.txt.png,text/www_rocheplus_es_medicina_personalizada_dialogos_phc_salud_digital_tecnologia_que_cuida_del_paciente_html.txt.txt.txt,"['Dilogos', 'PHC']",Other,Spain,Events,,,28.344782,14.96247,4,"The content discusses the evolution and significance of digital health and personalized medicine, highlighting the potential benefits of digital technologies in improving patient care. It mentions an upcoming discussion event, ""Dilogos PHC,"" featuring speakers with expertise in digital health, where they will address current challenges and advancements in the field. The content aims to inform healthcare professionals about the intersection of technology and patient care, fostering dialogue about implementing digital health solutions within healthcare systems and their sustainability.","technologies, artificial, ai",www.rocheplus.es,Falling,0.763903141354797,high,213,Technology
1135,https://www.rocheplus.es/medicina-personalizada/foundationmedicine.html,10,www_rocheplus_es_medicina_personalizada_foundationmedicine_html.txt,200,,Indexable,1,54,154,1019,5,3,1,www_rocheplus_es_medicina_personalizada_foundationmedicine_html.txt,image/www_rocheplus_es_medicina_personalizada_foundationmedicine_html.txt.png,text/www_rocheplus_es_medicina_personalizada_foundationmedicine_html.txt.txt,[],Oncology-Hematology,Spain,Offer outline,,,23.159235,-11.153548,12,The content of the content focuses on personalized medicine for cancer treatment. It highlights the uniqueness of each tumor and emphasizes the importance of finding tailored treatment paths. The website invites healthcare professionals to register for exclusive content and offers options for both professionals and the general public to seek more information about personalized oncology services. The overall design visually represents the concept of navigating complex pathways in cancer treatment.,"cancer, breast, lung",www.rocheplus.es,Falling,0.241699138249352,high,316,Disease Information
1136,https://www.rocheplus.es/search.html,8,www_rocheplus_es_search_html.txt,200,,Non-Indexable,2,6,0,726,2,2,0.941176470588235,www_rocheplus_es_search_html.txt.txt,image/www_rocheplus_es_search_html.txt.txt.png,text/www_rocheplus_es_search_html.txt.txt.txt,['Spain'],Other,Spain,Metainformation,,,-6.2076015,-22.840109,3,The content displays a search results page from a professional platform related to Roche. It prompts users to confirm if they are healthcare professionals and provides a search field for finding specific content. The page indicates no results were found for the search term entered. It emphasizes that the information is intended for healthcare professionals involved in prescription and dispensing of medications in Spain.,"users, page, website",www.rocheplus.es,Flat,0.285193261837162,high,253,Website Metadata
1137,https://www.rocheplus.es/servicios/alia.html,8,www_rocheplus_es_servicios_alia_html.txt,200,,Non-Indexable,1,33,0,1025,455,410,0.952380952380952,www_rocheplus_es_servicios_alia_html.txt.txt,image/www_rocheplus_es_servicios_alia_html.txt.txt.png,text/www_rocheplus_es_servicios_alia_html.txt.txt.txt,[],Oncology-Hematology,Spain,Patient support,lung cancer,lung cancer,0.90787816,-7.09353,7,"The content displays a section from Roche's website aimed at healthcare professionals. It encourages users to search, select, and share information necessary for patient care, particularly focused on lung cancer. The interface features filters for diagnostic information and treatment options, along with a section for accessing various articles for sharing. The overall purpose is to provide healthcare professionals with resources to support their patients effectively.","event, exclusive, website",www.rocheplus.es,Rising,0.717255631182731,high,432,Events & Patient Care
1138,https://www.rocheplus.es/servicios/alia/que-es-alia.html,7,www_rocheplus_es_servicios_alia_que_es_alia_html.txt,200,,Non-Indexable,2,13,0,873,20,5,1,www_rocheplus_es_servicios_alia_que_es_alia_html.txt,image/www_rocheplus_es_servicios_alia_que_es_alia_html.txt.png,text/www_rocheplus_es_servicios_alia_que_es_alia_html.txt.txt,['Alia'],Other,Spain,Patient support,,,4.6380367,0.49696204,7,"The content displays a section from Roche's website aimed at healthcare professionals. It features a call to action encouraging users to search, select, and share information tailored for their patients, specifically highlighting a resource called ""Alia."" The content mentions that Alia comprises over 150 original audiovisual materials, including articles, videos, and infographics that are continually updated to provide relevant advice to patients. Overall, the content focuses on supporting healthcare professionals with accessible and updated information for patient care.","event, exclusive, website",www.rocheplus.es,Falling,0.717969473268204,high,42,Events & Patient Care
1139,https://www.rocheplus.es/servicios/app-roche.html,11,www_rocheplus_es_servicios_app_roche_html.txt,200,,Non-Indexable,1,10,154,958,831,410,1,www_rocheplus_es_servicios_app_roche_html.txt,image/www_rocheplus_es_servicios_app_roche_html.txt.png,text/www_rocheplus_es_servicios_app_roche_html.txt.txt,[],Other,Spain,Technology,,,4.5761123,5.618006,7,"The content highlights the Roche+ app, designed specifically for healthcare professionals. It emphasizes its features related to accessibility and the ability to stay updated directly through a mobile device. The site also mentions resources such as training programs and access to live events, enhancing professional development and networking opportunities within the healthcare sector.","event, exclusive, website",www.rocheplus.es,All,0.155438174146964,high,223,Events & Patient Care
1140,https://www.rocheplus.es/servicios.html,11,www_rocheplus_es_servicios_html.txt,200,,Non-Indexable,1,18,179,992,1249,410,0.945945945945946,www_rocheplus_es_servicios_html.txt.txt,image/www_rocheplus_es_servicios_html.txt.txt.png,text/www_rocheplus_es_servicios_html.txt.txt.txt,['Alia'],Other,Spain,Technology,,,-8.568448,-15.807766,3,"The content showcases a section of Roche's professional online platform designed for healthcare professionals. It highlights the services offered, promoting an interactive platform for sharing experiences, practices, and the latest scientific studies in the health sector. Additionally, it introduces various resources like the Alia platform and the Roche+ app, emphasizing collaboration within the medical community. The overall purpose is to facilitate access to valuable resources and foster professional engagement.","users, page, website",www.rocheplus.es,Flat,0.898674418923868,high,244,Website Metadata
1141,https://www.rocheplus.es/servicios/podcast.html,11,www_rocheplus_es_servicios_podcast_html.txt,200,,Indexable,1,7,136,3168,838,410,1,www_rocheplus_es_servicios_podcast_html.txt,image/www_rocheplus_es_servicios_podcast_html.txt.png,text/www_rocheplus_es_servicios_podcast_html.txt.txt,['Each'],Other,Spain,Technology,,liver cancer,9.602276,6.2702255,7,"The content primarily serves as an overview of Roche's innovative projects and educational resources tailored for healthcare professionals. It highlights a series of podcasts discussing advancements in various medical fields, including ophthalmology, liver cancer, and the impact of robotics and artificial intelligence in healthcare. Each episode features expert interviews that focus on the latest technologies, diagnostic methods, and treatment protocols, aiming to enhance professional knowledge and improve patient care. Additionally, the content emphasizes the importance of early detection and multidisciplinary approaches in cancer treatment. Overall, the content is aimed at sharing cutting-edge medical information and fostering professional growth within the healthcare community.","event, exclusive, website",www.rocheplus.es,Rising,0.850259546731101,high,271,Events & Patient Care
1142,https://www.rocheplus.es/servicios/servicios-pairs.html,7,www_rocheplus_es_servicios_servicios_pairs_html.txt,200,,Non-Indexable,2,41,0,792,9,4,1,www_rocheplus_es_servicios_servicios_pairs_html.txt,image/www_rocheplus_es_servicios_servicios_pairs_html.txt.png,text/www_rocheplus_es_servicios_servicios_pairs_html.txt.txt,"['Registry', 'Supply', 'Access', 'PAIRS', 'Integrated', 'Patient']",Other,Spain,Patient support,,,-10.142939,-9.888257,0,The content provides information about Roche's Patient Access Integrated Registry Supply (PAIRS) platform. It welcomes healthcare professionals and explains that the system is used to process requests for evaluating possible access for candidates to receive medication through compassionate use or post-trial access programs. It also encourages interested professionals to contact Roche for more information.,"oncology, professionals, data",www.rocheplus.es,Rising,0.302224489744026,high,293,General Offer Outline
1143,https://www.rocheplus.es/servicios/solicitud-evaluacion-temperatura.html,10,www_rocheplus_es_servicios_solicitud_evaluacion_temperatura_html.txt,200,,Non-Indexable,1,35,103,934,829,410,1,www_rocheplus_es_servicios_solicitud_evaluacion_temperatura_html.txt,image/www_rocheplus_es_servicios_solicitud_evaluacion_temperatura_html.txt.png,text/www_rocheplus_es_servicios_solicitud_evaluacion_temperatura_html.txt.txt,[],Other,Spain,Offer outline,,,-5.7279005,-19.145811,3,"The content displays a section of Roche's professional website, inviting healthcare professionals to register for exclusive content. It highlights a service related to stability evaluation, indicating a focus on providing specialized resources and support for medical professionals. The user interface directs users to access different services and training opportunities available through the platform.","users, page, website",www.rocheplus.es,Rising,0.355044769509145,high,149,Website Metadata
1144,https://www.rocheplus.es/solicitar-colaboracion.html,7,www_rocheplus_es_solicitar_colaboracion_html.txt,200,,Non-Indexable,1,31,0,1059,836,410,1,www_rocheplus_es_solicitar_colaboracion_html.txt,image/www_rocheplus_es_solicitar_colaboracion_html.txt.png,text/www_rocheplus_es_solicitar_colaboracion_html.txt.txt,['Solicitar'],Other,Spain,Offer outline,,,-10.094461,-19.801579,3,"The content features a section dedicated to ""Solicitar colaboración,"" providing instructions on how to request medical collaboration with Roche. It highlights a video guide that explains the process in detail. The content is geared towards healthcare professionals, inviting them to learn more about collaboration opportunities with the company. The design includes illustrative elements related to scientific work, emphasizing Roche's focus on the medical and pharmaceutical sectors.","users, page, website",www.rocheplus.es,Falling,0.73276960410021,high,346,Website Metadata
